diff --git a/.github/workflows/main.yml b/.github/workflows/main.yml index 430a10d..ed7b70d 100644 --- a/.github/workflows/main.yml +++ b/.github/workflows/main.yml @@ -9,7 +9,7 @@ on: jobs: main: - runs-on: macos-latest + runs-on: ubuntu-24.04 strategy: matrix: part: [ @@ -18,6 +18,7 @@ jobs: introductory/Part_4_*.ipynb, introductory/Part_5_*.ipynb, introductory/Part_1_*.ipynb, + introductory/Part_6_*.ipynb, specialised/Comparing_Models_with_RegressionSuite.ipynb # this should work still # specialised/*.ipynb # To make it run, the SnomedCT file needs to be mocked ] diff --git a/README.md b/README.md index 4f55519..4975548 100644 --- a/README.md +++ b/README.md @@ -18,7 +18,8 @@ In this tutorial, we will walk you through each stage of a basic MedCAT project. | 4.2 | [Supervised training and fine-tuning + Meta-annotations](https://htmlpreview.github.io/?https://github.com/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_4_2_Supervised_Training_and_Meta_annotations.html) | [![Colab](https://colab.research.google.com/assets/colab-badge.svg)](https://colab.research.google.com/github/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_4_2_Supervised_Training_and_Meta_annotations.ipynb) | - | | 4.3 | [Annotating documents with the full MedCAT pipeline with MetaAnnotations](https://htmlpreview.github.io/?https://github.com/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_4_3_Annotating_documents_with_the_full_MedCAT_pipeline_with_MetaAnnotations.html) | [![Colab](https://colab.research.google.com/assets/colab-badge.svg)](https://colab.research.google.com/github/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_4_3_Annotating_documents_with_the_full_MedCAT_pipeline_with_MetaAnnotations.ipynb) | - | | 5 | [Analysing the results](https://htmlpreview.github.io/?https://github.com/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_5_Prevalence_of_Physical_and_Mental_Diseases.html) | [![Colab](https://colab.research.google.com/assets/colab-badge.svg)](https://colab.research.google.com/github/CogStack/MedCATtutorials/blob/main/notebooks/introductory/Part_5_Prevalence_of_Physical_and_Mental_Diseases.ipynb) | [TDS](https://medium.com/@w_is_h/prevalence-of-physical-and-mental-diseases-450c0f4f5851) | - +| 6.1 | [Supervised training Relation-annotations](https://htmlpreview.github.io/?https://github.com/CogStack/MedCATtutorials/blob/rel_cat_tutorials/notebooks/introductory/Part_6_1_Supervised_Training_Relation_Extraction.html) | - | - | +| 6.2 | [Infering relationships from annotations](https://htmlpreview.github.io/?https://github.com/CogStack/MedCATtutorials/blob/rel_cat_tutorials/notebooks/introductory/Part_6_2_Infering_relations_from_annotations_with_Relation_toolkit.html) | - | - | ## Specialised tutorials diff --git a/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.html b/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.html index a75a5a7..20b71db 100644 --- a/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.html +++ b/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.html @@ -13095,7 +13095,7 @@

MedCAT tutorial - logging with Me 
# Install medcat
-! pip install medcat~=1.14.0
+! pip install medcat~=1.16.0
 try:
     from medcat.cat import CAT
 except:
diff --git a/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.ipynb b/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.ipynb
index d8be18e..4d8c271 100644
--- a/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.ipynb
+++ b/notebooks/introductory/Part_1_1_OPTIONAL_Logging_With_MedCAT.ipynb
@@ -19,7 +19,7 @@
    "outputs": [],
    "source": [
     "# Install medcat\n",
-    "! pip install medcat~=1.14.0\n",
+    "! pip install medcat~=1.16.0\n",
     "try:\n",
     "    from medcat.cat import CAT\n",
     "except:\n",
@@ -189,7 +189,7 @@
  ],
  "metadata": {
   "kernelspec": {
-   "display_name": "Python 3.9.6 ('venv': venv)",
+   "display_name": "tvenv",
    "language": "python",
    "name": "python3"
   },
@@ -204,11 +204,6 @@
    "nbconvert_exporter": "python",
    "pygments_lexer": "ipython3",
    "version": "3.9.6"
-  },
-  "vscode": {
-   "interpreter": {
-    "hash": "0d20877e080635f7c4968c49fce8aa5e74c8d7837295e20d04554edce953f9c6"
-   }
   }
  },
  "nbformat": 4,
diff --git a/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.html b/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.html
index 69a215f..73b6407 100644
--- a/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.html
+++ b/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.html
@@ -13095,11 +13095,11 @@ 
First we need to install MedCAT
 

 

-
In [1]:

+
In [ ]:

 

     

 
# Install MedCAT
-! pip install medcat~=1.14.0
+! pip install medcat~=1.16.0
 # Get the scispacy model
 ! python -m spacy download en_core_web_md
 try:
diff --git a/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.ipynb b/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.ipynb
index 8128e63..6c3412b 100644
--- a/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.ipynb
+++ b/notebooks/introductory/Part_3_1_Building_a_Concept_Database_and_Vocabulary.ipynb
@@ -22,7 +22,7 @@
   },
   {
    "cell_type": "code",
-   "execution_count": 1,
+   "execution_count": null,
    "metadata": {
     "colab": {
      "base_uri": "https://localhost:8080/",
@@ -322,7 +322,7 @@
    ],
    "source": [
     "# Install MedCAT\n",
-    "! pip install medcat~=1.14.0\n",
+    "! pip install medcat~=1.16.0\n",
     "# Get the scispacy model\n",
     "! python -m spacy download en_core_web_md\n",
     "try:\n",
@@ -1371,7 +1371,7 @@
    "provenance": []
   },
   "kernelspec": {
-   "display_name": "Python 3.8.5 ('.venv': venv)",
+   "display_name": "Python 3",
    "language": "python",
    "name": "python3"
   },
@@ -1386,11 +1386,6 @@
    "nbconvert_exporter": "python",
    "pygments_lexer": "ipython3",
    "version": "3.9.6"
-  },
-  "vscode": {
-   "interpreter": {
-    "hash": "60954f76b319195d8b66f263176ecf047c3a086773bff2d42e03144b47421836"
-   }
   }
  },
  "nbformat": 4,
diff --git a/notebooks/introductory/Part_3_2_Extracting_Diseases_from_Electronic_Health_Records.html b/notebooks/introductory/Part_3_2_Extracting_Diseases_from_Electronic_Health_Records.html
index 724f875..dd2f6ea 100644
--- a/notebooks/introductory/Part_3_2_Extracting_Diseases_from_Electronic_Health_Records.html
+++ b/notebooks/introductory/Part_3_2_Extracting_Diseases_from_Electronic_Health_Records.html
@@ -13088,11 +13088,11 @@ 
Now let's s
 

 

 

-
In [1]:

+
In [ ]:

 

     

 
# Install medcat
-! pip install medcat~=1.14.0
+! pip install medcat~=1.16.0
 # install seaborn
 ! pip install seaborn
 try:
@@ -14706,10 +14706,10 @@ 
Use Multiprocessing

+

 

 
 
 
 
 
 
 
 
 
 
 
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
diff --git a/notebooks/introductory/Part_6_1_Supervised_Training_Relation_Extraction.ipynb b/notebooks/introductory/Part_6_1_Supervised_Training_Relation_Extraction.ipynb
new file mode 100644
index 0000000..bdab84d
--- /dev/null
+++ b/notebooks/introductory/Part_6_1_Supervised_Training_Relation_Extraction.ipynb
@@ -0,0 +1,903 @@
+{
+ "cells": [
+  {
+   "cell_type": "markdown",
+   "id": "92625d1d",
+   "metadata": {},
+   "source": [
+    "The current implementation offers support for HF LLama models and BERT models.\n",
+    "We will cover only BERT in this section as the Llama usage is the same, just different imports."
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 1,
+   "id": "b52c34cc",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0m\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0mCollecting medcat~=1.16.0\n",
+      "  Downloading medcat-1.16.0-py3-none-any.whl.metadata (9.1 kB)\n",
+      "Requirement already satisfied: numpy<2.0.0,>=1.26.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.26.4)\n",
+      "Requirement already satisfied: pandas>=1.4.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.2.3)\n",
+      "Requirement already satisfied: gensim<5.0.0,>=4.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.3.3)\n",
+      "Requirement already satisfied: spacy<4.0.0,>=3.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (3.7.5)\n",
+      "Requirement already satisfied: scipy<1.14.0,>=1.9.2 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.13.1)\n",
+      "Requirement already satisfied: transformers<5.0.0,>=4.48.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.51.3)\n",
+      "Requirement already satisfied: accelerate>=0.23.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.0)\n",
+      "Requirement already satisfied: torch<3.0.0,>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.7.0)\n",
+      "Requirement already satisfied: tqdm>=4.27 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (4.67.1)\n",
+      "Requirement already satisfied: scikit-learn<2.0.0,>=1.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.1)\n",
+      "Requirement already satisfied: dill<1.0.0,>=0.3.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.3.8)\n",
+      "Requirement already satisfied: datasets<3.0.0,>=2.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.21.0)\n",
+      "Requirement already satisfied: jsonpickle>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.0.5)\n",
+      "Requirement already satisfied: psutil>=5.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (7.0.0)\n",
+      "Requirement already satisfied: multiprocess~=0.70.12 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.70.16)\n",
+      "Requirement already satisfied: aiofiles>=0.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (24.1.0)\n",
+      "Requirement already satisfied: ipywidgets>=7.6.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.7)\n",
+      "Requirement already satisfied: xxhash>=3.0.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (3.5.0)\n",
+      "Requirement already satisfied: blis<1.0.0,>=0.7.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.7.11)\n",
+      "Requirement already satisfied: click>=8.0.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.8)\n",
+      "Requirement already satisfied: pydantic<3.0,>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.11.4)\n",
+      "Requirement already satisfied: humanfriendly~=10.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (10.0)\n",
+      "Requirement already satisfied: peft>=0.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.15.2)\n",
+      "Requirement already satisfied: filelock in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.18.0)\n",
+      "Requirement already satisfied: pyarrow>=15.0.0 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (20.0.0)\n",
+      "Requirement already satisfied: requests>=2.32.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.32.3)\n",
+      "Requirement already satisfied: fsspec<=2024.6.1,>=2023.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from fsspec[http]<=2024.6.1,>=2023.1.0->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2024.6.1)\n",
+      "Requirement already satisfied: aiohttp in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.11.18)\n",
+      "Requirement already satisfied: huggingface-hub>=0.21.2 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.31.2)\n",
+      "Requirement already satisfied: packaging in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.0)\n",
+      "Requirement already satisfied: pyyaml>=5.1 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.0.2)\n",
+      "Requirement already satisfied: smart-open>=1.8.1 in /opt/homebrew/lib/python3.11/site-packages (from gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (7.1.0)\n",
+      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.7.0)\n",
+      "Requirement already satisfied: pydantic-core==2.33.2 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (2.33.2)\n",
+      "Requirement already satisfied: typing-extensions>=4.12.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (4.13.2)\n",
+      "Requirement already satisfied: typing-inspection>=0.4.0 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.4.0)\n",
+      "Requirement already satisfied: joblib>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (1.5.0)\n",
+      "Requirement already satisfied: threadpoolctl>=3.1.0 in /opt/homebrew/lib/python3.11/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (3.6.0)\n",
+      "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.12)\n",
+      "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.5)\n",
+      "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.12)\n",
+      "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.11)\n",
+      "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.9)\n",
+      "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (8.2.5)\n",
+      "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.1.3)\n",
+      "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.5.1)\n",
+      "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.10)\n",
+      "Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.4.1)\n",
+      "Requirement already satisfied: typer<1.0.0,>=0.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.15.3)\n",
+      "Requirement already satisfied: jinja2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.1.6)\n",
+      "Requirement already satisfied: setuptools in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (75.8.0)\n",
+      "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.5.0)\n",
+      "Requirement already satisfied: language-data>=1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.3.0)\n",
+      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.4.2)\n",
+      "Requirement already satisfied: idna<4,>=2.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.10)\n",
+      "Requirement already satisfied: urllib3<3,>=1.21.1 in /opt/homebrew/lib/python3.11/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.4.0)\n",
+      "Requirement already satisfied: certifi>=2017.4.17 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2025.4.26)\n",
+      "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from thinc<8.3.0,>=8.2.2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.5)\n",
+      "Requirement already satisfied: sympy>=1.13.3 in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.14.0)\n",
+      "Requirement already satisfied: networkx in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (3.4.2)\n",
+      "Requirement already satisfied: regex!=2019.12.17 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (2024.11.6)\n",
+      "Requirement already satisfied: tokenizers<0.22,>=0.21 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.21.1)\n",
+      "Requirement already satisfied: safetensors>=0.4.3 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.5.3)\n",
+      "Requirement already satisfied: shellingham>=1.3.0 in /opt/homebrew/lib/python3.11/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.5.4)\n",
+      "Requirement already satisfied: rich>=10.11.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (14.0.0)\n",
+      "Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from weasel<0.5.0,>=0.1.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.21.0)\n",
+      "Requirement already satisfied: wrapt in /opt/homebrew/lib/python3.11/site-packages (from smart-open>=1.8.1->gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (1.17.2)\n",
+      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.6.1)\n",
+      "Requirement already satisfied: aiosignal>=1.1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.3.2)\n",
+      "Requirement already satisfied: attrs>=17.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.3.0)\n",
+      "Requirement already satisfied: frozenlist>=1.1.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.6.0)\n",
+      "Requirement already satisfied: multidict<7.0,>=4.5 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.4.3)\n",
+      "Requirement already satisfied: propcache>=0.2.0 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.3.1)\n",
+      "Requirement already satisfied: yarl<2.0,>=1.17.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.20.0)\n",
+      "Requirement already satisfied: comm>=0.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.2)\n",
+      "Requirement already satisfied: ipython>=6.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (9.2.0)\n",
+      "Requirement already satisfied: traitlets>=4.3.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (5.14.3)\n",
+      "Requirement already satisfied: widgetsnbextension~=4.0.14 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (4.0.14)\n",
+      "Requirement already satisfied: jupyterlab_widgets~=3.0.15 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.15)\n",
+      "Requirement already satisfied: decorator in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (5.2.1)\n",
+      "Requirement already satisfied: ipython-pygments-lexers in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (1.1.1)\n",
+      "Requirement already satisfied: jedi>=0.16 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.19.2)\n",
+      "Requirement already satisfied: matplotlib-inline in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.1.7)\n",
+      "Requirement already satisfied: pexpect>4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (4.9.0)\n",
+      "Requirement already satisfied: prompt_toolkit<3.1.0,>=3.0.41 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.51)\n",
+      "Requirement already satisfied: pygments>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.19.1)\n",
+      "Requirement already satisfied: stack_data in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.6.3)\n",
+      "Requirement already satisfied: wcwidth in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from prompt_toolkit<3.1.0,>=3.0.41->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.13)\n",
+      "Requirement already satisfied: parso<0.9.0,>=0.8.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from jedi>=0.16->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.8.4)\n",
+      "Requirement already satisfied: marisa-trie>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.2.1)\n",
+      "Requirement already satisfied: python-dateutil>=2.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2.9.0.post0)\n",
+      "Requirement already satisfied: pytz>=2020.1 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)\n",
+      "Requirement already satisfied: tzdata>=2022.7 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)\n",
+      "Requirement already satisfied: ptyprocess>=0.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pexpect>4.3->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.7.0)\n",
+      "Requirement already satisfied: six>=1.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from python-dateutil>=2.8.2->pandas>=1.4.2->medcat~=1.16.0) (1.17.0)\n",
+      "Requirement already satisfied: markdown-it-py>=2.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.0)\n",
+      "Requirement already satisfied: mdurl~=0.1 in /opt/homebrew/lib/python3.11/site-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.2)\n",
+      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from sympy>=1.13.3->torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.3.0)\n",
+      "Requirement already satisfied: MarkupSafe>=2.0 in /opt/homebrew/lib/python3.11/site-packages (from jinja2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.2)\n",
+      "Requirement already satisfied: executing>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.2.0)\n",
+      "Requirement already satisfied: asttokens>=2.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.0)\n",
+      "Requirement already satisfied: pure-eval in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.3)\n",
+      "Downloading medcat-1.16.0-py3-none-any.whl (262 kB)\n",
+      "\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0mInstalling collected packages: medcat\n",
+      "  Attempting uninstall: medcat\n",
+      "\u001b[33m    WARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0m    Found existing installation: medcat 0.0.2.dev121\n",
+      "    Uninstalling medcat-0.0.2.dev121:\n",
+      "      Successfully uninstalled medcat-0.0.2.dev121\n",
+      "\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0mSuccessfully installed medcat-1.16.0\n"
+     ]
+    }
+   ],
+   "source": [
+    "# Install medcat\n",
+    "! pip install medcat~=1.16.0"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 2,
+   "id": "163fa4b8",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "import logging\n",
+    "from medcat.cdb import CDB\n",
+    "from medcat.config_rel_cat import ConfigRelCAT\n",
+    "from medcat.rel_cat import RelCAT\n",
+    "from medcat.utils.relation_extraction.base_component import BaseComponent_RelationExtraction\n",
+    "from medcat.utils.relation_extraction.bert.model import BaseModel_RelationExtraction\n",
+    "from medcat.utils.relation_extraction.bert.config import BaseConfig_RelationExtraction\n",
+    "from medcat.utils.relation_extraction.tokenizer import BaseTokenizerWrapper_RelationExtraction"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "c3c91056",
+   "metadata": {},
+   "source": [
+    "
Training RelCAT models with custom datasets from scratch.
\n",
+    "
1. create the RelCAT config and set the parameters
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 3,
+   "id": "95e50349",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "config = ConfigRelCAT()\n",
+    "config.general.log_level = logging.INFO\n",
+    "config.general.model_name = \"bert-base-uncased\" # base model that you want to use, we're going to use the HuggingFace bert-base-uncased model"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "b830b9f0",
+   "metadata": {},
+   "source": [
+    "
 1.1 Based on what model you use, you might want to keep an eye on config.model.hidden_size, config.model.model_size and config.model.hidden_layers
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 4,
+   "id": "bac65030",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "config.model.hidden_size= 256\n",
+    "config.model.model_size = 2304 # 4096 for llama"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "cbcb3f1e",
+   "metadata": {},
+   "source": [
+    "
 1.2 Other notable configurations
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 5,
+   "id": "ec2855a0",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "config.general.cntx_left = 15 # how many tokens to the left of the start entity we select\n",
+    "config.general.cntx_right = 15 # how many tokens to the right of the end entity we selecd\n",
+    "config.general.window_size = 300 # distance (in characters) between two entities to be considered a relation\n",
+    "config.train.nclasses = 2 # number of classes in your medcat export / dataset\n",
+    "config.train.nepochs = 10 # number of epochs to train for\n",
+    "config.model.freeze_layers = False # whether to freeze the layers of the base model\n",
+    "config.general.limit_samples_per_class = 300 # limit the number of training samples per class to this number, to avoid overfitting in unbalanced datasets\n",
+    "config.train.batch_size = 32 # batch size\n",
+    "config.train.lr = 3e-5\n",
+    "config.train.adam_epsilon = 1e-8\n",
+    "config.train.adam_weight_decay = 0.0005"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "36f30ac1",
+   "metadata": {},
+   "source": []
+  },
+  {
+   "cell_type": "markdown",
+   "id": "a046775c",
+   "metadata": {},
+   "source": [
+    "
2. create a CDB, it can be a CDB from another model of your choice or an empty one.\n",
+    "The CDB is used only when filtering by concept unique identifiers (CUI) or concept type ids (TUI)."
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 6,
+   "id": "26a2d4fd",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "cdb = CDB()"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "ac85c6f1",
+   "metadata": {},
+   "source": [
+    "
3. Create a tokenizer"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 7,
+   "id": "c8abdf9e",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "tokenizer = BaseTokenizerWrapper_RelationExtraction.load(tokenizer_path=config.general.model_name,\n",
+    "                                                                           relcat_config=config)   "
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "a3aa53da",
+   "metadata": {},
+   "source": [
+    "
4. Add token tags to tokenizer.\n",
+    " This step is optional because the [s1], [e1], [s2], [e2] tags are already located in the default RelCATConfig.\n",
+    " If you are using a LLama based model, you will need to add the [PAD] token to the tokenizer, as shown below."
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 8,
+   "id": "58815c89",
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/plain": [
+       "0"
+      ]
+     },
+     "execution_count": 8,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "special_ent_tokens = [\"[s1]\", \"[e1]\", \"[s2]\", \"[e2]\"]\n",
+    "tokenizer.hf_tokenizers.add_tokens(special_ent_tokens, special_tokens=True)\n",
+    "tokenizer.hf_tokenizers.add_special_tokens({'pad_token': '[PAD]'}) # used in llama tokenizer"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "0cf3d22a",
+   "metadata": {},
+   "source": [
+    "
5. Add tokens to the RelCATConfig"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 9,
+   "id": "4c8d6d93",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "config.general.tokenizer_relation_annotation_special_tokens_tags = special_ent_tokens\n",
+    "config.general.annotation_schema_tag_ids = tokenizer.hf_tokenizers.convert_tokens_to_ids(special_ent_tokens)"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "10865722",
+   "metadata": {},
+   "source": [
+    "
6. Create the relCAT object and initialize its components
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 10,
+   "id": "597acf66",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "INFO:medcat.utils.relation_extraction.base_component:BaseComponent_RelationExtraction initialized\n"
+     ]
+    }
+   ],
+   "source": [
+    "# if you wish to skip the steps in section 6.1 you can pass the init_model=True arguement to intialize the components with the default ConfigRelCAT settings.\n",
+    "relCAT = RelCAT(cdb, config=config)"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "24cdfcf7",
+   "metadata": {},
+   "source": [
+    "
6.1 Use the BaseComponent object, this one holds the tokenizer, model and model config. We will have to initialize each component beforehand.
"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "ba21d0e1",
+   "metadata": {},
+   "source": [
+    "
Resize token embeddings since we added the tokens before, this should be done after adding tokens to the tokenizer. It is not required after creating and saving/loading a model as the value will be retained.
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 11,
+   "id": "0cb2f815",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "You are using a model of type bert to instantiate a model of type . This is not supported for all configurations of models and can yield errors.\n",
+      "INFO:medcat.utils.relation_extraction.config:Loaded config from : bert-base-uncased/model_config.json\n",
+      "INFO:medcat.utils.relation_extraction.models:RelCAT model config: PretrainedConfig {\n",
+      "  \"_attn_implementation_autoset\": true,\n",
+      "  \"architectures\": [\n",
+      "    \"BertForMaskedLM\"\n",
+      "  ],\n",
+      "  \"attention_probs_dropout_prob\": 0.1,\n",
+      "  \"gradient_checkpointing\": false,\n",
+      "  \"hidden_act\": \"gelu\",\n",
+      "  \"hidden_dropout_prob\": 0.1,\n",
+      "  \"hidden_size\": 768,\n",
+      "  \"initializer_range\": 0.02,\n",
+      "  \"intermediate_size\": 3072,\n",
+      "  \"layer_norm_eps\": 1e-12,\n",
+      "  \"max_position_embeddings\": 512,\n",
+      "  \"num_attention_heads\": 12,\n",
+      "  \"num_hidden_layers\": 12,\n",
+      "  \"pad_token_id\": 0,\n",
+      "  \"position_embedding_type\": \"absolute\",\n",
+      "  \"transformers_version\": \"4.51.3\",\n",
+      "  \"type_vocab_size\": 2,\n",
+      "  \"use_cache\": true,\n",
+      "  \"vocab_size\": 30526\n",
+      "}\n",
+      "\n",
+      "INFO:medcat.utils.relation_extraction.bert.model:RelCAT model config: PretrainedConfig {\n",
+      "  \"_attn_implementation_autoset\": true,\n",
+      "  \"architectures\": [\n",
+      "    \"BertForMaskedLM\"\n",
+      "  ],\n",
+      "  \"attention_probs_dropout_prob\": 0.1,\n",
+      "  \"gradient_checkpointing\": false,\n",
+      "  \"hidden_act\": \"gelu\",\n",
+      "  \"hidden_dropout_prob\": 0.1,\n",
+      "  \"hidden_size\": 768,\n",
+      "  \"initializer_range\": 0.02,\n",
+      "  \"intermediate_size\": 3072,\n",
+      "  \"layer_norm_eps\": 1e-12,\n",
+      "  \"max_position_embeddings\": 512,\n",
+      "  \"num_attention_heads\": 12,\n",
+      "  \"num_hidden_layers\": 12,\n",
+      "  \"pad_token_id\": 0,\n",
+      "  \"position_embedding_type\": \"absolute\",\n",
+      "  \"transformers_version\": \"4.51.3\",\n",
+      "  \"type_vocab_size\": 2,\n",
+      "  \"use_cache\": true,\n",
+      "  \"vocab_size\": 30526\n",
+      "}\n",
+      "\n",
+      "Some weights of BertModel were not initialized from the model checkpoint at bert-base-uncased and are newly initialized because the shapes did not match:\n",
+      "- embeddings.word_embeddings.weight: found shape torch.Size([30522, 768]) in the checkpoint and torch.Size([30526, 768]) in the model instantiated\n",
+      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n",
+      "INFO:medcat.utils.relation_extraction.bert.model:Loaded model from pretrained: bert-base-uncased\n",
+      "INFO:medcat.utils.relation_extraction.models:Loaded BertModel_RelationExtraction from pretrained_model_name_or_path: bert-base-uncased\n",
+      "INFO:medcat.utils.relation_extraction.base_component:BaseComponent_RelationExtraction initialized\n"
+     ]
+    }
+   ],
+   "source": [
+    "model_config = BaseConfig_RelationExtraction.load(pretrained_model_name_or_path=config.general.model_name,\n",
+    "                                                                   relcat_config=config)\n",
+    "\n",
+    "# update the model config with the proper vocab size, since we added special tokens to the tokenizer\n",
+    "model_config.hf_model_config.vocab_size = tokenizer.get_size()\n",
+    "\n",
+    "# set the padding idx in the model config and relcat config, this is necesasry as it depends on what tokenizer you use\n",
+    "config.model.padding_idx = model_config.pad_token_id = tokenizer.get_pad_id()\n",
+    "\n",
+    "model = BaseModel_RelationExtraction.load(pretrained_model_name_or_path=config.general.model_name,\n",
+    "                                                                   model_config=model_config,\n",
+    "                                                                   relcat_config=config)\n",
+    "\n",
+    "# we have to update the model to reflect the new token embeddings, since we added special tokens to the tokenizer\n",
+    "model.hf_model.resize_token_embeddings(len(tokenizer.hf_tokenizers)) # type: ignore\n",
+    "\n",
+    "component = BaseComponent_RelationExtraction(tokenizer=tokenizer, config=config)\n",
+    "component.model = model\n",
+    "component.model_config = model_config\n",
+    "component.relcat_config = config\n",
+    "component.tokenizer = tokenizer\n",
+    "\n",
+    "relCAT.component = component"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "5429819a",
+   "metadata": {},
+   "source": [
+    "
 7. Train the model from the ADE dataset. 
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 12,
+   "id": "899abe12",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "! rm -rf \"./ade_relcat_model\"\n",
+    "! mkdir -p \"./ade_relcat_model\""
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 13,
+   "id": "1fc17a58",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "INFO:medcat.utils.relation_extraction.rel_dataset:CSV dataset | No. of relations detected:7093| from : ./data/rel_cat_ADE_V2.tsv | nclasses: 2 | idx2label: {0: 'DRUG-DOSE', 1: 'DRUG-AE'}\n",
+      "INFO:medcat.utils.relation_extraction.rel_dataset:Samples per class: \n",
+      "INFO:medcat.utils.relation_extraction.rel_dataset: label: DRUG-DOSE | samples: 279\n",
+      "INFO:medcat.utils.relation_extraction.rel_dataset: label: DRUG-AE | samples: 6814\n",
+      "INFO:root:Relations after train, test split :  train - 524 | test - 115\n",
+      "INFO:root: label: DRUG-AE samples | train 300 | test 60\n",
+      "INFO:root: label: DRUG-DOSE samples | train 224 | test 55\n",
+      "INFO:root:Attempting to load RelCAT model on device: cpu\n",
+      "INFO:medcat.rel_cat:Starting training process...\n",
+      "INFO:medcat.rel_cat:Total epochs on this model: 10 | currently training epoch 0\n",
+      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
+      "To disable this warning, you can either:\n",
+      "\t- Avoid using `tokenizers` before the fork if possible\n",
+      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
+      "  0%|          | 0/524 [00:00
+
+
+
+Part_6_2_Infering_relations_from_annotations_with_Relation_toolkit
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+    
+    
+    
+    
+
+  

+    

+
+

+

+
In [1]:

+

+    

+
# Install medcat
+! pip install medcat~=1.16.0
+

+
+    

+

+

+
+

+

+
+
+

+
+    

+
+
+

+
WARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)
+WARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)
+Requirement already satisfied: medcat~=1.16.0 in /opt/homebrew/lib/python3.11/site-packages (1.16.0)
+Requirement already satisfied: numpy<2.0.0,>=1.26.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.26.4)
+Requirement already satisfied: pandas>=1.4.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.2.3)
+Requirement already satisfied: gensim<5.0.0,>=4.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.3.3)
+Requirement already satisfied: spacy<4.0.0,>=3.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (3.7.5)
+Requirement already satisfied: scipy<1.14.0,>=1.9.2 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.13.1)
+Requirement already satisfied: transformers<5.0.0,>=4.48.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.51.3)
+Requirement already satisfied: accelerate>=0.23.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.0)
+Requirement already satisfied: torch<3.0.0,>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.7.0)
+Requirement already satisfied: tqdm>=4.27 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (4.67.1)
+Requirement already satisfied: scikit-learn<2.0.0,>=1.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.1)
+Requirement already satisfied: dill<1.0.0,>=0.3.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.3.8)
+Requirement already satisfied: datasets<3.0.0,>=2.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.21.0)
+Requirement already satisfied: jsonpickle>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.0.5)
+Requirement already satisfied: psutil>=5.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (7.0.0)
+Requirement already satisfied: multiprocess~=0.70.12 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.70.16)
+Requirement already satisfied: aiofiles>=0.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (24.1.0)
+Requirement already satisfied: ipywidgets>=7.6.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.7)
+Requirement already satisfied: xxhash>=3.0.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (3.5.0)
+Requirement already satisfied: blis<1.0.0,>=0.7.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.7.11)
+Requirement already satisfied: click>=8.0.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.8)
+Requirement already satisfied: pydantic<3.0,>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.11.4)
+Requirement already satisfied: humanfriendly~=10.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (10.0)
+Requirement already satisfied: peft>=0.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.15.2)
+Requirement already satisfied: filelock in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.18.0)
+Requirement already satisfied: pyarrow>=15.0.0 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (20.0.0)
+Requirement already satisfied: requests>=2.32.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.32.3)
+Requirement already satisfied: fsspec<=2024.6.1,>=2023.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from fsspec[http]<=2024.6.1,>=2023.1.0->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2024.6.1)
+Requirement already satisfied: aiohttp in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.11.18)
+Requirement already satisfied: huggingface-hub>=0.21.2 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.31.2)
+Requirement already satisfied: packaging in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.0)
+Requirement already satisfied: pyyaml>=5.1 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.0.2)
+Requirement already satisfied: smart-open>=1.8.1 in /opt/homebrew/lib/python3.11/site-packages (from gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (7.1.0)
+Requirement already satisfied: annotated-types>=0.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.7.0)
+Requirement already satisfied: pydantic-core==2.33.2 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (2.33.2)
+Requirement already satisfied: typing-extensions>=4.12.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (4.13.2)
+Requirement already satisfied: typing-inspection>=0.4.0 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.4.0)
+Requirement already satisfied: joblib>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (1.5.0)
+Requirement already satisfied: threadpoolctl>=3.1.0 in /opt/homebrew/lib/python3.11/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (3.6.0)
+Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.12)
+Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.5)
+Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.12)
+Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.11)
+Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.9)
+Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (8.2.5)
+Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.1.3)
+Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.5.1)
+Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.10)
+Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.4.1)
+Requirement already satisfied: typer<1.0.0,>=0.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.15.3)
+Requirement already satisfied: jinja2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.1.6)
+Requirement already satisfied: setuptools in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (75.8.0)
+Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.5.0)
+Requirement already satisfied: language-data>=1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.3.0)
+Requirement already satisfied: charset-normalizer<4,>=2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.4.2)
+Requirement already satisfied: idna<4,>=2.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.10)
+Requirement already satisfied: urllib3<3,>=1.21.1 in /opt/homebrew/lib/python3.11/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.4.0)
+Requirement already satisfied: certifi>=2017.4.17 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2025.4.26)
+Requirement already satisfied: confection<1.0.0,>=0.0.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from thinc<8.3.0,>=8.2.2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.5)
+Requirement already satisfied: sympy>=1.13.3 in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.14.0)
+Requirement already satisfied: networkx in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (3.4.2)
+Requirement already satisfied: regex!=2019.12.17 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (2024.11.6)
+Requirement already satisfied: tokenizers<0.22,>=0.21 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.21.1)
+Requirement already satisfied: safetensors>=0.4.3 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.5.3)
+Requirement already satisfied: shellingham>=1.3.0 in /opt/homebrew/lib/python3.11/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.5.4)
+Requirement already satisfied: rich>=10.11.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (14.0.0)
+Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from weasel<0.5.0,>=0.1.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.21.0)
+Requirement already satisfied: wrapt in /opt/homebrew/lib/python3.11/site-packages (from smart-open>=1.8.1->gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (1.17.2)
+Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.6.1)
+Requirement already satisfied: aiosignal>=1.1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.3.2)
+Requirement already satisfied: attrs>=17.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.3.0)
+Requirement already satisfied: frozenlist>=1.1.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.6.0)
+Requirement already satisfied: multidict<7.0,>=4.5 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.4.3)
+Requirement already satisfied: propcache>=0.2.0 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.3.1)
+Requirement already satisfied: yarl<2.0,>=1.17.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.20.0)
+Requirement already satisfied: comm>=0.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.2)
+Requirement already satisfied: ipython>=6.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (9.2.0)
+Requirement already satisfied: traitlets>=4.3.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (5.14.3)
+Requirement already satisfied: widgetsnbextension~=4.0.14 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (4.0.14)
+Requirement already satisfied: jupyterlab_widgets~=3.0.15 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.15)
+Requirement already satisfied: decorator in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (5.2.1)
+Requirement already satisfied: ipython-pygments-lexers in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (1.1.1)
+Requirement already satisfied: jedi>=0.16 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.19.2)
+Requirement already satisfied: matplotlib-inline in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.1.7)
+Requirement already satisfied: pexpect>4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (4.9.0)
+Requirement already satisfied: prompt_toolkit<3.1.0,>=3.0.41 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.51)
+Requirement already satisfied: pygments>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.19.1)
+Requirement already satisfied: stack_data in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.6.3)
+Requirement already satisfied: wcwidth in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from prompt_toolkit<3.1.0,>=3.0.41->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.13)
+Requirement already satisfied: parso<0.9.0,>=0.8.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from jedi>=0.16->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.8.4)
+Requirement already satisfied: marisa-trie>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.2.1)
+Requirement already satisfied: python-dateutil>=2.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2.9.0.post0)
+Requirement already satisfied: pytz>=2020.1 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)
+Requirement already satisfied: tzdata>=2022.7 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)
+Requirement already satisfied: ptyprocess>=0.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pexpect>4.3->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.7.0)
+Requirement already satisfied: six>=1.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from python-dateutil>=2.8.2->pandas>=1.4.2->medcat~=1.16.0) (1.17.0)
+Requirement already satisfied: markdown-it-py>=2.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.0)
+Requirement already satisfied: mdurl~=0.1 in /opt/homebrew/lib/python3.11/site-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.2)
+Requirement already satisfied: mpmath<1.4,>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from sympy>=1.13.3->torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.3.0)
+Requirement already satisfied: MarkupSafe>=2.0 in /opt/homebrew/lib/python3.11/site-packages (from jinja2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.2)
+Requirement already satisfied: executing>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.2.0)
+Requirement already satisfied: asttokens>=2.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.0)
+Requirement already satisfied: pure-eval in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.3)
+WARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)
+WARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)
+

+

+

+
+

+

+
+

+

+

+
In [ ]:

+

+    

+
! wget "https://drive.usercontent.google.com/download?id=1nGI3Igrd7V0fayUAMVafZU9C8GSgEmDS&export=download&confirm=t&uuid=da8b7d44-401a-40f4-8e16-f1adc0ff827f" -O part_6_2_ade_relcat_model.zip
+! unzip part_6_2_ade_relcat_model.zip -d part_6_2
+

+
+    

+

+

+
+

+

+
+
+

+
+    

+
+
+

+
--2025-05-19 12:47:32--  https://drive.usercontent.google.com/download?id=1nGI3Igrd7V0fayUAMVafZU9C8GSgEmDS&export=download&confirm=t&uuid=da8b7d44-401a-40f4-8e16-f1adc0ff827f
+Resolving drive.usercontent.google.com (drive.usercontent.google.com)... 142.250.200.1
+Connecting to drive.usercontent.google.com (drive.usercontent.google.com)|142.250.200.1|:443... connected.
+HTTP request sent, awaiting response... 

+

+

+
+

+

+
+

+

+

+
In [ ]:

+

+    

+
from medcat.rel_cat import RelCAT
+

+
+    

+

+

+
+

+

+

+

+
 1. Load the model of your choice. 

+

+

+

+

+

+

+
+

+

+

+

+

+
In [ ]:

+

+    

+
import os
+try:
+    rc_path = "./part_6_2/ade_relcat_model"
+    relCAT = RelCAT.load(rc_path)
+except Exception as e:
+    raise ValueError(
+        f"Unable to load RelCAT model from '{rc_path}'. "
+        f"Exists? {os.path.exists(rc_path)}; isdir? {os.path.isdir(rc_path)} "
+        f"Stuff in dir: {os.listdir(rc_path) if os.path.isdir(rc_path) else ['NOT A DIR']}")
+

+
+    

+

+

+
+

+

+

+

+
 2. Prepare the text for relation extraction. We assume that there are annotations already present. 

+

+

+

+

+

+
In [ ]:

+

+    

+
docs_with_anns = {"text": "REASON FOR CONSULTATION: , Left hip fracture.,HISTORY OF PRESENT ILLNESS: , The patient is a pleasant 53-year-old female with a known history of sciatica, apparently presented to the emergency room due to severe pain in the left lower extremity and unable to bear weight.  History was obtained from the patient.  As per the history, she reported that she has been having back pain with left leg pain since past 4 weeks.  She has been using a walker for ambulation due to disabling pain in her left thigh and lower back.  She was seen by her primary care physician and was scheduled to go for MRI yesterday.  However, she was walking and her right foot got caught on some type of rug leading to place excessive weight on her left lower extremity to prevent her fall.  Since then, she was unable to ambulate.  The patient called paramedics and was brought to the emergency room.  She denied any history of fall.  She reported that she stepped the wrong way causing the pain to become worse.  She is complaining of severe pain in her lower extremity and back pain.  Denies any tingling or numbness.  Denies any neurological symptoms.  Denies any bowel or bladder incontinence.,X-rays were obtained which were remarkable for left hip fracture.  Orthopedic consultation was called for further evaluation and management.  On further interview with the patient, it is noted that she has a history of malignant melanoma, which was diagnosed approximately 4 to 5 years ago.  She underwent surgery at that time and subsequently, she was noted to have a spread to the lymphatic system and lymph nodes for which she underwent surgery in 3/2008.,PAST MEDICAL HISTORY: , Sciatica and melanoma.,PAST SURGICAL HISTORY:  ,As discussed above, surgery for melanoma and hysterectomy.,ALLERGIES: , NONE.,SOCIAL HISTORY: , Denies any tobacco or alcohol use.  She is divorced with 2 children.  She lives with her son.,PHYSICAL EXAMINATION:,GENERAL:  The patient is well developed, well nourished in mild distress secondary to left lower extremity and back pain.,MUSCULOSKELETAL:  Examination of the left lower extremity, there is presence of apparent shortening and external rotation deformity.  Tenderness to palpation is present.  Leg rolling is positive for severe pain in the left proximal hip.  Further examination of the spine is incomplete secondary to severe leg pain.  She is unable to perform a straight leg raising.  EHL/EDL 5/5.  2+ pulses are present distally.  Calf is soft and nontender.  Homans sign is negative.  Sensation to light touch is intact.,IMAGING:,  AP view of the hip is reviewed.  Only 1 limited view is obtained.  This is a poor quality x-ray with a lot of soft tissue shadow.  This x-ray is significant for basicervical-type femoral neck fracture.  Lesser trochanter is intact.  This is a high intertrochanteric fracture/basicervical.  There is presence of lytic lesion around the femoral neck, which is not well delineated on this particular x-ray.  We need to order repeat x-rays including AP pelvis, femur, and knee.,LABS:,  Have been reviewed.,ASSESSMENT: , The patient is a 53-year-old female with probable pathological fracture of the left proximal femur.,DISCUSSION AND PLAN: , Nature and course of the diagnosis has been discussed with the patient.  Based on her presentation without any history of obvious fall or trauma and past history of malignant melanoma, this appears to be a pathological fracture of the left proximal hip.  At the present time, I would recommend obtaining a bone scan and repeat x-rays, which will include AP pelvis, femur, hip including knee.  She denies any pain elsewhere.  She does have a past history of back pain and sciatica, but at the present time, this appears to be a metastatic bone lesion with pathological fracture.  I have discussed the case with Dr. X and recommended oncology consultation.,With the above fracture and presentation, she needs a left hip hemiarthroplasty versus calcar hemiarthroplasty, cemented type.  Indication, risk, and benefits of left hip hemiarthroplasty has been discussed with the patient, which includes, but not limited to bleeding, infection, nerve injury, blood vessel injury, dislocation early and late, persistent pain, leg length discrepancy, myositis ossificans, intraoperative fracture, prosthetic fracture, need for conversion to total hip replacement surgery, revision surgery, DVT, pulmonary embolism, risk of anesthesia, need for blood transfusion, and cardiac arrest.  She understands above and is willing to undergo further procedure.  The goal and the functional outcome have been explained.  Further plan will be discussed with her once we obtain the bone scan and the radiographic studies.  We will also await for the oncology feedback and clearance.,Thank you very much for allowing me to participate in the care of this patient.  I will continue to follow up.",
+                   "annotations": [{
+                            "id": 1011,
+                            "user": "admin",
+                            "cui": "161432005",
+                            "value": "history of malignant melanoma",
+                            "start": 1382,
+                            "end": 1411,
+  
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1012,
+                            "user": "admin",
+                            "cui": "161432005",
+                            "value": "history of malignant melanoma",
+                            "start": 3347,
+                            "end": 3376,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1013,
+                            "user": "admin",
+                            "cui": "52734007",
+                            "value": "total hip replacement surgery",
+                            "start": 4323,
+                            "end": 4352,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1014,
+                            "user": "admin",
+                            "cui": "127287001",
+                            "value": "intertrochanteric fracture",
+                            "start": 2802,
+                            "end": 2828,
+   
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1015,
+                            "user": "admin",
+                            "cui": "213270002",
+                            "value": "intraoperative fracture",
+                            "start": 4254,
+                            "end": 4277,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1016,
+                            "user": "admin",
+                            "cui": "446050000",
+                            "value": "primary care physician",
+                            "start": 541,
+                            "end": 563,
+           
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1017,
+                            "user": "admin",
+                            "cui": "5913000",
+                            "value": "femoral neck fracture",
+                            "start": 2733,
+                            "end": 2754,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1018,
+                            "user": "admin",
+                            "cui": "268029009",
+                            "value": "pathological fracture",
+                            "start": 3120,
+                            "end": 3141,
+  
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1019,
+                            "user": "admin",
+                            "cui": "268029009",
+                            "value": "pathological fracture",
+                            "start": 3399,
+                            "end": 3420,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1020,
+                            "user": "admin",
+                            "cui": "268029009",
+                            "value": "pathological fracture",
+                            "start": 3748,
+                            "end": 3769,
+   
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1021,
+                            "user": "admin",
+                            "cui": "32153003",
+                            "value": "left lower extremity",
+                            "start": 224,
+                            "end": 244,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1022,
+                            "user": "admin",
+                            "cui": "32153003",
+                            "value": "left lower extremity",
+                            "start": 724,
+                            "end": 744,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1023,
+                            "user": "admin",
+                            "cui": "165232002",
+                            "value": "bladder incontinence",
+                            "start": 1152,
+                            "end": 1172,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1024,
+                            "user": "admin",
+                            "cui": "5880005",
+                            "value": "PHYSICAL EXAMINATION",
+                            "start": 1895,
+                            "end": 1915,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1025,
+                            "user": "admin",
+                            "cui": "32153003",
+                            "value": "left lower extremity",
+                            "start": 2003,
+                            "end": 2023,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1026,
+                            "user": "admin",
+                            "cui": "32153003",
+                            "value": "left lower extremity",
+                            "start": 2076,
+                            "end": 2096,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1027,
+                            "user": "admin",
+                            "cui": "57662003",
+                            "value": "injury, blood vessel",
+                            "start": 4135,
+                            "end": 4155,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1028,
+                            "user": "admin",
+                            "cui": "44551007",
+                            "value": "myositis ossificans",
+                            "start": 4233,
+                            "end": 4252,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1029,
+                            "user": "admin",
+                            "cui": "59282003",
+                            "value": "pulmonary embolism",
+                            "start": 4377,
+                            "end": 4395,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1030,
+                            "user": "admin",
+                            "cui": "116859006",
+                            "value": "blood transfusion",
+                            "start": 4426,
+                            "end": 4443,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1031,
+                            "user": "admin",
+                            "cui": "224994002",
+                            "value": "excessive weight",
+                            "start": 700,
+                            "end": 716,
+
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1032,
+                            "user": "admin",
+                            "cui": "89890002",
+                            "value": "lymphatic system",
+                            "start": 1557,
+                            "end": 1573,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1033,
+                            "user": "admin",
+                            "cui": "261554009",
+                            "value": "revision surgery",
+                            "start": 4354,
+                            "end": 4370,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1034,
+                            "user": "admin",
+                            "cui": "428942009",
+                            "value": "history of fall",
+                            "start": 893,
+                            "end": 908,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1035,
+                            "user": "admin",
+                            "cui": "61685007",
+                            "value": "lower extremity",
+                            "start": 1031,
+                            "end": 1046,
+   
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1036,
+                            "user": "admin",
+                            "cui": "392521001",
+                            "value": "MEDICAL HISTORY",
+                            "start": 1638,
+                            "end": 1653,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1037,
+                            "user": "admin",
+                            "cui": "106028002",
+                            "value": "MUSCULOSKELETAL",
+                            "start": 2039,
+                            "end": 2054,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1038,
+                            "user": "admin",
+                            "cui": "417662000",
+                            "value": "past history of",
+                            "start": 3634,
+                            "end": 3649,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1039,
+                            "user": "admin",
+                            "cui": "225728007",
+                            "value": "emergency room",
+                            "start": 183,
+                            "end": 197,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1040,
+                            "user": "admin",
+                            "cui": "225728007",
+                            "value": "emergency room",
+                            "start": 861,
+                            "end": 875,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1041,
+                            "user": "admin",
+                            "cui": "160476009",
+                            "value": "SOCIAL HISTORY",
+                            "start": 1783,
+                            "end": 1797,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1042,
+                            "user": "admin",
+                            "cui": "248324001",
+                            "value": "well nourished",
+                            "start": 1958,
+                            "end": 1972,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1043,
+                            "user": "admin",
+                            "cui": "244696009",
+                            "value": "proximal femur",
+                            "start": 3154,
+                            "end": 3168,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1044,
+                            "user": "admin",
+                            "cui": "410429000",
+                            "value": "cardiac arrest",
+                            "start": 4449,
+                            "end": 4463,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1045,
+                            "user": "admin",
+                            "cui": "287047008",
+                            "value": "left leg pain",
+                            "start": 386,
+                            "end": 399,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1046,
+                            "user": "admin",
+                            "cui": "161891005",
+                            "value": "and back pain",
+                            "start": 1047,
+                            "end": 1060,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1047,
+                            "user": "admin",
+                            "cui": "26175008",
+                            "value": "approximately",
+                            "start": 1433,
+                            "end": 1446,
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1048,
+                            "user": "admin",
+                            "cui": "161891005",
+                            "value": "and back pain",
+                            "start": 2024,
+                            "end": 2037,
+
+                            "acc": 1.0,
+                            "meta_anns": {}
+                        },
+                        {
+                            "id": 1049,
+                            "user": "admin",
+                            "cui": "1199008",
+                            "value": "neurological",
+                            "start": 1108,
+                            "end": 1120
+                        }
+                        ]}
+

+
+    

+

+

+
+

+

+

+

+
3. Predict relations 

+

+

+

+

+

+
In [ ]:

+

+    

+
output_doc_with_relations = relCAT.predict_text_with_anns(text=docs_with_anns["text"], annotations=docs_with_anns["annotations"])
+

+
+    

+

+

+
+

+

+

+

+
4. Examine relations 

+

+

+

+

+

+
In [ ]:

+

+    

+
output_doc_with_relations._.relations
+

+
+    

+

+

+
+

+

+

+

+
Most relations in our case make no sense as we only have two classes that relate to drug and adverse effects and drug-dosage. It is recommended that you apply a TUI/CUI filter to the NER config step first to only focus on relevant concepts.

+
+

+

+

+

+

+
In [ ]:

+

+    

+
 
+

+
+    

+

+

+
+

+    

+  

+
+
+ 
+
+
+
diff --git a/notebooks/introductory/Part_6_2_Infering_relations_from_annotations_with_Relation_toolkit.ipynb b/notebooks/introductory/Part_6_2_Infering_relations_from_annotations_with_Relation_toolkit.ipynb
new file mode 100644
index 0000000..0a46667
--- /dev/null
+++ b/notebooks/introductory/Part_6_2_Infering_relations_from_annotations_with_Relation_toolkit.ipynb
@@ -0,0 +1,701 @@
+{
+ "cells": [
+  {
+   "cell_type": "code",
+   "execution_count": 1,
+   "id": "ec4a8509",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0m\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0mRequirement already satisfied: medcat~=1.16.0 in /opt/homebrew/lib/python3.11/site-packages (1.16.0)\n",
+      "Requirement already satisfied: numpy<2.0.0,>=1.26.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.26.4)\n",
+      "Requirement already satisfied: pandas>=1.4.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.2.3)\n",
+      "Requirement already satisfied: gensim<5.0.0,>=4.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.3.3)\n",
+      "Requirement already satisfied: spacy<4.0.0,>=3.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (3.7.5)\n",
+      "Requirement already satisfied: scipy<1.14.0,>=1.9.2 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (1.13.1)\n",
+      "Requirement already satisfied: transformers<5.0.0,>=4.48.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.51.3)\n",
+      "Requirement already satisfied: accelerate>=0.23.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.0)\n",
+      "Requirement already satisfied: torch<3.0.0,>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.7.0)\n",
+      "Requirement already satisfied: tqdm>=4.27 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (4.67.1)\n",
+      "Requirement already satisfied: scikit-learn<2.0.0,>=1.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (1.6.1)\n",
+      "Requirement already satisfied: dill<1.0.0,>=0.3.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.3.8)\n",
+      "Requirement already satisfied: datasets<3.0.0,>=2.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.21.0)\n",
+      "Requirement already satisfied: jsonpickle>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (4.0.5)\n",
+      "Requirement already satisfied: psutil>=5.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (7.0.0)\n",
+      "Requirement already satisfied: multiprocess~=0.70.12 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.70.16)\n",
+      "Requirement already satisfied: aiofiles>=0.8.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (24.1.0)\n",
+      "Requirement already satisfied: ipywidgets>=7.6.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.7)\n",
+      "Requirement already satisfied: xxhash>=3.0.0 in /opt/homebrew/lib/python3.11/site-packages (from medcat~=1.16.0) (3.5.0)\n",
+      "Requirement already satisfied: blis<1.0.0,>=0.7.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.7.11)\n",
+      "Requirement already satisfied: click>=8.0.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (8.1.8)\n",
+      "Requirement already satisfied: pydantic<3.0,>=2.0.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (2.11.4)\n",
+      "Requirement already satisfied: humanfriendly~=10.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (10.0)\n",
+      "Requirement already satisfied: peft>=0.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from medcat~=1.16.0) (0.15.2)\n",
+      "Requirement already satisfied: filelock in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.18.0)\n",
+      "Requirement already satisfied: pyarrow>=15.0.0 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (20.0.0)\n",
+      "Requirement already satisfied: requests>=2.32.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.32.3)\n",
+      "Requirement already satisfied: fsspec<=2024.6.1,>=2023.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from fsspec[http]<=2024.6.1,>=2023.1.0->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2024.6.1)\n",
+      "Requirement already satisfied: aiohttp in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.11.18)\n",
+      "Requirement already satisfied: huggingface-hub>=0.21.2 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.31.2)\n",
+      "Requirement already satisfied: packaging in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.0)\n",
+      "Requirement already satisfied: pyyaml>=5.1 in /opt/homebrew/lib/python3.11/site-packages (from datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.0.2)\n",
+      "Requirement already satisfied: smart-open>=1.8.1 in /opt/homebrew/lib/python3.11/site-packages (from gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (7.1.0)\n",
+      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.7.0)\n",
+      "Requirement already satisfied: pydantic-core==2.33.2 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (2.33.2)\n",
+      "Requirement already satisfied: typing-extensions>=4.12.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (4.13.2)\n",
+      "Requirement already satisfied: typing-inspection>=0.4.0 in /opt/homebrew/lib/python3.11/site-packages (from pydantic<3.0,>=2.0.0->medcat~=1.16.0) (0.4.0)\n",
+      "Requirement already satisfied: joblib>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (1.5.0)\n",
+      "Requirement already satisfied: threadpoolctl>=3.1.0 in /opt/homebrew/lib/python3.11/site-packages (from scikit-learn<2.0.0,>=1.1.3->medcat~=1.16.0) (3.6.0)\n",
+      "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.12)\n",
+      "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.5)\n",
+      "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.0.12)\n",
+      "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.11)\n",
+      "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.9)\n",
+      "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (8.2.5)\n",
+      "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.1.3)\n",
+      "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.5.1)\n",
+      "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (2.0.10)\n",
+      "Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.4.1)\n",
+      "Requirement already satisfied: typer<1.0.0,>=0.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.15.3)\n",
+      "Requirement already satisfied: jinja2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.1.6)\n",
+      "Requirement already satisfied: setuptools in /opt/homebrew/lib/python3.11/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (75.8.0)\n",
+      "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.5.0)\n",
+      "Requirement already satisfied: language-data>=1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.3.0)\n",
+      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.4.2)\n",
+      "Requirement already satisfied: idna<4,>=2.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (3.10)\n",
+      "Requirement already satisfied: urllib3<3,>=1.21.1 in /opt/homebrew/lib/python3.11/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.4.0)\n",
+      "Requirement already satisfied: certifi>=2017.4.17 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from requests>=2.32.2->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2025.4.26)\n",
+      "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from thinc<8.3.0,>=8.2.2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.5)\n",
+      "Requirement already satisfied: sympy>=1.13.3 in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.14.0)\n",
+      "Requirement already satisfied: networkx in /opt/homebrew/lib/python3.11/site-packages (from torch<3.0.0,>=2.4.0->medcat~=1.16.0) (3.4.2)\n",
+      "Requirement already satisfied: regex!=2019.12.17 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (2024.11.6)\n",
+      "Requirement already satisfied: tokenizers<0.22,>=0.21 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.21.1)\n",
+      "Requirement already satisfied: safetensors>=0.4.3 in /opt/homebrew/lib/python3.11/site-packages (from transformers<5.0.0,>=4.48.1->medcat~=1.16.0) (0.5.3)\n",
+      "Requirement already satisfied: shellingham>=1.3.0 in /opt/homebrew/lib/python3.11/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.5.4)\n",
+      "Requirement already satisfied: rich>=10.11.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (14.0.0)\n",
+      "Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from weasel<0.5.0,>=0.1.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.21.0)\n",
+      "Requirement already satisfied: wrapt in /opt/homebrew/lib/python3.11/site-packages (from smart-open>=1.8.1->gensim<5.0.0,>=4.3.0->medcat~=1.16.0) (1.17.2)\n",
+      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (2.6.1)\n",
+      "Requirement already satisfied: aiosignal>=1.1.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.3.2)\n",
+      "Requirement already satisfied: attrs>=17.3.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (25.3.0)\n",
+      "Requirement already satisfied: frozenlist>=1.1.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.6.0)\n",
+      "Requirement already satisfied: multidict<7.0,>=4.5 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (6.4.3)\n",
+      "Requirement already satisfied: propcache>=0.2.0 in /opt/homebrew/lib/python3.11/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (0.3.1)\n",
+      "Requirement already satisfied: yarl<2.0,>=1.17.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from aiohttp->datasets<3.0.0,>=2.2.2->medcat~=1.16.0) (1.20.0)\n",
+      "Requirement already satisfied: comm>=0.1.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.2)\n",
+      "Requirement already satisfied: ipython>=6.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (9.2.0)\n",
+      "Requirement already satisfied: traitlets>=4.3.1 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (5.14.3)\n",
+      "Requirement already satisfied: widgetsnbextension~=4.0.14 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (4.0.14)\n",
+      "Requirement already satisfied: jupyterlab_widgets~=3.0.15 in /opt/homebrew/lib/python3.11/site-packages (from ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.15)\n",
+      "Requirement already satisfied: decorator in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (5.2.1)\n",
+      "Requirement already satisfied: ipython-pygments-lexers in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (1.1.1)\n",
+      "Requirement already satisfied: jedi>=0.16 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.19.2)\n",
+      "Requirement already satisfied: matplotlib-inline in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.1.7)\n",
+      "Requirement already satisfied: pexpect>4.3 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (4.9.0)\n",
+      "Requirement already satisfied: prompt_toolkit<3.1.0,>=3.0.41 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.51)\n",
+      "Requirement already satisfied: pygments>=2.4.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.19.1)\n",
+      "Requirement already satisfied: stack_data in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.6.3)\n",
+      "Requirement already satisfied: wcwidth in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from prompt_toolkit<3.1.0,>=3.0.41->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.13)\n",
+      "Requirement already satisfied: parso<0.9.0,>=0.8.4 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from jedi>=0.16->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.8.4)\n",
+      "Requirement already satisfied: marisa-trie>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (1.2.1)\n",
+      "Requirement already satisfied: python-dateutil>=2.8.2 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2.9.0.post0)\n",
+      "Requirement already satisfied: pytz>=2020.1 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)\n",
+      "Requirement already satisfied: tzdata>=2022.7 in /opt/homebrew/lib/python3.11/site-packages (from pandas>=1.4.2->medcat~=1.16.0) (2025.2)\n",
+      "Requirement already satisfied: ptyprocess>=0.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from pexpect>4.3->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.7.0)\n",
+      "Requirement already satisfied: six>=1.5 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from python-dateutil>=2.8.2->pandas>=1.4.2->medcat~=1.16.0) (1.17.0)\n",
+      "Requirement already satisfied: markdown-it-py>=2.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.0)\n",
+      "Requirement already satisfied: mdurl~=0.1 in /opt/homebrew/lib/python3.11/site-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (0.1.2)\n",
+      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /opt/homebrew/lib/python3.11/site-packages (from sympy>=1.13.3->torch<3.0.0,>=2.4.0->medcat~=1.16.0) (1.3.0)\n",
+      "Requirement already satisfied: MarkupSafe>=2.0 in /opt/homebrew/lib/python3.11/site-packages (from jinja2->spacy<4.0.0,>=3.6.0->medcat~=1.16.0) (3.0.2)\n",
+      "Requirement already satisfied: executing>=1.2.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (2.2.0)\n",
+      "Requirement already satisfied: asttokens>=2.1.0 in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (3.0.0)\n",
+      "Requirement already satisfied: pure-eval in /Users/vladd/Library/Python/3.11/lib/python/site-packages (from stack_data->ipython>=6.1.0->ipywidgets>=7.6.5->medcat~=1.16.0) (0.2.3)\n",
+      "\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0m\u001b[33mWARNING: Ignoring invalid distribution ~umpy (/opt/homebrew/lib/python3.11/site-packages)\u001b[0m\u001b[33m\n",
+      "\u001b[0m"
+     ]
+    }
+   ],
+   "source": [
+    "# Install medcat\n",
+    "! pip install medcat~=1.16.0"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "090eade8",
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "--2025-05-19 12:47:32--  https://drive.usercontent.google.com/download?id=1nGI3Igrd7V0fayUAMVafZU9C8GSgEmDS&export=download&confirm=t&uuid=da8b7d44-401a-40f4-8e16-f1adc0ff827f\n",
+      "Resolving drive.usercontent.google.com (drive.usercontent.google.com)... 142.250.200.1\n",
+      "Connecting to drive.usercontent.google.com (drive.usercontent.google.com)|142.250.200.1|:443... connected.\n",
+      "HTTP request sent, awaiting response... "
+     ]
+    }
+   ],
+   "source": [
+    "! wget \"https://drive.usercontent.google.com/download?id=1nGI3Igrd7V0fayUAMVafZU9C8GSgEmDS&export=download&confirm=t&uuid=da8b7d44-401a-40f4-8e16-f1adc0ff827f\" -O part_6_2_ade_relcat_model.zip\n",
+    "! unzip part_6_2_ade_relcat_model.zip -d part_6_2"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "64cb2bf1",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "from medcat.rel_cat import RelCAT"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "f38beaab",
+   "metadata": {},
+   "source": [
+    "
 1. Load the model of your choice. 
"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "d5c03835",
+   "metadata": {},
+   "source": []
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "4453261f",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "import os\n",
+    "try:\n",
+    "    rc_path = \"./part_6_2/ade_relcat_model\"\n",
+    "    relCAT = RelCAT.load(rc_path)\n",
+    "except Exception as e:\n",
+    "    raise ValueError(\n",
+    "        f\"Unable to load RelCAT model from '{rc_path}'. \"\n",
+    "        f\"Exists? {os.path.exists(rc_path)}; isdir? {os.path.isdir(rc_path)} \"\n",
+    "        f\"Stuff in dir: {os.listdir(rc_path) if os.path.isdir(rc_path) else ['NOT A DIR']}\")"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "931a91e7",
+   "metadata": {},
+   "source": [
+    "
 2. Prepare the text for relation extraction. We assume that there are annotations already present. 
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "d223b463",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "docs_with_anns = {\"text\": \"REASON FOR CONSULTATION: , Left hip fracture.,HISTORY OF PRESENT ILLNESS: , The patient is a pleasant 53-year-old female with a known history of sciatica, apparently presented to the emergency room due to severe pain in the left lower extremity and unable to bear weight.  History was obtained from the patient.  As per the history, she reported that she has been having back pain with left leg pain since past 4 weeks.  She has been using a walker for ambulation due to disabling pain in her left thigh and lower back.  She was seen by her primary care physician and was scheduled to go for MRI yesterday.  However, she was walking and her right foot got caught on some type of rug leading to place excessive weight on her left lower extremity to prevent her fall.  Since then, she was unable to ambulate.  The patient called paramedics and was brought to the emergency room.  She denied any history of fall.  She reported that she stepped the wrong way causing the pain to become worse.  She is complaining of severe pain in her lower extremity and back pain.  Denies any tingling or numbness.  Denies any neurological symptoms.  Denies any bowel or bladder incontinence.,X-rays were obtained which were remarkable for left hip fracture.  Orthopedic consultation was called for further evaluation and management.  On further interview with the patient, it is noted that she has a history of malignant melanoma, which was diagnosed approximately 4 to 5 years ago.  She underwent surgery at that time and subsequently, she was noted to have a spread to the lymphatic system and lymph nodes for which she underwent surgery in 3/2008.,PAST MEDICAL HISTORY: , Sciatica and melanoma.,PAST SURGICAL HISTORY:  ,As discussed above, surgery for melanoma and hysterectomy.,ALLERGIES: , NONE.,SOCIAL HISTORY: , Denies any tobacco or alcohol use.  She is divorced with 2 children.  She lives with her son.,PHYSICAL EXAMINATION:,GENERAL:  The patient is well developed, well nourished in mild distress secondary to left lower extremity and back pain.,MUSCULOSKELETAL:  Examination of the left lower extremity, there is presence of apparent shortening and external rotation deformity.  Tenderness to palpation is present.  Leg rolling is positive for severe pain in the left proximal hip.  Further examination of the spine is incomplete secondary to severe leg pain.  She is unable to perform a straight leg raising.  EHL/EDL 5/5.  2+ pulses are present distally.  Calf is soft and nontender.  Homans sign is negative.  Sensation to light touch is intact.,IMAGING:,  AP view of the hip is reviewed.  Only 1 limited view is obtained.  This is a poor quality x-ray with a lot of soft tissue shadow.  This x-ray is significant for basicervical-type femoral neck fracture.  Lesser trochanter is intact.  This is a high intertrochanteric fracture/basicervical.  There is presence of lytic lesion around the femoral neck, which is not well delineated on this particular x-ray.  We need to order repeat x-rays including AP pelvis, femur, and knee.,LABS:,  Have been reviewed.,ASSESSMENT: , The patient is a 53-year-old female with probable pathological fracture of the left proximal femur.,DISCUSSION AND PLAN: , Nature and course of the diagnosis has been discussed with the patient.  Based on her presentation without any history of obvious fall or trauma and past history of malignant melanoma, this appears to be a pathological fracture of the left proximal hip.  At the present time, I would recommend obtaining a bone scan and repeat x-rays, which will include AP pelvis, femur, hip including knee.  She denies any pain elsewhere.  She does have a past history of back pain and sciatica, but at the present time, this appears to be a metastatic bone lesion with pathological fracture.  I have discussed the case with Dr. X and recommended oncology consultation.,With the above fracture and presentation, she needs a left hip hemiarthroplasty versus calcar hemiarthroplasty, cemented type.  Indication, risk, and benefits of left hip hemiarthroplasty has been discussed with the patient, which includes, but not limited to bleeding, infection, nerve injury, blood vessel injury, dislocation early and late, persistent pain, leg length discrepancy, myositis ossificans, intraoperative fracture, prosthetic fracture, need for conversion to total hip replacement surgery, revision surgery, DVT, pulmonary embolism, risk of anesthesia, need for blood transfusion, and cardiac arrest.  She understands above and is willing to undergo further procedure.  The goal and the functional outcome have been explained.  Further plan will be discussed with her once we obtain the bone scan and the radiographic studies.  We will also await for the oncology feedback and clearance.,Thank you very much for allowing me to participate in the care of this patient.  I will continue to follow up.\",\n",
+    "                   \"annotations\": [{\n",
+    "                            \"id\": 1011,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"161432005\",\n",
+    "                            \"value\": \"history of malignant melanoma\",\n",
+    "                            \"start\": 1382,\n",
+    "                            \"end\": 1411,\n",
+    "  \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1012,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"161432005\",\n",
+    "                            \"value\": \"history of malignant melanoma\",\n",
+    "                            \"start\": 3347,\n",
+    "                            \"end\": 3376,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1013,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"52734007\",\n",
+    "                            \"value\": \"total hip replacement surgery\",\n",
+    "                            \"start\": 4323,\n",
+    "                            \"end\": 4352,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1014,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"127287001\",\n",
+    "                            \"value\": \"intertrochanteric fracture\",\n",
+    "                            \"start\": 2802,\n",
+    "                            \"end\": 2828,\n",
+    "   \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1015,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"213270002\",\n",
+    "                            \"value\": \"intraoperative fracture\",\n",
+    "                            \"start\": 4254,\n",
+    "                            \"end\": 4277,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1016,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"446050000\",\n",
+    "                            \"value\": \"primary care physician\",\n",
+    "                            \"start\": 541,\n",
+    "                            \"end\": 563,\n",
+    "           \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1017,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"5913000\",\n",
+    "                            \"value\": \"femoral neck fracture\",\n",
+    "                            \"start\": 2733,\n",
+    "                            \"end\": 2754,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1018,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"268029009\",\n",
+    "                            \"value\": \"pathological fracture\",\n",
+    "                            \"start\": 3120,\n",
+    "                            \"end\": 3141,\n",
+    "  \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1019,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"268029009\",\n",
+    "                            \"value\": \"pathological fracture\",\n",
+    "                            \"start\": 3399,\n",
+    "                            \"end\": 3420,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1020,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"268029009\",\n",
+    "                            \"value\": \"pathological fracture\",\n",
+    "                            \"start\": 3748,\n",
+    "                            \"end\": 3769,\n",
+    "   \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1021,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"32153003\",\n",
+    "                            \"value\": \"left lower extremity\",\n",
+    "                            \"start\": 224,\n",
+    "                            \"end\": 244,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1022,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"32153003\",\n",
+    "                            \"value\": \"left lower extremity\",\n",
+    "                            \"start\": 724,\n",
+    "                            \"end\": 744,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1023,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"165232002\",\n",
+    "                            \"value\": \"bladder incontinence\",\n",
+    "                            \"start\": 1152,\n",
+    "                            \"end\": 1172,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1024,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"5880005\",\n",
+    "                            \"value\": \"PHYSICAL EXAMINATION\",\n",
+    "                            \"start\": 1895,\n",
+    "                            \"end\": 1915,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1025,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"32153003\",\n",
+    "                            \"value\": \"left lower extremity\",\n",
+    "                            \"start\": 2003,\n",
+    "                            \"end\": 2023,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1026,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"32153003\",\n",
+    "                            \"value\": \"left lower extremity\",\n",
+    "                            \"start\": 2076,\n",
+    "                            \"end\": 2096,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1027,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"57662003\",\n",
+    "                            \"value\": \"injury, blood vessel\",\n",
+    "                            \"start\": 4135,\n",
+    "                            \"end\": 4155,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1028,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"44551007\",\n",
+    "                            \"value\": \"myositis ossificans\",\n",
+    "                            \"start\": 4233,\n",
+    "                            \"end\": 4252,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1029,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"59282003\",\n",
+    "                            \"value\": \"pulmonary embolism\",\n",
+    "                            \"start\": 4377,\n",
+    "                            \"end\": 4395,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1030,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"116859006\",\n",
+    "                            \"value\": \"blood transfusion\",\n",
+    "                            \"start\": 4426,\n",
+    "                            \"end\": 4443,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1031,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"224994002\",\n",
+    "                            \"value\": \"excessive weight\",\n",
+    "                            \"start\": 700,\n",
+    "                            \"end\": 716,\n",
+    "\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1032,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"89890002\",\n",
+    "                            \"value\": \"lymphatic system\",\n",
+    "                            \"start\": 1557,\n",
+    "                            \"end\": 1573,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1033,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"261554009\",\n",
+    "                            \"value\": \"revision surgery\",\n",
+    "                            \"start\": 4354,\n",
+    "                            \"end\": 4370,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1034,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"428942009\",\n",
+    "                            \"value\": \"history of fall\",\n",
+    "                            \"start\": 893,\n",
+    "                            \"end\": 908,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1035,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"61685007\",\n",
+    "                            \"value\": \"lower extremity\",\n",
+    "                            \"start\": 1031,\n",
+    "                            \"end\": 1046,\n",
+    "   \n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1036,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"392521001\",\n",
+    "                            \"value\": \"MEDICAL HISTORY\",\n",
+    "                            \"start\": 1638,\n",
+    "                            \"end\": 1653,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1037,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"106028002\",\n",
+    "                            \"value\": \"MUSCULOSKELETAL\",\n",
+    "                            \"start\": 2039,\n",
+    "                            \"end\": 2054,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1038,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"417662000\",\n",
+    "                            \"value\": \"past history of\",\n",
+    "                            \"start\": 3634,\n",
+    "                            \"end\": 3649,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1039,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"225728007\",\n",
+    "                            \"value\": \"emergency room\",\n",
+    "                            \"start\": 183,\n",
+    "                            \"end\": 197,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1040,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"225728007\",\n",
+    "                            \"value\": \"emergency room\",\n",
+    "                            \"start\": 861,\n",
+    "                            \"end\": 875,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1041,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"160476009\",\n",
+    "                            \"value\": \"SOCIAL HISTORY\",\n",
+    "                            \"start\": 1783,\n",
+    "                            \"end\": 1797,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1042,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"248324001\",\n",
+    "                            \"value\": \"well nourished\",\n",
+    "                            \"start\": 1958,\n",
+    "                            \"end\": 1972,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1043,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"244696009\",\n",
+    "                            \"value\": \"proximal femur\",\n",
+    "                            \"start\": 3154,\n",
+    "                            \"end\": 3168,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1044,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"410429000\",\n",
+    "                            \"value\": \"cardiac arrest\",\n",
+    "                            \"start\": 4449,\n",
+    "                            \"end\": 4463,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1045,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"287047008\",\n",
+    "                            \"value\": \"left leg pain\",\n",
+    "                            \"start\": 386,\n",
+    "                            \"end\": 399,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1046,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"161891005\",\n",
+    "                            \"value\": \"and back pain\",\n",
+    "                            \"start\": 1047,\n",
+    "                            \"end\": 1060,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1047,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"26175008\",\n",
+    "                            \"value\": \"approximately\",\n",
+    "                            \"start\": 1433,\n",
+    "                            \"end\": 1446,\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1048,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"161891005\",\n",
+    "                            \"value\": \"and back pain\",\n",
+    "                            \"start\": 2024,\n",
+    "                            \"end\": 2037,\n",
+    "\n",
+    "                            \"acc\": 1.0,\n",
+    "                            \"meta_anns\": {}\n",
+    "                        },\n",
+    "                        {\n",
+    "                            \"id\": 1049,\n",
+    "                            \"user\": \"admin\",\n",
+    "                            \"cui\": \"1199008\",\n",
+    "                            \"value\": \"neurological\",\n",
+    "                            \"start\": 1108,\n",
+    "                            \"end\": 1120\n",
+    "                        }\n",
+    "                        ]}"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "57925b49",
+   "metadata": {},
+   "source": [
+    "
3. Predict relations 
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "94fcce58",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "output_doc_with_relations = relCAT.predict_text_with_anns(text=docs_with_anns[\"text\"], annotations=docs_with_anns[\"annotations\"])"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "ca337881",
+   "metadata": {},
+   "source": [
+    "
4. Examine relations 
"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "2bea7a4d",
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "output_doc_with_relations._.relations"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "id": "cb0a4ea7",
+   "metadata": {},
+   "source": [
+    "Most relations in our case make no sense as we only have two classes that relate to drug and adverse effects and drug-dosage. It is recommended that you apply a TUI/CUI filter to the NER config step first to only focus on relevant concepts."
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "id": "0759b0d3",
+   "metadata": {},
+   "outputs": [],
+   "source": []
+  }
+ ],
+ "metadata": {
+  "kernelspec": {
+   "display_name": "Python 3",
+   "language": "python",
+   "name": "python3"
+  },
+  "language_info": {
+   "codemirror_mode": {
+    "name": "ipython",
+    "version": 3
+   },
+   "file_extension": ".py",
+   "mimetype": "text/x-python",
+   "name": "python",
+   "nbconvert_exporter": "python",
+   "pygments_lexer": "ipython3",
+   "version": "3.11.12"
+  }
+ },
+ "nbformat": 4,
+ "nbformat_minor": 5
+}
diff --git a/notebooks/introductory/data/MedCAT_Export_relation_extraction.json b/notebooks/introductory/data/MedCAT_Export_relation_extraction.json
new file mode 100644
index 0000000..2eec308
--- /dev/null
+++ b/notebooks/introductory/data/MedCAT_Export_relation_extraction.json
@@ -0,0 +1 @@
+{"projects":[{"name":"Example Project - SNOMED CT All","id":2,"cuis":"","project_status":"A","project_locked":false,"documents":[{"id":21,"name":"0-81322","text":"EXAM:,MRI LEFT KNEE WITHOUT CONTRAST,CLINICAL:,This is a 53-year-old female with left knee pain being evaluated for ACL tear.,FINDINGS:,This examination was performed on 10-14-05.,Normal medial meniscus without intrasubstance degeneration, surface fraying or discrete meniscal tear.,There is a discoid lateral meniscus and although there may be minimal superficial fraying along the inner edge of the body, there is no discrete tear (series #6 images #7-12).,There is a near-complete or complete tear of the femoral attachment of the anterior cruciate ligament. The ligament has a balled-up appearance consistent with at least partial retraction of most of the fibers of the ligament. There may be a few fibers still intact (series #4 images #12-14; series #5 images #12-14). The tibial fibers are normal.,Normal posterior cruciate ligament.,There is a sprain of the medial collateral ligament, with mild separation of the deep and superficial fibers at the femoral attachment (series #7 images #6-12). There is no complete tear or discontinuity and there is no meniscocapsular separation.,There is a sprain of the lateral ligament complex without focal tear or discontinuity of any of the intraarticular components.,Normal iliotibial band.,Normal quadriceps and patellar tendons.,There is contusion within the posterolateral corner of the tibia. There is also contusion within the patella at the midline patellar ridge where there is an area of focal chondral flattening (series #8 images #10-13). The medial and lateral patellar facets are otherwise normal as is the femoral trochlea in the there is no patellar subluxation.,There is a mild strain of the vastus medialis oblique muscle extending into the medial patellofemoral ligament and medial patellar retinaculum but there is no complete tear or discontinuity.,Normal lateral patellar retinaculum. There is a joint effusion and plica.,IMPRESSION:, Discoid lateral meniscus without a tear although there may be minimal superficial fraying along the inner edge of the body.  Near-complete if not complete tear of the femoral attachment of the anterior cruciate ligament.  Medial capsule sprain with associated strain of the vastus medialis oblique muscle.  There is focal contusion within the patella at the midline patella ridge. Joint effusion and plica.","last_modified":"2024-03-21 12:33:28.464465","annotations":[{"id":940,"user":"admin","cui":"202099003","value":"discoid lateral meniscus","start":294,"end":318,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.887245","last_modified":"2024-03-21 12:54:09.725742","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":941,"user":"admin","cui":"202099003","value":"Discoid lateral meniscus","start":1905,"end":1929,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.894252","last_modified":"2024-03-21 12:54:16.815702","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":942,"user":"admin","cui":"245928007","value":"patellar retinaculum","start":1749,"end":1769,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.898731","last_modified":"2024-03-21 12:54:16.117101","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":943,"user":"admin","cui":"245928007","value":"patellar retinaculum","start":1833,"end":1853,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.903564","last_modified":"2024-03-21 12:54:16.554192","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":944,"user":"admin","cui":"34411009","value":"lateral ligament","start":1115,"end":1131,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.907755","last_modified":"2024-03-21 12:54:13.015985","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":945,"user":"admin","cui":"18033002","value":"patellar tendons","start":1263,"end":1279,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.911457","last_modified":"2024-03-21 12:54:13.900229","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":946,"user":"admin","cui":"11716007","value":"femoral trochlea","start":1569,"end":1585,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.915777","last_modified":"2024-03-21 12:54:15.250069","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":947,"user":"admin","cui":"7480001","value":"iliotibial band","start":1224,"end":1239,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.920674","last_modified":"2024-03-21 12:54:13.599444","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":948,"user":"admin","cui":"90069004","value":"posterolateral","start":1311,"end":1325,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.925301","last_modified":"2024-03-21 12:54:14.049785","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":949,"user":"admin","cui":"387637008","value":"joint effusion","start":1866,"end":1880,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.929598","last_modified":"2024-03-21 12:54:16.685589","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":950,"user":"admin","cui":"387637008","value":"Joint effusion","start":2286,"end":2300,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.934026","last_modified":"2024-03-21 12:54:18.459770","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":951,"user":"admin","cui":"239720000","value":"meniscal tear","start":268,"end":281,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.938627","last_modified":"2024-03-21 12:54:07.378249","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":952,"user":"admin","cui":"263722006","value":"complete tear","start":487,"end":500,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.942438","last_modified":"2024-03-21 12:54:10.406439","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":953,"user":"admin","cui":"263722006","value":"complete tear","start":1015,"end":1028,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.946925","last_modified":"2024-03-21 12:54:12.724874","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":954,"user":"admin","cui":"263722006","value":"complete tear","start":1786,"end":1799,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.951414","last_modified":"2024-03-21 12:54:16.267250","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":955,"user":"admin","cui":"263722006","value":"complete tear","start":2051,"end":2064,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.956173","last_modified":"2024-03-21 12:54:17.250445","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":956,"user":"admin","cui":"33359002","value":"degeneration","start":226,"end":238,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.959620","last_modified":"2024-03-21 12:53:54.021156","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":957,"user":"admin","cui":"26283006","value":"superficial","start":353,"end":364,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.963439","last_modified":"2024-03-21 12:54:09.840589","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":958,"user":"admin","cui":"26283006","value":"superficial","start":932,"end":943,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.967688","last_modified":"2024-03-21 12:54:12.276253","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":959,"user":"admin","cui":"26396009","value":"subluxation","start":1614,"end":1625,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.972635","last_modified":"2024-03-21 12:54:15.401342","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":960,"user":"admin","cui":"26283006","value":"superficial","start":1975,"end":1986,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.976384","last_modified":"2024-03-21 12:54:16.952231","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":961,"user":"admin","cui":"1431002","value":"attachment","start":516,"end":526,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.980286","last_modified":"2024-03-21 12:54:10.558286","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":962,"user":"admin","cui":"385433004","value":"consistent","start":602,"end":612,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.984803","last_modified":"2024-03-21 12:54:10.692442","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":963,"user":"admin","cui":"37794007","value":"retraction","start":635,"end":645,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.988561","last_modified":"2024-03-21 12:54:10.973770","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":964,"user":"admin","cui":"397406000","value":"collateral","start":874,"end":884,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.991914","last_modified":"2024-03-21 12:54:12.145268","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":965,"user":"admin","cui":"1431002","value":"attachment","start":966,"end":976,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:08.995766","last_modified":"2024-03-21 12:54:12.426715","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":966,"user":"admin","cui":"246093002","value":"components","start":1205,"end":1215,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.000526","last_modified":"2024-03-21 12:54:13.465503","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":967,"user":"admin","cui":"21989003","value":"quadriceps","start":1248,"end":1258,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.004644","last_modified":"2024-03-21 12:54:13.749820","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":968,"user":"admin","cui":"1431002","value":"attachment","start":2080,"end":2090,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.008021","last_modified":"2024-03-21 12:54:17.400256","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":969,"user":"admin","cui":"47429007","value":"associated","start":2154,"end":2164,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.011822","last_modified":"2024-03-21 12:54:17.870739","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":970,"user":"admin","cui":"30989003","value":"knee pain","start":86,"end":95,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.016210","last_modified":"2024-03-21 12:54:22.608262","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":971,"user":"admin","cui":"398166005","value":"performed","start":157,"end":166,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.020390","last_modified":"2024-03-21 12:54:24.352563","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":972,"user":"admin","cui":"66211004","value":"extending","start":1688,"end":1697,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.024007","last_modified":"2024-03-21 12:54:15.699438","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":973,"user":"admin","cui":"263543005","value":"CONTRAST","start":28,"end":36,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.027362","last_modified":"2024-03-21 12:54:22.274480","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":974,"user":"admin","cui":"58147004","value":"CLINICAL","start":37,"end":45,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.031279","last_modified":"2024-03-21 12:54:22.440527","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":975,"user":"admin","cui":"239725005","value":"ACL tear","start":116,"end":124,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.035900","last_modified":"2024-03-21 12:54:22.724976","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":976,"user":"admin","cui":"163121000000106","value":"FINDINGS","start":126,"end":134,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.039910","last_modified":"2024-03-21 12:54:22.975558","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":977,"user":"admin","cui":"263869007","value":"discrete","start":259,"end":267,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.043389","last_modified":"2024-03-21 12:53:57.874497","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":978,"user":"admin","cui":"263869007","value":"discrete","start":419,"end":427,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.046918","last_modified":"2024-03-21 12:54:10.126731","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":979,"user":"admin","cui":"149016008","value":"may be a","start":691,"end":699,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.051499","last_modified":"2024-03-21 12:54:11.124482","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":980,"user":"admin","cui":"264265004","value":"chondral","start":1452,"end":1460,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.055233","last_modified":"2024-03-21 12:54:14.501854","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":981,"user":"admin","cui":"255609007","value":"partial","start":627,"end":634,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.058899","last_modified":"2024-03-21 12:54:10.841722","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":982,"user":"admin","cui":"103360007","value":"complex","start":1132,"end":1139,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.063199","last_modified":"2024-03-21 12:54:13.168582","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":983,"user":"admin","cui":"49370004","value":"lateral","start":1514,"end":1521,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.067437","last_modified":"2024-03-21 12:54:14.953925","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":984,"user":"admin","cui":"21114003","value":"oblique","start":1673,"end":1680,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.071387","last_modified":"2024-03-21 12:54:15.549512","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":985,"user":"admin","cui":"49370004","value":"lateral","start":1825,"end":1832,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.074967","last_modified":"2024-03-21 12:54:16.405230","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":986,"user":"admin","cui":"21114003","value":"oblique","start":2195,"end":2202,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.078350","last_modified":"2024-03-21 12:54:18.002678","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":987,"user":"admin","cui":"255561001","value":"medial","start":187,"end":193,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.083224","last_modified":"2024-03-21 12:54:24.812622","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":988,"user":"admin","cui":"13039001","value":"series","start":434,"end":440,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.087291","last_modified":"2024-03-21 12:54:10.274186","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":989,"user":"admin","cui":"11163003","value":"intact","start":717,"end":723,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.091298","last_modified":"2024-03-21 12:54:11.274459","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":990,"user":"admin","cui":"13039001","value":"series","start":725,"end":731,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.094782","last_modified":"2024-03-21 12:54:11.408124","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":991,"user":"admin","cui":"13039001","value":"series","start":750,"end":756,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.099274","last_modified":"2024-03-21 12:54:11.557206","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":992,"user":"admin","cui":"12611008","value":"tibial","start":780,"end":786,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.103289","last_modified":"2024-03-21 12:54:11.708989","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":993,"user":"admin","cui":"384709000","value":"sprain","start":853,"end":859,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.107056","last_modified":"2024-03-21 12:54:11.858187","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":994,"user":"admin","cui":"255561001","value":"medial","start":867,"end":873,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.110447","last_modified":"2024-03-21 12:54:12.008187","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":995,"user":"admin","cui":"13039001","value":"series","start":978,"end":984,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.115323","last_modified":"2024-03-21 12:54:12.574935","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":996,"user":"admin","cui":"384709000","value":"sprain","start":1101,"end":1107,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.119668","last_modified":"2024-03-21 12:54:12.862159","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":997,"user":"admin","cui":"13039001","value":"series","start":1473,"end":1479,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.123199","last_modified":"2024-03-21 12:54:14.649104","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":998,"user":"admin","cui":"255561001","value":"medial","start":1503,"end":1509,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.126658","last_modified":"2024-03-21 12:54:14.804656","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":999,"user":"admin","cui":"70746003","value":"facets","start":1531,"end":1537,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.130854","last_modified":"2024-03-21 12:54:15.099335","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1000,"user":"admin","cui":"255561001","value":"medial","start":1707,"end":1713,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.135093","last_modified":"2024-03-21 12:54:15.853155","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1001,"user":"admin","cui":"255561001","value":"medial","start":1742,"end":1748,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.139375","last_modified":"2024-03-21 12:54:16.001783","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1002,"user":"admin","cui":"255561001","value":"Medial","start":2127,"end":2133,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.142805","last_modified":"2024-03-21 12:54:17.552066","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1003,"user":"admin","cui":"384709000","value":"sprain","start":2142,"end":2148,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.147204","last_modified":"2024-03-21 12:54:17.699228","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1004,"user":"admin","cui":"260521003","value":"inner","start":383,"end":388,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.151492","last_modified":"2024-03-21 12:54:09.990905","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1005,"user":"admin","cui":"87017008","value":"focal","start":1148,"end":1153,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.155060","last_modified":"2024-03-21 12:54:13.315902","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1006,"user":"admin","cui":"26833005","value":"ridge","start":1414,"end":1419,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.158568","last_modified":"2024-03-21 12:54:14.201695","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1007,"user":"admin","cui":"87017008","value":"focal","start":1446,"end":1451,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.162416","last_modified":"2024-03-21 12:54:14.350554","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1008,"user":"admin","cui":"260521003","value":"inner","start":2005,"end":2010,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.166453","last_modified":"2024-03-21 12:54:17.107780","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1009,"user":"admin","cui":"87017008","value":"focal","start":2221,"end":2226,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.169890","last_modified":"2024-03-21 12:54:18.151276","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1010,"user":"admin","cui":"26833005","value":"ridge","start":2279,"end":2284,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:46:09.173355","last_modified":"2024-03-21 12:54:18.301673","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}}],"relations":[{"start_entity":977,"start_entity_cui":"263869007","start_entity_value":"discrete","start_entity_start_idx":259,"start_entity_end_idx":267,"end_entity":956,"end_entity_cui":"33359002","end_entity_value":"degeneration","end_entity_start_idx":226,"end_entity_end_idx":238,"user":"admin","relation":"disease/disability_procedure","validated":true}]},{"id":22,"name":"1-88811","text":"REASON FOR CONSULTATION: , Left hip fracture.,HISTORY OF PRESENT ILLNESS: , The patient is a pleasant 53-year-old female with a known history of sciatica, apparently presented to the emergency room due to severe pain in the left lower extremity and unable to bear weight.  History was obtained from the patient.  As per the history, she reported that she has been having back pain with left leg pain since past 4 weeks.  She has been using a walker for ambulation due to disabling pain in her left thigh and lower back.  She was seen by her primary care physician and was scheduled to go for MRI yesterday.  However, she was walking and her right foot got caught on some type of rug leading to place excessive weight on her left lower extremity to prevent her fall.  Since then, she was unable to ambulate.  The patient called paramedics and was brought to the emergency room.  She denied any history of fall.  She reported that she stepped the wrong way causing the pain to become worse.  She is complaining of severe pain in her lower extremity and back pain.  Denies any tingling or numbness.  Denies any neurological symptoms.  Denies any bowel or bladder incontinence.,X-rays were obtained which were remarkable for left hip fracture.  Orthopedic consultation was called for further evaluation and management.  On further interview with the patient, it is noted that she has a history of malignant melanoma, which was diagnosed approximately 4 to 5 years ago.  She underwent surgery at that time and subsequently, she was noted to have a spread to the lymphatic system and lymph nodes for which she underwent surgery in 3/2008.,PAST MEDICAL HISTORY: , Sciatica and melanoma.,PAST SURGICAL HISTORY:  ,As discussed above, surgery for melanoma and hysterectomy.,ALLERGIES: , NONE.,SOCIAL HISTORY: , Denies any tobacco or alcohol use.  She is divorced with 2 children.  She lives with her son.,PHYSICAL EXAMINATION:,GENERAL:  The patient is well developed, well nourished in mild distress secondary to left lower extremity and back pain.,MUSCULOSKELETAL:  Examination of the left lower extremity, there is presence of apparent shortening and external rotation deformity.  Tenderness to palpation is present.  Leg rolling is positive for severe pain in the left proximal hip.  Further examination of the spine is incomplete secondary to severe leg pain.  She is unable to perform a straight leg raising.  EHL/EDL 5/5.  2+ pulses are present distally.  Calf is soft and nontender.  Homans sign is negative.  Sensation to light touch is intact.,IMAGING:,  AP view of the hip is reviewed.  Only 1 limited view is obtained.  This is a poor quality x-ray with a lot of soft tissue shadow.  This x-ray is significant for basicervical-type femoral neck fracture.  Lesser trochanter is intact.  This is a high intertrochanteric fracture/basicervical.  There is presence of lytic lesion around the femoral neck, which is not well delineated on this particular x-ray.  We need to order repeat x-rays including AP pelvis, femur, and knee.,LABS:,  Have been reviewed.,ASSESSMENT: , The patient is a 53-year-old female with probable pathological fracture of the left proximal femur.,DISCUSSION AND PLAN: , Nature and course of the diagnosis has been discussed with the patient.  Based on her presentation without any history of obvious fall or trauma and past history of malignant melanoma, this appears to be a pathological fracture of the left proximal hip.  At the present time, I would recommend obtaining a bone scan and repeat x-rays, which will include AP pelvis, femur, hip including knee.  She denies any pain elsewhere.  She does have a past history of back pain and sciatica, but at the present time, this appears to be a metastatic bone lesion with pathological fracture.  I have discussed the case with Dr. X and recommended oncology consultation.,With the above fracture and presentation, she needs a left hip hemiarthroplasty versus calcar hemiarthroplasty, cemented type.  Indication, risk, and benefits of left hip hemiarthroplasty has been discussed with the patient, which includes, but not limited to bleeding, infection, nerve injury, blood vessel injury, dislocation early and late, persistent pain, leg length discrepancy, myositis ossificans, intraoperative fracture, prosthetic fracture, need for conversion to total hip replacement surgery, revision surgery, DVT, pulmonary embolism, risk of anesthesia, need for blood transfusion, and cardiac arrest.  She understands above and is willing to undergo further procedure.  The goal and the functional outcome have been explained.  Further plan will be discussed with her once we obtain the bone scan and the radiographic studies.  We will also await for the oncology feedback and clearance.,Thank you very much for allowing me to participate in the care of this patient.  I will continue to follow up.","last_modified":"2024-03-21 12:33:28.488556","annotations":[{"id":1011,"user":"admin","cui":"161432005","value":"history of malignant melanoma","start":1382,"end":1411,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.954741","last_modified":"2024-03-21 12:55:42.363452","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1012,"user":"admin","cui":"161432005","value":"history of malignant melanoma","start":3347,"end":3376,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.961058","last_modified":"2024-03-21 12:55:52.478126","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1013,"user":"admin","cui":"52734007","value":"total hip replacement surgery","start":4323,"end":4352,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.964688","last_modified":"2024-03-21 12:55:56.825336","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1014,"user":"admin","cui":"127287001","value":"intertrochanteric fracture","start":2802,"end":2828,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.968320","last_modified":"2024-03-21 12:55:49.881776","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1015,"user":"admin","cui":"213270002","value":"intraoperative fracture","start":4254,"end":4277,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.971714","last_modified":"2024-03-21 12:55:56.366960","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1016,"user":"admin","cui":"446050000","value":"primary care physician","start":541,"end":563,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.975035","last_modified":"2024-03-21 12:55:39.347171","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1017,"user":"admin","cui":"5913000","value":"femoral neck fracture","start":2733,"end":2754,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.978817","last_modified":"2024-03-21 12:55:49.546224","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1018,"user":"admin","cui":"268029009","value":"pathological fracture","start":3120,"end":3141,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.982082","last_modified":"2024-03-21 12:55:51.282602","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1019,"user":"admin","cui":"268029009","value":"pathological fracture","start":3399,"end":3420,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.985489","last_modified":"2024-03-21 12:55:52.645645","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1020,"user":"admin","cui":"268029009","value":"pathological fracture","start":3748,"end":3769,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.988919","last_modified":"2024-03-21 12:55:54.548989","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1021,"user":"admin","cui":"32153003","value":"left lower extremity","start":224,"end":244,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.992197","last_modified":"2024-03-21 12:55:38.238308","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1022,"user":"admin","cui":"32153003","value":"left lower extremity","start":724,"end":744,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.995806","last_modified":"2024-03-21 12:55:39.747698","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1023,"user":"admin","cui":"165232002","value":"bladder incontinence","start":1152,"end":1172,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:09.999232","last_modified":"2024-03-21 12:55:41.806866","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1024,"user":"admin","cui":"5880005","value":"PHYSICAL EXAMINATION","start":1895,"end":1915,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.003108","last_modified":"2024-03-21 12:55:45.173783","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1025,"user":"admin","cui":"32153003","value":"left lower extremity","start":2003,"end":2023,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.006535","last_modified":"2024-03-21 12:55:45.902156","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1026,"user":"admin","cui":"32153003","value":"left lower extremity","start":2076,"end":2096,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.010271","last_modified":"2024-03-21 12:55:46.303955","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1027,"user":"admin","cui":"57662003","value":"injury, blood vessel","start":4135,"end":4155,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.013605","last_modified":"2024-03-21 12:55:55.310682","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1028,"user":"admin","cui":"44551007","value":"myositis ossificans","start":4233,"end":4252,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.016979","last_modified":"2024-03-21 12:55:56.252400","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1029,"user":"admin","cui":"59282003","value":"pulmonary embolism","start":4377,"end":4395,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.020525","last_modified":"2024-03-21 12:55:57.127503","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1030,"user":"admin","cui":"116859006","value":"blood transfusion","start":4426,"end":4443,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.023777","last_modified":"2024-03-21 12:55:57.714351","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1031,"user":"admin","cui":"224994002","value":"excessive weight","start":700,"end":716,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.027248","last_modified":"2024-03-21 12:55:39.616282","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1032,"user":"admin","cui":"89890002","value":"lymphatic system","start":1557,"end":1573,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.030538","last_modified":"2024-03-21 12:55:43.111941","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1033,"user":"admin","cui":"261554009","value":"revision surgery","start":4354,"end":4370,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.034040","last_modified":"2024-03-21 12:55:56.977592","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1034,"user":"admin","cui":"428942009","value":"history of fall","start":893,"end":908,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.037434","last_modified":"2024-03-21 12:55:40.609310","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1035,"user":"admin","cui":"61685007","value":"lower extremity","start":1031,"end":1046,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.040696","last_modified":"2024-03-21 12:55:41.064797","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1036,"user":"admin","cui":"392521001","value":"MEDICAL HISTORY","start":1638,"end":1653,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.044223","last_modified":"2024-03-21 12:55:43.399211","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1037,"user":"admin","cui":"106028002","value":"MUSCULOSKELETAL","start":2039,"end":2054,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.047629","last_modified":"2024-03-21 12:55:46.165897","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1038,"user":"admin","cui":"417662000","value":"past history of","start":3634,"end":3649,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.050955","last_modified":"2024-03-21 12:55:53.625927","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1039,"user":"admin","cui":"225728007","value":"emergency room","start":183,"end":197,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.054330","last_modified":"2024-03-21 12:55:36.951663","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1040,"user":"admin","cui":"225728007","value":"emergency room","start":861,"end":875,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.058215","last_modified":"2024-03-21 12:55:40.323486","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1041,"user":"admin","cui":"160476009","value":"SOCIAL HISTORY","start":1783,"end":1797,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.061698","last_modified":"2024-03-21 12:55:44.413399","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1042,"user":"admin","cui":"248324001","value":"well nourished","start":1958,"end":1972,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.065207","last_modified":"2024-03-21 12:55:45.498560","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1043,"user":"admin","cui":"244696009","value":"proximal femur","start":3154,"end":3168,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.068543","last_modified":"2024-03-21 12:55:51.450347","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1044,"user":"admin","cui":"410429000","value":"cardiac arrest","start":4449,"end":4463,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.071929","last_modified":"2024-03-21 12:55:57.868597","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1045,"user":"admin","cui":"287047008","value":"left leg pain","start":386,"end":399,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.075231","last_modified":"2024-03-21 12:55:38.779030","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1046,"user":"admin","cui":"161891005","value":"and back pain","start":1047,"end":1060,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.078909","last_modified":"2024-03-21 12:55:41.201006","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1047,"user":"admin","cui":"26175008","value":"approximately","start":1433,"end":1446,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.082320","last_modified":"2024-03-21 12:55:42.651799","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1048,"user":"admin","cui":"161891005","value":"and back pain","start":2024,"end":2037,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.085703","last_modified":"2024-03-21 12:55:46.066797","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1049,"user":"admin","cui":"1199008","value":"neurological","start":1108,"end":1120,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.089141","last_modified":"2024-03-21 12:55:41.503366","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1050,"user":"admin","cui":"236886002","value":"hysterectomy","start":1750,"end":1762,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.092461","last_modified":"2024-03-21 12:55:44.143161","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1051,"user":"admin","cui":"2603003","value":"secondary to","start":1990,"end":2002,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.095703","last_modified":"2024-03-21 12:55:45.748813","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1052,"user":"admin","cui":"10828004","value":"positive for","start":2225,"end":2237,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.098865","last_modified":"2024-03-21 12:55:47.231737","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1053,"user":"admin","cui":"2603003","value":"secondary to","start":2324,"end":2336,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.102261","last_modified":"2024-03-21 12:55:47.687626","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1054,"user":"admin","cui":"29627003","value":"femoral neck","start":2889,"end":2901,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.105584","last_modified":"2024-03-21 12:55:50.373009","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1055,"user":"admin","cui":"246105001","value":"presentation","start":3279,"end":3291,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.108841","last_modified":"2024-03-21 12:55:52.344676","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1056,"user":"admin","cui":"717351000000103","value":"present time","start":3455,"end":3467,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.112172","last_modified":"2024-03-21 12:55:52.915195","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1057,"user":"admin","cui":"717351000000103","value":"present time","start":3685,"end":3697,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.115315","last_modified":"2024-03-21 12:55:54.094112","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1058,"user":"admin","cui":"246105001","value":"presentation","start":3876,"end":3888,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.118527","last_modified":"2024-03-21 12:55:54.697678","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1059,"user":"admin","cui":"258106000","value":"radiographic","start":4669,"end":4681,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.121868","last_modified":"2024-03-21 12:55:58.945039","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1060,"user":"admin","cui":"76948002","value":"severe pain","start":205,"end":216,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.125137","last_modified":"2024-03-21 12:55:38.090063","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1061,"user":"admin","cui":"76948002","value":"severe pain","start":1012,"end":1023,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.128385","last_modified":"2024-03-21 12:55:40.912311","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1062,"user":"admin","cui":"160573003","value":"alcohol use","start":1823,"end":1834,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.131342","last_modified":"2024-03-21 12:55:44.582822","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1063,"user":"admin","cui":"52101004","value":"presence of","start":2107,"end":2118,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.134640","last_modified":"2024-03-21 12:55:46.453522","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1064,"user":"admin","cui":"76948002","value":"severe pain","start":2238,"end":2249,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.137698","last_modified":"2024-03-21 12:55:47.384464","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1065,"user":"admin","cui":"247311004","value":"light touch","start":2520,"end":2531,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.140618","last_modified":"2024-03-21 12:55:48.764267","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1066,"user":"admin","cui":"386134007","value":"significant","start":2699,"end":2710,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.143665","last_modified":"2024-03-21 12:55:49.392813","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1067,"user":"admin","cui":"52101004","value":"presence of","start":2853,"end":2864,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.147041","last_modified":"2024-03-21 12:55:50.037329","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1068,"user":"admin","cui":"87642003","value":"dislocation","start":4164,"end":4175,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.150030","last_modified":"2024-03-21 12:55:55.475042","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1069,"user":"admin","cui":"110287002","value":"discrepancy","start":4220,"end":4231,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.153222","last_modified":"2024-03-21 12:55:56.099625","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1070,"user":"admin","cui":"66216009","value":"understands","start":4470,"end":4481,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.156135","last_modified":"2024-03-21 12:55:58.033569","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1071,"user":"admin","cui":"224130005","value":"lives with","start":1875,"end":1885,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.159278","last_modified":"2024-03-21 12:55:45.021923","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1072,"user":"admin","cui":"129350004","value":"shortening","start":2128,"end":2138,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.162414","last_modified":"2024-03-21 12:55:46.607237","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1073,"user":"admin","cui":"247348008","value":"Tenderness","start":2173,"end":2183,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.165320","last_modified":"2024-03-21 12:55:46.928828","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1074,"user":"admin","cui":"223482009","value":"DISCUSSION","start":3170,"end":3180,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.168690","last_modified":"2024-03-21 12:55:51.604035","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1075,"user":"admin","cui":"77879006","value":"metastatic","start":3720,"end":3730,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.171733","last_modified":"2024-03-21 12:55:54.245370","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1076,"user":"admin","cui":"31807009","value":"persistent","start":4192,"end":4202,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.174643","last_modified":"2024-03-21 12:55:55.797229","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1077,"user":"admin","cui":"249839000","value":"leg length","start":4209,"end":4219,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.178107","last_modified":"2024-03-21 12:55:55.948159","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1078,"user":"admin","cui":"272148004","value":"conversion","start":4309,"end":4319,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.181148","last_modified":"2024-03-21 12:55:56.674691","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1079,"user":"admin","cui":"33653009","value":"anesthesia","start":4405,"end":4415,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.184348","last_modified":"2024-03-21 12:55:57.429690","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1080,"user":"admin","cui":"40143009","value":"functional","start":4551,"end":4561,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.187474","last_modified":"2024-03-21 12:55:58.489951","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1081,"user":"admin","cui":"246105001","value":"presented","start":166,"end":175,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.190470","last_modified":"2024-03-21 12:56:03.682992","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1082,"user":"admin","cui":"161891005","value":"back pain","start":371,"end":380,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.193647","last_modified":"2024-03-21 12:55:38.642645","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1083,"user":"admin","cui":"723941000000100","value":"interview","start":1327,"end":1336,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.196745","last_modified":"2024-03-21 12:55:42.097455","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1084,"user":"admin","cui":"439401001","value":"diagnosed","start":1423,"end":1432,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.199922","last_modified":"2024-03-21 12:55:42.539081","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1085,"user":"admin","cui":"419076005","value":"ALLERGIES","start":1764,"end":1773,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.203234","last_modified":"2024-03-21 12:55:44.277113","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1086,"user":"admin","cui":"113011001","value":"palpation","start":2187,"end":2196,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.206512","last_modified":"2024-03-21 12:55:47.081732","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1087,"user":"admin","cui":"55919000","value":"including","start":2990,"end":2999,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.209677","last_modified":"2024-03-21 12:55:50.829212","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1088,"user":"admin","cui":"41747008","value":"bone scan","start":3499,"end":3508,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.213204","last_modified":"2024-03-21 12:55:53.069372","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1089,"user":"admin","cui":"55919000","value":"including","start":3569,"end":3578,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.216251","last_modified":"2024-03-21 12:55:53.490362","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1090,"user":"admin","cui":"161891005","value":"back pain","start":3650,"end":3659,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.219398","last_modified":"2024-03-21 12:55:53.778336","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1091,"user":"admin","cui":"40733004","value":"infection","start":4118,"end":4127,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.222530","last_modified":"2024-03-21 12:55:55.155669","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1092,"user":"admin","cui":"71388002","value":"procedure","start":4522,"end":4531,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.225541","last_modified":"2024-03-21 12:55:58.339443","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1093,"user":"admin","cui":"41747008","value":"bone scan","start":4651,"end":4660,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.228590","last_modified":"2024-03-21 12:55:58.791826","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1094,"user":"admin","cui":"260695007","value":"clearance","start":4741,"end":4750,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.231708","last_modified":"2024-03-21 12:55:59.097032","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1095,"user":"admin","cui":"260358002","value":"very much","start":4762,"end":4771,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.234647","last_modified":"2024-03-21 12:55:59.246861","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1096,"user":"admin","cui":"308273005","value":"follow up","start":4852,"end":4861,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.237946","last_modified":"2024-03-21 12:56:00.035649","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1097,"user":"admin","cui":"23056005","value":"sciatica","start":145,"end":153,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.240895","last_modified":"2024-03-21 12:56:03.517373","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1098,"user":"admin","cui":"398092000","value":"obtained","start":285,"end":293,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.244167","last_modified":"2024-03-21 12:55:38.372251","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1099,"user":"admin","cui":"44077006","value":"numbness","start":1086,"end":1094,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.247369","last_modified":"2024-03-21 12:55:41.369851","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1100,"user":"admin","cui":"398092000","value":"obtained","start":1186,"end":1194,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.250312","last_modified":"2024-03-21 12:55:41.942715","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1101,"user":"admin","cui":"23056005","value":"Sciatica","start":1657,"end":1665,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.253506","last_modified":"2024-03-21 12:55:43.549130","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1102,"user":"admin","cui":"2092003","value":"melanoma","start":1670,"end":1678,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.256512","last_modified":"2024-03-21 12:55:43.702524","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1103,"user":"admin","cui":"2092003","value":"melanoma","start":1737,"end":1745,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.259380","last_modified":"2024-03-21 12:55:43.914744","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1104,"user":"admin","cui":"20295000","value":"divorced","start":1844,"end":1852,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.262942","last_modified":"2024-03-21 12:55:44.739134","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1105,"user":"admin","cui":"160499008","value":"children","start":1860,"end":1868,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.265925","last_modified":"2024-03-21 12:55:44.856597","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1106,"user":"admin","cui":"261074009","value":"external","start":2143,"end":2151,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.269178","last_modified":"2024-03-21 12:55:46.774858","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1107,"user":"admin","cui":"40415009","value":"proximal","start":2262,"end":2270,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.272217","last_modified":"2024-03-21 12:55:47.536152","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1108,"user":"admin","cui":"10601006","value":"leg pain","start":2344,"end":2352,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.275110","last_modified":"2024-03-21 12:55:48.007882","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1109,"user":"admin","cui":"260385009","value":"negative","start":2496,"end":2504,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.278321","last_modified":"2024-03-21 12:55:48.613220","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1110,"user":"admin","cui":"398092000","value":"obtained","start":2610,"end":2618,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.281472","last_modified":"2024-03-21 12:55:49.088482","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1111,"user":"admin","cui":"2931005","value":"probable","start":3111,"end":3119,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.284805","last_modified":"2024-03-21 12:55:51.148755","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1112,"user":"admin","cui":"40415009","value":"proximal","start":3433,"end":3441,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.288110","last_modified":"2024-03-21 12:55:52.780751","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1113,"user":"admin","cui":"23056005","value":"sciatica","start":3664,"end":3672,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.291256","last_modified":"2024-03-21 12:55:53.924638","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1114,"user":"admin","cui":"55919000","value":"includes","start":4079,"end":4087,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.295010","last_modified":"2024-03-21 12:55:55.003529","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1115,"user":"admin","cui":"103325001","value":"need for","start":4300,"end":4308,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.298310","last_modified":"2024-03-21 12:55:56.538734","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1116,"user":"admin","cui":"103325001","value":"need for","start":4417,"end":4425,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.301866","last_modified":"2024-03-21 12:55:57.562541","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1117,"user":"admin","cui":"255238004","value":"continue","start":4840,"end":4848,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.305371","last_modified":"2024-03-21 12:55:59.733420","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1118,"user":"admin","cui":"39104002","value":"ILLNESS","start":65,"end":72,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.308823","last_modified":"2024-03-21 12:56:02.998816","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1119,"user":"admin","cui":"116154003","value":"patient","start":80,"end":87,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.312665","last_modified":"2024-03-21 12:56:03.180897","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1120,"user":"admin","cui":"116154003","value":"patient","start":303,"end":310,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.316076","last_modified":"2024-03-21 12:55:38.510359","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1121,"user":"admin","cui":"129006008","value":"walking","start":625,"end":632,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.319567","last_modified":"2024-03-21 12:55:39.464007","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1122,"user":"admin","cui":"116699007","value":"prevent","start":748,"end":755,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.322938","last_modified":"2024-03-21 12:55:39.885595","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1123,"user":"admin","cui":"116154003","value":"patient","start":812,"end":819,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.326365","last_modified":"2024-03-21 12:55:40.037331","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1124,"user":"admin","cui":"68369002","value":"brought","start":846,"end":853,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.329874","last_modified":"2024-03-21 12:55:40.189360","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1125,"user":"admin","cui":"23981006","value":"causing","start":955,"end":962,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.333429","last_modified":"2024-03-21 12:55:40.763274","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1126,"user":"admin","cui":"116154003","value":"patient","start":1346,"end":1353,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.336844","last_modified":"2024-03-21 12:55:42.227521","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1127,"user":"admin","cui":"116154003","value":"patient","start":1931,"end":1938,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.340251","last_modified":"2024-03-21 12:55:45.328785","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1128,"user":"admin","cui":"398166005","value":"perform","start":2372,"end":2379,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.343624","last_modified":"2024-03-21 12:55:48.160076","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1129,"user":"admin","cui":"116154003","value":"patient","start":3074,"end":3081,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.346962","last_modified":"2024-03-21 12:55:50.978229","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1130,"user":"admin","cui":"116154003","value":"patient","start":3256,"end":3263,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.350238","last_modified":"2024-03-21 12:55:52.193153","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1131,"user":"admin","cui":"55919000","value":"include","start":3539,"end":3546,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.353731","last_modified":"2024-03-21 12:55:53.340699","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1132,"user":"admin","cui":"116154003","value":"patient","start":4064,"end":4071,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.357075","last_modified":"2024-03-21 12:55:54.835592","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1133,"user":"admin","cui":"30207005","value":"risk of","start":4397,"end":4404,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.360390","last_modified":"2024-03-21 12:55:57.275999","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1134,"user":"admin","cui":"225466006","value":"willing","start":4495,"end":4502,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.363759","last_modified":"2024-03-21 12:55:58.187194","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1135,"user":"admin","cui":"116154003","value":"patient","start":4823,"end":4830,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.367017","last_modified":"2024-03-21 12:55:59.579610","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1136,"user":"admin","cui":"88952004","value":"REASON","start":0,"end":6,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.370415","last_modified":"2024-03-21 12:56:02.843052","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1137,"user":"admin","cui":"42752001","value":"due to","start":198,"end":204,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.373696","last_modified":"2024-03-21 12:55:37.936895","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1138,"user":"admin","cui":"705406009","value":"walker","start":442,"end":448,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.376995","last_modified":"2024-03-21 12:55:39.065236","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1139,"user":"admin","cui":"42752001","value":"due to","start":464,"end":470,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.380462","last_modified":"2024-03-21 12:55:39.197216","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1140,"user":"admin","cui":"441889009","value":"denied","start":882,"end":888,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.383608","last_modified":"2024-03-21 12:55:40.475925","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1141,"user":"admin","cui":"410677005","value":"spread","start":1543,"end":1549,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.386962","last_modified":"2024-03-21 12:55:42.955388","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1142,"user":"admin","cui":"24484000","value":"severe","start":2337,"end":2343,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.390130","last_modified":"2024-03-21 12:55:47.839329","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1143,"user":"admin","cui":"8499008","value":"pulses","start":2422,"end":2428,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.393538","last_modified":"2024-03-21 12:55:48.442968","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1144,"user":"admin","cui":"11163003","value":"intact","start":2535,"end":2541,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.396863","last_modified":"2024-03-21 12:55:48.932534","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1145,"user":"admin","cui":"85756007","value":"tissue","start":2669,"end":2675,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.400110","last_modified":"2024-03-21 12:55:49.240016","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1146,"user":"admin","cui":"11163003","value":"intact","start":2778,"end":2784,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.403363","last_modified":"2024-03-21 12:55:49.714670","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1147,"user":"admin","cui":"52988006","value":"lesion","start":2871,"end":2877,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.406496","last_modified":"2024-03-21 12:55:50.206541","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1148,"user":"admin","cui":"27582007","value":"repeat","start":2976,"end":2982,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.409813","last_modified":"2024-03-21 12:55:50.694943","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1149,"user":"admin","cui":"246425008","value":"Nature","start":3193,"end":3199,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.412981","last_modified":"2024-03-21 12:55:51.888238","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1150,"user":"admin","cui":"288524001","value":"course","start":3204,"end":3210,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.416043","last_modified":"2024-03-21 12:55:52.043592","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1151,"user":"admin","cui":"27582007","value":"repeat","start":3513,"end":3519,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.419605","last_modified":"2024-03-21 12:55:53.223968","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1152,"user":"admin","cui":"52988006","value":"lesion","start":3736,"end":3742,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.423023","last_modified":"2024-03-21 12:55:54.379681","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1153,"user":"admin","cui":"398092000","value":"obtain","start":4640,"end":4646,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.426681","last_modified":"2024-03-21 12:55:58.642397","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1154,"user":"admin","cui":"36692007","value":"known","start":128,"end":133,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.430158","last_modified":"2024-03-21 12:56:03.346889","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1155,"user":"admin","cui":"258705008","value":"weeks","start":413,"end":418,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.433456","last_modified":"2024-03-21 12:55:38.928075","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1156,"user":"admin","cui":"113276009","value":"bowel","start":1143,"end":1148,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.436824","last_modified":"2024-03-21 12:55:41.656841","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1157,"user":"admin","cui":"258707000","value":"years","start":1454,"end":1459,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.440099","last_modified":"2024-03-21 12:55:42.806259","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1158,"user":"admin","cui":"38000004","value":"lymph","start":1578,"end":1583,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.443495","last_modified":"2024-03-21 12:55:43.264034","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1159,"user":"admin","cui":"732766004","value":"5.  2","start":2415,"end":2420,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.446899","last_modified":"2024-03-21 12:55:48.293097","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1160,"user":"admin","cui":"721963009","value":"order","start":2970,"end":2975,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.450208","last_modified":"2024-03-21 12:55:50.543437","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}},{"id":1161,"user":"admin","cui":"264499004","value":"early","start":4176,"end":4181,"validated":true,"correct":true,"deleted":false,"alternative":false,"killed":false,"irrelevant":false,"create_time":"2024-03-21 12:55:10.453601","last_modified":"2024-03-21 12:55:55.645644","comment":null,"manually_created":false,"acc":1.0,"meta_anns":{}}],"relations":[{"start_entity":1060,"start_entity_cui":"76948002","start_entity_value":"severe pain","start_entity_start_idx":205,"start_entity_end_idx":216,"end_entity":1039,"end_entity_cui":"225728007","end_entity_value":"emergency room","end_entity_start_idx":183,"end_entity_end_idx":197,"user":"admin","relation":"disease/disability_procedure","validated":true},{"start_entity":1021,"start_entity_cui":"32153003","start_entity_value":"left lower extremity","start_entity_start_idx":224,"start_entity_end_idx":244,"end_entity":1039,"end_entity_cui":"225728007","end_entity_value":"emergency room","end_entity_start_idx":183,"end_entity_end_idx":197,"user":"admin","relation":"disease/disability_procedure","validated":true},{"start_entity":1029,"start_entity_cui":"59282003","start_entity_value":"pulmonary embolism","start_entity_start_idx":4377,"start_entity_end_idx":4395,"end_entity":1044,"end_entity_cui":"410429000","end_entity_value":"cardiac arrest","end_entity_start_idx":4449,"end_entity_end_idx":4463,"user":"admin","relation":"non_relation","validated":true}]}]}]}
\ No newline at end of file
diff --git a/notebooks/introductory/data/rel_cat_ADE_V2.tsv b/notebooks/introductory/data/rel_cat_ADE_V2.tsv
new file mode 100755
index 0000000..0a67a93
--- /dev/null
+++ b/notebooks/introductory/data/rel_cat_ADE_V2.tsv
@@ -0,0 +1,7100 @@
+relation_token_span_ids	ent1_ent2_start	ent1	ent2	label	label_id	ent1_type	ent2_type	ent1_id	ent2_id	ent1_cui	ent2_cui	doc_id	text
+	(3, 11)	azithromycin	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	0	Intravenous [s1]azithromycin[e1] induced [s2]ototoxicity[e2] 
+	(20, 40)	dihydrotachysterol	increased calcium-release	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1	Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of [s1]dihydrotachysterol[e1] by rifampicin, could have led to [s2]increased calcium-release[e2] into the circulation.
+	(5, 24)	hypercalcemia	dihydrotachysterol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2	Unaccountable severe [s1]hypercalcemia[e1] in a patient treated for hypoparathyroidism with [s2]dihydrotachysterol[e2] 
+	(7, 15)	pseudoporphyria	naproxen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3	METHODS: We report two cases of [s1]pseudoporphyria[e1] caused by [s2]naproxen[e2] and oxaprozin.
+	(7, 20)	pseudoporphyria	oxaprozin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4	METHODS: We report two cases of [s1]pseudoporphyria[e1] caused by naproxen and [s2]oxaprozin[e2] 
+	(0, 32)	Naproxen	erythropoietic protoporphyria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5	 [s1]Naproxen[e1]  the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating [s2]erythropoietic protoporphyria[e2] in the pediatric population.
+	(10, 47)	naproxen	cutaneous fragility	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6	RESULTS: A 44-year-old man taking [s1]naproxen[e1] for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and [s2]cutaneous fragility[e2] on the face and the back of the hands.
+	(28, 47)	oxaprozin	cutaneous fragility	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	7	RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on [s1]oxaprozin[e1] for rheumatoid arthritis presented with tense bullae and [s2]cutaneous fragility[e2] on the face and the back of the hands.
+	(10, 43)	naproxen	tense bullae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	8	RESULTS: A 44-year-old man taking [s1]naproxen[e1] for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with [s2]tense bullae[e2] and cutaneous fragility on the face and the back of the hands.
+	(28, 43)	oxaprozin	tense bullae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	9	RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on [s1]oxaprozin[e1] for rheumatoid arthritis presented with [s2]tense bullae[e2] and cutaneous fragility on the face and the back of the hands.
+	(12, 24)	clozapine	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	10	BACKGROUND: How to best treat psychotic patients who have had past [s1]clozapine[e1] induced agranulocytosis or [s2]granulocytopenia[e2] remains a problem.
+	(16, 22)	clozapine	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	11	CONCLUSION: The results suggest that olanzapine may be useful in treating patients with [s1]clozapine[e1] induced [s2]granulocytopenia[e2] without the risk of recurrence of hematologic side effects.
+	(2, 12)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	12	Prolonged severe [s1]5-fluorouracil[e1] associated [s2]neurotoxicity[e2] in a patient with dihydropyrimidine dehydrogenase deficiency.
+	(6, 40)	5-FU	neurologic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	13	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and [s2]neurologic toxicity[e2] that required admission to the intensive care unit.
+	(6, 31)	5-FU	prolonged myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	14	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, [s2]prolonged myelosuppression[e2]  and neurologic toxicity that required admission to the intensive care unit.
+	(6, 18)	5-FU	severe mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	15	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered [s2]severe mucositis[e2]  desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.
+	(4, 44)	BH-AC	encephalopathy syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	16	This case suggests that [s1]BH-AC[e1]  a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible [s2]encephalopathy syndrome[e2] 
+	(8, 44)	encephalopathy syndrome	BH-AC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	17	We report a case of reversible [s1]encephalopathy syndrome[e1] in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of [s2]BH-AC[e2] (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.
+	(8, 74)	encephalopathy syndrome	idarubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	18	We report a case of reversible [s1]encephalopathy syndrome[e1] in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and [s2]idarubicin[e2] 
+	(10, 24)	riluzole	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	19	In one case, the readministration of [s1]riluzole[e1] was followed by the relapse of [s2]hepatitis[e2] 
+	(10, 15)	hepatitis	riluzole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	20	We report the cases of two patients who developed acute [s1]hepatitis[e1] after taking [s2]riluzole[e2] at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.
+	(0, 9)	Lupus-like syndrome	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	21	 [s1]Lupus-like syndrome[e1] caused by [s2]5-aminosalicylic acid[e2] in patients with inflammatory bowel disease.
+	(12, 26)	methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	22	Although the two local anesthetics usually do not cause [s1]methemoglobinemia[e1]  we suspect that the displacement of [s2]lidocaine[e2] from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.
+	(0, 14)	Methemoglobinemia	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	23	 [s1]Methemoglobinemia[e1] after axillary block with [s2]bupivacaine[e2] and additional injection of lidocaine in the operative field.
+	(0, 22)	Methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	24	 [s1]Methemoglobinemia[e1] after axillary block with bupivacaine and additional injection of [s2]lidocaine[e2] in the operative field.
+	(19, 34)	methemoglobinemia	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	25	We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant [s1]methemoglobinemia[e1] after an axillary block with [s2]bupivacaine[e2] and additional injection of lidocaine in the operative field.
+	(19, 42)	methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	26	We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant [s1]methemoglobinemia[e1] after an axillary block with bupivacaine and additional injection of [s2]lidocaine[e2] in the operative field.
+	(14, 20)	aspirin	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	27	Detection of activated eosinophils in nasal polyps of an [s1]aspirin[e1] induced [s2]asthma[e2] patient.
+	(6, 22)	encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	28	An episode of subacute [s1]encephalopathy[e1] after the infusion of a moderate dose of [s2]methotrexate[e2] (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.
+	(12, 17)	MTX	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	29	We believe that this represents an unusual case of moderate-dose [s1]MTX[e1] induced [s2]neurotoxicity[e2] in a patient with gastric cancer, which has not previously been reported.
+	(9, 18)	epoprostenol	pulmonary edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	30	We describe a life threatening side effect of acute [s1]epoprostenol[e1] infusion  [s2]pulmonary edema[e2]  in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology.
+	(14, 24)	pruritic bullous eruption	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	31	A 14-year-old girl with newly diagnosed SLE developed a [s1]pruritic bullous eruption[e1] while on [s2]prednisone[e2] 
+	(0, 7)	Hydroxyurea	acute interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	32	 [s1]Hydroxyurea[e1] induced [s2]acute interstitial pneumonitis[e2] in a patient with essential thrombocythemia.
+	(6, 19)	interstitial pneumonitis	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	33	The clinical course suggests that the [s1]interstitial pneumonitis[e1] was induced by [s2]hydroxyurea[e2] 
+	(6, 13)	hydroxyurea	acute interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	34	This is the first case of [s1]hydroxyurea[e1] induced [s2]acute interstitial pneumonitis[e2] reported in the literature.
+	(2, 12)	irritant contact dermatitis	calcipotriol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	35	Allergic and [s1]irritant contact dermatitis[e1] to [s2]calcipotriol[e2] 
+	(0, 28)	Calcipotriol	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	36	 [s1]Calcipotriol[e1] (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas [s2]allergic reactions[e2] are less common.
+	(0, 22)	Calcipotriol	irritation of the skin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	37	 [s1]Calcipotriol[e1] (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause [s2]irritation of the skin[e2]  whereas allergic reactions are less common.
+	(32, 43)	irritant type of reaction	calcipotriol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	38	The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an [s1]irritant type of reaction[e1] after treatment with [s2]calcipotriol[e2] 
+	(0, 18)	Myotonia	pravastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	39	 [s1]Myotonia[e1] associated with sarcoidosis: marked exacerbation with [s2]pravastatin[e2] 
+	(0, 9)	Pravastatin	myotonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	40	 [s1]Pravastatin[e1] is associated with [s2]myotonia[e2] in animals.
+	(9, 21)	pravastatin	myotonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	41	This case suggests that sarcoidosis and [s1]pravastatin[e1]  two entities not frequently associated with [s2]myotonia[e2]  may interact in a synergistic manner to produce severe clinical myotonia in humans.
+	(5, 23)	aspirin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	42	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, urticaria and/or [s2]angioedema[e2]  or a systemic anaphylactoid reaction.
+	(5, 30)	aspirin	systemic anaphylactoid reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	43	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, urticaria and/or angioedema, or a [s2]systemic anaphylactoid reaction[e2] 
+	(5, 17)	aspirin	urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	44	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, [s2]urticaria[e2] and/or angioedema, or a systemic anaphylactoid reaction.
+	(4, 20)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	45	CONCLUSION: Fixed drug [s1]eruption[e1] is associated with many drugs but this is the first such report with [s2]omeprazole[e2] 
+	(2, 9)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	46	Fixed drug [s1]eruption[e1] in hands caused by [s2]omeprazole[e2] 
+	(13, 19)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	47	The objective of this report is to describe a case of fixed drug [s1]eruption[e1] that occurred during [s2]omeprazole[e2] treatment.
+	(27, 59)	diffuse erythema	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	48	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with [s1]diffuse erythema[e1] and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
+	(45, 59)	fever up to 39 degrees C	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	49	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and [s1]fever up to 39 degrees C[e1] one day after the administration of [s2]salazosulfapyridine[e2] 
+	(41, 58)	malaise	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	50	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, [s1]malaise[e1]  and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
+	(32, 59)	pustules	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	51	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and [s1]pustules[e1] on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
+	(0, 15)	Acute generalized exanthematous pustulosis	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	52	 [s1]Acute generalized exanthematous pustulosis[e1] induced by [s2]salazosulfapyridine[e2] in a patient with ulcerative colitis.
+	(5, 24)	acute generalized exanthematous pustulosis	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	53	We report a case of [s1]acute generalized exanthematous pustulosis[e1] (AGEP) induced by [s2]salazosulfapyridine[e2] in a patient with ulcerative colitis.
+	(20, 27)	olanzapine	elevated serum CK concentration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	54	CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with [s1]olanzapine[e1] developed an [s2]elevated serum CK concentration[e2] with a peak concentration of 4000 IU/L (normal < 230).
+	(2, 20)	Olanzapine	muscle injury with concomitant elevations of serum CK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	55	DISCUSSION: [s1]Olanzapine[e1]  like other atypical antipsychotic drugs, may cause [s2]muscle injury with concomitant elevations of serum CK[e2] of muscle origin.
+	(1, 12)	elevation of serum creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	56	Marked [s1]elevation of serum creatine kinase[e1] associated with [s2]olanzapine[e2] therapy.
+	(8, 22)	elevation of serum creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	57	OBJECTIVE: To report a case of marked [s1]elevation of serum creatine kinase[e1] (CK) associated with [s2]olanzapine[e2] therapy.
+	(0, 8)	Diclofenac	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	58	 [s1]Diclofenac[e1] associated [s2]hepatitis[e2] 
+	(17, 26)	hepatitis	diclofenac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	59	This patient, who had a history of osteoarthritis, had severe [s1]hepatitis[e1] 5 weeks after being started on [s2]diclofenac[e2] for increasing pain in the joints.
+	(0, 8)	2-CdA	lymphocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	60	 [s1]2-CdA[e1] induces [s2]lymphocytopenia[e2]  which may explain the improvement in this patient's psoriasis.
+	(3, 10)	priapism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	61	One case of [s1]priapism[e1] occurred during [s2]heparin[e2] therapy for a previous surgical operation to the knee is reported.
+	(0, 10)	Priapism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	62	 [s1]Priapism[e1] as a complication of [s2]heparin[e2] therapy.
+	(3, 16)	heparin	abnormal platelet aggregation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	63	The association between [s1]heparin[e1] and priapism is often recognized; [s2]abnormal platelet aggregation[e2] could play a role in the pathogenesis of this side effect.
+	(3, 9)	heparin	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	64	The association between [s1]heparin[e1] and [s2]priapism[e2] is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.
+	(13, 32)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	65	It carries a well-known risk of neutropenia and [s1]agranulocytosis[e1]  which necessitates the immediate discontinuation of [s2]clozapine[e2] 
+	(8, 33)	neutropenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	66	It carries a well-known risk of [s1]neutropenia[e1] and agranulocytosis, which necessitates the immediate discontinuation of [s2]clozapine[e2] 
+	(13, 28)	clozapine	diurnal variation of the white blood cells	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	67	OBJECTIVE: We report a patient who developed neutropenia on [s1]clozapine[e1]  but behind the cell count decrease showed to be a [s2]diurnal variation of the white blood cells[e2] (WBC).
+	(0, 13)	Acute neutrophilic dermatosis	all-trans-retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	68	 [s1]Acute neutrophilic dermatosis[e1] induced by [s2]all-trans-retinoic acid[e2] treatment for acute promyelocytic leukemia.
+	(16, 26)	hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	69	Findings on discontinuation and rechallenge supported the assumption that the [s1]hair loss[e1] was a side effect of the [s2]paroxetine[e2] 
+	(0, 6)	Hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	70	 [s1]Hair loss[e1] associated with [s2]paroxetine[e2] treatment: a case report.
+	(14, 19)	hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	71	We report on a 37-year-old female who complained of moderate [s1]hair loss[e1] during [s2]paroxetine[e2] treatment.
+	(4, 32)	insulin	protamine allergy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	72	CONCLUSION: Patients with [s1]insulin[e1] allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant [s2]protamine allergy[e2] 
+	(5, 18)	insulin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	73	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, [s2]angioedema[e2]  and occasional wheezing resulting from her insulin dose.
+	(5, 18)	insulin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	74	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, [s2]angioedema[e2]  and occasional wheezing resulting from her insulin dose.
+	(5, 13)	insulin	severe urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	75	METHODS: The patient required [s1]insulin[e1] desensitization for [s2]severe urticaria[e2]  angioedema, and occasional wheezing resulting from her insulin dose.
+	(5, 13)	insulin	severe urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	76	METHODS: The patient required [s1]insulin[e1] desensitization for [s2]severe urticaria[e2]  angioedema, and occasional wheezing resulting from her insulin dose.
+	(5, 25)	insulin	wheezing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	77	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, angioedema, and occasional [s2]wheezing[e2] resulting from her insulin dose.
+	(5, 25)	insulin	wheezing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	78	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, angioedema, and occasional [s2]wheezing[e2] resulting from her insulin dose.
+	(18, 33)	insulin	allergic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	79	OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH [s1]insulin[e1]  as well as standard insulin desensitization, could control [s2]allergic symptoms[e2] in a patient allergic to both NPH and regular insulin.
+	(16, 33)	NPH insulin	allergic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	80	OBJECTIVE: The purpose of this study was to determine whether desensitization to [s1]NPH insulin[e1]  as well as standard insulin desensitization, could control [s2]allergic symptoms[e2] in a patient allergic to both NPH and regular insulin.
+	(2, 24)	neutral protamine Hagedorn (NPH) insulin	protamine hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	81	Patients receiving [s1]neutral protamine Hagedorn (NPH) insulin[e1] are at increased risk for the development of [s2]protamine hypersensitivity[e2] 
+	(0, 12)	Protamine allergy	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	82	 [s1]Protamine allergy[e1] as a complication of [s2]insulin[e2] hypersensitivity: A case report.
+	(5, 20)	insulin	hives	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	83	She continued to receive regular [s1]insulin[e1] 4 times per day over the following 3 years with only occasional [s2]hives[e2] 
+	(11, 41)	angioedema	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	84	The patient had recurrence of urticaria and [s1]angioedema[e1] a year and a half later, at which point the NPH was stopped and she was desensitized to regular [s2]insulin[e2] 
+	(11, 28)	angioedema	NPH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	85	The patient had recurrence of urticaria and [s1]angioedema[e1] a year and a half later, at which point the [s2]NPH[e2] was stopped and she was desensitized to regular insulin.
+	(7, 41)	urticaria	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	86	The patient had recurrence of [s1]urticaria[e1] and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular [s2]insulin[e2] 
+	(7, 28)	urticaria	NPH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	87	The patient had recurrence of [s1]urticaria[e1] and angioedema a year and a half later, at which point the [s2]NPH[e2] was stopped and she was desensitized to regular insulin.
+	(8, 21)	lethargic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	88	A 5-month-old infant became [s1]lethargic[e1] and poorly responsive after receiving 1 drop of [s2]brimonidine[e2] in each eye.
+	(12, 21)	poorly responsive	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	89	A 5-month-old infant became lethargic and [s1]poorly responsive[e1] after receiving 1 drop of [s2]brimonidine[e2] in each eye.
+	(12, 22)	apneic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	90	An 11-day-old infant became lethargic and [s1]apneic[e1] after a single drop of [s2]brimonidine[e2] 
+	(8, 22)	lethargic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	91	An 11-day-old infant became [s1]lethargic[e1] and apneic after a single drop of [s2]brimonidine[e2] 
+	(1, 14)	central nervous system depression	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	92	Apparent [s1]central nervous system depression[e1] in infants after the use of topical [s2]brimonidine[e2] 
+	(3, 13)	brimonidine	central nervous system depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	93	CONCLUSIONS: Topical [s1]brimonidine[e1] may be associated with [s2]central nervous system depression[e2] in infants.
+	(9, 18)	brimonidine	central nervous system depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	94	PURPOSE: To report two cases in which topical [s1]brimonidine[e1] resulted in apparent [s2]central nervous system depression[e2] and unresponsiveness in an infant.
+	(24, 32)	ceftriaxone	elevated hepato-biliary enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	95	Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of [s1]ceftriaxone[e1] with [s2]elevated hepato-biliary enzymes[e2] and transient biliary stasis.
+	(24, 42)	ceftriaxone	transient biliary stasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	96	Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of [s1]ceftriaxone[e1] with elevated hepato-biliary enzymes and [s2]transient biliary stasis[e2] 
+	(0, 12)	Hepato-biliary abnormalities	ceftriaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	97	 [s1]Hepato-biliary abnormalities[e1] secondary to [s2]ceftriaxone[e2] use: a case report.
+	(0, 16)	Anterior lumbosacral radiculopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	98	 [s1]Anterior lumbosacral radiculopathy[e1] after intrathecal [s2]methotrexate[e2] treatment.
+	(6, 16)	progressive paraparesis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	99	Reported are three children who developed [s1]progressive paraparesis[e1] after intrathecal [s2]methotrexate[e2] administration followed by complete or partial recovery.
+	(5, 13)	arsenic trioxide	decrease in the D-dimers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	100	During the first days of [s1]arsenic trioxide[e1] treatment a rapid [s2]decrease in the D-dimers[e2] was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.
+	(5, 34)	arsenic trioxide	slight decrease in peripheral blood leukocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	101	During the first days of [s1]arsenic trioxide[e1] treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a [s2]slight decrease in peripheral blood leukocytes[e2] 
+	(11, 44)	chills	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	102	A 22-year-old black man developed fever, [s1]chills[e1]  fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
+	(14, 44)	fatigue	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	103	A 22-year-old black man developed fever, chills, [s1]fatigue[e1]  night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
+	(9, 44)	fever	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	104	A 22-year-old black man developed [s1]fever[e1]  chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
+	(30, 45)	generalized, pruritic, macular eruption	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	105	A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a [s1]generalized, pruritic, macular eruption[e1] 3 weeks after starting [s2]minocycline[e2] therapy for acne.
+	(16, 44)	night sweats	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	106	A 22-year-old black man developed fever, chills, fatigue, [s1]night sweats[e1]  tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
+	(16, 28)	mononucleosis-like syndrome	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	107	With the negative viral serologies, the clinical picture was most consistent with an infectious [s1]mononucleosis-like syndrome[e1] produced by the [s2]minocycline[e2] ingestion.
+	(12, 32)	5-FU	life-threatening toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	108	We conclude that the presence of this metabolic defect combined with topical [s1]5-FU[e1] (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of [s2]life-threatening toxicity[e2] after treatment with a topical drug.
+	(10, 20)	life-threatening complications	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	109	We now report the first known cancer patient who developed [s1]life-threatening complications[e1] after treatment with topical [s2]5-FU[e2] and was shown subsequently to have profound DPD deficiency.
+	(1, 14)	acute ischaemic event	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	110	An [s1]acute ischaemic event[e1] associated with the use of [s2]venlafaxine[e2]  a case report and proposed pathophysiological mechanisms.
+	(3, 12)	venlafaxine	ischaemic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	111	The association of [s1]venlafaxine[e1] treatment with [s2]ischaemic events[e2] could be explained by its unique pharmacological and haemodynamic properties.
+	(11, 17)	acute cardiovascular event	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	112	This is the first report of a possible association between an [s1]acute cardiovascular event[e1] and [s2]venlafaxine[e2] 
+	(26, 35)	venlafaxine	acute myocardial ischaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	113	We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with [s1]venlafaxine[e1]  and developed [s2]acute myocardial ischaemia[e2] within the first week of treatment.
+	(1, 15)	cyclophosphamide	embryopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	114	Apparent [s1]cyclophosphamide[e1] (cytoxan) [s2]embryopathy[e2]  a distinct phenotype?
+	(15, 31)	CP	embryopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	115	The purpose of this report is to document a new case of in utero [s1]CP[e1] exposure with multiple congenital anomalies and to establish an apparent CP [s2]embryopathy[e2] phenotype.
+	(15, 20)	CP	multiple congenital anomalies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	116	The purpose of this report is to document a new case of in utero [s1]CP[e1] exposure with [s2]multiple congenital anomalies[e2] and to establish an apparent CP embryopathy phenotype.
+	(9, 40)	cyclosposphamide	blepharophimosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	117	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, [s2]blepharophimosis[e2]  flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
+	(9, 33)	cyclosposphamide	craniosynostosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	118	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, [s2]craniosynostosis[e2]  blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
+	(9, 30)	cyclosposphamide	developmental delay	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	119	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, [s2]developmental delay[e2]  craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
+	(9, 55)	cyclosposphamide	distal limb defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	120	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and [s2]distal limb defects[e2] including hypoplastic thumbs and oligodactyly.
+	(9, 47)	cyclosposphamide	flat nasal bridge	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	121	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, [s2]flat nasal bridge[e2]  abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
+	(9, 59)	cyclosposphamide	hypoplastic thumbs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	122	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including [s2]hypoplastic thumbs[e2] and oligodactyly.
+	(9, 65)	cyclosposphamide	oligodactyly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	123	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and [s2]oligodactyly[e2] 
+	(6, 16)	cyclophosphamide	human teratogen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	124	We conclude that (a) [s1]cyclophosphamide[e1] is a [s2]human teratogen[e2]  (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question.
+	(4, 12)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	125	In all cases, [s1]seizures[e1] were controlled by withdrawal of [s2]phenytoin[e2] and reduction of drug levels.
+	(2, 6)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	126	Paradoxical [s1]seizures[e1] in [s2]phenytoin[e2] toxicity.
+	(7, 12)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	127	We present three patients with paradoxical [s1]seizures[e1]  their serum [s2]phenytoin[e2] levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL.
+	(6, 16)	losartan	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	128	CONCLUSIONS: This case suggests that [s1]losartan[e1] can induce late-onset [s2]angioedema[e2] in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.
+	(0, 6)	Losartan	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	129	 [s1]Losartan[e1] induced [s2]angioedema[e2] 
+	(7, 15)	angioedema	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	130	OBJECTIVE: To report a case of [s1]angioedema[e1] associated with [s2]losartan[e2] administration.
+	(3, 11)	angioedema	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	131	The incidence of [s1]angioedema[e1] secondary to [s2]losartan[e2]  an angiotensin II receptor antagonist, is unknown.
+	(15, 26)	hepatic adenomas	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	132	We report the case of a female acromegalic patient in whom multiple [s1]hepatic adenomas[e1] appeared soon after [s2]danazol[e2] treatment for uterine fibromatosis.
+	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	133	 [s1]Heparin[e1] induced [s2]thrombocytopenia[e2] is a rare and serious complication of anticoagulation therapy.
+	(1, 7)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	134	Pediatric [s1]heparin[e1] induced [s2]thrombocytopenia[e2]  management with Danaparoid (orgaran).
+	(30, 36)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	135	There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with [s1]heparin[e1] induced [s2]thrombocytopenia[e2]  especially in children.
+	(6, 20)	heparin	hemorrhagic complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	136	We report the successful treatment of [s1]heparin[e1] induced thrombocytopenia and subsequent [s2]hemorrhagic complications[e2] postoperatively in a 2-year-old child with Danaparoid (orgaran).
+	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	137	We report the successful treatment of [s1]heparin[e1] induced [s2]thrombocytopenia[e2] and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).
+	(0, 5)	Taxane	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	138	 [s1]Taxane[e1] induced [s2]glaucoma[e2] 
+	(5, 13)	glaucoma	doxetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	139	We report a case of [s1]glaucoma[e1] induced by [s2]doxetaxel[e2] therapy for metastatic breast cancer.
+	(1, 10)	hyperphosphatemia	sodium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	140	Acute [s1]hyperphosphatemia[e1] caused by [s2]sodium phosphate[e2] enema in a patient with liver dysfunction and chronic renal failure.
+	(6, 22)	hyperphosphatemia	sodium biphosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	141	We report a case of acute [s1]hyperphosphatemia[e1] secondary to rectal administration of sodium phosphate and [s2]sodium biphosphate[e2] (Fleet enema).
+	(6, 19)	hyperphosphatemia	sodium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	142	We report a case of acute [s1]hyperphosphatemia[e1] secondary to rectal administration of [s2]sodium phosphate[e2] and sodium biphosphate (Fleet enema).
+	(0, 26)	Prolongation of the QT interval	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	143	 [s1]Prolongation of the QT interval[e1] and ventricular tachyarrhymias have been described in patients on [s2]amiodarone[e2] therapy.
+	(9, 26)	ventricular tachyarrhymias	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	144	Prolongation of the QT interval and [s1]ventricular tachyarrhymias[e1] have been described in patients on [s2]amiodarone[e2] therapy.
+	(7, 26)	torsades de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	145	We report a case of recurrent [s1]torsades de pointes[e1] following treatment with pentavalent antimonial drugs and [s2]amiodarone[e2] 
+	(7, 16)	diphenylhydantoin	gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	146	Emphasis is given to the differentiation of [s1]diphenylhydantoin[e1] induced [s2]gingival hyperplasia[e2] from the angiomatous enlargement of the gingiva before any treatment is planned.
+	(15, 34)	anemia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	147	A 66-year-old Japanese woman with severe scleroderma developed [s1]anemia[e1] and thrombocytopenia due to D-penicillamine  [s2]D-Pen[e2]  treatment, although the leukopenia was not markedly severe.
+	(15, 28)	anemia	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	148	A 66-year-old Japanese woman with severe scleroderma developed [s1]anemia[e1] and thrombocytopenia due to [s2]D-penicillamine[e2] (D-Pen) treatment, although the leukopenia was not markedly severe.
+	(18, 34)	thrombocytopenia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	149	A 66-year-old Japanese woman with severe scleroderma developed anemia and [s1]thrombocytopenia[e1] due to D-penicillamine  [s2]D-Pen[e2]  treatment, although the leukopenia was not markedly severe.
+	(18, 28)	thrombocytopenia	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	150	A 66-year-old Japanese woman with severe scleroderma developed anemia and [s1]thrombocytopenia[e1] due to [s2]D-penicillamine[e2] (D-Pen) treatment, although the leukopenia was not markedly severe.
+	(4, 24)	D-Pen	bicytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	151	Cessation of [s1]D-Pen[e1] and the start of corticosteroid therapy were followed by recovery from [s2]bicytopenia[e2] 
+	(2, 21)	inhibition of hematopoiesis	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	152	In vitro [s1]inhibition of hematopoiesis[e1] in a patient with systemic sclerosis treated with [s2]D-penicillamine[e2] 
+	(4, 16)	bicytopenia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	153	These findings suggest that [s1]bicytopenia[e1] in this patient was caused by [s2]D-Pen[e2] and may be due to different sensitivities in the hematopoietic lineage.
+	(17, 24)	methimazole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	154	A 48-year-old woman who was treated for thyrotoxicosis with [s1]methimazole[e1] developed [s2]agranulocytosis[e2] 
+	(3, 27)	hypocalcemic tetany	alendronate sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	155	Postoperative [s1]hypocalcemic tetany[e1] caused by fleet phospho-soda preparation in a patient taking [s2]alendronate sodium[e2]  report of a case.
+	(3, 15)	hypocalcemic tetany	fleet phospho-soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	156	Postoperative [s1]hypocalcemic tetany[e1] caused by [s2]fleet phospho-soda[e2] preparation in a patient taking alendronate sodium: report of a case.
+	(10, 34)	alendronate	hypocalcemic tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	157	This case report describes a patient who was previously prescribed [s1]alendronate[e1] (Fosamax) and presented with postoperative hypophosphatemia and [s2]hypocalcemic tetany[e2] after bowel preparation with Fleet Phospho-Soda.
+	(32, 47)	hypocalcemic tetany	Fleet Phospho-Soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	158	This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and [s1]hypocalcemic tetany[e1] after bowel preparation with [s2]Fleet Phospho-Soda[e2] 
+	(14, 32)	Fosamax	hypocalcemic tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	159	This case report describes a patient who was previously prescribed alendronate  [s1]Fosamax[e1]  and presented with postoperative hypophosphatemia and [s2]hypocalcemic tetany[e2] after bowel preparation with Fleet Phospho-Soda.
+	(10, 27)	alendronate	hypophosphatemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	160	This case report describes a patient who was previously prescribed [s1]alendronate[e1] (Fosamax) and presented with postoperative [s2]hypophosphatemia[e2] and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.
+	(25, 47)	hypophosphatemia	Fleet Phospho-Soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	161	This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative [s1]hypophosphatemia[e1] and hypocalcemic tetany after bowel preparation with [s2]Fleet Phospho-Soda[e2] 
+	(14, 25)	Fosamax	hypophosphatemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	162	This case report describes a patient who was previously prescribed alendronate  [s1]Fosamax[e1]  and presented with postoperative [s2]hypophosphatemia[e2] and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.
+	(7, 33)	thrombotic microangiopathy	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	163	Described here are 2 patients who developed [s1]thrombotic microangiopathy[e1] of the kidneys after receiving high cumulative doses of the new anticancer drug [s2]gemcitabine[e2] 
+	(9, 17)	renal failure	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	164	Thrombotic microangiopathy with [s1]renal failure[e1] in two patients undergoing [s2]gemcitabine[e2] chemotherapy.
+	(0, 17)	Thrombotic microangiopathy	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	165	 [s1]Thrombotic microangiopathy[e1] with renal failure in two patients undergoing [s2]gemcitabine[e2] chemotherapy.
+	(24, 48)	B-cell non-Hodgkin's lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	166	The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom [s1]B-cell non-Hodgkin's lymphoma[e1] was diagnosed 9 months after treatment with [s2]infliximab[e2] 
+	(3, 12)	infliximab	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	167	The relationship between [s1]infliximab[e1] treatment and [s2]lymphoma[e2] in Crohn's disease.
+	(14, 39)	nodular sclerosing Hodgkin's lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	168	The second is a 29-year-old man with CD in whom [s1]nodular sclerosing Hodgkin's lymphoma[e1] was diagnosed 3 weeks after infusion with [s2]infliximab[e2] 
+	(20, 31)	lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	169	We describe the clinical course of 2 patients with Crohn's disease (CD) in whom [s1]lymphoma[e1] was diagnosed after treatment with [s2]infliximab[e2] 
+	(0, 11)	Codeine intoxication	Codeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	170	 [s1]Codeine intoxication[e1] in the neonate [s2]Codeine[e2] intoxication in the neonate.
+	(5, 12)	codeine intoxication	codeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	171	We report a case of [s1]codeine intoxication[e1]  [s2]codeine[e2] intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.
+	(0, 25)	Hydroxyurea	increase fetal hemoglobin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	172	 [s1]Hydroxyurea[e1] (HU) and sodium phenylbutyrate (SPB) have been shown to [s2]increase fetal hemoglobin[e2] (Hb F) levels in patients with thalassemia intermedia.
+	(8, 25)	sodium phenylbutyrate	increase fetal hemoglobin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	173	Hydroxyurea (HU) and [s1]sodium phenylbutyrate[e1] (SPB) have been shown to [s2]increase fetal hemoglobin[e2] (Hb F) levels in patients with thalassemia intermedia.
+	(7, 12)	HU	increase in total Hb	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	174	Of the four patients who responded to [s1]HU[e1] with an [s2]increase in total Hb[e2]  all reported symptomatic improvement and three have not required further transfusions.
+	(8, 35)	HU	hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	175	Prolonged responses were achieved with low doses of [s1]HU[e1] (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or [s2]hepatic toxicity[e2] and no further increases in Hb.
+	(8, 27)	HU	mild reversible hematologic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	176	Prolonged responses were achieved with low doses of [s1]HU[e1] (3-10 mg/kg/day) and higher doses were associated with [s2]mild reversible hematologic[e2] or hepatic toxicity and no further increases in Hb.
+	(12, 30)	HU	increasing Hb F	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	177	Sodium phenylbutyrate was added to treatment with [s1]HU[e1] in two patients, but failed to produce an increase in total Hb despite [s2]increasing Hb F[e2] levels.
+	(0, 30)	Sodium phenylbutyrate	increasing Hb F	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	178	 [s1]Sodium phenylbutyrate[e1] was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite [s2]increasing Hb F[e2] levels.
+	(6, 19)	HU	increase total Hb	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	179	We conclude that low-dose [s1]HU[e1] therapy in patients with thalassemia intermedia may [s2]increase total Hb[e2] levels sufficiently to eliminate the need for transfusions.
+	(9, 33)	increases in total Hb	HU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	180	We describe the clinical response, as determined by [s1]increases in total Hb[e1] and decreased transfusion needs, in five patients with thalassemia intermedia treated with [s2]HU[e2] alone or in combination with SPB.
+	(9, 39)	increases in total Hb	SPB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	181	We describe the clinical response, as determined by [s1]increases in total Hb[e1] and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with [s2]SPB[e2] 
+	(17, 32)	oolong tea	delirious	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	182	A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of [s1]oolong tea[e1] that eventually reached 15 L each day, became [s2]delirious[e2] and was admitted to a psychiatric hospital.
+	(5, 12)	oolong tea	delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	183	After abstinence from [s1]oolong tea[e1] his [s2]delirium[e2] resolved.
+	(17, 25)	caffeine intoxication	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	184	Severe rhabdomyolysis following massive ingestion of oolong tea: [s1]caffeine intoxication[e1]  [s2]caffeine[e2] intoxication with coexisting hyponatremia.
+	(12, 18)	oolong tea	caffeine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	185	Severe rhabdomyolysis following massive ingestion of [s1]oolong tea[e1]  [s2]caffeine intoxication[e2] with coexisting hyponatremia.
+	(1, 19)	rhabdomyolysis	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	186	Severe [s1]rhabdomyolysis[e1] following massive ingestion of oolong tea: [s2]caffeine[e2] intoxication with coexisting hyponatremia.
+	(1, 14)	rhabdomyolysis	oolong tea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	187	Severe [s1]rhabdomyolysis[e1] following massive ingestion of [s2]oolong tea[e2]  caffeine intoxication with coexisting hyponatremia.
+	(5, 33)	caffeine	delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	188	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the [s2]delirium[e2]  although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
+	(5, 39)	caffeine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	189	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe [s2]hyponatremia[e2] has been reported to cause rhabdomyolysis on rare occasions.
+	(5, 24)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	190	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the [s2]rhabdomyolysis[e2] as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
+	(5, 24)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	191	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the [s2]rhabdomyolysis[e2] as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
+	(4, 29)	rhabdomyolysis	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	192	The possibility of severe [s1]rhabdomyolysis[e1] should be considered in a patient with water intoxication due to massive ingestion of [s2]caffeine[e2] containing beverages.
+	(16, 29)	water intoxication	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	193	The possibility of severe rhabdomyolysis should be considered in a patient with [s1]water intoxication[e1] due to massive ingestion of [s2]caffeine[e2] containing beverages.
+	(7, 13)	caffeine toxicity	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	194	We hypothesize that [s1]caffeine toxicity[e1]  [s2]caffeine[e2] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
+	(7, 31)	caffeine	coexisting hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	195	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the [s2]coexisting hyponatremia[e2]  to result in unusually severe rhabdomyolysis.
+	(7, 13)	caffeine	injured the muscle cells	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	196	We hypothesize that [s1]caffeine[e1] toxicity [s2]injured the muscle cells[e2]  which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
+	(7, 24)	caffeine	potassium depletion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	197	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the [s2]potassium depletion[e2] induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
+	(7, 46)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	198	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe [s2]rhabdomyolysis[e2] 
+	(4, 23)	citalopram	8-hydroacy-desmethylclomipramine plasma level decrease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	199	After the addition of [s1]citalopram[e1]  a desmethylclomipramine plasma level increase and an [s2]8-hydroacy-desmethylclomipramine plasma level decrease[e2] were observed.
+	(4, 11)	citalopram	desmethylclomipramine plasma level increase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	200	After the addition of [s1]citalopram[e1]  a [s2]desmethylclomipramine plasma level increase[e2] and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.
+	(16, 38)	angiolipomas	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	201	We report 3 cases of HIV-1 infected patients who experienced symptomatic [s1]angiolipomas[e1] shortly after starting antiretroviral therapy including the protease inhibitor [s2]indinavir[e2] 
+	(0, 9)	Elevated serum triglycerides	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	202	 [s1]Elevated serum triglycerides[e1] with [s2]clozapine[e2] resolved with risperidone in four patients.
+	(3, 18)	clozapine	serum triglyceride levels increased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	203	In two patients [s1]clozapine[e1] was reinstated after risperidone was discontinued; [s2]serum triglyceride levels increased[e2] 
+	(3, 25)	clozapine	elevated serum triglyceride levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	204	This increase when [s1]clozapine[e1] was switched to risperidone and vice versa is consistent with our previous report of [s2]elevated serum triglyceride levels[e2] in clozapine-treated patients.
+	(3, 11)	valproate	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	205	Intravenous [s1]valproate[e1] associated with significant [s2]hypotension[e2] in the treatment of status epilepticus.
+	(11, 23)	hypotension	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	206	To our knowledge, this is the first report of significant [s1]hypotension[e1] associated with intravenous [s2]valproate[e2] in the treatment of status epilepticus in the pediatric population.
+	(6, 18)	hypotension	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	207	We report a case of severe [s1]hypotension[e1] associated with intravenous [s2]valproate[e2] used to treat status epilepticus in an 11-year-old girl.
+	(4, 11)	rippling phenomena worsened	pyridostigmine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	208	In both patients the [s1]rippling phenomena worsened[e1] with [s2]pyridostigmine[e2] treatment but markedly improved after immunosuppression with azathioprine.
+	(4, 11)	theophylline poisoning	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	209	A diagnosis of masked [s1]theophylline poisoning[e1]  [s2]theophylline[e2] poisoning should be considered in similar situations involving a rapid decrease of insulin requirements.
+	(4, 13)	intoxication	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	210	Salicylate [s1]intoxication[e1] was excluded, and [s2]theophylline[e2] was finally incriminated.
+	(0, 22)	Theophylline intoxication	Theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	211	 [s1]Theophylline intoxication[e1] mimicking diabetic ketoacidosis in a child [s2]Theophylline[e2] intoxication mimicking diabetic ketoacidosis in a child.
+	(16, 23)	theophylline poisoning	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	212	This compound, used by adults in the child's home, had caused accidental [s1]theophylline poisoning[e1]  [s2]theophylline[e2] poisoning, mimicking diabetic ketoacidosis.
+	(9, 22)	ifosfamide-induced encephalopathy	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	213	Methylene blue in the treatment and prevention of [s1]ifosfamide-induced encephalopathy[e1]  [s2]ifosfamide[e2] induced encephalopathy: report of 12 cases and a review of the literature.
+	(8, 16)	ifosfamide	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	214	Ten to 15% of patients treated with [s1]ifosfamide[e1] develop an [s2]encephalopathy[e2] 
+	(9, 22)	ifosfamide-induced encephalopathy	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	215	We conclude that MB is an effective treatment for [s1]ifosfamide-induced encephalopathy[e1]  [s2]ifosfamide[e2] induced encephalopathy.
+	(0, 33)	Portal vein thrombosis	F VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	216	 [s1]Portal vein thrombosis[e1] in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of [s2]F VIII[e2] after intramural jejunal bleeding--successful thrombolysis under heparin therapy.
+	(21, 34)	portal vein thrombosis	F VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	217	We report on a 14-year-old boy with severe haemophilia A who developed a [s1]portal vein thrombosis[e1] during continuous infusion of [s2]F VIII[e2] 
+	(18, 33)	acute icteric hepatitis-like illness	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	218	A 60-year-old woman with diabetes mellitus (type 2) developed an [s1]acute icteric hepatitis-like illness[e1] 6 weeks after the initiation of [s2]gliclazide[e2] therapy.
+	(0, 8)	Gliclazide	acute hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	219	 [s1]Gliclazide[e1] induced [s2]acute hepatitis[e2] 
+	(8, 17)	gliclazide	acute icteric liver necro-inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	220	In conclusion, this case strongly suggests that [s1]gliclazide[e1] can induce [s2]acute icteric liver necro-inflammation[e2] which may be misdiagnosed clinically as acute viral hepatitis.
+	(9, 23)	acute hepatitis	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	221	We believe that this is the first description of [s1]acute hepatitis[e1] caused by an idiosyncratic adverse reaction to [s2]gliclazide[e2] or to one of its metabolites.
+	(5, 11)	acute hepatitis	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	222	We describe the case of [s1]acute hepatitis[e1] induced by [s2]gliclazide[e2]  a second generation sulfonylurea.
+	(13, 23)	TCA	Cushing's syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	223	Caution is, therefore, needed to prevent undesired accumulation of [s1]TCA[e1] that may lead to protracted [s2]Cushing's syndrome[e2] 
+	(0, 13)	Cushing's syndrome	TCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	224	 [s1]Cushing's syndrome[e1] persisted more than 6 months while [s2]TCA[e2] concentrations remained detectable for at least 80 days.
+	(8, 14)	TCA	Cushing's syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	225	The presented patient was treated with 200 mg [s1]TCA[e1] and developed [s2]Cushing's syndrome[e2] 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).
+	(6, 18)	abnormal computed tomographic scans	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	226	Both had impaired lung function and [s1]abnormal computed tomographic scans[e1]  and their condition improved when [s2]nitrofurantoin[e2] was withdrawn and corticosteroid treatment commenced.
+	(2, 19)	impaired lung function	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	227	Both had [s1]impaired lung function[e1] and abnormal computed tomographic scans, and their condition improved when [s2]nitrofurantoin[e2] was withdrawn and corticosteroid treatment commenced.
+	(0, 17)	Bronchiolitis obliterans organising pneumonia	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	228	 [s1]Bronchiolitis obliterans organising pneumonia[e1] associated with the use of [s2]nitrofurantoin[e2] 
+	(17, 40)	nitrofurantoin	BOOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	229	The case histories are presented of two patients who developed lung disease associated with the use of [s1]nitrofurantoin[e1] with histological features of bronchiolitis obliterans organising pneumonia  [s2]BOOP[e2] , a rare but recognised form of drug induced injury.
+	(17, 30)	nitrofurantoin	bronchiolitis obliterans organising pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	230	The case histories are presented of two patients who developed lung disease associated with the use of [s1]nitrofurantoin[e1] with histological features of [s2]bronchiolitis obliterans organising pneumonia[e2] (BOOP), a rare but recognised form of drug induced injury.
+	(10, 19)	lung disease	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	231	The case histories are presented of two patients who developed [s1]lung disease[e1] associated with the use of [s2]nitrofurantoin[e2] with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.
+	(10, 21)	fatal outcome	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	232	The favourable outcome in these two patients contrasts with the [s1]fatal outcome[e1] of the two other reported cases of [s2]nitrofurantoin[e2] induced BOOP.
+	(19, 29)	nitrofurantoin induced BOOP	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	233	The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of [s1]nitrofurantoin induced BOOP[e1]  [s2]nitrofurantoin[e2] induced BOOP.
+	(3, 10)	nitrofurantoin	lung injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	234	The spectrum of [s1]nitrofurantoin[e1]  [s2]lung injury[e2] continues to widen.
+	(7, 15)	respiratory symptoms	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	235	The two middle aged women presented with [s1]respiratory symptoms[e1] after prolonged treatment with [s2]nitrofurantoin[e2] 
+	(7, 17)	nitrofurantoin induced lung injury	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	236	"We suggest that the previous classification of [s1]nitrofurantoin induced lung injury[e1]  [s2]nitrofurantoin[e2] induced lung injury into ""acute"" and ""chronic"" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged."
+	(16, 24)	akathisia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	237	Intravenous administration of levodopa ameliorated a refractory [s1]akathisia[e1] case induced by [s2]interferon-alpha[e2] 
+	(11, 17)	akathisia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	238	The present report illustrates a rare case of refractory [s1]akathisia[e1] after [s2]interferon-alpha[e2] treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.
+	(15, 39)	interferon-alpha	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	239	The present report illustrates a rare case of refractory akathisia after [s1]interferon-alpha[e1] treatment and also that levodopa treatment would be theoretically and practically useful in reducing the [s2]neurotoxicity[e2] associated with interferon-alpha.
+	(0, 9)	Acute erythroid leukemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	240	 [s1]Acute erythroid leukemia[e1] after [s2]cyclophosphamide[e2] therapy for multiple myeloma: report of two cases.
+	(9, 25)	carcinoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	241	The development of erythroid leukemia plus [s1]carcinoma[e1] in these two men suggests mutagenic change secondary to [s2]cyclophosphamide[e2] therapy.
+	(0, 18)	Scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	242	 [s1]Scleroderma-like reaction[e1] induced by uracil-tegafur  [s2]UFT[e2] , a second-generation anticancer agent.
+	(0, 11)	Scleroderma-like reaction	uracil-tegafur	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	243	 [s1]Scleroderma-like reaction[e1] induced by [s2]uracil-tegafur[e2] (UFT), a second-generation anticancer agent.
+	(6, 19)	UFT-induced scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	244	This is the first report of [s1]UFT-induced scleroderma-like reaction[e1]  [s2]UFT[e2] induced scleroderma-like reaction.
+	(6, 22)	scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	245	We report a case of a [s1]scleroderma-like reaction[e1] induced by long-term administration of [s2]UFT[e2] 
+	(0, 9)	Central nervous system manifestations	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	246	 [s1]Central nervous system manifestations[e1] of an [s2]ibuprofen[e2] overdose reversed by naloxone.
+	(0, 14)	Ibuprofen	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	247	 [s1]Ibuprofen[e1] overdose is usually characterized by GI upset, [s2]dizziness[e2]  and mild sedation.
+	(0, 11)	Ibuprofen	GI upset	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	248	 [s1]Ibuprofen[e1] overdose is usually characterized by [s2]GI upset[e2]  dizziness, and mild sedation.
+	(0, 18)	Ibuprofen	mild sedation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	249	 [s1]Ibuprofen[e1] overdose is usually characterized by GI upset, dizziness, and [s2]mild sedation[e2] 
+	(5, 14)	ibuprofen intoxication	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	250	Presently, treatment of acute [s1]ibuprofen intoxication[e1]  [s2]ibuprofen[e2] intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours.
+	(15, 26)	depressed level of consciousness	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	251	We report the case of an 11-month-old female infant with a [s1]depressed level of consciousness[e1] after ingestion of [s2]ibuprofen[e2] whose mental status markedly improved with administration of naloxone.
+	(0, 13)	Flecainide	acute respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	252	 [s1]Flecainide[e1] associated pneumonitis with [s2]acute respiratory failure[e2] in a patient with the LEOPARD syndrome.
+	(0, 7)	Flecainide	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	253	 [s1]Flecainide[e1] associated [s2]pneumonitis[e2] with acute respiratory failure in a patient with the LEOPARD syndrome.
+	(0, 11)	Flecainide	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	254	 [s1]Flecainide[e1] is a rare cause of [s2]hypersensitivity pneumonitis[e2]  and few cases have been reported.
+	(5, 24)	interstitial hypoxaemiant pneumonitis	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	255	We describe a case of [s1]interstitial hypoxaemiant pneumonitis[e1] probably related to [s2]flecainide[e2] in a patient with the LEOPARD syndrome, a rare congenital disorder.
+	(0, 19)	Sagittal sinus thrombosis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	256	 [s1]Sagittal sinus thrombosis[e1] associated with transient free protein S deficiency after [s2]L-asparaginase[e2] treatment: case report and review of the literature.
+	(11, 19)	transient free protein S deficiency	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	257	Sagittal sinus thrombosis associated with [s1]transient free protein S deficiency[e1] after [s2]L-asparaginase[e2] treatment: case report and review of the literature.
+	(28, 35)	seizure	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	258	We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a [s1]seizure[e1] during consolidation treatment with [s2]L-asparaginase[e2] 
+	(20, 35)	transient ischemic attacks	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	259	We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated [s1]transient ischemic attacks[e1] followed by a seizure during consolidation treatment with [s2]L-asparaginase[e2] 
+	(7, 22)	benign intracranial hypertension	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	260	We report on a young adolescent with [s1]benign intracranial hypertension[e1] which we attribute to the use of [s2]minocycline[e2] for acne.
+	(6, 15)	polyarteritis nodosa	vaccination against hepatitis B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	261	We report 2 patients who developed [s1]polyarteritis nodosa[e1] following [s2]vaccination against hepatitis B[e2] 
+	(23, 37)	methotrexate	lung cancer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	262	In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose [s1]methotrexate[e1] therapy might have promoted the development of [s2]lung cancer[e2] 
+	(39, 43)	cocaine	refractory coronary vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	263	This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with [s1]cocaine[e1] induced [s2]refractory coronary vasospasm[e2] 
+	(16, 23)	troglitazone	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	264	However, as illustrated by these and other cases reported to date, the onset of [s1]troglitazone[e1] induced [s2]liver injury[e2] is insidious and temporally variable.
+	(7, 17)	hepatotoxicity	troglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	265	It remains to be seen whether the [s1]hepatotoxicity[e1] associated with [s2]troglitazone[e2] is a drug-class effect or specific to troglitazone.
+	(7, 17)	hepatotoxicity	troglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	266	It remains to be seen whether the [s1]hepatotoxicity[e1] associated with [s2]troglitazone[e2] is a drug-class effect or specific to troglitazone.
+	(21, 29)	troglitazone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	267	Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of [s1]troglitazone[e1] without significant [s2]hepatotoxicity[e2] 
+	(6, 27)	troglitazone	irreversible liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	268	The three reported cases demonstrate that [s1]troglitazone[e1] is an idiosyncratic hepatotoxin that can lead to [s2]irreversible liver injury[e2] 
+	(0, 7)	Troglitazone	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	269	 [s1]Troglitazone[e1] induced [s2]fulminant hepatic failure[e2] 
+	(0, 8)	Nitrofurantoin	lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	270	 [s1]Nitrofurantoin[e1] induced [s2]lung disease[e2]  two cases demonstrating resolution of apparently irreversible CT abnormalities.
+	(5, 30)	nitrofurantoin	distortion of the lung parenchyma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	271	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated [s2]distortion of the lung parenchyma[e2]  thought to represent established fibrosis.
+	(5, 43)	nitrofurantoin	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	272	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established [s2]fibrosis[e2] 
+	(5, 13)	nitrofurantoin	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	273	We present two cases of [s1]nitrofurantoin[e1] induced [s2]pulmonary toxicity[e2] in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.
+	(5, 23)	nitrofurantoin	widespread reticular pattern	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	274	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a [s2]widespread reticular pattern[e2] and associated distortion of the lung parenchyma, thought to represent established fibrosis.
+	(0, 7)	Fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	275	 [s1]Fluoxetine[e1] related [s2]death[e2] in a child with cytochrome P-450 2D6 genetic deficiency.
+	(7, 12)	death	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	276	The medical examiner's report indicated [s1]death[e1] caused by [s2]fluoxetine[e2] toxicity.
+	(10, 17)	fluoxetine toxicity	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	277	The medical examiner's report indicated death caused by [s1]fluoxetine toxicity[e1]  [s2]fluoxetine[e2] toxicity.
+	(7, 14)	fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	278	This is the first report of a [s1]fluoxetine[e1] related [s2]death[e2] in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.
+	(28, 38)	spinal cord lesion	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	279	A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a [s1]spinal cord lesion[e1] following the use of [s2]zolmitriptan[e2] 
+	(0, 10)	Spinal cord infarction	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	280	 [s1]Spinal cord infarction[e1] during use of [s2]zolmitriptan[e2]  a case report.
+	(6, 20)	spinal cord infarction	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	281	The temporal relationship suggests that the [s1]spinal cord infarction[e1] may be related to the use of [s2]zolmitriptan[e2] 
+	(19, 27)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	282	CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a [s1]hypersensitivity[e1] reaction to [s2]carboplatin[e2] after nine courses.
+	(11, 19)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	283	This regimen could prove useful for other patients who develop [s1]hypersensitivity[e1] reactions to [s2]carboplatin[e2] and allow therapy to continue.
+	(9, 19)	renal insufficiency	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	284	Perinatal vasoconstrictive [s1]renal insufficiency[e1] associated with maternal [s2]nimesulide[e2] use.
+	(7, 21)	adverse effect of fetal renal circulation	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	285	This is the first report of an [s1]adverse effect of fetal renal circulation[e1] by maternal ingestion of [s2]nimesulide[e2] 
+	(2, 11)	t-AML	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	286	Although the [s1]t-AML[e1] developed following oral [s2]etoposide[e2] therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.
+	(0, 16)	Secondary leukemia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	287	 [s1]Secondary leukemia[e1] in a child with neuroblastoma while on oral [s2]etoposide[e2]  what is the cause?
+	(6, 31)	t-AML	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	288	The authors present a case of [s1]t-AML[e1] that developed in a child with metastatic neuroblastoma 18 months after he received oral [s2]etoposide[e2]  given for palliation purpose.
+	(2, 24)	Cyanamide	hepatic lesion with ground-glass inclusion bodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	289	BACKGROUND: [s1]Cyanamide[e1]  an aversive agent widely used in Japan, is known to induce various degrees of [s2]hepatic lesion with ground-glass inclusion bodies[e2] 
+	(17, 29)	cyanamide	general fatigue	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	290	Case 2: A 43-year-old male alcoholic remained completely abstinent with [s1]cyanamide[e1] treatment for 5 years and complained of [s2]general fatigue[e2] 
+	(14, 31)	fatigue	cyanamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	291	Case 3: A 29-year-old female alcoholic complained of general [s1]fatigue[e1] and a slight fever after 1.5 years of abstinence with [s2]cyanamide[e2] treatment.
+	(18, 31)	fever	cyanamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	292	Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight [s1]fever[e1] after 1.5 years of abstinence with [s2]cyanamide[e2] treatment.
+	(19, 29)	cyanamide	elevation of serum transaminases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	293	Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking [s1]cyanamide[e1] for 3 years showed slight [s2]elevation of serum transaminases[e2] 
+	(9, 33)	cyanamide	ground-glass hepatocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	294	CONCLUSION: In some abstainers who take [s1]cyanamide[e1] for several years, thin septum-like liver fibrosis progresses along with the emergence of [s2]ground-glass hepatocytes[e2] 
+	(9, 19)	cyanamide	septum-like liver fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	295	CONCLUSION: In some abstainers who take [s1]cyanamide[e1] for several years, thin [s2]septum-like liver fibrosis[e2] progresses along with the emergence of ground-glass hepatocytes.
+	(0, 6)	Cyanamide	liver dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	296	 [s1]Cyanamide[e1] induced [s2]liver dysfunction[e2] after abstinence in alcoholics: a long-term follow-up study on four cases.
+	(1, 17)	cyanamide	inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	297	When [s1]cyanamide[e1] treated alcoholics relapse into drinking, more severe [s2]inflammation[e2] develops in the liver.
+	(14, 23)	tacrolimus	sudden cutaneous reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	298	A patient with an allergy to a macrolide antibiotic was given [s1]tacrolimus[e1] and developed a [s2]sudden cutaneous reaction[e2] 
+	(17, 35)	nonconvulsive status epilepticus	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	299	A 77-year-old woman with no history of epilepsy presented a probable [s1]nonconvulsive status epilepticus[e1] while receiving continuous intravenous [s2]morphine[e2] for back pain relating to vertebral metastasis of a malignant lymphoma.
+	(1, 20)	generalized tonic-clonic seizure	naloxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	300	A [s1]generalized tonic-clonic seizure[e1] occurred a few minutes after injection of the morphine antagonist [s2]naloxone[e2] 
+	(0, 15)	Nonconvulsive status epilepticus	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	301	 [s1]Nonconvulsive status epilepticus[e1]  the role of [s2]morphine[e2] and its antagonist.
+	(1, 13)	bacterial peritonitis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	302	Spontaneous [s1]bacterial peritonitis[e1] induced by intraarterial [s2]vasopressin[e2] therapy.
+	(7, 60)	risperidone	EPS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	303	Although the literature on the use of [s1]risperidone[e1] in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms  [s2]EPS[e2] .
+	(7, 55)	risperidone	extrapyramidal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	304	Although the literature on the use of [s1]risperidone[e1] in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of [s2]extrapyramidal symptoms[e2] (EPS).
+	(8, 31)	multiple abscesses	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	305	Three months following splenectomy, [s1]multiple abscesses[e1] occurred in the muscles of both thighs while the patient was receiving the third course of the [s2]CHOP[e2] regimen.
+	(16, 42)	ethambutol	anti-native DNA antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	306	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, rash and hepatitis in association with [s2]anti-native DNA antibodies[e2] and positive antinuclear factor.
+	(16, 38)	ethambutol	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	307	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, rash and [s2]hepatitis[e2] in association with anti-native DNA antibodies and positive antinuclear factor.
+	(16, 31)	ethambutol	polyarthritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	308	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed [s2]polyarthritis[e2]  rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.
+	(16, 36)	ethambutol	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	309	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, [s2]rash[e2] and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.
+	(7, 17)	anti-native DNA antibodies	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	310	Polyarthritis, hepatitis and [s1]anti-native DNA antibodies[e1] after treatment with [s2]ethambutol[e2] and rifampicin.
+	(7, 23)	anti-native DNA antibodies	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	311	Polyarthritis, hepatitis and [s1]anti-native DNA antibodies[e1] after treatment with ethambutol and [s2]rifampicin[e2] 
+	(5, 17)	hepatitis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	312	Polyarthritis, [s1]hepatitis[e1] and anti-native DNA antibodies after treatment with [s2]ethambutol[e2] and rifampicin.
+	(5, 23)	hepatitis	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	313	Polyarthritis, [s1]hepatitis[e1] and anti-native DNA antibodies after treatment with ethambutol and [s2]rifampicin[e2] 
+	(0, 16)	Polyarthritis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	314	 [s1]Polyarthritis[e1]  hepatitis and anti-native DNA antibodies after treatment with [s2]ethambutol[e2] and rifampicin.
+	(0, 22)	Polyarthritis	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	315	 [s1]Polyarthritis[e1]  hepatitis and anti-native DNA antibodies after treatment with ethambutol and [s2]rifampicin[e2] 
+	(3, 19)	normotensive scleroderma renal crisis	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	316	A case of [s1]normotensive scleroderma renal crisis[e1] after high-dose [s2]methylprednisolone[e2] treatment.
+	(0, 21)	HUS	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	317	 [s1]HUS[e1] has been reported after several anticancer chemotherapies and most often after [s2]mitomycin C[e2] based chemotherapy regimens.
+	(0, 20)	Severe hemolytic uremic syndrome	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	318	 [s1]Severe hemolytic uremic syndrome[e1] in an advanced ovarian cancer patient treated with [s2]carboplatin[e2] and gemcitabine.
+	(0, 25)	Severe hemolytic uremic syndrome	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	319	 [s1]Severe hemolytic uremic syndrome[e1] in an advanced ovarian cancer patient treated with carboplatin and [s2]gemcitabine[e2] 
+	(5, 19)	HUS	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	320	We present a case of [s1]HUS[e1] in an advanced ovarian cancer patient treated with [s2]carboplatin[e2] and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.
+	(5, 24)	HUS	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	321	We present a case of [s1]HUS[e1] in an advanced ovarian cancer patient treated with carboplatin and [s2]gemcitabine[e2]  and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.
+	(20, 34)	valproate	menstrual cycle disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	322	An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with [s1]valproate[e1] for epilepsy, especially if they develop [s2]menstrual cycle disturbances[e2] during treatment.
+	(23, 37)	hyperandrogenism	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	323	BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and [s1]hyperandrogenism[e1] seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
+	(9, 36)	menstrual disorders	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	324	BACKGROUND: Reproductive endocrine disorders characterized by [s1]menstrual disorders[e1]  polycystic ovaries, and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
+	(15, 36)	polycystic ovaries	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	325	BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, [s1]polycystic ovaries[e1]  and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
+	(2, 37)	Reproductive endocrine disorders	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	326	BACKGROUND: [s1]Reproductive endocrine disorders[e1] characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
+	(11, 22)	reproductive endocrine disorders	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	327	CONCLUSIONS: The 3 cases presented here illustrate the development of [s1]reproductive endocrine disorders[e1] after the initiation of [s2]valproate[e2] therapy in women with epilepsy.
+	(7, 13)	valproate	reproductive endocrine disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	328	OBJECTIVE: To describe the development of [s1]valproate[e1] related [s2]reproductive endocrine disorders[e2] in women with epilepsy.
+	(6, 16)	reproductive endocrine disorder	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	329	PATIENTS: Three patients developed a [s1]reproductive endocrine disorder[e1] during treatment with [s2]valproate[e2] 
+	(3, 19)	valproate	serum testosterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	330	RESULTS: Replacing [s1]valproate[e1] with lamotrigine resulted in a decrease in [s2]serum testosterone[e2] concentrations in all 3 women.
+	(17, 36)	valproate	amenorrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	331	The polycystic changes disappeared from the ovaries in 2 of the women after [s1]valproate[e1] therapy was discontinued, and the 2 women who had gained weight and developed [s2]amenorrhea[e2] while being treated with valproate lost weight and resumed menstruating after the change in medication.
+	(17, 32)	valproate	gained weight	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	332	The polycystic changes disappeared from the ovaries in 2 of the women after [s1]valproate[e1] therapy was discontinued, and the 2 women who had [s2]gained weight[e2] and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.
+	(1, 19)	polycystic changes	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	333	The [s1]polycystic changes[e1] disappeared from the ovaries in 2 of the women after [s2]valproate[e2] therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.
+	(4, 17)	staphylococcus aureus sepsis	CyA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	334	However, recurrent [s1]staphylococcus aureus sepsis[e1] developed during [s2]CyA[e2] therapy.
+	(6, 13)	lethal	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	335	Recurrent septicemia with [s1]lethal[e1] outcome during and after [s2]cyclosporine[e2] therapy in severe ulcerative colitis.
+	(2, 13)	septicemia	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	336	Recurrent [s1]septicemia[e1] with lethal outcome during and after [s2]cyclosporine[e2] therapy in severe ulcerative colitis.
+	(12, 26)	proximal muscle weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	337	A 60 year-old woman with chronic renal failure developed acute [s1]proximal muscle weakness[e1] after receiving a regular dosage of [s2]colchicine[e2] 
+	(0, 6)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	338	 [s1]Colchicine[e1] induced [s2]myopathy[e2] in renal failure.
+	(20, 26)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	339	Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of [s1]colchicine[e1] induced [s2]myopathy[e2] 
+	(11, 22)	vacuolated fibers	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	340	Muscle biopsy revealed variation in muscle fiber size and few [s1]vacuolated fibers[e1] which were features of [s2]colchicine[e2] induced myopathy.
+	(4, 22)	variation in muscle fiber size	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	341	Muscle biopsy revealed [s1]variation in muscle fiber size[e1] and few vacuolated fibers which were features of [s2]colchicine[e2] induced myopathy.
+	(4, 32)	disabling neurotoxicity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	342	A third patient experienced [s1]disabling neurotoxicity[e1] in the extremity of a prior ulnar nerve and tendon transposition after receiving [s2]paclitaxel[e2] 
+	(7, 13)	paclitaxel	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	343	Phantom limb pain as a manifestation of [s1]paclitaxel[e1]  [s2]neurotoxicity[e2] 
+	(0, 9)	Phantom limb pain	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	344	 [s1]Phantom limb pain[e1] as a manifestation of [s2]paclitaxel[e2] neurotoxicity.
+	(5, 14)	PLP	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	345	Physicians should be aware that [s1]PLP[e1] can occur after initiation of [s2]paclitaxel[e2] 
+	(10, 21)	phantom limb pain	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	346	We describe 2 patients with prior amputation who experienced [s1]phantom limb pain[e1] (PLP) after receiving [s2]paclitaxel[e2] therapy.
+	(13, 19)	PLP	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	347	We describe 2 patients with prior amputation who experienced phantom limb pain  [s1]PLP[e1]  after receiving [s2]paclitaxel[e2] therapy.
+	(7, 16)	phenylbutazone	serum sickness-like reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	348	Skin manifestations of a case of [s1]phenylbutazone[e1] induced [s2]serum sickness-like reactions[e2] 
+	(0, 9)	Skin manifestations	phenylbutazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	349	 [s1]Skin manifestations[e1] of a case of [s2]phenylbutazone[e2] induced serum sickness-like reactions.
+	(12, 19)	atenolol toxicity	atenolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	350	Our experience supports hemodialysis for ESRF patients with [s1]atenolol toxicity[e1]  [s2]atenolol[e2] toxicity.
+	(3, 13)	gemfibrozil	eosinophilic gastroenteritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	351	Allergic reaction to [s1]gemfibrozil[e1] manifesting as [s2]eosinophilic gastroenteritis[e2] 
+	(5, 15)	EGE	gemfibrozil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	352	We describe a case of [s1]EGE[e1] manifested as an allergy to [s2]gemfibrozil[e2] 
+	(6, 21)	lactic acidosis	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	353	This is the second report of [s1]lactic acidosis[e1] in a patient on stavudine and [s2]lamivudine[e2] 
+	(6, 16)	lactic acidosis	stavudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	354	This is the second report of [s1]lactic acidosis[e1] in a patient on [s2]stavudine[e2] and lamivudine.
+	(9, 21)	lactic acidosis	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	355	We present an AIDS patient with severe and prolonged [s1]lactic acidosis[e1] on stavudine and [s2]lamivudine[e2] 
+	(9, 16)	lactic acidosis	stavudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	356	We present an AIDS patient with severe and prolonged [s1]lactic acidosis[e1] on [s2]stavudine[e2] and lamivudine.
+	(0, 6)	Ataxia	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	357	 [s1]Ataxia[e1] caused by [s2]propafenone[e2] has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature.
+	(4, 17)	adverse central nervous system effects	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	358	A wide variety of [s1]adverse central nervous system effects[e1] have been reported in association with [s2]propafenone[e2]  dizziness is the most common.
+	(15, 21)	propafenone	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	359	A wide variety of adverse central nervous system effects have been reported in association with [s1]propafenone[e1]  [s2]dizziness[e2] is the most common.
+	(0, 7)	Propafenone	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	360	 [s1]Propafenone[e1] induced [s2]ataxia[e2]  report of three cases.
+	(9, 19)	ataxia	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	361	We describe 3 elderly patients with moderate to severe [s1]ataxia[e1] that occurred while they were taking [s2]propafenone[e2] 
+	(11, 47)	pilsicainide	loss of consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	362	A 74-year-old man received oral administration of [s1]pilsicainide[e1]  a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed [s2]loss of consciousness[e2] two days later.
+	(1, 28)	pilsicainide	life-threatening arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	363	When [s1]pilsicainide[e1] is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid [s2]life-threatening arrhythmias[e2] due to high plasma concentrations of the drug.
+	(10, 23)	dystonia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	364	The cases are important in documenting that drug-induced [s1]dystonia[e1]  do occur in patients with dementia, that [s2]risperidone[e2] appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.
+	(3, 17)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	365	Provocation of [s1]non-convulsive status epilepticus[e1] by [s2]tiagabine[e2] in three adolescent patients.
+	(3, 20)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	366	The events of [s1]non-convulsive status epilepticus[e1] subsided following reduction in [s2]tiagabine[e2] dosages.
+	(6, 21)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	367	This is the first report of [s1]non-convulsive status epilepticus[e1] provoked by [s2]tiagabine[e2] in adolescent patients.
+	(7, 11)	lithium	organic brain syndromes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	368	There have been many reports of probable [s1]lithium[e1] induced [s2]organic brain syndromes[e2] occurring when serum lithium levels are within or close to the therapeutic range.
+	(13, 29)	intense anxiety	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	369	When the acute manic state is characterized by marked psychotic symptoms and [s1]intense anxiety[e1]  it may be associated with increased vulnerability to the development of severe [s2]lithium[e2] neurotoxicity.
+	(28, 31)	lithium	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	370	When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe [s1]lithium[e1]  [s2]neurotoxicity[e2] 
+	(10, 30)	psychotic symptoms	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	371	When the acute manic state is characterized by marked [s1]psychotic symptoms[e1] and intense anxiety, it may be associated with increased vulnerability to the development of severe [s2]lithium[e2] neurotoxicity.
+	(6, 14)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	372	Protease inhibitor-induced [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity.
+	(29, 37)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	373	Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity.
+	(4, 30)	ritonavir	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	374	Protease inhibitors  [s1]ritonavir[e1] and saquinavir) were added to the treatment and the patient developed progressive ataxia related to [s2]carbamazepine toxicity[e2] 
+	(10, 30)	saquinavir	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	375	Protease inhibitors (ritonavir and [s1]saquinavir[e1]  were added to the treatment and the patient developed progressive ataxia related to [s2]carbamazepine toxicity[e2] 
+	(24, 31)	progressive ataxia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	376	Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed [s1]progressive ataxia[e1] related to [s2]carbamazepine[e2] toxicity.
+	(4, 25)	ritonavir	progressive ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	377	Protease inhibitors  [s1]ritonavir[e1] and saquinavir) were added to the treatment and the patient developed [s2]progressive ataxia[e2] related to carbamazepine toxicity.
+	(10, 25)	saquinavir	progressive ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	378	Protease inhibitors (ritonavir and [s1]saquinavir[e1]  were added to the treatment and the patient developed [s2]progressive ataxia[e2] related to carbamazepine toxicity.
+	(0, 34)	Ritonavir	clinical toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	379	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and [s2]clinical toxicity[e2] 
+	(0, 16)	Ritonavir	diminishing carbamazepine metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	380	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, [s2]diminishing carbamazepine metabolism[e2] and provoking an increase in serum levels and clinical toxicity.
+	(0, 29)	Ritonavir	increase in serum levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	381	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an [s2]increase in serum levels[e2] and clinical toxicity.
+	(5, 13)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	382	The patient was diagnosed with [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity related to the introduction of ritonavir.
+	(5, 18)	carbamazepine toxicity	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	383	The patient was diagnosed with [s1]carbamazepine toxicity[e1] related to the introduction of [s2]ritonavir[e2] 
+	(0, 8)	Anaphylaxis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	384	 [s1]Anaphylaxis[e1] to [s2]calcitonin[e2] 
+	(8, 16)	anaphylaxis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	385	CONCLUSION: We have introduced a case of [s1]anaphylaxis[e1] by [s2]calcitonin[e2] that suggest an IgE mediated hypersensitivity reaction.
+	(10, 20)	Miacalcic	anaphylactic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	386	The intramuscular challenge test with 25 UI of [s1]Miacalcic[e1] was positive with an immediate [s2]anaphylactic reaction[e2] 
+	(19, 37)	conjunctivitis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	387	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, [s1]conjunctivitis[e1] and perspiration immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
+	(19, 49)	conjunctivitis	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	388	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, [s1]conjunctivitis[e1] and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
+	(25, 37)	perspiration	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	389	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and [s1]perspiration[e1] immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
+	(25, 49)	perspiration	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	390	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and [s1]perspiration[e1] immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
+	(15, 36)	rhinitis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	391	We introduce a case of a sixty years old woman with several previous episodes of [s1]rhinitis[e1]  conjunctivitis and perspiration immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
+	(15, 48)	rhinitis	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	392	We introduce a case of a sixty years old woman with several previous episodes of [s1]rhinitis[e1]  conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
+	(0, 14)	Minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	393	 [s1]Minocycline[e1] as a cause of drug-induced [s2]autoimmune hepatitis[e2] 
+	(0, 8)	Minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	394	 [s1]Minocycline[e1] induced [s2]autoimmune hepatitis[e2] is usually identical to sporadic autoimmune hepatitis.
+	(17, 25)	minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	395	We describe the clinical and liver biopsy morphologic features for 4 patients with [s1]minocycline[e1] induced [s2]autoimmune hepatitis[e2] (group 1).
+	(0, 14)	L-asparaginase	central nervous toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	396	 [s1]L-asparaginase[e1] provoked seizures as singular expression of [s2]central nervous toxicity[e2] 
+	(0, 9)	L-asparaginase	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	397	 [s1]L-asparaginase[e1] provoked [s2]seizures[e2] as singular expression of central nervous toxicity.
+	(3, 14)	L-asparaginase	hemorrhagic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	398	Patients treated with [s1]L-asparaginase[e1] may present with [s2]hemorrhagic[e2] and thrombotic cerebrovascular events.
+	(3, 20)	L-asparaginase	thrombotic cerebrovascular events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	399	Patients treated with [s1]L-asparaginase[e1] may present with hemorrhagic and [s2]thrombotic cerebrovascular events[e2] 
+	(5, 10)	seizure	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	400	We report a case of [s1]seizure[e1] associated with [s2]L-asparaginase[e2] therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.
+	(14, 23)	cilastatin	neutropenic fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	401	Eighty-two patients with various malignancies who received imipenem [s1]cilastatin[e1] 143 times for [s2]neutropenic fever[e2] between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.
+	(11, 23)	imipenem	neutropenic fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	402	Eighty-two patients with various malignancies who received [s1]imipenem[e1] cilastatin 143 times for [s2]neutropenic fever[e2] between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.
+	(2, 14)	seizures	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	403	Incidence of [s1]seizures[e1] in pediatric cancer patients treated with imipenem [s2]cilastatin[e2] 
+	(2, 11)	seizures	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	404	Incidence of [s1]seizures[e1] in pediatric cancer patients treated with [s2]imipenem[e2] cilastatin.
+	(0, 12)	Proconvulsive	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	405	 [s1]Proconvulsive[e1] tendency of imipenem [s2]cilastatin[e2] is one of its well-known side effects.
+	(0, 9)	Proconvulsive	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	406	 [s1]Proconvulsive[e1] tendency of [s2]imipenem[e2] cilastatin is one of its well-known side effects.
+	(5, 16)	convulsions	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	407	Three of these patients had [s1]convulsions[e1] attributed to imipenem [s2]cilastatin[e2]  3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(5, 13)	convulsions	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	408	Three of these patients had [s1]convulsions[e1] attributed to [s2]imipenem[e2] cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(14, 28)	cilastatin	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	409	Three of these patients had convulsions attributed to imipenem [s1]cilastatin[e1]  3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(11, 29)	imipenem	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	410	Three of these patients had convulsions attributed to [s1]imipenem[e1] cilastatin; 3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(14, 28)	cilastatin	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	411	Three of these patients had convulsions attributed to imipenem [s1]cilastatin[e1]  3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(11, 29)	imipenem	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	412	Three of these patients had convulsions attributed to [s1]imipenem[e1] cilastatin; 3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
+	(0, 10)	Gabapentin	hypomanic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	413	 [s1]Gabapentin[e1] induced mood changes with [s2]hypomanic[e2] features in adults.
+	(0, 7)	Gabapentin	mood changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	414	 [s1]Gabapentin[e1] induced [s2]mood changes[e2] with hypomanic features in adults.
+	(6, 19)	gabapentin	behavioural side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	415	We report two adults who received [s1]gabapentin[e1] (GBP) and subsequently developed [s2]behavioural side effects[e2] 
+	(10, 17)	GBP	behavioural side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	416	We report two adults who received gabapentin  [s1]GBP[e1]  and subsequently developed [s2]behavioural side effects[e2] 
+	(0, 23)	Acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	417	 [s1]Acute pancreatitis[e1] in a child with idiopathic ulcerative colitis on long-term [s2]5-aminosalicylic acid[e2] therapy.
+	(17, 31)	acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	418	We describe a 10-year-old boy with ulcerative colitis who developed [s1]acute pancreatitis[e1] while on long-term treatment with [s2]5-aminosalicylic acid[e2] 
+	(3, 16)	visual field constriction	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	419	CONCLUSION: Marked [s1]visual field constriction[e1] appears to be associated with [s2]vigabatrin[e2] therapy.
+	(29, 36)	vigabatrin	visual field constriction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	420	Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with [s1]vigabatrin[e1] attributed [s2]visual field constriction[e2] 
+	(6, 19)	visual field constriction	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	421	PURPOSE: Symptomatic [s1]visual field constriction[e1] thought to be associated with [s2]vigabatrin[e2] has been reported.
+	(18, 25)	vigabatrin	visual field loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	422	The current study investigated the visual fields and visual electrophysiology of eight patients with known [s1]vigabatrin[e1] attributed [s2]visual field loss[e2]  three of whom were reported previously.
+	(1, 14)	field defects	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	423	The [s1]field defects[e1] and some electrophysiological abnormalities persist when [s2]vigabatrin[e2] therapy is withdrawn.
+	(0, 7)	Depressive symptoms	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	424	 [s1]Depressive symptoms[e1] disappeared after [s2]interferon[e2] therapy was stopped.
+	(10, 30)	IFN-alpha	psychiatric side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	425	Treatment of chronic hepatitis C with interferon alpha  [s1]IFN-alpha[e1]  is relatively contraindicated in patients with psychiatric disorders because of possible severe [s2]psychiatric side effects[e2] 
+	(6, 32)	interferon alpha	psychiatric side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	426	Treatment of chronic hepatitis C with [s1]interferon alpha[e1] (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe [s2]psychiatric side effects[e2] 
+	(23, 43)	changes in serotonergic or noradrenergic neurotransmission	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	427	While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent [s1]changes in serotonergic or noradrenergic neurotransmission[e1] caused by [s2]IFN-alpha[e2] 
+	(15, 22)	vancomycin toxicity	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	428	Intensive high-flux hemodiafiltration is often used in the management of [s1]vancomycin toxicity[e1]  [s2]vancomycin[e2] toxicity.
+	(21, 28)	vancomycin toxicity	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	429	Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of [s1]vancomycin toxicity[e1]  [s2]vancomycin[e2] toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.
+	(11, 20)	morbidity	hyperbaric oxygen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	430	We describe 2 children with cerebral palsy who suffered significant [s1]morbidity[e1] immediately after treatment with [s2]hyperbaric oxygen[e2] 
+	(9, 34)	brown discolouration of the fingernails	0.1% tretinoin cream	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	431	A 33-year-old male presented with [s1]brown discolouration of the fingernails[e1] following the application of 4% hydroquinone in sorbolene cream and [s2]0.1% tretinoin cream[e2] to the face intermittently for 9 months.
+	(9, 22)	brown discolouration of the fingernails	4% hydroquinone in sorbolene cream	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	432	A 33-year-old male presented with [s1]brown discolouration of the fingernails[e1] following the application of [s2]4% hydroquinone in sorbolene cream[e2] and 0.1% tretinoin cream to the face intermittently for 9 months.
+	(0, 6)	Nail staining	hydroquinone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	433	 [s1]Nail staining[e1] from [s2]hydroquinone[e2] cream.
+	(0, 9)	Gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	434	 [s1]Gangrene[e1] of the fingertips after [s2]bleomycin[e2] and methotrexate.
+	(0, 14)	Gangrene	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	435	 [s1]Gangrene[e1] of the fingertips after bleomycin and [s2]methotrexate[e2] 
+	(8, 16)	bleomycin	acral vascular toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	436	This supports the well-reported potential of [s1]bleomycin[e1] to trigger [s2]acral vascular toxicity[e2] 
+	(20, 36)	acute digital ischemia	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	437	We describe a 57-year-old man with acral erythrocyanosis progressing to [s1]acute digital ischemia[e1] and gangrene that developed after combined chemotherapy  [s2]bleomycin[e2] and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.
+	(20, 42)	acute digital ischemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	438	We describe a 57-year-old man with acral erythrocyanosis progressing to [s1]acute digital ischemia[e1] and gangrene that developed after combined chemotherapy (bleomycin and [s2]methotrexate[e2]  used to treat a metastatic squamous cell carcinoma of the hypopharynx.
+	(26, 36)	gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	439	We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and [s1]gangrene[e1] that developed after combined chemotherapy  [s2]bleomycin[e2] and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.
+	(26, 42)	gangrene	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	440	We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and [s1]gangrene[e1] that developed after combined chemotherapy (bleomycin and [s2]methotrexate[e2]  used to treat a metastatic squamous cell carcinoma of the hypopharynx.
+	(0, 17)	Diarrhea-associated over-anticoagulation	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	441	 [s1]Diarrhea-associated over-anticoagulation[e1] in a patient taking [s2]warfarin[e2]  therapeutic role of cholestyramine.
+	(21, 30)	diarrhea	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	442	We present a case of significant over-anticoagulation temporally associated with a bout of protracted [s1]diarrhea[e1] in a patient on [s2]warfarin[e2] therapy.
+	(6, 30)	over-anticoagulation	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	443	We present a case of significant [s1]over-anticoagulation[e1] temporally associated with a bout of protracted diarrhea in a patient on [s2]warfarin[e2] therapy.
+	(0, 13)	MI	PCCs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	444	 [s1]MI[e1] related to the use of activated and non-activated [s2]PCCs[e2] predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate.
+	(13, 22)	prothrombin complex concentrate	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	445	Recombinant VIIa concentrate in the management of bleeding following [s1]prothrombin complex concentrate[e1] related [s2]myocardial infarction[e2] in patients with haemophilia and inhibitors.
+	(23, 28)	PCC	MI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	446	We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following [s1]PCC[e1] related [s2]MI[e2] 
+	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	447	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
+	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	448	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
+	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	449	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
+	(1, 6)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	450	Occult [s1]quinine[e1] induced [s2]thrombocytopenia[e2] 
+	(12, 39)	thrombocytopenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	451	Only after three subsequent episodes of severe, symptomatic [s1]thrombocytopenia[e1] over the next four weeks did he say, upon repeat questioning, that he had continued to take [s2]quinine[e2] for night leg cramps.
+	(17, 25)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	452	An 8-year-old child with familial Mediterranean fever exhibited signs of [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication while receiving prophylactic doses of the drug.
+	(14, 22)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	453	CONCLUSION: To the best of our knowledge, this is the first time [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication in this age group has been described in the English literature.
+	(3, 11)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	454	Near fatal acute [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication in a child.
+	(0, 5)	Near fatal	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	455	 [s1]Near fatal[e1] acute [s2]colchicine[e2] intoxication in a child.
+	(0, 23)	Acute myeloid leukemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	456	 [s1]Acute myeloid leukemia[e1] and lung cancer occurring in a chronic lymphocytic leukemia patient treated with [s2]fludarabine[e2] and autologous peripheral blood stem-cell transplantation.
+	(6, 23)	lung cancer	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	457	Acute myeloid leukemia and [s1]lung cancer[e1] occurring in a chronic lymphocytic leukemia patient treated with [s2]fludarabine[e2] and autologous peripheral blood stem-cell transplantation.
+	(6, 27)	AML	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	458	We describe the exceptional development of [s1]AML[e1] and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after [s2]fludarabine[e2] treatment followed by autologous peripheral blood stem-cell transplantation.
+	(9, 27)	lung cancer	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	459	We describe the exceptional development of AML and [s1]lung cancer[e1] in a patient with previously diagnosed CLL in minimal residual disease status after [s2]fludarabine[e2] treatment followed by autologous peripheral blood stem-cell transplantation.
+	(11, 29)	lithium carbonate	incontinence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	460	In 2 of the 3 cases the patients were also taking [s1]lithium carbonate[e1] and beta-blockers, both of which could have contributed to the [s2]incontinence[e2] 
+	(12, 29)	incontinence	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	461	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors [s2]paroxetine[e2] and sertraline, as well as a third who developed this side effect on venlafaxine.
+	(12, 34)	incontinence	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	462	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors paroxetine and [s2]sertraline[e2]  as well as a third who developed this side effect on venlafaxine.
+	(12, 49)	incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	463	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on [s2]venlafaxine[e2] 
+	(7, 15)	incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	464	This concerns 2 male patients who experienced [s1]incontinence[e1] while taking [s2]venlafaxine[e2] 
+	(3, 9)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	465	Case studies in [s1]heparin[e1] induced [s2]thrombocytopenia[e2] 
+	(10, 19)	HIT	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	466	Major points illustrated are, (1) occurrence of [s1]HIT[e1] with any dose or form of [s2]heparin[e2]  (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time.
+	(2, 8)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	467	Type II [s1]heparin[e1] induced [s2]thrombocytopenia[e2] (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.
+	(17, 23)	high blood lead level	lead	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	468	After several unrevealing medical work-ups, he was found to have a [s1]high blood lead level[e1]  [s2]lead[e2] level (122 microg/dL); he has a history of scraping and sanding lead paint without adequate protective measures.
+	(20, 29)	lead	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	469	It also highlights a current major etiologic question, that is, whether and to what degree [s1]lead[e1] exposure contributes to the development of [s2]hypertension[e2]  and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.
+	(20, 38)	lead	lead-induced hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	470	It also highlights a current major etiologic question, that is, whether and to what degree [s1]lead[e1] exposure contributes to the development of hypertension, and raises the issue of whether [s2]lead-induced hypertension[e2] constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.
+	(9, 13)	lead toxicity	lead	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	471	Poorly controlled hypertension in a painter with chronic [s1]lead toxicity[e1]  [s2]lead[e2] toxicity.
+	(17, 48)	lead	lead toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	472	This case demonstrates an occupational activity (construction) that has now become the dominant source of [s1]lead[e1] exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic [s2]lead toxicity[e2]  and the importance of preventing further exposure and using proper methods to treat acute toxicity.
+	(0, 20)	Severe rash	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	473	 [s1]Severe rash[e1]  including the Stevens-Johnson syndrome (SJS), is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
+	(9, 19)	SJS	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	474	Severe rash, including the Stevens-Johnson syndrome  [s1]SJS[e1] , is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
+	(5, 21)	Stevens-Johnson syndrome	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	475	Severe rash, including the [s1]Stevens-Johnson syndrome[e1] (SJS), is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
+	(0, 15)	Stevens-Johnson syndrome	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	476	 [s1]Stevens-Johnson syndrome[e1] caused by the antiretroviral drug [s2]nevirapine[e2] 
+	(22, 28)	nevirapine	SJS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	477	Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of [s1]nevirapine[e1] associated [s2]SJS[e2] has been documented in the dermatology literature.
+	(5, 11)	SJS	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	478	We describe 2 cases of [s1]SJS[e1] related to [s2]nevirapine[e2] use and review the literature on this newly recognized association.
+	(3, 14)	acarbose	ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	479	Oral intake and [s1]acarbose[e1] were withheld and the [s2]ileus[e2] spontaneously resolved after 2 days.
+	(13, 18)	losartan	increases urate excretion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	480	There is evidence that the angiotensin II receptor antagonist, [s1]losartan[e1]  [s2]increases urate excretion[e2] by reducing reabsorption of urate in the renal proximal tubule.
+	(0, 12)	Atrial fibrillation	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	481	 [s1]Atrial fibrillation[e1] occurring in a patient taking [s2]etanercept[e2] plus methotrexate for rheumatoid arthritis.
+	(0, 17)	Atrial fibrillation	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	482	 [s1]Atrial fibrillation[e1] occurring in a patient taking etanercept plus [s2]methotrexate[e2] for rheumatoid arthritis.
+	(10, 26)	hepatic angiosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	483	A review of the literature revealed two other cases of [s1]hepatic angiosarcoma[e1] in patients after long-term [s2]cyclophosphamide[e2] treatment.
+	(0, 12)	Hepatic angiosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	484	 [s1]Hepatic angiosarcoma[e1] occurring after [s2]cyclophosphamide[e2] therapy: case report and review of the literature.
+	(3, 22)	cyclophosphamide	hepatic angiosarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	485	We propose that [s1]cyclophosphamide[e1] be added to the list of exposures potentially associated with [s2]hepatic angiosarcoma[e2] 
+	(0, 9)	ARA-C	dermatologic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	486	 [s1]ARA-C[e1] is frequently associated with [s2]dermatologic toxicity[e2]  but this is only the second case of toxic epidermal necrolysis described in connection with this drug.
+	(0, 23)	ARA-C	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	487	 [s1]ARA-C[e1] is frequently associated with dermatologic toxicity, but this is only the second case of [s2]toxic epidermal necrolysis[e2] described in connection with this drug.
+	(11, 31)	ARA-C	bullous lesions on the hands and soles that disseminated, evolving to necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	488	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed [s2]bullous lesions on the hands and soles that disseminated, evolving to necrosis[e2]  sepsis, and death on the 22nd day.
+	(11, 54)	ARA-C	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	489	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and [s2]death[e2] on the 22nd day.
+	(11, 50)	ARA-C	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	490	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, [s2]sepsis[e2]  and death on the 22nd day.
+	(0, 16)	Toxic epidermal necrolysis	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	491	 [s1]Toxic epidermal necrolysis[e1] after the use of high-dose [s2]cytosine arabinoside[e2] 
+	(13, 28)	TEN	ARA-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	492	We report a fatal case of toxic epidermal necrolysis  [s1]TEN[e1]  resulting from a high dose of cytosine arabinoside  [s2]ARA-C[e2] .
+	(13, 22)	TEN	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	493	We report a fatal case of toxic epidermal necrolysis  [s1]TEN[e1]  resulting from a high dose of [s2]cytosine arabinoside[e2] (ARA-C).
+	(6, 30)	toxic epidermal necrolysis	ARA-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	494	We report a fatal case of [s1]toxic epidermal necrolysis[e1] (TEN) resulting from a high dose of cytosine arabinoside  [s2]ARA-C[e2] .
+	(6, 24)	toxic epidermal necrolysis	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	495	We report a fatal case of [s1]toxic epidermal necrolysis[e1] (TEN) resulting from a high dose of [s2]cytosine arabinoside[e2] (ARA-C).
+	(0, 6)	Quetiapine	obsessive-compulsive symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	496	 [s1]Quetiapine[e1] and [s2]obsessive-compulsive symptoms[e2] (OCS): case report and review of atypical antipsychotic-induced OCS.
+	(0, 15)	Quetiapine	OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	497	 [s1]Quetiapine[e1] and obsessive-compulsive symptoms  [s2]OCS[e2] : case report and review of atypical antipsychotic-induced OCS.
+	(0, 15)	Quetiapine	OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	498	 [s1]Quetiapine[e1] and obsessive-compulsive symptoms  [s2]OCS[e2] : case report and review of atypical antipsychotic-induced OCS.
+	(5, 10)	quetiapine	exacerbating OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	499	The first known report of [s1]quetiapine[e1]  [s2]exacerbating OCS[e2] in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented.
+	(5, 15)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	500	He was diagnosed with possible [s1]serotonin syndrome[e1]  his symptoms resolved after [s2]clomipramine[e2] was stopped but before clozapine was restarted eight days later.
+	(9, 19)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	501	OBJECTIVE: To report on the possible development of [s1]serotonin syndrome[e1] in a patient receiving [s2]clomipramine[e2] after clozapine was withdrawn from the treatment regimen.
+	(9, 24)	serotonin syndrome	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	502	OBJECTIVE: To report on the possible development of [s1]serotonin syndrome[e1] in a patient receiving clomipramine after [s2]clozapine[e2] was withdrawn from the treatment regimen.
+	(1, 9)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	503	Possible [s1]serotonin syndrome[e1] associated with [s2]clomipramine[e2] after withdrawal of clozapine.
+	(1, 16)	serotonin syndrome	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	504	Possible [s1]serotonin syndrome[e1] associated with clomipramine after withdrawal of [s2]clozapine[e2] 
+	(14, 46)	clomipramine	agitated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	505	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, [s2]agitated[e2]  and confused.
+	(3, 46)	clozapine	agitated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	506	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, [s2]agitated[e2]  and confused.
+	(14, 27)	clomipramine	behaving oddly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	507	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began [s2]behaving oddly[e2]  started sweating profusely, shivering, and became tremulous, agitated, and confused.
+	(3, 27)	clozapine	behaving oddly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	508	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began [s2]behaving oddly[e2]  started sweating profusely, shivering, and became tremulous, agitated, and confused.
+	(14, 49)	clomipramine	confused	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	509	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and [s2]confused[e2] 
+	(3, 49)	clozapine	confused	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	510	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and [s2]confused[e2] 
+	(14, 38)	clomipramine	shivering	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	511	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, [s2]shivering[e2]  and became tremulous, agitated, and confused.
+	(3, 38)	clozapine	shivering	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	512	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, [s2]shivering[e2]  and became tremulous, agitated, and confused.
+	(14, 33)	clomipramine	sweating profusely	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	513	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started [s2]sweating profusely[e2]  shivering, and became tremulous, agitated, and confused.
+	(3, 33)	clozapine	sweating profusely	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	514	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started [s2]sweating profusely[e2]  shivering, and became tremulous, agitated, and confused.
+	(14, 42)	clomipramine	tremulous	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	515	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became [s2]tremulous[e2]  agitated, and confused.
+	(3, 42)	clozapine	tremulous	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	516	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became [s2]tremulous[e2]  agitated, and confused.
+	(0, 5)	Quinine	coagulopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	517	 [s1]Quinine[e1] induced [s2]coagulopathy[e2] -a near fatal experience.
+	(7, 24)	severe thrombocytopoaenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	518	The cause of his bleeding was a [s1]severe thrombocytopoaenia[e1]  induced by chronic ingestion of [s2]quinine[e2] 
+	(3, 9)	olanzapine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	519	Dose-dependent [s1]olanzapine[e1] associated [s2]leukopenia[e2]  three case reports.
+	(16, 24)	agranulocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	520	These cases suggest the possibility that, in some patients, leukopenia or [s1]agranulocytosis[e1] during [s2]olanzapine[e2] treatment might be dose-related.
+	(11, 24)	leukopenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	521	These cases suggest the possibility that, in some patients, [s1]leukopenia[e1] or agranulocytosis during [s2]olanzapine[e2] treatment might be dose-related.
+	(8, 15)	leukopenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	522	We report three cases of patients who developed [s1]leukopenia[e1] during [s2]olanzapine[e2] treatment.
+	(9, 23)	dermatologic and ocular 5-FU toxicities	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	523	CONCLUSION: This case illustrates a potential link between [s1]dermatologic and ocular 5-FU toxicities[e1]  [s2]5-FU[e2] toxicities.
+	(20, 26)	5-FU	ectropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	524	Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and [s1]5-FU[e1] induced [s2]ectropion[e2] 
+	(4, 10)	5-FU	ectropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	525	DISCUSSION: Patients with [s1]5-FU[e1] induced [s2]ectropion[e2] experience tender, red, scaled lids, making contact lens wear difficult.
+	(4, 15)	5-FU	tender, red, scaled lids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	526	DISCUSSION: Patients with [s1]5-FU[e1] induced ectropion experience [s2]tender, red, scaled lids[e2]  making contact lens wear difficult.
+	(0, 12)	Ectropion	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	527	 [s1]Ectropion[e1] secondary to bolus injection of [s2]5-fluorouracil[e2] 
+	(5, 10)	5-FU	dermatologic toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	528	Exacerbation of [s1]5-FU[e1]  [s2]dermatologic toxicities[e2] in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.
+	(5, 12)	acute renal failure	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	529	Presented is a case of [s1]acute renal failure[e1] induced by [s2]acetazolamide[e2] therapy for glaucoma.
+	(0, 6)	Renal failure	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	530	 [s1]Renal failure[e1] associated with [s2]acetazolamide[e2] therapy for glaucoma.
+	(14, 22)	acetazolamide	calcium phosphate nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	531	This sulfonamide like nephropathy should be differentiated from [s1]acetazolamide[e1] related [s2]calcium phosphate nephrolithiasis[e2] 
+	(0, 12)	Ischaemic colitis	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	532	 [s1]Ischaemic colitis[e1] in a patient taking [s2]meloxicam[e2] 
+	(2, 15)	endoscopic lesions	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	533	Symptoms and [s1]endoscopic lesions[e1] quickly regressed within 1 week of [s2]meloxicam[e2] withdrawal.
+	(7, 17)	bloody diarrhoea	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	534	We describe a patient who presented with [s1]bloody diarrhoea[e1] after 15 mg [s2]meloxicam[e2] daily for 10 days for osteoarthritis.
+	(3, 11)	meloxicam	intestinal toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	535	We suggest that [s1]meloxicam[e1] might have [s2]intestinal toxic effects[e2] when taken in high doses, because of reduced COX-2 selectivity.
+	(14, 37)	spironolactone	diarrhoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	536	As these cases revealed, close monitoring of blood chemistry is mandatory after starting [s1]spironolactone[e1]  and patients should be advised to stop spironolactone immediately if [s2]diarrhoea[e2] develops.
+	(7, 22)	spironolactone	serious and, occasionally, fatal hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	537	In patients with chronic heart failure, [s1]spironolactone[e1] added to conventional treatment may lead to [s2]serious and, occasionally, fatal hyperkalaemia[e2] 
+	(8, 17)	spironolactone	diarrhoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	538	In some cases this seems to happen because [s1]spironolactone[e1] causes [s2]diarrhoea[e2] 
+	(0, 13)	Serious adverse events	spironolactone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	539	 [s1]Serious adverse events[e1] experienced by patients with chronic heart failure taking [s2]spironolactone[e2] 
+	(25, 35)	oxaliplatin	dermnatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	540	We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with [s1]oxaliplatin[e1] and developed a peculiar [s2]dermnatitis[e2] in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin.
+	(9, 20)	severe enteropathy	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	541	An 11-year-old boy developed a [s1]severe enteropathy[e1] 2 years after initiation of [s2]clofazimine[e2] treatment for graft-versus-host disease.
+	(0, 6)	Clofazimine	enteropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	542	 [s1]Clofazimine[e1]  [s2]enteropathy[e2] caused by crystal deposition can be life-threatening.
+	(0, 15)	Clofazimine	life-threatening	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	543	 [s1]Clofazimine[e1] enteropathy caused by crystal deposition can be [s2]life-threatening[e2] 
+	(0, 6)	Clofazimine	enteropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	544	 [s1]Clofazimine[e1]  [s2]enteropathy[e2] in a pediatric bone marrow transplant recipient.
+	(3, 17)	severe urticarial rash	Enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	545	She developed a [s1]severe urticarial rash[e1] 3 weeks following initiation of therapy with [s2]Enoxaparin[e2] 
+	(12, 26)	blurred vision	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	546	We cared for a patient with progressive renal impairment who presented with [s1]blurred vision[e1]  QRS broadening and cardiac failure due to chronic [s2]cibenzoline[e2] intoxication.
+	(20, 27)	cardiac failure	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	547	We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and [s1]cardiac failure[e1] due to chronic [s2]cibenzoline[e2] intoxication.
+	(25, 34)	cibenzoline intoxication	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	548	We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic [s1]cibenzoline intoxication[e1]  [s2]cibenzoline[e2] intoxication.
+	(15, 27)	QRS broadening	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	549	We cared for a patient with progressive renal impairment who presented with blurred vision, [s1]QRS broadening[e1] and cardiac failure due to chronic [s2]cibenzoline[e2] intoxication.
+	(2, 13)	aspergillus arthritis	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	550	Indolent [s1]aspergillus arthritis[e1] complicating [s2]fludarabine[e2] based non-myeloablative stem cell transplantation.
+	(5, 17)	aspergillus arthritis of the knee joint	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	551	We describe two patients with [s1]aspergillus arthritis of the knee joint[e1] following [s2]fludarabine[e2] based non-myeloablative stem cell transplantation.
+	(7, 15)	fluvoxamine	increased libido	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	552	CONCLUSION: The present findings suggest that [s1]fluvoxamine[e1] can cause [s2]increased libido[e2] in some patients.
+	(0, 11)	Increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	553	 [s1]Increased libido[e1] in a woman treated with [s2]fluvoxamine[e2]  a case report.
+	(13, 20)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	554	OBJECTIVE: The aim of this paper is to describe a case of [s1]increased libido[e1] during [s2]fluvoxamine[e2] therapy.
+	(22, 32)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	555	RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an [s1]increased libido[e1] with the administration of [s2]fluvoxamine[e2] 
+	(1, 9)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	556	The [s1]increased libido[e1] disappeared after [s2]fluvoxamine[e2] was discontinued.
+	(4, 11)	pancreatitis	meglumine antimoniate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	557	An infant who developed [s1]pancreatitis[e1] during [s2]meglumine antimoniate[e2] treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.
+	(27, 35)	pancreatitis	meglumine antimoniate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	558	Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed [s1]pancreatitis[e1] caused by [s2]meglumine antimoniate[e2] 
+	(11, 20)	Hashimoto's disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	559	CONCLUSIONS: This case report showed that the clinical appearance of [s1]Hashimoto's disease[e1] after [s2]IFN-alpha[e2] therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.
+	(31, 51)	autoimmune thyroiditis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	560	Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop [s1]autoimmune thyroiditis[e1]  in order to make a early diagnosis of thyroid disorders during the [s2]IFN-alpha[e2] treatment.
+	(46, 52)	thyroid disorders	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	561	Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of [s1]thyroid disorders[e1] during the [s2]IFN-alpha[e2] treatment.
+	(0, 9)	Hashimoto's disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	562	 [s1]Hashimoto's disease[e1] during [s2]interferon-alpha[e2] therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.
+	(8, 22)	Hashimoto's disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	563	OBJECTIVES: The authors described a case of [s1]Hashimoto's disease[e1] during interferon-alpha  [s2]IFN-alpha[e2]  treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.
+	(8, 17)	Hashimoto's disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	564	OBJECTIVES: The authors described a case of [s1]Hashimoto's disease[e1] during [s2]interferon-alpha[e2] (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.
+	(12, 46)	omeprazole	peripheral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	565	During dose-finding studies for intravenous proton pump inhibitors [s1]omeprazole[e1] and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed [s2]peripheral edema[e2] within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.
+	(17, 45)	pantoprazole	peripheral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	566	During dose-finding studies for intravenous proton pump inhibitors omeprazole and [s1]pantoprazole[e1]  three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed [s2]peripheral edema[e2] within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.
+	(0, 24)	Pheripheral edema	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	567	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors omeprazole, [s2]lansoprazole[e2]  or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.
+	(0, 19)	Pheripheral edema	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	568	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors [s2]omeprazole[e2]  lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.
+	(0, 30)	Pheripheral edema	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	569	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or [s2]pantoprazole[e2] for 7-15 days for peptic acid diseases in recommended standard doses.
+	(0, 11)	Motor fluctuations	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	570	 [s1]Motor fluctuations[e1] appear after 2-3 years of [s2]levodopa[e2] treatment, and affect at least 50% of patients after five years.
+	(3, 23)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	571	CONCLUSION: Significant [s1]weight loss[e1] is a potential adverse event in patients with rheumatoid arthritis treated with [s2]leflunomide[e2] 
+	(0, 7)	Leflunomide	weight loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	572	 [s1]Leflunomide[e1] associated [s2]weight loss[e2] in rheumatoid arthritis.
+	(22, 36)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	573	METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if [s1]weight loss[e1] had occurred as an adverse event in patients treated with [s2]leflunomide[e2] between November 1998 and January 2000.
+	(7, 15)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	574	OBJECTIVE: To determine the frequency of [s1]weight loss[e1] in patients treated with [s2]leflunomide[e2] for rheumatoid arthritis at an arthritis referral center.
+	(9, 18)	leflunomide	weight loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	575	RESULTS: Five of 70 patients who had begun [s1]leflunomide[e1] therapy had significant [s2]weight loss[e2] that could not be linked to other identifiable etiologies.
+	(9, 23)	valacyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	576	It is increasingly recognized that dose adjustment of oral [s1]valacyclovir[e1] in renal failure is necessary to avoid [s2]neurotoxicity[e2] 
+	(0, 8)	Neurotoxicity	valacyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	577	 [s1]Neurotoxicity[e1] of [s2]valacyclovir[e2] in peritoneal dialysis: a pharmacokinetic study.
+	(2, 15)	neurotoxicity	valacyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	578	She developed [s1]neurotoxicity[e1] with an adjustment dosage of [s2]valacyclovir[e2] for a cutaneous zoster infection.
+	(0, 19)	Avascular necrosis of the femoral head	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	579	 [s1]Avascular necrosis of the femoral head[e1] in patients with prostate cancer treated with [s2]cyproterone acetate[e2] and radiotherapy.
+	(42, 68)	cyproterone acetate	femoral head avascular necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	580	We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of [s1]cyproterone acetate[e1] prior to radical or palliative pelvic irradiation, and who subsequently developed [s2]femoral head avascular necrosis[e2] 
+	(0, 8)	Levofloxacin	polymorphic ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	581	 [s1]Levofloxacin[e1] induced [s2]polymorphic ventricular tachycardia[e2] with normal QT interval.
+	(6, 28)	polymorphic ventricular tachycardia	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	582	We report the first case of [s1]polymorphic ventricular tachycardia[e1] with normal QT interval associated with the oral use of [s2]levofloxacin[e2] in the absence of other etiologies known to cause these arrhythmias.
+	(6, 13)	pulmonary side effects	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	583	So far, few cases of [s1]pulmonary side effects[e1] caused by [s2]ticlopidine[e2] have been reported.
+	(6, 14)	pulmonary symptoms	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	584	Special care should be taken when [s1]pulmonary symptoms[e1] appear in association with [s2]ticlopidine[e2] treatment.
+	(0, 8)	Ticlopidine	interstitial pulmonary disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	585	 [s1]Ticlopidine[e1] induced [s2]interstitial pulmonary disease[e2]  a case report.
+	(5, 26)	interstitial pulmonary disease	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	586	We report a case of [s1]interstitial pulmonary disease[e1] that occurred together with lymphocytic colitis during treatment with [s2]ticlopidine[e2] 
+	(14, 26)	lymphocytic colitis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	587	We report a case of interstitial pulmonary disease that occurred together with [s1]lymphocytic colitis[e1] during treatment with [s2]ticlopidine[e2] 
+	(4, 15)	methadone	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	588	A patient that received [s1]methadone[e1] for cancer-associated pain developed [s2]myoclonus[e2] as a side effect.
+	(0, 6)	Methadone	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	589	 [s1]Methadone[e1] induced [s2]myoclonus[e2] in advanced cancer.
+	(7, 15)	fatal hyperkalemia	succinylcholine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	590	OBJECTIVE: To report a case of [s1]fatal hyperkalemia[e1] owing to [s2]succinylcholine[e2] administration in a patient with mucositis secondary to chemotherapy.
+	(0, 9)	Succinylcholine	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	591	 [s1]Succinylcholine[e1] induced [s2]hyperkalemia[e2] in a patient with mucositis secondary to chemotherapy.
+	(14, 23)	fatal hyperkalemia	succinylcholine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	592	We believe that mucositis was a contributing factor to this case of [s1]fatal hyperkalemia[e1] after administration of [s2]succinylcholine[e2]  with a mechanism similar to that reported with thermal injury.
+	(0, 13)	Cutaneous seeding	ethanol injection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	593	 [s1]Cutaneous seeding[e1] after ultrasound-guided percutaneous [s2]ethanol injection[e2] for treatment of hepatocellular carcinoma.
+	(8, 34)	cutaneous seeding	ethanol injection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	594	We describe a case of needle-track [s1]cutaneous seeding[e1] of hepatocellular carcinoma (HCC) after sonographically guided percutaneous [s2]ethanol injection[e2] (PEI).
+	(0, 6)	Adenosine	ventricular fibrillation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	595	 [s1]Adenosine[e1] induced [s2]ventricular fibrillation[e2] 
+	(2, 28)	adenosine	acceleration of the ventricular rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	596	However, [s1]adenosine[e1] shortens the antegrade refractoriness of accessory atrioventricular connections and may cause [s2]acceleration of the ventricular rate[e2] during atrial fibrillation.
+	(2, 34)	ventricular fibrillation	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	597	We observed [s1]ventricular fibrillation[e1] in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of [s2]adenosine[e2] 
+	(4, 50)	methylprednisolone	psychotic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	598	After the dose of [s1]methylprednisolone[e1] was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the [s2]psychotic reaction[e2] disappeared a few hours later.
+	(8, 18)	seizures	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	599	Continuous EEG monitoring is helpful in managing [s1]seizures[e1] that occur as a complication of [s2]CBZ[e2] OD, after the course of recovery or worsening, and in providing assistance with prognosis.
+	(1, 20)	CBZ	cortical hyperexcitability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	600	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes [s2]cortical hyperexcitability[e2]  a profound burst-suppression EEG pattern, and cranial nerve areflexia.
+	(1, 38)	CBZ	cranial nerve areflexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	601	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and [s2]cranial nerve areflexia[e2] 
+	(1, 29)	CBZ	profound burst-suppression EEG pattern	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	602	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a [s2]profound burst-suppression EEG pattern[e2]  and cranial nerve areflexia.
+	(1, 10)	CBZ	reversible encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	603	Massive [s1]CBZ[e1] OD may produce a [s2]reversible encephalopathy[e2] that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.
+	(8, 15)	methimazole	bone marrow toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	604	Massive plasmocytosis due to [s1]methimazole[e1] induced [s2]bone marrow toxicity[e2] 
+	(0, 10)	Massive plasmocytosis	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	605	 [s1]Massive plasmocytosis[e1] due to [s2]methimazole[e2] induced bone marrow toxicity.
+	(15, 31)	MMI	massive plasmocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	606	To our knowledge this is the first report of pancytopenia due to [s1]MMI[e1]  where the usual hypoplasia found is replaced by [s2]massive plasmocytosis[e2] 
+	(9, 17)	pancytopenia	MMI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	607	To our knowledge this is the first report of [s1]pancytopenia[e1] due to [s2]MMI[e2]  where the usual hypoplasia found is replaced by massive plasmocytosis.
+	(5, 17)	fulminant hepatic failure	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	608	We report a case of [s1]fulminant hepatic failure[e1] associated with [s2]didanosine[e2] and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.
+	(6, 28)	bilateral avascular necrosis of the femoral heads	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	609	This report details a case of [s1]bilateral avascular necrosis of the femoral heads[e1] in a patient receiving 'standard' doses of [s2]dexamethasone[e2] as part of the antiemetic regimen used in cisplatin-based combination chemotherapy.
+	(30, 41)	hemorrhage	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	610	Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following [s1]hemorrhage[e1] may have been favored by [s2]metformin[e2] 
+	(12, 26)	metformin	severe inferior digestive hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	611	An obese patient, not diabetic, treated with [s1]metformin[e1] for some weeks, was referred to us with [s2]severe inferior digestive hemorrhage[e2]  diagnosed with Meckel's diverticulum.
+	(0, 21)	Digestive hemorrhage	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	612	 [s1]Digestive hemorrhage[e1] caused by a Meckel's diverticulum in a [s2]metformin[e2] treated patient: is there any connection?
+	(0, 12)	Ulcer became worse	gentamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	613	 [s1]Ulcer became worse[e1] after tobramycin and [s2]gentamycin[e2] treatment for 2 days.
+	(0, 7)	Ulcer became worse	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	614	 [s1]Ulcer became worse[e1] after [s2]tobramycin[e2] and gentamycin treatment for 2 days.
+	(4, 11)	amprenavir	intracranial bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	615	Possible linkage of [s1]amprenavir[e1] with [s2]intracranial bleeding[e2] in an HIV-infected hemophiliac.
+	(1, 11)	bleeding	APV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	616	The [s1]bleeding[e1] resolved on discontinuation of [s2]APV[e2] 
+	(6, 36)	intracranial bleeding	amprenavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	617	We report the occurrence of spontaneous [s1]intracranial bleeding[e1] in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving [s2]amprenavir[e2] (APV).
+	(12, 20)	gemcitabine	cutaneous eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	618	According to the Naranjo probability scale, the relationship of [s1]gemcitabine[e1] treatment with [s2]cutaneous eruption[e2] in our patient is possible.
+	(8, 15)	gemcitabine	LABD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	619	CONCLUSIONS: We report the first case of [s1]gemcitabine[e1] induced [s2]LABD[e2] 
+	(0, 17)	Linear immunoglobulin A bullous dermatosis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	620	 [s1]Linear immunoglobulin A bullous dermatosis[e1] induced by [s2]gemcitabine[e2] 
+	(24, 30)	LABD	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	621	OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis  [s1]LABD[e1]  induced by [s2]gemcitabine[e2] 
+	(7, 32)	linear immunoglobulin (Ig) A bullous dermatosis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	622	OBJECTIVE: To report a case of [s1]linear immunoglobulin (Ig) A bullous dermatosis[e1] (LABD) induced by [s2]gemcitabine[e2] 
+	(8, 15)	gemcitabine	symmetric, bullous, herpetiform eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	623	Twenty-four hours after the administration of [s1]gemcitabine[e1]  a [s2]symmetric, bullous, herpetiform eruption[e2] appeared on his trunk and upper limbs.
+	(0, 21)	Vancomycin	LABD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	624	 [s1]Vancomycin[e1] is the most frequently implicated drug, but other agents have been reported to cause [s2]LABD[e2] 
+	(1, 16)	taxol	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	625	Although [s1]taxol[e1] has shown significant activity in advanced ovarian cancer, [s2]peripheral neuropathy[e2] is likely to become the major dose-limiting toxicity.
+	(13, 23)	difficulty walking	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	626	A rare case of advanced ovarian carcinoma who developed [s1]difficulty walking[e1] 25 days after treatment with weekly [s2]paclitaxel[e2] 
+	(14, 41)	difficulty walking	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	627	We describe a case of advanced ovarian carcinoma who developed [s1]difficulty walking[e1] because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
+	(28, 41)	loss of proprioception	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	628	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and [s1]loss of proprioception[e1] 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
+	(18, 41)	marked pain	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	629	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of [s1]marked pain[e1] in the lower extremities and loss of proprioception 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
+	(7, 12)	morphine	spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	630	Relief by naloxone of [s1]morphine[e1] induced [s2]spasm[e2] of the sphincter of Oddi in a post-cholecystectomy patient.
+	(21, 37)	morphine	biliary colic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	631	We present the case of a patient who had undergone cholecystectomy previously, but in whom [s1]morphine[e1] given in the Emergency Department precipitated pain consistent with [s2]biliary colic[e2]  the pain resolved promptly after administration of naloxone.
+	(21, 34)	morphine	pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	632	We present the case of a patient who had undergone cholecystectomy previously, but in whom [s1]morphine[e1] given in the Emergency Department precipitated [s2]pain[e2] consistent with biliary colic; the pain resolved promptly after administration of naloxone.
+	(0, 13)	Myasthenia gravis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	633	 [s1]Myasthenia gravis[e1] during low-dose [s2]IFN-alpha[e2] therapy for chronic hepatitis C.
+	(12, 26)	intrahepatic cholestasis	sodium aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	634	A patient with rheumatoid arthritis developed an acute [s1]intrahepatic cholestasis[e1] after 100 mg of [s2]sodium aurothiomalate[e2] 
+	(0, 7)	Acute lung injury	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	635	 [s1]Acute lung injury[e1] associated with [s2]5-fluorouracil[e2] and oxaliplatinum combined chemotherapy.
+	(0, 15)	Acute lung injury	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	636	 [s1]Acute lung injury[e1] associated with 5-fluorouracil and [s2]oxaliplatinum[e2] combined chemotherapy.
+	(16, 44)	bilateral patchy pulmonary infiltrates	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	637	Diarrhoea, T-CD4+ lymphopenia and [s1]bilateral patchy pulmonary infiltrates[e1] developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
+	(16, 38)	bilateral patchy pulmonary infiltrates	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	638	Diarrhoea, T-CD4+ lymphopenia and [s1]bilateral patchy pulmonary infiltrates[e1] developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
+	(0, 43)	Diarrhoea	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	639	 [s1]Diarrhoea[e1]  T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
+	(0, 37)	Diarrhoea	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	640	 [s1]Diarrhoea[e1]  T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
+	(5, 44)	T-CD4+ lymphopenia	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	641	Diarrhoea, [s1]T-CD4+ lymphopenia[e1] and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
+	(5, 38)	T-CD4+ lymphopenia	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	642	Diarrhoea, [s1]T-CD4+ lymphopenia[e1] and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
+	(17, 34)	pulmonary adverse reaction	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	643	It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a [s1]pulmonary adverse reaction[e1]  a feature never previously associated with oxaliplatinum and [s2]5-fluorouracil[e2] regimens.
+	(17, 28)	pulmonary adverse reaction	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	644	It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a [s1]pulmonary adverse reaction[e1]  a feature never previously associated with [s2]oxaliplatinum[e2] and 5-fluorouracil regimens.
+	(2, 8)	Accutane	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	645	BACKGROUND: [s1]Accutane[e1] a [s2]teratogenic[e2] prescription drug licensed to treat severe, recalcitrant nodular acne.
+	(6, 34)	Accutane	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	646	RESULTS: The estimated number of [s1]Accutane[e1] prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used [s2]teratogenic[e2] drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to Accutane in 1999.
+	(9, 30)	pranlukast	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	647	A 62-year-old woman treated with [s1]pranlukast[e1] for 2 months developed interstitial pneumonitis with a [s2]high fever[e2] 
+	(9, 20)	pranlukast	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	648	A 62-year-old woman treated with [s1]pranlukast[e1] for 2 months developed [s2]interstitial pneumonitis[e2] with a high fever.
+	(1, 9)	interstitial pneumonia	ONO-1078	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	649	Acute [s1]interstitial pneumonia[e1] induced by [s2]ONO-1078[e2] (pranlukast), a leukotriene receptor antagonist.
+	(1, 13)	interstitial pneumonia	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	650	Acute [s1]interstitial pneumonia[e1] induced by ONO-1078  [s2]pranlukast[e2] , a leukotriene receptor antagonist.
+	(14, 23)	renal colicky pain	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	651	An asymptomatic HIV-infected woman experienced right-sided [s1]renal colicky pain[e1] during treatment with [s2]indinavir[e2] 
+	(0, 14)	Indinavir	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	652	 [s1]Indinavir[e1] associated nephrolithiasis and chronic [s2]interstitial nephritis[e2] were the only possible causes identified in this patient.
+	(0, 6)	Indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	653	 [s1]Indinavir[e1] associated [s2]nephrolithiasis[e2] and chronic interstitial nephritis were the only possible causes identified in this patient.
+	(0, 15)	Papillary necrosis	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	654	 [s1]Papillary necrosis[e1] associated with the HIV protease inhibitor [s2]indinavir[e2] 
+	(5, 10)	indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	655	Physicians should be aware that [s1]indinavir[e1]  [s2]nephrolithiasis[e2] may cause papillary necrosis.
+	(5, 18)	indinavir	papillary necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	656	Physicians should be aware that [s1]indinavir[e1] nephrolithiasis may cause [s2]papillary necrosis[e2] 
+	(6, 20)	indinavir	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	657	The HIV protease inhibitor [s1]indinavir[e1] may cause nephrolithiasis and [s2]interstitial nephritis[e2] 
+	(6, 13)	indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	658	The HIV protease inhibitor [s1]indinavir[e1] may cause [s2]nephrolithiasis[e2] and interstitial nephritis.
+	(4, 10)	indinavir	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	659	The renal consequences of [s1]indinavir[e1] associated [s2]nephrotoxicity[e2] are uncertain.
+	(5, 17)	papillary necrosis	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	660	We report a case of [s1]papillary necrosis[e1] in a patient treated with [s2]indinavir[e2] 
+	(37, 69)	decline in glomerular filtration rate	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	661	We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked [s1]decline in glomerular filtration rate[e1] in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), [s2]rofecoxib[e2] 
+	(2, 16)	LTG	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	662	CONCLUSIONS: [s1]LTG[e1] overdose may result in a severe but reversible [s2]encephalopathy[e2]  a previously undescribed phenomenon.
+	(2, 9)	elevated serum LTG levels	LTG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	663	Evaluation revealed [s1]elevated serum LTG levels[e1]  [s2]LTG[e2] levels and no other etiology for encephalopathy.
+	(10, 18)	stuporous	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	664	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with [s2]lamotrigine[e2] (LTG) and valproic acid (VPA) tablets.
+	(10, 23)	stuporous	LTG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	665	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine  [s2]LTG[e2]  and valproic acid (VPA) tablets.
+	(10, 28)	stuporous	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	666	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine (LTG) and [s2]valproic acid[e2] (VPA) tablets.
+	(10, 32)	stuporous	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	667	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine (LTG) and valproic acid  [s2]VPA[e2]  tablets.
+	(6, 18)	lamotrigine	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	668	PURPOSE: To report that acute [s1]lamotrigine[e1] poisoning may result in severe [s2]encephalopathy[e2] 
+	(0, 5)	Stupor	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	669	 [s1]Stupor[e1] from [s2]lamotrigine[e2] toxicity.
+	(8, 15)	acute intoxication	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	670	The cause of death was determined to be [s1]acute intoxication[e1] by [s2]olanzapine[e2]  and the manner of death was accidental.
+	(14, 23)	dead	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	671	This article describes the case of a 25-year-old man found [s1]dead[e1] at home who had been prescribed [s2]olanzapine[e2] for schizophrenia.
+	(0, 8)	Lichenoid drug eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	672	 [s1]Lichenoid drug eruption[e1] to [s2]salsalate[e2] 
+	(1, 11)	eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	673	This [s1]eruption[e1] emerged after 1 month of therapy with [s2]salsalate[e2]  persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.
+	(7, 17)	lichenoid eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	674	We describe a patient who experienced a [s1]lichenoid eruption[e1] after the initiation of [s2]salsalate[e2] for relief of arthritic pain.
+	(0, 8)	Amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	675	 [s1]Amphotericin B[e1] induced [s2]seizures[e2] in a patient with AIDS.
+	(16, 28)	grand mal seizures	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	676	CASE SUMMARY: A 46-year-old African-American man experienced recurrent [s1]grand mal seizures[e1] during intravenous infusion of [s2]amphotericin B[e2]  then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.
+	(2, 17)	Amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	677	CONCLUSIONS: [s1]Amphotericin B[e1] seems to be the probable cause of the [s2]seizures[e2] 
+	(14, 22)	seizures	amphotercin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	678	Despite administration of phenytoin and lorazepam, the [s1]seizures[e1] persisted and occurred only during [s2]amphotercin B[e2] administration.
+	(0, 12)	Didanosine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	679	 [s1]Didanosine[e1] also has a potential for inducing [s2]seizures[e2] 
+	(10, 19)	seizure	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	680	OBJECTIVE: To report a case of multiple episodes of [s1]seizure[e1] activity in an AIDS patent following [s2]amphotericin B[e2] infusion.
+	(7, 19)	amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	681	The time course of events suggested that [s1]amphotericin B[e1] was the cause of the [s2]seizures[e2] in this AIDS patient.
+	(7, 12)	seizures	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	682	To date, only three cases of [s1]seizures[e1] associated with [s2]amphotericin B[e2] have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.
+	(0, 17)	Vocal cord paralysis	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	683	 [s1]Vocal cord paralysis[e1] as a consequence of peritonsillar infiltration with [s2]bupivacaine[e2] 
+	(14, 29)	bilateral vocal cord paralysis	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	684	We present the case of a 5-year-old girl who developed [s1]bilateral vocal cord paralysis[e1] following preoperative peritonsillar [s2]bupivacaine[e2] infiltration.
+	(20, 37)	right bundle branch block	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	685	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete [s1]right bundle branch block[e1] after ingestion of 10 g and 4 g of [s2]carbamazepine[e2] respectively.
+	(0, 8)	Carbamazepine	right bundle branch block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	686	 [s1]Carbamazepine[e1] induced [s2]right bundle branch block[e2] in a Greenlandic patient.
+	(0, 13)	Cicatricial entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	687	 [s1]Cicatricial entropion[e1] associated with chronic [s2]dipivefrin[e2] application.
+	(38, 51)	dipivefrin	entropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	688	CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including [s1]dipivefrin[e1] is a possible mechanism of action for [s2]entropion[e2] 
+	(24, 47)	cicatricial entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	689	Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of [s1]cicatricial entropion[e1] after at least 2 years of twice-a-day application of [s2]dipivefrin[e2] 
+	(19, 33)	cicatrical entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	690	PURPOSE: To report patients who presented to the oculoplastics department for repair of [s1]cicatrical entropion[e1] after topical use of [s2]dipivefrin[e2] 
+	(9, 37)	constellation of dermatitis	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	691	A 34-year-old lady developed a [s1]constellation of dermatitis[e1]  fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
+	(15, 37)	fever	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	692	A 34-year-old lady developed a constellation of dermatitis, [s1]fever[e1]  lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
+	(24, 37)	hepatitis	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	693	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and [s1]hepatitis[e1]  beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
+	(17, 38)	lymphadenopathy	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	694	A 34-year-old lady developed a constellation of dermatitis, fever, [s1]lymphadenopathy[e1] and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
+	(29, 44)	sulphasalazine	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	695	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often [s2]fatal[e2]  immunoallergic reaction to sulphasalazine."
+	(29, 44)	sulphasalazine	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	696	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often [s2]fatal[e2]  immunoallergic reaction to sulphasalazine."
+	(29, 46)	sulphasalazine	immunoallergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	697	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often fatal, [s2]immunoallergic reaction[e2] to sulphasalazine."
+	(29, 46)	sulphasalazine	immunoallergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	698	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often fatal, [s2]immunoallergic reaction[e2] to sulphasalazine."
+	(29, 37)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	699	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine."
+	(29, 37)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	700	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine."
+	(4, 12)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	701	The 3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome strikes again.
+	(29, 44)	SIADH	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	702	Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the [s1]SIADH[e1] was most likely to have been induced by administration of [s2]CDDP[e2] 
+	(8, 14)	SIADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	703	Syndrome of inappropriate secretion of ADH  [s1]SIADH[e1]  following [s2]cisplatin[e2] administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.
+	(0, 16)	Syndrome of inappropriate secretion of ADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	704	 [s1]Syndrome of inappropriate secretion of ADH[e1] (SIADH) following [s2]cisplatin[e2] administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.
+	(25, 37)	SIADH	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	705	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin  [s2]CDDP[e2]  and vindesine (VDS).
+	(25, 34)	SIADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	706	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with [s2]cisplatin[e2] (CDDP) and vindesine (VDS).
+	(25, 45)	SIADH	VDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	707	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin (CDDP) and vindesine  [s2]VDS[e2] .
+	(25, 42)	SIADH	vindesine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	708	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin (CDDP) and [s2]vindesine[e2] (VDS).
+	(14, 39)	syndrome of inappropriate secretion of antidiuretic hormone	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	709	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin  [s2]CDDP[e2]  and vindesine (VDS).
+	(14, 36)	syndrome of inappropriate secretion of antidiuretic hormone	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	710	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with [s2]cisplatin[e2] (CDDP) and vindesine (VDS).
+	(14, 47)	syndrome of inappropriate secretion of antidiuretic hormone	VDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	711	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine  [s2]VDS[e2] .
+	(14, 44)	syndrome of inappropriate secretion of antidiuretic hormone	vindesine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	712	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin (CDDP) and [s2]vindesine[e2] (VDS).
+	(12, 25)	anisocoria	scopolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	713	After extensive neurological 'work up', we realized that the [s1]anisocoria[e1] was related to the transdermal [s2]scopolamine[e2] patch that we had prescribed for weaning off the opioid.
+	(0, 10)	Anisocoria	scopolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	714	 [s1]Anisocoria[e1] from transdermal [s2]scopolamine[e2] 
+	(0, 12)	De novo absence status	lorazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	715	 [s1]De novo absence status[e1] of late onset following withdrawal of [s2]lorazepam[e2]  a case report.
+	(30, 47)	nonconvulsive generalized status epilepticus	lorazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	716	The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a [s1]nonconvulsive generalized status epilepticus[e1] following acute withdrawal of [s2]lorazepam[e2] 
+	(14, 28)	life-threatening vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	717	Early recognition of hereditary motor and sensory neuropathy type 1 can avoid [s1]life-threatening vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity.
+	(23, 40)	severe neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	718	Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent [s1]severe neurotoxicity[e1] of polychemotherapy by avoiding [s2]vincristine[e2] 
+	(8, 19)	vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	719	The disease predisposes to severe [s1]vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity.
+	(34, 53)	severe motor neuropathy	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	720	We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed [s1]severe motor neuropathy[e1] 3 weeks after the first cycle of treatment including 2 mg of [s2]vincristine[e2] 
+	(1, 20)	asymptomatic hepatitis	amodiaquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	721	Acute [s1]asymptomatic hepatitis[e1] in a healthy normal volunteer exposed to 2 oral doses of [s2]amodiaquine[e2] and artesunate.
+	(1, 26)	asymptomatic hepatitis	artesunate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	722	Acute [s1]asymptomatic hepatitis[e1] in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and [s2]artesunate[e2] 
+	(8, 22)	hepatitis	amodiaquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	723	This report describes an unexpected drug-induced [s1]hepatitis[e1] in a previously healthy young woman exposed to 2 doses of [s2]amodiaquine[e2] and artesunate.
+	(8, 28)	hepatitis	artesunate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	724	This report describes an unexpected drug-induced [s1]hepatitis[e1] in a previously healthy young woman exposed to 2 doses of amodiaquine and [s2]artesunate[e2] 
+	(0, 9)	Systemic allergic contact dermatitis	8-methoxypsoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	725	 [s1]Systemic allergic contact dermatitis[e1] to [s2]8-methoxypsoralen[e2] (8-MOP).
+	(0, 17)	Systemic allergic contact dermatitis	8-MOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	726	 [s1]Systemic allergic contact dermatitis[e1] to 8-methoxypsoralen  [s2]8-MOP[e2] .
+	(7, 16)	systemic allergic contact dermatitis	8-MOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	727	We describe a patient who had a [s1]systemic allergic contact dermatitis[e1] to [s2]8-MOP[e2] develop during her second course of PUVA treatment for psoriasis.
+	(12, 26)	benztropine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	728	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with confusion, [s2]abdominal pain[e2]  and distention.
+	(12, 24)	benztropine	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	729	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with [s2]confusion[e2]  abdominal pain, and distention.
+	(12, 30)	benztropine	distention	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	730	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with confusion, abdominal pain, and [s2]distention[e2] 
+	(0, 15)	Agranulocytosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	731	 [s1]Agranulocytosis[e1] and granulocytopenia associated with [s2]quetiapine[e2] 
+	(6, 15)	granulocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	732	Agranulocytosis and [s1]granulocytopenia[e1] associated with [s2]quetiapine[e2] 
+	(20, 29)	agranulocytosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	733	CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of [s1]agranulocytosis[e1] while using [s2]quetiapine[e2] 
+	(9, 18)	haematological adverse effects	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	734	METHOD: We describe three case-reports concerning [s1]haematological adverse effects[e1] of [s2]quetiapine[e2] 
+	(2, 21)	Quetiapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	735	RESULTS: [s1]Quetiapine[e1] was associated with leucopenia in two patients and clinically apparent [s2]agranulocytosis[e2] in one patient.
+	(2, 10)	Quetiapine	leucopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	736	RESULTS: [s1]Quetiapine[e1] was associated with [s2]leucopenia[e2] in two patients and clinically apparent agranulocytosis in one patient.
+	(9, 16)	ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	737	CONCLUSIONS: There is very little published information regarding [s1]ofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] 
+	(13, 29)	Stevens-Johnson syndrome	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	738	However, a large case-control study included three cases of either [s1]Stevens-Johnson syndrome[e1] or toxic epidermal necrolysis associated with [s2]ofloxacin[e2] use, but no details of the cases were given.
+	(18, 29)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	739	However, a large case-control study included three cases of either Stevens-Johnson syndrome or [s1]toxic epidermal necrolysis[e1] associated with [s2]ofloxacin[e2] use, but no details of the cases were given.
+	(10, 17)	ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	740	It is hoped that this case report creates awareness that [s1]ofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] is possible.
+	(8, 25)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	741	OBJECTIVE: To report a fatal case of [s1]toxic epidermal necrolysis[e1] in a man who was treated with oral [s2]ofloxacin[e2] for epididymitis.
+	(0, 10)	Ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	742	 [s1]Ofloxacin[e1]  a probable cause of [s2]toxic epidermal necrolysis[e2] 
+	(7, 20)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	743	This report rules out other causes of [s1]toxic epidermal necrolysis[e1] and implicates [s2]ofloxacin[e2] in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.
+	(7, 20)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	744	This report rules out other causes of [s1]toxic epidermal necrolysis[e1] and implicates [s2]ofloxacin[e2] in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.
+	(15, 27)	multiple erythematous nodules	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	745	A boy with chronic neutropenia and recurrent inflammatory skin lesions developed [s1]multiple erythematous nodules[e1] following administration of [s2]G-CSF[e2] 
+	(16, 40)	erythematous papular eruption	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	746	A girl with cystic fibrosis and cyclic neutropenia developed an [s1]erythematous papular eruption[e1] without fever or neutrophilia 7 months after commencing therapy with [s2]G-CSF[e2] 
+	(0, 32)	Neutrophilic dermatoses	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	747	 [s1]Neutrophilic dermatoses[e1] in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor  [s2]G-CSF[e2]  therapy.
+	(0, 24)	Neutrophilic dermatoses	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	748	 [s1]Neutrophilic dermatoses[e1] in two children with idiopathic neutropenia: association with [s2]granulocyte colony-stimulating factor[e2] (G-CSF) therapy.
+	(1, 24)	neutrophilic skin lesions	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	749	Painful [s1]neutrophilic skin lesions[e1] were observed in two children receiving granulocyte colony-stimulating factor  [s2]G-CSF[e2]  for treatment of idiopathic neutropenia.
+	(1, 16)	neutrophilic skin lesions	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	750	Painful [s1]neutrophilic skin lesions[e1] were observed in two children receiving [s2]granulocyte colony-stimulating factor[e2] (G-CSF) for treatment of idiopathic neutropenia.
+	(0, 24)	Painful	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	751	 [s1]Painful[e1] neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor  [s2]G-CSF[e2]  for treatment of idiopathic neutropenia.
+	(0, 16)	Painful	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	752	 [s1]Painful[e1] neutrophilic skin lesions were observed in two children receiving [s2]granulocyte colony-stimulating factor[e2] (G-CSF) for treatment of idiopathic neutropenia.
+	(11, 28)	neutrophilic dermatoses	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	753	We believe that these skin eruptions belong to a spectrum of [s1]neutrophilic dermatoses[e1] that can be induced or aggravated by [s2]G-CSF[e2] therapy.
+	(4, 28)	skin eruptions	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	754	We believe that these [s1]skin eruptions[e1] belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by [s2]G-CSF[e2] therapy.
+	(7, 23)	liothyronine	hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	755	There is a putative role of [s1]liothyronine[e1] administration in precipitating or activating [s2]hyperthyroidism[e2] 
+	(0, 9)	Triiodothyronine	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	756	 [s1]Triiodothyronine[e1] induced [s2]thyrotoxicosis[e2] in ophthalmic Graves disease.
+	(15, 30)	VFDs	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	757	This case report describes the development of asymptomatic visual field defects  [s1]VFDs[e1]  in a psychiatric patient with bipolar disorder receiving adjunctive [s2]tiagabine[e2] treatment.
+	(12, 32)	visual field defects	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	758	This case report describes the development of asymptomatic [s1]visual field defects[e1] (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive [s2]tiagabine[e2] treatment.
+	(0, 5)	Pulmonary toxicity	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	759	 [s1]Pulmonary toxicity[e1] with [s2]mefloquine[e2] 
+	(6, 19)	acute lung injury	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	760	This is the second report of [s1]acute lung injury[e1] and diffuse alveolar damage caused by [s2]mefloquine[e2] 
+	(10, 19)	diffuse alveolar damage	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	761	This is the second report of acute lung injury and [s1]diffuse alveolar damage[e1] caused by [s2]mefloquine[e2] 
+	(6, 17)	acute lung injury	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	762	This report presents a case of [s1]acute lung injury[e1] developing within hours after administration of [s2]mefloquine[e2] for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.
+	(5, 13)	central blindness	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	763	An adult male presented with [s1]central blindness[e1] after ingesting [s2]methanol[e2] 
+	(3, 9)	methanol	visual impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	764	Reversal of severe [s1]methanol[e1] induced [s2]visual impairment[e2]  no evidence of retinal toxicity due to fomepizole.
+	(7, 25)	octreotide	intrahepatic bile stasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	765	Extra caution should be taken in using [s1]octreotide[e1] or its long-acting analog in patients otherwise predisposed to [s2]intrahepatic bile stasis[e2] 
+	(3, 13)	bile sludge	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	766	Gallstones and [s1]bile sludge[e1] are common side effects of [s2]octreotide[e2] therapy but rarely become symptomatic or require treatment.
+	(0, 13)	Gallstones	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	767	 [s1]Gallstones[e1] and bile sludge are common side effects of [s2]octreotide[e2] therapy but rarely become symptomatic or require treatment.
+	(0, 16)	Hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	768	 [s1]Hepatolithiasis[e1] (intrahepatic stone) during [s2]octreotide[e2] therapy for acromegaly: a case report.
+	(14, 19)	octreotide	alters bile acid composition	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	769	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1]  [s2]alters bile acid composition[e2] and may thus hasten intrahepatic sludge and stone formation.
+	(7, 15)	gallbladder stasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	770	In addition to its known effect on [s1]gallbladder stasis[e1]  [s2]octreotide[e2] alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.
+	(14, 27)	octreotide	hasten intrahepatic sludge	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	771	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1] alters bile acid composition and may thus [s2]hasten intrahepatic sludge[e2] and stone formation.
+	(14, 36)	octreotide	stone formation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	772	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1] alters bile acid composition and may thus hasten intrahepatic sludge and [s2]stone formation[e2] 
+	(7, 16)	hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	773	This is the first reported case of [s1]hepatolithiasis[e1] during [s2]octreotide[e2] therapy.
+	(5, 41)	hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	774	We report a case of [s1]hepatolithiasis[e1] (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with [s2]octreotide[e2] 
+	(25, 41)	tamoxifen	endometrial carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	775	However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between [s1]tamoxifen[e1] therapy in women with breast cancer and the development of [s2]endometrial carcinoma[e2] 
+	(10, 21)	endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	776	In this healthy population, the relative risk of developing [s1]endometrial carcinoma[e1] in the [s2]tamoxifen[e2] arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.
+	(0, 10)	INH	drug eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	777	 [s1]INH[e1]  which is a leading cause of [s2]drug eruptions[e2] in the above group of drugs was withdrawn.
+	(0, 12)	Isonicotinic acid hydrazide	anagen effluvium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	778	 [s1]Isonicotinic acid hydrazide[e1] induced [s2]anagen effluvium[e2] and associated lichenoid eruption.
+	(0, 21)	Isonicotinic acid hydrazide	lichenoid eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	779	 [s1]Isonicotinic acid hydrazide[e1] induced anagen effluvium and associated [s2]lichenoid eruption[e2] 
+	(1, 16)	anagen effluvium	INH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	780	Such [s1]anagen effluvium[e1] with lichenoid eruption following [s2]INH[e2] therapy has not been observed previously.
+	(9, 16)	lichenoid eruption	INH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	781	Such anagen effluvium with [s1]lichenoid eruption[e1] following [s2]INH[e2] therapy has not been observed previously.
+	(0, 12)	Linear IgA bullous dermatosis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	782	 [s1]Linear IgA bullous dermatosis[e1] occurring after [s2]carbamazepine[e2] 
+	(6, 13)	LABD	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	783	We report a patient who experienced [s1]LABD[e1] shortly after starting [s2]carbamazepine[e2] therapy.
+	(5, 24)	metoclopramide	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	784	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, [s2]agitation[e2]  fever, diaphoresis, tachypnea, tachycardia, and hypertension.
+	(5, 22)	metoclopramide	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	785	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with [s2]confusion[e2]  agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.
+	(5, 28)	metoclopramide	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	786	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, [s2]diaphoresis[e2]  tachypnea, tachycardia, and hypertension.
+	(5, 26)	metoclopramide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	787	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, [s2]fever[e2]  diaphoresis, tachypnea, tachycardia, and hypertension.
+	(5, 44)	metoclopramide	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	788	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and [s2]hypertension[e2] 
+	(5, 38)	metoclopramide	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	789	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, [s2]tachycardia[e2]  and hypertension.
+	(5, 33)	metoclopramide	tachypnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	790	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, [s2]tachypnea[e2]  tachycardia, and hypertension.
+	(17, 37)	extrapyramidal reactions	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	791	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving sertraline or venlafaxine when [s2]metoclopramide[e2] is coadministered even in a single, conventional dose.
+	(17, 27)	extrapyramidal reactions	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	792	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving [s2]sertraline[e2] or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.
+	(17, 31)	extrapyramidal reactions	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	793	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving sertraline or [s2]venlafaxine[e2] when metoclopramide is coadministered even in a single, conventional dose.
+	(11, 37)	serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	794	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when [s2]metoclopramide[e2] is coadministered even in a single, conventional dose.
+	(11, 27)	serotonin syndrome	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	795	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving [s2]sertraline[e2] or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.
+	(11, 31)	serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	796	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving sertraline or [s2]venlafaxine[e2] when metoclopramide is coadministered even in a single, conventional dose.
+	(13, 23)	extrapyramidal movement disorders	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	797	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when [s2]metoclopramide[e2] was coadministered with sertraline or venlafaxine.
+	(13, 35)	extrapyramidal movement disorders	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	798	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when metoclopramide was coadministered with [s2]sertraline[e2] or venlafaxine.
+	(13, 39)	extrapyramidal movement disorders	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	799	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when metoclopramide was coadministered with sertraline or [s2]venlafaxine[e2] 
+	(7, 23)	serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	800	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when [s2]metoclopramide[e2] was coadministered with sertraline or venlafaxine.
+	(7, 35)	serotonin syndrome	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	801	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with [s2]sertraline[e2] or venlafaxine.
+	(7, 39)	serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	802	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or [s2]venlafaxine[e2] 
+	(0, 17)	Serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	803	 [s1]Serotonin syndrome[e1] caused by selective serotonin reuptake-inhibitors [s2]metoclopramide[e2] interaction.
+	(3, 21)	metoclopramide	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	804	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed [s2]agitation[e2]  dysarthria, diaphoresis, and a movement disorder.
+	(3, 28)	metoclopramide	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	805	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, dysarthria, [s2]diaphoresis[e2]  and a movement disorder.
+	(3, 23)	metoclopramide	dysarthria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	806	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, [s2]dysarthria[e2]  diaphoresis, and a movement disorder.
+	(3, 35)	metoclopramide	movement disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	807	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a [s2]movement disorder[e2] 
+	(11, 20)	metoclopramide	movement disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	808	She was admitted following a fall and, after being given [s1]metoclopramide[e1]  developed [s2]movement disorder[e2] and a period of unresponsiveness.
+	(11, 26)	metoclopramide	unresponsiveness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	809	She was admitted following a fall and, after being given [s1]metoclopramide[e1]  developed movement disorder and a period of [s2]unresponsiveness[e2] 
+	(10, 28)	malignant neuroleptic syndrome	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	810	A patient suffering from a rare enzyme deficiency developed a [s1]malignant neuroleptic syndrome[e1] after having been treated with one single dose of [s2]haloperidol[e2] 
+	(4, 12)	delated cutaneous reactions	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	811	BACKGROUND: reports on [s1]delated cutaneous reactions[e1] to [s2]captopril[e2] have been seldom reported.
+	(0, 20)	Captopril	cutaneous side-effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	812	 [s1]Captopril[e1] is an angiotensin-converting enzyme (ACE) inhibitor and their [s2]cutaneous side-effects[e2] are documented, but little has been published concerning the usefulness of patch test when they occur.
+	(0, 6)	Dermatitis	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	813	 [s1]Dermatitis[e1] to [s2]captopril[e2] 
+	(10, 17)	cutaneous reaction	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	814	We presented the case of a patient who developed a [s1]cutaneous reaction[e1] induced by [s2]captopril[e2] with positive patch test.
+	(17, 26)	warfarin	hematochezia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	815	A 62-year-old Caucasian man with atrial fibrillation who was taking [s1]warfarin[e1] reported an episode of [s2]hematochezia[e2]  his international normalized ratio (INR) was 1.74.
+	(0, 6)	Warfarin	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	816	 [s1]Warfarin[e1] associated [s2]bleeding[e2] complication saved life.
+	(0, 6)	Warfarin	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	817	 [s1]Warfarin[e1] associated [s2]bleeding[e2] generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.
+	(8, 18)	dilated cardiomyopathy	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	818	A case of polymyositis with [s1]dilated cardiomyopathy[e1] associated with [s2]interferon alpha[e2] treatment for hepatitis B.
+	(3, 18)	polymyositis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	819	A case of [s1]polymyositis[e1] with dilated cardiomyopathy associated with [s2]interferon alpha[e2] treatment for hepatitis B.
+	(4, 16)	interferon alpha	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	820	In this case, [s1]interferon alpha[e1] induced polymyositis and [s2]cardiomyopathy[e2] is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.
+	(4, 11)	interferon alpha	polymyositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	821	In this case, [s1]interferon alpha[e1] induced [s2]polymyositis[e2] and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.
+	(0, 12)	Polymyositis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	822	 [s1]Polymyositis[e1] is a rare complication of [s2]interferon alpha[e2] treatment as a result of immune-modulating role of the drug itself.
+	(5, 18)	interferon alpha	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	823	To treat hepatitis B, [s1]interferon alpha[e1] was administered until the proximal [s2]muscle weakness[e2] developed.
+	(7, 21)	neoplastic seeding	ethanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	824	Long-term follow-up after [s1]neoplastic seeding[e1] complicating percutaneous [s2]ethanol[e2] injection for treatment of hepatocellular carcinoma.
+	(5, 21)	subcutaneous metastasis	ethanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	825	We describe a case of [s1]subcutaneous metastasis[e1] along the needle track after percutaneous [s2]ethanol[e2] injection (PEI) for treatment of hepatocellular carcinoma.
+	(0, 17)	Aggressive endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	826	 [s1]Aggressive endometrial carcinoma[e1] in a breast cancer patient treated with [s2]tamoxifen[e2] with normal transvaginal ultrasonography.
+	(1, 10)	tamoxifen	endometrial disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	827	Since [s1]tamoxifen[e1] therapy can induce [s2]endometrial disorders[e2]  surveillance schemes of women taking tamoxifen have been recommended.
+	(1, 10)	tamoxifen	endometrial disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	828	Since [s1]tamoxifen[e1] therapy can induce [s2]endometrial disorders[e2]  surveillance schemes of women taking tamoxifen have been recommended.
+	(15, 24)	endometrial cancer	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	829	We described a very atypical case of a high stage, high grade [s1]endometrial cancer[e1] associated with [s2]tamoxifen[e2] in a 64-year-old woman with a past history of breast cancer.
+	(11, 29)	itraconazole	cholangiopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	830	Beginning ductopenia was present in two, suggesting that [s1]itraconazole[e1] might be responsible for the occurrence of prolonged drug-induced [s2]cholangiopathy[e2] 
+	(1, 13)	ductopenia	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	831	Beginning [s1]ductopenia[e1] was present in two, suggesting that [s2]itraconazole[e2] might be responsible for the occurrence of prolonged drug-induced cholangiopathy.
+	(2, 15)	Itraconazole	cholestatic pattern of injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	832	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a [s2]cholestatic pattern of injury[e2] with damage to the interlobular bile ducts, possibly leading to ductopenia.
+	(2, 23)	Itraconazole	damage to the interlobular bile ducts	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	833	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a cholestatic pattern of injury with [s2]damage to the interlobular bile ducts[e2]  possibly leading to ductopenia.
+	(2, 36)	Itraconazole	ductopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	834	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to [s2]ductopenia[e2] 
+	(2, 10)	Itraconazole	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	835	CONCLUSIONS: [s1]Itraconazole[e1] induced [s2]liver injury[e2] presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.
+	(0, 10)	Hepatotoxicity	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	836	 [s1]Hepatotoxicity[e1] related to [s2]itraconazole[e2]  report of three cases.
+	(6, 14)	itraconazole	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	837	METHODS: Three patients with apparent [s1]itraconazole[e1] induced [s2]liver injury[e2] were studied.
+	(4, 11)	hepatitis	ketoconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	838	The occurrence of acute [s1]hepatitis[e1] is best known for [s2]ketoconazole[e2] 
+	(8, 15)	liver damage	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	839	We report on three patients who developed acute [s1]liver damage[e1] during therapy with [s2]itraconazole[e2]  and in whom liver biopsy specimens were obtained.
+	(3, 27)	itraconazole	vanishing bile duct syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	840	We suggest that [s1]itraconazole[e1] should be added to the list of drugs that may be responsible for a drug-induced [s2]vanishing bile duct syndrome[e2] 
+	(1, 8)	itraconazole	hepatotoxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	841	With [s1]itraconazole[e1]  [s2]hepatotoxic[e2] reactions have only very rarely been reported, and histologic data are lacking.
+	(0, 12)	Thrombotic stroke	porcine factor VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	842	 [s1]Thrombotic stroke[e1] associated with the use of [s2]porcine factor VIII[e2] in a patient with acquired haemophilia.
+	(16, 32)	thrombotic left middle cerebral artery distribution stroke	pFVIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	843	We have recently encountered a patient with acquired haemophilia who developed a [s1]thrombotic left middle cerebral artery distribution stroke[e1] while being treated with [s2]pFVIII[e2] 
+	(9, 19)	pFVIII	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	844	We speculate that platelet activation induced by [s1]pFVIII[e1] may have contributed to [s2]thrombosis[e2] and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.
+	(0, 9)	Cutaneous sarcoidosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	845	 [s1]Cutaneous sarcoidosis[e1] during [s2]interferon alfa[e2] and ribavirin treatment of hepatitis C virus infection: two cases.
+	(0, 14)	Cutaneous sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	846	 [s1]Cutaneous sarcoidosis[e1] during interferon alfa and [s2]ribavirin[e2] treatment of hepatitis C virus infection: two cases.
+	(16, 23)	granulomatosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	847	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with [s2]interferon alfa[e2] and more recently with the combination of interferon alfa plus ribavirin.
+	(16, 23)	granulomatosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	848	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with [s2]interferon alfa[e2] and more recently with the combination of interferon alfa plus ribavirin.
+	(16, 39)	granulomatosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	849	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with interferon alfa and more recently with the combination of interferon alfa plus [s2]ribavirin[e2] 
+	(6, 22)	sarcoidosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	850	We report two new cases of [s1]sarcoidosis[e1] in two patients with hepatitis C virus infection treated with [s2]interferon alfa[e2] and ribavirin.
+	(6, 27)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	851	We report two new cases of [s1]sarcoidosis[e1] in two patients with hepatitis C virus infection treated with interferon alfa and [s2]ribavirin[e2] 
+	(3, 24)	mirtazapine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	852	CONCLUSIONS: Although [s1]mirtazapine[e1] offers clinicians a combination of strong efficacy and good safety, we suggest bearing [s2]SS[e2] in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.
+	(1, 16)	SS	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	853	DISC [s1]SS[e1] ON: A review of the cases of SS with implication of [s2]mirtazapine[e2] as the cause was performed.
+	(7, 18)	serotonin syndrome	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	854	OBJECTIVE: To document a case of [s1]serotonin syndrome[e1] (SS) associated with [s2]mirtazapine[e2] monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.
+	(11, 16)	SS	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	855	OBJECTIVE: To document a case of serotonin syndrome  [s1]SS[e1]  associated with [s2]mirtazapine[e2] monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.
+	(1, 9)	serotonin syndrome	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	856	Severe [s1]serotonin syndrome[e1] induced by [s2]mirtazapine[e2] monotherapy.
+	(0, 6)	Pulmonary toxicity	procarbazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	857	 [s1]Pulmonary toxicity[e1] secondary to [s2]procarbazine[e2] 
+	(9, 17)	proteinuria	interferon (IFN)-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	858	A 64-year-old man presented with [s1]proteinuria[e1] during postoperative [s2]interferon (IFN)-beta[e2] therapy against malignant melanoma.
+	(0, 14)	Minimal change nephrotic syndrome	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	859	 [s1]Minimal change nephrotic syndrome[e1] developing during postoperative [s2]interferon-beta[e2] therapy for malignant melanoma.
+	(10, 27)	histological abnormalities of the glomerulus	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	860	To our knowledge this is the first report that demonstrates [s1]histological abnormalities of the glomerulus[e1] associated with postoperative [s2]IFN-beta[e2] therapy for the malignant melanoma.
+	(6, 19)	delayed elimination	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	861	The authors report two cases of [s1]delayed elimination[e1] of methotrexate in patients receiving [s2]ciprofloxacin[e2]  with severe toxicity.
+	(6, 11)	delayed elimination	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	862	The authors report two cases of [s1]delayed elimination[e1] of [s2]methotrexate[e2] in patients receiving ciprofloxacin, with severe toxicity.
+	(17, 27)	ciprofloxacin	toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	863	The authors report two cases of delayed elimination of methotrexate in patients receiving [s1]ciprofloxacin[e1]  with severe [s2]toxicity[e2] 
+	(12, 21)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	864	CONCLUSIONS: Clinicians should be aware of the possible association of [s1]thrombocytopenia[e1] with [s2]lansoprazole[e2] and discontinue the drug if thrombocytopenia becomes apparent.
+	(11, 22)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	865	DISCUSSION: After exclusion of other causes, the onset of [s1]thrombocytopenia[e1] after administration of [s2]lansoprazole[e2]  the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.
+	(20, 68)	lansoprazole	thrombocytopenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	866	DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of [s1]lansoprazole[e1]  the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic [s2]thrombocytopenic[e2] response to lansoprazole.
+	(5, 23)	lansoprazole	platelet count decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	867	He was started on oral [s1]lansoprazole[e1] 60 mg twice daily and, on hospital day 2, his [s2]platelet count decreased[e2] to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).
+	(0, 7)	Lansoprazole	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	868	 [s1]Lansoprazole[e1] induced [s2]thrombocytopenia[e2] 
+	(7, 20)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	869	OBJECTIVE: To describe a case of [s1]thrombocytopenia[e1] associated with the administration of [s2]lansoprazole[e2] 
+	(15, 25)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	870	To date, this is the first reported case of what appears to be isolated [s1]thrombocytopenia[e1] associated with [s2]lansoprazole[e2] 
+	(3, 12)	anaphylactoid reaction	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	871	Life-threatening [s1]anaphylactoid reaction[e1] to [s2]amifostine[e2] used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.
+	(7, 30)	amifostine	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	872	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, hypotension, hypocalcemia and [s2]allergic reactions[e2] 
+	(7, 24)	amifostine	hypocalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	873	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, hypotension, [s2]hypocalcemia[e2] and allergic reactions.
+	(7, 18)	amifostine	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	874	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, [s2]hypotension[e2]  hypocalcemia and allergic reactions.
+	(7, 14)	amifostine	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	875	The most common side effects associated with [s1]amifostine[e1] are [s2]nausea[e2]  vomiting, hypotension, hypocalcemia and allergic reactions.
+	(7, 16)	amifostine	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	876	The most common side effects associated with [s1]amifostine[e1] are nausea, [s2]vomiting[e2]  hypotension, hypocalcemia and allergic reactions.
+	(4, 16)	life-threatening anaphylactoid reaction	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	877	The patient suffered a [s1]life-threatening anaphylactoid reaction[e1] to [s2]amifostine[e2] 
+	(0, 8)	Agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	878	 [s1]Agranulocytosis[e1] during [s2]clozapine[e2] therapy.
+	(6, 22)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	879	Granulocytopenia and [s1]agranulocytosis[e1] are considered among the most dangerous adverse effects of [s2]clozapine[e2] 
+	(0, 22)	Granulocytopenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	880	 [s1]Granulocytopenia[e1] and agranulocytosis are considered among the most dangerous adverse effects of [s2]clozapine[e2] 
+	(4, 19)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	881	The female patient received [s1]clozapine[e1] in a daily dose of 400 mg, which induced [s2]agranulocytosis[e2] after 2 months.
+	(11, 23)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	882	The male patient was treated with 225-mg/day [s1]clozapine[e1] and the time to the diagnosis of [s2]agranulocytosis[e2] was 6 weeks.
+	(8, 17)	NMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	883	A 53-year-old man developed [s1]NMS[e1] without rigidity while taking [s2]olanzapine[e2] 
+	(3, 14)	neuroleptic malignant syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	884	Atypical [s1]neuroleptic malignant syndrome[e1] associated with [s2]olanzapine[e2] 
+	(24, 52)	zuclopenthixol	painful erection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	885	CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral [s1]zuclopenthixol[e1]  an antipsychotic from the thioxanthene family, who developed an acute, [s2]painful erection[e2] 
+	(2, 16)	Priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	886	CONCLUSIONS: [s1]Priapism[e1] is an uncommon but potentially serious adverse effect of [s2]zuclopenthixol[e2] that practitioners, as with many other antipsychotics, should be aware of.
+	(5, 16)	priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	887	DISCUSSION: The occurrence of [s1]priapism[e1] in our patient was related to [s2]zuclopenthixol[e2] 
+	(8, 17)	zuclopenthixol	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	888	OBJECTIVE: To present a single case of [s1]zuclopenthixol[e1] induced [s2]priapism[e2] and a literature review.
+	(0, 7)	Priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	889	 [s1]Priapism[e1] associated with [s2]zuclopenthixol[e2] 
+	(3, 13)	zuclopenthixol	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	890	The capacity of [s1]zuclopenthixol[e1] to induce [s2]priapism[e2] is thought to be due to its antagonist activity on alpha-adrenergic receptors.
+	(21, 27)	sepsis	metamizole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	891	After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming [s1]sepsis[e1] associated with [s2]metamizole[e2] use.
+	(0, 30)	Metamizole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	892	 [s1]Metamizole[e1]  a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of [s2]agranulocytosis[e2] but is widely used in Mexico and other countries.
+	(10, 16)	mitomycin	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	893	Erythropoietin is beneficial in [s1]mitomycin[e1] induced [s2]hemolytic-uremic syndrome[e2] 
+	(6, 13)	HUS	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	894	We describe a patient who developed [s1]HUS[e1] after treatment with [s2]mitomycin C[e2] (total dose 144 mg/m2) due to a carcinoma of the ascending colon.
+	(0, 8)	Levofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	895	 [s1]Levofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] in an elderly patient.
+	(12, 20)	levofloxacin	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	896	To our knowledge, this case is the first published report of [s1]levofloxacin[e1] induced [s2]TEN[e2] 
+	(11, 29)	grand mal seizures	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	897	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with cisplatin, vinblastine and [s2]bleomycin[e2] for germ cell ovarian cancer stage Ic.
+	(11, 20)	grand mal seizures	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	898	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with [s2]cisplatin[e2]  vinblastine and bleomycin for germ cell ovarian cancer stage Ic.
+	(11, 24)	grand mal seizures	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	899	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with cisplatin, [s2]vinblastine[e2] and bleomycin for germ cell ovarian cancer stage Ic.
+	(0, 15)	Posterior leukoencephalopathy	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	900	 [s1]Posterior leukoencephalopathy[e1] following cisplatin, [s2]bleomycin[e2] and vinblastine therapy for germ cell tumor of the ovary.
+	(0, 11)	Posterior leukoencephalopathy	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	901	 [s1]Posterior leukoencephalopathy[e1] following [s2]cisplatin[e2]  bleomycin and vinblastine therapy for germ cell tumor of the ovary.
+	(0, 20)	Posterior leukoencephalopathy	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	902	 [s1]Posterior leukoencephalopathy[e1] following cisplatin, bleomycin and [s2]vinblastine[e2] therapy for germ cell tumor of the ovary.
+	(6, 15)	IL-2	hemorrhagic lesion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	903	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a [s2]hemorrhagic lesion[e2] that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.
+	(6, 38)	IL-2	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	904	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 [s2]pancytopenia[e2] 
+	(6, 25)	IL-2	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	905	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a hemorrhagic lesion that progressed to [s2]toxic epidermal necrolysis[e2]  as well as grade 4 pancytopenia.
+	(7, 21)	cutaneous and hematologic toxicity	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	906	OBJECTIVE: To report a case of [s1]cutaneous and hematologic toxicity[e1] in a patient treated with [s2]IL-2[e2] 
+	(3, 16)	IL-2	mortality rate <3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	907	Subcutaneous [s1]IL-2[e1] is safe and well tolerated, with a [s2]mortality rate <3[e2] .
+	(0, 11)	Toxic epidermal necrolysis	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	908	 [s1]Toxic epidermal necrolysis[e1] associated with [s2]interleukin-2[e2] 
+	(3, 17)	anaphylactoid reaction	Gelofusine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	909	A case of [s1]anaphylactoid reaction[e1] due solely to the use of [s2]Gelofusine[e2] in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.
+	(0, 14)	Gelofusine allergy	Gelofusine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	910	 [s1]Gelofusine allergy[e1] -the need for identification jewellery [s2]Gelofusine[e2] allergy--the need for identification jewellery.
+	(3, 9)	valproate	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	911	The authors describe [s1]valproate[e1] induced [s2]hyperammonemia[e2] and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.
+	(3, 14)	valproate	mental status changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	912	The authors describe [s1]valproate[e1] induced hyperammonemia and [s2]mental status changes[e2] in an 88-year-old man, the first known reported case in an elderly patient.
+	(0, 14)	Valproate	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	913	 [s1]Valproate[e1] induced hyperammonemia as a cause of [s2]altered mental status[e2] 
+	(0, 6)	Valproate	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	914	 [s1]Valproate[e1] induced [s2]hyperammonemia[e2] as a cause of altered mental status.
+	(0, 13)	Leiomyosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	915	 [s1]Leiomyosarcoma[e1] in urinary bladder after [s2]cyclophosphamide[e2] therapy for retinoblastoma and review of bladder sarcomas.
+	(5, 24)	NMS	amisulpride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	916	The epivodes of [s1]NMS[e1] occured under treatment with clozapine, risperidone, and [s2]amisulpride[e2] 
+	(5, 14)	NMS	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	917	The epivodes of [s1]NMS[e1] occured under treatment with [s2]clozapine[e2]  risperidone, and amisulpride.
+	(5, 18)	NMS	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	918	The epivodes of [s1]NMS[e1] occured under treatment with clozapine, [s2]risperidone[e2]  and amisulpride.
+	(11, 22)	cough	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	919	A 73-year-old woman presented with fever and [s1]cough[e1] 2 weeks after completing the third cycle of [s2]fludarabine[e2] for chronic lymphocytic leukemia (CLL).
+	(9, 22)	fever	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	920	A 73-year-old woman presented with [s1]fever[e1] and cough 2 weeks after completing the third cycle of [s2]fludarabine[e2] for chronic lymphocytic leukemia (CLL).
+	(0, 21)	Fludarabine	lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	921	 [s1]Fludarabine[e1] induced lung toxicity must be considered in all patients who develop unexplained [s2]lung disease[e2] while receiving fludarabine.
+	(19, 25)	lung disease	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	922	Fludarabine induced lung toxicity must be considered in all patients who develop unexplained [s1]lung disease[e1] while receiving [s2]fludarabine[e2] 
+	(0, 6)	Fludarabine	lung toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	923	 [s1]Fludarabine[e1] induced [s2]lung toxicity[e2] must be considered in all patients who develop unexplained lung disease while receiving fludarabine.
+	(0, 10)	Multiple pulmonary nodules	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	924	 [s1]Multiple pulmonary nodules[e1]  an unusual presentation of [s2]fludarabine[e2] pulmonary toxicity: case report and review of literature.
+	(9, 14)	fludarabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	925	Multiple pulmonary nodules: an unusual presentation of [s1]fludarabine[e1]  [s2]pulmonary toxicity[e2]  case report and review of literature.
+	(6, 15)	fludarabine	pulmonary nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	926	This case extends the spectrum of [s1]fludarabine[e1] pulmonary toxicity to include [s2]pulmonary nodules[e2] 
+	(6, 11)	fludarabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	927	This case extends the spectrum of [s1]fludarabine[e1]  [s2]pulmonary toxicity[e2] to include pulmonary nodules.
+	(7, 19)	interstitial pneumonitis	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	928	To our knowledge, four cases of [s1]interstitial pneumonitis[e1] associated with [s2]fludarabine[e2] have been reported in medical literature.
+	(0, 13)	Epoprostenol	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	929	 [s1]Epoprostenol[e1] may be associated rarely with severe [s2]erythroderma[e2] 
+	(1, 14)	erythroderma	epoprostenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	930	Severe [s1]erythroderma[e1] as a complication of continuous [s2]epoprostenol[e2] therapy.
+	(29, 51)	epoprostenol	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	931	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, nausea and vomiting, and [s2]fever[e2] 
+	(29, 46)	epoprostenol	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	932	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, [s2]nausea[e2] and vomiting, and fever.
+	(29, 38)	epoprostenol	rapidly progressive erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	933	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with [s2]rapidly progressive erythema[e2]  scaling, nausea and vomiting, and fever.
+	(29, 44)	epoprostenol	scaling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	934	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, [s2]scaling[e2]  nausea and vomiting, and fever.
+	(29, 48)	epoprostenol	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	935	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, nausea and [s2]vomiting[e2]  and fever.
+	(19, 27)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	936	A 50-year-old diabetic and hypertensive male patient is reported who had [s1]ticlopidine[e1] induced [s2]marrow aplasia[e2] partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.
+	(8, 16)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	937	There is no consensus on the treatment of [s1]ticlopidine[e1] induced [s2]marrow aplasia[e2] 
+	(0, 8)	Ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	938	 [s1]Ticlopidine[e1] induced [s2]marrow aplasia[e2] treated with cyclosporine.
+	(8, 17)	lower leg edema	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	939	A 53-year-old man developed [s1]lower leg edema[e1] 4 weeks after [s2]rosiglitazone[e2] was increased from 4 mg once/day to 4 mg twice/day.
+	(8, 25)	bilateral lower leg edema	pioglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	940	A 75-year-old man developed [s1]bilateral lower leg edema[e1] 6 months after switching from troglitazone to [s2]pioglitazone[e2] 
+	(8, 21)	ankle, hand, and facial swelling	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	941	A 77-year-old man developed [s1]ankle, hand, and facial swelling[e1] 2 weeks after starting [s2]rosiglitazone[e2] 
+	(3, 19)	polymorphic ventricular tachycardia	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	942	Two cases of [s1]polymorphic ventricular tachycardia[e1] induced by the administration of [s2]verapamil[e2] against paroxysmal supraventricular tachycardia.
+	(0, 34)	Verapamil	proarrhythmic effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	943	 [s1]Verapamil[e1] is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little [s2]proarrhythmic effect[e2] 
+	(11, 28)	non-sustained polymorphic ventricular tachycardia	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	944	We describe two cases of PSVT that changed to [s1]non-sustained polymorphic ventricular tachycardia[e1] after administration of [s2]verapamil[e2] 
+	(0, 10)	Epsilon-aminocaproic acid	renal complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	945	 [s1]Epsilon-aminocaproic acid[e1] and [s2]renal complications[e2]  case report and review of the literature.
+	(2, 11)	mydriasis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	946	Neonatal [s1]mydriasis[e1]  intravenous [s2]lidocaine[e2] adverse reaction.
+	(13, 23)	pupillary mydriasis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	947	We present a neonate with a seizure disorder who acutely developed [s1]pupillary mydriasis[e1] secondary to [s2]lidocaine[e2] overdose.
+	(14, 26)	lidocaine	dilated pupils	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	948	We suggest adding this side effect to the list of untoward effects of [s1]lidocaine[e1] and to the differential diagnosis of fixed [s2]dilated pupils[e2] in neonates treated with lidocaine.
+	(8, 23)	acute myeloid leukemia	2-deoxycoformycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	949	Myelodysplasia terminating in [s1]acute myeloid leukemia[e1] in a hairy cell leukemia patient treated with [s2]2-deoxycoformycin[e2] 
+	(0, 23)	Myelodysplasia	2-deoxycoformycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	950	 [s1]Myelodysplasia[e1] terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with [s2]2-deoxycoformycin[e2] 
+	(11, 31)	AML	2-chlorodeoxyadenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	951	To the best of our knowledge only two previous cases of [s1]AML[e1] have been linked to treatment of HCL with purine analogs, both with [s2]2-chlorodeoxyadenosine[e2] 
+	(8, 26)	vasopressin	ischemic skin complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	952	CONCLUSIONS: Peripheral administration of low-dose [s1]vasopressin[e1] for septic shock should be discouraged because of the risk of [s2]ischemic skin complications[e2] 
+	(8, 24)	skin necrosis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	953	OBJECTIVE: To describe a case of severe [s1]skin necrosis[e1] resulting from peripheral intravenous administration of low-dose [s2]vasopressin[e2] in a patient with catecholamine-resistant septic shock.
+	(0, 13)	Skin necrosis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	954	 [s1]Skin necrosis[e1] after extravasation of low-dose [s2]vasopressin[e2] administered for septic shock.
+	(0, 8)	Mitomycin-C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	955	 [s1]Mitomycin-C[e1] induced [s2]hemolytic uremic syndrome[e2]  a case report.
+	(0, 30)	Mitomycin-C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	956	 [s1]Mitomycin-C[e1] is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of [s2]hemolytic uremic syndrome[e2] 
+	(1, 30)	vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	957	Although [s1]vasculitis[e1] has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of [s2]cladribine[e2] treatment.
+	(0, 18)	Systemic vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	958	 [s1]Systemic vasculitis[e1] complicating hairy cell leukaemia treatment with [s2]cladribine[e2] 
+	(12, 33)	systemic vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	959	We describe a 73-year-old woman who developed serious [s1]systemic vasculitis[e1] with associated thrombocytopenia in the course of treatment with [s2]cladribine[e2] 
+	(19, 33)	thrombocytopenia	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	960	We describe a 73-year-old woman who developed serious systemic vasculitis with associated [s1]thrombocytopenia[e1] in the course of treatment with [s2]cladribine[e2] 
+	(3, 19)	mammary hyperplasias	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	961	Drug-induced [s1]mammary hyperplasias[e1] have been reported as rare complications of [s2]D-penicillamine[e2] and Neothetazone.
+	(3, 26)	mammary hyperplasias	Neothetazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	962	Drug-induced [s1]mammary hyperplasias[e1] have been reported as rare complications of D-penicillamine and [s2]Neothetazone[e2] 
+	(0, 8)	Gigantomastia	bucillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	963	 [s1]Gigantomastia[e1] induced by [s2]bucillamine[e2] 
+	(3, 17)	bucillamine	giant hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	964	Retrospectively, [s1]bucillamine[e1] was believed to be the cause of the [s2]giant hypertrophy[e2] because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.
+	(25, 43)	D-penicillamine	mammary hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	965	Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to [s1]D-penicillamine[e1]  which was the subject of an abundance of reports of [s2]mammary hyperplasia[e2] 
+	(7, 14)	bucillamine	giant mammary hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	966	The authors report the first case of [s1]bucillamine[e1] induced [s2]giant mammary hyperplasia[e2] 
+	(10, 26)	FVS	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	967	The authors describe three families in whom the occurrence of [s1]FVS[e1] in all the siblings strongly suggests hereditary susceptibility to [s2]valproic acid[e2] induced adverse outcome.
+	(2, 27)	valproate	developmental delay	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	968	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and [s2]developmental delay[e2] 
+	(2, 15)	valproate	distinctive facial appearance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	969	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by [s2]distinctive facial appearance[e2]  major and minor malformations, and developmental delay.
+	(1, 8)	fetal valproate syndrome	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	970	The [s1]fetal valproate syndrome[e1]  [s2]valproate[e2] syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.
+	(2, 8)	valproate	FVS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	971	The fetal [s1]valproate[e1] syndrome  [s2]FVS[e2]  is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.
+	(2, 19)	valproate	major and minor malformations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	972	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by distinctive facial appearance, [s2]major and minor malformations[e2]  and developmental delay.
+	(0, 21)	Valproate embryopathy	Valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	973	 [s1]Valproate embryopathy[e1] in three sets of siblings: further proof of hereditary susceptibility [s2]Valproate[e2] embryopathy in three sets of siblings: further proof of hereditary susceptibility.
+	(0, 12)	Generalised pustular psoriasis	cyclosporin a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	974	 [s1]Generalised pustular psoriasis[e1] induced by [s2]cyclosporin a[e2] withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
+	(34, 55)	cyclosporin A	aggravation of the joint condition	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	975	We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of [s1]cyclosporin A[e1] induced a generalised pustular exacerbation and a [s2]aggravation of the joint condition[e2] 
+	(34, 44)	cyclosporin A	generalised pustular exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	976	We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of [s1]cyclosporin A[e1] induced a [s2]generalised pustular exacerbation[e2] and a aggravation of the joint condition.
+	(14, 28)	aplastic anemia	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	977	The first case concerns a 70-year-old man who developed severe [s1]aplastic anemia[e1] 7 weeks after treatment with 500 mg of [s2]ticlopidine[e2] daily.
+	(11, 39)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	978	The second was an 82-year-old man receiving [s1]ticlopidine[e1] for 2 years when, during a febrile episode, he was found neutropenic with [s2]marrow aplasia[e2] 
+	(11, 33)	ticlopidine	neutropenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	979	The second was an 82-year-old man receiving [s1]ticlopidine[e1] for 2 years when, during a febrile episode, he was found [s2]neutropenic[e2] with marrow aplasia.
+	(0, 8)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	980	 [s1]Ticlopidine[e1] induced [s2]aplastic anemia[e2] (TIAA) is considered very uncommon.
+	(0, 12)	Ticlopidine	TIAA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	981	 [s1]Ticlopidine[e1] induced aplastic anemia  [s2]TIAA[e2]  is considered very uncommon.
+	(0, 8)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	982	 [s1]Ticlopidine[e1] induced [s2]aplastic anemia[e2]  two new case reports, review, and meta-analysis of 55 additional cases.
+	(15, 24)	cytotoxic effect	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	983	When the data of the 57 patients are evaluated, a reversible direct [s1]cytotoxic effect[e1] of [s2]ticlopidine[e2] on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.
+	(0, 6)	Fixed drug eruption	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	984	 [s1]Fixed drug eruption[e1] to [s2]rofecoxib[e2] 
+	(0, 18)	Rofecoxib	herpetiform fixed drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	985	 [s1]Rofecoxib[e1]  used for dysmenorrhea, caused a [s2]herpetiform fixed drug eruption[e2] predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.
+	(0, 38)	Rofecoxib	red-brown lesion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	986	 [s1]Rofecoxib[e1]  used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a [s2]red-brown lesion[e2] on the dorsal hand.
+	(10, 21)	thyroid hormone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	987	A patient who had been treated with large doses of [s1]thyroid hormone[e1] for several years developed features of secondary [s2]hypothyroidism[e2] after thyroid hormone withdrawal.
+	(14, 21)	gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	988	BACKGROUND: Gemcitabine has mild renal toxicity, but cases of [s1]gemcitabine[e1] associated [s2]hemolytic-uremic syndrome[e2] (HUS) have been reported.
+	(2, 22)	Gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	989	BACKGROUND: [s1]Gemcitabine[e1] has mild renal toxicity, but cases of gemcitabine-associated [s2]hemolytic-uremic syndrome[e2] (HUS) have been reported.
+	(14, 29)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	990	BACKGROUND: Gemcitabine has mild renal toxicity, but cases of [s1]gemcitabine[e1] associated hemolytic-uremic syndrome  [s2]HUS[e2]  have been reported.
+	(2, 30)	Gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	991	BACKGROUND: [s1]Gemcitabine[e1] has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome  [s2]HUS[e2]  have been reported.
+	(2, 10)	Gemcitabine	renal toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	992	BACKGROUND: [s1]Gemcitabine[e1] has mild [s2]renal toxicity[e2]  but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.
+	(10, 17)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	993	CONCLUSION: There are only a few confirmed cases of [s1]gemcitabine[e1] associated [s2]HUS[e2] despite the widespread use of the drug.
+	(0, 7)	Gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	994	 [s1]Gemcitabine[e1] associated [s2]hemolytic-uremic syndrome[e2] 
+	(5, 15)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	995	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of [s2]HUS[e2] was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.
+	(5, 15)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	996	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of [s2]HUS[e2] was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.
+	(16, 30)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	997	METHODS: A case is presented of a 45-year-old woman on prolonged [s1]gemcitabine[e1] treatment for ovarian cancer who developed [s2]HUS[e2] and recovered after drug discontinuation.
+	(13, 20)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	998	RESULTS: Including our own patient, a total of 26 cases of [s1]gemcitabine[e1] associated [s2]HUS[e2] were identified.
+	(1, 6)	amiodarone	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	999	An [s1]amiodarone[e1]  [s2]optic neuropathy[e2] has been described.
+	(6, 11)	amiodarone	corneal deposits	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1000	Biomicroscopy revealed [s1]amiodarone[e1]  [s2]corneal deposits[e2] 
+	(7, 41)	amiodarone HCl	color vision anomalies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1001	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" glare, [s2]color vision anomalies[e2]  and gradually decreased vision."
+	(7, 49)	amiodarone HCl	decreased vision	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1002	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" glare, color vision anomalies, and gradually [s2]decreased vision[e2] "
+	(7, 39)	amiodarone HCl	glare	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1003	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" [s2]glare[e2]  color vision anomalies, and gradually decreased vision."
+	(7, 34)	amiodarone HCl	"visual ""shining"	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1004	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of [s2]visual ""shining[e2] "" glare, color vision anomalies, and gradually decreased vision."
+	(0, 8)	Visual changes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1005	 [s1]Visual changes[e1] secondary to initiation of [s2]amiodarone[e2]  a case report and review involving ocular management in cardiac polypharmacy.
+	(2, 18)	amiodarone	ocular effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1006	While both [s1]amiodarone[e1] and digoxin can cause permanent visual changes, the [s2]ocular effects[e2] are often reversible.
+	(6, 18)	digoxin	ocular effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1007	While both amiodarone and [s1]digoxin[e1] can cause permanent visual changes, the [s2]ocular effects[e2] are often reversible.
+	(2, 14)	amiodarone	visual changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1008	While both [s1]amiodarone[e1] and digoxin can cause permanent [s2]visual changes[e2]  the ocular effects are often reversible.
+	(6, 14)	digoxin	visual changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1009	While both amiodarone and [s1]digoxin[e1] can cause permanent [s2]visual changes[e2]  the ocular effects are often reversible.
+	(4, 22)	circumoral and pharyngeal burns	benzalkonium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1010	Infant twins sustained severe [s1]circumoral and pharyngeal burns[e1] from a concentrated solution of [s2]benzalkonium[e2] (Zephiran) chloride prescribed for treatment of candidiasis.
+	(4, 26)	circumoral and pharyngeal burns	Zephiran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1011	Infant twins sustained severe [s1]circumoral and pharyngeal burns[e1] from a concentrated solution of benzalkonium  [s2]Zephiran[e2]  chloride prescribed for treatment of candidiasis.
+	(7, 26)	rifabutin	side-effect on retinal function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1012	CONCLUSION: Long-term treatment with [s1]rifabutin[e1] may have a reversible and previously undescribed [s2]side-effect on retinal function[e2] 
+	(17, 29)	decreased vision	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1013	PURPOSE: To describe the clinical and electrophysiological findings in a young boy with [s1]decreased vision[e1] possibly due to retinal damage by [s2]rifabutin[e2] 
+	(22, 29)	retinal damage	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1014	PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to [s1]retinal damage[e1] by [s2]rifabutin[e2] 
+	(5, 15)	anterior segment deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1015	Retinal dysfunction and [s1]anterior segment deposits[e1] in a patient treated with [s2]rifabutin[e2] 
+	(0, 15)	Retinal dysfunction	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1016	 [s1]Retinal dysfunction[e1] and anterior segment deposits in a patient treated with [s2]rifabutin[e2] 
+	(22, 29)	visual disturbance	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1017	We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with [s1]visual disturbance[e1] during treatment with [s2]rifabutin[e2] 
+	(9, 24)	benzodiazepine withdrawal symptoms	nefazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1018	A case is presented of a patient who experienced [s1]benzodiazepine withdrawal symptoms[e1] on discontinuation of [s2]nefazodone[e2]  an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.
+	(3, 10)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1019	A case of [s1]SIADH[e1] induced by [s2]mizoribin[e2] administration.
+	(0, 19)	ADH hypersecretion	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1020	 [s1]ADH hypersecretion[e1] in relation to plasma osmolality was reversed by [s2]mizoribin[e2] withdrawal, suggesting that bredinin might adversely induce SIADH.
+	(25, 34)	bredinin	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1021	ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that [s1]bredinin[e1] might adversely induce [s2]SIADH[e2] 
+	(11, 23)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1022	In summary, we report herein the first case of [s1]SIADH[e1] believed to be an adverse effect of [s2]mizoribin[e2]  which may therefore needed to be added to the list of drugs which can induce SIADH.
+	(11, 23)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1023	In summary, we report herein the first case of [s1]SIADH[e1] believed to be an adverse effect of [s2]mizoribin[e2]  which may therefore needed to be added to the list of drugs which can induce SIADH.
+	(32, 44)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1024	We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  1.5 months after commencement of [s2]mizoribin[e2] prescription when his arthritis was improved.
+	(21, 46)	syndrome of inappropriate secretion of antidiuretic hormone	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1025	We describe a 74-year-old man with rheumatoid arthritis (RA) who developed [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) 1.5 months after commencement of [s2]mizoribin[e2] prescription when his arthritis was improved.
+	(9, 28)	cyclosporin	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1026	The disease-modifying drugs he was taking, [s1]cyclosporin[e1] and methotrexate, were stopped, and the [s2]lymphoma[e2] resolved spontaneously without the use of chemotherapy.
+	(15, 27)	methotrexate	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1027	The disease-modifying drugs he was taking, cyclosporin and [s1]methotrexate[e1]  were stopped, and the [s2]lymphoma[e2] resolved spontaneously without the use of chemotherapy.
+	(3, 11)	nephrotic syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1028	Acute onset of [s1]nephrotic syndrome[e1] during [s2]interferon-alpha[e2] retreatment for chronic active hepatitis C.
+	(11, 19)	nephrotic syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1029	We herein report this rare case of acute onset of [s1]nephrotic syndrome[e1] during [s2]interferon-alpha[e2] retreatment.
+	(32, 39)	seizures	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1030	A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced [s1]seizures[e1] after receiving therapy with [s2]interferon beta-1a[e2] 
+	(2, 40)	extrapyramidal symptoms	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1031	Seizures and [s1]extrapyramidal symptoms[e1] in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and [s2]clomipramine[e2] 
+	(2, 33)	extrapyramidal symptoms	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1032	Seizures and [s1]extrapyramidal symptoms[e1] in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with [s2]interferon beta-1a[e2] and clomipramine.
+	(0, 40)	Seizures	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1033	 [s1]Seizures[e1] and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and [s2]clomipramine[e2] 
+	(0, 33)	Seizures	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1034	 [s1]Seizures[e1] and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with [s2]interferon beta-1a[e2] and clomipramine.
+	(16, 22)	collapsed	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1035	A 68-year-old female patient with advanced ovarian carcinoma [s1]collapsed[e1] whilst receiving a [s2]carboplatin[e2] and cyclophosphamide infusion.
+	(16, 27)	collapsed	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1036	A 68-year-old female patient with advanced ovarian carcinoma [s1]collapsed[e1] whilst receiving a carboplatin and [s2]cyclophosphamide[e2] infusion.
+	(0, 12)	Carboplatin	coronary vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1037	 [s1]Carboplatin[e1] hypersensitivity presenting as [s2]coronary vasospasm[e2] - a case report.
+	(5, 28)	carboplatin	hyperacute changes on ECG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1038	Hypersensitivity to [s1]carboplatin[e1] is a rare but real complication of therapy and should be considered in patients presenting with [s2]hyperacute changes on ECG[e2] whilst receiving carboplatin therapy.
+	(0, 7)	Hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1039	 [s1]Hypersensitivity[e1] to [s2]carboplatin[e2] is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.
+	(17, 32)	acute respiratory failure	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1040	A 60-year-old white man with chronic bronchitis was noted to develop [s1]acute respiratory failure[e1] and metabolic acidosis four days after being started on [s2]methazolamide[e2] (Neptazane) for an ophthalmologic problem.
+	(17, 37)	acute respiratory failure	Neptazane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1041	A 60-year-old white man with chronic bronchitis was noted to develop [s1]acute respiratory failure[e1] and metabolic acidosis four days after being started on methazolamide  [s2]Neptazane[e2]  for an ophthalmologic problem.
+	(21, 32)	metabolic acidosis	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1042	A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and [s1]metabolic acidosis[e1] four days after being started on [s2]methazolamide[e2] (Neptazane) for an ophthalmologic problem.
+	(21, 37)	metabolic acidosis	Neptazane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1043	A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and [s1]metabolic acidosis[e1] four days after being started on methazolamide  [s2]Neptazane[e2]  for an ophthalmologic problem.
+	(0, 10)	Capecitabine	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1044	 [s1]Capecitabine[e1] was discontinued and the [s2]allergic reactions[e2] resolved after the woman took diphenhydramine for 1 week.
+	(22, 27)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1045	CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
+	(6, 11)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1046	Fluorouracil for [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
+	(6, 15)	allergic reaction	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1047	It was postulated that the [s1]allergic reaction[e1] was most likely caused by [s2]capecitabine[e2] or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.
+	(21, 26)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1048	OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
+	(13, 25)	dizziness	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1049	She developed a generalized rash and itching, sore throat, and [s1]dizziness[e1] approximately 4 hours after the first dose of [s2]capecitabine[e2] 
+	(3, 25)	generalized rash	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1050	She developed a [s1]generalized rash[e1] and itching, sore throat, and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
+	(6, 24)	itching	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1051	She developed a generalized rash and [s1]itching[e1]  sore throat, and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
+	(9, 24)	sore throat	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1052	She developed a generalized rash and itching, [s1]sore throat[e1]  and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
+	(10, 21)	methylprednisolone	steroid diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1053	After five and six weeks of continuous oral administration of [s1]methylprednisolone[e1]  the boys developed [s2]steroid diabetes[e2] 
+	(2, 21)	methylprednisolone	glycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1054	Reduction of [s1]methylprednisolone[e1] dosage rather than insulin therapy resulted in better control of [s2]glycemia[e2] 
+	(17, 26)	cytarabine	PPE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1055	Contrary to previous recommendations, our experience cautions against the further use of high-dose [s1]cytarabine[e1] in patients who develop [s2]PPE[e2]  and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.
+	(5, 11)	PPE	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1056	It has been suggested that [s1]PPE[e1] caused by [s2]cytarabine[e2] does not recur with subsequent cytarabine re-challenge.
+	(2, 22)	palmar-plantar erythrodysaesthesia	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1057	Recurrent [s1]palmar-plantar erythrodysaesthesia[e1] following high-dose [s2]cytarabine[e2] treatment for acute lymphoblastic leukemia.
+	(20, 32)	bullous eruption	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1058	We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe [s1]bullous eruption[e1]  following successive cycles of high-dose [s2]cytarabine[e2] for the treatment of acute lymphoblastic leukaemia.
+	(12, 32)	PPE	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1059	We report a patient with recurrent, increasingly severe episodes of [s1]PPE[e1]  ultimately complicated by a severe bullous eruption, following successive cycles of high-dose [s2]cytarabine[e2] for the treatment of acute lymphoblastic leukaemia.
+	(21, 28)	tamoxifen	malignant transformation of endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1060	Atypical endometriosis may act as a precancerous lesion in the process of [s1]tamoxifen[e1] induced [s2]malignant transformation of endometriosis[e2] 
+	(2, 26)	Ovarian cancer	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1061	BACKGROUND: [s1]Ovarian cancer[e1] arising from an endometriotic cyst in a postmenopausal woman under [s2]tamoxifen[e2] therapy is rare.
+	(2, 10)	Tamoxifen	malignant transformation of endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1062	CONCLUSION: [s1]Tamoxifen[e1] may cause [s2]malignant transformation of endometriosis[e2] through atypical endometriosis even in the postmenopausal state.
+	(0, 32)	Ovarian endometrioid adenocarcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1063	 [s1]Ovarian endometrioid adenocarcinoma[e1] arising from an endometriotic cyst in a postmenopausal woman under [s2]tamoxifen[e2] therapy for breast cancer: a case report.
+	(0, 18)	Clinical, spectroscopic, and imaging abnormalities	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1064	 [s1]Clinical, spectroscopic, and imaging abnormalities[e1] resolved with discontinuation of [s2]metronidazole[e2] 
+	(6, 12)	lactate elevation	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1065	Proton MRS examination demonstrated a persistent [s1]lactate elevation[e1] during [s2]metronidazole[e2] treatment.
+	(0, 14)	Reversible MR imaging and MR spectroscopy abnormalities	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1066	 [s1]Reversible MR imaging and MR spectroscopy abnormalities[e1] in association with [s2]metronidazole[e2] therapy.
+	(11, 19)	anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1067	After nine previous uncomplicated cycles she developed severe [s1]anaphylaxis[e1] to [s2]cisplatin[e2] 
+	(0, 8)	Anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1068	 [s1]Anaphylaxis[e1] to [s2]cisplatin[e2] following nine previous uncomplicated cycles.
+	(0, 8)	Anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1069	 [s1]Anaphylaxis[e1] to [s2]cisplatin[e2] is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin.
+	(1, 11)	isradipine	hepatocellular injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1070	Although [s1]isradipine[e1] has been associated with [s2]hepatocellular injury[e2]  there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity.
+	(7, 22)	clarithromycin	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1071	A second possibility is an interaction between [s1]clarithromycin[e1] and isradipine, potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
+	(14, 21)	isradipine	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1072	A second possibility is an interaction between clarithromycin and [s1]isradipine[e1]  potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
+	(14, 21)	isradipine	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1073	A second possibility is an interaction between clarithromycin and [s1]isradipine[e1]  potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
+	(12, 29)	fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1074	CASE SUMMARY: A 58-year-old white woman developed [s1]fulminant liver failure[e1] while being treated with the macrolide antibiotic [s2]clarithromycin[e2] for pneumonia.
+	(2, 15)	Clarithromycin	fulminant liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1075	CONCLUSIONS: [s1]Clarithromycin[e1] may be a cause of [s2]fulminant liver failure[e2] either alone or by inhibiting the metabolism of other drugs.
+	(0, 10)	Fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1076	 [s1]Fulminant liver failure[e1] associated with [s2]clarithromycin[e2] 
+	(7, 19)	fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1077	OBJECTIVE: To report a patient developing [s1]fulminant liver failure[e1] while being treated with [s2]clarithromycin[e2] for pneumonia.
+	(14, 34)	clarithromycin	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1078	The most likely cause of liver failure in this patient was, therefore, [s1]clarithromycin[e1]  which undergoes hepatic metabolism and has been reported to cause [s2]fulminant hepatic failure[e2] 
+	(5, 16)	liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1079	The most likely cause of [s1]liver failure[e1] in this patient was, therefore, [s2]clarithromycin[e2]  which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.
+	(1, 9)	paradoxical ocular effect	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1080	A [s1]paradoxical ocular effect[e1] of [s2]brimonidine[e2] 
+	(6, 14)	brimonidine	paradoxical raised IOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1081	CONCLUSION: Under certain circumstances topical [s1]brimonidine[e1] can cause [s2]paradoxical raised IOP[e2] necessitating vigilance in follow-up of patients on topical brimonidine.
+	(6, 12)	paradoxical effect	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1082	PURPOSE: We report an unusual [s1]paradoxical effect[e1] of [s2]brimonidine[e2] 
+	(2, 12)	Brimonidine	IOP elevation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1083	RESULTS: [s1]Brimonidine[e1] was observed to cause [s2]IOP elevation[e2]  confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.
+	(1, 16)	gabapentin	anxiety	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1084	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of [s2]anxiety[e2]  diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
+	(1, 18)	gabapentin	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1085	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, [s2]diaphoresis[e2]  and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
+	(1, 35)	gabapentin	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1086	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with [s2]generalized seizures[e2] and status epilepticus secondary to gabapentin withdrawal.
+	(1, 35)	gabapentin	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1087	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with [s2]generalized seizures[e2] and status epilepticus secondary to gabapentin withdrawal.
+	(1, 24)	gabapentin	palpitations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1088	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and [s2]palpitations[e2]  this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
+	(1, 38)	gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1089	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and [s2]status epilepticus[e2] secondary to gabapentin withdrawal.
+	(1, 38)	gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1090	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and [s2]status epilepticus[e2] secondary to gabapentin withdrawal.
+	(0, 9)	Gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1091	 [s1]Gabapentin[e1] withdrawal presenting as [s2]status epilepticus[e2] 
+	(29, 35)	altered mental status	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1092	Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and [s1]altered mental status[e1] after [s2]zonisamide[e2] treatment was begun or its dosage increased.
+	(1, 35)	visual hallucinations	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1093	Although [s1]visual hallucinations[e1] have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after [s2]zonisamide[e2] treatment was begun or its dosage increased.
+	(0, 8)	Visual hallucinations	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1094	 [s1]Visual hallucinations[e1] associated with [s2]zonisamide[e2] 
+	(0, 8)	Doxycycline	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1095	 [s1]Doxycycline[e1] induced [s2]hypoglycemia[e2] in a nondiabetic young man.
+	(6, 14)	doxycycline	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1096	We report the first case of [s1]doxycycline[e1] induced [s2]hypoglycemia[e2] in a young nondiabetic man.
+	(13, 21)	anaphylactic reactions	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1097	For patients who suffer from osteogenic sarcoma and have [s1]anaphylactic reactions[e1] to [s2]MTX[e2]  this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy.
+	(14, 32)	MTX	chest tightness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1098	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, facial swelling, cough, and [s2]chest tightness[e2] 
+	(14, 29)	MTX	cough	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1099	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, facial swelling, [s2]cough[e2]  and chest tightness.
+	(14, 21)	MTX	diffuse urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1100	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with [s2]diffuse urticaria[e2]  facial swelling, cough, and chest tightness.
+	(14, 26)	MTX	facial swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1101	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, [s2]facial swelling[e2]  cough, and chest tightness.
+	(4, 16)	hypersensitivity reaction	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1102	He had an immediate [s1]hypersensitivity reaction[e1] during the initiation of the [s2]MTX[e2] infusion with diffuse urticaria, facial swelling, cough, and chest tightness.
+	(7, 12)	allergy	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1103	He was later skin tested to confirm [s1]allergy[e1] to [s2]MTX[e2] 
+	(9, 17)	methotrexate	systemic anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1104	Successful desensitization to high-dose [s1]methotrexate[e1] after [s2]systemic anaphylaxis[e2] 
+	(15, 23)	anaphylactic reactions	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1105	The successful development and implementation of this protocol will have impact on patients who have [s1]anaphylactic reactions[e1] to [s2]MTX[e2] but require this medication for specific diseases.
+	(6, 36)	Balint syndrome	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1106	The authors report a case of [s1]Balint syndrome[e1] with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and [s2]cytarabine[e2] 
+	(6, 30)	Balint syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1107	The authors report a case of [s1]Balint syndrome[e1] with irreversible posterior leukoencephalopathy on MRI following intrathecal [s2]methotrexate[e2] and cytarabine.
+	(14, 36)	posterior leukoencephalopathy	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1108	The authors report a case of Balint syndrome with irreversible [s1]posterior leukoencephalopathy[e1] on MRI following intrathecal methotrexate and [s2]cytarabine[e2] 
+	(14, 30)	posterior leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1109	The authors report a case of Balint syndrome with irreversible [s1]posterior leukoencephalopathy[e1] on MRI following intrathecal [s2]methotrexate[e2] and cytarabine.
+	(6, 20)	GTBM	Melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1110	We present a unique case of [s1]GTBM[e1] in a patient with myeloma following treatment with [s2]Melphalan[e2] 
+	(15, 34)	L-asparaginase	cortical venous thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1111	Patients with lymphoblastic lymphoma who had treatment with [s1]L-asparaginase[e1] and steroid are predisposed to the development of [s2]cortical venous thrombosis[e2] and may have this syndrome in addition to a dural puncture headache.
+	(15, 52)	L-asparaginase	dural puncture headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1112	Patients with lymphoblastic lymphoma who had treatment with [s1]L-asparaginase[e1] and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a [s2]dural puncture headache[e2] 
+	(0, 12)	Interstitial pneumonitis	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1113	 [s1]Interstitial pneumonitis[e1] associated with [s2]sirolimus[e2]  a dilemma for lung transplantation.
+	(0, 10)	Rapamycin	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1114	 [s1]Rapamycin[e1] sirolimus-induced [s2]pneumonitis[e2] has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.
+	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1115	Rapamycin [s1]sirolimus[e1] induced [s2]pneumonitis[e2] has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.
+	(0, 38)	Rapamycin	pulmonary infiltrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1116	 [s1]Rapamycin[e1] sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s2]pulmonary infiltrate[e2] that reversed after ceasing SR therapy.
+	(3, 37)	sirolimus	pulmonary infiltrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1117	Rapamycin [s1]sirolimus[e1] induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s2]pulmonary infiltrate[e2] that reversed after ceasing SR therapy.
+	(37, 47)	pulmonary infiltrate	SR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1118	Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s1]pulmonary infiltrate[e1] that reversed after ceasing [s2]SR[e2] therapy.
+	(13, 53)	Rapammune	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1119	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
+	(0, 52)	Rapamycin	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1120	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
+	(3, 52)	sirolimus	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1121	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
+	(7, 51)	SR	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1122	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
+	(13, 50)	Rapammune	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1123	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
+	(0, 49)	Rapamycin	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1124	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
+	(3, 49)	sirolimus	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1125	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
+	(7, 48)	SR	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1126	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
+	(13, 59)	Rapammune	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1127	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
+	(0, 58)	Rapamycin	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1128	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
+	(3, 58)	sirolimus	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1129	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
+	(7, 57)	SR	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1130	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
+	(13, 43)	Rapammune	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1131	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
+	(0, 42)	Rapamycin	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1132	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
+	(3, 42)	sirolimus	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1133	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
+	(7, 41)	SR	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1134	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
+	(8, 41)	fever	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1135	A 16-year-old boy developed [s1]fever[e1]  generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
+	(8, 37)	fever	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1136	A 16-year-old boy developed [s1]fever[e1]  generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
+	(10, 41)	generalized rigidity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1137	A 16-year-old boy developed fever, [s1]generalized rigidity[e1]  leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
+	(10, 37)	generalized rigidity	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1138	A 16-year-old boy developed fever, [s1]generalized rigidity[e1]  leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
+	(21, 42)	increased serum transaminase and creatine kinase	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1139	A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and [s1]increased serum transaminase and creatine kinase[e1] levels while receiving treatment with olanzapine and [s2]lithium[e2] 
+	(21, 38)	increased serum transaminase and creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1140	A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and [s1]increased serum transaminase and creatine kinase[e1] levels while receiving treatment with [s2]olanzapine[e2] and lithium.
+	(14, 41)	leukocytosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1141	A 16-year-old boy developed fever, generalized rigidity, [s1]leukocytosis[e1]  and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
+	(14, 37)	leukocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1142	A 16-year-old boy developed fever, generalized rigidity, [s1]leukocytosis[e1]  and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
+	(6, 19)	lithium	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1143	Concomitant administration of [s1]lithium[e1] with olanzapine may place patients at risk for [s2]NMS[e2] 
+	(8, 19)	olanzapine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1144	Concomitant administration of lithium with [s1]olanzapine[e1] may place patients at risk for [s2]NMS[e2] 
+	(0, 16)	Neuroleptic malignant syndrome	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1145	 [s1]Neuroleptic malignant syndrome[e1] in an adolescent receiving olanzapine [s2]lithium[e2] combination therapy.
+	(0, 13)	Neuroleptic malignant syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1146	 [s1]Neuroleptic malignant syndrome[e1] in an adolescent receiving [s2]olanzapine[e2] lithium combination therapy.
+	(1, 17)	6-MP	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1147	Both [s1]6-MP[e1] and AZA are widely used and are known to cause [s2]hepatotoxicity[e2] in a proportion of patients.
+	(5, 17)	AZA	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1148	Both 6-MP and [s1]AZA[e1] are widely used and are known to cause [s2]hepatotoxicity[e2] in a proportion of patients.
+	(0, 10)	Hepatotoxicity	6-thioguanine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1149	 [s1]Hepatotoxicity[e1] associated with [s2]6-thioguanine[e2] therapy for Crohn's disease.
+	(29, 36)	thiopurine	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1150	This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of [s1]thiopurine[e1] induced [s2]hepatic injury[e2] 
+	(7, 30)	abnormal liver enzymes	6-TG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1151	We believe the temporal association of the [s1]abnormal liver enzymes[e1] in this patient, in the absence of other offending agents, argues strongly in favor of [s2]6-TG[e2] as a cause of liver enzyme abnormalities.
+	(28, 38)	6-TG	liver enzyme abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1152	We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of [s1]6-TG[e1] as a cause of [s2]liver enzyme abnormalities[e2] 
+	(6, 19)	elevation of serum transaminases	6-TG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1153	We describe a case of significant [s1]elevation of serum transaminases[e1] in a patient treated with [s2]6-TG[e2] for a flare of Crohn's disease.
+	(13, 20)	lisinopril	multiorgan failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1154	Early peritoneal dialysis has not previously been reported for [s1]lisinopril[e1] induced [s2]multiorgan failure[e2] 
+	(3, 35)	panhypogammaglobulinaemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1155	We observed transient [s1]panhypogammaglobulinaemia[e1] in a patient with neuropsychiatric SLE after treatment with prednisolone and [s2]cyclophosphamide[e2] 
+	(3, 29)	panhypogammaglobulinaemia	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1156	We observed transient [s1]panhypogammaglobulinaemia[e1] in a patient with neuropsychiatric SLE after treatment with [s2]prednisolone[e2] and cyclophosphamide.
+	(0, 32)	Fulminant hepatic failure	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1157	 [s1]Fulminant hepatic failure[e1] developed in a 24-year-old black woman who had been treated with propylthiouracil and [s2]propranolol[e2] for hyperthyroidism.
+	(0, 25)	Fulminant hepatic failure	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1158	 [s1]Fulminant hepatic failure[e1] developed in a 24-year-old black woman who had been treated with [s2]propylthiouracil[e2] and propranolol for hyperthyroidism.
+	(0, 18)	Fulminant hepatitis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1159	 [s1]Fulminant hepatitis[e1] and lymphocyte sensitization due to [s2]propylthiouracil[e2] 
+	(17, 41)	propylthiouracil	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1160	These observations indicate that submassive hepatic necrosis may result from treatment with [s1]propylthiouracil[e1] and are consistent with the notion that sensitization mechanisms may be responsible for the [s2]hepatic injury[e2] induced by this drug.
+	(4, 19)	submassive hepatic necrosis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1161	These observations indicate that [s1]submassive hepatic necrosis[e1] may result from treatment with [s2]propylthiouracil[e2] and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.
+	(3, 28)	hypothermia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1162	The diagnosis of [s1]hypothermia[e1] was delayed until it was apparent for several days but resolved with the discontinuation of [s2]risperidone[e2] and continuation of clozapine.
+	(9, 25)	hypothermia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1163	This is a case report of subtle, mild [s1]hypothermia[e1] in a 54-year old female patient receiving [s2]risperidone[e2] for schizophrenia.
+	(0, 24)	Akathisia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1164	 [s1]Akathisia[e1] is a relatively rare side effect with the newer atypical antipsychotic agents, particularly [s2]clozapine[e2]  and is easily misdiagnosed in children.
+	(0, 6)	Clozapine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1165	 [s1]Clozapine[e1] induced [s2]akathisia[e2] in children with schizophrenia.
+	(9, 15)	clozapine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1166	Two cases of childhood-onset schizophrenia associated with [s1]clozapine[e1] induced [s2]akathisia[e2] responsive to beta-blocker treatment are described.
+	(14, 27)	lithium	blindness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1167	After reviewing the literature we suggest the CPM was a complication of [s1]lithium[e1] toxicity which affected the lateral geniculate nucleus which produced [s2]blindness[e2] 
+	(7, 16)	CPM	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1168	After reviewing the literature we suggest the [s1]CPM[e1] was a complication of [s2]lithium[e2] toxicity which affected the lateral geniculate nucleus which produced blindness.
+	(0, 19)	Central pontine myelinolysis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1169	 [s1]Central pontine myelinolysis[e1] manifested by temporary blindness: a possible complication of [s2]lithium[e2] toxicity.
+	(9, 18)	temporary blindness	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1170	Central pontine myelinolysis manifested by [s1]temporary blindness[e1]  a possible complication of [s2]lithium[e2] toxicity.
+	(5, 19)	propylthiouracil	elevated hepatic enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1171	Antithyroid treatment with [s1]propylthiouracil[e1] (PTU) resulted in [s2]elevated hepatic enzymes[e2] and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).
+	(11, 17)	PTU	elevated hepatic enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1172	Antithyroid treatment with propylthiouracil  [s1]PTU[e1]  resulted in [s2]elevated hepatic enzymes[e2] and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).
+	(15, 22)	hepatic impairment	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1173	Successful treatment with carbimazole of a hyperthyroid pregnancy with [s1]hepatic impairment[e1] after [s2]propylthiouracil[e2] administration: a case report.
+	(5, 24)	IFN-alpha	MPGN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1174	Interferon-alpha  [s1]IFN-alpha[e1]  may precipitate or exacerbate the occurrence of [s2]MPGN[e2] 
+	(0, 26)	Interferon-alpha	MPGN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1175	 [s1]Interferon-alpha[e1] (IFN-alpha) may precipitate or exacerbate the occurrence of [s2]MPGN[e2] 
+	(0, 9)	Minimal change disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1176	 [s1]Minimal change disease[e1] in a patient receiving [s2]IFN-alpha[e2] therapy for chronic hepatitis C virus infection.
+	(21, 41)	chronic myeloid leukaemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1177	A 58-yr-old male patient with essential thrombocythaemia (ET) developed [s1]chronic myeloid leukaemia[e1] (CML) after continuous uneventful treatment with [s2]hydroxyurea[e2] for 18 yr.
+	(28, 39)	CML	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1178	A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia  [s1]CML[e1]  after continuous uneventful treatment with [s2]hydroxyurea[e2] for 18 yr.
+	(2, 16)	Philadelphia positive chronic myeloid leukaemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1179	Emergence of [s1]Philadelphia positive chronic myeloid leukaemia[e1] during treatment with [s2]hydroxyurea[e2] for Philadelphia negative essential thrombocythaemia.
+	(12, 19)	CML	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1180	There are no previous reports in the literature about the emergence of [s1]CML[e1] during treatment with [s2]hydroxyurea[e2] 
+	(12, 20)	chloroquine toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1181	His fever resolved, but he developed symptoms consistent with those of [s1]chloroquine toxicity[e1]  [s2]chloroquine[e2] toxicity.
+	(7, 16)	severe chloroquine toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1182	OBJECTIVE: To report a case of [s1]severe chloroquine toxicity[e1]  [s2]chloroquine[e2] toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.
+	(0, 5)	Toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1183	 [s1]Toxicity[e1] related to [s2]chloroquine[e2] treatment of resistant vivax malaria.
+	(21, 28)	fever	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1184	A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and [s1]fever[e1] two weeks after starting [s2]carbimazole[e2] 
+	(18, 28)	sore throat	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1185	A 72-year-old woman with a history of thyrotoxicosis presented with [s1]sore throat[e1] and fever two weeks after starting [s2]carbimazole[e2] 
+	(2, 10)	carbimazole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1186	Treatment of [s1]carbimazole[e1] induced [s2]agranulocytosis[e2] and sepsis with granulocyte colony stimulating factor.
+	(2, 16)	carbimazole	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1187	Treatment of [s1]carbimazole[e1] induced agranulocytosis and [s2]sepsis[e2] with granulocyte colony stimulating factor.
+	(5, 22)	agranulocytosis	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1188	We present the management of [s1]agranulocytosis[e1] and neutropenic sepsis secondary to [s2]carbimazole[e2] with recombinant human granulocyte colony stimulating factor (G-CSF).
+	(11, 22)	neutropenic sepsis	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1189	We present the management of agranulocytosis and [s1]neutropenic sepsis[e1] secondary to [s2]carbimazole[e2] with recombinant human granulocyte colony stimulating factor (G-CSF).
+	(0, 20)	Comeoscleral perforation	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1190	 [s1]Comeoscleral perforation[e1] after pterygium excision and intraoperative [s2]mitomycin C[e2] 
+	(7, 30)	corneoscleral melting	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1191	To the best of our knowledge, [s1]corneoscleral melting[e1] in the first postoperative week after a single intraoperative application of [s2]mitomycin C[e2] has not been reported.
+	(15, 23)	bullous drug reaction	sulfonamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1192	A 71-year-old man, who had a history of a previous [s1]bullous drug reaction[e1] to a [s2]sulfonamide[e2]  began receiving an ophthalmic preparation that contained sulfacetamide sodium.
+	(9, 26)	sulfonamide	Stevens-Johnson syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1193	The patient received only the ophthalmic [s1]sulfonamide[e1]  and it was used for one day, but he developed [s2]Stevens-Johnson syndrome[e2] 
+	(1, 15)	sulfonamides	erythema multiforme	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1194	The [s1]sulfonamides[e1] are the best verified drug-trigger for [s2]erythema multiforme[e2] and Stevens-Johnson syndrome.
+	(1, 22)	sulfonamides	Stevens-Johnson syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1195	The [s1]sulfonamides[e1] are the best verified drug-trigger for erythema multiforme and [s2]Stevens-Johnson syndrome[e2] 
+	(10, 19)	diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1196	Based on these findings, the patient was diagnosed with [s1]diabetes insipidus[e1] secondary to [s2]lithium[e2] therapy and was treated successfully with amiloride.
+	(6, 10)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1197	Clinicians have been aware of [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.
+	(6, 31)	lithium	nephrogenic diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1198	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and [s2]nephrogenic diabetes insipidus[e2] 
+	(6, 31)	lithium	nephrogenic diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1199	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and [s2]nephrogenic diabetes insipidus[e2] 
+	(6, 28)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1200	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced [s2]polyuria[e2] and nephrogenic diabetes insipidus.
+	(6, 28)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1201	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced [s2]polyuria[e2] and nephrogenic diabetes insipidus.
+	(2, 6)	lithium	diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1202	Treatment of [s1]lithium[e1] induced [s2]diabetes insipidus[e2] with amiloride.
+	(0, 17)	Systemic capillary leak syndrome	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1203	 [s1]Systemic capillary leak syndrome[e1] after granulocyte colony-stimulating factor  [s2]G-CSF[e2] .
+	(0, 9)	Systemic capillary leak syndrome	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1204	 [s1]Systemic capillary leak syndrome[e1] after [s2]granulocyte colony-stimulating factor[e2] (G-CSF).
+	(10, 22)	CLS	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1205	We present two cases in which both patients suffered with [s1]CLS[e1]  which we believe was caused following administration of [s2]granulocyte colony-stimulating factor[e2]  to our knowledge not described in the intensive care patient previously.
+	(0, 37)	FK506	neurologic abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1206	 [s1]FK506[e1]  which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before [s2]neurologic abnormalities[e2] began.
+	(3, 9)	speech loss	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1207	Rapid identification of [s1]speech loss[e1] linked to [s2]FK506[e2] may be important because reduction or cessation of the drug may be associated with reverse of speech loss.
+	(4, 22)	FK506	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1208	Tacrolimus  [s1]FK506[e1] , an immunosuppressant, has been associated with [s2]mutism[e2] in adults after liver transplant.
+	(0, 24)	Tacrolimus	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1209	 [s1]Tacrolimus[e1] (FK506), an immunosuppressant, has been associated with [s2]mutism[e2] in adults after liver transplant.
+	(4, 11)	FK506	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1210	Tacrolimus  [s1]FK506[e1] -induced [s2]mutism[e2] after liver transplant.
+	(0, 13)	Tacrolimus	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1211	 [s1]Tacrolimus[e1] (FK506)-induced [s2]mutism[e2] after liver transplant.
+	(4, 26)	insulin	oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1212	Does the use of [s1]insulin[e1] in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin [s2]oedema[e2] 
+	(4, 23)	insulin	ascites	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1213	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked peripheral oedema, [s2]ascites[e2] and pleural effusion.
+	(4, 18)	insulin	peripheral oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1214	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked [s2]peripheral oedema[e2]  ascites and pleural effusion.
+	(4, 27)	insulin	pleural effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1215	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked peripheral oedema, ascites and [s2]pleural effusion[e2] 
+	(4, 11)	insulin	severe anasarca	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1216	Soon after introduction of [s1]insulin[e1] therapy, she developed [s2]severe anasarca[e2]  including marked peripheral oedema, ascites and pleural effusion.
+	(17, 38)	insulin	hyperinsulinaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1217	The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of [s1]insulin[e1] (> 110 units/day), suggesting the existence of insulin insensitivity and [s2]hyperinsulinaemia[e2] 
+	(17, 32)	insulin	insulin insensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1218	The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of [s1]insulin[e1] (> 110 units/day), suggesting the existence of [s2]insulin insensitivity[e2] and hyperinsulinaemia.
+	(8, 13)	insulin	anti-natriuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1219	We conjectured that the side effects of [s1]insulin[e1]  such as [s2]anti-natriuresis[e2] and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.
+	(8, 48)	insulin	hyperinsulinaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1220	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, [s2]hyperinsulinaemia[e2] and hypoalbuminaemia.
+	(8, 54)	insulin	hypoalbuminaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1221	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and [s2]hypoalbuminaemia[e2] 
+	(8, 20)	insulin	increased vascular permeability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1222	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and [s2]increased vascular permeability[e2]  might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.
+	(8, 42)	insulin	insulin insensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1223	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies [s2]insulin insensitivity[e2]  hyperinsulinaemia and hypoalbuminaemia.
+	(6, 21)	prednisolone	diabetic milieu deteriorated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1224	While 40 mg/day of [s1]prednisolone[e1] improved hepatic dysfunction dramatically, her [s2]diabetic milieu deteriorated[e2] seriously.
+	(3, 11)	methotrexate	acute cerebellar syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1225	Intrathecal [s1]methotrexate[e1] induced [s2]acute cerebellar syndrome[e2] 
+	(6, 21)	acute cerebellar syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1226	We describe a patient who developed [s1]acute cerebellar syndrome[e1] after prophylactic intrathecal [s2]methotrexate[e2] administration and recovered spontaneously.
+	(0, 21)	Angioimmunoblastic lymphadenopathy with dysproteinemia	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1227	 [s1]Angioimmunoblastic lymphadenopathy with dysproteinemia[e1] following [s2]doxycycline[e2] administration.
+	(5, 34)	AILD	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1228	We report a case of [s1]AILD[e1] in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following [s2]doxycycline[e2] administration.
+	(30, 34)	fever	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1229	We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and [s1]fever[e1] following [s2]doxycycline[e2] administration.
+	(19, 34)	generalized pruritic maculopapular eruption	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1230	We report a case of AILD in an 80-year-old male who presented with a [s1]generalized pruritic maculopapular eruption[e1] and fever following [s2]doxycycline[e2] administration.
+	(0, 8)	Anaphylaxis	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1231	 [s1]Anaphylaxis[e1] from [s2]isoniazid[e2] is a possible side effect to this commonly prescribed antibiotic.
+	(0, 7)	Isoniazid	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1232	 [s1]Isoniazid[e1] induced [s2]anaphylaxis[e2] 
+	(15, 35)	low plasma parathyroid hormone	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1233	A case is reported in which severe hypocalcemia, with a [s1]low plasma parathyroid hormone[e1] (PTH) concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
+	(21, 33)	PTH	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1234	A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone  [s1]PTH[e1]  concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
+	(6, 34)	severe hypocalcemia	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1235	A case is reported in which [s1]severe hypocalcemia[e1]  with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
+	(0, 8)	Carbamazepine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1236	 [s1]Carbamazepine[e1] related [s2]hyponatremia[e2] following cardiopulmonary bypass.
+	(5, 13)	carbamazepine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1237	We discuss the association between [s1]carbamazepine[e1] and [s2]hyponatremia[e2] and the causes of hyponatremia after cardiopulmonary bypass.
+	(1, 10)	5-ASA	polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1238	After [s1]5-ASA[e1] was discontinued, the [s2]polyneuropathy[e2] symptoms recovered gradually.
+	(0, 10)	Sensorimotor polyneuropathy	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1239	 [s1]Sensorimotor polyneuropathy[e1] with [s2]5-aminosalicylic acid[e2]  a case report.
+	(6, 20)	sensorimotor polyneuropathy	5-ASA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1240	This clinical course suggests that the [s1]sensorimotor polyneuropathy[e1] may have been caused by [s2]5-ASA[e2] 
+	(6, 34)	5-aminosalicylic acid	atrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1241	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and [s2]atrophy[e2] in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
+	(14, 32)	5-ASA	atrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1242	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and [s2]atrophy[e2] in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
+	(6, 58)	5-aminosalicylic acid	gait disturbance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1243	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and [s2]gait disturbance[e2] 
+	(14, 56)	5-ASA	gait disturbance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1244	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and [s2]gait disturbance[e2] 
+	(6, 32)	5-aminosalicylic acid	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1245	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed [s2]weakness[e2] and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
+	(14, 30)	5-ASA	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1246	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed [s2]weakness[e2] and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
+	(6, 45)	5-aminosalicylic acid	worsening of the dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1247	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive [s2]worsening of the dysesthesia[e2] in his legs and gait disturbance.
+	(14, 43)	5-ASA	worsening of the dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1248	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive [s2]worsening of the dysesthesia[e2] in his legs and gait disturbance.
+	(0, 16)	Disseminated cellulitic cryptococcosis	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1249	 [s1]Disseminated cellulitic cryptococcosis[e1] in the setting of [s2]prednisone[e2] monotherapy for pemphigus vulgaris.
+	(13, 31)	atypical lymphocytosis	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1250	In both cases, high fever, skin rash, liver dysfunction and [s1]atypical lymphocytosis[e1] developed 3 weeks after initiating treatment with [s2]SASP[e2] 
+	(4, 30)	high fever	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1251	In both cases, [s1]high fever[e1]  skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
+	(10, 31)	liver dysfunction	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1252	In both cases, high fever, skin rash, [s1]liver dysfunction[e1] and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
+	(7, 30)	skin rash	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1253	In both cases, high fever, [s1]skin rash[e1]  liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
+	(14, 26)	infectious mononucleosis-like syndrome	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1254	Slow acetylator genotypes as a possible risk factor for [s1]infectious mononucleosis-like syndrome[e1] induced by [s2]salazosulfapyridine[e2] 
+	(5, 17)	infectious mononucleosis-like syndrome	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1255	We report two patients with [s1]infectious mononucleosis-like syndrome[e1] induced by [s2]salazosulfapyridine[e2] (SASP).
+	(5, 25)	infectious mononucleosis-like syndrome	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1256	We report two patients with [s1]infectious mononucleosis-like syndrome[e1] induced by salazosulfapyridine  [s2]SASP[e2] .
+	(24, 43)	infliximab	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1257	A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance [s1]infliximab[e1] infusions and methotrexate, developed a [s2]lupus-like syndrome[e2] eight months after her initial infusion.
+	(33, 42)	methotrexate	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1258	A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and [s1]methotrexate[e1]  developed a [s2]lupus-like syndrome[e2] eight months after her initial infusion.
+	(1, 10)	lupus-like syndrome	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1259	A [s1]lupus-like syndrome[e1] associated with [s2]infliximab[e2] therapy.
+	(0, 11)	Infliximab	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1260	 [s1]Infliximab[e1] therapy may cause a [s2]lupus-like syndrome[e2] that is reversible upon discontinuing this agent.
+	(9, 22)	infliximab	lupus-like clinical syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1261	We report in detail an unusual adverse reaction to [s1]infliximab[e1] therapy, a drug-induced [s2]lupus-like clinical syndrome[e2] 
+	(19, 29)	IFNalpha	renal dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1262	Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha  [s1]IFNalpha[e1]  have all been associated with [s2]renal dysfunction[e2] 
+	(15, 31)	interferon alpha	renal dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1263	Chronic myelogenous leukemia (CML), hepatitis C, and [s1]interferon alpha[e1] (IFNalpha) have all been associated with [s2]renal dysfunction[e2] 
+	(9, 15)	renal abnormalities	IFNalpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1264	Despite the underlying hepatitis C, this case represents [s1]renal abnormalities[e1] consistent with [s2]IFNalpha[e2] therapy for CML.
+	(0, 8)	Interferon-alpha	focal segmental glomerulosclerosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1265	 [s1]Interferon-alpha[e1] induced [s2]focal segmental glomerulosclerosis[e2] in chronic myelogenous leukemia: a case report and review of the literature.
+	(5, 31)	focal segmental glomerulosclerosis	IFNalpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1266	The renal biopsy showed [s1]focal segmental glomerulosclerosis[e1]  which has only been previously reported in two cases of CML treated with [s2]IFNalpha[e2] 
+	(1, 13)	autoimmune hemolytic anemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1267	Severe [s1]autoimmune hemolytic anemia[e1] following [s2]rituximab[e2] therapy in a patient with a lymphoproliferative disorder.
+	(22, 31)	destruction of CD20 positive cells	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1268	The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after [s1]destruction of CD20 positive cells[e1] by [s2]rituximab[e2] 
+	(16, 31)	massive cytokines liberation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1269	The pathophysiological mechanisms remain unknown, although the drug could act through [s1]massive cytokines liberation[e1] after destruction of CD20 positive cells by [s2]rituximab[e2] 
+	(11, 19)	rituximab	autoimmune hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1270	We report the first case, to our knowledge, of [s1]rituximab[e1] related [s2]autoimmune hemolytic anemia[e2] 
+	(3, 11)	acute transverse myelitis	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1271	Early-onset [s1]acute transverse myelitis[e1] following [s2]hepatitis B vaccination[e2] and respiratory infection: case report.
+	(16, 34)	acute onset tetraparesia	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1272	In this paper, we report a case of 3 years-old boy who developed [s1]acute onset tetraparesia[e1] following a viral respiratory infecction and [s2]hepatitis B vaccination[e2] 
+	(14, 22)	diphenhydramine	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1273	Although it would be expected that, like other type IA toxicities, [s1]diphenhydramine[e1] induced [s2]cardiotoxicity[e2] could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated.
+	(0, 10)	Diphenhydramine	dysrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1274	 [s1]Diphenhydramine[e1] induced wide complex [s2]dysrhythmia[e2] responds to treatment with sodium bicarbonate.
+	(3, 18)	diphenhydramine	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1275	However, because [s1]diphenhydramine[e1] also exhibits type IA sodium channel blockade, [s2]cardiac toxicity[e2] is also possible.
+	(5, 13)	diphenhydramine	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1276	We describe 3 cases of [s1]diphenhydramine[e1] induced [s2]cardiac toxicity[e2] that were responsive to bicarbonate.
+	(20, 30)	systemic candidiasis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1277	We describe a patient with extranodal non-Hodgkin lymphoma who developed [s1]systemic candidiasis[e1] after treatment with a [s2]cyclophosphamide[e2] based chemotherapy regimen.
+	(0, 16)	Stevens-Johnson syndrome	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1278	 [s1]Stevens-Johnson syndrome[e1] in a boy with nephrotic syndrome during [s2]prednisolone[e2] therapy.
+	(5, 29)	SJS	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1279	We report a case of [s1]SJS[e1] in a 14-year-old male with nephrotic syndrome, who was treated with oral [s2]prednisolone[e2] for 6 weeks.
+	(24, 30)	reversal reaction	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1280	A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a [s1]reversal reaction[e1] after starting [s2]dapsone[e2] and rifampin therapy is presented.
+	(24, 34)	reversal reaction	rifampin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1281	A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a [s1]reversal reaction[e1] after starting dapsone and [s2]rifampin[e2] therapy is presented.
+	(6, 15)	neuropathic side effects	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1282	However, in order to avoid [s1]neuropathic side effects[e1]  patients under [s2]thalidomide[e2] therapy should be monitored every 6 months with nerve conduction studies while taking the drug.
+	(13, 29)	interferon alpha	neurological manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1283	After a two-month interruption of interferon administration, natural [s1]interferon alpha[e1] was given but followed by another episode of the same [s2]neurological manifestations[e2] 
+	(12, 44)	bilateral optic neuritis	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1284	Case 1, a 62-year-old woman, developed [s1]bilateral optic neuritis[e1] with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
+	(18, 44)	decreased sensation of vibration	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1285	Case 1, a 62-year-old woman, developed bilateral optic neuritis with [s1]decreased sensation of vibration[e1] and increased deep tendon reflex in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
+	(23, 44)	increased deep tendon reflex	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1286	Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and [s1]increased deep tendon reflex[e1] in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
+	(12, 45)	bilateral optic neuritis	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1287	Case 2, a 29-year-old woman, developed [s1]bilateral optic neuritis[e1] combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
+	(31, 45)	bowel and bladder dysfunction	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1288	Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as [s1]bowel and bladder dysfunction[e1] after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
+	(19, 45)	numbness of the lower extremities	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1289	Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with [s1]numbness of the lower extremities[e1] as well as bowel and bladder dysfunction after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
+	(10, 37)	neurological signs	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1290	CONCLUSIONS: Optic neuritis in combination with other [s1]neurological signs[e1]  simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural [s2]interferon alpha[e2] administration.
+	(2, 38)	Optic neuritis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1291	CONCLUSIONS: [s1]Optic neuritis[e1] in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural [s2]interferon alpha[e2] administration.
+	(0, 11)	Multiple sclerosis-like disease	alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1292	 [s1]Multiple sclerosis-like disease[e1] secondary to [s2]alpha interferon[e2] 
+	(4, 24)	bilateral optic neuritis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1293	PURPOSE: To describe [s1]bilateral optic neuritis[e1] that occurred as an adverse effect of recombinant and natural [s2]interferon alpha[e2] administration.
+	(0, 19)	Acute abdomen	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1294	 [s1]Acute abdomen[e1] due to endometriosis in a premenopausal woman taking [s2]tamoxifen[e2] 
+	(4, 19)	endometriosis	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1295	Acute abdomen due to [s1]endometriosis[e1] in a premenopausal woman taking [s2]tamoxifen[e2] 
+	(13, 33)	tamoxifen	endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1296	We describe a premenopausal woman who, while having [s1]tamoxifen[e1] due to a diagnosis of in situ ductal carcinoma, developed [s2]endometriosis[e2] requiring surgery.
+	(5, 11)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1297	A case report of fatal [s1]dapsone[e1] induced [s2]agranulocytosis[e2] in an Indian mid-borderline leprosy patient.
+	(0, 16)	Fatal agranulocytosis	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1298	 [s1]Fatal agranulocytosis[e1] in an Indian male receiving 100mg of [s2]dapsone[e2] daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported.
+	(4, 10)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1299	Various case reports concerning [s1]dapsone[e1] induced [s2]agranulocytosis[e2] are reviewed.
+	(0, 12)	Massive pulmonary embolism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1300	 [s1]Massive pulmonary embolism[e1] due to late-onset [s2]heparin[e2] induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.
+	(10, 16)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1301	Massive pulmonary embolism due to late-onset [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following coronary artery bypass graft surgery: successful treatment with lepirudin.
+	(9, 35)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1302	Most cardiac surgical patients have had previous exposure to [s1]heparin[e1] for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced [s2]thrombocytopenia[e2] (HIT) postoperatively.
+	(0, 7)	Acute psychosis	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1303	 [s1]Acute psychosis[e1] associated with [s2]levetiracetam[e2] 
+	(21, 32)	acute psychosis	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1304	A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed [s1]acute psychosis[e1] 10 days after the administration of [s2]levetiracetam[e2] 
+	(1, 15)	psychotic behavior	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1305	The [s1]psychotic behavior[e1] resolved completely soon after the discontinuation of [s2]levetiracetam[e2] 
+	(23, 39)	obsessive-compulsive symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1306	"CASES: ""A"" was an 8-year-old boy with attention deficit and chronic tic disorder who developed [s1]obsessive-compulsive symptoms[e1] within 2 weeks of starting [s2]risperidone[e2] "
+	(0, 17)	Obsessive-compulsive symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1307	 [s1]Obsessive-compulsive symptoms[e1] suddenly emerged 10 days after starting [s2]risperidone[e2] and resolved within 3 days of discontinuation.
+	(0, 7)	Risperidone	obsessive-compulsive symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1308	 [s1]Risperidone[e1] induced [s2]obsessive-compulsive symptoms[e2] in two children.
+	(0, 16)	Proliferation of abnormal bone marrow histiocytes	granulocyte macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1309	 [s1]Proliferation of abnormal bone marrow histiocytes[e1]  an undesired effect of [s2]granulocyte macrophage-colony-stimulating factor[e2] therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation.
+	(1, 11)	heart failure exacerbation	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1310	Possible [s1]heart failure exacerbation[e1] associated with [s2]rosiglitazone[e2]  case report and literature review.
+	(0, 7)	Enoxaparin	generalized exanthem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1311	 [s1]Enoxaparin[e1] induced [s2]generalized exanthem[e2] 
+	(5, 15)	generalized maculopapular rash	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1312	Only one case of a [s1]generalized maculopapular rash[e1] with [s2]enoxaparin[e2] has been reported in Europe.
+	(16, 29)	generalized exanthem	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1313	To our knowledge, this is the first case reported in the English literature of a [s1]generalized exanthem[e1] due to subcutaneous injection of [s2]enoxaparin[e2] 
+	(5, 16)	clonazepam	aggression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1314	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, [s2]aggression[e2]  hyperactivity, irritability, property destruction, and temper tantrums.
+	(5, 14)	clonazepam	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1315	Behavioral side effects associated with [s1]clonazepam[e1] may include [s2]agitation[e2]  aggression, hyperactivity, irritability, property destruction, and temper tantrums.
+	(5, 18)	clonazepam	hyperactivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1316	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, [s2]hyperactivity[e2]  irritability, property destruction, and temper tantrums.
+	(5, 22)	clonazepam	irritability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1317	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, [s2]irritability[e2]  property destruction, and temper tantrums.
+	(5, 26)	clonazepam	property destruction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1318	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, irritability, [s2]property destruction[e2]  and temper tantrums.
+	(5, 30)	clonazepam	temper tantrums	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1319	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, irritability, property destruction, and [s2]temper tantrums[e2] 
+	(12, 21)	behavioral exacerbation	clonazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1320	This report describes an individual with mental retardation who experienced [s1]behavioral exacerbation[e1] associated with [s2]clonazepam[e2] prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method.
+	(0, 7)	Cefuroxime	immune hemolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1321	 [s1]Cefuroxime[e1] induced [s2]immune hemolysis[e2] 
+	(6, 12)	IHA	cefuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1322	We report the first case of [s1]IHA[e1] associated with [s2]cefuroxime[e2] administration.
+	(4, 17)	argatroban	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1323	After 39 hours on [s1]argatroban[e1]  the infusion was stopped when minor [s2]bleeding[e2] was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.
+	(5, 11)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1324	Argatroban for [s1]heparin[e1] induced [s2]thrombocytopenia[e2] in hepato-renal failure and CVVHD.
+	(0, 36)	Argatroban	hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1325	 [s1]Argatroban[e1] is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in [s2]hepatic failure[e2] 
+	(8, 20)	hepatic and renal failure	argatroban	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1326	OBJECTIVE: To report a case of significant [s1]hepatic and renal failure[e1] with the use of [s2]argatroban[e2] in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).
+	(26, 32)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1327	OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with [s1]heparin[e1] induced [s2]thrombocytopenia[e2] (HIT) requiring continuous veno-veno hemodialysis (CVVHD).
+	(0, 10)	Schneiderian first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1328	 [s1]Schneiderian first-rank symptoms[e1] associated with [s2]fluvoxamine[e2] treatment: a case report.
+	(17, 24)	first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1329	The patient, a 28-year-old man suffering from panic disorder, developed several [s1]first-rank symptoms[e1] during [s2]fluvoxamine[e2] administration.
+	(7, 21)	Schneiderian first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1330	This communication describes a patient who developed [s1]Schneiderian first-rank symptoms[e1] in the course of treatment with [s2]fluvoxamine[e2] 
+	(4, 15)	fluvoxamine	Schneiderian first-rank symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1331	This finding suggests that [s1]fluvoxamine[e1] can precipitate [s2]Schneiderian first-rank symptoms[e2] in some susceptible patients.
+	(17, 24)	clozapine	EPS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1332	We present a surprising case of a woman schizophrenic patient treated with [s1]clozapine[e1] suffering from [s2]EPS[e2] 
+	(0, 7)	Hyperpigmentation	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1333	 [s1]Hyperpigmentation[e1] during [s2]interferon-alpha[e2] therapy for chronic hepatitis C virus infection.
+	(1, 21)	skin lesions	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1334	These [s1]skin lesions[e1] may be induced or worsened during antiviral therapy with interferon-alpha  [s2]IFN[e2] .
+	(1, 16)	skin lesions	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1335	These [s1]skin lesions[e1] may be induced or worsened during antiviral therapy with [s2]interferon-alpha[e2] (IFN).
+	(9, 23)	hyperpigmented skin	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1336	We describe two dark-skinned patients who developed [s1]hyperpigmented skin[e1] and tongue lesions during combination therapy with [s2]IFN[e2] and ribavirin.
+	(9, 26)	hyperpigmented skin	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1337	We describe two dark-skinned patients who developed [s1]hyperpigmented skin[e1] and tongue lesions during combination therapy with IFN and [s2]ribavirin[e2] 
+	(15, 23)	tongue lesions	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1338	We describe two dark-skinned patients who developed hyperpigmented skin and [s1]tongue lesions[e1] during combination therapy with [s2]IFN[e2] and ribavirin.
+	(15, 26)	tongue lesions	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1339	We describe two dark-skinned patients who developed hyperpigmented skin and [s1]tongue lesions[e1] during combination therapy with IFN and [s2]ribavirin[e2] 
+	(7, 29)	ciprofloxacin	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1340	It is concluded that simultaneous administration of [s1]ciprofloxacin[e1] and tazobactam/piperacillin may cause marked [s2]thrombocytosis[e2] 
+	(19, 28)	piperacillin	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1341	It is concluded that simultaneous administration of ciprofloxacin and tazobactam [s1]piperacillin[e1] may cause marked [s2]thrombocytosis[e2] 
+	(14, 28)	tazobactam	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1342	It is concluded that simultaneous administration of ciprofloxacin and [s1]tazobactam[e1] piperacillin may cause marked [s2]thrombocytosis[e2] 
+	(2, 25)	thrombocyte count started to increase	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1343	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of [s2]ciprofloxacin[e2] and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
+	(2, 37)	thrombocyte count started to increase	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1344	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam [s2]piperacillin[e2] and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
+	(2, 32)	thrombocyte count started to increase	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1345	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and [s2]tazobactam[e2] piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
+	(0, 8)	Thrombocytosis	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1346	 [s1]Thrombocytosis[e1] under [s2]ciprofloxacin[e2] and tazobactam/piperacillin.
+	(0, 20)	Thrombocytosis	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1347	 [s1]Thrombocytosis[e1] under ciprofloxacin and tazobactam [s2]piperacillin[e2] 
+	(0, 15)	Thrombocytosis	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1348	 [s1]Thrombocytosis[e1] under ciprofloxacin and [s2]tazobactam[e2] piperacillin.
+	(0, 11)	Anaphylaxis	chymopapain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1349	 [s1]Anaphylaxis[e1] after the injection of [s2]chymopapain[e2] occurs in about 1% of such cases.
+	(4, 14)	hypotensive	chymopapain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1350	Both patients suddenly became [s1]hypotensive[e1] after injection of [s2]chymopapain[e2] into a disk.
+	(0, 9)	Lethargy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1351	 [s1]Lethargy[e1] in a newborn: [s2]lithium[e2] toxicity or lab error?
+	(7, 11)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1352	Lethargy in a newborn: [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity or lab error?
+	(8, 20)	lethargy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1353	The newborn manifested a four day course of [s1]lethargy[e1] with unexplained high [s2]lithium[e2] levels in the adult toxic range.
+	(26, 47)	fever	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1354	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
+	(26, 52)	fever	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1355	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
+	(26, 56)	fever	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1356	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
+	(28, 48)	leukopenia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1357	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
+	(28, 53)	leukopenia	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1358	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
+	(28, 57)	leukopenia	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1359	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
+	(33, 48)	positive anti-nuclear antibody	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1360	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
+	(33, 53)	positive anti-nuclear antibody	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1361	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
+	(33, 57)	positive anti-nuclear antibody	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1362	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
+	(24, 47)	rash	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1363	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
+	(24, 52)	rash	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1364	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
+	(24, 56)	rash	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1365	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
+	(8, 47)	systemic lupus erythematosus (SLE)-like symptoms	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1366	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
+	(8, 52)	systemic lupus erythematosus (SLE)-like symptoms	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1367	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
+	(8, 56)	systemic lupus erythematosus (SLE)-like symptoms	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1368	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
+	(0, 8)	Carbamazepine	systemic lupus erythematosus-like disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1369	 [s1]Carbamazepine[e1] induced [s2]systemic lupus erythematosus-like disease[e2] 
+	(3, 8)	CBZ	SLE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1370	The cases of [s1]CBZ[e1] induced [s2]SLE[e2] reported in the literature were reviewed.
+	(6, 13)	RH	bilateral gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1371	After four months, while receiving [s1]RH[e1]  he developed painful [s2]bilateral gynaecomastia[e2] 
+	(0, 17)	Gynaecomastia	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1372	 [s1]Gynaecomastia[e1] is a rarely reported adverse drug reaction due to [s2]isoniazid[e2] therapy.
+	(0, 10)	Isoniazid	bilateral gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1373	 [s1]Isoniazid[e1] associated, painful, [s2]bilateral gynaecomastia[e2] 
+	(4, 30)	heparin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1374	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), recurrent arteriothromboses, and [s2]acute renal failure[e2] after treatment with standard heparin is described.
+	(4, 30)	heparin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1375	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), recurrent arteriothromboses, and [s2]acute renal failure[e2] after treatment with standard heparin is described.
+	(4, 16)	heparin	HAT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1376	A patient suffering from [s1]heparin[e1] associated thrombocytopenia  [s2]HAT[e2] , recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
+	(4, 16)	heparin	HAT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1377	A patient suffering from [s1]heparin[e1] associated thrombocytopenia  [s2]HAT[e2] , recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
+	(4, 20)	heparin	recurrent arteriothromboses	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1378	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), [s2]recurrent arteriothromboses[e2]  and acute renal failure after treatment with standard heparin is described.
+	(4, 20)	heparin	recurrent arteriothromboses	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1379	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), [s2]recurrent arteriothromboses[e2]  and acute renal failure after treatment with standard heparin is described.
+	(4, 10)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1380	A patient suffering from [s1]heparin[e1] associated [s2]thrombocytopenia[e2] (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
+	(4, 10)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1381	A patient suffering from [s1]heparin[e1] associated [s2]thrombocytopenia[e2] (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
+	(11, 67)	platelet activation	Clexane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1382	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine [s2]Clexane[e2] (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
+	(11, 38)	platelet activation	Fragmin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1383	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins [s2]Fragmin[e2] and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
+	(11, 42)	platelet activation	Fraxiparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1384	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and [s2]Fraxiparin[e2] (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
+	(6, 12)	heparin	platelet activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1385	By means of the in vitro [s1]heparin[e1] induced [s2]platelet activation[e2] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
+	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1386	 [s1]Heparin[e1] associated [s2]thrombocytopenia[e2]  successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.
+	(0, 8)	Hemodynamic collapse	labetalol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1387	 [s1]Hemodynamic collapse[e1] following [s2]labetalol[e2] administration in preeclampsia.
+	(11, 27)	bromocriptine	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1388	A patient with Parkinson's disease, initially treated with [s1]bromocriptine[e1] and subsequently with cabergoline, developed progressive [s2]pleuropulmonary abnormalities[e2] during the latter therapy.
+	(18, 26)	cabergoline	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1389	A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with [s1]cabergoline[e1]  developed progressive [s2]pleuropulmonary abnormalities[e2] during the latter therapy.
+	(0, 26)	Pleuropulmonary changes	cabergoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1390	 [s1]Pleuropulmonary changes[e1] during treatment of Parkinson's disease with a long-acting ergot derivative, [s2]cabergoline[e2] 
+	(8, 18)	pleuropulmonary abnormalities	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1391	Thus cabergoline may cause similar [s1]pleuropulmonary abnormalities[e1] to [s2]bromocriptine[e2] 
+	(1, 10)	cabergoline	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1392	Thus [s1]cabergoline[e1] may cause similar [s2]pleuropulmonary abnormalities[e2] to bromocriptine.
+	(0, 24)	Acute myopathy	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1393	 [s1]Acute myopathy[e1] with selective degeneration of myosin filaments following status asthmaticus treated with [s2]methylprednisolone[e2] and vecuronium.
+	(0, 31)	Acute myopathy	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1394	 [s1]Acute myopathy[e1] with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and [s2]vecuronium[e2] 
+	(6, 24)	degeneration of myosin filaments	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1395	Acute myopathy with selective [s1]degeneration of myosin filaments[e1] following status asthmaticus treated with [s2]methylprednisolone[e2] and vecuronium.
+	(6, 31)	degeneration of myosin filaments	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1396	Acute myopathy with selective [s1]degeneration of myosin filaments[e1] following status asthmaticus treated with methylprednisolone and [s2]vecuronium[e2] 
+	(0, 18)	Flaccid quadriparesis	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1397	 [s1]Flaccid quadriparesis[e1] was noted after discontinuation of [s2]vecuronium[e2] 
+	(18, 30)	vecuronium	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1398	This entity is probably related to a combination of high doses of corticosteroids, [s1]vecuronium[e1] administration and metabolic abnormalities associated with [s2]respiratory failure[e2] 
+	(13, 28)	diffuse pulmonary shadowing	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1399	A patient with ulcerative colitis developed skin pigmentation and [s1]diffuse pulmonary shadowing[e1] without respiratory symptomatology, while taking [s2]sulfasalazine[e2] 
+	(9, 28)	skin pigmentation	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1400	A patient with ulcerative colitis developed [s1]skin pigmentation[e1] and diffuse pulmonary shadowing without respiratory symptomatology, while taking [s2]sulfasalazine[e2] 
+	(0, 11)	Pulmonary infiltrates	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1401	 [s1]Pulmonary infiltrates[e1] and skin pigmentation associated with [s2]sulfasalazine[e2] 
+	(4, 11)	skin pigmentation	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1402	Pulmonary infiltrates and [s1]skin pigmentation[e1] associated with [s2]sulfasalazine[e2] 
+	(0, 8)	Sulfasalazine	lung disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1403	 [s1]Sulfasalazine[e1] induced [s2]lung disorder[e2] is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.
+	(0, 21)	Sulfasalazine	ulcerative colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1404	 [s1]Sulfasalazine[e1] induced lung disorder is an extremely rare entity which must be considered in all [s2]ulcerative colitis[e2] patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.
+	(20, 30)	ulcerative colitis	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1405	Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all [s1]ulcerative colitis[e1] patients while on [s2]sulfasalazine[e2] therapy, despite the absence of pulmonary symptomatology.
+	(3, 23)	sclerotic changes of lumbar spine and femur	isotretinoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1406	Reversible [s1]sclerotic changes of lumbar spine and femur[e1] due to long-term oral [s2]isotretinoin[e2] therapy.
+	(6, 16)	bleomycin	scleroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1407	Although an association between exposure to [s1]bleomycin[e1] and the development of [s2]scleroderma[e2] has been suspected, few cases are reported.
+	(10, 17)	bleomycin	scleroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1408	Our series of 3 patients supports a causal connection between [s1]bleomycin[e1] and [s2]scleroderma[e2] 
+	(0, 12)	Scleroderma	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1409	 [s1]Scleroderma[e1] in association with the use of [s2]bleomycin[e2]  a report of 3 cases.
+	(5, 22)	cutaneous scleroderma	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1410	We describe the development of [s1]cutaneous scleroderma[e1] in 3 patients coincident with the use of [s2]bleomycin[e2] in low cumulative doses of less than 100 U.
+	(4, 19)	dilated cardiomyopathy	adrenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1411	A patient presented with [s1]dilated cardiomyopathy[e1] after many years of overusing an [s2]adrenaline[e2] inhaler.
+	(0, 15)	Dilated cardiomyopathy	adrenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1412	 [s1]Dilated cardiomyopathy[e1] associated with chronic overuse of an [s2]adrenaline[e2] inhaler.
+	(22, 35)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1413	A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus  [s1]SLE[e1]  with characteristic laboratory findings, 18 months after starting [s2]carbamazepine[e2] maintenance treatment.
+	(14, 37)	systemic lupus erythematosus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1414	A 21-year-old woman suffering from bipolar affective disorder developed [s1]systemic lupus erythematosus[e1] (SLE) with characteristic laboratory findings, 18 months after starting [s2]carbamazepine[e2] maintenance treatment.
+	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1415	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
+	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1416	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
+	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1417	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
+	(0, 8)	Carbamazepine	systemic lupus erythematosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1418	 [s1]Carbamazepine[e1] induced [s2]systemic lupus erythematosus[e2] 
+	(0, 9)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1419	 [s1]SLE[e1] receded after withdrawal of [s2]carbamazepine[e2] and treatment with anti-inflammatory drugs.
+	(5, 17)	acne fulminans	13-cis-retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1420	We report a case of [s1]acne fulminans[e1] occurring during treatment with [s2]13-cis-retinoic acid[e2] for cystic acne.
+	(13, 20)	valproic acid	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1421	Carbamyl phosphate synthetase-1 deficiency discovered after [s1]valproic acid[e1] induced [s2]coma[e2] 
+	(0, 7)	Valproic acid	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1422	 [s1]Valproic acid[e1] induced [s2]coma[e2] is presented in an adult patient without a history of metabolic disease.
+	(0, 8)	Asterixis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1423	 [s1]Asterixis[e1] induced by [s2]carbamazepine[e2] therapy.
+	(20, 31)	asterixis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1424	In this report we present four patients treated with a combination of different psychotropic drugs, in whom [s1]asterixis[e1] was triggered either by adding [s2]carbamazepine[e2] (CBZ) to a treatment regimen, or by increasing its dosage.
+	(20, 36)	asterixis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1425	In this report we present four patients treated with a combination of different psychotropic drugs, in whom [s1]asterixis[e1] was triggered either by adding carbamazepine  [s2]CBZ[e2]  to a treatment regimen, or by increasing its dosage.
+	(2, 47)	asterixis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1426	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
+	(2, 39)	asterixis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1427	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
+	(2, 37)	asterixis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1428	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
+	(13, 46)	neurotoxicity	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1429	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
+	(13, 38)	neurotoxicity	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1430	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
+	(13, 36)	neurotoxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1431	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
+	(0, 14)	Encephalopathy	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1432	 [s1]Encephalopathy[e1] and seizures induced by intravesical [s2]alum[e2] irrigations.
+	(6, 14)	seizures	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1433	Encephalopathy and [s1]seizures[e1] induced by intravesical [s2]alum[e2] irrigations.
+	(0, 16)	Hemorrhagic cystitis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1434	 [s1]Hemorrhagic cystitis[e1] is a significant toxic effect of [s2]cyclophosphamide[e2] therapy.
+	(13, 18)	elevated aluminum levels	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1435	We report four cases of encephalopathy coincident with [s1]elevated aluminum levels[e1]  [s2]alum[e2] num levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.
+	(5, 16)	encephalopathy	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1436	We report four cases of [s1]encephalopathy[e1] coincident with elevated [s2]alum[e2] num levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.
+	(14, 28)	alum	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1437	We report four cases of encephalopathy coincident with elevated [s1]alum[e1] num levels as well as one patient who developed [s2]seizures[e2] while receiving continuous bladder irrigations with alum.
+	(2, 13)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1438	Seizure with [s1]hyponatremia[e1] in a child prescribed [s2]desmopressin[e2] for nocturnal enuresis.
+	(0, 13)	Seizure	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1439	 [s1]Seizure[e1] with hyponatremia in a child prescribed [s2]desmopressin[e2] for nocturnal enuresis.
+	(13, 29)	grand mal seizure	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1440	We report a case of hyponatremia associated with a [s1]grand mal seizure[e1] in a 28 month-old child after intra-nasal [s2]desmopressin[e2] administration for high fluid intake with nocturnal enuresis.
+	(5, 29)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1441	We report a case of [s1]hyponatremia[e1] associated with a grand mal seizure in a 28 month-old child after intra-nasal [s2]desmopressin[e2] administration for high fluid intake with nocturnal enuresis.
+	(13, 23)	SIADH	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1442	This case report describes a 38-year-old male in whom [s1]SIADH[e1] was strongly suspected secondary to [s2]Tegretol[e2] therapy to control a seizure disorder.
+	(0, 26)	Gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1443	 [s1]Gestational diabetes[e1] was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with [s2]norethisterone[e2] 
+	(14, 26)	norethisterone	diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1444	However, follow-up revealed that gestational diabetes when associated with [s1]norethisterone[e1] had a lesser risk of emerging [s2]diabetes mellitus[e2] and impaired glucose tolerance.
+	(7, 16)	gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1445	However, follow-up revealed that [s1]gestational diabetes[e1] when associated with [s2]norethisterone[e2] had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.
+	(14, 31)	norethisterone	impaired glucose tolerance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1446	However, follow-up revealed that gestational diabetes when associated with [s1]norethisterone[e1] had a lesser risk of emerging diabetes mellitus and [s2]impaired glucose tolerance[e2] 
+	(15, 27)	gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1447	In a single practice during the 21 years 1971-1991, the incidence of [s1]gestational diabetes[e1] in pregnancies in which [s2]norethisterone[e2] was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).
+	(22, 32)	norethisterone	clitoral hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1448	Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to [s1]norethisterone[e1]  all were cases of [s2]clitoral hypertrophy[e2] not requiring surgical treatment.
+	(0, 24)	Masculinization of a female fetus	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1449	 [s1]Masculinization of a female fetus[e1] occurred in 5 of 39 (12.8%) exposed to [s2]norethisterone[e2]  all were cases of clitoral hypertrophy not requiring surgical treatment.
+	(0, 25)	Norethisterone	clitoral hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1450	 [s1]Norethisterone[e1] in these 69 pregnancies accounted for 33.3% (5 of 15) cases of [s2]clitoral hypertrophy[e2] diagnosed in 100,756 consecutive births.
+	(4, 15)	IFN	CHF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1451	An adverse reaction to [s1]IFN[e1] was strongly suspected as the cause of [s2]CHF[e2] 
+	(6, 17)	congestive heart failure	recombinant alpha-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1452	Multiple myeloma complicated by [s1]congestive heart failure[e1] following first administration of [s2]recombinant alpha-interferon[e2] 
+	(7, 24)	IFN	CHF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1453	Sixteen hours after the first administration of [s1]IFN[e1]  IFN was suspended by the symptoms of congestive heart failure  [s2]CHF[e2] .
+	(7, 19)	IFN	congestive heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1454	Sixteen hours after the first administration of [s1]IFN[e1]  IFN was suspended by the symptoms of [s2]congestive heart failure[e2] (CHF).
+	(0, 32)	Neutrophilic eccrine hidradenitis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1455	 [s1]Neutrophilic eccrine hidradenitis[e1] mimicking cutaneous vasculitis in a lupus patient: a complication of [s2]cyclophosphamide[e2] 
+	(5, 24)	NEH	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1456	We report a case of [s1]NEH[e1] masquerading as cutaneous vasculitis in a woman receiving [s2]cyclophosphamide[e2] for lupus nephritis.
+	(0, 9)	Generalised cutaneous rash	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1457	 [s1]Generalised cutaneous rash[e1] associated with [s2]ganciclovir[e2] therapy has rarely been reported in literature.
+	(0, 11)	Skin rash	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1458	 [s1]Skin rash[e1] and splinter hemorrhages from [s2]ganciclovir[e2] 
+	(3, 11)	splinter hemorrhages	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1459	Skin rash and [s1]splinter hemorrhages[e1] from [s2]ganciclovir[e2] 
+	(8, 15)	betamethasone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1460	Can roxithromycin and [s1]betamethasone[e1] induce [s2]acute pancreatitis[e2]  A case report.
+	(1, 15)	roxithromycin	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1461	Can [s1]roxithromycin[e1] and betamethasone induce [s2]acute pancreatitis[e2]  A case report.
+	(28, 35)	betamethasone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1462	CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and [s1]betamethasone[e1]  manifested [s2]acute pancreatitis[e2] 
+	(21, 36)	roxithromycin	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1463	CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with [s1]roxithromycin[e1] and betamethasone, manifested [s2]acute pancreatitis[e2] 
+	(0, 8)	Renal tubular acidosis	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1464	 [s1]Renal tubular acidosis[e1] secondary to [s2]FK506[e2] in living donor liver transplantation: a case report.
+	(6, 16)	nephrotoxicity	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1465	RTA is one type of [s1]nephrotoxicity[e1] induced by [s2]FK506[e2]  and it is reversible in mild cases when appropriately treated.
+	(0, 16)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1466	 [s1]RTA[e1] is one type of nephrotoxicity induced by [s2]FK506[e2]  and it is reversible in mild cases when appropriately treated.
+	(11, 18)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1467	Surgeons and physicians should therefore be aware of the potential for [s1]RTA[e1] to occur with [s2]FK506[e2] after any organ transplantation.
+	(3, 9)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1468	The mechanism of [s1]RTA[e1] induced by [s2]FK506[e2] has not yet been clearly elucidated.
+	(15, 27)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1469	The treatment for acidosis and hyperkalaemia should be started as soon as [s1]RTA[e1] is diagnosed, and the dosage of [s2]FK506[e2] should also be reduced if possible.
+	(5, 11)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1470	We report a case of [s1]RTA[e1] secondary to [s2]FK506[e2] administration in liver transplantation.
+	(18, 38)	unintended sleep episodes	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1471	A 74-year-old patient with idiopathic Parkinson's disease was evaluated for [s1]unintended sleep episodes[e1] that occurred after long-term treatment with 400 mg/day of [s2]L-dopa[e2] 
+	(0, 8)	L-DOPA	daytime sleepiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1472	 [s1]L-DOPA[e1] induced excessive [s2]daytime sleepiness[e2] in PD: a placebo-controlled case with MSLT assessment.
+	(6, 14)	L-dopa	daytime somnolence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1473	The authors' results suggest that [s1]L-dopa[e1] may cause [s2]daytime somnolence[e2] in some patients with Parkinson's disease.
+	(0, 11)	Neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1474	 [s1]Neurotoxicity[e1] of intrathecal [s2]methotrexate[e2]  MR imaging findings.
+	(9, 23)	cytotoxic edema	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1475	We attribute the clinical and radiographic findings to [s1]cytotoxic edema[e1] secondary to intrathecal [s2]methotrexate[e2] 
+	(8, 27)	methotrexate	aphasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1476	We report a case of intrathecal [s1]methotrexate[e1] neurotoxicity manifesting as left arm weakness and [s2]aphasia[e2] 
+	(8, 23)	methotrexate	left arm weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1477	We report a case of intrathecal [s1]methotrexate[e1] neurotoxicity manifesting as [s2]left arm weakness[e2] and aphasia.
+	(8, 15)	methotrexate	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1478	We report a case of intrathecal [s1]methotrexate[e1]  [s2]neurotoxicity[e2] manifesting as left arm weakness and aphasia.
+	(3, 33)	lithium	Epstein's anomaly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1479	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in [s2]Epstein's anomaly[e2]  a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
+	(3, 33)	lithium	Epstein's anomaly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1480	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in [s2]Epstein's anomaly[e2]  a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
+	(3, 22)	lithium	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1481	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential [s2]teratogenicity[e2]  and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
+	(3, 22)	lithium	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1482	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential [s2]teratogenicity[e2]  and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
+	(18, 28)	glyburide	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1483	We present a case of a 20-year-old woman who ingested 900 mg of [s1]glyburide[e1] causing refractory [s2]hypoglycemia[e2] resistant to treatment with intravenous dextrose, glucagon, and diazoxide.
+	(0, 10)	Ocular ethambutol toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1484	 [s1]Ocular ethambutol toxicity[e1]  [s2]ethambutol[e2] toxicity.
+	(7, 15)	ethambutol	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1485	The most commonly recognized toxic effect of [s1]ethambutol[e1] is [s2]optic neuropathy[e2]  which generally is considered uncommon and reversible in medical literature.
+	(15, 23)	ethambutol toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1486	This case and a review of the literature show the severe and unpredictable nature of [s1]ethambutol toxicity[e1]  [s2]ethambutol[e2] toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.
+	(15, 31)	ethambutol	vision loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1487	This case and a review of the literature show the severe and unpredictable nature of [s1]ethambutol[e1] toxicity and its potential for irreversible [s2]vision loss[e2] despite careful ophthalmologic monitoring.
+	(15, 25)	bilateral optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1488	We describe a 43-year-old man who developed signs and symptoms of [s1]bilateral optic neuropathy[e1] during treatment with [s2]ethambutol[e2] 
+	(10, 20)	fatality	brompheniramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1489	The case history and toxicological findings of an infant [s1]fatality[e1] involving pseudoephedrine, [s2]brompheniramine[e2]  and dextromethorphan are presented.
+	(10, 27)	fatality	dextromethorphan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1490	The case history and toxicological findings of an infant [s1]fatality[e1] involving pseudoephedrine, brompheniramine, and [s2]dextromethorphan[e2] are presented.
+	(10, 15)	fatality	pseudoephedrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1491	The case history and toxicological findings of an infant [s1]fatality[e1] involving [s2]pseudoephedrine[e2]  brompheniramine, and dextromethorphan are presented.
+	(1, 9)	overanticoagulation	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1492	Early [s1]overanticoagulation[e1] with [s2]acenocoumarol[e2] due to a genetic polymorphism of cytochrome P450 CYP2C9.
+	(13, 22)	overanticoagulation	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1493	We report the case of a young healthy woman who presented an early [s1]overanticoagulation[e1] when receiving [s2]acenocoumarol[e2] for a first thromboembolic episode.
+	(0, 6)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1494	 [s1]Colchicine[e1] induced [s2]myopathy[e2] in a teenager with familial Mediterranean fever.
+	(2, 8)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1495	CONCLUSIONS: [s1]Colchicine[e1] induced [s2]myopathy[e2] should be excluded in patients with FMF who present with generalized muscle weakness.
+	(2, 19)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1496	DISCUSSION: [s1]Colchicine[e1]  the most important drug in treatment of FMF, can cause [s2]myopathy[e2] in patients with impaired renal and hepatic function.
+	(14, 27)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1497	In our patient, an objective causality scale showed that therapeutic doses of [s1]colchicine[e1] for FMF were the definite cause of [s2]myopathy[e2]  even though his renal and hepatic function were normal.
+	(7, 13)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1498	OBJECTIVE: To report a case of [s1]colchicine[e1] induced [s2]myopathy[e2] in a teenager with familial Mediterranean fever (FMF).
+	(0, 18)	Angioedema	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1499	 [s1]Angioedema[e1] and dysphagia caused by contact allergy to inhaled [s2]budesonide[e2] 
+	(5, 18)	dysphagia	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1500	Angioedema and [s1]dysphagia[e1] caused by contact allergy to inhaled [s2]budesonide[e2] 
+	(22, 38)	dysphagia	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1501	We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and [s1]dysphagia[e1]  2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
+	(22, 34)	dysphagia	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1502	We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and [s1]dysphagia[e1]  2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
+	(11, 38)	sore throat	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1503	We report a 43-year-old woman who developed [s1]sore throat[e1]  swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
+	(11, 34)	sore throat	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1504	We report a 43-year-old woman who developed [s1]sore throat[e1]  swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
+	(14, 39)	swelling of the lips and oral cavity	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1505	We report a 43-year-old woman who developed sore throat, [s1]swelling of the lips and oral cavity[e1] and dysphagia, 2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
+	(14, 35)	swelling of the lips and oral cavity	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1506	We report a 43-year-old woman who developed sore throat, [s1]swelling of the lips and oral cavity[e1] and dysphagia, 2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
+	(0, 5)	Infectious toxicity	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1507	 [s1]Infectious toxicity[e1] of [s2]dexamethasone[e2] during all remission-induction chemotherapy: report of two cases and literature review.
+	(17, 68)	dexamethasone	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1508	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1] (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of [s2]infectious complications[e2] with dexamethasone.
+	(3, 19)	infectious toxicities	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1509	We describe the [s1]infectious toxicities[e1] experienced by the first two patients in our institution treated with [s2]dexamethasone[e2] (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
+	(6, 26)	NEH	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1510	We describe a patient who developed [s1]NEH[e1] on three separate occasions provoked by two different chemotherapeutic agents- [s2]cytarabine[e2] and mitoxantrone.
+	(6, 31)	NEH	mitoxantrone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1511	We describe a patient who developed [s1]NEH[e1] on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and [s2]mitoxantrone[e2] 
+	(3, 11)	infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1512	A diagnosis of [s1]infliximab[e1] induced [s2]lupus[e2] was made and the drug treatment was withdrawn.
+	(0, 8)	Infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1513	 [s1]Infliximab[e1] induced [s2]lupus[e2] in Crohn's disease: a case report.
+	(14, 22)	infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1514	This is the first case, to our knowledge, of onset of prolonged [s1]infliximab[e1] induced [s2]lupus[e2] 
+	(2, 27)	infliximab	anti-double-stranded DNA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1515	Treatment with [s1]infliximab[e1] is known to produce an increase of autoantibodies (antinuclear antibodies, [s2]anti-double-stranded DNA[e2] , but not clinical disease.
+	(2, 20)	infliximab	antinuclear antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1516	Treatment with [s1]infliximab[e1] is known to produce an increase of autoantibodies  [s2]antinuclear antibodies[e2]  anti-double-stranded DNA), but not clinical disease.
+	(2, 14)	infliximab	increase of autoantibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1517	Treatment with [s1]infliximab[e1] is known to produce an [s2]increase of autoantibodies[e2] (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.
+	(0, 9)	Severe Raynaud's phenomenon	yohimbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1518	 [s1]Severe Raynaud's phenomenon[e1] with [s2]yohimbine[e2] therapy for erectile dysfunction.
+	(43, 55)	worsening of Raynaud's phenomenon	yohimbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1519	We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced [s1]worsening of Raynaud's phenomenon[e1] when using [s2]yohimbine[e2] for ED.
+	(4, 35)	vitamin D3	serum level of calcium and urinary excretion of calcium increased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1520	After initiation of topical [s1]vitamin D3[e1] ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the [s2]serum level of calcium and urinary excretion of calcium increased[e2] gradually.
+	(3, 17)	hypercalcemia	1,24(OH)2D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1521	Iatrogenic [s1]hypercalcemia[e1] due to vitamin D3 ointment  [s2]1,24(OH)2D3[e2]  combined with thiazide diuretics in a case of psoriasis.
+	(3, 29)	hypercalcemia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1522	Iatrogenic [s1]hypercalcemia[e1] due to vitamin D3 ointment (1,24(OH)2D3) combined with [s2]thiazide[e2] diuretics in a case of psoriasis.
+	(3, 11)	hypercalcemia	vitamin D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1523	Iatrogenic [s1]hypercalcemia[e1] due to [s2]vitamin D3[e2] ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.
+	(8, 23)	hypercalcemia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1524	The present case is the first report of [s1]hypercalcemia[e1] induced by vitamin D3 ointment and [s2]thiazide[e2] simultaneously.
+	(8, 16)	hypercalcemia	vitamin D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1525	The present case is the first report of [s1]hypercalcemia[e1] induced by [s2]vitamin D3[e2] ointment and thiazide simultaneously.
+	(17, 41)	tacalcitol	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1526	We experienced a male patient with psoriasis and hypertension whose conditions were treated with [s1]tacalcitol[e1] ointment and thiazide, respectively, resulting in hypercalciuria and [s2]hypercalcemia[e2] 
+	(25, 40)	thiazide	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1527	We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and [s1]thiazide[e1]  respectively, resulting in hypercalciuria and [s2]hypercalcemia[e2] 
+	(17, 36)	tacalcitol	hypercalciuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1528	We experienced a male patient with psoriasis and hypertension whose conditions were treated with [s1]tacalcitol[e1] ointment and thiazide, respectively, resulting in [s2]hypercalciuria[e2] and hypercalcemia.
+	(25, 35)	thiazide	hypercalciuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1529	We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and [s1]thiazide[e1]  respectively, resulting in [s2]hypercalciuria[e2] and hypercalcemia.
+	(0, 14)	2-CdA	immunodeficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1530	 [s1]2-CdA[e1] typically causes a long-lasting state of [s2]immunodeficiency[e2] and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.
+	(0, 37)	2-CdA	secondary neoplasms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1531	 [s1]2-CdA[e1] typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of [s2]secondary neoplasms[e2] after its use.
+	(0, 32)	2-Chloro-deoxyadenosine	non-Hodgkin's lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1532	 [s1]2-Chloro-deoxyadenosine[e1] induces durable complete remission in Castleman's disease but may accelerate its transformation to [s2]non-Hodgkin's lymphoma[e2] 
+	(11, 47)	2-CdA	transformation of MCD to NHL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1533	Therefore, it is reasonable to conclude that: 1) [s1]2-CdA[e1] can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the [s2]transformation of MCD to NHL[e2] cannot be ruled out.
+	(11, 21)	DGTX	cardiac DGTX toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1534	Since this amount of FAB was insufficient to bind all [s1]DGTX[e1] present in the serum, [s2]cardiac DGTX toxicity[e2] (total AV-block) persisted.
+	(11, 26)	DGTX	total AV-block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1535	Since this amount of FAB was insufficient to bind all [s1]DGTX[e1] present in the serum, cardiac DGTX toxicity  [s2]total AV-block[e2]  persisted.
+	(4, 32)	phenytoin	skin lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1536	All patients had taken [s1]phenytoin[e1] for variable time periods (range 16-80 days; mean: 40) and were on the medication when the [s2]skin lesions[e2] first appeared.
+	(0, 10)	Erythema multiforme	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1537	 [s1]Erythema multiforme[e1] associated with [s2]phenytoin[e2] and cranial radiation therapy: a report of three patients and review of the literature.
+	(3, 27)	RSDS	CyA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1538	In conclusion, [s1]RSDS[e1] is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug  [s2]CyA[e2] or tacrolimus), even under monotherapy or with a low steroid dose.
+	(3, 31)	RSDS	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1539	In conclusion, [s1]RSDS[e1] is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or [s2]tacrolimus[e2] , even under monotherapy or with a low steroid dose.
+	(0, 22)	Reflex sympathetic dystrophy syndrome	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1540	 [s1]Reflex sympathetic dystrophy syndrome[e1] in renal transplanted patients under immunosuppression with [s2]tacrolimus[e2] 
+	(6, 16)	RSDS	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1541	We now present four cases of [s1]RSDS[e1] in kidney transplant recipients treated with [s2]tacrolimus[e2] 
+	(2, 39)	Topiramate	acute myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1542	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in [s2]acute myopia[e2] and angle-closure glaucoma.
+	(2, 44)	Topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1543	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and [s2]angle-closure glaucoma[e2] 
+	(2, 32)	Topiramate	anterior chamber shallowing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1544	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and [s2]anterior chamber shallowing[e2]  resulting in acute myopia and angle-closure glaucoma.
+	(2, 11)	Topiramate	ciliochoroidal effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1545	CONCLUSIONS: [s1]Topiramate[e1] may be associated with [s2]ciliochoroidal effusion[e2] with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.
+	(2, 21)	Topiramate	displacement of the lens-iris diaphragm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1546	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward [s2]displacement of the lens-iris diaphragm[e2] and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.
+	(2, 8)	topiramate	acute-onset myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1547	Mechanism of [s1]topiramate[e1] induced [s2]acute-onset myopia[e2] and angle closure glaucoma.
+	(2, 15)	topiramate	angle closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1548	Mechanism of [s1]topiramate[e1] induced acute-onset myopia and [s2]angle closure glaucoma[e2] 
+	(17, 25)	acute myopia	topiramate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1549	METHODS: In an institutional practice setting, two women, aged 25 and 45, developed [s1]acute myopia[e1] after starting [s2]topiramate[e2] for epilepsy.
+	(0, 8)	Doxycycline	photo-onycholysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1550	 [s1]Doxycycline[e1] induced [s2]photo-onycholysis[e2] 
+	(5, 18)	photo-onycholysis	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1551	We present a case of [s1]photo-onycholysis[e1] in a patient treated with [s2]doxycycline[e2] for acne vulgaris.
+	(4, 12)	minocycline	cutaneous hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1552	A new type of [s1]minocycline[e1] induced [s2]cutaneous hyperpigmentation[e2] 
+	(0, 23)	Pigmentary disorders	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1553	 [s1]Pigmentary disorders[e1] are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, [s2]minocycline[e2] 
+	(6, 13)	minocycline	hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1554	This fourth type of cutaneous [s1]minocycline[e1]  [s2]hyperpigmentation[e2] may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.
+	(4, 12)	minocycline	cutaneous pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1555	Three distinct types of [s1]minocycline[e1] induced [s2]cutaneous pigmentation[e2] have been described.
+	(14, 22)	minocycline	cutaneous pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1556	We report two patients with acne vulgaris with a fourth type of [s1]minocycline[e1] induced [s2]cutaneous pigmentation[e2] 
+	(0, 9)	Ciprofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1557	 [s1]Ciprofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] in a patient with systemic lupus erythematosus.
+	(6, 12)	TEN	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1558	We report here a case of [s1]TEN[e1] after administration of [s2]ciprofloxacin[e2] 
+	(23, 31)	fever	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1559	A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed [s1]fever[e1] concurrent with the administration of [s2]amifostine[e2] 
+	(0, 7)	Amifostine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1560	 [s1]Amifostine[e1] induced [s2]fever[e2]  case report and review of the literature.
+	(2, 11)	amifostine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1561	Patients receiving [s1]amifostine[e1] who develop only [s2]fever[e2] should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.
+	(2, 28)	amifostine	fevers of neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1562	Patients receiving [s1]amifostine[e1] who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and [s2]fevers of neutropenia[e2]  and it may be necessary to discontinue the drug.
+	(2, 25)	amifostine	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1563	Patients receiving [s1]amifostine[e1] who develop only fever should be evaluated for an adverse drug reaction, as well as for [s2]sepsis[e2] and fevers of neutropenia, and it may be necessary to discontinue the drug.
+	(15, 22)	fever	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1564	To our knowledge, this is the first case report that demonstrates the occurrence of [s1]fever[e1] with low-dose [s2]amifostine[e2] therapy without the manifestation of accompanying rash or hypotension.
+	(0, 12)	Acute interstitial nephritis	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1565	 [s1]Acute interstitial nephritis[e1] due to [s2]pantoprazole[e2] 
+	(9, 17)	pantoprazole	general malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1566	After 5 weeks of therapy, she stopped taking [s1]pantoprazole[e1] due to [s2]general malaise[e2] 
+	(25, 40)	acute interstitial nephritis	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1567	OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of [s1]acute interstitial nephritis[e1] (AIN) due to [s2]pantoprazole[e2] 
+	(12, 16)	AIN	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1568	The Naranjo probability scale suggests a highly probable relationship between [s1]AIN[e1] and [s2]pantoprazole[e2] therapy in this patient.
+	(7, 14)	omeprazole	AIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1569	There have been several reported cases of [s1]omeprazole[e1] induced [s2]AIN[e2] 
+	(5, 14)	finasteride	anterior subcapsular opacity on the lens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1570	It was highly suspected that [s1]finasteride[e1] was associated with the [s2]anterior subcapsular opacity on the lens[e2]  and the patient therefore discontinued use of finasteride.
+	(5, 14)	finasteride	anterior subcapsular opacity on the lens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1571	It was highly suspected that [s1]finasteride[e1] was associated with the [s2]anterior subcapsular opacity on the lens[e2]  and the patient therefore discontinued use of finasteride.
+	(0, 6)	Propecia	bilateral cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1572	 [s1]Propecia[e1] associated [s2]bilateral cataract[e2] 
+	(16, 22)	Propecia	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1573	To the best of the authors' knowledge, this is the first reported case of [s1]Propecia[e1] associated [s2]cataract[e2] 
+	(0, 24)	Scleromyxedema	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1574	 [s1]Scleromyxedema[e1] in a patient with multiple sclerosis and monoclonal gammopathy on [s2]interferon beta-1a[e2] 
+	(11, 22)	methylphenidate	fixed drug eruption of the scrotum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1575	CASE SUMMARY: Two children with attention deficit disorder treated with [s1]methylphenidate[e1] as a simple drug developed [s2]fixed drug eruption of the scrotum[e2] 
+	(2, 9)	Fixed drug rash	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1576	CONCLUSIONS: [s1]Fixed drug rash[e1] induced by [s2]methylphenidate[e2] is a possible but rare phenomenon.
+	(0, 12)	Fixed drug eruption of the scrotum	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1577	 [s1]Fixed drug eruption of the scrotum[e1] due to [s2]methylphenidate[e2] 
+	(7, 14)	fixed drug eruption	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1578	OBJECTIVE: To report two cases of [s1]fixed drug eruption[e1] induced by [s2]methylphenidate[e2] 
+	(0, 7)	Methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1579	 [s1]Methotrexate[e1]  [s2]pneumonitis[e2] in nonsurgical treatment of ectopic pregnancy.
+	(5, 16)	pneumonitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1580	We describe a case of [s1]pneumonitis[e1] following local administration of [s2]methotrexate[e2] for nonsurgical termination of an ectopic pregnancy.
+	(8, 22)	warfarin	haemorrhagic side-effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1581	BACKGROUND: The risk/benefit ratio of [s1]warfarin[e1] therapy changes in the over 75s, when [s2]haemorrhagic side-effects[e2] become more common.
+	(13, 22)	warfarin	acute dissecting thoracic aortic aneurysm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1582	CASE REPORT: A woman of 80 years, on long-term [s1]warfarin[e1] therapy presented with an [s2]acute dissecting thoracic aortic aneurysm[e2]  on investigation the only precipitating factor found was an international normalised ratio of 4.8.
+	(0, 6)	Warfarin	thoracic aortic dissection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1583	 [s1]Warfarin[e1] associated [s2]thoracic aortic dissection[e2] in an elderly woman.
+	(0, 10)	Cutaneous vasculitis	ramipril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1584	 [s1]Cutaneous vasculitis[e1] secondary to [s2]ramipril[e2] 
+	(3, 9)	ramipril	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1585	Here we report [s1]ramipril[e1] induced [s2]cutaneous vasculitis[e2] in a patient who required steroid therapy to control it.
+	(0, 6)	Ramipril	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1586	 [s1]Ramipril[e1] induced [s2]cutaneous vasculitis[e2] is particularly rare and our case was atypical because the patient had tolerated lisinopril before.
+	(13, 26)	severe myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1587	CONCLUSION: This is, to our knowledge, the first report of [s1]severe myelopathy[e1] following accidental intrathecal administration of [s2]doxorubicin[e2] 
+	(6, 19)	toxic myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1588	Neurological improvement and rehabilitation potential following [s1]toxic myelopathy[e1] due to intrathecal injection of [s2]doxorubicin[e2] 
+	(10, 23)	severe myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1589	RESULTS: Evidence of neurological improvement and rehabilitation potential after [s1]severe myelopathy[e1] due to intrathecal injection of [s2]doxorubicin[e2] 
+	(16, 29)	toxic myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1590	STUDY DESIGN: Case report of a 31-year-old woman who presented with [s1]toxic myelopathy[e1] due to intrathecal administration of [s2]doxorubicin[e2] 
+	(1, 15)	infliximab	increase in the number of apneic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1591	After [s1]infliximab[e1] treatment, additional sleep studies revealed an [s2]increase in the number of apneic events[e2] and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.
+	(1, 25)	infliximab	SaO2 dips	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1592	After [s1]infliximab[e1] treatment, additional sleep studies revealed an increase in the number of apneic events and [s2]SaO2 dips[e2] suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.
+	(5, 29)	sleep disordered breathing	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1593	Thus, clinical recognition of [s1]sleep disordered breathing[e1] should be taken into account when rheumatoid arthritis patients are to be treated with [s2]infliximab[e2] 
+	(0, 16)	Hypernatraemia	Kayexalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1594	 [s1]Hypernatraemia[e1] induced by sodium polystyrene sulphonate  [s2]Kayexalate[e2]  in two extremely low birth weight newborns.
+	(0, 8)	Hypernatraemia	sodium polystyrene sulphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1595	 [s1]Hypernatraemia[e1] induced by [s2]sodium polystyrene sulphonate[e2] (Kayexalate) in two extremely low birth weight newborns.
+	(15, 23)	Kayexalate	hypernatraemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1596	We describe two ELBW infants affected by hyperkalaemia, treated with [s1]Kayexalate[e1]  who developed serious [s2]hypernatraemia[e2]  that has never been reported before in preterm infants.
+	(0, 12)	Bull's-eye maculopathy	quinacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1597	 [s1]Bull's-eye maculopathy[e1] associated with [s2]quinacrine[e2] therapy for malaria.
+	(24, 36)	maculopathy	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1598	CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe [s1]maculopathy[e1] indistinguishable from [s2]chloroquine[e2] maculopathy in certain patients.
+	(6, 25)	quinacrine	severe maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1599	CONCLUSIONS: Low dosages of [s1]quinacrine[e1] used for malaria prophylaxis can be associated with a delayed, [s2]severe maculopathy[e2] indistinguishable from chloroquine maculopathy in certain patients.
+	(6, 23)	bilaterally symmetric bull's-eye maculopathy	quinacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1600	RESULTS: A patient developed a [s1]bilaterally symmetric bull's-eye maculopathy[e1] 45 years after taking [s2]quinacrine[e2] for 18 months as prophylaxis against malaria.
+	(8, 23)	chloroquine	maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1601	The clinical picture was identical to that of [s1]chloroquine[e1] and hydroxychloroquine [s2]maculopathy[e2] 
+	(14, 23)	hydroxychloroquine	maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1602	The clinical picture was identical to that of chloroquine and [s1]hydroxychloroquine[e1]  [s2]maculopathy[e2] 
+	(0, 12)	Cerebral infarcts	phenylpropanolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1603	 [s1]Cerebral infarcts[e1] in a pediatric patient secondary to [s2]phenylpropanolamine[e2]  a recalled medication.
+	(0, 25)	Phenylpropanolamine	neurologic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1604	 [s1]Phenylpropanolamine[e1] (PPA) recently has been publicly implicated as a cause of stroke and other [s2]neurologic events[e2] 
+	(7, 23)	PPA	neurologic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1605	Phenylpropanolamine  [s1]PPA[e1]  recently has been publicly implicated as a cause of stroke and other [s2]neurologic events[e2] 
+	(0, 22)	Phenylpropanolamine	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1606	 [s1]Phenylpropanolamine[e1] (PPA) recently has been publicly implicated as a cause of [s2]stroke[e2] and other neurologic events.
+	(7, 20)	PPA	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1607	Phenylpropanolamine  [s1]PPA[e1]  recently has been publicly implicated as a cause of [s2]stroke[e2] and other neurologic events.
+	(15, 23)	extremely elevated levels of PPA	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1608	The patient developed occipital infarcts and was found to have [s1]extremely elevated levels of PPA[e1]  [s2]PPA[e2] in his blood and dialysis fluid.
+	(3, 21)	occipital infarcts	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1609	The patient developed [s1]occipital infarcts[e1] and was found to have extremely elevated levels of [s2]PPA[e2] in his blood and dialysis fluid.
+	(5, 9)	stroke	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1610	We present a case of [s1]stroke[e1] after [s2]PPA[e2] ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.
+	(6, 35)	ciprofloxacin	hallucinations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1611	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and [s2]hallucinations[e2] have been reported.
+	(6, 26)	ciprofloxacin	mild headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1612	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or [s2]mild headache[e2]  although rare occurrences of seizures and hallucinations have been reported.
+	(6, 22)	ciprofloxacin	minor dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1613	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of [s2]minor dizziness[e2] or mild headache, although rare occurrences of seizures and hallucinations have been reported.
+	(6, 33)	ciprofloxacin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1614	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of [s2]seizures[e2] and hallucinations have been reported.
+	(0, 9)	Ciprofloxacin	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1615	 [s1]Ciprofloxacin[e1] induced [s2]psychosis[e2] 
+	(13, 23)	severe psychosis	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1616	DATA SYNTHESIS: A 49-year-old man developed symptoms of [s1]severe psychosis[e1] concomitant with [s2]ciprofloxacin[e2] (250 mg bid) treatment.
+	(7, 16)	ciprofloxacin	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1617	OBJECTIVE: To report a case of [s1]ciprofloxacin[e1] induced [s2]psychosis[e2] and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction.
+	(0, 9)	Agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1618	 [s1]Agranulocytosis[e1] induced by [s2]vancomycin[e2] in an ESRD patient on CAPD.
+	(0, 15)	Agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1619	 [s1]Agranulocytosis[e1] is a rare adverse effect associated with prolonged [s2]vancomycin[e2] therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.
+	(20, 27)	vancomycin	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1620	We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed [s1]vancomycin[e1] induced [s2]agranulocytosis[e2] during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.
+	(6, 27)	dexamethasone	osteonecrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1621	It is very likely that the [s1]dexamethasone[e1] used in the antiemetic drug regimen contributed to the development of [s2]osteonecrosis[e2] in these patients.
+	(0, 18)	Osteonecrosis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1622	 [s1]Osteonecrosis[e1] is a serious side effect of antiemetic treatment with [s2]dexamethasone[e2] and this serious complication should be incorporated in the current guidelines.
+	(8, 17)	osteonecrosis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1623	Patients should be informed about the risk of [s1]osteonecrosis[e1] when taking [s2]dexamethasone[e2] as an antiemetic drug.
+	(2, 15)	Peyronie's disease	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1624	Development of [s1]Peyronie's disease[e1] during long-term [s2]colchicine[e2] treatment.
+	(9, 15)	PD	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1625	However here we reported two patients, presenting with [s1]PD[e1] during high dose [s2]colchicine[e2] treatment for familiar mediterranean fever (FMF).
+	(3, 14)	cholestatic hepatitis	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1626	A patient developed [s1]cholestatic hepatitis[e1] while being treated with [s2]nitrofurantoin[e2] 
+	(4, 19)	jaundice	furazolidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1627	A second episode of [s1]jaundice[e1] followed the intravaginal administration of a mixture of [s2]furazolidone[e2] and nifuroxime.
+	(4, 25)	jaundice	nifuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1628	A second episode of [s1]jaundice[e1] followed the intravaginal administration of a mixture of furazolidone and [s2]nifuroxime[e2] 
+	(3, 10)	phenobarbital	exacerbation of a preexisting maladaptive behavior	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1629	A case of [s1]phenobarbital[e1]  [s2]exacerbation of a preexisting maladaptive behavior[e2] partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.
+	(12, 24)	phenobarbital	maladaptive behaviors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1630	Ten years of behavioral data are presented to support the hypothesis that [s1]phenobarbital[e1] was exacerbating [s2]maladaptive behaviors[e2] 
+	(14, 21)	phenobarbital	behavioral side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1631	"This profile should trigger a ""red flag"" as to the possibility of [s1]phenobarbital[e1]  [s2]behavioral side effects[e2] or exacerbation of preexisting maladaptive behaviors."
+	(14, 25)	phenobarbital	exacerbation of preexisting maladaptive behaviors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1632	"This profile should trigger a ""red flag"" as to the possibility of [s1]phenobarbital[e1] behavioral side effects or [s2]exacerbation of preexisting maladaptive behaviors[e2] "
+	(0, 15)	Pilocarpine toxicity	Pilocarpine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1633	 [s1]Pilocarpine toxicity[e1] and the treatment of xerostomia [s2]Pilocarpine[e2] toxicity and the treatment of xerostomia.
+	(12, 22)	pilocarpine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1634	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in [s2]bradycardia[e2]  mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.
+	(12, 26)	pilocarpine	mild hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1635	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in bradycardia, [s2]mild hypotension[e2]  and muscarinic symptoms in a patient with Sjogren's syndrome.
+	(12, 34)	pilocarpine	muscarinic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1636	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in bradycardia, mild hypotension, and [s2]muscarinic symptoms[e2] in a patient with Sjogren's syndrome.
+	(3, 46)	belladonna	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1637	Although combinations of [s1]belladonna[e1]  ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
+	(7, 46)	ergotamine	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1638	Although combinations of belladonna, [s1]ergotamine[e1]  and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
+	(13, 47)	phenobarbital	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1639	Although combinations of belladonna, ergotamine, and [s1]phenobarbital[e1] have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
+	(0, 14)	Anticonvulsant hypersensitivity syndrome	Bellamine S	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1640	 [s1]Anticonvulsant hypersensitivity syndrome[e1] associated with [s2]Bellamine S[e2]  a therapy for menopausal symptoms.
+	(17, 34)	anticonvulsant hypersensitivity syndrome	belladonna alkaloids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1641	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S  [s2]belladonna alkaloids[e2]  ergotamine; phenobarbital) for hot flashes.
+	(17, 31)	anticonvulsant hypersensitivity syndrome	Bellamine S	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1642	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking [s2]Bellamine S[e2] (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.
+	(17, 42)	anticonvulsant hypersensitivity syndrome	ergotamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1643	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S (belladonna alkaloids; [s2]ergotamine[e2]  phenobarbital) for hot flashes.
+	(17, 47)	anticonvulsant hypersensitivity syndrome	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1644	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S (belladonna alkaloids; ergotamine; [s2]phenobarbital[e2]  for hot flashes.
+	(3, 23)	heatstroke	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1645	A case of [s1]heatstroke[e1] is reported in a 32-year-old man diagnosed with schizophrenia and on [s2]clozapine[e2] monotherapy.
+	(0, 7)	Heat stroke	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1646	 [s1]Heat stroke[e1] in schizophrenia during [s2]clozapine[e2] treatment: rapid recognition and management.
+	(0, 7)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1647	 [s1]Gemcitabine[e1] related [s2]radiation recall[e2] preferentially involves internal tissue and organs.
+	(8, 52)	myositis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1648	The authors also determined that their case of [s1]myositis[e1] developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
+	(36, 51)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1649	The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of [s1]radiation recall[e1]  thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
+	(36, 51)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1650	The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of [s1]radiation recall[e1]  thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
+	(7, 13)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1651	The literature search found 12 cases of [s1]radiation recall[e1] caused by [s2]gemcitabine[e2] 
+	(3, 10)	radiation recall reactions	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1652	The majority of [s1]radiation recall reactions[e1] attributed to [s2]gemcitabine[e2] are reported to affect internal tissue or organs.
+	(0, 24)	Cystoid macular edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1653	 [s1]Cystoid macular edema[e1] in a low-risk patient after switching from latanoprost to [s2]bimatoprost[e2] 
+	(0, 18)	Cystoid macular edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1654	 [s1]Cystoid macular edema[e1] in a low-risk patient after switching from [s2]latanoprost[e2] to bimatoprost.
+	(19, 37)	cystoid macula edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1655	METHODS: A 68-year-old man developed intense conjunctival hyperemia and [s1]cystoid macula edema[e1] after switching from latanoprost to [s2]bimatoprost[e2] 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
+	(19, 31)	cystoid macula edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1656	METHODS: A 68-year-old man developed intense conjunctival hyperemia and [s1]cystoid macula edema[e1] after switching from [s2]latanoprost[e2] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
+	(35, 58)	bimatoprost	cystoid macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1657	METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to [s1]bimatoprost[e1] 9 months after cataract surgery in an eye at low-risk for this [s2]cystoid macular edema[e2] 
+	(29, 58)	latanoprost	cystoid macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1658	METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from [s1]latanoprost[e1] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this [s2]cystoid macular edema[e2] 
+	(10, 37)	intense conjunctival hyperemia	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1659	METHODS: A 68-year-old man developed [s1]intense conjunctival hyperemia[e1] and cystoid macula edema after switching from latanoprost to [s2]bimatoprost[e2] 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
+	(10, 31)	intense conjunctival hyperemia	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1660	METHODS: A 68-year-old man developed [s1]intense conjunctival hyperemia[e1] and cystoid macula edema after switching from [s2]latanoprost[e2] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
+	(12, 36)	cystoid macula edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1661	PURPOSE: To report a case of angiographically documented [s1]cystoid macula edema[e1] occurring after switching a pseudophakic patient from latanoprost to [s2]bimatoprost[e2] 
+	(12, 30)	cystoid macula edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1662	PURPOSE: To report a case of angiographically documented [s1]cystoid macula edema[e1] occurring after switching a pseudophakic patient from [s2]latanoprost[e2] to bimatoprost.
+	(2, 13)	hemolytic reaction	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1663	An immediate [s1]hemolytic reaction[e1] induced by repeated administration of [s2]oxaliplatin[e2] 
+	(10, 40)	DAT-positive hemolytic episode	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1664	CASE REPORT: We report a patient who developed a [s1]DAT-positive hemolytic episode[e1] after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of [s2]oxaliplatin[e2] 
+	(12, 21)	methotrexate	fatal acute neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1665	Although neurotoxicity is a frequent complication of [s1]methotrexate[e1] therapy, [s2]fatal acute neurotoxicity[e2] is extremely uncommon, especially in adults.
+	(1, 14)	neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1666	Although [s1]neurotoxicity[e1] is a frequent complication of [s2]methotrexate[e2] therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults.
+	(11, 33)	neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1667	Clinicians should be aware of the signs and symptoms of [s1]neurotoxicity[e1] during treatment, as well as predisposing factors that put patients receiving [s2]methotrexate[e2] at risk for neurotoxic effects.
+	(0, 19)	Fatal acute encephalomyelitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1668	 [s1]Fatal acute encephalomyelitis[e1] after a single dose of intrathecal [s2]methotrexate[e2] 
+	(3, 16)	methotrexate	severe back pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1669	The day after [s1]methotrexate[e1] administration, the patient complained of [s2]severe back pain[e2] and urinary retention.
+	(3, 20)	methotrexate	urinary retention	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1670	The day after [s1]methotrexate[e1] administration, the patient complained of severe back pain and [s2]urinary retention[e2] 
+	(12, 27)	fatal encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1671	This patient rapidly progressed from mild neurotoxicity to [s1]fatal encephalopathy[e1] after one dose of intrathecal [s2]methotrexate[e2] during his third cycle of chemotherapy.
+	(5, 27)	mild neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1672	This patient rapidly progressed from [s1]mild neurotoxicity[e1] to fatal encephalopathy after one dose of intrathecal [s2]methotrexate[e2] during his third cycle of chemotherapy.
+	(23, 34)	ampicillin	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1673	We report a third case of a 6-week-old infant with Escherichia coli sepsis who received [s1]ampicillin[e1] and other antibiotics and subsequently developed [s2]TEN[e2] 
+	(3, 22)	large intramural esophageal hematoma	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1674	One patient developed [s1]large intramural esophageal hematoma[e1] as a complication of [s2]heparin[e2] therapy.
+	(0, 16)	Eosinophilic cystitis	dimethyl sulfoxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1675	 [s1]Eosinophilic cystitis[e1] after bladder instillation with [s2]dimethyl sulfoxide[e2] 
+	(10, 34)	eosinophilic cystitis	dimethyl sulfoxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1676	We report the first case of an acute flare of [s1]eosinophilic cystitis[e1] in a 51-year-old woman after bladder instillation with [s2]dimethyl sulfoxide[e2] (DMSO) for presumed interstitial cystitis.
+	(10, 40)	eosinophilic cystitis	DMSO	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1677	We report the first case of an acute flare of [s1]eosinophilic cystitis[e1] in a 51-year-old woman after bladder instillation with dimethyl sulfoxide  [s2]DMSO[e2]  for presumed interstitial cystitis.
+	(0, 7)	Acute dystonia	pegylated interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1678	 [s1]Acute dystonia[e1] during [s2]pegylated interferon alpha[e2] therapy in a case with chronic hepatitis B infection.
+	(20, 32)	acute dystonia	pegylated interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1679	In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed [s1]acute dystonia[e1] soon after the first dose of [s2]pegylated interferon alpha[e2] 
+	(2, 27)	IFN-alpha	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1680	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, [s2]akathisia[e2]  seizure, and depressive disorders.
+	(2, 34)	IFN-alpha	depressive disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1681	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and [s2]depressive disorders[e2] 
+	(2, 15)	IFN-alpha	neuropsychiatric symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1682	Therapy with [s1]IFN-alpha[e1] may be associated with a number of [s2]neuropsychiatric symptoms[e2]  such as Parkinsonism, akathisia, seizure, and depressive disorders.
+	(2, 24)	IFN-alpha	Parkinsonism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1683	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as [s2]Parkinsonism[e2]  akathisia, seizure, and depressive disorders.
+	(2, 31)	IFN-alpha	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1684	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, [s2]seizure[e2]  and depressive disorders.
+	(3, 18)	restless legs symptoms	IFN alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1685	A patient developed [s1]restless legs symptoms[e1] paralleling the course of interferon-alpha  [s2]IFN alpha[e2]  therapy for chronic hepatitis C.
+	(3, 13)	restless legs symptoms	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1686	A patient developed [s1]restless legs symptoms[e1] paralleling the course of [s2]interferon-alpha[e2] (IFN alpha) therapy for chronic hepatitis C.
+	(0, 7)	Restless legs syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1687	 [s1]Restless legs syndrome[e1] due to [s2]interferon-alpha[e2] 
+	(0, 12)	Restless legs syndrome	IFN alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1688	 [s1]Restless legs syndrome[e1] may thus be an adverse effect of [s2]IFN alpha[e2] treatment.
+	(10, 23)	hepatotoxicity	naltrexone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1689	Many clinicians appear to be concerned about the potential [s1]hepatotoxicity[e1] of the opiate antagonist [s2]naltrexone[e2] (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.
+	(10, 28)	hepatotoxicity	NTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1690	Many clinicians appear to be concerned about the potential [s1]hepatotoxicity[e1] of the opiate antagonist naltrexone  [s2]NTX[e2]  and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.
+	(14, 33)	acute hepatitis B and C	naltrexone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1691	We describe a heroin abuser in whom clinical and laboratory manifestations of [s1]acute hepatitis B and C[e1] appeared a few days after the insertion of a subcutaneous [s2]naltrexone[e2] implant.
+	(0, 8)	Sweet's syndrome	sargramostim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1692	 [s1]Sweet's syndrome[e1] associated with [s2]sargramostim[e2] (granulocyte-macrophage colony stimulating factor) treatment.
+	(6, 30)	acute febrile neutrophilic dermatosis	filgrastim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1693	Sweet's syndrome is an [s1]acute febrile neutrophilic dermatosis[e1] that is a known complication of the administration of [s2]filgrastim[e2]  a drug that causes increased neutrophil proliferation and differentiation.
+	(0, 30)	Sweet's syndrome	filgrastim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1694	 [s1]Sweet's syndrome[e1] is an acute febrile neutrophilic dermatosis that is a known complication of the administration of [s2]filgrastim[e2]  a drug that causes increased neutrophil proliferation and differentiation.
+	(5, 14)	Sweet's syndrome	sargramostim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1695	We report a case of [s1]Sweet's syndrome[e1] in association with [s2]sargramostim[e2] treatment following chemotherapy for acute myelogenous leukemia.
+	(5, 16)	hypersensitivity myocarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1696	Sudden cardiac death due to [s1]hypersensitivity myocarditis[e1] during [s2]clozapine[e2] treatment.
+	(0, 16)	Sudden cardiac death	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1697	 [s1]Sudden cardiac death[e1] due to hypersensitivity myocarditis during [s2]clozapine[e2] treatment.
+	(12, 18)	clozapine	hypersensitivity myocarditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1698	The autopsy findings and a detailed medical history supported the conclusion that [s1]clozapine[e1] induced [s2]hypersensitivity myocarditis[e2] was the most likely cause of death.
+	(4, 17)	sudden death	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1699	The case concerns the [s1]sudden death[e1] of a 29-year-old male during [s2]clozapine[e2] therapy started 2 weeks before.
+	(8, 35)	purple discoloration	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1700	Purple glove syndrome, named for its distinctive [s1]purple discoloration[e1] and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
+	(0, 34)	Purple glove syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1701	 [s1]Purple glove syndrome[e1]  named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
+	(13, 35)	swelling of the hands	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1702	Purple glove syndrome, named for its distinctive purple discoloration and [s1]swelling of the hands[e1] in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
+	(19, 27)	phenytoin	purple glove syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1703	The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of [s1]phenytoin[e1]  also termed [s2]purple glove syndrome[e2] 
+	(8, 21)	soft-tissue injury	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1704	The findings were judged to be consistent with [s1]soft-tissue injury[e1] associated with intravenous administration of [s2]phenytoin[e2]  also termed purple glove syndrome.
+	(21, 39)	levodopa	completely bald	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1705	Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received [s1]levodopa[e1] and anti-cholinergic drugs and whose head had become almost [s2]completely bald[e2] 
+	(13, 26)	trichiasis	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1706	A patient with monocular open-angle glaucoma had [s1]trichiasis[e1]  a condition associated with the use of a [s2]prostaglandin[e2] analog.
+	(0, 17)	Increased lash length	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1707	 [s1]Increased lash length[e1]  thickness, and pigmentation are well-documented side effects of [s2]prostaglandin[e2] analog glaucoma drops.
+	(7, 18)	pigmentation	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1708	Increased lash length, thickness, and [s1]pigmentation[e1] are well-documented side effects of [s2]prostaglandin[e2] analog glaucoma drops.
+	(0, 7)	Trichiasis	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1709	 [s1]Trichiasis[e1] associated with [s2]prostaglandin[e2] analog use.
+	(0, 9)	Fatal pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1710	 [s1]Fatal pulmonary fibrosis[e1] associated with [s2]BCNU[e2]  the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
+	(0, 22)	Pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1711	 [s1]Pulmonary fibrosis[e1] is a severe complication associated with bis-chloronitrosourea  [s2]BCNU[e2]  therapy.
+	(0, 13)	Pulmonary fibrosis	bis-chloronitrosourea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1712	 [s1]Pulmonary fibrosis[e1] is a severe complication associated with [s2]bis-chloronitrosourea[e2] (BCNU) therapy.
+	(12, 17)	BCNU	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1713	These novel findings may offer specific therapeutic targets in the treatment of [s1]BCNU[e1] associated [s2]pulmonary fibrosis[e2] 
+	(78, 83)	BCNU	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1714	We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of [s1]BCNU[e1] related [s2]pulmonary fibrosis[e2] 
+	(23, 39)	severe pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1715	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of [s1]severe pulmonary fibrosis[e1] 81 days after the administration of high-dose [s2]BCNU[e2] (600 mg/m2).
+	(0, 7)	Dorzolamide	choroidal detachment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1716	 [s1]Dorzolamide[e1] induced [s2]choroidal detachment[e2] in a surgically untreated eye.
+	(27, 40)	choroidal detachment	dorzolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1717	METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a [s1]choroidal detachment[e1] 12 hours after initiation of therapy with [s2]dorzolamide[e2] eye drops.
+	(8, 17)	choroidal detachment	dorzolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1718	We document the abrupt development of an extensive [s1]choroidal detachment[e1] after initiation of [s2]dorzolamide[e2] therapy in a surgically untreated eye with primary open-angle glaucoma.
+	(0, 10)	Deepening of lid sulcus	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1719	 [s1]Deepening of lid sulcus[e1] from topical [s2]bimatoprost[e2] therapy.
+	(8, 30)	alteration of eyelid appearance	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1720	In each of the three reported patients, [s1]alteration of eyelid appearance[e1] with deepening of the lid sulcus was evident as the result of topical [s2]bimatoprost[e2] therapy.
+	(14, 30)	deepening of the lid sulcus	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1721	In each of the three reported patients, alteration of eyelid appearance with [s1]deepening of the lid sulcus[e1] was evident as the result of topical [s2]bimatoprost[e2] therapy.
+	(0, 8)	Lichen planus	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1722	 [s1]Lichen planus[e1] induced by [s2]hepatitis B vaccination[e2]  a new case and review of the literature.
+	(3, 16)	life-threatening hypoglycaemia	sulfadoxine-pyrimethamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1723	Case report: [s1]life-threatening hypoglycaemia[e1] associated with [s2]sulfadoxine-pyrimethamine[e2]  a commonly used antimalarial drug.
+	(9, 21)	hypoglycaemic coma	SP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1724	In this report, we present a case of [s1]hypoglycaemic coma[e1] associated with [s2]SP[e2]  an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
+	(9, 21)	hypoglycaemic coma	SP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1725	In this report, we present a case of [s1]hypoglycaemic coma[e1] associated with [s2]SP[e2]  an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
+	(3, 33)	heparin	fatal intracerebral haemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1726	Initial treatment with [s1]heparin[e1] was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by [s2]fatal intracerebral haemorrhage[e2] 
+	(0, 14)	Extensive forearm deep venous thrombosis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1727	 [s1]Extensive forearm deep venous thrombosis[e1] following a severe [s2]infliximab[e2] infusion reaction.
+	(16, 26)	infliximab	IIR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1728	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction  [s2]IIR[e2] , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
+	(16, 26)	infliximab	IIR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1729	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction  [s2]IIR[e2] , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
+	(15, 26)	severe infliximab infusion reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1730	Here we describe a patient with Crohn's disease who developed a [s1]severe infliximab infusion reaction[e1]  [s2]infliximab[e2] infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
+	(15, 26)	severe infliximab infusion reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1731	Here we describe a patient with Crohn's disease who developed a [s1]severe infliximab infusion reaction[e1]  [s2]infliximab[e2] infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
+	(16, 36)	infliximab	severe swelling of the forearm and hand ipsilateral	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1732	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction (IIR), complicated 1 day later by [s2]severe swelling of the forearm and hand ipsilateral[e2] to the site of infliximab infusion.
+	(16, 36)	infliximab	severe swelling of the forearm and hand ipsilateral	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1733	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction (IIR), complicated 1 day later by [s2]severe swelling of the forearm and hand ipsilateral[e2] to the site of infliximab infusion.
+	(19, 26)	hypersensitivity	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1734	The site of thrombosis and the chronological relationship with the IIR implicates a [s1]hypersensitivity[e1] to [s2]infliximab[e2] in the causation of the venous thrombosis in this case.
+	(13, 26)	IIR	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1735	The site of thrombosis and the chronological relationship with the [s1]IIR[e1] implicates a hypersensitivity to [s2]infliximab[e2] in the causation of the venous thrombosis in this case.
+	(24, 38)	infliximab	venous thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1736	The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to [s1]infliximab[e1] in the causation of the [s2]venous thrombosis[e2] in this case.
+	(11, 23)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1737	After 3- to 13-month period of therapy without [s1]indapamide[e1]  glucose levels of all patients decreased and [s2]diabetes[e2] disappeared.
+	(2, 7)	indapamide	glucose tolerance impairing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1738	After stopping [s1]indapamide[e1]  [s2]glucose tolerance impairing[e2] may be reversed.
+	(4, 11)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1739	CONCLUSION: Therapy with [s1]indapamide[e1] may induce [s2]diabetes[e2] in essential hypertension patients.
+	(6, 36)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1740	OBJECTIVE: To study therapy with [s1]indapamide[e1] impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of [s2]diabetes[e2] induced by indapamide.
+	(6, 36)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1741	OBJECTIVE: To study therapy with [s1]indapamide[e1] impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of [s2]diabetes[e2] induced by indapamide.
+	(6, 11)	indapamide	impairing carbohydrate metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1742	OBJECTIVE: To study therapy with [s1]indapamide[e1]  [s2]impairing carbohydrate metabolism[e2] in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.
+	(3, 12)	diabetes	indapamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1743	Possible induction of [s1]diabetes[e1] by treatment of hypertension with [s2]indapamide[e2] (with four case reports).
+	(28, 78)	fosinopril	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1744	RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and [s1]fosinopril[e1] (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
+	(16, 78)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1745	RESULTS: After 4- to 14-month period of therapy with the combination of [s1]indapamide[e1] (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
+	(16, 78)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1746	RESULTS: After 4- to 14-month period of therapy with the combination of [s1]indapamide[e1] (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
+	(6, 30)	discrepancies between hematologic, marrow morphologic, and cytogenetic responses	imatinib mesylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1747	CONTEXT: Previous investigators have reported [s1]discrepancies between hematologic, marrow morphologic, and cytogenetic responses[e1] to [s2]imatinib mesylate[e2] among patients with chronic myeloid leukemia (CML).
+	(26, 36)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1748	Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to [s1]blast crisis[e1] at 7 to 10 months of [s2]imatinib[e2] therapy.
+	(18, 23)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1749	In addition to disease refractoriness, rare instances of disease progression from chronic phase to [s1]blast crisis[e1] during [s2]imatinib[e2] therapy have recently been anecdotally reported.
+	(24, 30)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1750	OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to [s1]blast crisis[e1] while taking [s2]imatinib[e2] and to perform a review of the literature.
+	(5, 17)	progression of marrow reticulin fibrosis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1751	Our findings suggest that significant [s1]progression of marrow reticulin fibrosis[e1] during [s2]imatinib[e2] therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.
+	(8, 15)	blast crisis	imatinib mesylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1752	Progression of chronic myeloid leukemia to [s1]blast crisis[e1] during treatment with [s2]imatinib mesylate[e2] 
+	(9, 18)	hypotension	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1753	Easily reversible hypoxemia and [s1]hypotension[e1] induced by [s2]nimodipine[e2] 
+	(4, 18)	hypoxemia	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1754	Easily reversible [s1]hypoxemia[e1] and hypotension induced by [s2]nimodipine[e2] 
+	(8, 26)	nimodipine	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1755	In this paper we report a case of [s1]nimodipine[e1] overdosage resulting in prolonged hypotension and [s2]hypoxemia[e2]  which was successfully treated with calcium gluconate.
+	(8, 19)	nimodipine	prolonged hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1756	In this paper we report a case of [s1]nimodipine[e1] overdosage resulting in [s2]prolonged hypotension[e2] and hypoxemia, which was successfully treated with calcium gluconate.
+	(0, 12)	Refractory hypoglycemia	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1757	 [s1]Refractory hypoglycemia[e1] from [s2]ciprofloxacin[e2] and glyburide interaction.
+	(0, 19)	Refractory hypoglycemia	glyburide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1758	 [s1]Refractory hypoglycemia[e1] from ciprofloxacin and [s2]glyburide[e2] interaction.
+	(18, 28)	ciprofloxacin	prolonged hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1759	We present a case of a diabetic patient taking glyburide who was prescribed [s1]ciprofloxacin[e1] and developed [s2]prolonged hypoglycemia[e2]  which persisted for over 24 hours.
+	(11, 28)	glyburide	prolonged hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1760	We present a case of a diabetic patient taking [s1]glyburide[e1] who was prescribed ciprofloxacin and developed [s2]prolonged hypoglycemia[e2]  which persisted for over 24 hours.
+	(0, 18)	Aminophylline hypersensitivity	Aminophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1761	 [s1]Aminophylline hypersensitivity[e1] apparently due to ethylenediamine [s2]Aminophylline[e2] hypersensitivity apparently due to ethylenediamine.
+	(0, 13)	Aminophylline hypersensitivity	ethylenediamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1762	 [s1]Aminophylline hypersensitivity[e1] apparently due to [s2]ethylenediamine[e2] 
+	(12, 32)	delayed hypersensitivity reaction	aminophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1763	We present a case of ethylenediamine-induced [s1]delayed hypersensitivity reaction[e1] in a 46-year-old woman who received parenteral [s2]aminophylline[e2] for an acute asthma exacerbation.
+	(5, 13)	ethylenediamine	delayed hypersensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1764	We present a case of [s1]ethylenediamine[e1] induced [s2]delayed hypersensitivity reaction[e2] in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation.
+	(0, 18)	L-asparaginase	lethal complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1765	 [s1]L-asparaginase[e1] induced pancreatitis is an uncommon but potential [s2]lethal complication[e2] of the treatment of leukemia.
+	(0, 9)	L-asparaginase	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1766	 [s1]L-asparaginase[e1] induced [s2]pancreatitis[e2] is an uncommon but potential lethal complication of the treatment of leukemia.
+	(0, 9)	L-asparaginase	severe necrotizing pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1767	 [s1]L-asparaginase[e1] induced [s2]severe necrotizing pancreatitis[e2] successfully treated with percutaneous drainage.
+	(3, 11)	pancreatitis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1768	Most cases of [s1]pancreatitis[e1] associated with [s2]L-asparaginase[e2] toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.
+	(0, 24)	Pancreatitis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1769	 [s1]Pancreatitis[e1] has been noted to be a complication in 2-16% of patients undergoing treatment with [s2]L-asparaginase[e2] for a variety of pediatric neoplasms.
+	(11, 20)	L-asparaginase	necrotizing pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1770	We present a pediatric patient with leukemia and a severe, [s1]L-asparaginase[e1] induced [s2]necrotizing pancreatitis[e2]  treated successfully with percutaneous drainage used to flush the infected necrotic parts.
+	(0, 7)	Disulfiram	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1771	 [s1]Disulfiram[e1] induced [s2]fulminant hepatic failure[e2] in an active duty soldier.
+	(0, 16)	Fulminant hepatic failure	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1772	 [s1]Fulminant hepatic failure[e1] is a rare complication of [s2]disulfiram[e2] treatment for alcoholism.
+	(3, 17)	fulminant hepatic failure	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1773	This case describes [s1]fulminant hepatic failure[e1] in a patient taking [s2]disulfiram[e2] with no previous liver disease and report of being compliant with alcohol abstinence.
+	(0, 8)	Tiagabine	unusual array of neurological symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1774	 [s1]Tiagabine[e1] overdose causes an [s2]unusual array of neurological symptoms[e2]  many similar to reported adverse effects during therapeutic use.
+	(3, 31)	sideroblastic anemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1775	A case of [s1]sideroblastic anemia[e1] is presented in a patient with a left ventricular assist device drive-line infection who was receiving [s2]linezolid[e2]  an antibiotic used for serious infections with gram-positive organisms.
+	(1, 11)	linezolid	hematologic side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1776	As [s1]linezolid[e1] has been shown to have [s2]hematologic side effects[e2]  blood count monitoring is recommended in patients receiving this drug for long-term therapy.
+	(0, 10)	Sideroblastic anemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1777	 [s1]Sideroblastic anemia[e1] due to [s2]linezolid[e2] in a patient with a left ventricular assist device.
+	(15, 35)	harlequin color change	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1778	In this report, two newborns with congenital heart anomalies demonstrated the [s1]harlequin color change[e1]  one whose skin findings showed a course related to the dose of systemic [s2]prostaglandin E1[e2]  suggesting a possible association.
+	(1, 11)	harlequin color change	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1779	The [s1]harlequin color change[e1] and association with [s2]prostaglandin E1[e2] 
+	(0, 17)	Acute renal insufficiency	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1780	 [s1]Acute renal insufficiency[e1] is known to occur in patients who are taking [s2]ciprofloxacin[e2]  particularly the elderly.
+	(0, 9)	Ciprofloxacin	renal insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1781	 [s1]Ciprofloxacin[e1] induced [s2]renal insufficiency[e2] in cystic fibrosis.
+	(3, 12)	ciprofloxacin	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1782	Multiple mechanisms for [s1]ciprofloxacin[e1] induced [s2]nephrotoxicity[e2] have been proposed.
+	(14, 29)	acute renal insufficiency	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1783	We report two young patients with cystic fibrosis who presented with [s1]acute renal insufficiency[e1] after 2-3 weeks of oral [s2]ciprofloxacin[e2] therapy.
+	(5, 15)	necrotizing vasculitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1784	Sensory neuropathy revealing [s1]necrotizing vasculitis[e1] during [s2]infliximab[e2] therapy for rheumatoid arthritis.
+	(0, 15)	Sensory neuropathy	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1785	 [s1]Sensory neuropathy[e1] revealing necrotizing vasculitis during [s2]infliximab[e2] therapy for rheumatoid arthritis.
+	(30, 47)	infliximab	necrotizing vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1786	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with peripheral neuropathy due to [s2]necrotizing vasculitis[e2] in one patient and to progression of preexisting mononeuritis multiplex in the other.
+	(30, 41)	infliximab	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1787	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with [s2]peripheral neuropathy[e2] due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.
+	(30, 59)	infliximab	progression of preexisting mononeuritis multiplex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1788	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to [s2]progression of preexisting mononeuritis multiplex[e2] in the other.
+	(0, 9)	Progressive anemia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1789	 [s1]Progressive anemia[e1] following combination therapy with [s2]interferon-alpha[e2] and interleukin-2 in a patient with metastatic renal cell carcinoma.
+	(0, 15)	Progressive anemia	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1790	 [s1]Progressive anemia[e1] following combination therapy with interferon-alpha and [s2]interleukin-2[e2] in a patient with metastatic renal cell carcinoma.
+	(5, 26)	severe anemia	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1791	We report a case of [s1]severe anemia[e1]  which responded well to steroid therapy, in a patient receiving IL-2 plus [s2]IFN-alpha[e2] for metastatic renal cell carcinoma.
+	(5, 22)	severe anemia	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1792	We report a case of [s1]severe anemia[e1]  which responded well to steroid therapy, in a patient receiving [s2]IL-2[e2] plus IFN-alpha for metastatic renal cell carcinoma.
+	(10, 18)	clotting abnormality	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1793	An objective causality assessment indicated a probable relationship between [s1]clotting abnormality[e1] and [s2]warfarin[e2] administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure.
+	(18, 26)	abnormal hypersensitivity	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1794	Based on the clinical status of the patient, it was suspected that several conditions contributed to the [s1]abnormal hypersensitivity[e1] to [s2]warfarin[e2] 
+	(6, 36)	warfarin	bleeding symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1795	Despite the low dosage of [s1]warfarin[e1]  international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and [s2]bleeding symptoms[e2] concurrently developed.
+	(32, 42)	fatal haemorrhage	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1796	In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid [s1]fatal haemorrhage[e1] after initiating [s2]warfarin[e2] therapy regardless of the dosage.
+	(1, 8)	hypersensitivity	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1797	Unusual [s1]hypersensitivity[e1] to [s2]warfarin[e2] in a critically ill patient.
+	(13, 36)	CMV infection	cidofovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1798	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with ganciclovir, foscarnet, and [s2]cidofovir[e2] 
+	(13, 30)	CMV infection	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1799	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with ganciclovir, [s2]foscarnet[e2]  and cidofovir.
+	(13, 25)	CMV infection	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1800	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with [s2]ganciclovir[e2]  foscarnet, and cidofovir.
+	(0, 16)	5-fluorouracil	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1801	 [s1]5-fluorouracil[e1] (5-FU)-associated [s2]peripheral neuropathy[e2] is an uncommon event.
+	(7, 14)	5-FU	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1802	5-fluorouracil  [s1]5-FU[e1] -associated [s2]peripheral neuropathy[e2] is an uncommon event.
+	(6, 41)	CAP	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1803	During analysis of 28 patients receiving [s1]CAP[e1] with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with [s2]peripheral neuropathy[e2] 
+	(6, 19)	CAP	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1804	Knowledge regarding potential adverse effects of [s1]CAP[e1] is paramount and dose modification is indicated with development of [s2]neurotoxicity[e2] 
+	(0, 9)	Neurologic symptoms	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1805	 [s1]Neurologic symptoms[e1] resolved after stopping [s2]CAP[e2] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.
+	(0, 9)	Neurologic symptoms	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1806	 [s1]Neurologic symptoms[e1] resolved after stopping [s2]CAP[e2] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.
+	(6, 14)	foot drop	CAP-XRT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1807	Patient A reported right leg weakness  [s1]foot drop[e1]  during week 4 of [s2]CAP-XRT[e2] (1600 mg/m2).
+	(3, 16)	right leg weakness	CAP-XRT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1808	Patient A reported [s1]right leg weakness[e1] (foot drop) during week 4 of [s2]CAP-XRT[e2] (1600 mg/m2).
+	(3, 21)	perioral and upper extremity paresthesias	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1809	Patient B developed [s1]perioral and upper extremity paresthesias[e1] during the fourth cycle of [s2]CAP[e2] alone (2500 mg/m2).
+	(0, 8)	Peripheral neuropathy	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1810	 [s1]Peripheral neuropathy[e1] associated with [s2]capecitabine[e2] 
+	(2, 9)	peripheral neuropathy	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1811	We conclude [s1]peripheral neuropathy[e1] with [s2]5-FU[e2] is rare.
+	(0, 17)	Severe hypo-alpha-lipoproteinemia	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1812	 [s1]Severe hypo-alpha-lipoproteinemia[e1] during treatment with [s2]rosiglitazone[e2] 
+	(26, 49)	reduction in plasma HDL cholesterol and apolipoprotein AI levels	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1813	We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound [s1]reduction in plasma HDL cholesterol and apolipoprotein AI levels[e1] soon after the initiation of [s2]rosiglitazone[e2] therapy.
+	(7, 22)	mild hepatotoxicity	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1814	Severe leukopenia associated with [s1]mild hepatotoxicity[e1] in an HIV carrier treated with [s2]nevirapine[e2] 
+	(0, 22)	Severe leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1815	 [s1]Severe leukopenia[e1] associated with mild hepatotoxicity in an HIV carrier treated with [s2]nevirapine[e2] 
+	(10, 22)	leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1816	We report an HIV-infected woman who developed mild [s1]leukopenia[e1] as the first sign of a [s2]nevirapine[e2] related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
+	(10, 22)	leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1817	We report an HIV-infected woman who developed mild [s1]leukopenia[e1] as the first sign of a [s2]nevirapine[e2] related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
+	(20, 33)	nevirapine	skin and hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1818	We report an HIV-infected woman who developed mild leukopenia as the first sign of a [s1]nevirapine[e1] related adverse event, which was followed by [s2]skin and hepatic toxicity[e2] associated with a more severe leukopenia.
+	(8, 28)	quetiapine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1819	In all cases, drugs in addition to [s1]quetiapine[e1] were detected, but in cases #1 and #2, the cause of [s2]death[e2] was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.
+	(10, 25)	deaths	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1820	These cases were chosen for study because they were all [s1]deaths[e1] as a result of suicidal ingestion of drugs in which [s2]quetiapine[e2] was considered a significant factor.
+	(17, 25)	suicidal overdose deaths	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1821	We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which [s1]suicidal overdose deaths[e1] were associated with [s2]quetiapine[e2] 
+	(5, 14)	sertraline	intense itching sensation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1822	After approximately two weeks of [s1]sertraline[e1] treatment he noted an [s2]intense itching sensation[e2] in his scalp after eating a piece of chocolate cake.
+	(0, 10)	Itch	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1823	 [s1]Itch[e1] and skin rash from chocolate during [s2]fluoxetine[e2] and sertraline treatment: case report.
+	(0, 15)	Itch	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1824	 [s1]Itch[e1] and skin rash from chocolate during fluoxetine and [s2]sertraline[e2] treatment: case report.
+	(3, 10)	skin rash	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1825	Itch and [s1]skin rash[e1] from chocolate during [s2]fluoxetine[e2] and sertraline treatment: case report.
+	(3, 15)	skin rash	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1826	Itch and [s1]skin rash[e1] from chocolate during fluoxetine and [s2]sertraline[e2] treatment: case report.
+	(0, 16)	Pulmonary lymphohistiocytic reactions	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1827	 [s1]Pulmonary lymphohistiocytic reactions[e1] temporally related to [s2]etanercept[e2] therapy.
+	(25, 44)	pulmonary signs and symptoms with alveolar infiltrates	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1828	This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of [s1]pulmonary signs and symptoms with alveolar infiltrates[e1] temporally related to the institution of [s2]etanercept[e2] therapy.
+	(0, 13)	Paradoxical cerebral cortical hyperexcitability	flupirtine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1829	 [s1]Paradoxical cerebral cortical hyperexcitability[e1] following [s2]flupirtine[e2] overdose.
+	(8, 23)	increased cerebral cortical excitability	flupirtine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1830	We report the case of a patient with [s1]increased cerebral cortical excitability[e1] following intoxication with [s2]flupirtine[e2]  a centrally acting analgesic and antispastic drug.
+	(12, 18)	celiac disease	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1831	AIM: Report of a case of a woman patient who developed [s1]celiac disease[e1] after [s2]pegylated interferon alpha-2a[e2] and ribavirin use for chronic hepatitis C.
+	(12, 28)	celiac disease	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1832	AIM: Report of a case of a woman patient who developed [s1]celiac disease[e1] after pegylated interferon alpha-2a and [s2]ribavirin[e2] use for chronic hepatitis C.
+	(0, 7)	Celiac disease	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1833	 [s1]Celiac disease[e1] onset after [s2]pegylated interferon[e2] and ribavirin treatment of chronic hepatitis C.
+	(0, 14)	Celiac disease	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1834	 [s1]Celiac disease[e1] onset after pegylated interferon and [s2]ribavirin[e2] treatment of chronic hepatitis C.
+	(21, 45)	pegylated interferon alpha-2a	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1835	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving [s1]pegylated interferon alpha-2a[e1] and ribavirin for 6 months, developed progressive malaise and [s2]anemia[e2] 6 months after the end of treatment.
+	(31, 45)	ribavirin	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1836	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and [s1]ribavirin[e1] for 6 months, developed progressive malaise and [s2]anemia[e2] 6 months after the end of treatment.
+	(21, 41)	pegylated interferon alpha-2a	progressive malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1837	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving [s1]pegylated interferon alpha-2a[e1] and ribavirin for 6 months, developed [s2]progressive malaise[e2] and anemia 6 months after the end of treatment.
+	(31, 41)	ribavirin	progressive malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1838	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and [s1]ribavirin[e1] for 6 months, developed [s2]progressive malaise[e2] and anemia 6 months after the end of treatment.
+	(5, 41)	anaphylaxis	metaraminol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1839	We present two cases of [s1]anaphylaxis[e1] under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist [s2]metaraminol[e2] 
+	(15, 27)	glatiramer acetate	localized panniculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1840	In this article, we describe another case of subcutaneous changes following repeated [s1]glatiramer acetate[e1] injection, presented as [s2]localized panniculitis[e2] in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
+	(15, 27)	glatiramer acetate	localized panniculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1841	In this article, we describe another case of subcutaneous changes following repeated [s1]glatiramer acetate[e1] injection, presented as [s2]localized panniculitis[e2] in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
+	(9, 17)	subcutaneous changes	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1842	In this article, we describe another case of [s1]subcutaneous changes[e1] following repeated [s2]glatiramer acetate[e2] injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
+	(7, 23)	lipoatrophy	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1843	Localized panniculitis and subsequent [s1]lipoatrophy[e1] with subcutaneous glatiramer acetate  [s2]Copaxone[e2]  injection for the treatment of multiple sclerosis.
+	(7, 17)	lipoatrophy	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1844	Localized panniculitis and subsequent [s1]lipoatrophy[e1] with subcutaneous [s2]glatiramer acetate[e2] (Copaxone) injection for the treatment of multiple sclerosis.
+	(0, 23)	Localized panniculitis	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1845	 [s1]Localized panniculitis[e1] and subsequent lipoatrophy with subcutaneous glatiramer acetate  [s2]Copaxone[e2]  injection for the treatment of multiple sclerosis.
+	(0, 17)	Localized panniculitis	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1846	 [s1]Localized panniculitis[e1] and subsequent lipoatrophy with subcutaneous [s2]glatiramer acetate[e2] (Copaxone) injection for the treatment of multiple sclerosis.
+	(19, 28)	verapamil	exacerbation in myasthenic weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1847	In a postoperative patient with pre-existent myasthenia gravis, oral [s1]verapamil[e1] caused a marked [s2]exacerbation in myasthenic weakness[e2] 
+	(15, 38)	hepatic veno-occlusive disease	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1848	In four patients, thrombosis occurred 2-45 days after severe [s1]hepatic veno-occlusive disease[e1] (HVOD) secondary to intensive chemotherapy containing [s2]busulfan[e2] 
+	(26, 36)	HVOD	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1849	In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease  [s1]HVOD[e1]  secondary to intensive chemotherapy containing [s2]busulfan[e2] 
+	(4, 38)	thrombosis	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1850	In four patients, [s1]thrombosis[e1] occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing [s2]busulfan[e2] 
+	(20, 30)	busulfan	HVOD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1851	PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing [s1]busulfan[e1] and to be associated with [s2]HVOD[e2] 
+	(0, 22)	PVT	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1852	 [s1]PVT[e1] during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing [s2]busulfan[e2] and to be associated with HVOD.
+	(7, 26)	Vogt-Koyanagi-Harada disease	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1853	Here, we describe a case of [s1]Vogt-Koyanagi-Harada disease[e1] occurring 4 months after the start of [s2]interferon[e2] alpha treatment, probably induced by the immunomodulatory effects of interferon.
+	(7, 26)	Vogt-Koyanagi-Harada disease	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1854	Here, we describe a case of [s1]Vogt-Koyanagi-Harada disease[e1] occurring 4 months after the start of [s2]interferon alpha[e2] treatment, probably induced by the immunomodulatory effects of interferon.
+	(0, 33)	Retinal abnormalities	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1855	" [s1]Retinal abnormalities[e1]  including retinal hemorrhage and ""cotton-wool"" spots, often occur within the first 8 weeks in the course of [s2]interferon[e2] therapy in patients with chronic hepatitis C."
+	(6, 34)	retinal hemorrhage	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1856	"Retinal abnormalities, including [s1]retinal hemorrhage[e1] and ""cotton-wool"" spots, often occur within the first 8 weeks in the course of [s2]interferon[e2] therapy in patients with chronic hepatitis C."
+	(0, 14)	Vogt-Koyanagi-Harada disease	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1857	 [s1]Vogt-Koyanagi-Harada disease[e1] occurring during [s2]interferon alpha[e2] therapy for chronic hepatitis C.
+	(0, 16)	Acute hepatic failure	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1858	 [s1]Acute hepatic failure[e1] is a rare and potentially lethal complication of [s2]propylthiouracil[e2] (PTU) use for hyperthyroidism.
+	(0, 22)	Acute hepatic failure	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1859	 [s1]Acute hepatic failure[e1] is a rare and potentially lethal complication of propylthiouracil  [s2]PTU[e2]  use for hyperthyroidism.
+	(34, 39)	PTU	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1860	After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with [s1]PTU[e1] induced [s2]fulminant hepatitis[e2] 
+	(15, 24)	propylthiouracil	acute hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1861	Successful treatment of hyperthyroidism with amiodarone in a patient with [s1]propylthiouracil[e1] induced [s2]acute hepatic failure[e2] 
+	(18, 23)	PTU	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1862	We present a 20-year-old woman with Basedow-Graves' disease who developed [s1]PTU[e1] induced [s2]fulminant hepatitis[e2]  which progressed to acute hepatic failure with grade III hepatic encephalopathy.
+	(0, 27)	Epstein-Barr virus-associated lymphoproliferative disorder	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1863	 [s1]Epstein-Barr virus-associated lymphoproliferative disorder[e1] in a patient with rheumatoid arthritis on [s2]methotrexate[e2] and rofecoxib: idiosyncratic reaction or pharmacogenetics?
+	(0, 33)	Epstein-Barr virus-associated lymphoproliferative disorder	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1864	 [s1]Epstein-Barr virus-associated lymphoproliferative disorder[e1] in a patient with rheumatoid arthritis on methotrexate and [s2]rofecoxib[e2]  idiosyncratic reaction or pharmacogenetics?
+	(0, 29)	Methotrexate	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1865	 [s1]Methotrexate[e1] (MTX) is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
+	(5, 27)	MTX	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1866	Methotrexate  [s1]MTX[e1]  is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
+	(5, 27)	MTX	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1867	Methotrexate  [s1]MTX[e1]  is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
+	(7, 35)	MTX	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1868	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including [s2]acute renal failure[e2]  pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
+	(7, 46)	MTX	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1869	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, [s2]diarrhea[e2]  elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
+	(7, 50)	MTX	elevated liver transaminases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1870	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, [s2]elevated liver transaminases[e2]  jaundice, mucosal ulcerations, and pyrexia.
+	(7, 56)	MTX	jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1871	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, [s2]jaundice[e2]  mucosal ulcerations, and pyrexia.
+	(7, 60)	MTX	mucosal ulcerations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1872	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, [s2]mucosal ulcerations[e2]  and pyrexia.
+	(7, 39)	MTX	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1873	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, [s2]pancytopenia[e2]  vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
+	(7, 68)	MTX	pyrexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1874	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and [s2]pyrexia[e2] 
+	(7, 44)	MTX	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1875	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, [s2]vomiting[e2]  diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
+	(11, 40)	MTX	EBV-associated lymphoproliferative disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1876	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the [s2]EBV-associated lymphoproliferative disease[e2] 
+	(11, 25)	MTX	hematopoietic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1877	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced [s2]hematopoietic toxicity[e2] and immunosuppression causing the EBV-associated lymphoproliferative disease.
+	(11, 32)	MTX	immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1878	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and [s2]immunosuppression[e2] causing the EBV-associated lymphoproliferative disease.
+	(4, 34)	aggravation and spreading of a psoriatic plaque	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1879	OBSERVATIONS: We observed [s1]aggravation and spreading of a psoriatic plaque[e1] when treated topically with the toll-like receptor (TLR) 7 agonist [s2]imiquimod[e2] 
+	(0, 14)	Psoriasis	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1880	 [s1]Psoriasis[e1] triggered by toll-like receptor 7 agonist [s2]imiquimod[e2] in the presence of dermal plasmacytoid dendritic cell precursors.
+	(1, 10)	imiquimod	large amounts of type I interferon production	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1881	Since [s1]imiquimod[e1] induces [s2]large amounts of type I interferon production[e2] from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin.
+	(1, 33)	exacerbation of psoriasis	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1882	The [s1]exacerbation of psoriasis[e1] was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after [s2]imiquimod[e2] therapy.
+	(0, 7)	Vision declined	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1883	 [s1]Vision declined[e1] after treatment with [s2]methylprednisolone[e2]  after which fundus examination became consistent with progressive outer retinal necrosis.
+	(4, 13)	AZA	allergic skin eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1884	Allergic side effects of [s1]AZA[e1] are rare, and reported [s2]allergic skin eruptions[e2] from AZA are very limited in Japan.
+	(4, 13)	AZA	allergic skin eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1885	Allergic side effects of [s1]AZA[e1] are rare, and reported [s2]allergic skin eruptions[e2] from AZA are very limited in Japan.
+	(8, 12)	AZA	allergy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1886	DLST is a good diagnostic tool for [s1]AZA[e1]  [s2]allergy[e2]  especially for severe drug allergy cases.
+	(0, 6)	Drug eruption	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1887	 [s1]Drug eruption[e1] caused by [s2]azathioprine[e2]  value of using the drug-induced lymphocytes stimulation test for diagnosis.
+	(2, 7)	AZA	drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1888	We report [s1]AZA[e1] induced [s2]drug eruption[e2] that developed in two cases of systemic scleroderma with polymyositis.
+	(0, 15)	Tardive dyskinesia	ziprasidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1889	 [s1]Tardive dyskinesia[e1] in 2 patients treated with [s2]ziprasidone[e2] 
+	(5, 15)	TD	ziprasidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1890	Two of our patients developed [s1]TD[e1] after 23 months and 34 months of [s2]ziprasidone[e2] monotherapy, respectively.
+	(0, 28)	Ziprasidone	extrapyramidal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1891	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing [s2]extrapyramidal symptoms[e2]  including tardive dyskinesia (TD).
+	(0, 35)	Ziprasidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1892	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including [s2]tardive dyskinesia[e2] (TD).
+	(0, 43)	Ziprasidone	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1893	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia  [s2]TD[e2] .
+	(0, 24)	Asthenozoospermia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1894	 [s1]Asthenozoospermia[e1]  possible association with long-term exposure to an anti-epileptic drug of [s2]carbamazepine[e2] 
+	(6, 28)	no motile sperm	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1895	The patient was found to have [s1]no motile sperm[e1] with a normal sperm count, while taking a dose of 400 mg/day of [s2]carbamazepine[e2] 
+	(0, 13)	Scrotal ulceration	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1896	 [s1]Scrotal ulceration[e1] induced by all-trans [s2]retinoic acid[e2] in a patient with acute promyelocytic leukemia.
+	(1, 18)	ulcer	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1897	The [s1]ulcer[e1] did not respond to antibiotic treatment and healed shortly after withholding [s2]ATRA[e2] 
+	(5, 32)	scrotal ulcer	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1898	We report the development of [s1]scrotal ulcer[e1] in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with [s2]ATRA[e2] at a dose of 40 mg orally twice daily.
+	(3, 9)	clozapine	tonic-clonic seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1899	A case of [s1]clozapine[e1] induced [s2]tonic-clonic seizures[e2] managed with valproate: implications for clinical care.
+	(6, 23)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1900	Following discontinuation of [s1]clozapine[e1]  she was rechallenged and again was observed to have [s2]seizures[e2] 
+	(4, 10)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1901	These findings suggest that [s1]clozapine[e1] induced [s2]seizures[e2] can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia.
+	(5, 11)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1902	We describe a case of [s1]clozapine[e1] induced [s2]seizures[e2] in a patient with treatment-resistant schizophrenia.
+	(9, 18)	colitis	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1903	CONCLUSIONS: Symptoms and pathologic changes of [s1]colitis[e1] are associated with exposure to [s2]rofecoxib[e2] 
+	(15, 26)	lower gastrointestinal symptoms	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1904	OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop [s1]lower gastrointestinal symptoms[e1] when exposed to [s2]rofecoxib[e2] 
+	(12, 17)	IBD	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1905	RESULTS: Three patients who developed symptoms of inflammatory bowel disease  [s1]IBD[e1]  during [s2]rofecoxib[e2] exposure are described along with pathology findings.
+	(8, 19)	inflammatory bowel disease	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1906	RESULTS: Three patients who developed symptoms of [s1]inflammatory bowel disease[e1] (IBD) during [s2]rofecoxib[e2] exposure are described along with pathology findings.
+	(32, 42)	Carbamazepine intoxication	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1907	After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of [s1]Carbamazepine intoxication[e1]  [s2]Carbamazepine[e2] intoxication.
+	(19, 33)	Dantrolene	Carbamazepine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1908	After administration of Oxybutynin concomitantly with an increase in the dose of [s1]Dantrolene[e1]  she presented the clinical symptoms and laboratory finding of [s2]Carbamazepine intoxication[e2] 
+	(3, 34)	Oxybutynin	Carbamazepine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1909	After administration of [s1]Oxybutynin[e1] concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of [s2]Carbamazepine intoxication[e2] 
+	(0, 23)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1910	 [s1]Carbamazepine toxicity[e1] following Oxybutynin and Dantrolene administration: a case report [s2]Carbamazepine[e2] toxicity following Oxybutynin and Dantrolene administration: a case report.
+	(0, 15)	Carbamazepine toxicity	Dantrolene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1911	 [s1]Carbamazepine toxicity[e1] following Oxybutynin and [s2]Dantrolene[e2] administration: a case report.
+	(0, 9)	Carbamazepine toxicity	Oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1912	 [s1]Carbamazepine toxicity[e1] following [s2]Oxybutynin[e2] and Dantrolene administration: a case report.
+	(7, 15)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1913	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1]  [s2]Carbamazepine[e2] toxicity following the administration of Oxybutynin and Dantrolene.
+	(7, 25)	Carbamazepine toxicity	Dantrolene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1914	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1] following the administration of Oxybutynin and [s2]Dantrolene[e2] 
+	(7, 19)	Carbamazepine toxicity	Oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1915	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1] following the administration of [s2]Oxybutynin[e2] and Dantrolene.
+	(14, 20)	captopril	pemphigus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1916	To the best of our knowledge, this is the first reported patient with [s1]captopril[e1] induced [s2]pemphigus[e2] in whom no new lesions developed after subsequent treatment with enalapril.
+	(8, 26)	pemphigus	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1917	We report a case of drug-induced [s1]pemphigus[e1] caused by an angiotensin-converting enzyme inhibitor, [s2]captopril[e2] 
+	(0, 11)	Neuropathy	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1918	 [s1]Neuropathy[e1] is a significant side effect of [s2]thalidomide[e2] therapy, which may limit its clinical use.
+	(0, 6)	Thalidomide	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1919	 [s1]Thalidomide[e1]  [s2]neuropathy[e2] in childhood.
+	(0, 6)	Thalidomide	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1920	 [s1]Thalidomide[e1]  [s2]neuropathy[e2] is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.
+	(0, 13)	Thalidomide	proximal weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1921	 [s1]Thalidomide[e1] neuropathy is often associated with [s2]proximal weakness[e2] and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.
+	(0, 17)	Thalidomide	teratogenic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1922	 [s1]Thalidomide[e1] was withdrawn from world markets in 1961 following recognition of its [s2]teratogenic effects[e2] 
+	(5, 25)	sensorimotor axonal neuropathy	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1923	We report four cases of [s1]sensorimotor axonal neuropathy[e1] in children aged 10-15 years, treated with [s2]thalidomide[e2] for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration.
+	(0, 7)	Cerebral edema	Gliadel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1924	 [s1]Cerebral edema[e1] associated with [s2]Gliadel[e2] wafers: two case studies.
+	(8, 18)	cerebral edema	Gliadel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1925	Following are two clinical case reports demonstrating profound [s1]cerebral edema[e1] associated with implantation of [s2]Gliadel[e2] wafers.
+	(4, 46)	carmustine	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1926	While the introduction of [s1]carmustine[e1] wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant [s2]cerebral edema[e2] is a potential adverse effect.
+	(9, 45)	Gliadel	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1927	While the introduction of carmustine wafers  [s1]Gliadel[e1] wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant [s2]cerebral edema[e2] is a potential adverse effect.
+	(0, 18)	Cis-retinoic acid	BMTN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1928	 [s1]Cis-retinoic acid[e1] (RA) may further increase the risk of developing [s2]BMTN[e2] 
+	(6, 16)	RA	BMTN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1929	Cis-retinoic acid  [s1]RA[e1]  may further increase the risk of developing [s2]BMTN[e2] 
+	(4, 10)	RA	deterioration in renal function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1930	It is likely that [s1]RA[e1] contributed to the [s2]deterioration in renal function[e2] in these patients.
+	(0, 11)	Retinoic acid	bone marrow transplant nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1931	 [s1]Retinoic acid[e1] may increase the risk of [s2]bone marrow transplant nephropathy[e2] 
+	(3, 13)	BMTN	RA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1932	The occurrence of [s1]BMTN[e1] in two children treated with [s2]RA[e2] in our unit is unlikely to be coincidental.
+	(4, 13)	secondary infection	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1933	He developed a late [s1]secondary infection[e1] in some sites treated with [s2]imiquimod[e2] 
+	(10, 23)	myoclonic jerks	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1934	A 64-year-old man with schizophrenia developed [s1]myoclonic jerks[e1] when given higher doses of [s2]quetiapine[e2] 
+	(0, 6)	Quetiapine	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1935	 [s1]Quetiapine[e1] induced [s2]myoclonus[e2] 
+	(5, 13)	myoclonus	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1936	We report a case of [s1]myoclonus[e1] induced by [s2]quetiapine[e2] 
+	(3, 12)	myelodysplastic syndrome	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1937	Treatment-related [s1]myelodysplastic syndrome[e1] after [s2]temozolomide[e2] for recurrent high-grade glioma.
+	(14, 37)	refractory anemia with excess blasts	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1938	We report a 44-year-old woman with t-MDS  [s1]refractory anemia with excess blasts[e1]  following treatment of recurrent anaplastic astrocytoma with [s2]temozolomide[e2] (TMZ).
+	(14, 42)	refractory anemia with excess blasts	TMZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1939	We report a 44-year-old woman with t-MDS  [s1]refractory anemia with excess blasts[e1]  following treatment of recurrent anaplastic astrocytoma with temozolomide  [s2]TMZ[e2] .
+	(5, 21)	neutropenia	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1940	Typically, drug-induced [s1]neutropenia[e1] occurs in a patient receiving a semisynthetic [s2]penicillin[e2] for two weeks or more.
+	(0, 10)	Livedo reticularis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1941	 [s1]Livedo reticularis[e1] associated with [s2]interferon alpha[e2] therapy in two melanoma patients.
+	(6, 21)	livedo reticularis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1942	These cases highlight the occurrence of [s1]livedo reticularis[e1] as an uncommon side-effect of [s2]interferon alpha[e2] treatment.
+	(7, 21)	livedo reticularis	interferon alpha 2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1943	We report two patients who developed intense [s1]livedo reticularis[e1] clearly related to the administration of [s2]interferon alpha 2b[e2] as an adjuvant therapy for melanoma.
+	(6, 11)	PTU	ANCA-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1944	CONCLUSION: This rare case of [s1]PTU[e1] induced [s2]ANCA-associated vasculitis[e2] manifested with ototoxicity in combination with systemic involvement.
+	(6, 21)	PTU	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1945	CONCLUSION: This rare case of [s1]PTU[e1] induced ANCA-associated vasculitis manifested with [s2]ototoxicity[e2] in combination with systemic involvement.
+	(23, 37)	propylthiouracil	antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1946	OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of [s1]propylthiouracil[e1] (PTU)-induced [s2]antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis[e2] 
+	(29, 35)	PTU	antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1947	OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil  [s1]PTU[e1] -induced [s2]antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis[e2] 
+	(16, 25)	ototoxicity	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1948	OBJECTIVE: To report the case of a young woman with Graves' disease in whom [s1]ototoxicity[e1] developed because of [s2]propylthiouracil[e2] (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
+	(16, 31)	ototoxicity	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1949	OBJECTIVE: To report the case of a young woman with Graves' disease in whom [s1]ototoxicity[e1] developed because of propylthiouracil  [s2]PTU[e2] -induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
+	(0, 16)	Propylthiouracil	antineutrophil cytoplasmic antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1950	 [s1]Propylthiouracil[e1] induced sensorineural hearing loss associated with [s2]antineutrophil cytoplasmic antibodies[e2] 
+	(0, 9)	Propylthiouracil	sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1951	 [s1]Propylthiouracil[e1] induced [s2]sensorineural hearing loss[e2] associated with antineutrophil cytoplasmic antibodies.
+	(20, 45)	hearing impairment in the left ear (with progression to the right ear)	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1952	RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, [s1]hearing impairment in the left ear (with progression to the right ear)[e1]  and vertigo developed after 3 years of therapy with [s2]PTU[e2] 
+	(16, 45)	tinnitus	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1953	RESULTS: In a 22-year-old Thai woman with Graves' disease, [s1]tinnitus[e1]  hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with [s2]PTU[e2] 
+	(36, 46)	vertigo	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1954	RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and [s1]vertigo[e1] developed after 3 years of therapy with [s2]PTU[e2] 
+	(1, 13)	hearing impairment	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1955	The [s1]hearing impairment[e1] and tinnitus were gradually reduced after [s2]PTU[e2] withdrawal and corticosteroid and azathioprine treatment.
+	(4, 13)	tinnitus	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1956	The hearing impairment and [s1]tinnitus[e1] were gradually reduced after [s2]PTU[e2] withdrawal and corticosteroid and azathioprine treatment.
+	(19, 27)	optic neuritis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1957	Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of [s1]optic neuritis[e1] secondary to [s2]ethambutol[e2] administration at another hospital.
+	(9, 17)	visual loss	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1958	During the anti-tuberculous therapy, [s1]visual loss[e1] can be related to [s2]ethambutol[e2] toxicity or the tuberculosis infection itself.
+	(3, 12)	ethambutol	visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1959	In addition, [s1]ethambutol[e1] rarely causes [s2]visual loss[e2] during the early period or when given at lower doses.
+	(0, 9)	Flucloxacillin	aplastic anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1960	 [s1]Flucloxacillin[e1] induced [s2]aplastic anaemia[e2] and liver failure.
+	(0, 14)	Flucloxacillin	liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1961	 [s1]Flucloxacillin[e1] induced aplastic anaemia and [s2]liver failure[e2] 
+	(6, 18)	flucloxacillin	fatal hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1962	It is well-recognized that [s1]flucloxacillin[e1] may occasionally result in [s2]fatal hepatic injury[e2] 
+	(23, 34)	aplastic anaemia	flucloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1963	We report the case of a 40-year-old woman who developed fulminant hepatic failure and [s1]aplastic anaemia[e1] following a course of oral [s2]flucloxacillin[e2] 
+	(14, 34)	fulminant hepatic failure	flucloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1964	We report the case of a 40-year-old woman who developed [s1]fulminant hepatic failure[e1] and aplastic anaemia following a course of oral [s2]flucloxacillin[e2] 
+	(6, 28)	Zoledronic acid	bronchospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1965	Four days after intravenous [s1]Zoledronic acid[e1]  the patient presented to emergency room with complaints of carpopedal spasm and [s2]bronchospasm[e2] 
+	(6, 22)	Zoledronic acid	carpopedal spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1966	Four days after intravenous [s1]Zoledronic acid[e1]  the patient presented to emergency room with complaints of [s2]carpopedal spasm[e2] and bronchospasm.
+	(0, 8)	Zoledronic acid	severe hypocalcaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1967	 [s1]Zoledronic acid[e1] induced [s2]severe hypocalcaemia[e2] in a prostate cancer patient with extensive osteoblastic bone metastases.
+	(7, 25)	severe lupus erythematosus	CY	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1968	This case report describes an adolescent with [s1]severe lupus erythematosus[e1] who received cyclophosphamide  [s2]CY[e2]  paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.
+	(7, 19)	severe lupus erythematosus	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1969	This case report describes an adolescent with [s1]severe lupus erythematosus[e1] who received [s2]cyclophosphamide[e2] (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.
+	(0, 16)	Mucosal pigmentation	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1970	 [s1]Mucosal pigmentation[e1] after oral lichen planus treatment with topical [s2]tacrolimus[e2] 
+	(3, 19)	tacrolimus	pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1971	The relation between [s1]tacrolimus[e1] treatment and staining was suggested by the appearance of [s2]pigmentation[e2] during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.
+	(3, 19)	tacrolimus	pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1972	The relation between [s1]tacrolimus[e1] treatment and staining was suggested by the appearance of [s2]pigmentation[e2] during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.
+	(12, 26)	oral mucosa pigmentation	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1973	We report the first histopathologically documented case of [s1]oral mucosa pigmentation[e1] after OLP treatment with topical [s2]tacrolimus[e2] 
+	(24, 36)	Methotrexate	malignant lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1974	Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with [s1]Methotrexate[e1] (MTX) and [s2]malignant lymphoma[e2] developing.
+	(29, 34)	MTX	malignant lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1975	Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate  [s1]MTX[e1]  and [s2]malignant lymphoma[e2] developing.
+	(0, 70)	Risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1976	 [s1]Risperidone[e1] is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including [s2]tardive dyskinesia[e2] (TD).
+	(0, 78)	Risperidone	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1977	 [s1]Risperidone[e1] is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia  [s2]TD[e2] .
+	(0, 9)	Risperidone	respiratory dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1978	 [s1]Risperidone[e1] withdrawal-related [s2]respiratory dyskinesia[e2]  a case diagnosed by spirography and fibroscopy.
+	(28, 50)	limb dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1979	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], [s1]limb dyskinesia[e1]  and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
+	(36, 50)	orofacial dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1980	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and [s1]orofacial dyskinesia[e1]  following abrupt withdrawal of [s2]risperidone[e2] therapy.
+	(24, 49)	RD	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1981	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia  [s1]RD[e1] , limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
+	(18, 51)	respiratory dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1982	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including [s1]respiratory dyskinesia[e1] [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
+	(11, 51)	TD	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1983	The authors present an elderly patient with mixed dementia who developed [s1]TD[e1] at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
+	(12, 26)	RD	SDA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1984	Therefore, clinicians should pay close attention to possible onset of [s1]RD[e1] in patients with multiple risk factors for TD, even when [s2]SDA[e2] therapy is used.
+	(12, 22)	BTX-B	parasympathetic dysfunction of the visual system	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1985	In this study, we report on three individual patients who received [s1]BTX-B[e1] and who subsequently developed [s2]parasympathetic dysfunction of the visual system[e2] after injections of BTX-B at remote sites.
+	(12, 22)	BTX-B	parasympathetic dysfunction of the visual system	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1986	In this study, we report on three individual patients who received [s1]BTX-B[e1] and who subsequently developed [s2]parasympathetic dysfunction of the visual system[e2] after injections of BTX-B at remote sites.
+	(9, 15)	visual disturbances	BTX-B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1987	To date, there have been few reports of [s1]visual disturbances[e1] associated with [s2]BTX-B[e2] use.
+	(6, 15)	parasympathetic dysfunction	botulinum toxin type B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1988	Visual system side effects caused by [s1]parasympathetic dysfunction[e1] after [s2]botulinum toxin type B[e2] injections.
+	(0, 15)	Visual system side effects	botulinum toxin type B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1989	 [s1]Visual system side effects[e1] caused by parasympathetic dysfunction after [s2]botulinum toxin type B[e2] injections.
+	(0, 7)	Enalapril	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1990	 [s1]Enalapril[e1] induced [s2]anemia[e2] in two kidney transplant recipients.
+	(5, 15)	anemia	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1991	Two renal transplant patients developed [s1]anemia[e1] during treatment of hypertension with [s2]enalapril[e2] medication.
+	(15, 39)	cerivastatin	muscle pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1992	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1] (0.15 mg/day) for 22 days complained of general muscle weakness and [s2]muscle pain[e2] 
+	(15, 36)	cerivastatin	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1993	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1] (0.15 mg/day) for 22 days complained of general [s2]muscle weakness[e2] and muscle pain.
+	(3, 24)	cerivastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1994	Clearance rates of [s1]cerivastatin[e1] metabolites in a patient with cerivastatin-induced [s2]rhabdomyolysis[e2] 
+	(7, 17)	acute rhabdomyolysis	cerivastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1995	We report on a patient who developed [s1]acute rhabdomyolysis[e1] after taking [s2]cerivastatin[e2] 
+	(0, 6)	Carboplatin	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1996	 [s1]Carboplatin[e1]  [s2]hypersensitivity[e2] induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
+	(4, 19)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1997	Carboplatin [s1]hypersensitivity[e1] induced by low-dose paclitaxel [s2]carboplatin[e2] in multiple platinum-treated patients with recurrent ovarian cancer.
+	(4, 15)	hypersensitivity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1998	Carboplatin [s1]hypersensitivity[e1] induced by low-dose [s2]paclitaxel[e2] carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
+	(15, 41)	apnea	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1999	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and [s1]apnea[e1]  and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
+	(12, 42)	cardiac arrest	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2000	However, one patient exhibited severe hypersensitivity reactions including [s1]cardiac arrest[e1] and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
+	(23, 41)	eruptions	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2001	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed [s1]eruptions[e1]  hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
+	(25, 41)	hypotension	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2002	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, [s1]hypotension[e1]  and tachycardia soon after administration of [s2]CBDCA[e2] 
+	(5, 42)	severe hypersensitivity reactions	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2003	However, one patient exhibited [s1]severe hypersensitivity reactions[e1] including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
+	(32, 42)	tachycardia	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2004	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and [s1]tachycardia[e1] soon after administration of [s2]CBDCA[e2] 
+	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2005	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
+	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2006	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
+	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2007	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
+	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2008	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
+	(5, 16)	carboplatin	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2009	We report five cases of [s1]carboplatin[e1] (CBDCA) [s2]hypersensitivity[e2] after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(9, 14)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2010	We report five cases of carboplatin  [s1]CBDCA[e1]  [s2]hypersensitivity[e2] after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(14, 25)	hypersensitivity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2011	We report five cases of carboplatin (CBDCA) [s1]hypersensitivity[e1] after weekly low-dose [s2]paclitaxel[e2] (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(17, 28)	cyclosporine	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2012	TREATMENT/OUTCOME: Standard anti-tuberculosis therapy was administered but was complicated by interaction with [s1]cyclosporine[e1] and drug-induced [s2]cholestasis[e2] 
+	(1, 9)	fentanyl	adrenocortical insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2013	Chronic [s1]fentanyl[e1] application induces [s2]adrenocortical insufficiency[e2] 
+	(14, 34)	adrenocortical insufficiency	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2014	We report a case of a 64-year-old man with secondary [s1]adrenocortical insufficiency[e1] who has been on a chronic transdermal [s2]fentanyl[e2] treatment because of sciatic pain syndrome.
+	(0, 7)	Fluphenazine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2015	 [s1]Fluphenazine[e1] induced [s2]neuroleptic malignant syndrome[e2] in a schizophrenic patient.
+	(7, 22)	neuroleptic malignant syndrome	fluphenazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2016	OBJECTIVE: To report a case of [s1]neuroleptic malignant syndrome[e1] (NMS) associated with [s2]fluphenazine[e2] in a schizophrenic patient and review the literature related to this condition.
+	(14, 20)	NMS	fluphenazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2017	OBJECTIVE: To report a case of neuroleptic malignant syndrome  [s1]NMS[e1]  associated with [s2]fluphenazine[e2] in a schizophrenic patient and review the literature related to this condition.
+	(4, 11)	vancomycin	cerebrospinal fluid eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2018	Intraventricular [s1]vancomycin[e1] induced [s2]cerebrospinal fluid eosinophilia[e2]  report of two patients.
+	(5, 35)	vancomycin	CSFE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2019	We propose a mechanism of [s1]vancomycin[e1] induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of [s2]CSFE[e2] 
+	(5, 31)	cerebrospinal fluid eosinophilia	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2020	We report two cases of [s1]cerebrospinal fluid eosinophilia[e1] (CSFE) secondary to the intraventricular administration of [s2]vancomycin[e2] 
+	(16, 29)	CSFE	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2021	We report two cases of cerebrospinal fluid eosinophilia  [s1]CSFE[e1]  secondary to the intraventricular administration of [s2]vancomycin[e2] 
+	(3, 15)	interstitial pneumonitis	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2022	Successful recovery from [s1]interstitial pneumonitis[e1]  induced by [s2]bicalutamide[e2] and leuprorelin acetate given as treatment for prostate cancer.
+	(3, 20)	interstitial pneumonitis	leuprorelin acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2023	Successful recovery from [s1]interstitial pneumonitis[e1]  induced by bicalutamide and [s2]leuprorelin acetate[e2] given as treatment for prostate cancer.
+	(5, 17)	interstitial pneumonitis	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2024	We report a case of [s1]interstitial pneumonitis[e1] induced by [s2]bicalutamide[e2] and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.
+	(5, 24)	interstitial pneumonitis	leuprorelin acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2025	We report a case of [s1]interstitial pneumonitis[e1] induced by bicalutamide and/or [s2]leuprorelin acetate[e2] given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.
+	(14, 30)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2026	CONCLUSIONS: In these 3 cases, the unique positive ocular finding was [s1]corneal endothelial deposits[e1]  which may be related to the use of [s2]rifabutin[e2] 
+	(0, 10)	Corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2027	 [s1]Corneal endothelial deposits[e1] associated with [s2]rifabutin[e2] use.
+	(15, 28)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2028	PURPOSE: The aim of this study was to report on the possible development of [s1]corneal endothelial deposits[e1] resulting from the use of [s2]rifabutin[e2] 
+	(5, 17)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2029	RESULTS: All cases developed [s1]corneal endothelial deposits[e1] after previous use of [s2]rifabutin[e2] 
+	(3, 35)	malignant mixed mesodermal tumor	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2030	CASE: A [s1]malignant mixed mesodermal tumor[e1] was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking [s2]raloxifene[e2] for osteoporosis prevention.
+	(8, 19)	raloxifene	malignant mixed mesodermal tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2031	CONCLUSION: There may be an association between [s1]raloxifene[e1] and the development of [s2]malignant mixed mesodermal tumor[e2] 
+	(0, 16)	Malignant mixed mullerian tumor of the uterus	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2032	 [s1]Malignant mixed mullerian tumor of the uterus[e1] in a patient taking [s2]raloxifene[e2] 
+	(10, 26)	malignant mixed mesodermal tumor	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2033	We report a case of a women in whom a [s1]malignant mixed mesodermal tumor[e1] was diagnosed while she was taking [s2]raloxifene[e2]  which is also a selective estrogen receptor modulator.
+	(13, 21)	neutropenia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2034	Herein we report four patients who underwent liver transplantation and developed [s1]neutropenia[e1] while receiving [s2]MMF[e2] 
+	(0, 12)	Mycophenolate mofetil	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2035	 [s1]Mycophenolate mofetil[e1] induced [s2]neutropenia[e2] in liver transplantation.
+	(5, 13)	MMF	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2036	The mean time from starting [s1]MMF[e1] to the development of [s2]neutropenia[e2] was 4 months.
+	(4, 10)	MMF	bone marrow toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2037	The side effects of [s1]MMF[e1]  such as [s2]bone marrow toxicity[e2]  have been reported.
+	(10, 25)	acute hemoglobinemia	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2038	A previous review described data on 15 patients who experienced [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP or secondary thrombocytopenia.
+	(17, 25)	hemoglobinuria	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2039	A previous review described data on 15 patients who experienced acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]anti-D IGIV[e2] administration for ITP or secondary thrombocytopenia.
+	(11, 26)	acute hemoglobinemia	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2040	Disseminated intravascular coagulation associated with [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
+	(0, 26)	Disseminated intravascular coagulation	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2041	 [s1]Disseminated intravascular coagulation[e1] associated with acute hemoglobinemia or hemoglobinuria following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
+	(18, 26)	hemoglobinuria	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2042	Disseminated intravascular coagulation associated with acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
+	(6, 39)	anti-D IGIV	DIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2043	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation  [s2]DIC[e2] .
+	(6, 30)	anti-D IGIV	disseminated intravascular coagulation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2044	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of hemoglobinemia, particularly [s2]disseminated intravascular coagulation[e2] (DIC).
+	(6, 23)	anti-D IGIV	hemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2045	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of [s2]hemoglobinemia[e2]  particularly disseminated intravascular coagulation (DIC).
+	(17, 31)	DIC	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2046	The purpose of this review is to increase awareness among physicians and other health care professionals that [s1]DIC[e1] may be a rare but potentially severe complication of [s2]anti-D IGIV[e2] treatment.
+	(12, 27)	acute hemoglobinemia	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2047	This review presents the first case series of DIC associated with [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP.
+	(8, 27)	DIC	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2048	This review presents the first case series of [s1]DIC[e1] associated with acute hemoglobinemia or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP.
+	(19, 27)	hemoglobinuria	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2049	This review presents the first case series of DIC associated with acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]anti-D IGIV[e2] administration for ITP.
+	(3, 19)	infliximab	severe transient neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2050	After the second [s1]infliximab[e1] infusion, he was found to have a [s2]severe transient neutropenia[e2] (0.5 x 10(9)/L).
+	(3, 13)	agranulocytosis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2051	Drug-induced [s1]agranulocytosis[e1] during treatment with [s2]infliximab[e2] in enteropathic spondyloarthropathy.
+	(4, 30)	infliximab	autoimmune agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2052	These data indicated that [s1]infliximab[e1] possibly triggered production of granulocyte and neutrophil autoantibodies with resultant [s2]autoimmune agranulocytosis[e2] 
+	(4, 13)	infliximab	production of granulocyte and neutrophil autoantibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2053	These data indicated that [s1]infliximab[e1] possibly triggered [s2]production of granulocyte and neutrophil autoantibodies[e2] with resultant autoimmune agranulocytosis.
+	(7, 14)	bone marrow depression	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2054	However, peripheral neuropathy and [s1]bone marrow depression[e1] led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
+	(3, 14)	neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2055	However, peripheral [s1]neuropathy[e1] and bone marrow depression led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
+	(2, 14)	peripheral neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2056	However, [s1]peripheral neuropathy[e1] and bone marrow depression led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
+	(10, 39)	bone marrow depression	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2057	Six patients developed peripheral neuropathy and five patients [s1]bone marrow depression[e1]  blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of [s2]linezolid[e2] 
+	(3, 40)	peripheral neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2058	Six patients developed [s1]peripheral neuropathy[e1] and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of [s2]linezolid[e2] 
+	(3, 45)	high-grade endometrial stromal sarcoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2059	A case of [s1]high-grade endometrial stromal sarcoma[e1]  confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant [s2]tamoxifen[e2] 
+	(20, 45)	intrauterine polypoid growth	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2060	A case of high-grade endometrial stromal sarcoma, confined into an [s1]intrauterine polypoid growth[e1]  in a woman with a history of breast cancer who was treated with adjuvant [s2]tamoxifen[e2] 
+	(0, 16)	High-grade endometrial stromal sarcoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2061	 [s1]High-grade endometrial stromal sarcoma[e1] after [s2]tamoxifen[e2] therapy for breast cancer.
+	(3, 32)	tamoxifen	endometrial adenocarcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2062	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including [s2]endometrial adenocarcinoma[e2] or uterine sarcoma.
+	(3, 32)	tamoxifen	endometrial adenocarcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2063	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including [s2]endometrial adenocarcinoma[e2] or uterine sarcoma.
+	(3, 42)	tamoxifen	uterine sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2064	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or [s2]uterine sarcoma[e2] 
+	(3, 42)	tamoxifen	uterine sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2065	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or [s2]uterine sarcoma[e2] 
+	(6, 20)	pentamidine	heart rate had decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2066	After only the third dose of [s1]pentamidine[e1]  it was noted that the patient's [s2]heart rate had decreased[e2] to 48 beats/minute.
+	(5, 12)	pentamidine	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2067	Although various manifestations of [s1]pentamidine[e1] induced [s2]cardiotoxicity[e2] have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.
+	(5, 25)	pentamidine	second-degree heart block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2068	Although various manifestations of [s1]pentamidine[e1] induced cardiotoxicity have been reported, to our knowledge, [s2]second-degree heart block[e2] associated with this agent has not been described.
+	(10, 20)	cardiotoxicity	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2069	Clinicians should be vigilant when monitoring for [s1]cardiotoxicity[e1] in patients receiving [s2]pentamidine[e2] throughout the duration of therapy.
+	(3, 10)	pentamidine	second-degree heart block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2070	Early-onset [s1]pentamidine[e1] associated [s2]second-degree heart block[e2] and sinus bradycardia: case report and review of the literature.
+	(3, 16)	pentamidine	sinus bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2071	Early-onset [s1]pentamidine[e1] associated second-degree heart block and [s2]sinus bradycardia[e2]  case report and review of the literature.
+	(0, 9)	Falling backward	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2072	 [s1]Falling backward[e1] in two elderly patients taking [s2]bupropion[e2] 
+	(14, 21)	falling backward	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2073	RESULTS: Both patients experienced a previously unreported side effect- [s1]falling backward[e1] -associated with [s2]bupropion[e2] use.
+	(0, 17)	Ophthalmologic and neurologic findings	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2074	 [s1]Ophthalmologic and neurologic findings[e1] in two children exposed to [s2]vigabatrin[e2] in utero.
+	(3, 8)	VGB	visual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2075	The knowledge concerning [s1]VGB[e1] associated [s2]visual dysfunction[e2] in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.
+	(0, 7)	Vigabatrin	visual field defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2076	 [s1]Vigabatrin[e1] induced [s2]visual field defects[e2] are at present the most important safety issue in the use of the drug.
+	(2, 24)	ophthalmic and neurologic findings	VGB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2077	We explored [s1]ophthalmic and neurologic findings[e1] in two children who have been exposed prenatally to [s2]VGB[e2] 
+	(5, 26)	IFN	cotton wool spots	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2078	BACKGROUND: Interferon  [s1]IFN[e1] -associated retinopathy is typically characterized by retinal hemorrhages and [s2]cotton wool spots[e2] at the posterior fundus, but visual function is usually maintained.
+	(2, 28)	Interferon	cotton wool spots	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2079	BACKGROUND: [s1]Interferon[e1] (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and [s2]cotton wool spots[e2] at the posterior fundus, but visual function is usually maintained.
+	(5, 18)	IFN	retinal hemorrhages	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2080	BACKGROUND: Interferon  [s1]IFN[e1] -associated retinopathy is typically characterized by [s2]retinal hemorrhages[e2] and cotton wool spots at the posterior fundus, but visual function is usually maintained.
+	(2, 20)	Interferon	retinal hemorrhages	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2081	BACKGROUND: [s1]Interferon[e1] (IFN)-associated retinopathy is typically characterized by [s2]retinal hemorrhages[e2] and cotton wool spots at the posterior fundus, but visual function is usually maintained.
+	(5, 11)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2082	BACKGROUND: Interferon  [s1]IFN[e1] -associated [s2]retinopathy[e2] is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.
+	(2, 13)	Interferon	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2083	BACKGROUND: [s1]Interferon[e1] (IFN)-associated [s2]retinopathy[e2] is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.
+	(3, 13)	macular edema	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2084	Clinical course of [s1]macular edema[e1] in two cases of [s2]interferon[e2] associated retinopathy observed by optical coherence tomography.
+	(11, 17)	interferon	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2085	Clinical course of macular edema in two cases of [s1]interferon[e1] associated [s2]retinopathy[e2] observed by optical coherence tomography.
+	(5, 27)	IFN	decreased vision	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2086	CONCLUSION: During and after [s1]IFN[e1] therapy, OCT is a useful examination technique for revealing macular edema in patients who have [s2]decreased vision[e2] 
+	(5, 19)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2087	CONCLUSION: During and after [s1]IFN[e1] therapy, OCT is a useful examination technique for revealing [s2]macular edema[e2] in patients who have decreased vision.
+	(15, 29)	IFN	hypoalbuminemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2088	Ophthalmologists should be aware of the ocular side effects of [s1]IFN[e1] therapy and carefully monitor patients for the possible occurrence of [s2]hypoalbuminemia[e2] and thrombocytopenia.
+	(10, 17)	ocular side effects	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2089	Ophthalmologists should be aware of the [s1]ocular side effects[e1] of [s2]IFN[e2] therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.
+	(15, 37)	IFN	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2090	Ophthalmologists should be aware of the ocular side effects of [s1]IFN[e1] therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and [s2]thrombocytopenia[e2] 
+	(8, 19)	visual acuity had decreased	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2091	The former patient had complained once that his [s1]visual acuity had decreased[e1] after the termination of [s2]IFN[e2] therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.
+	(8, 19)	visual acuity had decreased	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2092	The former patient had complained once that his [s1]visual acuity had decreased[e1] after the termination of [s2]IFN[e2] therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.
+	(17, 28)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2093	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed [s2]macular edema[e2] and reduced visual acuity during the clinical course of IFN therapy were observed.
+	(17, 28)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2094	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed [s2]macular edema[e2] and reduced visual acuity during the clinical course of IFN therapy were observed.
+	(17, 33)	IFN	reduced visual acuity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2095	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed macular edema and [s2]reduced visual acuity[e2] during the clinical course of IFN therapy were observed.
+	(17, 33)	IFN	reduced visual acuity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2096	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed macular edema and [s2]reduced visual acuity[e2] during the clinical course of IFN therapy were observed.
+	(17, 22)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2097	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated [s2]retinopathy[e2] who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.
+	(17, 22)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2098	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated [s2]retinopathy[e2] who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.
+	(3, 10)	diabetes mellitus	interferon-alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2099	Late development of [s1]diabetes mellitus[e1] after [s2]interferon-alfa[e2] and ribavirin therapy for chronic hepatitis C: a case report.
+	(3, 16)	diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2100	Late development of [s1]diabetes mellitus[e1] after interferon-alfa and [s2]ribavirin[e2] therapy for chronic hepatitis C: a case report.
+	(8, 20)	immune-mediated diabetes mellitus	alfa-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2101	OBJECTIVE: To report the late development of [s1]immune-mediated diabetes mellitus[e1] after completion of [s2]alfa-interferon[e2] therapy for hepatitis C in an Asian patient.
+	(0, 18)	Cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2102	 [s1]Cutaneous necrosis[e1] after injection of polyethylene glycol-modified [s2]interferon alfa[e2] 
+	(0, 10)	Cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2103	 [s1]Cutaneous necrosis[e1] as a result of [s2]interferon alfa[e2] is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.
+	(13, 45)	pegylated interferon alfa-2b	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2104	We report 5 patients (3 patients with chronic hepatitis C treated with [s1]pegylated interferon alfa-2b[e1] in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
+	(13, 45)	pegylated interferon alfa-2b	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2105	We report 5 patients (3 patients with chronic hepatitis C treated with [s1]pegylated interferon alfa-2b[e1] in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
+	(27, 45)	ribavirin	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2106	We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral [s1]ribavirin[e1] and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
+	(9, 19)	cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2107	We review the literature on previously reported cases of [s1]cutaneous necrosis[e1] after injection of standard [s2]interferon alfa[e2] or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.
+	(9, 24)	cutaneous necrosis	pegylated interferon alfa-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2108	We review the literature on previously reported cases of [s1]cutaneous necrosis[e1] after injection of standard interferon alfa or [s2]pegylated interferon alfa-2b[e2] and discuss the different pathophysiologic mechanisms that might be involved.
+	(7, 17)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2109	Potential mechanisms involved in the occurrence of [s1]ischemic colitis[e1] in patients receiving [s2]tegaserod[e2] are also discussed.
+	(0, 7)	Tegaserod	ischemic colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2110	 [s1]Tegaserod[e1] associated [s2]ischemic colitis[e2] 
+	(17, 41)	tegaserod	irritable bowel syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2111	We describe the development of ischemic colitis in a woman who was treated with [s1]tegaserod[e1] and review the relationship among ischemic colitis, tegaserod use, and [s2]irritable bowel syndrome[e2] 
+	(17, 41)	tegaserod	irritable bowel syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2112	We describe the development of ischemic colitis in a woman who was treated with [s1]tegaserod[e1] and review the relationship among ischemic colitis, tegaserod use, and [s2]irritable bowel syndrome[e2] 
+	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2113	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
+	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2114	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
+	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2115	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
+	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2116	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
+	(8, 31)	chronic, watery diarrhea	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2117	A 57-year-old man developed [s1]chronic, watery diarrhea[e1] four weeks after Helicobacter pylori eradication therapy including [s2]lansoprazole[e2] followed by lansoprazole monotherapy for gastroesophageal reflux disease.
+	(8, 31)	chronic, watery diarrhea	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2118	A 57-year-old man developed [s1]chronic, watery diarrhea[e1] four weeks after Helicobacter pylori eradication therapy including [s2]lansoprazole[e2] followed by lansoprazole monotherapy for gastroesophageal reflux disease.
+	(0, 7)	Lansoprazole	collagenous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2119	 [s1]Lansoprazole[e1] associated [s2]collagenous colitis[e2]  a case report.
+	(14, 24)	lansoprazole	collagenous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2120	The reported case represents an unusual association between medication with the proton pump inhibitor [s1]lansoprazole[e1] and the development of [s2]collagenous colitis[e2] suggesting the importance of evaluation of drug use in patients with microscopic colitis.
+	(7, 31)	painful ulcers	interferon beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2121	46-year-old woman developed [s1]painful ulcers[e1] over her lower abdomen in the form of reticulate erythema after injecting [s2]interferon beta-1b[e2] subcutaneously for multiple sclerosis.
+	(19, 31)	reticulate erythema	interferon beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2122	46-year-old woman developed painful ulcers over her lower abdomen in the form of [s1]reticulate erythema[e1] after injecting [s2]interferon beta-1b[e2] subcutaneously for multiple sclerosis.
+	(0, 13)	Abdominal wall ulceration	recombinant human interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2123	 [s1]Abdominal wall ulceration[e1] and mucinosis secondary to [s2]recombinant human interferon-beta-1b[e2] 
+	(6, 13)	mucinosis	recombinant human interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2124	Abdominal wall ulceration and [s1]mucinosis[e1] secondary to [s2]recombinant human interferon-beta-1b[e2] 
+	(0, 9)	Itraconazole	vincristine neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2125	 [s1]Itraconazole[e1] related increased [s2]vincristine neurotoxicity[e2]  case report and review of literature.
+	(8, 19)	vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2126	Itraconazole-related increased [s1]vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity: case report and review of literature.
+	(9, 18)	neurotoxicity	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2127	Nineteen cases of unusual enhanced vincristine [s1]neurotoxicity[e1] related to [s2]itraconazole[e2] have been reported in children.
+	(5, 11)	vincristine	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2128	Nineteen cases of unusual enhanced [s1]vincristine[e1]  [s2]neurotoxicity[e2] related to itraconazole have been reported in children.
+	(3, 32)	itraconazole	absence of deep reflexes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2129	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and [s2]absence of deep reflexes[e2]  with severe paralysis of the lower extremities and mild weakness of the upper extremities.
+	(3, 26)	itraconazole	mild left ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2130	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, [s2]mild left ptosis[e2]  and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
+	(3, 49)	itraconazole	mild weakness of the upper extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2131	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and [s2]mild weakness of the upper extremities[e2] 
+	(3, 21)	itraconazole	neurogenic bladder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2132	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, [s2]neurogenic bladder[e2]  mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
+	(3, 15)	itraconazole	paralytic ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2133	Ten days after [s1]itraconazole[e1] was started, he developed [s2]paralytic ileus[e2]  neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
+	(3, 39)	itraconazole	severe paralysis of the lower extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2134	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with [s2]severe paralysis of the lower extremities[e2] and mild weakness of the upper extremities.
+	(12, 42)	itraconazole	fatal toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2135	The authors suggest that in the absence of any proven benefit of [s1]itraconazole[e1] prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially [s2]fatal toxicities[e2]  the combination use of these drugs should be avoided.
+	(30, 42)	vincristine	fatal toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2136	The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with [s1]vincristine[e1] leading to severe and even potentially [s2]fatal toxicities[e2]  the combination use of these drugs should be avoided.
+	(8, 38)	intracerebral hemorrhage	pseudoephedrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2137	CASE REPORT: We report a case of [s1]intracerebral hemorrhage[e1] occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting [s2]pseudoephedrine[e2] daily for one year.
+	(4, 16)	phenylpropanolamine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2138	Only one report links [s1]phenylpropanolamine[e1] consumption to an [s2]intracerebral hemorrhage[e2] in a patient with an AVM.
+	(0, 14)	Pseudoephedrine	cerebral vascular malformation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2139	 [s1]Pseudoephedrine[e1] induced hemorrhage associated with a [s2]cerebral vascular malformation[e2] 
+	(0, 7)	Pseudoephedrine	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2140	 [s1]Pseudoephedrine[e1] induced [s2]hemorrhage[e2] associated with a cerebral vascular malformation.
+	(13, 23)	phenylpropanolamine	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2141	Since 1979, over 30 published case reports have documented the relationship between [s1]phenylpropanolamine[e1] and [s2]stroke[e2] 
+	(5, 12)	pseudoephedrine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2142	This is a case of [s1]pseudoephedrine[e1] induced [s2]intracerebral hemorrhage[e2] in a patient with an underlying vascular malformation.
+	(3, 9)	quetiapine	diabetic ketoacidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2143	Rapid onset of [s1]quetiapine[e1] induced [s2]diabetic ketoacidosis[e2] in an elderly patient: a case report.
+	(8, 29)	DKA	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2144	We report a case of reversible [s1]DKA[e1] and new-onset DM that developed in a demented patient who was treated with [s2]quetiapine[e2] for 14 days.
+	(14, 29)	DM	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2145	We report a case of reversible DKA and new-onset [s1]DM[e1] that developed in a demented patient who was treated with [s2]quetiapine[e2] for 14 days.
+	(0, 9)	Pulmonary leukostasis	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2146	 [s1]Pulmonary leukostasis[e1] secondary to [s2]all-trans retinoic acid[e2] in the treatment of acute promyelocytic leukemia in first relapse.
+	(0, 15)	Eruptive epidermoid cysts	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2147	 [s1]Eruptive epidermoid cysts[e1] resulting from treatment with [s2]imiquimod[e2] 
+	(12, 31)	imiquimod	verrucous plaque	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2148	METHODS: A 79-year-old woman being treated with [s1]imiquimod[e1] 5 days per week for a nodular basal cell developed a [s2]verrucous plaque[e2] over the treatment area after 7 weeks of therapy.
+	(1, 23)	multiple comedones	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2149	The [s1]multiple comedones[e1] and ruptured epidermoid cysts are newly reported adverse effects of [s2]imiquimod[e2] therapy.
+	(6, 23)	ruptured epidermoid cysts	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2150	The multiple comedones and [s1]ruptured epidermoid cysts[e1] are newly reported adverse effects of [s2]imiquimod[e2] therapy.
+	(7, 24)	fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2151	We report an unusual case of massive [s1]fluoxetine[e1] ingestion resulting in neurological and cardiovascular toxicity resulting in [s2]death[e2] 
+	(7, 18)	fluoxetine	neurological and cardiovascular toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2152	We report an unusual case of massive [s1]fluoxetine[e1] ingestion resulting in [s2]neurological and cardiovascular toxicity[e2] resulting in death.
+	(0, 12)	Hepatocellular damage	iron sucrose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2153	 [s1]Hepatocellular damage[e1] following therapeutic intravenous [s2]iron sucrose[e2] infusion in a child.
+	(16, 37)	iron sucrose	systemic iron toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2154	The case reported here is of a child given a large dose of intravenous [s1]iron sucrose[e1] (16 mg/kg) over 3 hours, who subsequently developed features of [s2]systemic iron toxicity[e2] 
+	(5, 18)	acute amnestic episode	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2155	Five personal observations of an [s1]acute amnestic episode[e1] in younger individuals after intake of [s2]clioquinol[e2] are described together with three observations from the medical literature.
+	(13, 34)	clioquinol	retrograde amnesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2156	The clinical aspect closely resembled classical transient global amnesia but the episode after [s1]clioquinol[e1] lasted longer (24 hours to three days) and a more or less extensive [s2]retrograde amnesia[e2] persisted permanently.
+	(6, 15)	transient global amnesia	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2157	The clinical aspect closely resembled classical [s1]transient global amnesia[e1] but the episode after [s2]clioquinol[e2] lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.
+	(0, 6)	Transient global amnesia	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2158	 [s1]Transient global amnesia[e1] after [s2]clioquinol[e2]  five personal observations from outside Japan.
+	(13, 27)	Neisseria mucosa knee arthritis	sodium hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2159	In the other patient, a 78-year-old woman, [s1]Neisseria mucosa knee arthritis[e1] occurred after a single [s2]sodium hyaluronate[e2] injection.
+	(14, 39)	Staphylococcus aureus knee arthritis	corticosteroids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2160	One patient was an 80-year-old woman who was admitted for [s1]Staphylococcus aureus knee arthritis[e1] after several intraarticular injections of sodium hyaluronate and [s2]corticosteroids[e2] 
+	(14, 33)	Staphylococcus aureus knee arthritis	sodium hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2161	One patient was an 80-year-old woman who was admitted for [s1]Staphylococcus aureus knee arthritis[e1] after several intraarticular injections of [s2]sodium hyaluronate[e2] and corticosteroids.
+	(0, 11)	Septic knee arthritis	hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2162	 [s1]Septic knee arthritis[e1] after intra-articular [s2]hyaluronate[e2] injection.
+	(0, 8)	Acute dystonia	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2163	 [s1]Acute dystonia[e1] induced by [s2]lamivudine[e2] 
+	(0, 33)	ADR	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2164	 [s1]ADR[e1] induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of [s2]lamivudine[e2] induced ADR in the English literature.
+	(6, 22)	acute dystonic reactions	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2165	The authors report two cases of [s1]acute dystonic reactions[e1] (ADRs) as a side effect of [s2]lamivudine[e2] 
+	(11, 20)	ADRs	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2166	The authors report two cases of acute dystonic reactions  [s1]ADRs[e1]  as a side effect of [s2]lamivudine[e2] 
+	(5, 21)	lamivudine	ADRs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2167	The authors think that although [s1]lamivudine[e1] is widely used and well tolerated, it can cause [s2]ADRs[e2]  which are reversible after drug withdrawal.
+	(0, 23)	Pleuropulmonary fibrosis	pergolide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2168	 [s1]Pleuropulmonary fibrosis[e1] after long-term treatment with the dopamine agonist [s2]pergolide[e2] for Parkinson Disease.
+	(10, 27)	risperidone	psychiatric and physical manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2169	"CONCLUSIONS: This observation of ""on-off"" [s1]risperidone[e1] treatment suggests that risperidone may have worsened both [s2]psychiatric and physical manifestations[e2] of the mitochondrial disorder in this adolescent."
+	(10, 27)	risperidone	psychiatric and physical manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2170	"CONCLUSIONS: This observation of ""on-off"" [s1]risperidone[e1] treatment suggests that risperidone may have worsened both [s2]psychiatric and physical manifestations[e2] of the mitochondrial disorder in this adolescent."
+	(31, 39)	increased mood symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2171	OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and [s1]increased mood symptoms[e1] during treatment with [s2]risperidone[e2] 
+	(0, 10)	Risperidone	depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2172	 [s1]Risperidone[e1] induced psychosis and [s2]depression[e2] in a child with a mitochondrial disorder.
+	(0, 7)	Risperidone	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2173	 [s1]Risperidone[e1] induced [s2]psychosis[e2] and depression in a child with a mitochondrial disorder.
+	(0, 11)	Fatal radiation myelopathy	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2174	 [s1]Fatal radiation myelopathy[e1] after high-dose [s2]busulfan[e2] and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
+	(0, 15)	Fatal radiation myelopathy	melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2175	 [s1]Fatal radiation myelopathy[e1] after high-dose busulfan and [s2]melphalan[e2] chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
+	(0, 7)	Gemcitabine	pericardial effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2176	 [s1]Gemcitabine[e1] induced [s2]pericardial effusion[e2] and tamponade after unblocked cardiac irradiation.
+	(0, 14)	Gemcitabine	tamponade	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2177	 [s1]Gemcitabine[e1] induced pericardial effusion and [s2]tamponade[e2] after unblocked cardiac irradiation.
+	(0, 11)	Gemcitabine	radiation recall reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2178	 [s1]Gemcitabine[e1] therapy has been associated with [s2]radiation recall reactions[e2] when used in the treatment of carcinoma.
+	(10, 28)	gemcitabine	pericardial effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2179	Physicians should be aware of the potential for developing a [s1]gemcitabine[e1] induced radiation recall reaction resulting in hemodynamically significant [s2]pericardial effusion[e2] 
+	(10, 17)	gemcitabine	radiation recall reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2180	Physicians should be aware of the potential for developing a [s1]gemcitabine[e1] induced [s2]radiation recall reaction[e2] resulting in hemodynamically significant pericardial effusion.
+	(11, 32)	pericardial effusion	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2181	We report four cases of hemodynamically significant [s1]pericardial effusion[e1] in patients with refractory lymphoma who were receiving [s2]gemcitabine[e2]  all of whom had a history of mediastinal radiation without subcarinal blocking.
+	(9, 14)	MM	CNS lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2182	A patient with generalized MG was effectively managed with [s1]MM[e1] but developed [s2]CNS lymphoma[e2] after 3 years of treatment.
+	(16, 26)	MM	lymphoproliferative disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2183	Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with [s1]MM[e1] may be associated with increased risk of [s2]lymphoproliferative disorders[e2] 
+	(1, 23)	CNS lymphoma	mycophenolate mofetil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2184	Primary [s1]CNS lymphoma[e1] complicating treatment of myasthenia gravis with [s2]mycophenolate mofetil[e2] 
+	(1, 14)	CNS lymphoma	MM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2185	Primary [s1]CNS lymphoma[e1] regressed on withdrawal of [s2]MM[e2] 
+	(0, 12)	Baclofen	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2186	 [s1]Baclofen[e1] withdrawal: a cause of prolonged [s2]fever[e2] in the intensive care unit.
+	(0, 6)	Baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2187	 [s1]Baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.
+	(4, 15)	withdrawal syndrome	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2188	Baclofen [s1]withdrawal syndrome[e1] resulting from underdosing of oral [s2]baclofen[e2] should be considered as a potential source of prolonged fever in the intensive care unit.
+	(7, 37)	autonomic instability	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2189	The patient continued to have fever and [s1]autonomic instability[e1] without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral [s2]baclofen[e2] 
+	(5, 37)	fever	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2190	The patient continued to have [s1]fever[e1] and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral [s2]baclofen[e2] 
+	(5, 11)	baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2191	We report a case of [s1]baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from oral baclofen underdosing.
+	(5, 11)	baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2192	We report a case of [s1]baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from oral baclofen underdosing.
+	(5, 26)	captopril	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2193	After discontinuing [s1]captopril[e1] and starting systemic steroids, her symptomatology rapidly improved, and her [s2]eosinophilia[e2] and radiographic abnormalities both resolved.
+	(5, 32)	captopril	radiographic abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2194	After discontinuing [s1]captopril[e1] and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and [s2]radiographic abnormalities[e2] both resolved.
+	(0, 6)	Captopril	pulmonary infiltrates with eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2195	 [s1]Captopril[e1] induced [s2]pulmonary infiltrates with eosinophilia[e2] in an infant with congenital heart disease.
+	(16, 31)	captopril	pulmonary infiltrates with eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2196	We report a case of an infant with complex congenital heart disease who was placed on [s1]captopril[e1] for afterload reduction following cardiac surgery and subsequently developed [s2]pulmonary infiltrates with eosinophilia[e2] 
+	(1, 10)	propofol	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2197	Can [s1]propofol[e1] precipitate [s2]pancreatitis[e2] in patients with Cushing's syndrome?
+	(38, 46)	acute pancreatitis	propofol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2198	Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to [s1]acute pancreatitis[e1] following [s2]propofol[e2] administration.
+	(32, 38)	focal seizure	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2199	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a [s1]focal seizure[e1]  of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
+	(22, 38)	prolonged seizure	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2200	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a [s1]prolonged seizure[e1]  a serotonin syndrome and a focal seizure) of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
+	(26, 39)	serotonin syndrome	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2201	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a [s1]serotonin syndrome[e1] and a focal seizure) of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
+	(0, 44)	CD20-negative T-cell-rich B-cell lymphoma	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2202	 [s1]CD20-negative T-cell-rich B-cell lymphoma[e1] as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with [s2]rituximab[e2]  a molecular analysis using laser capture microdissection.
+	(2, 13)	CD20-negative tumors	Rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2203	Recently, [s1]CD20-negative tumors[e1] have been described after [s2]Rituximab[e2] therapy.
+	(9, 25)	angio-oedema	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2204	A 51-year old physically fit woman experienced [s1]angio-oedema[e1] and hypotensive shock after [s2]irbesartan[e2] ingestion requiring noradrenaline infusion.
+	(16, 25)	hypotensive shock	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2205	A 51-year old physically fit woman experienced angio-oedema and [s1]hypotensive shock[e1] after [s2]irbesartan[e2] ingestion requiring noradrenaline infusion.
+	(14, 23)	angio-oedema	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2206	To our knowledge, our report is one of the first on shock and [s1]angio-oedema[e1] from [s2]irbesartan[e2] 
+	(12, 23)	shock	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2207	To our knowledge, our report is one of the first on [s1]shock[e1] and angio-oedema from [s2]irbesartan[e2] 
+	(7, 29)	congestive heart failure	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2208	She died within six weeks of developing [s1]congestive heart failure[e1] coupled with liver failure due to haemosiderosis despite regular use of [s2]desferrioxamine[e2] 
+	(18, 29)	haemosiderosis	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2209	She died within six weeks of developing congestive heart failure coupled with liver failure due to [s1]haemosiderosis[e1] despite regular use of [s2]desferrioxamine[e2] 
+	(14, 29)	liver failure	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2210	She died within six weeks of developing congestive heart failure coupled with [s1]liver failure[e1] due to haemosiderosis despite regular use of [s2]desferrioxamine[e2] 
+	(0, 16)	Transfusion haemosiderosis	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2211	 [s1]Transfusion haemosiderosis[e1] inspite of regular use of [s2]desferrioxamine[e2]  case report.
+	(11, 21)	triamcinolone	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2212	One of the side-effects of intravitreal [s1]triamcinolone[e1] is the development of [s2]cataract[e2]  and it is known that cataract extraction can exacerbate macular degeneration.
+	(7, 18)	cataract	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2213	Severe loss of vision after removal of [s1]cataract[e1] caused by intravitreal [s2]triamcinolone[e2] in combination with photodynamic therapy for exudative age-related macular degeneration.
+	(0, 18)	Severe loss of vision	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2214	 [s1]Severe loss of vision[e1] after removal of cataract caused by intravitreal [s2]triamcinolone[e2] in combination with photodynamic therapy for exudative age-related macular degeneration.
+	(0, 14)	Rhabdomyolysis	ritodrine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2215	 [s1]Rhabdomyolysis[e1] caused by tocolysis with oral [s2]ritodrine hydrochloride[e2] in a pregnant patient with myotonic dystrophy.
+	(0, 20)	Rhabdomyolysis	ritodrine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2216	 [s1]Rhabdomyolysis[e1] has been recognized as a complication of tocolytic therapy with [s2]ritodrine hydrochloride[e2] 
+	(7, 19)	ritodrine-hydrochloride	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2217	We report here a rare case of [s1]ritodrine-hydrochloride[e1] induced [s2]rhabdomyolysis[e2] in a pregnant patient with myotonic dystrophy.
+	(0, 16)	Acute myocardial ischemia	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2218	 [s1]Acute myocardial ischemia[e1] following accidental intravenous administration of [s2]epinephrine[e2] in high concentration.
+	(6, 17)	epinephrine	lethal complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2219	Inadvertent and accidental [s1]epinephrine[e1] overdose might result in potentially [s2]lethal complications[e2] 
+	(6, 15)	epinephrine	acute myocardial ischemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2220	We present a case of acute [s1]epinephrine[e1] toxicity resulting in [s2]acute myocardial ischemia[e2] in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
+	(6, 37)	epinephrine	severe allergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2221	We present a case of acute [s1]epinephrine[e1] toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed [s2]severe allergic reaction[e2] to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
+	(6, 37)	epinephrine	severe allergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2222	We present a case of acute [s1]epinephrine[e1] toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed [s2]severe allergic reaction[e2] to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
+	(12, 22)	levodopa	restless legs syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2223	Polysomnographic and pharmacokinetic findings in [s1]levodopa[e1] induced augmentation of [s2]restless legs syndrome[e2] 
+	(4, 14)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2224	Symptoms and signs of [s1]augmentation[e1] were related to low plasma [s2]levodopa[e2] levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.
+	(4, 14)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2225	Symptoms and signs of [s1]augmentation[e1] were related to low plasma [s2]levodopa[e2] levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.
+	(17, 35)	levodopa	anarchic discharges of motor unit potentials	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2226	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with [s2]anarchic discharges of motor unit potentials[e2]  tonic grouped discharges and flexor spasms, associated with painful dysesthesia.
+	(17, 51)	levodopa	flexor spasms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2227	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and [s2]flexor spasms[e2]  associated with painful dysesthesia.
+	(17, 24)	levodopa	marked motor hyperactivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2228	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated [s2]marked motor hyperactivity[e2] during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.
+	(17, 58)	levodopa	painful dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2229	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with [s2]painful dysesthesia[e2] 
+	(17, 46)	levodopa	tonic grouped discharges	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2230	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, [s2]tonic grouped discharges[e2] and flexor spasms, associated with painful dysesthesia.
+	(12, 21)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2231	We describe a patient with idiopathic RLS who developed [s1]augmentation[e1] after 8 months of [s2]levodopa[e2] treatment.
+	(5, 13)	infliximab	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2232	The major side effect of [s1]infliximab[e1] is [s2]infection[e2] 
+	(7, 15)	infliximab	membranous nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2233	This report describes a probable case of [s1]infliximab[e1] induced [s2]membranous nephropathy[e2] 
+	(0, 6)	Linezolid	dyserythropoiesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2234	 [s1]Linezolid[e1] induced [s2]dyserythropoiesis[e2]  chloramphenicol toxicity revisited.
+	(6, 22)	dyserythropoietic anaemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2235	We report here two cases of [s1]dyserythropoietic anaemia[e1] associated with long-term [s2]linezolid[e2] use that share striking similarities to chloramphenicol-associated myelotoxicity.
+	(29, 38)	chloramphenicol	myelotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2236	We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to [s1]chloramphenicol[e1] associated [s2]myelotoxicity[e2] 
+	(4, 14)	fluoxetine	eye movements in nonrapid eye movement (NREM) sleep	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2237	A selective association between [s1]fluoxetine[e1] and extensive, prominent [s2]eye movements in nonrapid eye movement (NREM) sleep[e2] was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison).
+	(21, 28)	RBD	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2238	In addition, a 31-year-old man with obsessive-compulsive disorder developed [s1]RBD[e1] soon after starting [s2]fluoxetine[e2] therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.
+	(21, 28)	RBD	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2239	In addition, a 31-year-old man with obsessive-compulsive disorder developed [s1]RBD[e1] soon after starting [s2]fluoxetine[e2] therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.
+	(0, 17)	Prominent eye movements during NREM sleep	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2240	 [s1]Prominent eye movements during NREM sleep[e1] and REM sleep behavior disorder associated with [s2]fluoxetine[e2] treatment of depression and obsessive-compulsive disorder.
+	(8, 17)	REM sleep behavior disorder	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2241	Prominent eye movements during NREM sleep and [s1]REM sleep behavior disorder[e1] associated with [s2]fluoxetine[e2] treatment of depression and obsessive-compulsive disorder.
+	(7, 23)	increase in the QT interval	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2242	Because of serious side effects of an [s1]increase in the QT interval[e1] causing torsades de pointes, [s2]dofetilide[e2] must be initiated with close monitoring of the QT interval in an inpatient setting.
+	(14, 22)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2243	Because of serious side effects of an increase in the QT interval causing [s1]torsades de pointes[e1]  [s2]dofetilide[e2] must be initiated with close monitoring of the QT interval in an inpatient setting.
+	(15, 26)	acute ischemia	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2244	Marked QT prolongation and torsades de pointes secondary to [s1]acute ischemia[e1] in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
+	(0, 26)	Marked QT prolongation	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2245	 [s1]Marked QT prolongation[e1] and torsades de pointes secondary to acute ischemia in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
+	(7, 26)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2246	Marked QT prolongation and [s1]torsades de pointes[e1] secondary to acute ischemia in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
+	(25, 42)	acute myocardial ischemia	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2247	We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from [s1]acute myocardial ischemia[e1] in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
+	(19, 42)	flash pulmonary edema	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2248	We report marked QT prolongation and torsades de pointes in a setting of [s1]flash pulmonary edema[e1] resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
+	(3, 42)	QT prolongation	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2249	We report marked [s1]QT prolongation[e1] and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
+	(9, 42)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2250	We report marked QT prolongation and [s1]torsades de pointes[e1] in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
+	(1, 14)	positive U waves	phenylephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2251	Prominent [s1]positive U waves[e1] appearing with high-dose intravenous [s2]phenylephrine[e2] 
+	(6, 16)	phenylephrine	positive U waves	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2252	While on a maximal dose of [s1]phenylephrine[e1] she developed prominent [s2]positive U waves[e2]  which disappeared with the cessation of the drug.
+	(0, 13)	Hepatoxicity	SRL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2253	 [s1]Hepatoxicity[e1] is a rare complication of [s2]SRL[e2] therapy and may be connected with some diagnostic and/or therapeutic problems.
+	(0, 6)	Sirolimus	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2254	 [s1]Sirolimus[e1] associated [s2]hepatotoxicity[e2] in the kidney graft recipient.
+	(8, 17)	hepatotoxicity	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2255	The aim of our paper was to describe [s1]hepatotoxicity[e1] of [s2]sirolimus[e2] (SRL) in a kidney graft recipient.
+	(22, 54)	nephrotic syndrome	interferon beta 1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2256	CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of [s1]nephrotic syndrome[e1] while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of [s2]interferon beta 1a[e2] 
+	(0, 16)	Nephrotic syndrome	interferon beta 1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2257	 [s1]Nephrotic syndrome[e1] in a multiple sclerosis patient treated with [s2]interferon beta 1a[e2] 
+	(4, 14)	nephrosis	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2258	SUBSEQUENT COURSE: The [s1]nephrosis[e1] resolved almost completely once the [s2]interferon[e2] was stopped and after immunosuppressive treatment.
+	(25, 30)	renal toxicity	interferons	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2259	This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential [s1]renal toxicity[e1] of [s2]interferons[e2] in MS.
+	(0, 7)	Capecitabine	multifocal leukoencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2260	 [s1]Capecitabine[e1] induced [s2]multifocal leukoencephalopathy[e2]  a report of five cases.
+	(7, 14)	capecitabine	multifocal leukoencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2261	The authors report five additional cases of [s1]capecitabine[e1] induced [s2]multifocal leukoencephalopathy[e2] 
+	(16, 26)	UI	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2262	A 56-year-old white woman with a diagnosis of reactive depression developed severe [s1]UI[e1] after a 30 days' treatment with [s2]venlafaxine[e2] 75 mg/day.
+	(13, 24)	UI	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2263	The authors report a case of urinary incontinence  [s1]UI[e1]  that occurred in a woman after administration of [s2]venlafaxine[e2] 
+	(6, 26)	urinary incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2264	The authors report a case of [s1]urinary incontinence[e1] (UI) that occurred in a woman after administration of [s2]venlafaxine[e2] 
+	(0, 8)	Venlafaxine	urinary incontinence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2265	 [s1]Venlafaxine[e1] induced [s2]urinary incontinence[e2] resolved after switching to sertraline.
+	(2, 22)	hypothyroidism	alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2266	Diagnosis of [s1]hypothyroidism[e1] during treatment can be difficult because of the common side effects of [s2]alpha interferon[e2] 
+	(0, 11)	Sustained hypothyroidism	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2267	 [s1]Sustained hypothyroidism[e1] induced by [s2]recombinant alpha interferon[e2] in patients with chronic hepatitis C.
+	(0, 15)	Thyroid dysfunction	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2268	 [s1]Thyroid dysfunction[e1] has been reported in patients with malignant disease treated with [s2]recombinant alpha interferon[e2] 
+	(3, 19)	hypothyroidism	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2269	Two cases of [s1]hypothyroidism[e1] in patients with chronic hepatitis C treated with [s2]recombinant alpha interferon[e2] are reported.
+	(0, 8)	Atrial fibrillation	vardenafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2270	 [s1]Atrial fibrillation[e1] after [s2]vardenafil[e2] therapy.
+	(11, 35)	symptomatic paroxysmal atrial fibrillation	vardenafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2271	We report a case admitted with a first-detected, [s1]symptomatic paroxysmal atrial fibrillation[e1] in a healthy patient after self-medication with [s2]vardenafil[e2] 
+	(7, 26)	Mycobacterium abscessus	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2272	We describe a case of infection with [s1]Mycobacterium abscessus[e1] in a 67-year-old woman receiving [s2]infliximab[e2] as a component of her therapy for RA.
+	(2, 12)	Interferon alpha-2b	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2273	DIAGNOSIS: [s1]Interferon alpha-2b[e1] induced [s2]cardiomyopathy[e2] 
+	(0, 13)	Reversible cardiomyopathy	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2274	 [s1]Reversible cardiomyopathy[e1] caused by administration of [s2]interferon alpha[e2] 
+	(3, 32)	senna	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2275	In this case [s1]senna[e1] was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related [s2]liver injury[e2] 
+	(3, 13)	senna	subacute cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2276	In this case [s1]senna[e1] was likely the cause of a [s2]subacute cholestatic hepatitis[e2] exemplifying again the potential role of herbal related liver injury.
+	(0, 16)	Subacute cholestatic hepatitis	senna	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2277	 [s1]Subacute cholestatic hepatitis[e1] likely related to the use of [s2]senna[e2] for chronic constipation.
+	(5, 10)	senna	cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2278	We report a case of [s1]senna[e1] induced [s2]cholestatic hepatitis[e2] which was not diagnosed at presentation.
+	(11, 15)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2279	Based on the history and clinical features, a diagnosis of [s1]insulin[e1] induced [s2]lipohypertrophy[e2] was made.
+	(0, 4)	Insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2280	 [s1]Insulin[e1] induced [s2]lipohypertrophy[e2]  report of a case with histopathology.
+	(8, 25)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2281	Thus, the possible in vivo effects of [s1]insulin[e1] on adipocytes were clearly observed in this case of insulin-induced [s2]lipohypertrophy[e2] 
+	(10, 14)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2282	To our knowledge, this is the first report of [s1]insulin[e1] induced [s2]lipohypertrophy[e2] with detailed histological examinations.
+	(8, 35)	diabetes mellitus	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2283	A 7-year-old girl developed [s1]diabetes mellitus[e1] and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with [s2]azathioprine[e2] and/or prednisone for idiopathic auto-immune haemolytic anaemia.
+	(8, 42)	diabetes mellitus	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2284	A 7-year-old girl developed [s1]diabetes mellitus[e1] and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or [s2]prednisone[e2] for idiopathic auto-immune haemolytic anaemia.
+	(13, 35)	exocrine pancreatic insufficiency	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2285	A 7-year-old girl developed diabetes mellitus and [s1]exocrine pancreatic insufficiency[e1] after 3.5 years of almost continuous treatment with [s2]azathioprine[e2] and/or prednisone for idiopathic auto-immune haemolytic anaemia.
+	(13, 42)	exocrine pancreatic insufficiency	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2286	A 7-year-old girl developed diabetes mellitus and [s1]exocrine pancreatic insufficiency[e1] after 3.5 years of almost continuous treatment with azathioprine and/or [s2]prednisone[e2] for idiopathic auto-immune haemolytic anaemia.
+	(8, 19)	JHR	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2287	An objective causality assessment suggests that the [s1]JHR[e1] in our patient was probably related to [s2]penicillin[e2] 
+	(35, 47)	JHR	penicillin G	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2288	CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with [s1]JHR[e1] after an initial intravenous dose of [s2]penicillin G[e2] for presumed neurosyphilis.
+	(0, 6)	Penicillin	Jarisch-Herxheimer reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2289	 [s1]Penicillin[e1] induced [s2]Jarisch-Herxheimer reaction[e2] 
+	(10, 25)	chills	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2290	The patient described feeling cold with worsening headache and [s1]chills[e1] approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
+	(3, 25)	feeling cold	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2291	The patient described [s1]feeling cold[e1] with worsening headache and chills approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
+	(6, 25)	worsening headache	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2292	The patient described feeling cold with [s1]worsening headache[e1] and chills approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
+	(0, 7)	Acute respiratory distress syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2293	 [s1]Acute respiratory distress syndrome[e1] after [s2]rituximab[e2] infusion.
+	(0, 25)	ARDS	gemtuzumab ozogamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2294	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as infliximab, [s2]gemtuzumab ozogamicin[e2]  and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
+	(0, 19)	ARDS	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2295	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as [s2]infliximab[e2]  gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
+	(0, 36)	ARDS	OKT3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2296	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and [s2]OKT3[e2] and is believed to be directly mediated by release of proinflammatory cytokines.
+	(0, 8)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2297	 [s1]ARDS[e1] is rarely associated with [s2]rituximab[e2] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
+	(0, 8)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2298	 [s1]ARDS[e1] is rarely associated with [s2]rituximab[e2] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
+	(6, 45)	rituximab	severe pulmonary symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2299	ARDS is rarely associated with [s1]rituximab[e1] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops [s2]severe pulmonary symptoms[e2] soon after infusion.
+	(0, 22)	Dyspnea	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2300	 [s1]Dyspnea[e1]  hypoxemia, and pleuritic chest pain occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
+	(5, 22)	hypoxemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2301	Dyspnea, [s1]hypoxemia[e1]  and pleuritic chest pain occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
+	(11, 23)	pleuritic chest pain	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2302	Dyspnea, hypoxemia, and [s1]pleuritic chest pain[e1] occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
+	(0, 19)	Progressive hypoxemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2303	 [s1]Progressive hypoxemia[e1] mandated endotracheal intubation 1 week after [s2]rituximab[e2] administration and led to death 4 weeks after admission.
+	(33, 49)	acute respiratory distress syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2304	We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed [s1]acute respiratory distress syndrome[e1] (ARDS) after a single infusion of [s2]rituximab[e2] 
+	(37, 47)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2305	We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome  [s1]ARDS[e1]  after a single infusion of [s2]rituximab[e2] 
+	(11, 17)	renal impairment	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2306	Symptomatic hypocalcaemia and [s1]renal impairment[e1] associated with [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
+	(0, 17)	Symptomatic hypocalcaemia	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2307	 [s1]Symptomatic hypocalcaemia[e1] and renal impairment associated with [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
+	(5, 20)	severe hypocalcaemia	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2308	We report three cases of [s1]severe hypocalcaemia[e1] associated with i.v. [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
+	(0, 7)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2309	 [s1]Gemcitabine[e1] related [s2]radiation recall[e2] in a patient with pancreatic cancer.
+	(0, 17)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2310	 [s1]Gemcitabine[e1] should be added to the list of drugs known to cause [s2]radiation recall[e2] 
+	(0, 5)	Radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2311	 [s1]Radiation recall[e1] from [s2]gemcitabine[e2] is rare, but can potentially arise in any site that has been previously irradiated.
+	(0, 6)	Radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2312	 [s1]Radiation recall[e1] related to [s2]gemcitabine[e2] has been reported in lung and breast cancer.
+	(14, 28)	gastrointestinal bleeding	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2313	We report a patient with inoperable pancreatic cancer who developed [s1]gastrointestinal bleeding[e1] secondary to radiation-recall related to [s2]gemcitabine[e2] and review literature.
+	(21, 28)	radiation-recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2314	We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to [s1]radiation-recall[e1] related to [s2]gemcitabine[e2] and review literature.
+	(6, 13)	gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2315	We suggest discontinuing [s1]gemcitabine[e1] if [s2]radiation recall[e2] is observed.
+	(16, 32)	acute renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2316	A 17-year-old boy with acute lymphoblastic leukemia developed [s1]acute renal failure[e1] within 48 h of an intravenous high-dose [s2]methotrexate[e2] (5 g/m2) infusion.
+	(3, 11)	methotrexate	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2317	High-dose [s1]methotrexate[e1] associated [s2]acute renal failure[e2] may be an avoidable complication.
+	(0, 8)	Methotrexate	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2318	 [s1]Methotrexate[e1] associated [s2]nephropathy[e2] is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development.
+	(1, 22)	prolapse of the urethral mucosa	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2319	Massive [s1]prolapse of the urethral mucosa[e1] following periurethral injection of [s2]calcium hydroxylapatite[e2] for stress urinary incontinence.
+	(8, 34)	granulomatous reaction	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2320	The authors present a case report of a [s1]granulomatous reaction[e1] leading to urethral prolapse, 3 months after the transurethral injection of [s2]calcium hydroxylapatite[e2] 
+	(15, 33)	urethral prolapse	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2321	The authors present a case report of a granulomatous reaction leading to [s1]urethral prolapse[e1]  3 months after the transurethral injection of [s2]calcium hydroxylapatite[e2] 
+	(8, 17)	granulomatous reaction	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2322	To our knowledge, this is the first [s1]granulomatous reaction[e1] described after [s2]calcium hydroxylapatite[e2] injection.
+	(38, 56)	pancreatitis	furosemide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2323	"CASE SUMMARY: A 57-year-old female with cardiomyopathy and ""sulfa"" (trimethoprim/sulfamethoxazole) allergy documented as [s1]pancreatitis[e1] presented with symptoms consistent with pancreatitis after use of [s2]furosemide[e2] "
+	(12, 19)	pancreatitis	furosemide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2324	In addition, while cases of loop diuretic-induced [s1]pancreatitis[e1]  including [s2]furosemide[e2]  have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes.
+	(0, 20)	Torsemide	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2325	 [s1]Torsemide[e1] appears to also be a part of a long list of agents that can cause [s2]pancreatitis[e2] 
+	(0, 14)	Heparin	massive thrombosis of the inferior vena cava	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2326	 [s1]Heparin[e1] induced thrombocytopenia complicated with [s2]massive thrombosis of the inferior vena cava[e2] after filter placement.
+	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2327	 [s1]Heparin[e1] induced [s2]thrombocytopenia[e2] complicated with massive thrombosis of the inferior vena cava after filter placement.
+	(20, 30)	heparin	IVC thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2328	On the 3rd day, an inferior vena cava (IVC) filter was placed with a [s1]heparin[e1] flush, after which massive [s2]IVC thrombosis[e2] developed.
+	(9, 29)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2329	The patient was positive for antibody against complexes of [s1]heparin[e1] and platelet factor 4, and was diagnosed as heparin-induced [s2]thrombocytopenia[e2] with thrombosis syndrome (HITTS).
+	(9, 36)	heparin	thrombosis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2330	The patient was positive for antibody against complexes of [s1]heparin[e1] and platelet factor 4, and was diagnosed as heparin-induced thrombocytopenia with [s2]thrombosis syndrome[e2] (HITTS).
+	(1, 9)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2331	When [s1]thrombosis[e1] develops during [s2]heparin[e2] treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.
+	(1, 15)	gastric-outlet obstruction	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2332	After [s1]gastric-outlet obstruction[e1] was recognized in several infants who received [s2]prostaglandin E1[e2]  we studied the association between the drug and this complication.
+	(5, 26)	prostaglandin E1	antral hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2333	CONCLUSIONS: The administration of [s1]prostaglandin E1[e1] to neonates can cause gastric-outlet obstruction due to [s2]antral hyperplasia[e2] 
+	(5, 19)	prostaglandin E1	gastric-outlet obstruction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2334	CONCLUSIONS: The administration of [s1]prostaglandin E1[e1] to neonates can cause [s2]gastric-outlet obstruction[e2] due to antral hyperplasia.
+	(18, 39)	cisplatin	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2335	Moreover, treatment with immunosuppressive drugs such as cyclosporine, [s1]cisplatin[e1]  tacrolimus, and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
+	(12, 39)	cyclosporine	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2336	Moreover, treatment with immunosuppressive drugs such as [s1]cyclosporine[e1]  cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
+	(28, 40)	interferon-alpha	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2337	Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and [s1]interferon-alpha[e1] can induce a condition resembling [s2]RPLS[e2] 
+	(22, 39)	tacrolimus	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2338	Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, [s1]tacrolimus[e1]  and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
+	(0, 32)	Reversible posterior leukoencephalopathy syndrome	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2339	 [s1]Reversible posterior leukoencephalopathy syndrome[e1] in systemic lupus erythematosus with thrombocytopenia treated with [s2]cyclosporine[e2] 
+	(27, 34)	headache	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2340	We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, [s1]headache[e1]  and seizure after receiving [s2]cyclosporine[e2] 
+	(30, 35)	seizure	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2341	We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and [s1]seizure[e1] after receiving [s2]cyclosporine[e2] 
+	(21, 34)	severe perspiration	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2342	We report a case of a young woman with SLE and thrombocytopenia, who developed [s1]severe perspiration[e1]  headache, and seizure after receiving [s2]cyclosporine[e2] 
+	(11, 20)	mania	lopinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2343	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between [s2]lopinavir[e2] ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.
+	(11, 23)	mania	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2344	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir [s2]ritonavir[e2] and valproic acid (VPA) and propose a mechanism of action for this interaction.
+	(11, 29)	mania	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2345	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir/ritonavir and [s2]valproic acid[e2] (VPA) and propose a mechanism of action for this interaction.
+	(11, 33)	mania	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2346	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir/ritonavir and valproic acid  [s2]VPA[e2]  and propose a mechanism of action for this interaction.
+	(3, 21)	lopinavir	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2347	Possible interaction between [s1]lopinavir[e1] ritonavir and valproic Acid exacerbates [s2]bipolar disorder[e2] 
+	(6, 21)	ritonavir	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2348	Possible interaction between lopinavir [s1]ritonavir[e1] and valproic Acid exacerbates [s2]bipolar disorder[e2] 
+	(12, 22)	valproic Acid	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2349	Possible interaction between lopinavir/ritonavir and [s1]valproic Acid[e1] exacerbates [s2]bipolar disorder[e2] 
+	(7, 16)	triamcinolone acetonide	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2350	After intravitreal injection of [s1]triamcinolone acetonide[e1]  [s2]cataract[e2] may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years.
+	(0, 15)	Arthritis	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2351	 [s1]Arthritis[e1] and bursitis in multiple sclerosis patients treated with [s2]interferon-beta[e2] 
+	(2, 15)	bursitis	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2352	Arthritis and [s1]bursitis[e1] in multiple sclerosis patients treated with [s2]interferon-beta[e2] 
+	(11, 19)	inflammatory arthritis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2353	Our literature review revealed an additional six cases of onset of [s1]inflammatory arthritis[e1] in MS patients receiving [s2]IFN-beta[e2] 
+	(5, 16)	monoarthritis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2354	The first patient developed a [s1]monoarthritis[e1] 2 weeks after initiation of [s2]IFN-beta[e2]  which persisted during the 14 months of therapy and resolved with discontinuation of the medication.
+	(2, 16)	IFN-beta	autoimmune disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2355	Therapy with [s1]IFN-beta[e1] has rarely been associated with the development of [s2]autoimmune disorders[e2] 
+	(5, 29)	autoimmune thyroid disease	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2356	The second patient developed both [s1]autoimmune thyroid disease[e1] and a refractory pre-patellar bursitis after 50 months of [s2]IFN-beta[e2] therapy.
+	(13, 29)	refractory pre-patellar bursitis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2357	The second patient developed both autoimmune thyroid disease and a [s1]refractory pre-patellar bursitis[e1] after 50 months of [s2]IFN-beta[e2] therapy.
+	(28, 40)	inflammatory musculoskeletal manifestations	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2358	We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed [s1]inflammatory musculoskeletal manifestations[e1]  following [s2]IFN-beta[e2] therapy.
+	(0, 15)	Trimethoprim-sulfamethoxazole	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2359	 [s1]Trimethoprim-sulfamethoxazole[e1] induced [s2]aseptic meningitis[e2] 
+	(29, 51)	meningitis	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2360	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim/sulfamethoxazole (TMP [s2]SMX[e2] .
+	(29, 40)	meningitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2361	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim [s2]sulfamethoxazole[e2] (TMP/SMX).
+	(29, 48)	meningitis	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2362	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim/sulfamethoxazole  [s2]TMP[e2] SMX).
+	(29, 36)	meningitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2363	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using [s2]trimethoprim[e2] sulfamethoxazole (TMP/SMX).
+	(18, 23)	SMX	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2364	We reviewed the literature in an attempt to characterize the pattern and predictors of TMP [s1]SMX[e1] induced [s2]aseptic meningitis[e2] 
+	(16, 24)	TMP	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2365	We reviewed the literature in an attempt to characterize the pattern and predictors of [s1]TMP[e1] SMX-induced [s2]aseptic meningitis[e2] 
+	(20, 29)	corticosteroid	disseminated nocardiosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2366	In this paper, we report a patient with primary anti-phospholipid syndrome treated by [s1]corticosteroid[e1]  who developed [s2]disseminated nocardiosis[e2] 
+	(0, 8)	Chloroquine	bilateral ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2367	 [s1]Chloroquine[e1] induced [s2]bilateral ptosis[e2] 
+	(0, 8)	Ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2368	 [s1]Ptosis[e1] occurring 24 h after [s2]chloroquine[e2] therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.
+	(0, 8)	Ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2369	 [s1]Ptosis[e1] occurring 24 h after [s2]chloroquine[e2] therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.
+	(6, 13)	bilateral ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2370	This report describes a case of [s1]bilateral ptosis[e1] induced by [s2]chloroquine[e2] 
+	(27, 38)	central neurological syndrome	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2371	DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a [s1]central neurological syndrome[e1] within days of intrathecal [s2]MTX[e2] 
+	(11, 19)	methotrexate	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2372	Diffusion-weighted MRI correlates of subacute [s1]methotrexate[e1] related [s2]neurotoxicity[e2] 
+	(4, 22)	stroke-like leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2373	OBJECTIVES: A delayed [s1]stroke-like leukoencephalopathy[e1] has been observed in patients receiving [s2]methotrexate[e2] (MTX) for childhood leukemia.
+	(4, 27)	stroke-like leukoencephalopathy	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2374	OBJECTIVES: A delayed [s1]stroke-like leukoencephalopathy[e1] has been observed in patients receiving methotrexate  [s2]MTX[e2]  for childhood leukemia.
+	(18, 32)	subacute neurotoxicity	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2375	Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered [s1]subacute neurotoxicity[e1] after intrathecal [s2]MTX[e2] 
+	(6, 12)	ARDS	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2376	This is a rare case of [s1]ARDS[e1] associated with [s2]lithium[e2] intoxication.
+	(52, 65)	dyskinesias	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2377	"CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the ""indirect"" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced [s1]dyskinesias[e1] may differ from those involved in [s2]L-dopa[e2] induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop."
+	(4, 10)	levodopa	dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2378	Prior to surgery, [s1]levodopa[e1] induced [s2]dyskinesia[e2] had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.
+	(19, 26)	triazolam	eating disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2379	A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent [s1]triazolam[e1] induced [s2]eating disorder[e2] 
+	(0, 12)	Triazolam	amnesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2380	 [s1]Triazolam[e1] induced nocturnal bingeing with [s2]amnesia[e2] 
+	(0, 7)	Triazolam	nocturnal bingeing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2381	 [s1]Triazolam[e1] induced [s2]nocturnal bingeing[e2] with amnesia.
+	(13, 30)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2382	Although interferon gamma has been implicated in the pathogenesis of [s1]sarcoidosis[e1]  only a few cases of sarcoidosis associated with [s2]interferon alpha[e2] therapy have been reported.
+	(2, 9)	sarcoidosis	interferon alpha 2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2383	Development of [s1]sarcoidosis[e1] during [s2]interferon alpha 2b[e2] and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.
+	(2, 16)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2384	Development of [s1]sarcoidosis[e1] during interferon alpha 2b and [s2]ribavirin[e2] combination therapy for chronic hepatitis C--a case report and review of the literature.
+	(14, 24)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2385	We report a case with chronic hepatitis C (CHC) who developed [s1]sarcoidosis[e1] after the treatment by [s2]interferon alpha[e2] and ribavirin.
+	(14, 29)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2386	We report a case with chronic hepatitis C (CHC) who developed [s1]sarcoidosis[e1] after the treatment by interferon alpha and [s2]ribavirin[e2] 
+	(3, 17)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2387	We suggest that [s1]sarcoidosis[e1] may develop in chronic hepatitis C patients during [s2]interferon alpha[e2] and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.
+	(3, 24)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2388	We suggest that [s1]sarcoidosis[e1] may develop in chronic hepatitis C patients during interferon alpha and/or [s2]ribavirin[e2] treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.
+	(0, 20)	Neutropenic colitis	irinotecan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2389	 [s1]Neutropenic colitis[e1] during standard dose combination chemotherapy with nedaplatin and [s2]irinotecan[e2] for testicular cancer.
+	(0, 15)	Neutropenic colitis	nedaplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2390	 [s1]Neutropenic colitis[e1] during standard dose combination chemotherapy with [s2]nedaplatin[e2] and irinotecan for testicular cancer.
+	(9, 36)	severe hypercalcemia	cinacalcet HCl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2391	In this paper, we report a case of [s1]severe hypercalcemia[e1] of immobilization in a 40-year-old hemodialyzed woman treated by [s2]cinacalcet HCl[e2] for a severe HPTH-II (PTH>1,000 pg/mL).
+	(7, 13)	sirolimus	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2392	Here, we present a case of [s1]sirolimus[e1] associated [s2]interstitial pneumonitis[e2] in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.
+	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2393	Reversible [s1]sirolimus[e1] associated [s2]pneumonitis[e2] after heart transplantation.
+	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2394	Two cases of [s1]sirolimus[e1] associated [s2]pneumonitis[e2] have been reported after cardiac transplantation.
+	(16, 22)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2395	An objective causality assessment by use of the Naranjo probability scale revealed that [s1]NCSE[e1] due to [s2]ifosfamide[e2] was probable.
+	(9, 18)	ifosfamide	NCSE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2396	CASE SUMMARIES: Two patients who received [s1]ifosfamide[e1] containing chemotherapy developed [s2]NCSE[e2] 
+	(7, 13)	ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2397	CONCLUSIONS: Among the many presentations of [s1]ifosfamide[e1]  [s2]neurotoxicity[e2]  clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.
+	(0, 29)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2398	 [s1]NCSE[e1]  an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving [s2]ifosfamide[e2] 
+	(0, 14)	Nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2399	 [s1]Nonconvulsive status epilepticus[e1] due to [s2]ifosfamide[e2] 
+	(17, 25)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2400	OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus  [s1]NCSE[e1]  following infusion of [s2]ifosfamide[e2] 
+	(7, 27)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2401	OBJECTIVE: To report 2 cases of [s1]nonconvulsive status epilepticus[e1] (NCSE) following infusion of [s2]ifosfamide[e2] 
+	(8, 14)	gelatine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2402	We describe a case of intraoperative [s1]gelatine[e1] induced [s2]anaphylaxis[e2] whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.
+	(8, 14)	gelatine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2403	We describe a case of intraoperative [s1]gelatine[e1] induced [s2]anaphylaxis[e2] whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.
+	(0, 14)	Cutaneous mycobacterial infection	BCG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2404	 [s1]Cutaneous mycobacterial infection[e1] post intravesical [s2]BCG[e2] installation.
+	(0, 13)	Disseminated tuberculous lesions	BCG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2405	 [s1]Disseminated tuberculous lesions[e1] post intravesical [s2]BCG[e2] therapy are rare but need to be identified and treated quickly.
+	(3, 13)	hypersensitivity rash	HCQ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2406	Some patients develop [s1]hypersensitivity rash[e1] in response to [s2]HCQ[e2] 
+	(2, 36)	sumatriptan	symptomatic cerebral vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2407	Administration of [s1]sumatriptan[e1] in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce [s2]symptomatic cerebral vasospasm[e2] with potentially dangerous consequences.
+	(9, 22)	diabetic ketoacidosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2408	METHOD: We describe two patients who presented with [s1]diabetic ketoacidosis[e1] after treatment with [s2]quetiapine[e2] and risperidone, respectively.
+	(9, 26)	diabetic ketoacidosis	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2409	METHOD: We describe two patients who presented with [s1]diabetic ketoacidosis[e1] after treatment with quetiapine and [s2]risperidone[e2]  respectively.
+	(56, 93)	atypical lymphocytosis	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2410	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(56, 85)	atypical lymphocytosis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2411	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(56, 81)	atypical lymphocytosis	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2412	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(56, 77)	atypical lymphocytosis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2413	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(39, 93)	cervical lymphadenopathy	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2414	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(39, 85)	cervical lymphadenopathy	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2415	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(39, 81)	cervical lymphadenopathy	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2416	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(39, 77)	cervical lymphadenopathy	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2417	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(67, 94)	eosinophilia	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2418	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(67, 86)	eosinophilia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2419	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(67, 82)	eosinophilia	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2420	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(67, 78)	eosinophilia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2421	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(34, 93)	fever	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2422	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(34, 85)	fever	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2423	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(34, 81)	fever	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2424	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(34, 77)	fever	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2425	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(47, 93)	hepatosplenomegaly	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2426	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(47, 85)	hepatosplenomegaly	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2427	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(47, 81)	hepatosplenomegaly	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2428	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(47, 77)	hepatosplenomegaly	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2429	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(36, 93)	skin eruptions	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2430	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
+	(36, 85)	skin eruptions	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2431	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
+	(36, 81)	skin eruptions	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2432	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
+	(36, 77)	skin eruptions	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2433	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
+	(6, 14)	TMP-SMX	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2434	This is the first case of [s1]TMP-SMX[e1] induced [s2]hypersensitivity syndrome[e2] associated with the reactivation of a latent viral infection.
+	(0, 15)	Trimethoprim-sulfamethoxazole	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2435	 [s1]Trimethoprim-sulfamethoxazole[e1] induced [s2]hypersensitivity syndrome[e2] associated with reactivation of human herpesvirus-6.
+	(8, 16)	corticosteroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2436	PURPOSE: To report a case of severe [s1]corticosteroid[e1] induced [s2]glaucoma[e2] after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.
+	(15, 28)	glaucoma	triamcinolone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2437	PURPOSE: To report a case of severe corticosteroid-induced [s1]glaucoma[e1] after intravitreal injection of [s2]triamcinolone acetate[e2] in a 34-year-old man without a history of glaucoma.
+	(14, 29)	severe vision loss	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2438	RESULTS: A 34-year-old man acquired visual field defects and [s1]severe vision loss[e1] in both eyes after intravitreal injection of [s2]triamcinolone[e2] for diabetic macular edema.
+	(10, 29)	visual field defects	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2439	RESULTS: A 34-year-old man acquired [s1]visual field defects[e1] and severe vision loss in both eyes after intravitreal injection of [s2]triamcinolone[e2] for diabetic macular edema.
+	(1, 6)	steroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2440	Severe [s1]steroid[e1] induced [s2]glaucoma[e2] following intravitreal injection of triamcinolone acetonide.
+	(5, 18)	glaucoma	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2441	Severe steroid-induced [s1]glaucoma[e1] following intravitreal injection of [s2]triamcinolone acetonide[e2] 
+	(16, 24)	corticosteroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2442	This treatment has the potential to cause severe vision loss as a result of intractable [s1]corticosteroid[e1] induced [s2]glaucoma[e2] 
+	(7, 18)	severe vision loss	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2443	This treatment has the potential to cause [s1]severe vision loss[e1] as a result of intractable [s2]corticosteroid[e2] induced glaucoma.
+	(0, 20)	Autoimmune thyroid disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2444	 [s1]Autoimmune thyroid disease[e1] is a common side-effect of interferon-alpha  [s2]IFN-alpha[e2]  treatment of viral hepatitis C.
+	(0, 15)	Autoimmune thyroid disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2445	 [s1]Autoimmune thyroid disease[e1] is a common side-effect of [s2]interferon-alpha[e2] (IFN-alpha) treatment of viral hepatitis C.
+	(13, 21)	IFN-alpha	Graves' hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2446	Destructive thyrotoxicosis appeared 4-6 months after starting [s1]IFN-alpha[e1]  followed by [s2]Graves' hyperthyroidism[e2] within 8 to 11 months.
+	(1, 15)	thyrotoxicosis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2447	Destructive [s1]thyrotoxicosis[e1] appeared 4-6 months after starting [s2]IFN-alpha[e2]  followed by Graves' hyperthyroidism within 8 to 11 months.
+	(2, 10)	hyperthyroidism	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2448	Hence, [s1]hyperthyroidism[e1] induced by [s2]IFN-alpha[e2] could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both.
+	(0, 8)	Interferon-alpha	hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2449	 [s1]Interferon-alpha[e1] induced [s2]hyperthyroidism[e2]  a three-stage evolution from silent thyroiditis towards Graves' disease.
+	(10, 34)	IFN-alpha	hyperthryroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2450	We have described three patients with hepatitis C for whom [s1]IFN-alpha[e1] and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by [s2]hyperthryroidism[e2] relapse due to Graves' disease.
+	(15, 34)	ribavirin	hyperthryroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2451	We have described three patients with hepatitis C for whom IFN-alpha and [s1]ribavirin[e1] were prescribed and who developed two successive phases of silent thyroiditis followed by [s2]hyperthryroidism[e2] relapse due to Graves' disease.
+	(10, 30)	IFN-alpha	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2452	We have described three patients with hepatitis C for whom [s1]IFN-alpha[e1] and ribavirin were prescribed and who developed two successive phases of silent [s2]thyroiditis[e2] followed by hyperthryroidism relapse due to Graves' disease.
+	(15, 30)	ribavirin	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2453	We have described three patients with hepatitis C for whom IFN-alpha and [s1]ribavirin[e1] were prescribed and who developed two successive phases of silent [s2]thyroiditis[e2] followed by hyperthryroidism relapse due to Graves' disease.
+	(0, 40)	Dipyrone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2454	 [s1]Dipyrone[e1]  also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with [s2]agranulocytosis[e2] 
+	(7, 40)	metamizole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2455	Dipyrone, also known as [s1]metamizole[e1]  is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with [s2]agranulocytosis[e2] 
+	(0, 6)	Dipyrone	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2456	 [s1]Dipyrone[e1] induced [s2]granulocytopenia[e2]  a case for awareness.
+	(6, 17)	granulocytopenia	dipyrone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2457	We describe a patient who developed [s1]granulocytopenia[e1] and fever after taking [s2]dipyrone[e2] and discuss the available literature.
+	(10, 28)	CD8+ cutaneous lymphoproliferative disorders	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2458	Herein, we describe 2 patients who developed unusual [s1]CD8+ cutaneous lymphoproliferative disorders[e1] after treatment with [s2]efalizumab[e2] and infliximab.
+	(10, 35)	CD8+ cutaneous lymphoproliferative disorders	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2459	Herein, we describe 2 patients who developed unusual [s1]CD8+ cutaneous lymphoproliferative disorders[e1] after treatment with efalizumab and [s2]infliximab[e2] 
+	(16, 45)	pyrimethamine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2460	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, [s2]abdominal pain[e2] and transaminitis, persisting weeks after withholding medicines.
+	(22, 45)	sulfadiazine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2461	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, [s2]abdominal pain[e2] and transaminitis, persisting weeks after withholding medicines.
+	(16, 36)	pyrimethamine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2462	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed [s2]fever[e2]  severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(22, 36)	sulfadiazine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2463	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed [s2]fever[e2]  severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(16, 38)	pyrimethamine	severe cutaneous involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2464	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, [s2]severe cutaneous involvement[e2]  swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(22, 38)	sulfadiazine	severe cutaneous involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2465	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, [s2]severe cutaneous involvement[e2]  swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(16, 43)	pyrimethamine	swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2466	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, [s2]swelling[e2]  abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(22, 43)	sulfadiazine	swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2467	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, [s2]swelling[e2]  abdominal pain and transaminitis, persisting weeks after withholding medicines.
+	(16, 48)	pyrimethamine	transaminitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2468	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and [s2]transaminitis[e2]  persisting weeks after withholding medicines.
+	(22, 48)	sulfadiazine	transaminitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2469	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and [s2]transaminitis[e2]  persisting weeks after withholding medicines.
+	(1, 7)	sulfadiazine	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2470	Severe [s1]sulfadiazine[e1]  [s2]hypersensitivity[e2] in a child with reactivated congenital toxoplasmic chorioretinitis.
+	(10, 16)	sulfadiazine	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2471	This case underscores problems in clinical management with [s1]sulfadiazine[e1]  [s2]hypersensitivity[e2]  potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis.
+	(0, 44)	Fatal lung fibrosis	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2472	 [s1]Fatal lung fibrosis[e1] caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and [s2]carboplatin[e2] as combination chemotherapy for advanced ovarian cancer.
+	(0, 9)	Fatal lung fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2473	 [s1]Fatal lung fibrosis[e1] caused by [s2]paclitaxel[e2] toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.
+	(0, 9)	Fatal lung fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2474	 [s1]Fatal lung fibrosis[e1] caused by [s2]paclitaxel[e2] toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.
+	(0, 9)	Fatal pulmonary fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2475	 [s1]Fatal pulmonary fibrosis[e1] induced by [s2]paclitaxel[e2]  a case report and review of the literature.
+	(10, 27)	paclitaxel	lung fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2476	Physicians should keep in mind that taxanes such as [s1]paclitaxel[e1] have the potential to cause pneumonitis and [s2]lung fibrosis[e2] 
+	(10, 21)	paclitaxel	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2477	Physicians should keep in mind that taxanes such as [s1]paclitaxel[e1] have the potential to cause [s2]pneumonitis[e2] and lung fibrosis.
+	(0, 11)	Pulmonary fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2478	 [s1]Pulmonary fibrosis[e1] is a complication of [s2]paclitaxel[e2] therapy that may occur despite treatments with corticosteroids.
+	(0, 12)	Infections	anti-TNF-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2479	 [s1]Infections[e1] are a major adverse effect during the treatment with [s2]anti-TNF-alpha[e2] 
+	(19, 33)	subfulminant hepatitis B	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2480	In this case report, we have described a patient with Crohn's disease who developed [s1]subfulminant hepatitis B[e1] after the fourth infusion of [s2]infliximab[e2] due to an unrecognized HBs-antigen carrier state.
+	(0, 9)	Subfulminant hepatitis B	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2481	 [s1]Subfulminant hepatitis B[e1] after [s2]infliximab[e2] in Crohn's disease: need for HBV-screening?
+	(0, 15)	Acute unilateral total visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2482	 [s1]Acute unilateral total visual loss[e1] after retrogasserian [s2]phenol[e2] injection for the treatment of trigeminal neuralgia: a case report.
+	(10, 15)	phenol	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2483	The visual loss in this patient seems to result from [s1]phenol[e1]  [s2]neurotoxicity[e2] rather than mechanical compression of the intraorbital optic nerve.
+	(1, 12)	visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2484	The [s1]visual loss[e1] in this patient seems to result from [s2]phenol[e2] neurotoxicity rather than mechanical compression of the intraorbital optic nerve.
+	(11, 26)	acute unilateral total visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2485	We report a 78-year-old man who had [s1]acute unilateral total visual loss[e1] after retrogasserian [s2]phenol[e2] injection for the treatment of trigeminal neuralgia.
+	(2, 13)	liver injury	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2486	Drug induced [s1]liver injury[e1] secondary to interferon-beta  [s2]IFN-beta[e2]  in multiple sclerosis.
+	(2, 8)	liver injury	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2487	Drug induced [s1]liver injury[e1] secondary to [s2]interferon-beta[e2] (IFN-beta) in multiple sclerosis.
+	(0, 40)	Grade 3 hepatotoxicity	IFN beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2488	 [s1]Grade 3 hepatotoxicity[e1] (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on [s2]IFN beta[e2] 
+	(9, 29)	IFN beta	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2489	Post marketing studies of Interferon-beta  [s1]IFN beta[e1]  therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of [s2]hepatotoxicity[e2] 
+	(4, 31)	Interferon-beta	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2490	Post marketing studies of [s1]Interferon-beta[e1] (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of [s2]hepatotoxicity[e2] 
+	(5, 11)	IFN beta	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2491	We report three cases of [s1]IFN beta[e1] induced [s2]hepatitis[e2] in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.
+	(5, 26)	IFN beta	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2492	We report three cases of [s1]IFN beta[e1] induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced [s2]liver injury[e2] 
+	(11, 33)	acute urticaria	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2493	A 55-year-old woman presented an episode of [s1]acute urticaria[e1] and labial angioedema 60 minutes after ingesting 500 mg of [s2]cloxacillin[e2] for a skin abscess.
+	(16, 33)	labial angioedema	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2494	A 55-year-old woman presented an episode of acute urticaria and [s1]labial angioedema[e1] 60 minutes after ingesting 500 mg of [s2]cloxacillin[e2] for a skin abscess.
+	(0, 5)	Allergy	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2495	 [s1]Allergy[e1] to [s2]cloxacillin[e2] with normal tolerance to amoxicillin and cefuroxime.
+	(1, 9)	hypersensitivity	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2496	Several [s1]hypersensitivity[e1] reactions to [s2]cloxacillin[e2] have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.
+	(7, 19)	cloxacillin	IgE-mediated allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2497	Several hypersensitivity reactions to [s1]cloxacillin[e1] have been reported, although [s2]IgE-mediated allergic reactions[e2] to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.
+	(0, 6)	Cardiac toxicity	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2498	 [s1]Cardiac toxicity[e1] related to [s2]BCNU[e2] has not been described well.
+	(0, 13)	Myocardial ischemia	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2499	 [s1]Myocardial ischemia[e1] associated with high-dose [s2]carmustine[e2] infusion.
+	(23, 35)	myocardial ischemia	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2500	Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of [s1]myocardial ischemia[e1] during and immediately after [s2]BCNU[e2] infusion.
+	(6, 12)	aspirin	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2501	Adverse reaction in a patient with [s1]aspirin[e1] induced [s2]asthma[e2] treated with zafirlukast.
+	(5, 15)	hypereosinophilia	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2502	We present a case of [s1]hypereosinophilia[e1] related to [s2]zafirlukast[e2] therapy.
+	(7, 27)	pegfilgrastim	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2503	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, rapidly progressive erythema, [s2]edema[e2]  and pain in his right forearm.
+	(7, 31)	pegfilgrastim	pain in his right forearm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2504	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, rapidly progressive erythema, edema, and [s2]pain in his right forearm[e2] 
+	(7, 21)	pegfilgrastim	rapidly progressive erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2505	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, [s2]rapidly progressive erythema[e2]  edema, and pain in his right forearm.
+	(10, 21)	myasthenic syndrome	statin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2506	A few recent individual case reports have suggested that a [s1]myasthenic syndrome[e1] may be associated with [s2]statin[e2] treatment, but this association is not well described.
+	(0, 5)	Statin	myasthenia gravis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2507	 [s1]Statin[e1] associated [s2]myasthenia gravis[e2]  report of 4 cases and review of the literature.
+	(8, 25)	myasthenia gravis	statin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2508	We report 4 patients who developed symptoms of [s1]myasthenia gravis[e1] within 2 weeks of starting treatment with a [s2]statin[e2] drug.
+	(0, 31)	Reactivation of cytomegalovirus	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2509	 [s1]Reactivation of cytomegalovirus[e1] probably followed the treatment of Wegener's granulomatosis with corticosteroids and [s2]azathioprine[e2] 
+	(11, 22)	HCQ	ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2510	After excluding other causes of long QT syndrome, the [s1]HCQ[e1] was suspected as the cause of her [s2]ventricular tachycardia[e2] 
+	(1, 13)	hydroxychloroquine	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2511	Chronic [s1]hydroxychloroquine[e1] use associated with [s2]QT prolongation[e2] and refractory ventricular arrhythmia.
+	(1, 19)	hydroxychloroquine	refractory ventricular arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2512	Chronic [s1]hydroxychloroquine[e1] use associated with QT prolongation and [s2]refractory ventricular arrhythmia[e2] 
+	(6, 35)	HCQ	cardiac arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2513	CONCLUSION: The chronic use of [s1]HCQ[e1] for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal [s2]cardiac arrhythmias[e2] 
+	(8, 14)	HCQ	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2514	We report a case of chronic use of [s1]HCQ[e1] associated with [s2]torsade de pointes[e2] 
+	(13, 24)	metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2515	CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with [s1]metformin[e1] might result in more cases of [s2]lactic acidosis[e2] 
+	(0, 8)	Severe acidosis	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2516	 [s1]Severe acidosis[e1] in patients taking [s2]metformin[e2] -rapid reversal and survival despite high APACHE score.
+	(7, 26)	diabetes	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2517	Case report: lack of control of [s1]diabetes[e1] and weight gain in a patient on initiation and rechallenge of therapy with [s2]olanzapine[e2] 
+	(9, 26)	weight gain	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2518	Case report: lack of control of diabetes and [s1]weight gain[e1] in a patient on initiation and rechallenge of therapy with [s2]olanzapine[e2] 
+	(24, 34)	olanzapine	uncontrolled diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2519	The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of [s1]olanzapine[e1] to metabolic changes manifested as [s2]uncontrolled diabetes mellitus[e2] and weight gain.
+	(24, 43)	olanzapine	weight gain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2520	The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of [s1]olanzapine[e1] to metabolic changes manifested as uncontrolled diabetes mellitus and [s2]weight gain[e2] 
+	(20, 32)	olanzapine	uncontrolled diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2521	The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, [s1]olanzapine[e1] was discontinued because of weight gain and [s2]uncontrolled diabetes[e2] 
+	(20, 29)	olanzapine	weight gain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2522	The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, [s1]olanzapine[e1] was discontinued because of [s2]weight gain[e2] and uncontrolled diabetes.
+	(13, 25)	Enterobacter keratitis	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2523	PURPOSE: To report a case of traumatic flap dehiscence and [s1]Enterobacter keratitis[e1] 34 months after [s2]LASIK[e2] 
+	(7, 25)	traumatic flap dehiscence	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2524	PURPOSE: To report a case of [s1]traumatic flap dehiscence[e1] and Enterobacter keratitis 34 months after [s2]LASIK[e2] 
+	(7, 17)	Enterobacter keratitis	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2525	Traumatic late flap dehiscence and [s1]Enterobacter keratitis[e1] following [s2]LASIK[e2] 
+	(0, 17)	Traumatic late flap dehiscence	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2526	 [s1]Traumatic late flap dehiscence[e1] and Enterobacter keratitis following [s2]LASIK[e2] 
+	(26, 33)	BOOP	docetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2527	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with [s1]BOOP[e1] after chemotherapy with [s2]docetaxel[e2] and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.
+	(26, 38)	BOOP	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2528	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with [s1]BOOP[e1] after chemotherapy with docetaxel and [s2]gemcitabine[e2] producing severe respiratory insufficiency, and simulating a progression of the tumor.
+	(31, 54)	docetaxel	progression of the tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2529	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with [s1]docetaxel[e1] and gemcitabine producing severe respiratory insufficiency, and simulating a [s2]progression of the tumor[e2] 
+	(36, 54)	gemcitabine	progression of the tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2530	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and [s1]gemcitabine[e1] producing severe respiratory insufficiency, and simulating a [s2]progression of the tumor[e2] 
+	(31, 43)	docetaxel	severe respiratory insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2531	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with [s1]docetaxel[e1] and gemcitabine producing [s2]severe respiratory insufficiency[e2]  and simulating a progression of the tumor.
+	(36, 43)	gemcitabine	severe respiratory insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2532	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and [s1]gemcitabine[e1] producing [s2]severe respiratory insufficiency[e2]  and simulating a progression of the tumor.
+	(8, 33)	warfarin	bloody tears	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2533	A 65-year-old man on [s1]warfarin[e1] therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with [s2]bloody tears[e2] was assessed in the clinic following a referral from an optometrist.
+	(8, 20)	warfarin	sub-conjunctival haematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2534	A 65-year-old man on [s1]warfarin[e1] therapy with a sudden spontaneous onset of [s2]sub-conjunctival haematoma[e2] associated with bloody tears was assessed in the clinic following a referral from an optometrist.
+	(5, 22)	sub-conjunctival haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2535	An unusual presentation of spontaneous [s1]sub-conjunctival haematoma[e1] in a patient receiving [s2]warfarin[e2] 
+	(4, 24)	diplopia	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2536	Due to discomfort, [s1]diplopia[e1] and lagophthalmos, the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
+	(2, 23)	discomfort	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2537	Due to [s1]discomfort[e1]  diplopia and lagophthalmos, the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
+	(15, 24)	haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2538	Due to discomfort, diplopia and lagophthalmos, the [s1]haematoma[e1] necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
+	(8, 23)	lagophthalmos	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2539	Due to discomfort, diplopia and [s1]lagophthalmos[e1]  the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
+	(1, 18)	sub-conjunctival haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2540	The [s1]sub-conjunctival haematoma[e1] in a patient receiving [s2]warfarin[e2] can pose a significant management challenge.
+	(0, 15)	Angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2541	 [s1]Angioedema[e1] and maculopapular eruptions associated with [s2]carbamazepine[e2] administration.
+	(5, 15)	maculopapular eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2542	Angioedema and [s1]maculopapular eruptions[e1] associated with [s2]carbamazepine[e2] administration.
+	(0, 11)	Angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2543	 [s1]Angioedema[e1]  a rare side effect of [s2]carbamazepine[e2]  involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins.
+	(0, 12)	Cutaneous eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2544	 [s1]Cutaneous eruptions[e1] occur in 3% of individuals administered [s2]carbamazepine[e2] 
+	(0, 16)	Cutaneous rashes	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2545	 [s1]Cutaneous rashes[e1] and eruptions can be caused by many medications, including [s2]carbamazepine[e2] 
+	(5, 16)	eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2546	Cutaneous rashes and [s1]eruptions[e1] can be caused by many medications, including [s2]carbamazepine[e2] 
+	(22, 30)	angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2547	We report the case of a 27-year-old Indian woman who developed maculopapular rash and [s1]angioedema[e1] secondary to [s2]carbamazepine[e2] administration.
+	(15, 30)	maculopapular rash	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2548	We report the case of a 27-year-old Indian woman who developed [s1]maculopapular rash[e1] and angioedema secondary to [s2]carbamazepine[e2] administration.
+	(5, 10)	AVP	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2549	Severe adenovirus pneumonia  [s1]AVP[e1]  following [s2]infliximab[e2] infusion for the treatment of Crohn's disease.
+	(0, 12)	Severe adenovirus pneumonia	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2550	 [s1]Severe adenovirus pneumonia[e1] (AVP) following [s2]infliximab[e2] infusion for the treatment of Crohn's disease.
+	(5, 16)	severe AVP	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2551	We report a case of [s1]severe AVP[e1] three weeks following the administration of [s2]infliximab[e2] for the treatment of Crohn's disease (CD).
+	(3, 11)	ivermectin	severe hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2552	First case of [s1]ivermectin[e1] induced [s2]severe hepatitis[e2] 
+	(10, 18)	ivermectin	severe liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2553	To our knowledge, this is the first case of [s1]ivermectin[e1] induced [s2]severe liver disease[e2] published in the literature.
+	(27, 39)	severe hepatitis	ivermectin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2554	We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed [s1]severe hepatitis[e1]  identified 1 month after a single dose of [s2]ivermectin[e2] 
+	(16, 23)	myositis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2555	CASE REPORT: We hereby report a case of radiation recall dermatitis and [s1]myositis[e1] occurring on [s2]gemcitabine[e2] monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.
+	(10, 23)	radiation recall dermatitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2556	CASE REPORT: We hereby report a case of [s1]radiation recall dermatitis[e1] and myositis occurring on [s2]gemcitabine[e2] monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.
+	(10, 17)	gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2557	CONCLUSIONS: This is the second case report that describes [s1]gemcitabine[e1] induced [s2]radiation recall[e2] in rectus abdominus muscles after gemcitabine-based radiation therapy.
+	(0, 7)	Gemcitabine	rectus abdominus radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2558	 [s1]Gemcitabine[e1] induced [s2]rectus abdominus radiation recall[e2] 
+	(0, 11)	Sporadic rippling muscle disease	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2559	 [s1]Sporadic rippling muscle disease[e1] unmasked by [s2]simvastatin[e2] 
+	(12, 26)	rippling muscle disease	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2560	We report a 53-year-old-man who developed [s1]rippling muscle disease[e1] (RMD) 2 months after starting [s2]simvastatin[e2] therapy for hypercholesterolemia.
+	(16, 24)	RMD	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2561	We report a 53-year-old-man who developed rippling muscle disease  [s1]RMD[e1]  2 months after starting [s2]simvastatin[e2] therapy for hypercholesterolemia.
+	(0, 8)	Acute coronary syndrome	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2562	 [s1]Acute coronary syndrome[e1] induced by [s2]capecitabine[e2] therapy.
+	(7, 18)	acute coronary syndrome	Capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2563	This case highlights the possible development of [s1]acute coronary syndrome[e1] as a side effect of [s2]Capecitabine[e2] therapy.
+	(6, 18)	carbamazepine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2564	Acute severe intoxication with [s1]carbamazepine[e1] is associated with seizures, [s2]coma[e2] and respiratory depression.
+	(6, 20)	carbamazepine	respiratory depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2565	Acute severe intoxication with [s1]carbamazepine[e1] is associated with seizures, coma and [s2]respiratory depression[e2] 
+	(6, 16)	carbamazepine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2566	Acute severe intoxication with [s1]carbamazepine[e1] is associated with [s2]seizures[e2]  coma and respiratory depression.
+	(8, 17)	pegvisomant	hepatic enzyme disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2567	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the [s2]hepatic enzyme disturbances[e2] reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.
+	(8, 17)	pegvisomant	hepatic enzyme disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2568	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the [s2]hepatic enzyme disturbances[e2] reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.
+	(8, 64)	pegvisomant	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2569	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced [s2]hepatitis[e2] 
+	(3, 22)	hepatitis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2570	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with pegvisomant and [s2]octreotide[e2] long-acting repeatable attributed to the use of pegvisomant.
+	(3, 17)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2571	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with [s2]pegvisomant[e2] and octreotide long-acting repeatable attributed to the use of pegvisomant.
+	(3, 17)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2572	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with [s2]pegvisomant[e2] and octreotide long-acting repeatable attributed to the use of pegvisomant.
+	(1, 16)	hepatic enzyme disturbances	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2573	The [s1]hepatic enzyme disturbances[e1] normalized after discontinuation of [s2]pegvisomant[e2] 
+	(16, 33)	hepatitis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2574	We report on a patient with acromegaly who developed severe drug-induced [s1]hepatitis[e1] during combined treatment with the long-acting somatostatin-analog [s2]octreotide[e2] and the GH receptor antagonist pegvisomant.
+	(16, 42)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2575	We report on a patient with acromegaly who developed severe drug-induced [s1]hepatitis[e1] during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist [s2]pegvisomant[e2] 
+	(5, 23)	AmB	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2576	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, [s2]anaemia[e2]  fever, malaise, and hypokalaemia are common.
+	(0, 25)	Amphotericin B	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2577	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, [s2]anaemia[e2]  fever, malaise, and hypokalaemia are common.
+	(5, 26)	AmB	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2578	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, [s2]fever[e2]  malaise, and hypokalaemia are common.
+	(0, 28)	Amphotericin B	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2579	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, [s2]fever[e2]  malaise, and hypokalaemia are common.
+	(5, 32)	AmB	hypokalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2580	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and [s2]hypokalaemia[e2] are common.
+	(0, 34)	Amphotericin B	hypokalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2581	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and [s2]hypokalaemia[e2] are common.
+	(5, 28)	AmB	malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2582	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, [s2]malaise[e2]  and hypokalaemia are common.
+	(0, 30)	Amphotericin B	malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2583	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, [s2]malaise[e2]  and hypokalaemia are common.
+	(5, 20)	AmB	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2584	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: [s2]renal impairment[e2]  anaemia, fever, malaise, and hypokalaemia are common.
+	(0, 22)	Amphotericin B	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2585	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: [s2]renal impairment[e2]  anaemia, fever, malaise, and hypokalaemia are common.
+	(3, 60)	temozolomide	brain abscess with Listeria monocytogenes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2586	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, [s2]brain abscess with Listeria monocytogenes[e2]  and cutaneous Kaposi's sarcoma.
+	(3, 74)	temozolomide	cutaneous Kaposi's sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2587	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and [s2]cutaneous Kaposi's sarcoma[e2] 
+	(3, 11)	temozolomide	immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2588	DIAGNOSIS: Severe [s1]temozolomide[e1] induced [s2]immunosuppression[e2]  exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
+	(3, 47)	temozolomide	infections with Pneumocystis jiroveci pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2589	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic [s2]infections with Pneumocystis jiroveci pneumonia[e2]  brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
+	(3, 31)	temozolomide	T-cell lymphocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2590	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound [s2]T-cell lymphocytopenia[e2] and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
+	(15, 26)	Kaposi's sarcoma	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2591	Listeria brain abscess, Pneumocystis pneumonia and [s1]Kaposi's sarcoma[e1] after [s2]temozolomide[e2] 
+	(0, 25)	Listeria brain abscess	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2592	 [s1]Listeria brain abscess[e1]  Pneumocystis pneumonia and Kaposi's sarcoma after [s2]temozolomide[e2] 
+	(7, 26)	Pneumocystis pneumonia	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2593	Listeria brain abscess, [s1]Pneumocystis pneumonia[e1] and Kaposi's sarcoma after [s2]temozolomide[e2] 
+	(2, 8)	Topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2594	PURPOSE: [s1]Topiramate[e1] induced [s2]angle-closure glaucoma[e2] (TiACG) is believed to be related to its sulfonamide moiety.
+	(8, 25)	angle-closure glaucoma	mannitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2595	Rapid resolution of topiramate-induced [s1]angle-closure glaucoma[e1] with methylprednisolone and [s2]mannitol[e2] 
+	(8, 18)	angle-closure glaucoma	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2596	Rapid resolution of topiramate-induced [s1]angle-closure glaucoma[e1] with [s2]methylprednisolone[e2] and mannitol.
+	(3, 9)	topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2597	Rapid resolution of [s1]topiramate[e1] induced [s2]angle-closure glaucoma[e2] with methylprednisolone and mannitol.
+	(0, 11)	Spontaneous splenic infarction	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2598	 [s1]Spontaneous splenic infarction[e1] associated with [s2]sumatriptan[e2] use.
+	(14, 26)	myocardial infarction	triptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2599	Though they are generally considered safe, there have been a few reports of [s1]myocardial infarction[e1] and stroke associated with [s2]triptan[e2] use.
+	(21, 26)	stroke	triptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2600	Though they are generally considered safe, there have been a few reports of myocardial infarction and [s1]stroke[e1] associated with [s2]triptan[e2] use.
+	(6, 19)	spontaneous splenic infarction	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2601	We report a patient who developed [s1]spontaneous splenic infarction[e1] after the use of [s2]sumatriptan[e2] for the treatment of migraine headache.
+	(0, 13)	Acute myocardial infarction	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2602	 [s1]Acute myocardial infarction[e1] during high-dose [s2]methylprednisolone[e2] therapy for Graves' ophthalmopathy.
+	(1, 10)	hypothyroidism	radioiodine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2603	Except [s1]hypothyroidism[e1] after [s2]radioiodine[e2] treatment (euthyroid under substitutional therapy), she suffered from no other diseases.
+	(13, 44)	methylprednisolone	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2604	Here we present the case of a woman who received high doses of [s1]methylprednisolone[e1] (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by [s2]myocardial infarction[e2] on the fifth day of treatment.
+	(13, 39)	methylprednisolone	severe hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2605	Here we present the case of a woman who received high doses of [s1]methylprednisolone[e1] (1 g iv daily) for active Graves' ophthalmopathy, and developed [s2]severe hypertension[e2] followed by myocardial infarction on the fifth day of treatment.
+	(3, 20)	myocardial infarction	glucocorticoids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2606	We conclude that [s1]myocardial infarction[e1] may develop in patients treated with high-dose [s2]glucocorticoids[e2] for Graves' ophthalmopathy, and increased blood pressure may herald this complication.
+	(26, 36)	SASP	psoriasis-like skin reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2607	Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine  [s1]SASP[e1]  therapy developed a severe and lasting [s2]psoriasis-like skin reaction[e2] 
+	(21, 38)	sulphasalazine	psoriasis-like skin reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2608	Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of [s1]sulphasalazine[e1] (SASP) therapy developed a severe and lasting [s2]psoriasis-like skin reaction[e2] 
+	(0, 20)	Psoriasis-like skin reaction	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2609	 [s1]Psoriasis-like skin reaction[e1] in a patient with rheumatoid arthritis after [s2]sulphasalazine[e2] therapy.
+	(7, 16)	vincristine	bilateral ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2610	Five days after the fourth dose of [s1]vincristine[e1]  she presented with [s2]bilateral ptosis[e2] 
+	(0, 7)	Vincristine	cranial polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2611	 [s1]Vincristine[e1] induced [s2]cranial polyneuropathy[e2] 
+	(12, 19)	vincristine	cranial polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2612	We describe a 5-year-old girl showed recovery of [s1]vincristine[e1] induced [s2]cranial polyneuropathy[e2] with pyridoxine and pyridostigmine treatment.
+	(0, 15)	Acute generalized exanthematous pustulosis	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2613	 [s1]Acute generalized exanthematous pustulosis[e1] caused by [s2]morphine[e2]  confirmed by positive patch test and lymphocyte transformation test.
+	(0, 20)	Morphine	facial flushing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2614	 [s1]Morphine[e1]  an opium alkaloid, frequently causes side effects such as hyperhidrosis and [s2]facial flushing[e2]  but serious cutaneous adverse drug reactions are seldom observed.
+	(0, 16)	Morphine	hyperhidrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2615	 [s1]Morphine[e1]  an opium alkaloid, frequently causes side effects such as [s2]hyperhidrosis[e2] and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.
+	(15, 28)	erlotinib	skin manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2616	We describe a case of a man treated with an EGFR-inhibitor  [s1]erlotinib[e1]  for a cell lung cancer who developed [s2]skin manifestations[e2] localized in an uncommon area and with an atypical evolution.
+	(0, 6)	Olanzapine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2617	 [s1]Olanzapine[e1] associated [s2]neuroleptic malignant syndrome[e2] 
+	(0, 9)	Allergic contact angioedema	benzoyl peroxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2618	 [s1]Allergic contact angioedema[e1] to [s2]benzoyl peroxide[e2] 
+	(7, 17)	severe angioedematous reaction	BP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2619	Factors that suggested an association between the [s1]severe angioedematous reaction[e1] and [s2]BP[e2] topical application include the strong reaction to BP in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations.
+	(24, 36)	5-fluorouracil	acute confusional state	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2620	A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of [s1]5-fluorouracil[e1] as episodes of [s2]acute confusional state[e2] and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.
+	(9, 26)	neurotoxicity	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2621	A 35-year-old woman presented with [s1]neurotoxicity[e1] correlated to an i.v. regimen of [s2]5-fluorouracil[e2] as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.
+	(8, 17)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2622	Reversible findings of restricted diffusion in [s1]5-fluorouracil[e1]  [s2]neurotoxicity[e2] 
+	(20, 27)	caffeine	suicide attempt	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2623	We present the case of a 58-year-old woman who ingested more than 35 g of [s1]caffeine[e1] in a [s2]suicide attempt[e2] 
+	(15, 20)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2624	It may cause a severe adverse drug reaction with multiorgan involvement known as [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
+	(1, 6)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2625	Severe [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
+	(14, 19)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2626	We report the case of a 21-year-old female patient with [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
+	(0, 11)	Anaphylaxis	diamorphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2627	 [s1]Anaphylaxis[e1] to intrathecal [s2]diamorphine[e2] 
+	(11, 18)	diamorphine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2628	We believe this is the first report of intrathecal [s1]diamorphine[e1] causing [s2]anaphylaxis[e2] 
+	(5, 18)	systemic allergic reaction	aprotinin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2629	We highlight two instances of [s1]systemic allergic reaction[e1]  and discuss the potential side effects of local [s2]aprotinin[e2] injections in the orthopaedic setting as well as the evidence base for its use.
+	(33, 44)	carbamazepine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2630	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and [s1]carbamazepine[e1]  presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(21, 44)	divalproex sodium	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2631	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, [s1]divalproex sodium[e1]  risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(27, 44)	risperidone	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2632	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, [s1]risperidone[e1]  and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(17, 44)	topiramate	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2633	METHOD: Case analysis of a poly-drug overdose (venlafaxine, [s1]topiramate[e1]  divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(10, 43)	venlafaxine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2634	METHOD: Case analysis of a poly-drug overdose  [s1]venlafaxine[e1]  topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(33, 43)	carbamazepine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2635	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and [s1]carbamazepine[e1]  presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(21, 43)	divalproex sodium	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2636	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, [s1]divalproex sodium[e1]  risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(27, 43)	risperidone	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2637	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, [s1]risperidone[e1]  and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(17, 43)	topiramate	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2638	METHOD: Case analysis of a poly-drug overdose (venlafaxine, [s1]topiramate[e1]  divalproex sodium, risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(10, 42)	venlafaxine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2639	METHOD: Case analysis of a poly-drug overdose  [s1]venlafaxine[e1]  topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
+	(0, 16)	Fever	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2640	 [s1]Fever[e1] and maculopapular rashes appeared at 10 days after [s2]phenytoin[e2] initiation, and then the drug was discontinued.
+	(2, 16)	maculopapular rashes	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2641	Fever and [s1]maculopapular rashes[e1] appeared at 10 days after [s2]phenytoin[e2] initiation, and then the drug was discontinued.
+	(0, 8)	Localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2642	 [s1]Localized purpura[e1] associated with [s2]lamotrigine[e2] 
+	(8, 16)	localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2643	This case study is the second report of [s1]localized purpura[e1] after prolonged [s2]lamotrigine[e2] treatment suggesting this may be an atypical lamotrigine-induced drug reaction.
+	(26, 36)	localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2644	This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed [s1]localized purpura[e1] after 23 months of [s2]lamotrigine[e2] monotherapy.
+	(0, 6)	Acute renal failure	lisinopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2645	 [s1]Acute renal failure[e1] during [s2]lisinopril[e2] and losartan therapy for proteinuria.
+	(0, 11)	Acute renal failure	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2646	 [s1]Acute renal failure[e1] during lisinopril and [s2]losartan[e2] therapy for proteinuria.
+	(13, 33)	hypotension	lisinopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2647	This report describes a case of acute compromise of renal function associated with [s1]hypotension[e1] in a 7-year-old boy treated with the ACE inhibitor [s2]lisinopril[e2] and the ARB losartan.
+	(13, 41)	hypotension	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2648	This report describes a case of acute compromise of renal function associated with [s1]hypotension[e1] in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB [s2]losartan[e2] 
+	(0, 20)	Reversible corneal keratinization	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2649	 [s1]Reversible corneal keratinization[e1] following trabeculectomy and treatment with [s2]5-fluorouracil[e2] 
+	(0, 14)	Bronchiolitis obliterans with organizing pneumonia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2650	 [s1]Bronchiolitis obliterans with organizing pneumonia[e1] after [s2]rituximab[e2] therapy for non-Hodgkin's lymphoma.
+	(9, 14)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2651	Moreover, these findings suggest that the incidence of [s1]BOOP[e1] following [s2]rituximab[e2] therapy may be higher than has been previously appreciated.
+	(7, 16)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2652	This is the first reported case of [s1]BOOP[e1] associated with single-agent [s2]rituximab[e2]  and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.
+	(7, 16)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2653	This is the first reported case of [s1]BOOP[e1] associated with single-agent [s2]rituximab[e2]  and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.
+	(10, 32)	rituximab	bronchiolitis obliterans with organizing pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2654	We describe a case of an NHL patient who received [s1]rituximab[e1] and developed symptomatic, biopsy-proven multinodular [s2]bronchiolitis obliterans with organizing pneumonia[e2] (BOOP).
+	(9, 22)	severe arterial thrombotic events	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2655	Despite a very low complication rate, several [s1]severe arterial thrombotic events[e1] have been reported following [s2]thrombin[e2] injection of pseudoaneurysms.
+	(4, 16)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2656	Lower extremity [s1]arterial thrombosis[e1] following sonographically guided [s2]thrombin[e2] injection of a femoral pseudoaneurysm.
+	(1, 16)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2657	Native [s1]arterial thrombosis[e1]  though recognized as a severe complication of [s2]thrombin[e2] injection, has not been well described in the literature.
+	(9, 20)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2658	We report a case of successful surgical management of [s1]arterial thrombosis[e1] after percutaneous [s2]thrombin[e2] injection of a femoral artery pseudoaneurysm in a 69-year-old woman.
+	(4, 11)	oxaliplatin	hemolytic and/or thrombocytopenic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2659	A small number of [s1]oxaliplatin[e1] related [s2]hemolytic and/or thrombocytopenic reactions[e2] have been reported.
+	(0, 14)	Hemolytic uremic syndrome	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2660	 [s1]Hemolytic uremic syndrome[e1] following the infusion of [s2]oxaliplatin[e2]  case report.
+	(5, 30)	hemolytic-uremic syndrome	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2661	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with oxaliplatin, [s2]5-fluorouracil[e2] and leucovorin.
+	(5, 38)	hemolytic-uremic syndrome	leucovorin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2662	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and [s2]leucovorin[e2] 
+	(5, 25)	hemolytic-uremic syndrome	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2663	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with [s2]oxaliplatin[e2]  5-fluorouracil and leucovorin.
+	(20, 30)	agranulocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2664	First, a review of the literature produced 41 anecdotic cases of neutropenia or [s1]agranulocytosis[e1] during treatment with [s2]olanzapine[e2] (Zyprexa) reported in a total of 24 publications.
+	(20, 33)	agranulocytosis	Zyprexa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2665	First, a review of the literature produced 41 anecdotic cases of neutropenia or [s1]agranulocytosis[e1] during treatment with olanzapine  [s2]Zyprexa[e2]  reported in a total of 24 publications.
+	(15, 30)	neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2666	First, a review of the literature produced 41 anecdotic cases of [s1]neutropenia[e1] or agranulocytosis during treatment with [s2]olanzapine[e2] (Zyprexa) reported in a total of 24 publications.
+	(15, 33)	neutropenia	Zyprexa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2667	First, a review of the literature produced 41 anecdotic cases of [s1]neutropenia[e1] or agranulocytosis during treatment with olanzapine  [s2]Zyprexa[e2]  reported in a total of 24 publications.
+	(5, 24)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2668	Neutropenia and [s1]agranulocytosis[e1] are risks known to occur with phenothiazines and [s2]clozapine[e2] 
+	(5, 18)	agranulocytosis	phenothiazines	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2669	Neutropenia and [s1]agranulocytosis[e1] are risks known to occur with [s2]phenothiazines[e2] and clozapine.
+	(0, 24)	Neutropenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2670	 [s1]Neutropenia[e1] and agranulocytosis are risks known to occur with phenothiazines and [s2]clozapine[e2] 
+	(0, 18)	Neutropenia	phenothiazines	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2671	 [s1]Neutropenia[e1] and agranulocytosis are risks known to occur with [s2]phenothiazines[e2] and clozapine.
+	(7, 23)	neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2672	Second, we report a case of [s1]neutropenia[e1]  which proved to be fatal in a schizophrenia patient receiving [s2]olanzapine[e2] and thiazide.
+	(7, 27)	neutropenia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2673	Second, we report a case of [s1]neutropenia[e1]  which proved to be fatal in a schizophrenia patient receiving olanzapine and [s2]thiazide[e2] 
+	(4, 16)	severe neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2674	Thus any case of [s1]severe neutropenia[e1] occurring in a patient receiving [s2]olanzapine[e2] is alarming to clinicians.
+	(13, 23)	camptocormia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2675	We present a depressive patient who developed mild parkinsonian signs and [s1]camptocormia[e1] after the introduction of [s2]olanzapine[e2] 
+	(8, 23)	mild parkinsonian signs	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2676	We present a depressive patient who developed [s1]mild parkinsonian signs[e1] and camptocormia after the introduction of [s2]olanzapine[e2] 
+	(4, 14)	mirtazapine	symptomatic hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2677	Five months after initiating [s1]mirtazapine[e1] therapy, she developed [s2]symptomatic hyponatremia[e2] 
+	(9, 24)	hyponatremia	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2678	In this case, unlike those previously reported, [s1]hyponatremia[e1] recurred 5 months after switching from [s2]citalopram[e2] to mirtazapine, which is believed to be a safe antidepressant.
+	(9, 29)	hyponatremia	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2679	In this case, unlike those previously reported, [s1]hyponatremia[e1] recurred 5 months after switching from citalopram to [s2]mirtazapine[e2]  which is believed to be a safe antidepressant.
+	(0, 11)	Recurrent hyponatremia	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2680	 [s1]Recurrent hyponatremia[e1] associated with [s2]citalopram[e2] and mirtazapine.
+	(0, 16)	Recurrent hyponatremia	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2681	 [s1]Recurrent hyponatremia[e1] associated with citalopram and [s2]mirtazapine[e2] 
+	(16, 29)	nephrotic syndrome	interferon (IFN)-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2682	A 43-year-old woman with multiple sclerosis (MS) had [s1]nephrotic syndrome[e1] 21 months after starting treatment with [s2]interferon (IFN)-beta-1b[e2] (subcutaneous administration).
+	(1, 12)	nephrotic syndrome	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2683	Because [s1]nephrotic syndrome[e1] may be induced by [s2]IFN[e2] therapy, the IFN was stopped.
+	(1, 12)	nephrotic syndrome	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2684	Because [s1]nephrotic syndrome[e1] may be induced by [s2]IFN[e2] therapy, the IFN was stopped.
+	(0, 9)	Nephrotic syndrome	interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2685	 [s1]Nephrotic syndrome[e1] associated with [s2]interferon-beta-1b[e2] therapy for multiple sclerosis.
+	(4, 17)	nephrotic syndrome	IFN-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2686	Though proteinuria and [s1]nephrotic syndrome[e1] is a rare adverse effect of [s2]IFN-beta-1b[e2] therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
+	(1, 17)	proteinuria	IFN-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2687	Though [s1]proteinuria[e1] and nephrotic syndrome is a rare adverse effect of [s2]IFN-beta-1b[e2] therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
+	(14, 29)	dyspnea	homochlorcyclizine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2688	A 70-year-old man was admitted to our hospital because of [s1]dyspnea[e1] after taking an antihistaminic agent  [s2]homochlorcyclizine hydrochloride[e2]  for itching.
+	(0, 11)	Acute eosinophilic pneumonia	calcium stearate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2689	 [s1]Acute eosinophilic pneumonia[e1] caused by [s2]calcium stearate[e2]  an additive agent for an oral antihistaminic medication.
+	(9, 16)	pulmonary disease	calcium stearate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2690	Therefore, we concluded that this patient's [s1]pulmonary disease[e1] was caused by [s2]calcium stearate[e2]  an additive for an antihistaminic drug.
+	(0, 9)	Scleritis	zoledronic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2691	 [s1]Scleritis[e1] complicating [s2]zoledronic acid[e2] infusion.
+	(5, 18)	severe unilateral posterior scleritis	zoledronic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2692	We present a case of [s1]severe unilateral posterior scleritis[e1] associated with [s2]zoledronic acid[e2] administration that was recognized and treated in a timely manner.
+	(2, 10)	hepatitis B virus reactivation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2693	Late lethal [s1]hepatitis B virus reactivation[e1] after [s2]rituximab[e2] treatment of low-grade cutaneous B-cell lymphoma.
+	(2, 14)	HBV reactivations	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2694	Several such [s1]HBV reactivations[e1] were reported after combined [s2]rituximab[e2] and multiagent chemotherapy for B-cell lymphomas.
+	(6, 18)	HBV reactivation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2695	This is the first case of [s1]HBV reactivation[e1] occurring during the year following [s2]rituximab[e2] monotherapy in the absence of any other immunosuppressive factor.
+	(7, 37)	cryptococcal meningitis	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2696	This is a case report of fatal [s1]cryptococcal meningitis[e1] in a child with systemic lupus erythematosus being treated with prednisolone and [s2]azathioprine[e2] 
+	(7, 31)	cryptococcal meningitis	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2697	This is a case report of fatal [s1]cryptococcal meningitis[e1] in a child with systemic lupus erythematosus being treated with [s2]prednisolone[e2] and azathioprine.
+	(1, 15)	intertrigo-like eruption	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2698	An [s1]intertrigo-like eruption[e1] from pegylated liposomal [s2]doxorubicin[e2] 
+	(1, 13)	eruption	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2699	This [s1]eruption[e1] appears to be a distinct cutaneous toxicity of [s2]PLD[e2] 
+	(18, 30)	erosions in the axilla and groin	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2700	We report the case of a 60-year-old woman who developed erythema and [s1]erosions in the axilla and groin[e1] while on [s2]PLD[e2] for breast cancer.
+	(14, 30)	erythema	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2701	We report the case of a 60-year-old woman who developed [s1]erythema[e1] and erosions in the axilla and groin while on [s2]PLD[e2] for breast cancer.
+	(12, 18)	warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2702	Herein is reported an unusual case of coexistent [s1]warfarin[e1] induced [s2]skin necrosis[e2] and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.
+	(21, 27)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2703	Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.
+	(0, 6)	Warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2704	 [s1]Warfarin[e1] induced [s2]skin necrosis[e2] and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.
+	(9, 15)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2705	Warfarin-induced skin necrosis and [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following mitral valve replacement for marantic endocarditis.
+	(6, 27)	indomethacin	premature closure of the ductus arteriosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2706	Exposure of the fetus to [s1]indomethacin[e1] by administration of the drug to the mother may cause many side effects, including [s2]premature closure of the ductus arteriosus[e2] 
+	(0, 23)	Hypoxia	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2707	 [s1]Hypoxia[e1] is a predisposing factor for premature ductal closure and often occurs after maternal [s2]indomethacin[e2] therapy.
+	(12, 23)	premature ductal closure	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2708	Hypoxia is a predisposing factor for [s1]premature ductal closure[e1] and often occurs after maternal [s2]indomethacin[e2] therapy.
+	(0, 25)	Premature closure of the ductus arteriosus	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2709	 [s1]Premature closure of the ductus arteriosus[e1]  variable response among monozygotic twins after in utero exposure to [s2]indomethacin[e2] 
+	(30, 38)	ductal closure	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2710	This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to [s1]ductal closure[e1] in response to [s2]indomethacin[e2] exposure.
+	(20, 38)	hypoxia	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2711	This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to [s1]hypoxia[e1] and thus was more susceptible to ductal closure in response to [s2]indomethacin[e2] exposure.
+	(6, 20)	moxifloxacin	corneal ulcers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2712	CONCLUSION: These cases suggest that [s1]moxifloxacin[e1] may interfere with the healing of [s2]corneal ulcers[e2] 
+	(7, 30)	corneal ulcers	moxifloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2713	RESULTS: Both cases presented here describe [s1]corneal ulcers[e1] that persisted and showed signs of worsening during weeks of frequent topical dosing with [s2]moxifloxacin[e2] 
+	(0, 8)	Severe corneal toxicity	fluoroquinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2714	 [s1]Severe corneal toxicity[e1] after topical [s2]fluoroquinolone[e2] therapy: report of two cases.
+	(0, 15)	Acute generalized exanthematous pustulosis	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2715	 [s1]Acute generalized exanthematous pustulosis[e1] induced by [s2]nimesulide[e2] 
+	(5, 39)	acute generalized exanthematous pustulosis	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2716	We report a case of [s1]acute generalized exanthematous pustulosis[e1] (AGEP) in a 50-year-old woman that was attributed to the ingestion of [s2]nimesulide[e2] 
+	(16, 37)	AGEP	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2717	We report a case of acute generalized exanthematous pustulosis  [s1]AGEP[e1]  in a 50-year-old woman that was attributed to the ingestion of [s2]nimesulide[e2] 
+	(2, 32)	Amphotericin B deoxycholate	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2718	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and [s2]bradycardia[e2] reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
+	(2, 19)	Amphotericin B deoxycholate	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2719	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant [s2]cardiac toxicity[e2]  with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
+	(2, 23)	Amphotericin B deoxycholate	ventricular arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2720	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant cardiac toxicity, with [s2]ventricular arrhythmias[e2] and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
+	(26, 40)	fatal cardiac arrhythmia	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2721	OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a [s1]fatal cardiac arrhythmia[e1] after an acute overdose of [s2]amphotericin B[e2] and to review its toxicity.
+	(16, 21)	cardiac toxicity	amphotericin B deoxycholate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2722	Use of the Naranjo probability scale indicated a highly probable relationship between the observed [s1]cardiac toxicity[e1] and [s2]amphotericin B deoxycholate[e2] therapy in this patient.
+	(6, 22)	valvular heart disease	benfluorex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2723	The authors describe a case of [s1]valvular heart disease[e1] in a 48-year-old woman receiving [s2]benfluorex[e2] (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement.
+	(0, 11)	Valvular heart disease	benfluorex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2724	 [s1]Valvular heart disease[e1] in a patient taking [s2]benfluorex[e2] 
+	(6, 29)	Lp-TAE	liver dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2725	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, localized pain, myelo-suppression and [s2]liver dysfunction[e2]  but these were transient and eventually disappeared.
+	(6, 21)	Lp-TAE	localized pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2726	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, [s2]localized pain[e2]  myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.
+	(6, 16)	Lp-TAE	low-grade fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2727	The main side-effects of [s1]Lp-TAE[e1] combined with HT were [s2]low-grade fever[e2]  localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.
+	(6, 24)	Lp-TAE	myelo-suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2728	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, localized pain, [s2]myelo-suppression[e2] and liver dysfunction, but these were transient and eventually disappeared.
+	(0, 14)	Tacrolimus	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2729	 [s1]Tacrolimus[e1] induced HUS: an unusual cause of [s2]acute renal failure[e2] in nephrotic syndrome.
+	(0, 7)	Tacrolimus	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2730	 [s1]Tacrolimus[e1] induced [s2]HUS[e2]  an unusual cause of acute renal failure in nephrotic syndrome.
+	(2, 16)	tacrolimus	ARF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2731	Thus, [s1]tacrolimus[e1] induced HUS is a rare cause of [s2]ARF[e2] in nephrotic syndrome.
+	(2, 9)	tacrolimus	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2732	Thus, [s1]tacrolimus[e1] induced [s2]HUS[e2] is a rare cause of ARF in nephrotic syndrome.
+	(4, 13)	fulminant hepatitis	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2733	Liver transplantation for [s1]fulminant hepatitis[e1] related to [s2]nevirapine[e2] therapy.
+	(6, 15)	fulminant hepatitis	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2734	We describe a detailed case of [s1]fulminant hepatitis[e1] induced by [s2]nevirapine[e2] (Viramune) and treated by liver transplantation.
+	(6, 18)	fulminant hepatitis	Viramune	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2735	We describe a detailed case of [s1]fulminant hepatitis[e1] induced by nevirapine  [s2]Viramune[e2]  and treated by liver transplantation.
+	(0, 26)	Cholelithiasis	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2736	 [s1]Cholelithiasis[e1] and thrombosis of the central retinal vein in a renal transplant recipient treated with [s2]cyclosporin[e2] 
+	(6, 26)	thrombosis of the central retinal vein	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2737	Cholelithiasis and [s1]thrombosis of the central retinal vein[e1] in a renal transplant recipient treated with [s2]cyclosporin[e2] 
+	(45, 52)	azathioprine	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2738	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and [s1]azathioprine[e1]  developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
+	(34, 52)	cyclosporin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2739	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of [s1]cyclosporin[e1]  prednisone and azathioprine, developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
+	(40, 53)	prednisone	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2740	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, [s1]prednisone[e1] and azathioprine, developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
+	(3, 17)	cyclosporin	cholelithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2741	The use of [s1]cyclosporin[e1] has been associated with the development of [s2]cholelithiasis[e2] in transplant recipients.
+	(0, 10)	Hepatotoxicity	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2742	 [s1]Hepatotoxicity[e1] induced by [s2]cyproterone acetate[e2]  a report of three cases.
+	(13, 25)	severe hepatotoxic reactions	CPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2743	Three male patients aged 78-83 years are presented, in whom [s1]severe hepatotoxic reactions[e1] emerged after [s2]CPA[e2] administration.
+	(21, 80)	CS	cutaneous leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2744	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid  [s1]CS[e1] -treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after [s2]cutaneous leishmaniasis[e2] in a man receiving CS.
+	(6, 18)	Leishmania infantum leishmaniasis	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2745	CASE PRESENTATION: Three cases of [s1]Leishmania infantum leishmaniasis[e1] in [s2]corticosteroid[e2] (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
+	(6, 23)	Leishmania infantum leishmaniasis	CS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2746	CASE PRESENTATION: Three cases of [s1]Leishmania infantum leishmaniasis[e1] in corticosteroid  [s2]CS[e2] -treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
+	(16, 34)	corticosteroid	lingual leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2747	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in [s1]corticosteroid[e1] (CS)-treated patients are reported: an isolated [s2]lingual leishmaniasis[e2] in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
+	(21, 32)	CS	lingual leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2748	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid  [s1]CS[e1] -treated patients are reported: an isolated [s2]lingual leishmaniasis[e2] in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
+	(0, 12)	Leishmania infantum leishmaniasis	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2749	 [s1]Leishmania infantum leishmaniasis[e1] in [s2]corticosteroid[e2] -treated patients.
+	(5, 10)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2750	However, an association of [s1]Ritalin[e1] with [s2]glaucoma[e2] has been reported.
+	(3, 11)	methylphenidate	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2751	Large dose of [s1]methylphenidate[e1] may cause [s2]cataract[e2] and glaucoma.
+	(3, 15)	methylphenidate	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2752	Large dose of [s1]methylphenidate[e1] may cause cataract and [s2]glaucoma[e2] 
+	(0, 12)	Methylphenidate	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2753	 [s1]Methylphenidate[e1] (Ritalin)-associated [s2]cataract[e2] and glaucoma.
+	(4, 10)	Ritalin	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2754	Methylphenidate  [s1]Ritalin[e1] -associated [s2]cataract[e2] and glaucoma.
+	(0, 16)	Methylphenidate	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2755	 [s1]Methylphenidate[e1] (Ritalin)-associated cataract and [s2]glaucoma[e2] 
+	(4, 14)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2756	Methylphenidate  [s1]Ritalin[e1] -associated cataract and [s2]glaucoma[e2] 
+	(5, 10)	Ritalin	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2757	We report a case of [s1]Ritalin[e1] associated [s2]cataract[e2] and glaucoma.
+	(5, 14)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2758	We report a case of [s1]Ritalin[e1] associated cataract and [s2]glaucoma[e2] 
+	(12, 26)	CBS	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2759	CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome  [s1]CBS[e1]  in patients with severe AMD after intravitreal [s2]Avastin[e2] injections.
+	(8, 28)	Charles-Bonnet syndrome	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2760	CONCLUSIONS: We report a typical symptoms of [s1]Charles-Bonnet syndrome[e1] (CBS) in patients with severe AMD after intravitreal [s2]Avastin[e2] injections.
+	(4, 36)	transient structured visual hallucinations	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2761	PURPOSE: To describe [s1]transient structured visual hallucinations[e1] in a patient with vascular age-related macular degeneration (AMD), following an intravitreal [s2]Avastin[e2] injection.
+	(0, 13)	Visual hallucinations	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2762	 [s1]Visual hallucinations[e1] after intravitreal injection of [s2]bevacizumab[e2] in vascular age-related macular degeneration.
+	(3, 12)	metoclopramide	oculogyric crisis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2763	A case of [s1]metoclopramide[e1] induced [s2]oculogyric crisis[e2] in a 16-year-old girl with cystic fibrosis.
+	(3, 12)	oculogyric crisis	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2764	A case of [s1]oculogyric crisis[e1] induced by [s2]metoclopramide[e2] is described in this paper.
+	(2, 16)	cyclosporine	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2765	However, [s1]cyclosporine[e1] dependency is associated with the risk of [s2]nephrotoxicity[e2] 
+	(0, 26)	Quinapril	prolonged hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2766	 [s1]Quinapril[e1] is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to [s2]prolonged hypotension[e2] and, less frequently, transient renal impairment.
+	(0, 37)	Quinapril	transient renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2767	 [s1]Quinapril[e1] is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, [s2]transient renal impairment[e2] 
+	(0, 20)	Cardiomyopathy	actinomycin-D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2768	 [s1]Cardiomyopathy[e1] after widely separated courses of adriamycin exacerbated by [s2]actinomycin-D[e2] and mithramycin.
+	(0, 11)	Cardiomyopathy	adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2769	 [s1]Cardiomyopathy[e1] after widely separated courses of [s2]adriamycin[e2] exacerbated by actinomycin-D and mithramycin.
+	(0, 27)	Cardiomyopathy	mithramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2770	 [s1]Cardiomyopathy[e1] after widely separated courses of adriamycin exacerbated by actinomycin-D and [s2]mithramycin[e2] 
+	(0, 23)	Exacerbations of the heart failure	actinomycin-D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2771	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics [s2]actinomycin-D[e2] (NSC-3053) and mithramycin (NSC-24559).
+	(0, 37)	Exacerbations of the heart failure	mithramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2772	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and [s2]mithramycin[e2] (NSC-24559).
+	(0, 41)	Exacerbations of the heart failure	NSC-24559	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2773	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin  [s2]NSC-24559[e2] .
+	(0, 29)	Exacerbations of the heart failure	NSC-3053	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2774	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D  [s2]NSC-3053[e2]  and mithramycin (NSC-24559).
+	(9, 15)	adriamycin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2775	The pathogenic mechanisms involved in the development of [s1]adriamycin[e1]  [s2]cardiomyopathy[e2] are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed.
+	(0, 22)	Cardiac hypersensitivity	mesalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2776	 [s1]Cardiac hypersensitivity[e1] and myopericarditis have been reported during long-term treatment with [s2]mesalazine[e2] 
+	(6, 22)	myopericarditis	mesalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2777	Cardiac hypersensitivity and [s1]myopericarditis[e1] have been reported during long-term treatment with [s2]mesalazine[e2] 
+	(10, 27)	mesalazine	pericarditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2778	We report the case of a man, treated with [s1]mesalazine[e1] for Crohn's disease who developed drug-induced [s2]pericarditis[e2] 
+	(3, 8)	hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2779	Acute drug induced [s1]hepatitis[e1] due to [s2]erlotinib[e2] 
+	(8, 15)	acute severe hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2780	CASE REPORT: We report a case of [s1]acute severe hepatitis[e1] resulting from [s2]erlotinib[e2] monotherapy in a patient with locally advanced pancreatic cancer.
+	(2, 22)	Acute severe hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2781	CONCLUSIONS: [s1]Acute severe hepatitis[e1] though rare is occasionally observed with EGFR inhibitors gefitinib or [s2]erlotinib[e2] 
+	(2, 17)	Acute severe hepatitis	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2782	CONCLUSIONS: [s1]Acute severe hepatitis[e1] though rare is occasionally observed with EGFR inhibitors [s2]gefitinib[e2] or erlotinib.
+	(0, 10)	Hepatotoxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2783	 [s1]Hepatotoxicity[e1] resolved once [s2]erlotinib[e2] was discontinued and serum transaminases returned to baseline normal values.
+	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2784	 [s1]Heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis is a severe complication of systemic heparin therapy.
+	(5, 25)	thrombocytopenia	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2785	Heparin-associated [s1]thrombocytopenia[e1] and thrombosis is a severe complication of systemic [s2]heparin[e2] therapy.
+	(0, 13)	Heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2786	 [s1]Heparin[e1] associated thrombocytopenia and [s2]thrombosis[e2] is a severe complication of systemic heparin therapy.
+	(12, 25)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2787	Heparin-associated thrombocytopenia and [s1]thrombosis[e1] is a severe complication of systemic [s2]heparin[e2] therapy.
+	(6, 25)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2788	This experience supports the hypothesis that [s1]heparin[e1] can be readministered early to patients with heparin-associated [s2]thrombocytopenia[e2] and thrombosis, provided antiplatelet therapy is given.
+	(6, 32)	heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2789	This experience supports the hypothesis that [s1]heparin[e1] can be readministered early to patients with heparin-associated thrombocytopenia and [s2]thrombosis[e2]  provided antiplatelet therapy is given.
+	(11, 17)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2790	Usefulness of antiplatelet drugs in the management of [s1]heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis.
+	(11, 24)	heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2791	Usefulness of antiplatelet drugs in the management of [s1]heparin[e1] associated thrombocytopenia and [s2]thrombosis[e2] 
+	(6, 24)	fixed drug eruption	Cialis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2792	RESULTS: A clinical diagnosis of [s1]fixed drug eruption[e1] owing to use of the PDE5 inhibitor tadalafil  [s2]Cialis[e2]  was made.
+	(6, 20)	fixed drug eruption	tadalafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2793	RESULTS: A clinical diagnosis of [s1]fixed drug eruption[e1] owing to use of the PDE5 inhibitor [s2]tadalafil[e2] (Cialis) was made.
+	(18, 25)	docetaxel	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2794	Even though only a few cases of this adverse event have been reported in the literature, severe [s1]docetaxel[e1] induced [s2]pulmonary toxicity[e2] needs to be considered in the differential diagnosis when such patients present with respiratory symptoms.
+	(0, 13)	Fatal interstitial pneumonitis	docetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2795	 [s1]Fatal interstitial pneumonitis[e1] associated with [s2]docetaxel[e2] administration in a patient with hormone-refractory prostate cancer.
+	(28, 36)	docetaxel	subacute interstitial pneumonitis-related pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2796	The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 [s1]docetaxel[e1] who developed [s2]subacute interstitial pneumonitis-related pulmonary fibrosis[e2] after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment.
+	(4, 37)	fulminant microangiopathic hemolytic anemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2797	The patient presented with [s1]fulminant microangiopathic hemolytic anemia[e1] and thrombocytopenia within 48 hr of initiating therapy with trimethoprim [s2]sulfamethoxazole[e2] 
+	(4, 33)	fulminant microangiopathic hemolytic anemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2798	The patient presented with [s1]fulminant microangiopathic hemolytic anemia[e1] and thrombocytopenia within 48 hr of initiating therapy with [s2]trimethoprim[e2] sulfamethoxazole.
+	(18, 37)	thrombocytopenia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2799	The patient presented with fulminant microangiopathic hemolytic anemia and [s1]thrombocytopenia[e1] within 48 hr of initiating therapy with trimethoprim [s2]sulfamethoxazole[e2] 
+	(18, 33)	thrombocytopenia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2800	The patient presented with fulminant microangiopathic hemolytic anemia and [s1]thrombocytopenia[e1] within 48 hr of initiating therapy with [s2]trimethoprim[e2] sulfamethoxazole.
+	(0, 22)	Thrombotic thrombocytopenic purpura	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2801	 [s1]Thrombotic thrombocytopenic purpura[e1] induced by trimethoprim [s2]sulfamethoxazole[e2] in a Jehovah's Witness.
+	(0, 18)	Thrombotic thrombocytopenic purpura	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2802	 [s1]Thrombotic thrombocytopenic purpura[e1] induced by [s2]trimethoprim[e2] sulfamethoxazole in a Jehovah's Witness.
+	(5, 31)	Thrombotic Thrombocytopenic Purpura	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2803	We report a case of [s1]Thrombotic Thrombocytopenic Purpura[e1] occurring as an allergic response to trimethoprim [s2]sulfamethoxazole[e2] therapy (Bactrim, Septra) in a Jehovah's Witness patient.
+	(5, 27)	Thrombotic Thrombocytopenic Purpura	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2804	We report a case of [s1]Thrombotic Thrombocytopenic Purpura[e1] occurring as an allergic response to [s2]trimethoprim[e2] sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient.
+	(0, 12)	Juvenile absence epilepsy	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2805	 [s1]Juvenile absence epilepsy[e1] exacerbated by [s2]valproic acid[e2] 
+	(6, 19)	paradoxical	seizure exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2806	This report describes a case of [s1]paradoxical[e1]  intravenous valproic acid-induced [s2]seizure exacerbation[e2] in a child with juvenile absence epilepsy, documented by video-electroencephalography.
+	(12, 19)	valproic acid	seizure exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2807	This report describes a case of paradoxical, intravenous [s1]valproic acid[e1] induced [s2]seizure exacerbation[e2] in a child with juvenile absence epilepsy, documented by video-electroencephalography.
+	(0, 19)	Acute endophthalmitis	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2808	 [s1]Acute endophthalmitis[e1] following intravitreal bevacizumab  [s2]Avastin[e2]  injection.
+	(0, 14)	Acute endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2809	 [s1]Acute endophthalmitis[e1] following intravitreal [s2]bevacizumab[e2] (Avastin) injection.
+	(2, 21)	Infectious endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2810	CONCLUSIONS: [s1]Infectious endophthalmitis[e1] is a potential complication of intravitreal [s2]bevacizumab[e2] injection.
+	(8, 30)	age-related macular degeneration	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2811	METHODS: Two patients with exudative [s1]age-related macular degeneration[e1] were treated sequentially with an intravitreal injection of [s2]bevacizumab[e2] and developed signs of severe but painless infectious endophthalmitis 2 days later.
+	(28, 41)	bevacizumab	painless infectious endophthalmitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2812	METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of [s1]bevacizumab[e1] and developed signs of severe but [s2]painless infectious endophthalmitis[e2] 2 days later.
+	(7, 21)	acute endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2813	PURPOSE: To report two cases of [s1]acute endophthalmitis[e1] following intravitreal [s2]bevacizumab[e2] injection.
+	(0, 6)	Pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2814	 [s1]Pulmonary hypertension[e1] during [s2]lithium[e2] therapy: clinical case study.
+	(6, 12)	pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2815	The authors presented a case of [s1]pulmonary hypertension[e1] during [s2]lithium[e2] therapy, while she has been on lithium for 6 years.
+	(6, 16)	pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2816	This is the first report of [s1]pulmonary hypertension[e1] in an adult patient during [s2]lithium[e2] therapy.
+	(4, 14)	arthritis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2817	The patient's [s1]arthritis[e1] flared after the second infusion of [s2]infliximab[e2]  which was discontinued.
+	(20, 36)	circulatory collapse	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2818	A 32-year-old man with a family history of type 2 diabetes mellitus presented with [s1]circulatory collapse[e1] and deep coma after 9 days of treatment with [s2]perospirone hydrochloride[e2]  a recently developed atypical antipsychotic agent available only in Japan.
+	(26, 36)	deep coma	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2819	A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and [s1]deep coma[e1] after 9 days of treatment with [s2]perospirone hydrochloride[e2]  a recently developed atypical antipsychotic agent available only in Japan.
+	(6, 27)	diabetic ketoacidosis	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2820	The risk of new-onset [s1]diabetic ketoacidosis[e1] in patients with diabetic risk factors who are taking [s2]perospirone hydrochloride[e2] or other atypical antipsychotics should be kept in mind.
+	(0, 14)	Fatal venous thrombembolism	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2821	 [s1]Fatal venous thrombembolism[e1] complicating [s2]imatinib[e2] therapy in a patient with metastatic gastrointestinal stromal tumor.
+	(3, 45)	deep vein thrombosis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2822	The possibility of [s1]deep vein thrombosis[e1] caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with [s2]imatinib[e2] 
+	(22, 32)	status epilepticus	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2823	We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed [s1]status epilepticus[e1] shortly after receiving [s2]cisplatin[e2] and gemcitabine chemotherapy.
+	(22, 36)	status epilepticus	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2824	We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed [s1]status epilepticus[e1] shortly after receiving cisplatin and [s2]gemcitabine[e2] chemotherapy.
+	(8, 23)	fluctuation of the QT interval	methadone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2825	Of particular interest in this patient is the [s1]fluctuation of the QT interval[e1] at a stable dose of [s2]methadone[e2]  suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias.
+	(11, 21)	prolonged QT	methadone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2826	We present a case report of a patient who developed a [s1]prolonged QT[e1] while being treated with oral [s2]methadone[e2] for a chronic pain syndrome.
+	(7, 15)	piloerection	fluvoxamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2827	AIMS: To present a case of [s1]piloerection[e1] after replacing [s2]fluvoxamine maleate[e2] with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.
+	(7, 22)	piloerection	milnacipran hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2828	AIMS: To present a case of [s1]piloerection[e1] after replacing fluvoxamine maleate with [s2]milnacipran hydrochloride[e2]  and to analyse this effect based on receptor occupancy theory.
+	(3, 14)	piloerection	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2829	CONCLUSIONS: The [s1]piloerection[e1] observed after the replacement of [s2]fluvoxamine[e2] with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.
+	(3, 19)	piloerection	milnacipran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2830	CONCLUSIONS: The [s1]piloerection[e1] observed after the replacement of fluvoxamine with [s2]milnacipran[e2] in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.
+	(0, 9)	Piloerection	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2831	 [s1]Piloerection[e1] induced by replacing [s2]fluvoxamine[e2] with milnacipran.
+	(0, 14)	Piloerection	milnacipran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2832	 [s1]Piloerection[e1] induced by replacing fluvoxamine with [s2]milnacipran[e2] 
+	(11, 38)	recurrent eosinophilia	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2833	CASE PRESENTATION: We report a patient with CF who developed [s1]recurrent eosinophilia[e1] and severe persistent bronchospasm following repeated administration of preservative-free [s2]tobramycin[e2] by inhalation, beginning at 16 months of age.
+	(19, 38)	severe persistent bronchospasm	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2834	CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and [s1]severe persistent bronchospasm[e1] following repeated administration of preservative-free [s2]tobramycin[e2] by inhalation, beginning at 16 months of age.
+	(22, 32)	deterioration of pulmonary function	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2835	CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and [s1]deterioration of pulmonary function[e1] following the use of [s2]tobramycin[e2] by inhalation or by intravenous administration.
+	(14, 32)	recurrent eosinophilia	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2836	CONCLUSION: Hypersensitivity reaction should be considered in patients who develop [s1]recurrent eosinophilia[e1] and deterioration of pulmonary function following the use of [s2]tobramycin[e2] by inhalation or by intravenous administration.
+	(1, 10)	tobramycin	recurrent eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2837	Inhaled [s1]tobramycin[e1] solution-associated [s2]recurrent eosinophilia[e2] and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.
+	(1, 18)	tobramycin	severe persistent bronchospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2838	Inhaled [s1]tobramycin[e1] solution-associated recurrent eosinophilia and [s2]severe persistent bronchospasm[e2] in a patient with cystic fibrosis: a case report.
+	(7, 30)	bisphosphonate	osteonecrosis of the mandible	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2839	The most serious dental side effect of [s1]bisphosphonate[e1] treatment (particularly when it is administered intravenously) is, paradoxically, [s2]osteonecrosis of the mandible[e2] or the maxilla represented by exposed nonhealing bone.
+	(3, 19)	amiodarone	aggravation of arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2840	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, hepatotoxicity, [s2]aggravation of arrhythmia[e2]  and thyroid diseases are well understood.
+	(3, 12)	amiodarone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2841	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, [s2]hepatotoxicity[e2]  aggravation of arrhythmia, and thyroid diseases are well understood.
+	(3, 9)	amiodarone	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2842	Adverse effects of [s1]amiodarone[e1] including [s2]pulmonary toxicity[e2]  hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.
+	(3, 30)	amiodarone	thyroid diseases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2843	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and [s2]thyroid diseases[e2] are well understood.
+	(0, 17)	Pancreatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2844	 [s1]Pancreatitis[e1] is a very rare adverse effect associated with the use of [s2]amiodarone[e2]  and only four cases of amiodarone-induced pancreatitis have been reported in literature.
+	(15, 30)	amiodarone	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2845	Pancreatitis is a very rare adverse effect associated with the use of [s1]amiodarone[e1]  and only four cases of amiodarone-induced [s2]pancreatitis[e2] have been reported in literature.
+	(4, 10)	amiodarone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2846	Under the suspicion of [s1]amiodarone[e1] induced [s2]acute pancreatitis[e2]  amiodarone was substituted by propafenone.
+	(6, 14)	acute pancreatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2847	We report a patient who developed [s1]acute pancreatitis[e1] during [s2]amiodarone[e2] therapy.
+	(12, 23)	tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2848	DISCUSSION: To our knowledge this is the first reported case of [s1]tuberculous uveitis[e1] following treatment with [s2]etanercept[e2] 
+	(0, 11)	Tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2849	 [s1]Tuberculous uveitis[e1] after treatment with [s2]etanercept[e2] 
+	(6, 16)	tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2850	We report the first case of [s1]tuberculous uveitis[e1] due to [s2]etanercept[e2] 
+	(4, 18)	melanonychia	pemetrexed	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2851	A complex pattern of [s1]melanonychia[e1] and onycholysis after treatment with [s2]pemetrexed[e2] for lung cancer.
+	(9, 18)	onycholysis	pemetrexed	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2852	A complex pattern of melanonychia and [s1]onycholysis[e1] after treatment with [s2]pemetrexed[e2] for lung cancer.
+	(0, 19)	Infliximab	osteomyelitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2853	 [s1]Infliximab[e1] and its serious adverse effects are discussed, and other cases of [s2]osteomyelitis[e2] with infliximab use are also reviewed.
+	(17, 25)	osteomyelitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2854	Infliximab and its serious adverse effects are discussed, and other cases of [s1]osteomyelitis[e1] with [s2]infliximab[e2] use are also reviewed.
+	(0, 9)	Osteomyelitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2855	 [s1]Osteomyelitis[e1] occurring during [s2]infliximab[e2] treatment of severe psoriasis.
+	(9, 26)	serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2856	Based on the Naranjo probability scale, [s1]serotonin syndrome[e1] was a probable adverse reaction associated with co-administration of [s2]citalopram[e2] and fentanyl.
+	(9, 31)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2857	Based on the Naranjo probability scale, [s1]serotonin syndrome[e1] was a probable adverse reaction associated with co-administration of citalopram and [s2]fentanyl[e2] 
+	(27, 36)	citalopram	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2858	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, [s2]agitation[e2]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(34, 68)	agitation	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2859	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, [s1]agitation[e1]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(34, 68)	agitation	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2860	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, [s1]agitation[e1]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 34)	citalopram	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2861	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed [s2]confusion[e2]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(32, 68)	confusion	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2862	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed [s1]confusion[e1]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(32, 68)	confusion	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2863	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed [s1]confusion[e1]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 46)	citalopram	myoclonic jerks	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2864	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, [s2]myoclonic jerks[e2] and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(44, 69)	myoclonic jerks	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2865	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, [s1]myoclonic jerks[e1] and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(44, 69)	myoclonic jerks	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2866	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, [s1]myoclonic jerks[e1] and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 61)	citalopram	serotonin syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2867	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s2]serotonin syndrome[e2]  following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(59, 68)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2868	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s1]serotonin syndrome[e1]  following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(59, 68)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2869	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s1]serotonin syndrome[e1]  following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 38)	citalopram	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2870	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, [s2]tachycardia[e2]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(36, 68)	tachycardia	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2871	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, [s1]tachycardia[e1]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(36, 68)	tachycardia	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2872	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, [s1]tachycardia[e1]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 43)	citalopram	tremors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2873	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, [s2]tremors[e2]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(41, 68)	tremors	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2874	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, [s1]tremors[e1]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(41, 68)	tremors	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2875	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, [s1]tremors[e1]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(27, 53)	citalopram	unsteady gait	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2876	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s2]unsteady gait[e2]  consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
+	(51, 68)	unsteady gait	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2877	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s1]unsteady gait[e1]  consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(51, 68)	unsteady gait	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2878	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s1]unsteady gait[e1]  consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
+	(12, 25)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2879	CONCLUSION: Healthcare professionals should be aware of the possible development of [s1]serotonin syndrome[e1] as a complication of initiation of [s2]fentanyl[e2] and other phenylpiperidine opioids in patients treated with SSRIs.
+	(7, 21)	serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2880	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between fentanyl and [s2]citalopram[e2]  as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
+	(7, 17)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2881	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between [s2]fentanyl[e2] and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
+	(7, 17)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2882	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between [s2]fentanyl[e2] and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
+	(0, 10)	Serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2883	 [s1]Serotonin syndrome[e1] caused by interaction between [s2]citalopram[e2] and fentanyl.
+	(0, 15)	Serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2884	 [s1]Serotonin syndrome[e1] caused by interaction between citalopram and [s2]fentanyl[e2] 
+	(0, 8)	Renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2885	 [s1]Renal failure[e1] after high-dose [s2]methotrexate[e2] in a child homozygous for MTHFR C677T polymorphism.
+	(26, 43)	renal failure	HDMTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2886	We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented [s1]renal failure[e1] following the second cycle of high-dose methotrexate  [s2]HDMTX[e2] .
+	(26, 38)	renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2887	We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented [s1]renal failure[e1] following the second cycle of high-dose [s2]methotrexate[e2] (HDMTX).
+	(0, 7)	Docetaxel	Meibomian duct inflammation and blockage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2888	 [s1]Docetaxel[e1] induced [s2]Meibomian duct inflammation and blockage[e2] is the likely cause of this presentation in a patient with no history of eyelid masses in the past.
+	(0, 17)	Docetaxel	chalazion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2889	 [s1]Docetaxel[e1] induced Meibomian duct inflammation and blockage leading to [s2]chalazion[e2] formation.
+	(0, 7)	Docetaxel	Meibomian duct inflammation and blockage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2890	 [s1]Docetaxel[e1] induced [s2]Meibomian duct inflammation and blockage[e2] leading to chalazion formation.
+	(21, 33)	docetaxel	eye irritation and dryness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2891	We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly [s1]docetaxel[e1] for 12 weeks and developed significant [s2]eye irritation and dryness[e2] during treatment.
+	(3, 13)	recall pneumonitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2892	A case of [s1]recall pneumonitis[e1] induced by [s2]gemcitabine[e2] is reported.
+	(3, 20)	gemcitabine	dry cough	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2893	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed [s2]dry cough[e2]  subfebrile temperatures and dyspnea within 48 h.
+	(3, 29)	gemcitabine	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2894	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and [s2]dyspnea[e2] within 48 h.
+	(3, 23)	gemcitabine	subfebrile temperatures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2895	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed dry cough, [s2]subfebrile temperatures[e2] and dyspnea within 48 h.
+	(2, 9)	Gemcitabine	recall pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2896	CONCLUSION: [s1]Gemcitabine[e1] induced [s2]recall pneumonitis[e2] is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy.
+	(0, 11)	Radiation recall pneumonitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2897	 [s1]Radiation recall pneumonitis[e1] induced by [s2]gemcitabine[e2] 
+	(6, 13)	vancomycin	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2898	CONCLUSIONS: For all patients with [s1]vancomycin[e1] induced [s2]neutropenia[e2]  possible cross-reactivity of teicoplanin should be monitored.
+	(6, 50)	neutropenia	teicoplanin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2899	However, a new episode of [s1]neutropenia[e1]  with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after [s2]teicoplanin[e2] initiation.
+	(4, 12)	teicoplanin	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2900	OBJECTIVE: To report [s1]teicoplanin[e1] related [s2]neutropenia[e2] that developed after an episode of neutropenia induced by vancomycin therapy.
+	(11, 29)	neutropenia	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2901	OBJECTIVE: To report teicoplanin-related [s1]neutropenia[e1] that developed after an episode of neutropenia induced by [s2]vancomycin[e2] therapy.
+	(0, 8)	Teicoplanin	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2902	 [s1]Teicoplanin[e1] induced [s2]agranulocytosis[e2] that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.
+	(7, 16)	agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2903	Teicoplanin-induced [s1]agranulocytosis[e1] that followed [s2]vancomycin[e2] induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.
+	(0, 15)	Cutaneous ulceration	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2904	 [s1]Cutaneous ulceration[e1]  an unusual complication of intravenous [s2]pentamidine[e2] therapy.
+	(19, 38)	chemical cellulitis	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2905	This is a report of a renal transplant patient with Pneumocystis pneumonia who developed [s1]chemical cellulitis[e1] and ulceration following the extravasation of intravenous [s2]pentamidine[e2] into the soft tissues of the left hand and forearm.
+	(24, 38)	ulceration	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2906	This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and [s1]ulceration[e1] following the extravasation of intravenous [s2]pentamidine[e2] into the soft tissues of the left hand and forearm.
+	(11, 30)	disfiguring facial edema	peginterferon alfa-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2907	OBSERVATIONS: A 48-year-old woman presented with [s1]disfiguring facial edema[e1] 10 weeks after she began antiviral therapy with [s2]peginterferon alfa-2a[e2] and ribavirin for chronic hepatitis C infection.
+	(11, 39)	disfiguring facial edema	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2908	OBSERVATIONS: A 48-year-old woman presented with [s1]disfiguring facial edema[e1] 10 weeks after she began antiviral therapy with peginterferon alfa-2a and [s2]ribavirin[e2] for chronic hepatitis C infection.
+	(0, 13)	Tumor-volume increase	interferon alpha 2-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2909	 [s1]Tumor-volume increase[e1] at beginning of primary treatment with topical [s2]interferon alpha 2-beta[e2] in a case of conjunctiva-cornea intraepithelial neoplasia.
+	(0, 12)	Flecainide	cardiovascular collapse	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2910	 [s1]Flecainide[e1] overdose can rapidly result in profound [s2]cardiovascular collapse[e2]  and is associated with a relatively high mortality.
+	(1, 7)	cardiovascular collapse	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2911	Managing [s1]cardiovascular collapse[e1] in severe [s2]flecainide[e2] overdose without recourse to extracorporeal therapy.
+	(0, 8)	Ezetimibe	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2912	 [s1]Ezetimibe[e1] induced [s2]acute pancreatitis[e2] 
+	(13, 21)	ezetimibe	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2913	Since its FDA approval in 2002, there are no known citations of [s1]ezetimibe[e1] induced [s2]pancreatitis[e2] 
+	(6, 14)	raloxifene	aggravation of nonalcoholic steatohepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2914	Selective estrogen receptor modulator [s1]raloxifene[e1] associated [s2]aggravation of nonalcoholic steatohepatitis[e2] 
+	(11, 18)	NASH	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2915	This is the first histologically confirmed case of [s1]NASH[e1] that was aggravated by [s2]raloxifene[e2] 
+	(3, 10)	liver damage	Danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2916	A case of [s1]liver damage[e1] following treatment with [s2]Danazol[e2] for fibrocystic breast disease is reported.
+	(0, 7)	Hepatic damage	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2917	 [s1]Hepatic damage[e1] after [s2]danazol[e2] treatment.
+	(0, 19)	Hypersensitivity pneumonitis-like syndrome	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2918	 [s1]Hypersensitivity pneumonitis-like syndrome[e1] associated with the use of [s2]lenalidomide[e2] 
+	(9, 30)	lenalidomide	diffuse pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2919	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, fever, hypoxia, and [s2]diffuse pulmonary infiltrates[e2] developed.
+	(9, 17)	lenalidomide	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2920	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom [s2]dyspnea[e2]  fever, hypoxia, and diffuse pulmonary infiltrates developed.
+	(9, 22)	lenalidomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2921	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, [s2]fever[e2]  hypoxia, and diffuse pulmonary infiltrates developed.
+	(9, 24)	lenalidomide	hypoxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2922	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, fever, [s2]hypoxia[e2]  and diffuse pulmonary infiltrates developed.
+	(15, 32)	thalidomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2923	Physicians should be cognizant of this potential complication in patients receiving [s1]thalidomide[e1] or thalidomide-like drugs who present with [s2]fever[e2] and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.
+	(15, 34)	thalidomide	pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2924	Physicians should be cognizant of this potential complication in patients receiving [s1]thalidomide[e1] or thalidomide-like drugs who present with fever and [s2]pulmonary infiltrates[e2] and fail to improve despite treatment with broad-spectrum antibiotics.
+	(16, 23)	lenalidomide	hypersensitivity pneumonitis-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2925	Thus, the patient's clinical course and workup strongly support a diagnosis of [s1]lenalidomide[e1] induced [s2]hypersensitivity pneumonitis-like syndrome[e2] 
+	(4, 17)	triamcinolone	exacerbation of retinochoroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2926	Intravitreal [s1]triamcinolone[e1] may have had an influence on the [s2]exacerbation of retinochoroiditis[e2] in the posterior pole of the patient.
+	(22, 30)	rapid cognitive decline	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2927	A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced [s1]rapid cognitive decline[e1] after commencement of [s2]ethambutol[e2]  and symptoms fully resolved with cessation.
+	(0, 11)	Ethambutol	acute onset psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2928	 [s1]Ethambutol[e1] toxicity manifesting as [s2]acute onset psychosis[e2] 
+	(0, 7)	Psoriasis	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2929	 [s1]Psoriasis[e1] induced by [s2]interferon-alpha[e2] 
+	(0, 31)	Recombinant human interferon-alpha	exacerbate psoriasis or trigger off its onset	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2930	 [s1]Recombinant human interferon-alpha[e1] has been used in the treatment of several cancers, but there have been several reports that it may [s2]exacerbate psoriasis or trigger off its onset[e2] 
+	(10, 29)	psoriasis	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2931	We report four patients, three of whom first developed [s1]psoriasis[e1] and one who had an aggravation of the condition during treatment with [s2]interferon-alpha[e2] 
+	(27, 40)	generalized erythema	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2932	A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed [s1]generalized erythema[e1] with high fever 3 weeks after taking [s2]sulfamethoxazole[e2] trimethoprim.
+	(27, 47)	generalized erythema	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2933	A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed [s1]generalized erythema[e1] with high fever 3 weeks after taking sulfamethoxazole [s2]trimethoprim[e2] 
+	(23, 36)	raised intracranial pressure	sodium valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2934	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and [s1]raised intracranial pressure[e1] (ICP) after severe [s2]sodium valproic acid[e2] (VPA) intoxication.
+	(23, 41)	raised intracranial pressure	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2935	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and [s1]raised intracranial pressure[e1] (ICP) after severe sodium valproic acid  [s2]VPA[e2]  intoxication.
+	(19, 36)	severe cerebral swelling	sodium valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2936	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with [s1]severe cerebral swelling[e1] and raised intracranial pressure (ICP) after severe [s2]sodium valproic acid[e2] (VPA) intoxication.
+	(19, 41)	severe cerebral swelling	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2937	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with [s1]severe cerebral swelling[e1] and raised intracranial pressure (ICP) after severe sodium valproic acid  [s2]VPA[e2]  intoxication.
+	(8, 18)	raised intracranial pressure	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2938	Neurointensive care management of [s1]raised intracranial pressure[e1] caused by severe [s2]valproic acid[e2] intoxication.
+	(0, 7)	Bleomycin	hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2939	 [s1]Bleomycin[e1] induced [s2]hyperpigmentation[e2] with yolk sac tumor.
+	(26, 31)	skin toxicity	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2940	The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the [s1]skin toxicity[e1] of [s2]bleomycin[e2] 
+	(11, 35)	localized pigmentation	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2941	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included cisplatin, etoposide and [s2]bleomycin[e2] 
+	(11, 26)	localized pigmentation	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2942	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included [s2]cisplatin[e2]  etoposide and bleomycin.
+	(11, 30)	localized pigmentation	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2943	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included cisplatin, [s2]etoposide[e2] and bleomycin.
+	(6, 18)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2944	A cause-effect relationship to [s1]capecitabine[e1] was suggested due to resolution of [s2]headache[e2] with capecitabine withdrawal and reappearance with capecitabine rechallenge.
+	(2, 15)	Headaches	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2945	BACKGROUND: [s1]Headaches[e1] have been reported as a potential side effect of [s2]capecitabine[e2] therapy.
+	(0, 7)	Capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2946	 [s1]Capecitabine[e1] induced [s2]headache[e2] responding to diltiazem.
+	(9, 21)	5-FU	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2947	CCBs should be considered in the treatment of [s1]5-FU[e1] or capecitabine-induced [s2]headaches[e2] 
+	(13, 20)	capecitabine	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2948	CCBs should be considered in the treatment of 5-FU or [s1]capecitabine[e1] induced [s2]headaches[e2] 
+	(5, 12)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2949	The patient developed grade 3 [s1]capecitabine[e1] induced [s2]headache[e2] 
+	(7, 14)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2950	We hypothesize that [s1]capecitabine[e1] induced [s2]headache[e2] is vascular in nature.
+	(0, 19)	Brugada type electrocardiographic changes	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2951	 [s1]Brugada type electrocardiographic changes[e1] induced by concomitant use of [s2]lithium[e2] and propafenone in patient with Wolff-Parkinson-White syndrome.
+	(0, 21)	Brugada type electrocardiographic changes	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2952	 [s1]Brugada type electrocardiographic changes[e1] induced by concomitant use of lithium and [s2]propafenone[e2] in patient with Wolff-Parkinson-White syndrome.
+	(5, 26)	ST elevation in right precordial leads	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2953	We report a case of [s1]ST elevation in right precordial leads[e1] compatible with type 1 Brugada syndrome following administration of [s2]propafenone[e2] in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.
+	(15, 26)	type 1 Brugada syndrome	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2954	We report a case of ST elevation in right precordial leads compatible with [s1]type 1 Brugada syndrome[e1] following administration of [s2]propafenone[e2] in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.
+	(4, 11)	gastritis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2955	We postulate that [s1]gastritis[e1] caused by [s2]dexamethasone[e2]  mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.
+	(15, 22)	mucositis	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2956	We postulate that gastritis caused by dexamethasone, [s1]mucositis[e1] caused by [s2]doxorubicin[e2]  and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.
+	(0, 16)	Bortezomib	gastrointestinal side effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2957	 [s1]Bortezomib[e1] induced paralytic ileus is a potential [s2]gastrointestinal side effect[e2] of this first-in-class anticancer proteasome inhibitor.
+	(0, 8)	Bortezomib	paralytic ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2958	 [s1]Bortezomib[e1] induced [s2]paralytic ileus[e2] is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
+	(0, 10)	Paralytic ileus	bortezomib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2959	 [s1]Paralytic ileus[e1] in patients undergoing [s2]bortezomib[e2] treatment has been reported, although a definite attribution to bortezomib administration has not been established.
+	(9, 18)	severe paralytic ileus	bortezomib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2960	We report a myeloma patient who developed [s1]severe paralytic ileus[e1] during [s2]bortezomib[e2] therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship.
+	(3, 13)	delusional parasitosis	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2961	A woman developed [s1]delusional parasitosis[e1] when taking [s2]phenelzine[e2] 
+	(0, 10)	Delusional parasitosis	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2962	 [s1]Delusional parasitosis[e1] associated with [s2]phenelzine[e2] 
+	(9, 24)	alveolar hemorrhage	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2963	Interstitial pneumonitis and [s1]alveolar hemorrhage[e1] complicating use of [s2]rituximab[e2]  case report and review of the literature.
+	(0, 24)	Interstitial pneumonitis	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2964	 [s1]Interstitial pneumonitis[e1] and alveolar hemorrhage complicating use of [s2]rituximab[e2]  case report and review of the literature.
+	(3, 16)	rituximab	delayed pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2965	The use of [s1]rituximab[e1] has been uncommonly associated with [s2]delayed pulmonary toxicity[e2] 
+	(4, 13)	metoclopramide	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2966	Fulminant [s1]metoclopramide[e1] induced [s2]neuroleptic malignant syndrome[e2] rapidly responsive to intravenous dantrolene.
+	(9, 35)	neuroleptic malignant syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2967	We report a case of fulminant [s1]neuroleptic malignant syndrome[e1] in a man aged 70 developing within 12 hours of starting six-hourly intravenous [s2]metoclopramide[e2] 
+	(4, 22)	gastric mucosa foveolar hyperplasia	PGE1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2968	The clinical symptoms of [s1]gastric mucosa foveolar hyperplasia[e1] due to long-term [s2]PGE1[e2] therapy simulate hypertrophic pyloric stenosis.
+	(16, 32)	gastric mucosa foveolar hyperplasia	PGE1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2969	The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of [s1]gastric mucosa foveolar hyperplasia[e1] due to prolonged [s2]PGE1[e2] therapy.
+	(40, 56)	fatigue	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2970	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of [s1]fatigue[e1]  myalgia, and leg weakness, shortly after starting treatment with [s2]colchicine[e2] 
+	(47, 56)	leg weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2971	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and [s1]leg weakness[e1]  shortly after starting treatment with [s2]colchicine[e2] 
+	(42, 56)	myalgia	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2972	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, [s1]myalgia[e1]  and leg weakness, shortly after starting treatment with [s2]colchicine[e2] 
+	(3, 9)	colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2973	A case of [s1]colchicine[e1] induced [s2]rhabdomyolysis[e2] is reported.
+	(0, 6)	Colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2974	 [s1]Colchicine[e1] induced [s2]rhabdomyolysis[e2] is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.
+	(0, 6)	Colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2975	 [s1]Colchicine[e1] induced [s2]rhabdomyolysis[e2] 
+	(17, 32)	colchicine	rhabdomylysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2976	Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of [s1]colchicine[e1] resulted in resolution of clinical and biochemical features of [s2]rhabdomylysis[e2] 
+	(0, 9)	5-Fluorouracil	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2977	 [s1]5-Fluorouracil[e1]  [s2]cardiotoxicity[e2] complicating treatment of stage IIB cervical cancer--case report.
+	(2, 14)	Acetic acid	vagina bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2978	CONCLUSION: [s1]Acetic acid[e1] is corrosive and may cause [s2]vagina bleeding[e2] 
+	(2, 13)	systemic lupus erythematosus	interferon-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2979	Induction of [s1]systemic lupus erythematosus[e1] by [s2]interferon-gamma[e2] in a patient with rheumatoid arthritis.
+	(11, 21)	SLE	recombinant human interferon gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2980	The development of systemic lupus erythematosus  [s1]SLE[e1]  after 38 months of therapy with [s2]recombinant human interferon gamma[e2] (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
+	(11, 30)	SLE	rIFN-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2981	The development of systemic lupus erythematosus  [s1]SLE[e1]  after 38 months of therapy with recombinant human interferon gamma  [s2]rIFN-gamma[e2]  was observed in a patient with rheumatoid arthritis.
+	(3, 23)	systemic lupus erythematosus	recombinant human interferon gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2982	The development of [s1]systemic lupus erythematosus[e1] (SLE) after 38 months of therapy with [s2]recombinant human interferon gamma[e2] (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
+	(3, 32)	systemic lupus erythematosus	rIFN-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2983	The development of [s1]systemic lupus erythematosus[e1] (SLE) after 38 months of therapy with recombinant human interferon gamma  [s2]rIFN-gamma[e2]  was observed in a patient with rheumatoid arthritis.
+	(3, 16)	rIFN-gamma	SLE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2984	We assume that [s1]rIFN-gamma[e1] induced the de novo development of [s2]SLE[e2] in our patient.
+	(0, 8)	Bisphosphonate	osteochemonecrosis of the jaw	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2985	 [s1]Bisphosphonate[e1] induced [s2]osteochemonecrosis of the jaw[e2] mimicking a tumour.
+	(0, 6)	Clozapine	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2986	 [s1]Clozapine[e1] induced [s2]eosinophilia[e2] and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.
+	(3, 20)	eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2987	Drug-induced [s1]eosinophilia[e1] is a non-dose-dependent side effect of [s2]clozapine[e2] 
+	(7, 22)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2988	Occasionally, despite good therapeutic response, [s1]clozapine[e1] must be stopped due to dangerous side effects such as [s2]agranulocytosis[e2] 
+	(5, 24)	lactic acidosis	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2989	Metformin-associated [s1]lactic acidosis[e1] (MALA) is a serious metabolic complication that occurs because of [s2]metformin[e2] accumulation in patients who become dehydrated or developed acute renal failure.
+	(0, 6)	Metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2990	 [s1]Metformin[e1] associated [s2]lactic acidosis[e2] (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure.
+	(0, 6)	Metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2991	 [s1]Metformin[e1] associated [s2]lactic acidosis[e2] precipitated by diarrhea.
+	(9, 30)	MMF	red blood cell anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2992	An apparent link is described between the use of [s1]MMF[e1] with prednisone to treat pemphigus vulgaris and the development of [s2]red blood cell anemia[e2] 
+	(12, 30)	prednisone	red blood cell anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2993	An apparent link is described between the use of MMF with [s1]prednisone[e1] to treat pemphigus vulgaris and the development of [s2]red blood cell anemia[e2] 
+	(0, 22)	Red blood cell anemia	mycophenolate mofetil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2994	 [s1]Red blood cell anemia[e1] in a patient with pemphigus vulgaris induced by the use of [s2]mycophenolate mofetil[e2] and prednisone.
+	(0, 32)	Red blood cell anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2995	 [s1]Red blood cell anemia[e1] in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and [s2]prednisone[e2] 
+	(13, 24)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2996	The dermatology literature heretofore has not noted that [s1]anemia[e1] is a side effect of patients taking [s2]MMF[e2] to treat pemphigus.
+	(4, 45)	anemia	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2997	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, [s2]cyclosporine[e2] and prednisone is used.
+	(4, 12)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2998	This report suggests that [s1]anemia[e1] can occur due to [s2]MMF[e2]  in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
+	(4, 12)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2999	This report suggests that [s1]anemia[e1] can occur due to [s2]MMF[e2]  in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
+	(4, 22)	anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3000	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with [s2]prednisone[e2]  a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
+	(4, 22)	anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3001	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with [s2]prednisone[e2]  a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
+	(20, 28)	oxcarbazepine	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3002	A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of [s1]oxcarbazepine[e1] associated [s2]angioedema[e2] in pediatric patients aged 16 years and younger.
+	(3, 11)	oxcarbazepine	angioneurotic edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3003	Clinical profile of [s1]oxcarbazepine[e1] related [s2]angioneurotic edema[e2]  case report and review.
+	(0, 8)	Oxcarbazepine	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3004	 [s1]Oxcarbazepine[e1] associated [s2]angioedema[e2] manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital.
+	(28, 37)	angioedema	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3005	We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced [s1]angioedema[e1] during treatment with [s2]oxcarbazepine[e2] 
+	(6, 25)	VOD	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3006	Here we describe another case of [s1]VOD[e1] occurring after LT, but in which the causative role was played by [s2]azathioprine[e2] 
+	(3, 10)	tacrolimus	hepatic VOD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3007	One case of [s1]tacrolimus[e1] induced [s2]hepatic VOD[e2] developing after lung transplantation (LT) has been recently reported.
+	(0, 7)	Carbamazepine	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3008	 [s1]Carbamazepine[e1]  [s2]hypersensitivity syndrome[e2] is a rare, life-threatening condition.
+	(14, 23)	pulmonary toxicity	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3009	A patient with chronic myelomonocytic leukemia developed drug-induced [s1]pulmonary toxicity[e1] after using low dose oral [s2]etoposide[e2] 
+	(1, 8)	etoposide	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3010	Because [s1]etoposide[e1] induced [s2]pulmonary toxicity[e2] is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.
+	(5, 12)	etoposide	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3011	PET scintigraphy of [s1]etoposide[e1] induced [s2]pulmonary toxicity[e2] 
+	(16, 25)	L-tryptophan	eosinophilia-myalgia syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3012	Detection of antineutrophil cytoplasmic antibody in a patient with [s1]L-tryptophan[e1] induced [s2]eosinophilia-myalgia syndrome[e2] 
+	(11, 27)	eosinophilia-myalgia syndrome	L-tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3013	The Center for Disease Control has received numerous reports of an [s1]eosinophilia-myalgia syndrome[e1] related to products containing [s2]L-tryptophan[e2] 
+	(7, 12)	RFP	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3014	Here, we report a case of [s1]RFP[e1] induced [s2]hypothyroidism[e2] without underlying thyroid disease.
+	(0, 7)	Rifampin	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3015	 [s1]Rifampin[e1] induced [s2]hypothyroidism[e2] without underlying thyroid disease.
+	(4, 38)	RFP	Hashimoto's thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3016	Rifampin  [s1]RFP[e1]  increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with [s2]Hashimoto's thyroiditis[e2] 
+	(0, 40)	Rifampin	Hashimoto's thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3017	 [s1]Rifampin[e1] (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with [s2]Hashimoto's thyroiditis[e2] 
+	(4, 28)	RFP	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3018	Rifampin  [s1]RFP[e1]  increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced [s2]hypothyroidism[e2]  all associated with Hashimoto's thyroiditis.
+	(0, 30)	Rifampin	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3019	 [s1]Rifampin[e1] (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced [s2]hypothyroidism[e2]  all associated with Hashimoto's thyroiditis.
+	(10, 31)	pulmonary fibrosis	nabumetone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3020	A patient is described who developed a rapid onset of [s1]pulmonary fibrosis[e1] following treatment with a new non-steroidal anti-inflammatory drug, [s2]nabumetone[e2] 
+	(0, 8)	Pulmonary fibrosis	nabumetone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3021	 [s1]Pulmonary fibrosis[e1] associated with [s2]nabumetone[e2] 
+	(0, 28)	Cyclosporine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3022	 [s1]Cyclosporine[e1] is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced [s2]rhabdomyolysis[e2] 
+	(10, 28)	simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3023	Cyclosporine is a potent inhibitor of [s1]simvastatin[e1] metabolism, and may therefore facilitate simvastatin-induced [s2]rhabdomyolysis[e2] 
+	(10, 21)	cyclosporine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3024	Discontinuation of simvastatin and [s1]cyclosporine[e1] resulted in resolution of [s2]rhabdomyolysis[e2] and normalization of renal function.
+	(5, 21)	simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3025	Discontinuation of [s1]simvastatin[e1] and cyclosporine resulted in resolution of [s2]rhabdomyolysis[e2] and normalization of renal function.
+	(6, 14)	rhabdomyolysis	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3026	Simvastatin-induced [s1]rhabdomyolysis[e1] following [s2]cyclosporine[e2] treatment for uveitis.
+	(0, 7)	Simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3027	 [s1]Simvastatin[e1] induced [s2]rhabdomyolysis[e2] following cyclosporine treatment for uveitis.
+	(0, 14)	Generalized lichen nitidus	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3028	 [s1]Generalized lichen nitidus[e1] with involvement of the palms following [s2]interferon alpha[e2] treatment.
+	(7, 30)	generalized lichen nitidus	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3029	Here we present the case of a [s1]generalized lichen nitidus[e1] with involvement of the palms in a patient with hepatitis C after systemic treatment with [s2]interferon alpha[e2] and ribavirin.
+	(7, 35)	generalized lichen nitidus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3030	Here we present the case of a [s1]generalized lichen nitidus[e1] with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and [s2]ribavirin[e2] 
+	(7, 21)	interferon alpha	lichen nitidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3031	It is tempting to speculate that [s1]interferon alpha[e1] may be involved in the pathogenesis of [s2]lichen nitidus[e2] 
+	(0, 17)	Sirolimus-eluting stent thrombosis	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3032	 [s1]Sirolimus-eluting stent thrombosis[e1] several years after [s2]clopidogrel[e2] discontinuation.
+	(12, 22)	ATRA	teratogenic effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3033	Treatment of APL in pregnancy is controversial as the use of [s1]ATRA[e1] has been questioned due to the [s2]teratogenic effect[e2] of retinoids.
+	(5, 15)	ILD	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3034	Interstitial lung disease  [s1]ILD[e1]  related to therapy with the drug [s2]gefitinib[e2] has been well reported.
+	(0, 17)	Interstitial lung disease	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3035	 [s1]Interstitial lung disease[e1] (ILD) related to therapy with the drug [s2]gefitinib[e2] has been well reported.
+	(0, 6)	Pulmonary toxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3036	 [s1]Pulmonary toxicity[e1] associated with [s2]erlotinib[e2] 
+	(28, 40)	pulmonary fibrosis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3037	Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known [s1]pulmonary fibrosis[e1] may be at particular risk for [s2]erlotinib[e2] pulmonary toxicity.
+	(38, 44)	erlotinib	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3038	Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for [s1]erlotinib[e1]  [s2]pulmonary toxicity[e2] 
+	(14, 21)	erlotinib	ILD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3039	This case and other published evidence should alert physicians to the possibility of fatal [s1]erlotinib[e1] induced [s2]ILD[e2] 
+	(5, 23)	fatal pulmonary toxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3040	We report a case of [s1]fatal pulmonary toxicity[e1] in a patient with advanced non-small cell lung cancer who received [s2]erlotinib[e2] 
+	(5, 27)	fluoroquinolone	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3041	It has been reported that [s1]fluoroquinolone[e1] antimicrobials prolong the corrected QT interval but rarely cause [s2]torsade de pointes[e2] 
+	(0, 10)	Torsade de pointes	moxifloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3042	 [s1]Torsade de pointes[e1] associated with [s2]moxifloxacin[e2]  a rare but potentially fatal adverse event.
+	(8, 33)	skin necrosis	Glypressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3043	AIM: To report three cases of extensive [s1]skin necrosis[e1] in cirrhotic patients treated with the vasoconstrictor agent terlipressin  [s2]Glypressin[e2] .
+	(8, 29)	skin necrosis	terlipressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3044	AIM: To report three cases of extensive [s1]skin necrosis[e1] in cirrhotic patients treated with the vasoconstrictor agent [s2]terlipressin[e2] (Glypressin).
+	(1, 14)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3045	Both [s1]colchicine[e1] and statin therapy may be associated with [s2]myopathy[e2]  which usually occurs after several months of therapy.
+	(5, 14)	statin	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3046	Both colchicine and [s1]statin[e1] therapy may be associated with [s2]myopathy[e2]  which usually occurs after several months of therapy.
+	(3, 25)	muscle weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3047	Rapid onset of [s1]muscle weakness[e1] (rhabdomyolysis) associated with the combined use of simvastatin and [s2]colchicine[e2] 
+	(3, 20)	muscle weakness	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3048	Rapid onset of [s1]muscle weakness[e1] (rhabdomyolysis) associated with the combined use of [s2]simvastatin[e2] and colchicine.
+	(5, 23)	rhabdomyolysis	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3049	Rapid onset of muscle weakness  [s1]rhabdomyolysis[e1]  associated with the combined use of simvastatin and [s2]colchicine[e2] 
+	(5, 18)	rhabdomyolysis	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3050	Rapid onset of muscle weakness  [s1]rhabdomyolysis[e1]  associated with the combined use of [s2]simvastatin[e2] and colchicine.
+	(10, 26)	colchicine	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3051	The concomitant use, however, of [s1]colchicine[e1] and statin has been associated with the rapid onset of [s2]muscle weakness[e2] 
+	(14, 26)	statin	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3052	The concomitant use, however, of colchicine and [s1]statin[e1] has been associated with the rapid onset of [s2]muscle weakness[e2] 
+	(29, 42)	acute weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3053	We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed [s1]acute weakness[e1] within 3 weeks after the start of treatment with [s2]colchicine[e2] for acute gouty bursitis.
+	(19, 31)	simvastatin	acute weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3054	We report a case of a patient with mild chronic renal insufficiency who had been taking [s1]simvastatin[e1] for over a year and developed [s2]acute weakness[e2] within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.
+	(8, 21)	mild chronic renal insufficiency	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3055	We report a case of a patient with [s1]mild chronic renal insufficiency[e1] who had been taking [s2]simvastatin[e2] for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.
+	(0, 17)	Pneumocystis carinii pneumonia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3056	 [s1]Pneumocystis carinii pneumonia[e1] as a complication of [s2]methotrexate[e2] treatment of asthma.
+	(15, 25)	methotrexate	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3057	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with [s2]fever[e2]  pulmonary infiltrates, and hypoxia.
+	(15, 32)	methotrexate	hypoxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3058	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with fever, pulmonary infiltrates, and [s2]hypoxia[e2] 
+	(0, 17)	Pneumocystis pneumonia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3059	 [s1]Pneumocystis pneumonia[e1] should be considered in asthmatic patients taking [s2]methotrexate[e2] who present with fever, pulmonary infiltrates, and hypoxia.
+	(15, 27)	methotrexate	pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3060	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with fever, [s2]pulmonary infiltrates[e2]  and hypoxia.
+	(23, 34)	unilateral hearing loss	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3061	CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a [s1]unilateral hearing loss[e1] shortly after commencing [s2]desferrioxamine[e2] therapy.
+	(9, 51)	leflunomide	abdominal sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3062	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), [s2]abdominal sepsis[e2] (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(9, 25)	leflunomide	cellulitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3063	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), [s2]cellulitis[e2] (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(9, 32)	leflunomide	disseminated herpes zoster	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3064	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), [s2]disseminated herpes zoster[e2] (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(9, 69)	leflunomide	gastroenteritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3065	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and [s2]gastroenteritis[e2] (1).
+	(3, 11)	infection	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3066	Eleven patients developed [s1]infection[e1] requiring hospitalization while taking [s2]leflunomide[e2] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(9, 17)	leflunomide	lower respiratory tract infections	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3067	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: [s2]lower respiratory tract infections[e2] (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(9, 58)	leflunomide	mycotic aneurysm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3068	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), [s2]mycotic aneurysm[e2] (1) and gastroenteritis (1).
+	(9, 45)	leflunomide	TB liver	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3069	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable [s2]TB liver[e2] (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
+	(0, 7)	Leflunomide	infections	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3070	 [s1]Leflunomide[e1] associated [s2]infections[e2] in rheumatoid arthritis.
+	(15, 24)	severe infections	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3071	The NZ Pharmacovigilance Centre has received 7 additional reports of [s1]severe infections[e1] in patients with RA taking [s2]leflunomide[e2] 
+	(18, 44)	fever	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3072	A 58-year-old woman with rheumatoid arthritis (RA) developed [s1]fever[e1]  skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
+	(23, 44)	leukocytopenia	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3073	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, [s1]leukocytopenia[e1]  and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
+	(20, 44)	skin eruptions	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3074	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, [s1]skin eruptions[e1]  leukocytopenia, and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
+	(31, 44)	thrombocytopenia	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3075	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and [s1]thrombocytopenia[e1]  3 weeks after treatment with [s2]sulfasalazine[e2] 
+	(0, 14)	Sulfasalazine	hemophagocytic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3076	 [s1]Sulfasalazine[e1] induced hypersensitivity syndrome and [s2]hemophagocytic syndrome[e2] associated with reactivation of Epstein-Barr virus.
+	(0, 8)	Sulfasalazine	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3077	 [s1]Sulfasalazine[e1] induced [s2]hypersensitivity syndrome[e2] and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.
+	(5, 37)	hemophagocytic syndrome	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3078	This case illustrates that the [s1]hemophagocytic syndrome[e1] associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking [s2]sulfasalazine[e2] 
+	(26, 54)	status migrainosus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3079	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine (OXC), as part of a switch off from [s2]carbamazepine[e2] (CBZ).
+	(26, 59)	status migrainosus	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3080	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine  [s2]CBZ[e2] .
+	(26, 42)	status migrainosus	OXC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3081	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine  [s2]OXC[e2] , as part of a switch off from carbamazepine (CBZ).
+	(26, 37)	status migrainosus	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3082	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of [s2]oxcarbazepine[e2] (OXC), as part of a switch off from carbamazepine (CBZ).
+	(4, 9)	headache	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3083	Uncontrolled [s1]headache[e1] induced by [s2]oxcarbazepine[e2] 
+	(11, 22)	myoclonic muscle spasms	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3084	CONCLUSION: A patient with CHF and ESRD developed [s1]myoclonic muscle spasms[e1] after receiving [s2]dobutamine[e2] by continuous i.v. infusion.
+	(0, 9)	Myoclonus	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3085	 [s1]Myoclonus[e1] associated with continuous [s2]dobutamine[e2] infusion in a patient with end-stage renal disease.
+	(5, 21)	myoclonus	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3086	PURPOSE: The occurrence of [s1]myoclonus[e1] associated with continuous i.v. infusion of [s2]dobutamine[e2] in a patient with end-stage renal disease (ESRD) is described.
+	(2, 16)	colonic perforation	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3087	Reports of [s1]colonic perforation[e1] as a result of the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol are rare.
+	(2, 25)	colonic perforation	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3088	Reports of [s1]colonic perforation[e1] as a result of the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] are rare.
+	(4, 27)	colonic ulcer	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3089	We concluded that the [s1]colonic ulcer[e1] and the sigmoidovesical fistula had been caused by the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol.
+	(4, 36)	colonic ulcer	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3090	We concluded that the [s1]colonic ulcer[e1] and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] 
+	(10, 27)	sigmoidovesical fistula	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3091	We concluded that the colonic ulcer and the [s1]sigmoidovesical fistula[e1] had been caused by the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol.
+	(10, 36)	sigmoidovesical fistula	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3092	We concluded that the colonic ulcer and the [s1]sigmoidovesical fistula[e1] had been caused by the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] 
+	(0, 21)	Psychosis	efavirenz	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3093	 [s1]Psychosis[e1] in a 12-year-old HIV-positive girl with an increased serum concentration of [s2]efavirenz[e2] 
+	(18, 33)	psychosis	efavirenz	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3094	We report (to our knowledge, for the first time in a child) the emergence of [s1]psychosis[e1] in a 12-year old white girl with an increased [s2]efavirenz[e2] concentration and heterozygous gene polymorphism of the CYP2B6-G516T.
+	(0, 23)	Mycobacterium marinum infection	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3095	 [s1]Mycobacterium marinum infection[e1] complicating Crohn's disease, treated with [s2]infliximab[e2] 
+	(0, 13)	Sustained monomorphic ventricular tachycardia	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3096	 [s1]Sustained monomorphic ventricular tachycardia[e1] after [s2]adenosine[e2] infusion.
+	(6, 19)	sustained monomorphic ventricular tachycardia	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3097	We present a case of a [s1]sustained monomorphic ventricular tachycardia[e1] following [s2]adenosine[e2] infusion.
+	(10, 19)	tardive OGC	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3098	Surprisingly, we found that three patients appeared to develop [s1]tardive OGC[e1] while taking [s2]clozapine[e2] 
+	(0, 13)	Tardive oculogyric crisis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3099	 [s1]Tardive oculogyric crisis[e1] during treatment with [s2]clozapine[e2]  report of three cases.
+	(0, 7)	Metronidazole	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3100	 [s1]Metronidazole[e1]  [s2]neuropathy[e2] 
+	(6, 24)	sensory neuropathy	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3101	Two patients are described who developed [s1]sensory neuropathy[e1] after the ingestion of 30.6 and 114 g [s2]metronidazole[e2] respectively.
+	(19, 34)	methotrexate	infection with both M. tuberculosis and M. chelonae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3102	We report a case of a patient with rheumatoid arthritis treated with low-dose [s1]methotrexate[e1] (15 mg/week) who developed [s2]infection with both M. tuberculosis and M. chelonae[e2] after the revision of a prosthetic hip.
+	(2, 15)	Sustained ventricular tachycardia	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3103	DIAGNOSIS: [s1]Sustained ventricular tachycardia[e1] possibly owing to [s2]thalidomide[e2] treatment.
+	(0, 11)	Multiple syncopal episodes	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3104	 [s1]Multiple syncopal episodes[e1] started to occur during [s2]thalidomide[e2] treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.
+	(9, 33)	thalidomide	sustained ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3105	Multiple syncopal episodes started to occur during [s1]thalidomide[e1] treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of [s2]sustained ventricular tachycardia[e2] 
+	(0, 12)	Sustained ventricular tachycardia	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3106	 [s1]Sustained ventricular tachycardia[e1] in a [s2]thalidomide[e2] treated patient with primary plasma-cell leukemia.
+	(4, 17)	ECM	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3107	A patient developed typical [s1]ECM[e1] after subcutaneous selfinjection of [s2]glatiramer acetate[e2] for multiple sclerosis.
+	(0, 17)	Embolia cutis medicamentosa	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3108	 [s1]Embolia cutis medicamentosa[e1] following subcutaneous injection of [s2]glatiramer acetate[e2] 
+	(36, 46)	glatiramer acetate	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3109	This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) [s1]glatiramer acetate[e1] can induce [s2]skin necrosis[e2] as a side effect.
+	(12, 45)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3110	Although it is difficult to be certain of the direct link of [s1]amiodarone[e1] on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced [s2]hypothyroidism[e2] and that involution changes represent the hypofunctional status of this drug-induced disorder.
+	(0, 30)	Amiodarone	thyroid dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3111	 [s1]Amiodarone[e1] is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause [s2]thyroid dysfunction[e2] 
+	(8, 14)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3112	Histopathology of the thyroid in [s1]amiodarone[e1] induced [s2]hypothyroidism[e2] 
+	(19, 25)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3113	This is the first report on the histopathological findings of thyroid tissue from a patient with [s1]amiodarone[e1] induced [s2]hypothyroidism[e2] 
+	(14, 30)	leucocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3114	Although adverse effects are usually mild, the author reports here a case of [s1]leucocytopenia[e1] and thrombocytopenia with [s2]quetiapine[e2] treatment that required its discontinuation.
+	(21, 30)	thrombocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3115	Although adverse effects are usually mild, the author reports here a case of leucocytopenia and [s1]thrombocytopenia[e1] with [s2]quetiapine[e2] treatment that required its discontinuation.
+	(0, 6)	Quetiapine	leucopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3116	 [s1]Quetiapine[e1] induced [s2]leucopenia[e2] and thrombocytopenia.
+	(0, 11)	Quetiapine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3117	 [s1]Quetiapine[e1] induced leucopenia and [s2]thrombocytopenia[e2] 
+	(0, 8)	Amphotericin B	cutaneous leucocytoclastic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3118	 [s1]Amphotericin B[e1] induced [s2]cutaneous leucocytoclastic vasculitis[e2]  case report.
+	(0, 24)	Palpable purpuric skin lesions	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3119	 [s1]Palpable purpuric skin lesions[e1] on the anterior surface of both legs appeared on the 55th day of [s2]amphotericin B[e2] treatment.
+	(5, 21)	cutaneous leucocytoclastic vasculitis	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3120	We present a case of [s1]cutaneous leucocytoclastic vasculitis[e1] in which [s2]amphotericin B[e2] might presumably be the aetiological factor.
+	(3, 19)	5-fluorouracil	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3121	The incidence of [s1]5-fluorouracil[e1] (5-FU)-related [s2]cardiotoxicity[e2] seems to be dosage and schedule dependent.
+	(10, 17)	5-FU	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3122	The incidence of 5-fluorouracil  [s1]5-FU[e1] -related [s2]cardiotoxicity[e2] seems to be dosage and schedule dependent.
+	(0, 17)	Transient asymptomatic bradycardia	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3123	 [s1]Transient asymptomatic bradycardia[e1] in patients on infusional [s2]5-fluorouracil[e2] 
+	(9, 27)	transient asymptomatic bradycardia	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3124	We report such a series of patients who had [s1]transient asymptomatic bradycardia[e1] after being treated with continuous infusion [s2]5-FU[e2] 
+	(10, 20)	papular eruption	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3125	According to the Naranjo probability scale, the [s1]papular eruption[e1] was probably caused by [s2]methotrexate[e2] 
+	(6, 14)	methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3126	CONCLUSIONS: The pathogenesis of [s1]methotrexate[e1] induced [s2]papular eruption[e2] in collagen vascular diseases may suggest cutaneous small-vessel vasculitis.
+	(2, 10)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3127	DISCUSSION: [s1]Methotrexate[e1] induced [s2]papular eruption[e2] is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases.
+	(0, 8)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3128	 [s1]Methotrexate[e1] induced [s2]papular eruption[e2] following treatment of psoriasis has not been previously reported.
+	(0, 8)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3129	 [s1]Methotrexate[e1] induced [s2]papular eruption[e2] following treatment of psoriasis.
+	(8, 22)	diffuse papular eruption	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3130	OBJECTIVE: To report a case of a [s1]diffuse papular eruption[e1] following treatment of psoriasis with [s2]methotrexate[e2] injections.
+	(3, 34)	methotrexate	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3131	Pathogenesis of [s1]methotrexate[e1] induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate-induced [s2]cutaneous vasculitis[e2] in collagen vascular disease.
+	(3, 11)	methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3132	Pathogenesis of [s1]methotrexate[e1] induced [s2]papular eruption[e2] in psoriasis may involve immune mechanisms other than those of methotrexate-induced cutaneous vasculitis in collagen vascular disease.
+	(5, 18)	methotrexate	diffuse pruritic papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3133	Ten hours after the second [s1]methotrexate[e1] injection, the patient experienced a [s2]diffuse pruritic papular eruption[e2] located mainly on the limbs.
+	(0, 7)	Metabolic acidosis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3134	 [s1]Metabolic acidosis[e1] induced by [s2]acetazolamide[e2] 
+	(0, 11)	Pericardial hemorrhage	acetylsalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3135	 [s1]Pericardial hemorrhage[e1] due to [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
+	(3, 22)	pericardial hemorrhage	acetylsalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3136	The authors describe [s1]pericardial hemorrhage[e1]  which is related to the use of low-dose [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
+	(25, 31)	nelfinavir	cutaneous rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3137	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), [s1]nelfinavir[e1]  [s2]cutaneous rash[e2] , and efavirenz (nausea and temporary memory loss).
+	(14, 24)	indinavir	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3138	From 1996 to 2002 several medications were changed due to their adverse effects: [s1]indinavir[e1] (renal colic and [s2]fever[e2] , nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).
+	(36, 43)	efavirenz	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3139	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and [s1]efavirenz[e1]  [s2]nausea[e2] and temporary memory loss).
+	(14, 19)	indinavir	renal colic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3140	From 1996 to 2002 several medications were changed due to their adverse effects: [s1]indinavir[e1]  [s2]renal colic[e2] and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).
+	(36, 46)	efavirenz	temporary memory loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3141	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and [s1]efavirenz[e1] (nausea and [s2]temporary memory loss[e2] .
+	(8, 16)	methotrexate	sub-acute neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3142	Conventional and diffusion-weighted MRI findings of [s1]methotrexate[e1] related [s2]sub-acute neurotoxicity[e2] 
+	(13, 31)	sub-acute toxic leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3143	This case demonstrates the value of DWI in evaluation and diagnosis of [s1]sub-acute toxic leukoencephalopathy[e1] in patients being treated with [s2]methotrexate[e2] 
+	(9, 22)	sub-acute leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3144	We describe longitudinal diffusion-weighted MRI findings of [s1]sub-acute leukoencephalopathy[e1] following [s2]methotrexate[e2] therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally.
+	(3, 17)	CD	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3145	New onset of [s1]CD[e1] may be considered as an immune-mediated injury induced by [s2]etanercept[e2] 
+	(9, 17)	immune-mediated injury	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3146	New onset of CD may be considered as an [s1]immune-mediated injury[e1] induced by [s2]etanercept[e2] 
+	(3, 24)	Crohn's disease	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3147	New onset of [s1]Crohn's disease[e1] during treatment of active ankylosing spondylitis with [s2]etanercept[e2] 
+	(4, 18)	CD	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3148	Typical symptoms of active [s1]CD[e1] occurred 11, 12, and 26 months after start of [s2]etanercept[e2] therapy, respectively.
+	(7, 21)	etanercept	CD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3149	We describe 3 AS patients treated with [s1]etanercept[e1] for active AS who developed new onset of [s2]CD[e2] while AS related symptoms responded well to etanercept.
+	(0, 18)	Upper gastrointestinal haemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3150	 [s1]Upper gastrointestinal haemorrhage[e1] is a serious complication of [s2]aspirin[e2] and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.
+	(0, 22)	Upper gastrointestinal haemorrhage	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3151	 [s1]Upper gastrointestinal haemorrhage[e1] is a serious complication of aspirin and [s2]clopidogrel[e2] (dual) anti-platelet therapy with a high morbidity and mortality.
+	(1, 20)	doxorubicin	breathing distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3152	While [s1]doxorubicin[e1] was administered, the patient presented thoracic pain and [s2]breathing distress[e2] due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.
+	(1, 15)	doxorubicin	thoracic pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3153	While [s1]doxorubicin[e1] was administered, the patient presented [s2]thoracic pain[e2] and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.
+	(0, 9)	Severe hepatocellular dysfunction	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3154	 [s1]Severe hepatocellular dysfunction[e1] following [s2]cyproterone acetate[e2] therapy.
+	(13, 21)	CPA	fatal fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3155	We report 3 patients with severe hepatocellular damage due to [s1]CPA[e1] therapy, 2 with [s2]fatal fulminant hepatitis[e2] 
+	(5, 15)	severe hepatocellular damage	CPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3156	We report 3 patients with [s1]severe hepatocellular damage[e1] due to [s2]CPA[e2] therapy, 2 with fatal fulminant hepatitis.
+	(4, 14)	acyclovir	VZV antigen-positive zoster	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3157	She was treated with [s1]acyclovir[e1] and subsequently developed [s2]VZV antigen-positive zoster[e2] 
+	(15, 30)	temozolomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3158	According to the Naranjo adverse drug reaction probability scale, the likelihood that [s1]temozolomide[e1] was responsible for the adverse drug reaction of [s2]fever[e2] was probable (score of 6).
+	(12, 22)	exfoliative rash	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3159	Clinicians should be aware that an erythematous and [s1]exfoliative rash[e1] may be induced by [s2]temozolomide[e2]  and be familiar with the pharmacologic and supportive measures necessary for its treatment.
+	(6, 9)	rash	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3160	Due to the severity of the [s1]rash[e1]  [s2]temozolomide[e2] was permanently discontinued.
+	(0, 8)	Temozolomide	desquamative skin rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3161	 [s1]Temozolomide[e1] induced [s2]desquamative skin rash[e2] in a patient with metastatic melanoma.
+	(0, 18)	Temozolomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3162	 [s1]Temozolomide[e1] was restarted 2 months later; the patient again developed a [s2]fever[e2] 
+	(0, 10)	Exfoliative dermatitis	tobramycin sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3163	 [s1]Exfoliative dermatitis[e1] secondary to [s2]tobramycin sulfate[e2] 
+	(5, 27)	exfoliative dermatitis	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3164	We report a case of [s1]exfoliative dermatitis[e1] clearly linked to intravenous and intraperitoneal administration of [s2]tobramycin[e2] 
+	(0, 10)	Rituximab-CHOP	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3165	 [s1]Rituximab-CHOP[e1] induced [s2]interstitial pneumonitis[e2] in patients with disseminated extranodal marginal zone B cell lymphoma.
+	(0, 13)	Phenytoin	cerebellar syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3166	 [s1]Phenytoin[e1] toxicity: an easily missed cause of [s2]cerebellar syndrome[e2] 
+	(3, 11)	trastuzumab	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3167	A diagnosis of [s1]trastuzumab[e1] induced [s2]pneumonitis[e2] was made.
+	(20, 35)	plural effusion dyspnoea	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3168	A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a [s1]plural effusion dyspnoea[e1] after several months of [s2]trastuzumab[e2] treatment.
+	(14, 34)	pulmonary infiltrates	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3169	A female patient with HER2 positive, metastatic breast cancer presented with [s1]pulmonary infiltrates[e1]  and a plural effusion dyspnoea after several months of [s2]trastuzumab[e2] treatment.
+	(3, 12)	interstitial lung disease	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3170	Life-threatening [s1]interstitial lung disease[e1] associated with [s2]trastuzumab[e2]  case report.
+	(12, 22)	acute allergic contact dermatitis	4-chloro-7-nitrobenzofurazan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3171	A 30-year-old pharmacist suffered from [s1]acute allergic contact dermatitis[e1] due to [s2]4-chloro-7-nitrobenzofurazan[e2] (NBD-Cl).
+	(12, 37)	acute allergic contact dermatitis	NBD-Cl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3172	A 30-year-old pharmacist suffered from [s1]acute allergic contact dermatitis[e1] due to 4-chloro-7-nitrobenzofurazan  [s2]NBD-Cl[e2] .
+	(0, 8)	Allergic contact dermatitis	4-chloro-7-nitrobenzofurazan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3173	 [s1]Allergic contact dermatitis[e1] from [s2]4-chloro-7-nitrobenzofurazan[e2] 
+	(0, 14)	Photo-onycholysis	aripiprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3174	 [s1]Photo-onycholysis[e1] caused by olanzapine and [s2]aripiprazole[e2] 
+	(0, 10)	Photo-onycholysis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3175	 [s1]Photo-onycholysis[e1] caused by [s2]olanzapine[e2] and aripiprazole.
+	(9, 24)	photo-onycholysis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3176	We report the case of a woman who developed [s1]photo-onycholysis[e1] on multiple nails after uptake of [s2]olanzapine[e2] 
+	(0, 11)	Diffuse alveolar hemorrhage	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3177	 [s1]Diffuse alveolar hemorrhage[e1] after [s2]leflunomide[e2] therapy in a patient with rheumatoid arthritis.
+	(29, 46)	hemoptysis	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3178	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, [s1]hemoptysis[e1]  and severe weakness, about 2 weeks after the administration of [s2]leflunomide[e2] 
+	(35, 46)	severe weakness	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3179	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and [s1]severe weakness[e1]  about 2 weeks after the administration of [s2]leflunomide[e2] 
+	(23, 46)	short-of-breath	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3180	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset [s1]short-of-breath[e1]  hemoptysis, and severe weakness, about 2 weeks after the administration of [s2]leflunomide[e2] 
+	(0, 16)	Hyponatraemia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3181	 [s1]Hyponatraemia[e1] developed after rechallenge with controlled release [s2]carbamazepine[e2] 
+	(0, 11)	Hyponatraemia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3182	 [s1]Hyponatraemia[e1] during low-dose [s2]carbamazepine[e2] therapy.
+	(6, 20)	antidiuresis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3183	We report the syndrome of inappropriate [s1]antidiuresis[e1] as a much earlier side-effect of [s2]carbamazepine[e2] administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.
+	(15, 33)	severe systemic CMV infection	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3184	In the present paper, we describe two patients with active UC who developed a [s1]severe systemic CMV infection[e1] during a treatment with an oral microemulsion form of [s2]cyclosporine[e2] 
+	(4, 10)	imatinib	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3185	A short review on [s1]imatinib[e1] related [s2]hepatotoxicity[e2] is also presented.
+	(0, 9)	Imatinib mesylate	fatal acute hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3186	 [s1]Imatinib mesylate[e1] related [s2]fatal acute hepatic failure[e2] in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
+	(8, 15)	imatinib	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3187	Up to four percent of patients treated with [s1]imatinib[e1] may develop [s2]hepatotoxicity[e2]  which usually resolves with discontinuation of the drug.
+	(21, 35)	imatinib	acute liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3188	We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on [s1]imatinib[e1] treatment, presenting with herpetic rash and [s2]acute liver failure[e2] 
+	(21, 30)	imatinib	herpetic rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3189	We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on [s1]imatinib[e1] treatment, presenting with [s2]herpetic rash[e2] and acute liver failure.
+	(8, 22)	olanzapine	hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3190	CONCLUSIONS: Clinicians treating elderly patients with [s1]olanzapine[e1] should be aware of the potential for rapidly developing [s2]hyperglycemia[e2] and monitor such patients accordingly.
+	(9, 28)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3191	OBJECTIVE: To report a case of rapidly occurring [s1]hyperglycemia[e1] that occurred in a geriatric patient 3 days after treatment with [s2]olanzapine[e2] 
+	(2, 11)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3192	Rapidly developing [s1]hyperglycemia[e1] during treatment with [s2]olanzapine[e2] 
+	(4, 23)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3193	Subsequently, he developed [s1]hyperglycemia[e1] (fasting blood glucose 138 mg/dL) that resolved when [s2]olanzapine[e2] was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.
+	(7, 14)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3194	There have been numerous case reports of [s1]hyperglycemia[e1] with [s2]olanzapine[e2] in the literature, but none reported hyperglycemia within days of initiation of the medication.
+	(0, 9)	Adult respiratory distress syndrome	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3195	 [s1]Adult respiratory distress syndrome[e1] after treatment with [s2]pegylated interferon alpha-2a[e2] and ribavirin.
+	(0, 19)	Adult respiratory distress syndrome	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3196	 [s1]Adult respiratory distress syndrome[e1] after treatment with pegylated interferon alpha-2a and [s2]ribavirin[e2] 
+	(10, 31)	adult respiratory distress syndrome	pegIFNalpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3197	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with pegylated interferon alpha-2a  [s2]pegIFNalpha-2a[e2]  and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(10, 22)	adult respiratory distress syndrome	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3198	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with [s2]pegylated interferon alpha-2a[e2] (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(10, 40)	adult respiratory distress syndrome	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3199	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and [s2]ribavirin[e2] use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(14, 29)	ARDS	pegIFNalpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3200	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with pegylated interferon alpha-2a  [s2]pegIFNalpha-2a[e2]  and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(14, 20)	ARDS	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3201	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with [s2]pegylated interferon alpha-2a[e2] (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(14, 38)	ARDS	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3202	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and [s2]ribavirin[e2] use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
+	(0, 9)	Bilateral anterior uveitis	clomiphene citrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3203	 [s1]Bilateral anterior uveitis[e1] associated with [s2]clomiphene citrate[e2] 
+	(7, 22)	bilateral anterior uveitis	clomiphene citrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3204	PURPOSE: To report a case of [s1]bilateral anterior uveitis[e1] associated with ovulation induction therapy using [s2]clomiphene citrate[e2] 
+	(2, 15)	tics	atomoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3205	Development of [s1]tics[e1] in a thirteen-year-old male following [s2]atomoxetine[e2] use.
+	(15, 22)	tics	atomoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3206	There are, however, case studies describing patients experiencing recurrences of [s1]tics[e1] following treatment with [s2]atomoxetine[e2] 
+	(8, 26)	type 1 diabetes mellitus	alpha-2b peginterferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3207	A 51-year-old man developed [s1]type 1 diabetes mellitus[e1] following 24 weeks of treatment with recombinant [s2]alpha-2b peginterferon[e2] plus ribavirin for chronic hepatitis C.
+	(8, 36)	type 1 diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3208	A 51-year-old man developed [s1]type 1 diabetes mellitus[e1] following 24 weeks of treatment with recombinant alpha-2b peginterferon plus [s2]ribavirin[e2] for chronic hepatitis C.
+	(5, 25)	recombinant alpha-2b peginterferon	type 1 diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3209	The clinical course suggested that [s1]recombinant alpha-2b peginterferon[e1] plus ribavirin provoked [s2]type 1 diabetes mellitus[e2]  therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
+	(19, 25)	ribavirin	type 1 diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3210	The clinical course suggested that recombinant alpha-2b peginterferon plus [s1]ribavirin[e1] provoked [s2]type 1 diabetes mellitus[e2]  therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
+	(0, 10)	Type 1 diabetes mellitus	peginterferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3211	 [s1]Type 1 diabetes mellitus[e1] provoked by [s2]peginterferon alpha-2b[e2] plus ribavirin treatment for chronic hepatitis C.
+	(0, 20)	Type 1 diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3212	 [s1]Type 1 diabetes mellitus[e1] provoked by peginterferon alpha-2b plus [s2]ribavirin[e2] treatment for chronic hepatitis C.
+	(7, 19)	ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3213	BACKGROUND: To describe the occurrence of [s1]ocular hypertension[e1] in four patients following injection of [s2]ranibizumab[e2] intravitreally.
+	(4, 18)	sustained ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3214	CONCLUSION: Severe and [s1]sustained ocular hypertension[e1] may occur after intravitreal [s2]ranibizumab[e2] 
+	(0, 12)	Ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3215	 [s1]Ocular hypertension[e1] occurred 1 month after the second [s2]ranibizumab[e2] injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.
+	(0, 14)	Persisent ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3216	 [s1]Persisent ocular hypertension[e1] following intravitreal [s2]ranibizumab[e2] 
+	(5, 13)	dextroamphetamine	peripheral vasculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3217	Methylphenidate and [s1]dextroamphetamine[e1] induced [s2]peripheral vasculopathy[e2] 
+	(0, 14)	Methylphenidate	peripheral vasculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3218	 [s1]Methylphenidate[e1] and dextroamphetamine-induced [s2]peripheral vasculopathy[e2] 
+	(14, 24)	dextroamphetamine	acral cyanosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3219	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with [s2]acral cyanosis[e2]  livedo reticularis, or Raynaud phenomenon.
+	(7, 24)	methylphenidate	acral cyanosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3220	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with [s2]acral cyanosis[e2]  livedo reticularis, or Raynaud phenomenon.
+	(14, 30)	dextroamphetamine	livedo reticularis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3221	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with acral cyanosis, [s2]livedo reticularis[e2]  or Raynaud phenomenon.
+	(7, 30)	methylphenidate	livedo reticularis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3222	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with acral cyanosis, [s2]livedo reticularis[e2]  or Raynaud phenomenon.
+	(14, 38)	dextroamphetamine	Raynaud phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3223	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with acral cyanosis, livedo reticularis, or [s2]Raynaud phenomenon[e2] 
+	(7, 38)	methylphenidate	Raynaud phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3224	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or [s2]Raynaud phenomenon[e2] 
+	(0, 24)	Disseminated eruptive giant mollusca contagiosa	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3225	 [s1]Disseminated eruptive giant mollusca contagiosa[e1] in an adult psoriasis patient during [s2]efalizumab[e2] therapy.
+	(14, 34)	eruptive mollusca contagiosa	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3226	We report a 45-year-old psoriasis patient who developed [s1]eruptive mollusca contagiosa[e1] during an antipsoriatic treatment with [s2]efalizumab[e2] 
+	(12, 27)	cervical adenocarcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3227	Gastric tumor, endometrial carcinoma and [s1]cervical adenocarcinoma[e1] in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
+	(4, 27)	endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3228	Gastric tumor, [s1]endometrial carcinoma[e1] and cervical adenocarcinoma in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
+	(0, 26)	Gastric tumor	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3229	 [s1]Gastric tumor[e1]  endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
+	(0, 13)	Incomplete posterior hyaloid detachment	pegaptanib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3230	 [s1]Incomplete posterior hyaloid detachment[e1] after intravitreal [s2]pegaptanib[e2] injection in diabetic macular edema.
+	(6, 22)	incomplete posterior hyaloid detachment	pegaptanib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3231	The authors report one case of [s1]incomplete posterior hyaloid detachment[e1] (PHD) following intravitreal [s2]pegaptanib[e2] to treat DME.
+	(0, 8)	Enalaprilat	acute parotitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3232	 [s1]Enalaprilat[e1] induced [s2]acute parotitis[e2] 
+	(8, 22)	acute bilateral parotitis	enalaprilat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3233	We present here a female patient who developed [s1]acute bilateral parotitis[e1] within minutes of i.v. [s2]enalaprilat[e2] injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.
+	(12, 27)	acute bilateral blindness	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3234	We report a 4-year-old girl who presented with [s1]acute bilateral blindness[e1]  a focal seizure and hypertension 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
+	(17, 28)	focal seizure	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3235	We report a 4-year-old girl who presented with acute bilateral blindness, a [s1]focal seizure[e1] and hypertension 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
+	(20, 28)	hypertension	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3236	We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and [s1]hypertension[e1] 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
+	(0, 13)	Severe symptomatic hyponatremia	sibutramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3237	 [s1]Severe symptomatic hyponatremia[e1] during [s2]sibutramine[e2] therapy: a case report.
+	(5, 13)	sibutramine	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3238	The known side effects of [s1]sibutramine[e1]  ie, [s2]hypertension[e2] and tachycardia, depend on its adrenergic and serotoninergic effects.
+	(5, 16)	sibutramine	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3239	The known side effects of [s1]sibutramine[e1]  ie, hypertension and [s2]tachycardia[e2]  depend on its adrenergic and serotoninergic effects.
+	(8, 17)	hyponatremia	sibutramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3240	We describe a case of life-threatening [s1]hyponatremia[e1] associated with [s2]sibutramine[e2] use in an obese woman.
+	(13, 22)	pregabalin	cortical negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3241	Our findings reveal that even in patients without a history of seizures, [s1]pregabalin[e1] can cause a [s2]cortical negative myoclonus[e2] 
+	(0, 7)	Pregabalin	cortical negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3242	 [s1]Pregabalin[e1] induced [s2]cortical negative myoclonus[e2] in a patient with neuropathic pain.
+	(12, 28)	pregabalin	negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3243	We describe a patient who, after receiving his first dose of [s1]pregabalin[e1] to relieve neuropathic pain, presented with a [s2]negative myoclonus[e2] 
+	(0, 7)	Muzolimine	severe neuromyeloencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3244	 [s1]Muzolimine[e1] induced [s2]severe neuromyeloencephalopathy[e2]  report of seven cases.
+	(30, 46)	muzolimine	fatal neuromyeloencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3245	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic [s1]muzolimine[e1] (range 240 to 1440 mg per day) [s2]fatal neuromyeloencephalopathy[e2] 
+	(0, 9)	L-asparaginase	posterior reversible encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3246	 [s1]L-asparaginase[e1] induced [s2]posterior reversible encephalopathy[e2] syndrome during acute lymphoblastic leukemia treatment in children.
+	(14, 32)	posterior reversible encephalopathy syndrome	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3247	The purpose of this article is to present the first case-series of [s1]posterior reversible encephalopathy syndrome[e1] (PRES) associated with [s2]L-asparaginase[e2] treatment.
+	(24, 30)	PRES	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3248	The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome  [s1]PRES[e1]  associated with [s2]L-asparaginase[e2] treatment.
+	(18, 24)	altered sensorium	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3249	We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and [s1]altered sensorium[e1] after [s2]L-asparaginase[e2] therapy.
+	(16, 24)	seizures	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3250	We report 3 cases of children with acute lymphoblastic leukemia who developed [s1]seizures[e1] and altered sensorium after [s2]L-asparaginase[e2] therapy.
+	(0, 8)	Anastrozole	sclerosing glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3251	 [s1]Anastrozole[e1] associated [s2]sclerosing glomerulonephritis[e2] in a patient with breast cancer.
+	(2, 19)	Anastrozole	sclerosing glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3252	CONCLUSIONS: [s1]Anastrozole[e1] may be the causative factor in patients with [s2]sclerosing glomerulonephritis[e2] 
+	(2, 20)	sclerosing glomerulonephritis	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3253	Diagnosis of [s1]sclerosing glomerulonephritis[e1] occurred in this patient during [s2]anastrozole[e2] use, suggesting a newly defined side effect of anastrozole.
+	(0, 6)	Renal injury	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3254	 [s1]Renal injury[e1] due to [s2]anastrozole[e2] has not been published in the English literature.
+	(6, 14)	anastrozole	decrease in both lumbar spine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3255	There are major side effects of [s1]anastrozole[e1] including [s2]decrease in both lumbar spine[e2] and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.
+	(6, 50)	anastrozole	increase in the cholesterol level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3256	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and [s2]increase in the cholesterol level[e2] 
+	(6, 28)	anastrozole	increase in the incidence of all bone fractures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3257	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, [s2]increase in the incidence of all bone fractures[e2] (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.
+	(6, 47)	anastrozole	joint disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3258	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), [s2]joint disorders[e2] and increase in the cholesterol level.
+	(4, 15)	acute renal failure	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3259	We believe that the [s1]acute renal failure[e1] in our patient was associated with [s2]anastrozole[e2] 
+	(19, 37)	acute hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3260	CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed [s1]acute hepatitis[e1] one week after the final dose of a long-term course of pulse [s2]itraconazole[e2] therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.
+	(5, 24)	itraconazole	severe and irreversible hepatotoxic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3261	CONCLUSIONS: Prolonged exposure to [s1]itraconazole[e1]  administered either continuously or intermittently, may precipitate [s2]severe and irreversible hepatotoxic events[e2] 
+	(0, 9)	Fatal hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3262	 [s1]Fatal hepatitis[e1] after long-term pulse [s2]itraconazole[e2] treatment for onychomycosis.
+	(7, 21)	acute cytolytic hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3263	OBJECTIVE: To report the occurrence of [s1]acute cytolytic hepatitis[e1] in a patient exposed to pulse [s2]itraconazole[e2] therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.
+	(12, 21)	hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3264	OBJECTIVE: To report the occurrence of acute cytolytic [s1]hepatitis[e1] in a patient exposed to pulse [s2]itraconazole[e2] therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.
+	(4, 17)	severe symptomatic hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3265	Only one case of [s1]severe symptomatic hepatitis[e1] occurring after pulse therapy with [s2]itraconazole[e2] for onychomycosis and requiring transplantation has been reported previously.
+	(5, 12)	baclofen	impair sexual function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3266	CONCLUSIONS: Intrathecal [s1]baclofen[e1] can [s2]impair sexual function[e2] and ejaculation in some patients.
+	(17, 27)	baclofen	sexual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3267	RESULTS: A male and a female patient with spasticity treated with intrathecal [s1]baclofen[e1] were recognized to have [s2]sexual dysfunction[e2] side effects from treatment.
+	(0, 9)	Sexual dysfunction	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3268	 [s1]Sexual dysfunction[e1] associated with intrathecal [s2]baclofen[e2] use: a report of two cases.
+	(0, 8)	Anaphylactic reaction	recombinant insulin-like growth factor-I	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3269	 [s1]Anaphylactic reaction[e1] to [s2]recombinant insulin-like growth factor-I[e2] 
+	(13, 25)	anaphylaxis	Increlex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3270	We report a 13 year-old male who developed life-threatening [s1]anaphylaxis[e1] early in the course of [s2]Increlex[e2] therapy.
+	(2, 14)	olanzapine	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3271	Increasing the [s1]olanzapine[e1] dosage severely aggravated the symptoms of [s2]RLS[e2] 
+	(4, 14)	periodic limb movements during sleep	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3272	Restless legs syndrome and [s1]periodic limb movements during sleep[e1] probably associated with [s2]olanzapine[e2] 
+	(0, 14)	Restless legs syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3273	 [s1]Restless legs syndrome[e1] and periodic limb movements during sleep probably associated with [s2]olanzapine[e2] 
+	(7, 12)	agitation	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3274	The fifth patient exhibited paraesthesia and [s1]agitation[e1] caused by [s2]olanzapine[e2] that was misdiagnosed as psychotic agitation.
+	(4, 12)	paraesthesia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3275	The fifth patient exhibited [s1]paraesthesia[e1] and agitation caused by [s2]olanzapine[e2] that was misdiagnosed as psychotic agitation.
+	(4, 19)	RLS symptoms	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3276	The fourth patient showed [s1]RLS symptoms[e1] that were initially caused by a 20-mg daily [s2]olanzapine[e2] dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.
+	(5, 10)	PLMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3277	The second patient exhibited sudden [s1]PLMS[e1] following [s2]olanzapine[e2] injection.
+	(8, 26)	akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3278	The third patient had been suffering from serious [s1]akathisia[e1] while on risperidone, and was cured after switching to [s2]olanzapine[e2]  but thereafter the patient suffered from RLS at nighttime.
+	(8, 15)	akathisia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3279	The third patient had been suffering from serious [s1]akathisia[e1] while on [s2]risperidone[e2]  and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.
+	(24, 35)	olanzapine	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3280	The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to [s1]olanzapine[e1]  but thereafter the patient suffered from [s2]RLS[e2] at nighttime.
+	(13, 35)	risperidone	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3281	The third patient had been suffering from serious akathisia while on [s1]risperidone[e1]  and was cured after switching to olanzapine, but thereafter the patient suffered from [s2]RLS[e2] at nighttime.
+	(13, 29)	periodic limb movements during sleep	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3282	We report five cases of restless legs syndrome (RLS) and [s1]periodic limb movements during sleep[e1] (PLMS) that were probably associated with [s2]olanzapine[e2] 
+	(18, 27)	PLMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3283	We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep  [s1]PLMS[e1]  that were probably associated with [s2]olanzapine[e2] 
+	(5, 29)	restless legs syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3284	We report five cases of [s1]restless legs syndrome[e1] (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with [s2]olanzapine[e2] 
+	(8, 27)	RLS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3285	We report five cases of restless legs syndrome  [s1]RLS[e1]  and periodic limb movements during sleep (PLMS) that were probably associated with [s2]olanzapine[e2] 
+	(2, 10)	Alendronate	nodular scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3286	CONCLUSION: [s1]Alendronate[e1] led to [s2]nodular scleritis[e2] and rechallenge caused recurrence of scleritis.
+	(2, 12)	Alendronate	scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3287	CONCLUSION: [s1]Alendronate[e1] led to nodular [s2]scleritis[e2] and rechallenge caused recurrence of scleritis.
+	(0, 8)	Nodular scleritis	alendronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3288	 [s1]Nodular scleritis[e1] following [s2]alendronate[e2] therapy.
+	(7, 15)	nodular scleritis	alendronate sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3289	PURPOSE: To report a case of [s1]nodular scleritis[e1] following [s2]alendronate sodium[e2] 
+	(8, 22)	alendronate sodium	scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3290	Two weeks following rechallenge with [s1]alendronate sodium[e1] resulted in recurrence of his [s2]scleritis[e2] 
+	(8, 16)	prolonged ECT seizure	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3291	In addition, there is a report on [s1]prolonged ECT seizure[e1] related to [s2]ciprofloxacin[e2]  which has an epileptogenic property with a similar action to beta-lactam antibiotics.
+	(2, 22)	tardive seizures	cefotiam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3292	Thus, [s1]tardive seizures[e1] in our cases are thought to be related to piperacillin and [s2]cefotiam[e2] 
+	(2, 17)	tardive seizures	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3293	Thus, [s1]tardive seizures[e1] in our cases are thought to be related to [s2]piperacillin[e2] and cefotiam.
+	(0, 8)	Acute delirium	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3294	 [s1]Acute delirium[e1] resulting from [s2]levofloxacin[e2] therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients.
+	(35, 77)	gatifloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3295	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(21, 76)	grepafloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3296	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(8, 75)	levofloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3297	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(42, 76)	moxifloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3298	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(15, 76)	sparfloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3299	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(28, 76)	trovafloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3300	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
+	(35, 75)	gatifloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3301	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(21, 74)	grepafloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3302	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(8, 73)	levofloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3303	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(42, 74)	moxifloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3304	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(15, 74)	sparfloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3305	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(28, 74)	trovafloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3306	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
+	(35, 80)	gatifloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3307	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(21, 79)	grepafloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3308	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(8, 78)	levofloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3309	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(42, 79)	moxifloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3310	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(15, 79)	sparfloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3311	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(28, 79)	trovafloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3312	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
+	(4, 12)	levofloxacin	delirium with psychotic features	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3313	Here, we describe [s1]levofloxacin[e1] induced [s2]delirium with psychotic features[e2] in a relatively young, otherwise healthy female.
+	(0, 8)	Levofloxacin	delirium with psychotic features	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3314	 [s1]Levofloxacin[e1] induced [s2]delirium with psychotic features[e2] 
+	(13, 28)	acute-onset delirium with psychotic features	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3315	RESULTS: A previously healthy 42-year-old woman presented with [s1]acute-onset delirium with psychotic features[e1] as a consequence of [s2]levofloxacin[e2] therapy.
+	(8, 24)	Crohn's disease	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3316	CONCLUSIONS: Clinicians should be aware that [s1]Crohn's disease[e1] is a potential novel adverse drug effect of [s2]Copaxone[e2] 
+	(2, 20)	Crohn's disease	copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3317	Development of [s1]Crohn's disease[e1] in a patient with multiple sclerosis treated with [s2]copaxone[e2] 
+	(5, 15)	Crohn's disease	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3318	RESULTS: Our patient developed [s1]Crohn's disease[e1] while on [s2]Copaxone[e2] treatment as a consequence of long-term immunosuppression.
+	(13, 23)	Copaxone	long-term immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3319	RESULTS: Our patient developed Crohn's disease while on [s1]Copaxone[e1] treatment as a consequence of [s2]long-term immunosuppression[e2] 
+	(4, 21)	Copaxone	gastrointestinal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3320	She had been on [s1]Copaxone[e1] 20 mg/day treatment for 2 years when she first exhibited [s2]gastrointestinal symptoms[e2] 
+	(18, 38)	obsessional-like suicidal ideas and images	ketoconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3321	The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, [s1]obsessional-like suicidal ideas and images[e1] after ingestion of the anti-fungal drug [s2]ketoconazole[e2] 
+	(6, 40)	terlipressin	prolonged QT interval	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3322	During intravenous treatment with [s1]terlipressin[e1] for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly [s2]prolonged QT interval[e2] and torsade de pointes.
+	(6, 45)	terlipressin	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3323	During intravenous treatment with [s1]terlipressin[e1] for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and [s2]torsade de pointes[e2] 
+	(0, 7)	Terlipressin	ventricular arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3324	 [s1]Terlipressin[e1] induced [s2]ventricular arrhythmia[e2] 
+	(0, 14)	Spontaneous nasal septal perforation	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3325	 [s1]Spontaneous nasal septal perforation[e1] with antiangiogenic [s2]bevacizumab[e2] therapy.
+	(14, 32)	spontaneous nasal septal perforation	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3326	This case describes a 52-year-old white woman who developed a [s1]spontaneous nasal septal perforation[e1] after given the antiangiogenic drug, [s2]bevacizumab[e2]  for metastatic ovarian cancer treatment.
+	(25, 31)	VRC	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3327	A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous [s1]VRC[e1] and developed [s2]angio-oedema[e2] 10 days after starting therapy.
+	(0, 17)	Angio-oedema	voriconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3328	 [s1]Angio-oedema[e1] as an unusual tolerable side effect of [s2]voriconazole[e2] therapy.
+	(7, 17)	angio-oedema	VRC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3329	Here, we report a case of [s1]angio-oedema[e1] associated with [s2]VRC[e2] therapy.
+	(11, 21)	angio-oedema	VRC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3330	To our knowledge, this is the first report of an [s1]angio-oedema[e1] associated with [s2]VRC[e2] 
+	(0, 18)	Voriconazole	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3331	 [s1]Voriconazole[e1] (VRC) has not previously been reported to cause [s2]angio-oedema[e2] 
+	(5, 16)	VRC	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3332	Voriconazole  [s1]VRC[e1]  has not previously been reported to cause [s2]angio-oedema[e2] 
+	(0, 5)	Multiple seizures	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3333	 [s1]Multiple seizures[e1] after [s2]bupropion[e2] overdose in a small child.
+	(7, 35)	agitation	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3334	The patient experienced hallucinations, [s1]agitation[e1]  vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
+	(3, 35)	hallucinations	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3335	The patient experienced [s1]hallucinations[e1]  agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
+	(16, 36)	seizures	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3336	The patient experienced hallucinations, agitation, vomiting, tachycardia and [s1]seizures[e1] after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
+	(11, 36)	tachycardia	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3337	The patient experienced hallucinations, agitation, vomiting, [s1]tachycardia[e1] and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
+	(9, 35)	vomiting	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3338	The patient experienced hallucinations, agitation, [s1]vomiting[e1]  tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
+	(6, 17)	bupropion	multiple seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3339	We report a case of pediatric [s1]bupropion[e1] ingestion resulting in [s2]multiple seizures[e2] 
+	(0, 7)	Methylphenidate	enuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3340	 [s1]Methylphenidate[e1] associated [s2]enuresis[e2] in attention deficit hyperactivity disorder.
+	(9, 16)	methylphenidate	enuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3341	This is a case report of possible association of [s1]methylphenidate[e1] and [s2]enuresis[e2] in an 11-year-old boy with attention deficit hyperactivity disorder.
+	(0, 8)	Cephalosporin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3342	 [s1]Cephalosporin[e1] induced [s2]leukopenia[e2] following rechallenge with cefoxitin.
+	(2, 17)	Cefazolin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3343	CONCLUSIONS: [s1]Cefazolin[e1] was a probable cause of this patient's [s2]leukopenia[e2] 
+	(7, 14)	cefazolin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3344	OBJECTIVE: To describe a case of [s1]cefazolin[e1] induced [s2]leukopenia[e2] in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin.
+	(12, 21)	cephalosporin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3345	Use of the Naranjo probability scale determined the association between [s1]cephalosporin[e1] use and [s2]leukopenia[e2] to be probable.
+	(10, 16)	PRES	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3346	Posterior reversible encephalopathy syndrome  [s1]PRES[e1]  induced by [s2]cyclosporine[e2] use in a patient with collapsing focal glomeruloesclerosis.
+	(0, 12)	Posterior reversible encephalopathy syndrome	PRES	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3347	 [s1]Posterior reversible encephalopathy syndrome[e1]  [s2]PRES[e2]  induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.
+	(5, 38)	PRES	CSA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3348	We describe a case of [s1]PRES[e1] in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine  [s2]CSA[e2] .
+	(5, 33)	PRES	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3349	We describe a case of [s1]PRES[e1] in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of [s2]cyclosporine[e2] (CSA).
+	(0, 11)	Stuttering priapism	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3350	 [s1]Stuttering priapism[e1] complicating [s2]warfarin[e2] therapy in a patient with protein C deficiency.
+	(6, 12)	Warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3351	This therapy was also complicated by [s1]Warfarin[e1] induced [s2]skin necrosis[e2] 
+	(12, 27)	priapism	Warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3352	We report a rare case of recurrent (stuttering) [s1]priapism[e1] in a patient with protein C deficiency while maintained on [s2]Warfarin[e2] therapy.
+	(8, 25)	stuttering	Warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3353	We report a rare case of recurrent  [s1]stuttering[e1]  priapism in a patient with protein C deficiency while maintained on [s2]Warfarin[e2] therapy.
+	(13, 24)	pulmonary fibrosis	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3354	The patient expired after seven cycles of treatment had been completed because of [s1]pulmonary fibrosis[e1] and the drug toxicity of [s2]bleomycin[e2] 
+	(19, 27)	mild cognitive impairment	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3355	CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for [s1]mild cognitive impairment[e1]  had been taking [s2]propafenone[e2] 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.
+	(17, 43)	citalopram	coronary artery disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3356	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, dizziness, falls) and mimicked [s2]coronary artery disease[e2] 
+	(12, 44)	propafenone	coronary artery disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3357	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked [s2]coronary artery disease[e2] 
+	(17, 35)	citalopram	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3358	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, [s2]dizziness[e2]  falls) and mimicked coronary artery disease.
+	(12, 36)	propafenone	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3359	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, [s2]dizziness[e2]  falls) and mimicked coronary artery disease.
+	(17, 38)	citalopram	falls	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3360	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, dizziness, [s2]falls[e2]  and mimicked coronary artery disease.
+	(12, 39)	propafenone	falls	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3361	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, dizziness, [s2]falls[e2]  and mimicked coronary artery disease.
+	(4, 14)	citalopram	chest tightness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3362	Three months after starting [s1]citalopram[e1]  she experienced episodes of [s2]chest tightness[e2] and dizziness.
+	(4, 18)	citalopram	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3363	Three months after starting [s1]citalopram[e1]  she experienced episodes of chest tightness and [s2]dizziness[e2] 
+	(15, 34)	neurologic symptoms	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3364	CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex [s1]neurologic symptoms[e1] in patients who are receiving the antibiotic treatment described here, especially [s2]vancomycin[e2] 
+	(13, 38)	neuralgic amyotrophy	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3365	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, tobramycin, and [s2]piperacillin[e2] tazobactam.
+	(13, 42)	neuralgic amyotrophy	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3366	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin [s2]tazobactam[e2] 
+	(13, 32)	neuralgic amyotrophy	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3367	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, [s2]tobramycin[e2]  and piperacillin/tazobactam.
+	(13, 27)	neuralgic amyotrophy	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3368	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics [s2]vancomycin[e2]  tobramycin, and piperacillin/tazobactam.
+	(0, 11)	Seizures	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3369	 [s1]Seizures[e1] and transient blindness following intravenous pulse [s2]methylprednisolone[e2] in children with primary glomerulonephritis.
+	(2, 11)	transient blindness	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3370	Seizures and [s1]transient blindness[e1] following intravenous pulse [s2]methylprednisolone[e2] in children with primary glomerulonephritis.
+	(36, 51)	seizures	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3371	Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of [s1]seizures[e1] and transient blindness at different times after i.v. pulse [s2]methylprednisolone[e2] (IVPMP) treatment.
+	(38, 51)	transient blindness	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3372	Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and [s1]transient blindness[e1] at different times after i.v. pulse [s2]methylprednisolone[e2] (IVPMP) treatment.
+	(2, 32)	Hydroxyurea	mucocutaneous adverse events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3373	BACKGROUND: [s1]Hydroxyurea[e1] is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with [s2]mucocutaneous adverse events[e2] and nail hyperpigmentation.
+	(2, 39)	Hydroxyurea	nail hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3374	BACKGROUND: [s1]Hydroxyurea[e1] is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and [s2]nail hyperpigmentation[e2] 
+	(17, 45)	hydroxyurea	myeloproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3375	Based on the Naranjo algorithm, the adverse reaction observed was probably related to the [s1]hydroxyurea[e1] treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the [s2]myeloproliferative disorder[e2] 
+	(2, 21)	longitudinal melanonychia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3376	Both the [s1]longitudinal melanonychia[e1] and the multiple skin cancers first appeared after approximately 6 months of [s2]hydroxyurea[e2] treatment.
+	(9, 21)	multiple skin cancers	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3377	Both the longitudinal melanonychia and the [s1]multiple skin cancers[e1] first appeared after approximately 6 months of [s2]hydroxyurea[e2] treatment.
+	(14, 24)	multiple skin cancers	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3378	CONCLUSIONS: We report this case of the concomitant appearance of [s1]multiple skin cancers[e1] and nail changes associated with [s2]hydroxyurea[e2] use.
+	(18, 24)	nail changes	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3379	CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and [s1]nail changes[e1] associated with [s2]hydroxyurea[e2] use.
+	(0, 14)	Hydroxyurea	diffuse longitudinal melanonychia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3380	 [s1]Hydroxyurea[e1] associated with concomitant occurrence of [s2]diffuse longitudinal melanonychia[e2] and multiple squamous cell carcinomas in an elderly subject.
+	(0, 21)	Hydroxyurea	multiple squamous cell carcinomas	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3381	 [s1]Hydroxyurea[e1] associated with concomitant occurrence of diffuse longitudinal melanonychia and [s2]multiple squamous cell carcinomas[e2] in an elderly subject.
+	(26, 36)	diffuse nail hyperpigmentation	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3382	OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and [s1]diffuse nail hyperpigmentation[e1] associated with [s2]hydroxyurea[e2] treatment, and to describe a successful therapeutic approach using imiquimod 5%.
+	(17, 36)	multiple squamous cell carcinomas	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3383	OBJECTIVE: The purpose of this study was to report the concomitant occurrence of [s1]multiple squamous cell carcinomas[e1] and diffuse nail hyperpigmentation associated with [s2]hydroxyurea[e2] treatment, and to describe a successful therapeutic approach using imiquimod 5%.
+	(27, 37)	painful hand ulcer	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3384	The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a [s1]painful hand ulcer[e1]  possibly associated with the [s2]hydroxyurea[e2]  and new skin cancers were observed at the last follow-up visit.
+	(36, 44)	hydroxyurea	skin cancers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3385	The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the [s1]hydroxyurea[e1]  and new [s2]skin cancers[e2] were observed at the last follow-up visit.
+	(6, 15)	ciprofloxacin	VBDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3386	It is the first case of [s1]ciprofloxacin[e1] induced [s2]VBDS[e2] successfully treated with tacrolimus.
+	(4, 12)	Stevens-Johnson syndrome	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3387	Vanishing bile duct and [s1]Stevens-Johnson syndrome[e1] associated with [s2]ciprofloxacin[e2] treated with tacrolimus.
+	(0, 12)	Vanishing bile duct	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3388	 [s1]Vanishing bile duct[e1] and Stevens-Johnson syndrome associated with [s2]ciprofloxacin[e2] treated with tacrolimus.
+	(8, 17)	ciprofloxacin	SJS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3389	We report a case of a patient with [s1]ciprofloxacin[e1] induced [s2]SJS[e2] and acute onset of VBDS, and reviewed the related literature.
+	(8, 23)	ciprofloxacin	VBDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3390	We report a case of a patient with [s1]ciprofloxacin[e1] induced SJS and acute onset of [s2]VBDS[e2]  and reviewed the related literature.
+	(22, 30)	intracranial bleeding	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3391	A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for [s1]intracranial bleeding[e1] while receiving [s2]aspirin[e2] and clopidogrel.
+	(22, 34)	intracranial bleeding	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3392	A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for [s1]intracranial bleeding[e1] while receiving aspirin and [s2]clopidogrel[e2] 
+	(0, 13)	Disseminated salmonellosis	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3393	 [s1]Disseminated salmonellosis[e1] in a patient treated with [s2]temozolomide[e2] 
+	(6, 19)	disseminated salmonellosis	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3394	We describe the first case of [s1]disseminated salmonellosis[e1] in a patient treated with [s2]temozolomide[e2] 
+	(0, 8)	Ceftriaxone	fixed drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3395	 [s1]Ceftriaxone[e1] induced [s2]fixed drug eruption[e2]  first report.
+	(0, 5)	FDE	cephalosporins	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3396	 [s1]FDE[e1] from [s2]cephalosporins[e2] has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature.
+	(0, 28)	FDE	ceftriaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3397	 [s1]FDE[e1] from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of [s2]ceftriaxone[e2] induced FDE in the literature.
+	(17, 25)	ceftriaxone	FDE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3398	We report the first case of a 54-year-old Turkish woman who presented with [s1]ceftriaxone[e1] induced [s2]FDE[e2] 
+	(16, 33)	gabapentin	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3399	CONCLUSION: All doctors need to be aware of the need to review the indications for [s1]gabapentin[e1] use during periods of acute illness, especially with regard to [s2]renal impairment[e2] 
+	(0, 8)	Gabapentin	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3400	 [s1]Gabapentin[e1] toxicity in [s2]renal failure[e2]  the importance of dose adjustment.
+	(18, 28)	gabapentin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3401	OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of [s1]gabapentin[e1] during an episode of [s2]acute renal failure[e2] 
+	(0, 21)	Acute syphilitic posterior placoid chorioretinitis	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3402	 [s1]Acute syphilitic posterior placoid chorioretinitis[e1] following intravitreal [s2]triamcinolone acetonide[e2] injection.
+	(17, 52)	acute syphilitic posterior placoid chorioretinitis	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3403	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of [s1]acute syphilitic posterior placoid chorioretinitis[e1] (ASPPC) that developed after intravitreal triamcinolone acetonide  [s2]IVTA[e2]  injection.
+	(17, 45)	acute syphilitic posterior placoid chorioretinitis	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3404	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of [s1]acute syphilitic posterior placoid chorioretinitis[e1] (ASPPC) that developed after intravitreal [s2]triamcinolone acetonide[e2] (IVTA) injection.
+	(31, 50)	ASPPC	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3405	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis  [s1]ASPPC[e1]  that developed after intravitreal triamcinolone acetonide  [s2]IVTA[e2]  injection.
+	(31, 43)	ASPPC	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3406	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis  [s1]ASPPC[e1]  that developed after intravitreal [s2]triamcinolone acetonide[e2] (IVTA) injection.
+	(14, 20)	ASPPC	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3407	CONCLUSIONS: The fundus picture shown in these cases may be typical of [s1]ASPPC[e1] after [s2]IVTA[e2] injection.
+	(12, 21)	severe chorioretinitis	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3408	RESULTS: Two patients with ocular inflammation of unknown origin developed [s1]severe chorioretinitis[e1] after [s2]IVTA[e2] injection.
+	(7, 18)	intratumoral hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3409	Although it is difficult to solely attribute [s1]intratumoral hemorrhage[e1] to [s2]aspirin[e2]  we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.
+	(0, 22)	Hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3410	 [s1]Hemorrhage[e1] from a falx meningioma after internal use of low-dose [s2]aspirin[e2] 
+	(5, 14)	aspirin	enlargement of spontaneous hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3411	On the other hand, [s1]aspirin[e1] may have promoted the [s2]enlargement of spontaneous hemorrhage[e2] from meningioma.
+	(8, 25)	hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3412	Our case is the second one in which [s1]hemorrhage[e1] from a meningioma may have been induced by [s2]aspirin[e2] prophylaxis.
+	(6, 38)	hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3413	We report a case in which [s1]hemorrhage[e1] occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose [s2]aspirin[e2] for 16 months.
+	(0, 15)	Acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3414	 [s1]Acute coronary syndromes[e1] can be associated with the infusion of [s2]rituximab[e2] 
+	(0, 16)	Acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3415	 [s1]Acute coronary syndromes[e1] complicating the first infusion of [s2]rituximab[e2] 
+	(11, 22)	acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3416	The aim of this study was to describe the occurrence of [s1]acute coronary syndromes[e1] in 3 cases of [s2]rituximab[e2] infusions.
+	(10, 24)	acute coronary syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3417	The occurrence of symptoms that could be ascribed to an [s1]acute coronary syndrome[e1] should always be taken seriously during the first [s2]rituximab[e2] infusion and investigated aggressively.
+	(18, 32)	acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3418	We reviewed the records of 3 patients with lymphoproliferative disorders who experienced [s1]acute coronary syndromes[e1] associated with their initial infusion of [s2]rituximab[e2] 
+	(22, 42)	acenocoumarol	laryngeal hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3419	CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and [s1]acenocoumarol[e1] that resulted in overanticoagulation and a life-threatening [s2]laryngeal hematoma[e2] in this elderly patient.
+	(13, 42)	econazole	laryngeal hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3420	CONCLUSION: This report describes a case of a probable interaction between topical [s1]econazole[e1] lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening [s2]laryngeal hematoma[e2] in this elderly patient.
+	(0, 16)	Laryngeal dyspnea	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3421	 [s1]Laryngeal dyspnea[e1] in relation to an interaction between [s2]acenocoumarol[e2] and topical econazole lotion.
+	(0, 23)	Laryngeal dyspnea	econazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3422	 [s1]Laryngeal dyspnea[e1] in relation to an interaction between acenocoumarol and topical [s2]econazole[e2] lotion.
+	(0, 14)	Adrenal suppression in a fetus	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3423	 [s1]Adrenal suppression in a fetus[e1] due to administration of [s2]methylprednisolone[e2] has hitherto been rarely published.
+	(5, 38)	adrenal suppression	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3424	CONCLUSIONS: Life-threatening [s1]adrenal suppression[e1]  requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose [s2]methylprednisolone[e2] in late pregnancy.
+	(3, 23)	methylprednisolone	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3425	High-dose [s1]methylprednisolone[e1] in a pregnant woman with Crohn's disease and [s2]adrenal suppression[e2] in her newborn.
+	(18, 33)	moderately severe bronchospasm	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3426	A 10-year-old asthmatic boy began to suffer from urticarial rash and [s1]moderately severe bronchospasm[e1] after 8 weeks' treatment with [s2]disodium cromoglycate[e2] 
+	(13, 33)	urticarial rash	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3427	A 10-year-old asthmatic boy began to suffer from [s1]urticarial rash[e1] and moderately severe bronchospasm after 8 weeks' treatment with [s2]disodium cromoglycate[e2] 
+	(0, 8)	Asthma	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3428	 [s1]Asthma[e1] and urticaria during [s2]disodium cromoglycate[e2] treatment.
+	(2, 8)	urticaria	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3429	Asthma and [s1]urticaria[e1] during [s2]disodium cromoglycate[e2] treatment.
+	(1, 9)	DSCG	urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3430	When [s1]DSCG[e1] was withdrawn, [s2]urticaria[e2] vanished and the child remained symptom-free.
+	(6, 17)	propranolol	atrioventricular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3431	After the first oral dose of [s1]propranolol[e1]  syncope developed together with [s2]atrioventricular block[e2] 
+	(6, 12)	propranolol	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3432	After the first oral dose of [s1]propranolol[e1]  [s2]syncope[e2] developed together with atrioventricular block.
+	(0, 6)	Syncope	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3433	 [s1]Syncope[e1] induced by [s2]propranolol[e2] in hypertrophic cardiomyopathy.
+	(0, 6)	Olanzapine	hyperglycaemic coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3434	 [s1]Olanzapine[e1] induced [s2]hyperglycaemic coma[e2] and neuroleptic malignant syndrome: case report and review of literature.
+	(0, 13)	Olanzapine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3435	 [s1]Olanzapine[e1] induced hyperglycaemic coma and [s2]neuroleptic malignant syndrome[e2]  case report and review of literature.
+	(7, 33)	leflunomide	allergic skin reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3436	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and [s2]allergic skin reactions[e2] 
+	(7, 28)	leflunomide	alopecia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3437	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, hypertension, [s2]alopecia[e2]  and allergic skin reactions.
+	(7, 15)	leflunomide	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3438	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of [s2]diarrhea[e2]  nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.
+	(7, 25)	leflunomide	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3439	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, [s2]hypertension[e2]  alopecia, and allergic skin reactions.
+	(7, 21)	leflunomide	liver enzyme elevation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3440	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, [s2]liver enzyme elevation[e2]  hypertension, alopecia, and allergic skin reactions.
+	(7, 19)	leflunomide	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3441	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, [s2]nausea[e2]  liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.
+	(0, 7)	Leflunomide	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3442	 [s1]Leflunomide[e1] induced [s2]toxic epidermal necrolysis[e2] in a patient with rheumatoid arthritis.
+	(30, 51)	mediastinal lymphadenopathy	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3443	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), [s1]mediastinal lymphadenopathy[e1] and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
+	(40, 51)	pleurisy	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3444	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and [s1]pleurisy[e1] associated with systemic symptoms under [s2]Etanercept[e2] treatment.
+	(16, 51)	thymic enlargement	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3445	In this report we described a case of juvenile idiopathic arthritis patient who developed [s1]thymic enlargement[e1] (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
+	(23, 50)	thymic hyperplasia	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3446	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true [s1]thymic hyperplasia[e1] , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
+	(0, 17)	Thymic enlargement	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3447	 [s1]Thymic enlargement[e1] in a patient with juvenile idiopathic arthritis during [s2]etanercept[e2] therapy.
+	(0, 19)	Oxcarbazepine	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3448	 [s1]Oxcarbazepine[e1] induced Drug Reaction with Eosinophilia and Systemic Symptoms  [s2]DRESS[e2] .
+	(0, 8)	Oxcarbazepine	Drug Reaction with Eosinophilia and Systemic Symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3449	 [s1]Oxcarbazepine[e1] induced [s2]Drug Reaction with Eosinophilia and Systemic Symptoms[e2] (DRESS).
+	(19, 28)	severe rash	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3450	This is an image and brief case report of a 13-year-old boy who presented with [s1]severe rash[e1] and systemic symptoms after starting [s2]oxcarbazepine[e2] 
+	(13, 23)	Partusisten	supraventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3451	After treatment with a beta-sympathomimetic drug  [s1]Partusisten[e1]  one fetus developed [s2]supraventricular tachycardia[e2] 
+	(0, 8)	Rosaceiform eruption	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3452	 [s1]Rosaceiform eruption[e1] induced by [s2]erlotinib[e2] 
+	(11, 19)	rosaceiform eruption	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3453	The aim of this paper is to report the case of [s1]rosaceiform eruption[e1] induced by [s2]erlotinib[e2] in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.
+	(3, 11)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3454	In patients with [s1]methotrexate[e1] induced [s2]anaphylaxis[e2]  discontinuation of treatment may increase the risk of death due to cancer progression.
+	(8, 16)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3455	Management and successful desensitization in [s1]methotrexate[e1] induced [s2]anaphylaxis[e2] 
+	(20, 28)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3456	Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience [s1]methotrexate[e1] induced [s2]anaphylaxis[e2] 
+	(19, 33)	anaphylactic/anaphylactoid reaction	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3457	We report the case of a child with metastatic osteosarcoma, who experienced an [s1]anaphylactic/anaphylactoid reaction[e1] to [s2]methotrexate[e2] 
+	(3, 8)	fever	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3458	Drug-induced [s1]fever[e1] due to [s2]diltiazem[e2] 
+	(3, 21)	fever	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3459	Drug-induced [s1]fever[e1] should be considered in patients who have unexplained high temperatures during [s2]diltiazem[e2] therapy.
+	(7, 18)	fever	diltiazem hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3460	To our knowledge, drug-induced [s1]fever[e1] has not been reported with the use of [s2]diltiazem hydrochloride[e2]  a commonly prescribed calcium channel blocker.
+	(3, 19)	congestive heart failure	Adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3461	A case of [s1]congestive heart failure[e1] in a child with Wilms' tumor treated [s2]Adriamycin[e2] is presented and discussed.
+	(4, 10)	adriamycin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3462	Radiologic recognition of [s1]adriamycin[e1]  [s2]cardiotoxicity[e2] 
+	(3, 13)	Adriamycin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3463	The role of [s1]Adriamycin[e1] in the production of [s2]cardiotoxicity[e2] is reviewed.
+	(0, 8)	Carbamazepine	Diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3464	 [s1]Carbamazepine[e1] induced [s2]Diabetes mellitus[e2] 
+	(0, 12)	Diabetes Mellitus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3465	 [s1]Diabetes Mellitus[e1] was observed in a patient given [s2]carbamazepine[e2] 
+	(8, 32)	unusual weight fluctuation	aripiprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3466	The present study describes a patient who had [s1]unusual weight fluctuation[e1] under corticosteroid and psychotropic treatment such as mianserin and [s2]aripiprazole[e2] 
+	(8, 28)	unusual weight fluctuation	mianserin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3467	The present study describes a patient who had [s1]unusual weight fluctuation[e1] under corticosteroid and psychotropic treatment such as [s2]mianserin[e2] and aripiprazole.
+	(1, 15)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3468	Although [s1]heparin[e1] dependent antibodies (HDAs) typically manifest with [s2]thrombocytopenia[e2] as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.
+	(22, 31)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3469	Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing [s1]thrombosis[e1] who are receiving [s2]heparin[e2] therapy.
+	(12, 18)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3470	Heparin-dependent antibodies and thrombosis without [s1]heparin[e1] induced [s2]thrombocytopenia[e2] 
+	(13, 31)	venous thromboembolism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3471	Despite these antithrombotic effects, the patient developed repeated [s1]venous thromboembolism[e1] during treatment with low-molecular-weight [s2]heparin[e2] 
+	(22, 40)	progressive liver failure	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3472	Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for [s1]progressive liver failure[e1] and severe hepatocellular necrosis thought to be due to [s2]tacrolimus[e2] 
+	(26, 40)	severe hepatocellular necrosis	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3473	Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and [s1]severe hepatocellular necrosis[e1] thought to be due to [s2]tacrolimus[e2] 
+	(2, 30)	posaconazole	enterococcal peritonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3474	Initiation of [s1]posaconazole[e1] led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant [s2]enterococcal peritonitis[e2] 
+	(0, 12)	Iatrogenic Cushing syndrome	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3475	 [s1]Iatrogenic Cushing syndrome[e1] after epidural [s2]triamcinolone[e2] injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.
+	(42, 54)	Cushing syndrome	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3476	We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed [s1]Cushing syndrome[e1] with profound complications after epidural [s2]triamcinolone[e2] injections.
+	(11, 36)	flunitrazepam	acute ischaemia of the left leg	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3477	A 22-year-old drug-abuser injected [s1]flunitrazepam[e1] tablets dissolved in tap water into her left femoral artery and presented with clinical signs of [s2]acute ischaemia of the left leg[e2] 
+	(0, 17)	Acute ischaemia of the leg	flunitrazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3478	 [s1]Acute ischaemia of the leg[e1] following accidental intra-arterial injection of dissolved [s2]flunitrazepam[e2] tablets.
+	(27, 45)	syringotropic hypersensitivity reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3479	A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a [s1]syringotropic hypersensitivity reaction[e1] after 9 months of therapy with [s2]infliximab[e2] and leflunomide is described.
+	(27, 51)	syringotropic hypersensitivity reaction	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3480	A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a [s1]syringotropic hypersensitivity reaction[e1] after 9 months of therapy with infliximab and [s2]leflunomide[e2] is described.
+	(0, 14)	Syringotropic hypersensitivity reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3481	 [s1]Syringotropic hypersensitivity reaction[e1] associated with [s2]infliximab[e2] and leflunomide combination therapy in a child with psoriatic arthritis.
+	(0, 20)	Syringotropic hypersensitivity reaction	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3482	 [s1]Syringotropic hypersensitivity reaction[e1] associated with infliximab and [s2]leflunomide[e2] combination therapy in a child with psoriatic arthritis.
+	(3, 14)	severe aplastic anemia	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3483	A case of [s1]severe aplastic anemia[e1] secondary to treatment with [s2]lenalidomide[e2] for multiple myeloma.
+	(17, 23)	lenalidomide	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3484	Although moderate myelosuppression is not uncommonly seen in patients treated with [s1]lenalidomide[e1]  [s2]aplastic anemia[e2] has not previously been reported to be associated with this agent.
+	(10, 18)	AA	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3485	We describe a case of severe aplastic anemia  [s1]AA[e1]  that was probably induced by [s2]lenalidomide[e2] 
+	(5, 20)	severe aplastic anemia	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3486	We describe a case of [s1]severe aplastic anemia[e1] (AA) that was probably induced by [s2]lenalidomide[e2] 
+	(5, 11)	amantadine	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3487	After cessation of [s1]amantadine[e1]  the [s2]edema[e2] resolved, and the endothelial cell densities were  50% of patients being treated for endometriosis.
+	(8, 17)	acute pancreatitis	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5542	The present report describes the first case of [s1]acute pancreatitis[e1] associated with [s2]danazol[e2] treatment of endometriosis.
+	(0, 7)	Acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5543	 [s1]Acyclovir[e1]  [s2]neurotoxicity[e2]  clinical experience and review of the literature.
+	(0, 8)	Acyclovir	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5544	 [s1]Acyclovir[e1] produces [s2]neurologic symptoms[e2] that resemble extension of viral infection into the central nervous system.
+	(14, 21)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5545	Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of [s1]acyclovir[e1]  [s2]neurotoxicity[e2] 
+	(11, 18)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5546	We discuss our observations in the cases of two patients with [s1]acyclovir[e1]  [s2]neurotoxicity[e2] and review the findings of all previous reports in the English language literature.
+	(3, 10)	promethazine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5547	Response of a [s1]promethazine[e1] induced [s2]coma[e2] to flumazenil.
+	(10, 17)	promethazine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5548	We report the first case of a patient in a [s1]promethazine[e1] induced [s2]coma[e2] responding to treatment with flumazenil.
+	(0, 14)	Amebic abscess of the spleen	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5549	 [s1]Amebic abscess of the spleen[e1] complicated by [s2]metronidazole[e2] induced neurotoxicity: case report.
+	(12, 20)	metronidazole	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5550	Amebic abscess of the spleen complicated by [s1]metronidazole[e1] induced [s2]neurotoxicity[e2]  case report.
+	(23, 55)	metronidazole	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5551	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and [s2]ataxia[e2] and who relapsed 5 months later with a splenic abscess.
+	(6, 25)	liver abscess	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5552	We describe a patient with a [s1]liver abscess[e1] due to Entamoeba histolytica, in whom [s2]metronidazole[e2] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
+	(23, 44)	metronidazole	reversible deafness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5553	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by [s2]reversible deafness[e2]  tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
+	(23, 68)	metronidazole	splenic abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5554	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a [s2]splenic abscess[e2] 
+	(23, 50)	metronidazole	tinnitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5555	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, [s2]tinnitus[e2]  and ataxia and who relapsed 5 months later with a splenic abscess.
+	(0, 8)	Actinomycin D	hepatic veno-occlusive disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5556	 [s1]Actinomycin D[e1] associated [s2]hepatic veno-occlusive disease[e2] -a report of 2 cases.
+	(5, 15)	liver failure	AMD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5557	There are now reports of [s1]liver failure[e1] following treatment of childhood cancers with [s2]AMD[e2] 
+	(0, 10)	Phenylpropanolamine	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5558	 [s1]Phenylpropanolamine[e1] induced [s2]psychosis[e2] 
+	(6, 20)	paranoid psychosis	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5559	We report a cae of [s1]paranoid psychosis[e1] following use of a decongestant containing [s2]PPA[e2] and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines.
+	(18, 31)	PPA	psychiatric adverse effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5560	We report a cae of paranoid psychosis following use of a decongestant containing [s1]PPA[e1] and summarize the case report literature of [s2]psychiatric adverse effects[e2] to PPA in which doses were known and stated to be within recommended guidelines.
+	(3, 29)	budesonide	contact dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5561	CONCLUSIONS: Although [s1]budesonide[e1] may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing [s2]contact dermatitis[e2] 
+	(0, 8)	Contact dermatitis	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5562	 [s1]Contact dermatitis[e1] due to [s2]budesonide[e2]  report of five cases and review of the Japanese literature.
+	(5, 13)	contact dermatitis	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5563	METHODS: Five cases of [s1]contact dermatitis[e1] due to [s2]budesonide[e2]  a nonhalogenated steroid, are described.
+	(2, 10)	Budesonide	contact dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5564	RESULTS: [s1]Budesonide[e1] use can cause [s2]contact dermatitis[e2] 
+	(6, 16)	methemoglobinemia	methyl nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5565	Although other nitrites induce [s1]methemoglobinemia[e1]  exposure to [s2]methyl nitrite[e2] during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.
+	(6, 16)	methemoglobinemia	methyl nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5566	Although other nitrites induce [s1]methemoglobinemia[e1]  exposure to [s2]methyl nitrite[e2] during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.
+	(0, 12)	Methemoglobinemia	phenylpropanolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5567	 [s1]Methemoglobinemia[e1]  an occupational hazard of [s2]phenylpropanolamine[e2] production.
+	(3, 16)	IFN	IDDM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5568	During and after [s1]IFN[e1] therapy we should consider the possibility of occurrence of [s2]IDDM[e2] as well as other autoimmune diseases and observe the clinical course carefully.
+	(6, 16)	IFN	moderate hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5569	Four years after the beginning of [s1]IFN[e1] therapy, he acutely developed [s2]moderate hyperglycemia[e2] and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started.
+	(6, 22)	IFN	severe ketonuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5570	Four years after the beginning of [s1]IFN[e1] therapy, he acutely developed moderate hyperglycemia and [s2]severe ketonuria[e2] with positive islet cell antibody, and then 28 units/day of insulin injection was started.
+	(2, 7)	IDDM	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5571	Occurrence of [s1]IDDM[e1] during [s2]interferon[e2] therapy for chronic viral hepatitis.
+	(5, 12)	IDDM	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5572	We report a case of [s1]IDDM[e1] which occurred during [s2]interferon[e2] therapy for chronic hepatitis.
+	(16, 26)	hypersensitivity syndrome	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5573	Four patients who manifested symptoms of the antiepileptic drug (AED) [s1]hypersensitivity syndrome[e1] during therapy with [s2]carbamazepine[e2] are reported.
+	(0, 13)	Recurrent hypotension	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5574	 [s1]Recurrent hypotension[e1] immediately after seizures in [s2]nortriptyline[e2] overdose.
+	(9, 13)	seizures	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5575	Recurrent hypotension immediately after [s1]seizures[e1] in [s2]nortriptyline[e2] overdose.
+	(3, 51)	methotrexate	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5576	The use of [s1]methotrexate[e1] (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
+	(8, 49)	MTX	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5577	The use of methotrexate  [s1]MTX[e1]  has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
+	(8, 49)	MTX	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5578	The use of methotrexate  [s1]MTX[e1]  has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
+	(9, 31)	increase of INR	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5579	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of levamisole and [s2]5-FU[e2] to a previous regimen of warfarin alone.
+	(9, 26)	increase of INR	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5580	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of [s2]levamisole[e2] and 5-FU to a previous regimen of warfarin alone.
+	(9, 40)	increase of INR	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5581	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of [s2]warfarin[e2] alone.
+	(6, 16)	5-FU	increase in INR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5582	However, prolongation of [s1]5-FU[e1] half-life and an [s2]increase in INR[e2] have been reported with the concurrent use of 5-FU and warfarin.
+	(14, 32)	increase in INR	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5583	However, prolongation of 5-FU half-life and an [s1]increase in INR[e1] have been reported with the concurrent use of 5-FU and [s2]warfarin[e2] 
+	(0, 21)	Cholestatic liver disease	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5584	 [s1]Cholestatic liver disease[e1] with ductopenia (vanishing bile duct syndrome) after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
+	(0, 26)	Cholestatic liver disease	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5585	 [s1]Cholestatic liver disease[e1] with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
+	(7, 21)	ductopenia	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5586	Cholestatic liver disease with [s1]ductopenia[e1] (vanishing bile duct syndrome) after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
+	(7, 26)	ductopenia	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5587	Cholestatic liver disease with [s1]ductopenia[e1] (vanishing bile duct syndrome) after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
+	(10, 19)	vanishing bile duct syndrome	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5588	Cholestatic liver disease with ductopenia  [s1]vanishing bile duct syndrome[e1]  after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
+	(10, 24)	vanishing bile duct syndrome	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5589	Cholestatic liver disease with ductopenia  [s1]vanishing bile duct syndrome[e1]  after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
+	(4, 25)	clindamycin	bile duct injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5590	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, [s2]bile duct injury[e2] and bile duct paucity (ductopenia).
+	(4, 29)	clindamycin	bile duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5591	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and [s2]bile duct paucity[e2] (ductopenia).
+	(4, 33)	clindamycin	ductopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5592	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity  [s2]ductopenia[e2] .
+	(4, 16)	clindamycin	marked cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5593	One patient who received [s1]clindamycin[e1] had liver biopsy findings of [s2]marked cholestasis[e2]  portal inflammation, bile duct injury and bile duct paucity (ductopenia).
+	(4, 22)	clindamycin	portal inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5594	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, [s2]portal inflammation[e2]  bile duct injury and bile duct paucity (ductopenia).
+	(6, 14)	cholestasis	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5595	The second patient, who developed [s1]cholestasis[e1] after receiving [s2]trimethoprim-sulfamethoxazole[e2]  had marked duct paucity in the liver biopsy.
+	(12, 28)	trimethoprim-sulfamethoxazole	duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5596	The second patient, who developed cholestasis after receiving [s1]trimethoprim-sulfamethoxazole[e1]  had marked [s2]duct paucity[e2] in the liver biopsy.
+	(11, 19)	ductopenia	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5597	This is the first description, to our knowledge, of [s1]ductopenia[e1] apparently caused by [s2]clindamycin[e2] 
+	(6, 21)	ampicillin	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5598	Three years later, treatment with [s1]ampicillin[e1] caused another episode of cholestatic hepatitis with [s2]cholestasis[e2] and duct paucity on rebiopsy.
+	(6, 15)	ampicillin	cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5599	Three years later, treatment with [s1]ampicillin[e1] caused another episode of [s2]cholestatic hepatitis[e2] with cholestasis and duct paucity on rebiopsy.
+	(6, 26)	ampicillin	duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5600	Three years later, treatment with [s1]ampicillin[e1] caused another episode of cholestatic hepatitis with cholestasis and [s2]duct paucity[e2] on rebiopsy.
+	(9, 22)	vision loss	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5601	METHODS: A patient who developed dramatic, permanent [s1]vision loss[e1] after a 9-month course of treatment with [s2]ethambutol[e2] and isoniazid for pulmonary tuberculosis is presented.
+	(9, 28)	vision loss	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5602	METHODS: A patient who developed dramatic, permanent [s1]vision loss[e1] after a 9-month course of treatment with ethambutol and [s2]isoniazid[e2] for pulmonary tuberculosis is presented.
+	(2, 24)	Ethambutol	development of visually related side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5603	RESULTS: [s1]Ethambutol[e1]  and to a lesser extent isoniazid, are both implicated in the [s2]development of visually related side effects[e2] 
+	(13, 24)	isoniazid	development of visually related side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5604	RESULTS: Ethambutol, and to a lesser extent [s1]isoniazid[e1]  are both implicated in the [s2]development of visually related side effects[e2] 
+	(4, 10)	ocular toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5605	There is documentation of [s1]ocular toxicity[e1] with [s2]ethambutol[e2] when administered at dosages generally pronounced as being safe.
+	(0, 9)	Toxic optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5606	 [s1]Toxic optic neuropathy[e1] associated with [s2]ethambutol[e2]  implications for current therapy.
+	(4, 45)	zidovudine	fetal damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5607	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for [s2]fetal damage[e2] 
+	(4, 27)	zidovudine	fetotoxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5608	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially teratogenic and [s2]fetotoxic[e2] agent, any decision for its use requires evaluation of the potential for fetal damage.
+	(4, 23)	zidovudine	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5609	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially [s2]teratogenic[e2] and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage.
+	(15, 48)	zidovudine	fetal abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5610	In a series of 104 cases of intentional or inadvertent use of [s1]zidovudine[e1] at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of [s2]fetal abnormality[e2] occurring among a total of 88 cases where the pregnancy progressed.
+	(15, 33)	zidovudine	first trimester abortions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5611	In a series of 104 cases of intentional or inadvertent use of [s1]zidovudine[e1] at differing gestations in pregnancy, there were eight spontaneous [s2]first trimester abortions[e2]  eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed.
+	(0, 19)	Zidovudine	birth defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5612	 [s1]Zidovudine[e1] use in pregnancy: a report on 104 cases and the occurrence of [s2]birth defects[e2] 
+	(0, 6)	Celiprolol	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5613	 [s1]Celiprolol[e1]  [s2]pneumonitis[e2] 
+	(10, 23)	celiprolol	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5614	Inadvertent subsequent rechallenge with [s1]celiprolol[e1] led to recurrence of the [s2]pneumonitis[e2]  10 weeks after drug readministration.
+	(7, 27)	hypersensitivity pneumonitis	celiprolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5615	We report on a patient who developed [s1]hypersensitivity pneumonitis[e1] during treatment with the beta-blocker, [s2]celiprolol[e2] 
+	(0, 9)	Ibopamine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5616	 [s1]Ibopamine[e1] induced reversible [s2]leukopenia[e2] during treatment for congestive heart failure.
+	(0, 23)	Reversible leukopenia	ibopamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5617	 [s1]Reversible leukopenia[e1] was documented in an 81-year-old woman treated with adjunctive [s2]ibopamine[e2] 100 mg t.i.d. for chronic congestive heart failure.
+	(0, 21)	Diphenylhydantoin	acute intermittent porphyria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5618	 [s1]Diphenylhydantoin[e1] apparently adversely affected both the clinical and biochemical parameters of the [s2]acute intermittent porphyria[e2] 
+	(5, 14)	porphyria	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5619	Significant clinical improvement of the [s1]porphyria[e1] followed withdrawal of the [s2]diphenylhydantoin[e2] 
+	(17, 27)	schizophrenia	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5620	A 53-year-old male, without any prior history of psychosis, developed [s1]schizophrenia[e1] 4 days after starting low-dose [s2]bromocriptine[e2] therapy for a macroprolactinoma.
+	(0, 7)	Bromocriptine	schizophrenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5621	 [s1]Bromocriptine[e1] induced [s2]schizophrenia[e2] 
+	(0, 26)	Concurrent acute megaloblastic anaemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5622	 [s1]Concurrent acute megaloblastic anaemia[e1] and pneumonitis: a severe side-effect of low-dose [s2]methotrexate[e2] therapy during rheumatoid arthritis.
+	(9, 25)	pneumonitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5623	Concurrent acute megaloblastic anaemia and [s1]pneumonitis[e1]  a severe side-effect of low-dose [s2]methotrexate[e2] therapy during rheumatoid arthritis.
+	(26, 34)	methotrexate	acute megaloblastic anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5624	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose [s1]methotrexate[e1]  an [s2]acute megaloblastic anaemia[e2] and a pneumonitis.
+	(26, 43)	methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5625	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose [s1]methotrexate[e1]  an acute megaloblastic anaemia and a [s2]pneumonitis[e2] 
+	(25, 54)	Levemepromazine	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5626	An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate  [s1]Levemepromazine[e1]  a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from [s2]respiratory distress syndrome[e2] 
+	(16, 56)	methotrimeprazine meleate	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5627	An 11-year-old boy who was treated with a relatively high dose of [s1]methotrimeprazine meleate[e1] (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from [s2]respiratory distress syndrome[e2] 
+	(3, 12)	phenothiazine	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5628	The association of [s1]phenothiazine[e1] overdose and [s2]respiratory distress syndrome[e2] merits consideration.
+	(4, 22)	apomorphine	dyskinesias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5629	In two patients, [s1]apomorphine[e1] remained effective in the morning, but increased the intensity of the [s2]dyskinesias[e2] in the afternoon.
+	(10, 18)	levo-dopa	diphasic dyskinesias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5630	We report on three observations of parkinsonian patients with [s1]levo-dopa[e1] induced [s2]diphasic dyskinesias[e2]  who received subcutaneous apomorphine to reduce the duration of abnormal movements.
+	(0, 19)	Fulminant hepatitis	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5631	 [s1]Fulminant hepatitis[e1] with severe lactate acidosis in HIV-infected patients on [s2]didanosine[e2] therapy.
+	(6, 19)	severe lactate acidosis	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5632	Fulminant hepatitis with [s1]severe lactate acidosis[e1] in HIV-infected patients on [s2]didanosine[e2] therapy.
+	(6, 14)	ddI	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5633	This prompted us to suspect that [s1]ddI[e1] might be responsible for [s2]fulminant hepatitis[e2] in all three AIDS patients.
+	(5, 28)	fulminant hepatic failure	ddI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5634	We report two cases of [s1]fulminant hepatic failure[e1] in HIV-1-infected patients treated with didanosine  [s2]ddI[e2] .
+	(5, 24)	fulminant hepatic failure	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5635	We report two cases of [s1]fulminant hepatic failure[e1] in HIV-1-infected patients treated with [s2]didanosine[e2] (ddI).
+	(0, 11)	Generalized argyria	AgNO3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5636	 [s1]Generalized argyria[e1] after habitual use of [s2]AgNO3[e2] 
+	(3, 10)	fluoxetine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5637	A case of [s1]fluoxetine[e1] induced [s2]seizures[e2]  in a person with Down syndrome, is described.
+	(0, 5)	Seizures	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5638	 [s1]Seizures[e1] associated with [s2]fluoxetine[e2] therapy are uncommon.
+	(0, 5)	Seizures	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5639	 [s1]Seizures[e1] associated with [s2]fluoxetine[e2] therapy.
+	(1, 8)	fluoxetine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5640	Although [s1]fluoxetine[e1] induced [s2]headache[e2] occurred in one patient, the other five reported no side effects at the doses used.
+	(5, 42)	carbamazepine	psoriasiform eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5641	Sodium valproate and [s1]carbamazepine[e1]  antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce [s2]psoriasiform eruptions[e2] 
+	(0, 43)	Sodium valproate	psoriasiform eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5642	 [s1]Sodium valproate[e1] and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce [s2]psoriasiform eruptions[e2] 
+	(9, 30)	psoriasiform eruption	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5643	We present findings from three patients who experienced a [s1]psoriasiform eruption[e1] apparently due to the antiepileptic agents sodium valproate and [s2]carbamazepine[e2] 
+	(9, 25)	psoriasiform eruption	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5644	We present findings from three patients who experienced a [s1]psoriasiform eruption[e1] apparently due to the antiepileptic agents [s2]sodium valproate[e2] and carbamazepine.
+	(0, 17)	Severe diffuse interstitial pneumonitis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5645	 [s1]Severe diffuse interstitial pneumonitis[e1] induced by carmustine  [s2]BCNU[e2] .
+	(0, 14)	Severe diffuse interstitial pneumonitis	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5646	 [s1]Severe diffuse interstitial pneumonitis[e1] induced by [s2]carmustine[e2] (BCNU).
+	(3, 25)	fatal case of acute interstitial pneumonitis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5647	We report a [s1]fatal case of acute interstitial pneumonitis[e1] in a patient treated with carmustine  [s2]BCNU[e2]  for a brain tumor.
+	(3, 22)	fatal case of acute interstitial pneumonitis	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5648	We report a [s1]fatal case of acute interstitial pneumonitis[e1] in a patient treated with [s2]carmustine[e2] (BCNU) for a brain tumor.
+	(23, 28)	shocks	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5649	A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent [s1]shocks[e1] during oral [s2]procainamide[e2] therapy.
+	(0, 10)	Electrical proarrhythmia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5650	 [s1]Electrical proarrhythmia[e1] with [s2]procainamide[e2]  a new ICD-drug interaction.
+	(26, 43)	electrophysiologic effect	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5651	The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported [s1]electrophysiologic effect[e1] of, or idiosyncratic response to, [s2]procainamide[e2] 
+	(22, 32)	valproic acid	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5652	Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on [s1]valproic acid[e1] therapy who present with [s2]altered mental status[e2] 
+	(0, 14)	Hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5653	 [s1]Hyperammonemia[e1] has been described as a complication of [s2]valproic acid[e2] therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department.
+	(12, 28)	valproic acid	lethargy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5654	Hyperammonemia has been described as a complication of [s1]valproic acid[e1] therapy but may often be overlooked as a cause of [s2]lethargy[e2] in the postictal patient who presents to the emergency department.
+	(0, 8)	Hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5655	 [s1]Hyperammonemia[e1] secondary to [s2]valproic acid[e2] as a cause of lethargy in a postictal patient.
+	(6, 16)	valproic acid	lethargy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5656	Hyperammonemia secondary to [s1]valproic acid[e1] as a cause of [s2]lethargy[e2] in a postictal patient.
+	(15, 30)	hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5657	We present the case of a postictal patient with lethargy, [s1]hyperammonemia[e1]  otherwise normal liver function tests, and a therapeutic [s2]valproic acid[e2] level.
+	(11, 30)	lethargy	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5658	We present the case of a postictal patient with [s1]lethargy[e1]  hyperammonemia, otherwise normal liver function tests, and a therapeutic [s2]valproic acid[e2] level.
+	(0, 8)	Central nervous system toxicity	meperidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5659	 [s1]Central nervous system toxicity[e1] associated with [s2]meperidine[e2] use in hepatic disease.
+	(10, 21)	meperidine	accumulation of the parent drug	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5660	In patients with cirrhosis, the metabolism of [s1]meperidine[e1] is decreased, leading to [s2]accumulation of the parent drug[e2] and possible CNS depressive effects similar to hepatic encephalopathy.
+	(10, 28)	meperidine	CNS depressive effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5661	In patients with cirrhosis, the metabolism of [s1]meperidine[e1] is decreased, leading to accumulation of the parent drug and possible [s2]CNS depressive effects[e2] similar to hepatic encephalopathy.
+	(0, 25)	Meperidine	accumulation of the active metabolite normeperidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5662	 [s1]Meperidine[e1] associated central nervous system (CNS) excitatory toxicities are believed to be caused by [s2]accumulation of the active metabolite normeperidine[e2] 
+	(0, 7)	Meperidine	central nervous system (CNS) excitatory toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5663	 [s1]Meperidine[e1] associated [s2]central nervous system (CNS) excitatory toxicities[e2] are believed to be caused by accumulation of the active metabolite normeperidine.
+	(11, 21)	morphine	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5664	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed [s2]hypertension[e2]  status epilepticus, intracerebral hemorrhage, and respiratory failure.
+	(11, 30)	morphine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5665	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, status epilepticus, [s2]intracerebral hemorrhage[e2]  and respiratory failure.
+	(11, 40)	morphine	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5666	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and [s2]respiratory failure[e2] 
+	(11, 24)	morphine	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5667	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, [s2]status epilepticus[e2]  intracerebral hemorrhage, and respiratory failure.
+	(0, 23)	Mitomycin C	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5668	 [s1]Mitomycin C[e1] (MMC) is an alkylating agent that has been recently associated with the [s2]hemolytic-uremic syndrome[e2] (HUS).
+	(4, 21)	MMC	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5669	Mitomycin C  [s1]MMC[e1]  is an alkylating agent that has been recently associated with the [s2]hemolytic-uremic syndrome[e2] (HUS).
+	(0, 31)	Mitomycin C	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5670	 [s1]Mitomycin C[e1] (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome  [s2]HUS[e2] .
+	(4, 29)	MMC	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5671	Mitomycin C  [s1]MMC[e1]  is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome  [s2]HUS[e2] .
+	(10, 22)	hemolytic-uremic syndrome	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5672	Pulmonary hemorrhage as a clinical manifestation of [s1]hemolytic-uremic syndrome[e1] associated with [s2]mitomycin C[e2] therapy.
+	(0, 22)	Pulmonary hemorrhage	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5673	 [s1]Pulmonary hemorrhage[e1] as a clinical manifestation of hemolytic-uremic syndrome associated with [s2]mitomycin C[e2] therapy.
+	(11, 26)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5674	Pulmonary hemorrhage is an uncommon feature in the [s1]HUS[e1]  and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
+	(11, 26)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5675	Pulmonary hemorrhage is an uncommon feature in the [s1]HUS[e1]  and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
+	(0, 27)	Pulmonary hemorrhage	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5676	 [s1]Pulmonary hemorrhage[e1] is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
+	(6, 11)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5677	We describe two women who developed [s1]HUS[e1] after [s2]MMC[e2] therapy and presented massive pulmonary bleeding.
+	(9, 16)	MMC	massive pulmonary bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5678	We describe two women who developed HUS after [s1]MMC[e1] therapy and presented [s2]massive pulmonary bleeding[e2] 
+	(0, 6)	Clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5679	 [s1]Clonidine[e1] induced [s2]bradycardia[e2] in patients with spinal cord injury.
+	(4, 20)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5680	Possible mechanisms by which [s1]clonidine[e1] decreases spasticity are described, probable mechanisms of induced [s2]bradycardia[e2] are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.
+	(4, 20)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5681	Possible mechanisms by which [s1]clonidine[e1] decreases spasticity are described, probable mechanisms of induced [s2]bradycardia[e2] are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.
+	(26, 32)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5682	Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of [s1]clonidine[e1] induced [s2]bradycardia[e2] is less well recognized and is rare.
+	(11, 28)	constipation	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5683	Though hypotension, dry mouth, and [s1]constipation[e1] are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
+	(7, 27)	dry mouth	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5684	Though hypotension, [s1]dry mouth[e1]  and constipation are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
+	(1, 27)	hypotension	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5685	Though [s1]hypotension[e1]  dry mouth, and constipation are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
+	(4, 17)	cotrimoxazole	elevation of serum creatinine and blood urea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5686	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the [s2]elevation of serum creatinine and blood urea[e2]  and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
+	(4, 12)	cotrimoxazole	hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5687	A high dose of [s1]cotrimoxazole[e1] induced [s2]hyperkalaemia[e2] with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
+	(4, 30)	cotrimoxazole	increased urinary N-acetyl glucosaminase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5688	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and [s2]increased urinary N-acetyl glucosaminase[e2] after several days of the drug administration in these patients; one patient became unconscious.
+	(4, 55)	cotrimoxazole	one patient became unconscious	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5689	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; [s2]one patient became unconscious[e2] 
+	(0, 25)	Hyperkalaemia	co-trimoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5690	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim  [s2]co-trimoxazole[e2]  is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
+	(0, 13)	Hyperkalaemia	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5691	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by oral therapy of [s2]sulfamethoxazole-trimethoprim[e2] (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
+	(4, 25)	renal tubular dysfunction	co-trimoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5692	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by oral therapy of sulfamethoxazole-trimethoprim  [s2]co-trimoxazole[e2]  is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
+	(4, 13)	renal tubular dysfunction	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5693	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by oral therapy of [s2]sulfamethoxazole-trimethoprim[e2] (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
+	(0, 10)	Hyperkalaemia	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5694	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by [s2]sulfamethoxazole-trimethoprim[e2] for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.
+	(4, 10)	renal tubular dysfunction	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5695	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by [s2]sulfamethoxazole-trimethoprim[e2] for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.
+	(28, 42)	subacute combined degeneration of the spinal cord	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5696	Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed [s1]subacute combined degeneration of the spinal cord[e1] following [s2]nitrous oxide[e2] anesthesia.
+	(0, 10)	Neurologic degeneration	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5697	 [s1]Neurologic degeneration[e1] associated with [s2]nitrous oxide[e2] anesthesia in patients with vitamin B12 deficiency.
+	(11, 18)	neurologic deterioration	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5698	Patients with vitamin B12 deficiency are exceedingly sensitive to [s1]neurologic deterioration[e1] following [s2]nitrous oxide[e2] anesthesia.
+	(2, 24)	Fluoxetine	sexual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5699	BACKGROUND: [s1]Fluoxetine[e1]  a highly specific serotonin reuptake inhibitor, has been reported to cause [s2]sexual dysfunction[e2] in a minority of patients.
+	(0, 6)	Captopril	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5700	 [s1]Captopril[e1] induced [s2]bone marrow suppression[e2] in two cardiac patients with trisomy 21.
+	(0, 30)	Neutropenia	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5701	 [s1]Neutropenia[e1] is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, [s2]captopril[e2] 
+	(5, 12)	neutropenia	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5702	We report two cases of [s1]neutropenia[e1] following [s2]captopril[e2] use in cardiac patients with trisomy 21.
+	(1, 7)	magnesium sulfate	lactogenesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5703	Can [s1]magnesium sulfate[e1] therapy impact [s2]lactogenesis[e2] 
+	(13, 18)	magnesium sulfate	impeded lactogenesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5704	No explanation for this delay was found, other than the possibility that [s1]magnesium sulfate[e1] treatment [s2]impeded lactogenesis[e2] 
+	(12, 42)	goserelin acetate	flare-up	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5705	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a [s2]flare-up[e2] 
+	(12, 19)	goserelin acetate	severe dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5706	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  [s2]severe dyspnea[e2] developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.
+	(12, 27)	goserelin acetate	worsening pleuritis carcinomatosa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5707	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  severe dyspnea developed due to [s2]worsening pleuritis carcinomatosa[e2]  which was considered as a flare-up.
+	(0, 27)	Imidazoline intoxication	Imidazoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5708	 [s1]Imidazoline intoxication[e1] due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children [s2]Imidazoline[e2] intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.
+	(0, 11)	Imidazoline intoxication	Imidazoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5709	 [s1]Imidazoline intoxication[e1] in children [s2]Imidazoline[e2] intoxication in children.
+	(7, 21)	L-asparaginase	aphasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5710	Cerebrovascular complications of [s1]L-asparaginase[e1] therapy in children with leukemia: [s2]aphasia[e2] and other neuropsychological deficits.
+	(0, 9)	Cerebrovascular complications	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5711	 [s1]Cerebrovascular complications[e1] of [s2]L-asparaginase[e2] therapy in children with leukemia: aphasia and other neuropsychological deficits.
+	(7, 26)	L-asparaginase	neuropsychological deficits	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5712	Cerebrovascular complications of [s1]L-asparaginase[e1] therapy in children with leukemia: aphasia and other [s2]neuropsychological deficits[e2] 
+	(15, 27)	L-asparaginase	cerebral thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5713	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for [s2]cerebral thrombosis[e2] or hemorrhage because of coagulation protein deficiencies.
+	(15, 39)	L-asparaginase	coagulation protein deficiencies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5714	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for cerebral thrombosis or hemorrhage because of [s2]coagulation protein deficiencies[e2] 
+	(15, 33)	L-asparaginase	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5715	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for cerebral thrombosis or [s2]hemorrhage[e2] because of coagulation protein deficiencies.
+	(0, 15)	Myoclonus	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5716	 [s1]Myoclonus[e1] and seizures disappeared after discontinuation of [s2]L-dopa[e2] and the introduction of valproate sodium (VPA).
+	(5, 15)	seizures	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5717	Myoclonus and [s1]seizures[e1] disappeared after discontinuation of [s2]L-dopa[e2] and the introduction of valproate sodium (VPA).
+	(0, 17)	Myoclonus	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5718	 [s1]Myoclonus[e1] and seizures in a patient with parkinsonism: induction by [s2]levodopa[e2] and its confirmation on SEPs.
+	(5, 17)	seizures	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5719	Myoclonus and [s1]seizures[e1] in a patient with parkinsonism: induction by [s2]levodopa[e2] and its confirmation on SEPs.
+	(9, 17)	L-dopa	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5720	Myoclonus was induced and enhanced by [s1]L-dopa[e1]  developing into [s2]generalized seizures[e2] 
+	(0, 11)	Myoclonus	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5721	 [s1]Myoclonus[e1] was induced and enhanced by [s2]L-dopa[e2]  developing into generalized seizures.
+	(5, 12)	L-dopa	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5722	We described the occurrence of [s1]L-dopa[e1] induced [s2]myoclonus[e2] and seizures in a case of parkinsonism with its SEPs findings.
+	(5, 17)	L-dopa	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5723	We described the occurrence of [s1]L-dopa[e1] induced myoclonus and [s2]seizures[e2] in a case of parkinsonism with its SEPs findings.
+	(5, 23)	acyclovir	excessive maternal and physician anxiety	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5724	Unintended exposure to [s1]acyclovir[e1] early in pregnancy, which is not uncommon, may cause [s2]excessive maternal and physician anxiety[e2] 
+	(4, 13)	exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5725	A severe form of [s1]exophthalmos[e1] resulting from [s2]lithium[e2] therapy has not been described in the literature.
+	(0, 17)	Lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5726	 [s1]Lithium[e1] therapy was discontinued because of poor compliance to the medication and intolerable [s2]polyuria[e2] 
+	(2, 14)	thyrotoxic ophthalmopathy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5727	Regression of [s1]thyrotoxic ophthalmopathy[e1] following [s2]lithium[e2] withdrawal.
+	(14, 24)	severe exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5728	The case of a bipolar patient who developed thyrotoxicosis with [s1]severe exophthalmos[e1] while on [s2]lithium[e2] therapy is described.
+	(8, 24)	thyrotoxicosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5729	The case of a bipolar patient who developed [s1]thyrotoxicosis[e1] with severe exophthalmos while on [s2]lithium[e2] therapy is described.
+	(1, 17)	exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5730	The [s1]exophthalmos[e1] improved dramatically within 72 hours of the withdrawal of [s2]lithium[e2] 
+	(1, 9)	abdominal pain	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5731	Severe [s1]abdominal pain[e1] in low dosage [s2]clofazimine[e2] 
+	(17, 31)	clofazimine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5732	We describe a 41 yr old leprosy patient treated for 10 yrs with [s1]clofazimine[e1] who underwent laparotomy for severe [s2]abdominal pain[e2] 
+	(0, 13)	Amphotericin B	cardiac arrest	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5733	 [s1]Amphotericin B[e1] overdose in pediatric patients with associated [s2]cardiac arrest[e2] 
+	(2, 12)	Amphotericin B	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5734	CONCLUSIONS: [s1]Amphotericin B[e1] overdose can be [s2]fatal[e2] in children and infants.
+	(12, 23)	cardiac arrhythmias	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5735	Hydrocortisone may decrease the incidence of mortality associated with [s1]cardiac arrhythmias[e1] in children receiving [s2]amphotericin B[e2] overdoses.
+	(9, 23)	mortality	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5736	Hydrocortisone may decrease the incidence of [s1]mortality[e1] associated with cardiac arrhythmias in children receiving [s2]amphotericin B[e2] overdoses.
+	(4, 30)	Cardiac complications	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5737	INTERVENTIONS AND RESULTS: [s1]Cardiac complications[e1] were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of [s2]amphotericin B[e2] 
+	(9, 19)	amphotericin B	cardiac complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5738	OBJECTIVE: To report the first five cases of [s1]amphotericin B[e1] overdose with secondary [s2]cardiac complications[e2] in a pediatric population.
+	(0, 21)	Hypertension	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5739	 [s1]Hypertension[e1] develops in most patients after transplantation when immunosuppression is based on [s2]cyclosporine[e2] and prednisone.
+	(0, 27)	Hypertension	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5740	 [s1]Hypertension[e1] develops in most patients after transplantation when immunosuppression is based on cyclosporine and [s2]prednisone[e2] 
+	(0, 17)	Sudden death	sweet spirits of nitre	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5741	 [s1]Sudden death[e1] in an infant from methemoglobinemia after administration of  [s2]sweet spirits of nitre[e2] .
+	(10, 33)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	acute methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5742	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by [s2]acute methemoglobinemia[e2] and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
+	(3, 33)	sweet spirits of nitre	acute methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5743	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by [s2]acute methemoglobinemia[e2] and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.
+	(10, 69)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5744	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin [s2]died[e2] from the consequences of hypoxemia."
+	(3, 69)	sweet spirits of nitre	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5745	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin [s2]died[e2] from the consequences of hypoxemia.
+	(10, 74)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5746	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of [s2]hypoxemia[e2] "
+	(3, 74)	sweet spirits of nitre	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5747	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of [s2]hypoxemia[e2] 
+	(10, 41)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	severe anoxic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5748	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and [s2]severe anoxic metabolic acidosis[e2] in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
+	(3, 41)	sweet spirits of nitre	severe anoxic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5749	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and [s2]severe anoxic metabolic acidosis[e2] in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.
+	(0, 17)	Hepatotoxic effects	carnitine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5750	 [s1]Hepatotoxic effects[e1] in a child receiving valproate and [s2]carnitine[e2] 
+	(0, 13)	Hepatotoxic effects	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5751	 [s1]Hepatotoxic effects[e1] in a child receiving [s2]valproate[e2] and carnitine.
+	(13, 25)	fatal hepatotoxic effects	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5752	L-Carnitine supplementation has been recommended to prevent the [s1]fatal hepatotoxic effects[e1] associated with [s2]valproic acid[e2] 
+	(6, 9)	fatal	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5753	We report on a child with [s1]fatal[e1]  [s2]valproate[e2] related hepatotoxic effects despite this supplementation.
+	(7, 13)	valproate	hepatotoxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5754	We report on a child with fatal [s1]valproate[e1] related [s2]hepatotoxic effects[e2] despite this supplementation.
+	(16, 31)	IL-2	cognitive dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5755	A case is reported of a 40 year old woman treated with intraventricular [s1]IL-2[e1] for leptomeningeal disease who developed progressive [s2]cognitive dysfunction[e2] 
+	(1, 13)	neurotoxicity	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5756	Delayed [s1]neurotoxicity[e1] of intraventricular [s2]interleukin-2[e2]  a case report.
+	(4, 17)	brain injury	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5757	The potential for progressive [s1]brain injury[e1] and subsequent disability related to intraventricular [s2]IL-2[e2] therapy is discussed.
+	(8, 17)	disability	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5758	The potential for progressive brain injury and subsequent [s1]disability[e1] related to intraventricular [s2]IL-2[e2] therapy is discussed.
+	(7, 11)	lithium	thyroid dysfunctions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5759	Albeit rare among Western patients, such [s1]lithium[e1] associated [s2]thyroid dysfunctions[e2] appeared to be more likely to occur in Hong Kong Chinese.
+	(25, 34)	thyrotoxicosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5760	Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of [s1]thyrotoxicosis[e1] during maintenance [s2]lithium[e2] therapy.
+	(0, 4)	Lithium	transient thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5761	 [s1]Lithium[e1] associated [s2]transient thyrotoxicosis[e2] in 4 Chinese women with autoimmune thyroiditis.
+	(20, 32)	toxic and immunomodulatory roles	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5762	They seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the [s1]toxic and immunomodulatory roles[e1] of [s2]lithium[e2] and perhaps genetic and dietary factors.
+	(1, 21)	retinoic acid	fatal complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5763	"Although [s1]retinoic acid[e1] is well tolerated by the majority of patients with this disease, a potentially [s2]fatal complication[e2] of this kind of treatment has been reported: ""the retinoic acid syndrome""."
+	(1, 35)	retinoic acid	retinoic acid syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5764	"Although [s1]retinoic acid[e1] is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: ""the [s2]retinoic acid syndrome[e2] ."
+	(6, 15)	foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5765	CONCLUSIONS: It is probable that [s1]foscarnet[e1] contributed to the [s2]electrolyte disorders[e2] and symptomatology in this patient.
+	(2, 10)	Electrolyte disorders	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5766	DISCUSSION: [s1]Electrolyte disorders[e1] associated with [s2]foscarnet[e2] are reviewed.
+	(0, 16)	Foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5767	 [s1]Foscarnet[e1] induced severe hypomagnesemia and other [s2]electrolyte disorders[e2] 
+	(0, 7)	Foscarnet	severe hypomagnesemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5768	 [s1]Foscarnet[e1] induced [s2]severe hypomagnesemia[e2] and other electrolyte disorders.
+	(8, 24)	foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5769	OBJECTIVE: To report a case of possible [s1]foscarnet[e1] induced severe hypomagnesemia and other [s2]electrolyte disorders[e2] 
+	(8, 15)	foscarnet	severe hypomagnesemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5770	OBJECTIVE: To report a case of possible [s1]foscarnet[e1] induced [s2]severe hypomagnesemia[e2] and other electrolyte disorders.
+	(13, 20)	anxiety	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5771	The patient experienced muscle twitches, tremulousness, and [s1]anxiety[e1] on day 17 of [s2]foscarnet[e2] therapy.
+	(3, 19)	muscle twitches	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5772	The patient experienced [s1]muscle twitches[e1]  tremulousness, and anxiety on day 17 of [s2]foscarnet[e2] therapy.
+	(7, 19)	tremulousness	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5773	The patient experienced muscle twitches, [s1]tremulousness[e1]  and anxiety on day 17 of [s2]foscarnet[e2] therapy.
+	(0, 16)	Interference with the cortisol axis	CPH82	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5774	 [s1]Interference with the cortisol axis[e1] by the microtubule antagonist, [s2]CPH82[e2] 
+	(5, 39)	CPH82	hypercortisolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5775	The results clearly demonstrate that [s1]CPH82[e1] was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical [s2]hypercortisolism[e2] 
+	(5, 14)	CPH82	suppression of the endogeneous production of ACTH and cortisol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5776	The results clearly demonstrate that [s1]CPH82[e1] was associated with [s2]suppression of the endogeneous production of ACTH and cortisol[e2] with a concomitant paradoxical picture of clinical hypercortisolism.
+	(3, 14)	movement disorders	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5777	A variety of [s1]movement disorders[e1] are known to occur in association with [s2]carbamazepine[e2] (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
+	(3, 19)	movement disorders	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5778	A variety of [s1]movement disorders[e1] are known to occur in association with carbamazepine  [s2]CBZ[e2]  therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
+	(12, 32)	carbamazepine	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5779	A variety of movement disorders are known to occur in association with [s1]carbamazepine[e1] (CBZ) therapy in adults and children, but development of [s2]tics[e2] has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
+	(17, 30)	CBZ	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5780	A variety of movement disorders are known to occur in association with carbamazepine  [s1]CBZ[e1]  therapy in adults and children, but development of [s2]tics[e2] has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
+	(0, 8)	Carbamazepine	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5781	 [s1]Carbamazepine[e1] induced [s2]tics[e2] 
+	(6, 12)	tics	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5782	In the third child, the [s1]tics[e1] ceased after [s2]CBZ[e2] discontinuation.
+	(4, 11)	CBZ	motor tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5783	These cases demonstrate that [s1]CBZ[e1] can induce simple [s2]motor tics[e2] in children.
+	(10, 19)	facial motor tics	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5784	We report 3 children with epilepsy who developed [s1]facial motor tics[e1] after initiation of [s2]CBZ[e2] for complex partial seizures.
+	(0, 8)	Acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5785	 [s1]Acyclovir[e1] induced [s2]neurotoxicity[e2]  concentration-side effect relationship in acyclovir overdose.
+	(5, 22)	neurotoxicity	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5786	CONCLUSIONS: The observation that [s1]neurotoxicity[e1] developed with a delay of 24 to 48 hours after [s2]acyclovir[e2] peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.
+	(5, 22)	neurotoxicity	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5787	CONCLUSIONS: The observation that [s1]neurotoxicity[e1] developed with a delay of 24 to 48 hours after [s2]acyclovir[e2] peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.
+	(12, 22)	acyclovir	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5788	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1] overdose who developed [s2]coma[e2] and nonoliguric renal failure.
+	(12, 24)	acyclovir	nonoliguric renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5789	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1] overdose who developed coma and [s2]nonoliguric renal failure[e2] 
+	(15, 40)	acyclovir	central nervous system side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5790	PURPOSE: To investigate the concentration-side effect relationship in a patient with severe [s1]acyclovir[e1] induced neurotoxicity and to summarize the information available in the literature about [s2]central nervous system side effects[e2] due to acyclovir.
+	(15, 23)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5791	PURPOSE: To investigate the concentration-side effect relationship in a patient with severe [s1]acyclovir[e1] induced [s2]neurotoxicity[e2] and to summarize the information available in the literature about central nervous system side effects due to acyclovir.
+	(19, 40)	eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5792	A 16-year-old white male with acute biphenotypic leukemia developed evidence of the [s1]eosinophilia myalgia syndrome[e1] associated with total parenteral nutritional support with solutions containing [s2]tryptophan[e2]  which were given during his initial induction chemotherapy and also after autologous marrow transplantation.
+	(0, 27)	Fatal eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5793	 [s1]Fatal eosinophilia myalgia syndrome[e1] in a marrow transplant patient attributed to total parenteral nutrition with a solution containing [s2]tryptophan[e2] 
+	(3, 20)	eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5794	Thus, the [s1]eosinophilia myalgia syndrome[e1] can be associated with parenteral [s2]tryptophan[e2] administration.
+	(14, 33)	fatal rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5795	A patient with acute esophageal variceal bleeding developed [s1]fatal rhabdomyolysis[e1] during treatment with a continuous intravenous infusion of [s2]vasopressin[e2] 
+	(6, 54)	vasopressin	impaired tissue perfusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5796	Idiosyncratic factors involving [s1]vasopressin[e1] receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to [s2]impaired tissue perfusion[e2] 
+	(6, 23)	vasopressin	vasodilation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5797	Idiosyncratic factors involving [s1]vasopressin[e1] receptor affinity and distribution, vasopressin-associated [s2]vasodilation[e2] in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.
+	(0, 15)	Rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5798	 [s1]Rhabdomyolysis[e1] associated with the use of intravenous [s2]vasopressin[e2] 
+	(7, 20)	rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5799	These multiple overlapping factors probably lead to [s1]rhabdomyolysis[e1] in a minority of patients receiving [s2]vasopressin[e2] infusion.
+	(4, 14)	disulfiram	teratogen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5800	In one case, [s1]disulfiram[e1] was the only potential [s2]teratogen[e2] exposed to the fetus.
+	(5, 19)	significant abnormalities	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5801	Nonspecific but [s1]significant abnormalities[e1] have been described in the infants of women treated with [s2]disulfiram[e2] in the first trimester of their pregnancies.
+	(5, 23)	PV	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5802	Although the essential cause of [s1]PV[e1] is unclear, its onset has occasionally been associated with drug therapy, in particular [s2]penicillamine[e2] 
+	(0, 13)	Pemphigus vulgaris	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5803	 [s1]Pemphigus vulgaris[e1] precipitated by [s2]glibenclamide[e2] therapy.
+	(19, 28)	oral lesions of PV	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5804	The patient described in this paper was a 78-year-old diabetic man who developed [s1]oral lesions of PV[e1] following institution of [s2]glibenclamide[e2] therapy.
+	(0, 8)	Piritrexim	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5805	 [s1]Piritrexim[e1] induced [s2]pulmonary toxicity[e2] 
+	(1, 9)	pulmonary toxicity	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5806	The [s1]pulmonary toxicity[e1] is probably induced by [s2]piritrexim[e2] 
+	(21, 40)	abnormal chest x-ray with diffuse interstitial opacities	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5807	We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an [s1]abnormal chest x-ray with diffuse interstitial opacities[e1] while on chemotherapy with [s2]piritrexim[e2]  a methotrexate analog.
+	(17, 40)	respiratory dysfunction	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5808	We describe a patient with transitional cell carcinoma of the renal pelvis who developed [s1]respiratory dysfunction[e1] and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with [s2]piritrexim[e2]  a methotrexate analog.
+	(17, 25)	adenosine	acceleration of the heart rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5809	A 12 year old patient with atrial flutter is presented, in whom intravenous [s1]adenosine[e1] was followed by [s2]acceleration of the heart rate[e2] to a potentially dangerous arrhythmia.
+	(17, 34)	adenosine	arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5810	A 12 year old patient with atrial flutter is presented, in whom intravenous [s1]adenosine[e1] was followed by acceleration of the heart rate to a potentially dangerous [s2]arrhythmia[e2] 
+	(0, 16)	Acceleration of ventricular response	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5811	 [s1]Acceleration of ventricular response[e1] to atrial flutter after intravenous [s2]adenosine[e2] 
+	(0, 18)	Lymphoma	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5812	 [s1]Lymphoma[e1] developing in a patient with rheumatoid arthritis taking [s2]methotrexate[e2] 
+	(11, 34)	methotrexate	lymphoproliferative diseases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5813	The mild immunosuppression that occurs with [s1]methotrexate[e1] therapy probably places patients with rheumatoid arthritis at added risk of developing [s2]lymphoproliferative diseases[e2]  but coincidence cannot be excluded.
+	(5, 38)	non-Hodgkin lymphoma	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5814	We report one case of [s1]non-Hodgkin lymphoma[e1] in a patient, with a 30-year history of rheumatoid arthritis, taking low dose [s2]methotrexate[e2] weekly over a 10-month period.
+	(0, 9)	Hepatotoxicity	paracetamol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5815	 [s1]Hepatotoxicity[e1] of [s2]paracetamol[e2] enhanced by ingestion of alcohol: report of two cases.
+	(3, 29)	paracetamol	hepatotoxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5816	The biochemistry of [s1]paracetamol[e1] hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the [s2]hepatotoxic effects[e2] of paracetamol is remarked upon.
+	(3, 9)	paracetamol	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5817	The biochemistry of [s1]paracetamol[e1]  [s2]hepatotoxicity[e2] is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon.
+	(1, 8)	fatal	paracetamol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5818	Two [s1]fatal[e1] cases of poisoning by [s2]paracetamol[e2] are described.
+	(8, 48)	Kaposi's sarcoma	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5819	We report a case of drug-induced [s1]Kaposi's sarcoma[e1] (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy  [s2]prednisolone[e2] 25 mg/day) for pericardial effusion.
+	(0, 11)	Acute dystonic reaction	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5820	 [s1]Acute dystonic reaction[e1] with low-dose [s2]pimozide[e2] 
+	(21, 30)	acute dystonic reactions	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5821	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with [s2]pimozide[e2] administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
+	(21, 30)	acute dystonic reactions	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5822	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with [s2]pimozide[e2] administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
+	(21, 73)	acute dystonic reactions	thioridazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5823	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent [s2]thioridazine[e2] administration.
+	(15, 49)	t-PA	atheroembolic acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5824	Although there is one case report of cholesterol crystal embolization following [s1]t-PA[e1] therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of [s2]atheroembolic acute renal failure[e2] following t-PA therapy.
+	(7, 17)	cholesterol crystal embolization	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5825	Although there is one case report of [s1]cholesterol crystal embolization[e1] following [s2]t-PA[e2] therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.
+	(15, 23)	t-PA	extrarenal manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5826	Although there is one case report of cholesterol crystal embolization following [s1]t-PA[e1] therapy with only [s2]extrarenal manifestations[e2] (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.
+	(0, 19)	Cholesterol crystal embolization	tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5827	 [s1]Cholesterol crystal embolization[e1] associated renal failure after therapy with recombinant [s2]tissue-type plasminogen activator[e2] 
+	(9, 20)	renal failure	tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5828	Cholesterol crystal embolization-associated [s1]renal failure[e1] after therapy with recombinant [s2]tissue-type plasminogen activator[e2] 
+	(9, 28)	cholesterol crystal embolization	recombinant tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5829	We report the occurrence of renal failure due to [s1]cholesterol crystal embolization[e1] following thrombolytic therapy with intravenous [s2]recombinant tissue-type plasminogen activator[e2] (t-PA).
+	(9, 42)	cholesterol crystal embolization	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5830	We report the occurrence of renal failure due to [s1]cholesterol crystal embolization[e1] following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator  [s2]t-PA[e2] .
+	(5, 28)	renal failure	recombinant tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5831	We report the occurrence of [s1]renal failure[e1] due to cholesterol crystal embolization following thrombolytic therapy with intravenous [s2]recombinant tissue-type plasminogen activator[e2] (t-PA).
+	(5, 42)	renal failure	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5832	We report the occurrence of [s1]renal failure[e1] due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator  [s2]t-PA[e2] .
+	(3, 15)	haloperidol	multiform ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5833	Intravenous [s1]haloperidol[e1] is generally well tolerated, but [s2]multiform ventricular tachycardia[e2] has been reported.
+	(2, 16)	mucocutaneous side effects	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5834	All developed [s1]mucocutaneous side effects[e1] within 20 weeks of beginning im [s2]gold[e2] therapy, at a time when RA had improved markedly compared to pretreatment status.
+	(13, 19)	gold	mucocutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5835	How low can you go? Use of very low dosage of [s1]gold[e1] in patients with [s2]mucocutaneous reactions[e2] 
+	(0, 15)	Anterior spinal artery syndrome	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5836	 [s1]Anterior spinal artery syndrome[e1] -a complication of cervical intrathecal [s2]phenol[e2] injection.
+	(20, 38)	anterior spinal artery syndrome	phenol-glycerine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5837	We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of [s1]anterior spinal artery syndrome[e1]  developed following the injection of 0.3 ml of 10% [s2]phenol-glycerine[e2] into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.
+	(8, 25)	feeding gastrostomy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5838	One patient required nursing home placement and a [s1]feeding gastrostomy[e1] as a result of the worsening parkinsonism during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
+	(8, 25)	feeding gastrostomy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5839	One patient required nursing home placement and a [s1]feeding gastrostomy[e1] as a result of the worsening parkinsonism during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
+	(18, 25)	worsening parkinsonism	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5840	One patient required nursing home placement and a feeding gastrostomy as a result of the [s1]worsening parkinsonism[e1] during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
+	(18, 25)	worsening parkinsonism	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5841	One patient required nursing home placement and a feeding gastrostomy as a result of the [s1]worsening parkinsonism[e1] during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
+	(11, 19)	encephalopathy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5842	Two of the five patients who worsened motorically also developed [s1]encephalopathy[e1] during [s2]risperidone[e2] treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.
+	(6, 19)	worsened motorically	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5843	Two of the five patients who [s1]worsened motorically[e1] also developed encephalopathy during [s2]risperidone[e2] treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.
+	(0, 9)	Azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5844	 [s1]Azathioprine[e1] can cause severe [s2]myelosuppression[e2] 
+	(0, 7)	Azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5845	 [s1]Azathioprine[e1] induced [s2]myelosuppression[e2] due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
+	(1, 17)	azathioprine	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5846	The [s1]azathioprine[e1] dose was low (1 mg/kg) and [s2]pancytopenia[e2] occurred after 56 days therapy.
+	(23, 36)	myelosuppression	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5847	Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound [s1]myelosuppression[e1] after a short course of [s2]azathioprine[e2] 
+	(7, 15)	azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5848	We describe the first documented case of [s1]azathioprine[e1] induced severe [s2]myelosuppression[e2] due to thiopurine methyltransferase deficiency in autoimmune liver disease.
+	(0, 7)	Nabumetone	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5849	 [s1]Nabumetone[e1] associated [s2]interstitial nephritis[e2] 
+	(4, 26)	nabumetone	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5850	She had been taking [s1]nabumetone[e1] for 6 months, but had discontinued the agent 2 weeks before admission due to progressive [s2]edema[e2] 
+	(0, 21)	Acute myeloid leukemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5851	 [s1]Acute myeloid leukemia[e1] evolving from essential thrombocythemia in two patients treated with [s2]hydroxyurea[e2] 
+	(11, 33)	AL	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5852	In this report, two cases of ET which evolved into [s1]AL[e1] without prior exposure to radiation or alkylating agents, and which were treated with long-term [s2]hydroxyurea[e2] therapy, are described.
+	(3, 19)	hydroxyurea	acute leukemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5853	Prolonged used of [s1]hydroxyurea[e1] in patients with ET may lead to therapy-associated [s2]acute leukemia[e2] 
+	(18, 29)	cardiac effects	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5854	However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed [s1]cardiac effects[e1] of antimalarial treatment with [s2]halofantrine[e2]  including one sudden death after the treatment.
+	(27, 35)	halofantrine	sudden death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5855	However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with [s1]halofantrine[e1]  including one [s2]sudden death[e2] after the treatment.
+	(15, 25)	QT interval was prolonged	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5856	In the present paper, we discuss the first Japanese vivax malaria patient whose [s1]QT interval was prolonged[e1] after treatment with [s2]halofantrine[e2] 
+	(0, 22)	Prolongation of the QT interval	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5857	 [s1]Prolongation of the QT interval[e1] observed in a Japanese patient with vivax malaria following treatment with [s2]halofantrine[e2] 
+	(4, 11)	Halfan	cardiac arrests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5858	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 [s2]cardiac arrests[e2]  leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(9, 37)	cardiac arrests	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5859	The pharmaceutical company producing Halfan has reported 8 [s1]cardiac arrests[e1]  leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(4, 17)	Halfan	deaths	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5860	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 cardiac arrests, leading to 6 [s2]deaths[e2]  when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(15, 37)	deaths	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5861	The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 [s1]deaths[e1]  when a higher dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(0, 13)	Supravenous hyperpigmentation	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5862	 [s1]Supravenous hyperpigmentation[e1] in association with [s2]CHOP[e2] chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.
+	(6, 18)	supravenous hyperpigmentation	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5863	We report an unusual pattern of [s1]supravenous hyperpigmentation[e1] occurring after [s2]CHOP[e2] chemotherapy.
+	(0, 20)	Phenytoin toxicity	Phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5864	 [s1]Phenytoin toxicity[e1] due to concomitant antituberculosis therapy [s2]Phenytoin[e2] toxicity due to concomitant antituberculosis therapy.
+	(28, 42)	phenytoin	blood levels in the toxic range	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5865	Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on [s1]phenytoin[e1] and 11.6% of these had [s2]blood levels in the toxic range[e2] 
+	(27, 34)	phenytoin toxicity	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5866	Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of [s1]phenytoin toxicity[e1]  [s2]phenytoin[e2] toxicity when this drug is given together with antituberculosis therapy.
+	(4, 33)	phenytoin	phenytoin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5867	The wide use of [s1]phenytoin[e1] during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to [s2]phenytoin toxicity[e2] 
+	(4, 33)	phenytoin	phenytoin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5868	The wide use of [s1]phenytoin[e1] during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to [s2]phenytoin toxicity[e2] 
+	(0, 18)	Nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5869	 [s1]Nephrogenic diabetes insipidus[e1] and renal tubular acidosis secondary to [s2]foscarnet[e2] therapy.
+	(10, 18)	renal tubular acidosis	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5870	Nephrogenic diabetes insipidus and [s1]renal tubular acidosis[e1] secondary to [s2]foscarnet[e2] therapy.
+	(12, 32)	nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5871	No cases of renal acidosis, and only one case of [s1]nephrogenic diabetes insipidus[e1]  has been previously reported as a complication of [s2]foscarnet[e2] treatment.
+	(4, 29)	nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5872	Our patient developed both [s1]nephrogenic diabetes insipidus[e1] and renal tubular acidosis with a temporal pattern that demonstrated a link between [s2]foscarnet[e2] therapy and these abnormalities.
+	(14, 29)	renal tubular acidosis	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5873	Our patient developed both nephrogenic diabetes insipidus and [s1]renal tubular acidosis[e1] with a temporal pattern that demonstrated a link between [s2]foscarnet[e2] therapy and these abnormalities.
+	(16, 33)	foscarnet	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5874	We present a patient with human immunodeficiency virus infection under treatment with [s1]foscarnet[e1] for CMV retinitis who complained of thirst and [s2]polyuria[e2] 
+	(16, 31)	foscarnet	thirst	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5875	We present a patient with human immunodeficiency virus infection under treatment with [s1]foscarnet[e1] for CMV retinitis who complained of [s2]thirst[e2] and polyuria.
+	(0, 12)	Choroidal hemorrhage	tissue plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5876	 [s1]Choroidal hemorrhage[e1] associated with systemic [s2]tissue plasminogen activator[e2] 
+	(5, 22)	tissue plasminogen activator	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5877	CONCLUSION: The administration of [s1]tissue plasminogen activator[e1] was responsible for the large extent of [s2]hemorrhage[e2] and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.
+	(5, 35)	tissue plasminogen activator	hemorrhagic choroidal detachment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5878	CONCLUSION: The administration of [s1]tissue plasminogen activator[e1] was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of [s2]hemorrhagic choroidal detachment[e2] 
+	(7, 36)	spontaneous choroidal hemorrhage	tissue plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5879	PURPOSE: To determine the cause of [s1]spontaneous choroidal hemorrhage[e1] in a 67-year-old man after a myocardial infarction and administration of [s2]tissue plasminogen activator[e2] 
+	(0, 7)	Accelerated nodulosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5880	 [s1]Accelerated nodulosis[e1] during [s2]methotrexate[e2] therapy for juvenile rheumatoid arthritis.
+	(6, 29)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5881	Although they had only a few [s1]nodules[e1] at diagnosis, the nodules increased in number and size 3 to 4 months after the start of [s2]methotrexate[e2] therapy in both patients.
+	(6, 29)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5882	Although they had only a few [s1]nodules[e1] at diagnosis, the nodules increased in number and size 3 to 4 months after the start of [s2]methotrexate[e2] therapy in both patients.
+	(4, 24)	methotrexate	extraarticular side effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5883	Physicians treating patients with [s1]methotrexate[e1] for juvenile rheumatoid arthritis must be aware of this [s2]extraarticular side effect[e2] 
+	(1, 10)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5884	The [s1]nodules[e1] regressed after withdrawal of [s2]methotrexate[e2] therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.
+	(28, 36)	accelerated nodulosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5885	We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom [s1]accelerated nodulosis[e1] developed during [s2]methotrexate[e2] therapy.
+	(1, 11)	macrophage activation syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5886	A [s1]macrophage activation syndrome[e1]  possibly related to [s2]methotrexate[e2] toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.
+	(10, 18)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5887	A macrophage activation syndrome, possibly related to [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.
+	(0, 7)	Jaundice	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5888	 [s1]Jaundice[e1] induced by [s2]streptokinase[e2] 
+	(7, 15)	jaundice	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5889	Only a few reports of overt [s1]jaundice[e1] are associated with [s2]streptokinase[e2] 
+	(6, 41)	colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5890	Although both patients recovered from the [s1]colitis[e1] after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with [s2]cisplatin[e2] 
+	(10, 17)	cisplatin	C. difficile colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5891	Based on our findings, it is thus concluded that [s1]cisplatin[e1] may cause [s2]C. difficile colitis[e2] 
+	(13, 33)	cisplatin	colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5892	Both patients were then treated with a carboplatin alternative to [s1]cisplatin[e1] in the following courses, which resulted in neither a relapse of the [s2]colitis[e2] nor a recurrence of the malignancies up to this time.
+	(0, 14)	Clostridium difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5893	 [s1]Clostridium difficile colitis[e1] associated with [s2]cisplatin[e2] based chemotherapy in ovarian cancer patients.
+	(1, 23)	C. difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5894	Severe [s1]C. difficile colitis[e1] occurred in 2 patients (6.1%) after receiving [s2]cisplatin[e2] based combination chemotherapy for ovarian malignancies.
+	(13, 27)	Clostridium difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5895	The purpose of this study was to examine the incidence and cause of [s1]Clostridium difficile colitis[e1] occurring after [s2]cisplatin[e2] based combination chemotherapy in ovarian cancer patients.
+	(3, 15)	severe cholestatic jaundice	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5896	A patient with [s1]severe cholestatic jaundice[e1] induced by [s2]captopril[e2] is presented.
+	(0, 6)	Captopril	pseudocholangitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5897	 [s1]Captopril[e1] associated  [s2]pseudocholangitis[e2] .
+	(0, 11)	Captopril	dermatologic, hematologic, and pulmonary adverse effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5898	 [s1]Captopril[e1] is known to be associated with [s2]dermatologic, hematologic, and pulmonary adverse effects[e2] 
+	(3, 10)	captopril	atypical cholangitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5899	Patients treated with [s1]captopril[e1] who develop  [s2]atypical cholangitis[e2]  should be suspected of having captopril-associated liver damage.
+	(3, 28)	captopril	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5900	"Patients treated with [s1]captopril[e1] who develop ""atypical cholangitis"" should be suspected of having captopril-associated [s2]liver damage[e2] "
+	(2, 22)	nephrotic syndrome	macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5901	Development of [s1]nephrotic syndrome[e1] in a patient with acute myeloblastic leukemia after treatment with [s2]macrophage-colony-stimulating factor[e2] 
+	(10, 25)	nephrotic syndrome	M-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5902	It should be emphasized that the recurrence of [s1]nephrotic syndrome[e1] was observed after the following chemotherapy, including [s2]M-CSF[e2]  whereas the bone marrow still remained completely remitted.
+	(6, 38)	M-CSF	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5903	The possibility can be raised that [s1]M-CSF[e1] accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of [s2]nephrotic syndrome[e2] 
+	(6, 15)	M-CSF	renal disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5904	The possibility can be raised that [s1]M-CSF[e1] accelerated the underlying [s2]renal disease[e2] in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.
+	(22, 30)	M-CSF	macrophage-related glomerular injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5905	These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the [s1]M-CSF[e1] treatment and [s2]macrophage-related glomerular injury[e2] 
+	(17, 32)	nephrotic syndrome	macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5906	We describe a patient with acute myeloblastic leukemia (AML) who developed [s1]nephrotic syndrome[e1] after receiving several courses of chemotherapy, including [s2]macrophage-colony-stimulating factor[e2] (M-CSF).
+	(17, 40)	nephrotic syndrome	M-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5907	We describe a patient with acute myeloblastic leukemia (AML) who developed [s1]nephrotic syndrome[e1] after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor  [s2]M-CSF[e2] .
+	(22, 28)	betamethasone	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5908	On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and [s1]betamethasone[e1]  [s2]edema[e2] developed in both labia.
+	(9, 28)	magnesium sulfate	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5909	On the fifth day of tocolysis with [s1]magnesium sulfate[e1]  nifedipine, terbutaline and betamethasone, [s2]edema[e2] developed in both labia.
+	(12, 28)	nifedipine	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5910	On the fifth day of tocolysis with magnesium sulfate, [s1]nifedipine[e1]  terbutaline and betamethasone, [s2]edema[e2] developed in both labia.
+	(17, 29)	terbutaline	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5911	On the fifth day of tocolysis with magnesium sulfate, nifedipine, [s1]terbutaline[e1] and betamethasone, [s2]edema[e2] developed in both labia.
+	(0, 9)	Milk-alkali syndrome	1,25(OH)2D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5912	 [s1]Milk-alkali syndrome[e1] induced by [s2]1,25(OH)2D[e2] in a patient with hypoparathyroidism.
+	(20, 34)	calcitriol	milk-alkali syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5913	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and [s1]calcitriol[e1] resulting in two admissions to the hospital for [s2]milk-alkali syndrome[e2] 
+	(17, 34)	calcium carbonate	milk-alkali syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5914	This article presents a patient with hypoparathyroidism who was treated with [s1]calcium carbonate[e1] and calcitriol resulting in two admissions to the hospital for [s2]milk-alkali syndrome[e2] 
+	(5, 20)	ifosfamide	unresponsive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5915	After receiving 3 doses of [s1]ifosfamide[e1] mesna, she was found to be [s2]unresponsive[e2] 
+	(9, 19)	mesna	unresponsive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5916	After receiving 3 doses of ifosfamide [s1]mesna[e1]  she was found to be [s2]unresponsive[e2] 
+	(11, 26)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5917	CONCLUSIONS: There was a temporal relationship between the onset of [s1]nonconvulsive status epilepticus[e1] and initiation of [s2]ifosfamide[e2] infusion.
+	(2, 16)	Central nervous system (CNS) toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5918	DISCUSSION: [s1]Central nervous system (CNS) toxicity[e1] has been described with [s2]ifosfamide[e2]  with most cases reported in the pediatric population.
+	(0, 7)	Ifosfamide	nonconvulsive status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5919	 [s1]Ifosfamide[e1] induced [s2]nonconvulsive status epilepticus[e2] 
+	(7, 14)	ifosfamide	nonconvulsive status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5920	OBJECTIVE: To describe a patient with [s1]ifosfamide[e1] induced [s2]nonconvulsive status epilepticus[e2] 
+	(6, 20)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5921	This represents the first report of [s1]nonconvulsive status epilepticus[e1] induced by [s2]ifosfamide[e2] 
+	(0, 8)	Albendazole	pseudomembranous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5922	 [s1]Albendazole[e1] induced [s2]pseudomembranous colitis[e2] 
+	(6, 17)	metronidazole	pseudomembranous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5923	Although a few case reports link [s1]metronidazole[e1] with the development of [s2]pseudomembranous colitis[e2]  albendazole has not been associated with the development of this condition.
+	(4, 19)	albendazole	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5924	While undergoing treatment with [s1]albendazole[e1]  he developed worsening diarrhea with [s2]abdominal pain[e2] and fever.
+	(4, 22)	albendazole	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5925	While undergoing treatment with [s1]albendazole[e1]  he developed worsening diarrhea with abdominal pain and [s2]fever[e2] 
+	(4, 13)	albendazole	worsening diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5926	While undergoing treatment with [s1]albendazole[e1]  he developed [s2]worsening diarrhea[e2] with abdominal pain and fever.
+	(0, 20)	Aluminum intoxication	Aluminum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5927	 [s1]Aluminum intoxication[e1]  along with other factors, was considered to be the cause of TC development [s2]Aluminum[e2] intoxication, along with other factors, was considered to be the cause of TC development.
+	(0, 19)	Aluminum	TC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5928	 [s1]Aluminum[e1] intoxication, along with other factors, was considered to be the cause of [s2]TC[e2] development.
+	(0, 10)	Oculomotor disturbances	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5929	 [s1]Oculomotor disturbances[e1] associated with [s2]5-fluorouracil[e2] chemotherapy.
+	(11, 16)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5930	The ocular motor disturbances are probably an expression of regional [s1]5-FU[e1]  [s2]neurotoxicity[e2] primarily affecting the brain stem.
+	(1, 13)	ocular motor disturbances	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5931	The [s1]ocular motor disturbances[e1] are probably an expression of regional [s2]5-FU[e2] neurotoxicity primarily affecting the brain stem.
+	(4, 31)	5-fluorouracil	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5932	Two patients treated with [s1]5-fluorouracil[e1] (5-FU) for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
+	(11, 29)	5-FU	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5933	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
+	(11, 29)	5-FU	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5934	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
+	(4, 41)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5935	Two patients treated with [s1]5-fluorouracil[e1] (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
+	(11, 39)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5936	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
+	(11, 39)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5937	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
+	(8, 12)	insulin	hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5938	Assessment of cortisol response was by [s1]insulin[e1] induced [s2]hypoglycaemia[e2] in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.
+	(16, 29)	fluticasone propionate	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5939	FINDINGS: Six children with growth retardation noted after treatment with high-dose [s1]fluticasone propionate[e1] were found to have [s2]adrenal suppression[e2] 
+	(5, 18)	growth retardation	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5940	FINDINGS: Six children with [s1]growth retardation[e1] noted after treatment with high-dose [s2]fluticasone propionate[e2] were found to have adrenal suppression.
+	(0, 17)	Growth and adrenal suppression	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5941	 [s1]Growth and adrenal suppression[e1] in asthmatic children treated with high-dose [s2]fluticasone propionate[e2] 
+	(6, 25)	fluticasone propionate	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5942	INTERPRETATION: When high doses of [s1]fluticasone propionate[e1] are used, growth may be retarded and [s2]adrenal suppression[e2] may occur.
+	(6, 18)	fluticasone propionate	growth may be retarded	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5943	INTERPRETATION: When high doses of [s1]fluticasone propionate[e1] are used, [s2]growth may be retarded[e2] and adrenal suppression may occur.
+	(2, 22)	Growth retardation	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5944	METHODS: [s1]Growth retardation[e1] was observed in six severely asthmatic children after introduction of high-dose [s2]fluticasone propionate[e2] treatment (dry powder).
+	(0, 8)	Metipranolol	granulomatous anterior uveitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5945	 [s1]Metipranolol[e1] associated [s2]granulomatous anterior uveitis[e2]  not so uncommon as thought.
+	(4, 28)	bilateral granulomatous anterior uveitis	metripranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5946	Two case reports of [s1]bilateral granulomatous anterior uveitis[e1] are described in patients with open angle glaucoma treated with [s2]metripranolol[e2] 0.6% eye drops.
+	(16, 37)	desmopressin	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5947	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with hyponatremia, all of whom experienced seizures or [s2]altered mental status[e2] 
+	(16, 25)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5948	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with [s2]hyponatremia[e2]  all of whom experienced seizures or altered mental status.
+	(16, 35)	desmopressin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5949	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with hyponatremia, all of whom experienced [s2]seizures[e2] or altered mental status.
+	(3, 10)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5950	Intranasal [s1]desmopressin[e1] induced [s2]hyponatremia[e2] 
+	(5, 13)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5951	When vague symptoms develop during [s1]desmopressin[e1] therapy, [s2]hyponatremia[e2] must be considered as part of the differential diagnosis.
+	(1, 7)	vague symptoms	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5952	When [s1]vague symptoms[e1] develop during [s2]desmopressin[e2] therapy, hyponatremia must be considered as part of the differential diagnosis.
+	(11, 20)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5953	Within 24 hours of fluid restriction and cessation of [s1]desmopressin[e1]  her symptoms and [s2]hyponatremia[e2] resolved.
+	(5, 29)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5954	Without other causes for the [s1]hyponatremia[e1]  she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by [s2]desmopressin[e2] 
+	(16, 29)	syndrome of inappropriate antidiuretic hormone	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5955	Without other causes for the hyponatremia, she was diagnosed with the [s1]syndrome of inappropriate antidiuretic hormone[e1]  presumably caused by [s2]desmopressin[e2] 
+	(0, 33)	Uveitis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5956	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, [s2]clarithromycin[e2] and ethambutol.
+	(0, 40)	Uveitis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5957	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and [s2]ethambutol[e2] 
+	(0, 28)	Uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5958	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of [s2]rifabutin[e2]  clarithromycin and ethambutol.
+	(1, 8)	acyclovir	increase serum lithium levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5959	Does [s1]acyclovir[e1]  [s2]increase serum lithium levels[e2] 
+	(4, 15)	acyclovir	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5960	Six days after starting [s1]acyclovir[e1] she exhibited signs of [s2]lithium toxicity[e2] 
+	(13, 17)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5961	Six days after starting acyclovir she exhibited signs of [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity.
+	(4, 26)	acyclovir	increased serum lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5962	This case suggests that [s1]acyclovir[e1] when given intravenously in doses of 10 mg/kg may result in [s2]increased serum lithium[e2] concentrations.
+	(24, 29)	increased serum lithium	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5963	This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in [s1]increased serum lithium[e1]  [s2]lithium[e2] concentrations.
+	(10, 31)	acyclovir	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5964	Until additional data are available, if intravenous [s1]acyclovir[e1] is administered concurrently with lithium, we recommend closely monitoring patients for signs of [s2]lithium toxicity[e2] and measuring serum lithium levels every second or third day.
+	(19, 30)	lithium	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5965	Until additional data are available, if intravenous acyclovir is administered concurrently with [s1]lithium[e1]  we recommend closely monitoring patients for signs of [s2]lithium toxicity[e2] and measuring serum lithium levels every second or third day.
+	(4, 15)	serum lithium level had increased	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5966	When measured, the [s1]serum lithium level had increased[e1] 4-fold during [s2]acyclovir[e2] therapy.
+	(4, 11)	serum lithium level had increased	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5967	When measured, the [s1]serum lithium level had increased[e1]  [s2]lithium[e2] level had increased 4-fold during acyclovir therapy.
+	(0, 16)	Dapsone syndrome	Dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5968	 [s1]Dapsone syndrome[e1] in cutaneous lupus erythematosus [s2]Dapsone[e2] syndrome in cutaneous lupus erythematosus.
+	(7, 13)	lethal	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5969	Physicians should be aware of the potentially [s1]lethal[e1] side effects of [s2]dapsone[e2] 
+	(17, 23)	dapsone reaction	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5970	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone reaction[e1]  [s2]dapsone[e2] reaction after low dose therapy, with a fatal outcome in one.
+	(17, 30)	dapsone	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5971	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone[e1] reaction after low dose therapy, with a [s2]fatal[e2] outcome in one.
+	(8, 13)	fatal interaction	minoxidil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5972	A case is presented which illustrates a probably [s1]fatal interaction[e1] between [s2]minoxidil[e2] and a coagulation disorder.
+	(9, 21)	NDI	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5973	Nephrogenic diabetes insipidus  [s1]NDI[e1]  is a well-documented complication of [s2]lithium[e2] use.
+	(0, 23)	Nephrogenic diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5974	 [s1]Nephrogenic diabetes insipidus[e1] (NDI) is a well-documented complication of [s2]lithium[e2] use.
+	(10, 14)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5975	Potential mechanisms regarding the pathophysiology of [s1]lithium[e1] associated [s2]CDI[e2] are discussed.
+	(9, 14)	CDI	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5976	The association of central diabetes insipidus  [s1]CDI[e1]  with [s2]lithium[e2] use is rare.
+	(3, 16)	central diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5977	The association of [s1]central diabetes insipidus[e1] (CDI) with [s2]lithium[e2] use is rare.
+	(9, 13)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5978	This case emphasizes the importance of the evaluation of [s1]lithium[e1] associated [s2]polyuria[e2] with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.
+	(13, 17)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5979	To the best of our knowledge, this is the first case of [s1]lithium[e1] associated [s2]CDI[e2] and NDI presenting concurrently.
+	(13, 20)	lithium	NDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5980	To the best of our knowledge, this is the first case of [s1]lithium[e1] associated CDI and [s2]NDI[e2] presenting concurrently.
+	(0, 26)	Transient central diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5981	 [s1]Transient central diabetes insipidus[e1] in the setting of underlying chronic nephrogenic diabetes insipidus associated with [s2]lithium[e2] use.
+	(6, 15)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5982	We report a patient receiving chronic [s1]lithium[e1] therapy who presented with a transient [s2]CDI[e2] occurring in the setting of underlying chronic NDI.
+	(11, 16)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5983	CASE: We report a case of a woman with severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM.
+	(15, 27)	lipoatrophy	recombinant DNA human insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5984	CASE: We report a case of a woman with severe human insulin-induced [s1]lipoatrophy[e1] who has been treated exclusively with [s2]recombinant DNA human insulin[e2] since the onset of IDDM.
+	(18, 23)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5985	CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] 
+	(0, 5)	Human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5986	 [s1]Human insulin[e1] induced [s2]lipoatrophy[e2] 
+	(26, 31)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5987	OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] 
+	(8, 17)	neurotoxic effects	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5988	Improved awareness of and further investigation into the [s1]neurotoxic effects[e1] of [s2]ofloxacin[e2] may enhance its safe use.
+	(0, 5)	Seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5989	 [s1]Seizures[e1] associated with [s2]ofloxacin[e2] therapy.
+	(1, 22)	renal insufficiency	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5990	The [s1]renal insufficiency[e1] of three patients and the timing of the seizures implicate accumulation of [s2]ofloxacin[e2] as a contributing factor.
+	(14, 22)	seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5991	The renal insufficiency of three patients and the timing of the [s1]seizures[e1] implicate accumulation of [s2]ofloxacin[e2] as a contributing factor.
+	(6, 11)	seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5992	We describe four patients who had [s1]seizures[e1] while receiving [s2]ofloxacin[e2]  no other causes were evident.
+	(9, 50)	phenytoin	abnormal liver function tests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5993	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and [s2]abnormal liver function tests[e2] 
+	(9, 27)	phenytoin	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5994	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, [s2]erythroderma[e2]  tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
+	(9, 25)	phenytoin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5995	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including [s2]fever[e2]  erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
+	(9, 20)	phenytoin hypersensitivity syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5996	A patient is described with the characteristic features of [s1]phenytoin hypersensitivity syndrome[e1]  [s2]phenytoin[e2] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
+	(9, 41)	phenytoin	pinhead-sized facial pustules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5997	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, [s2]pinhead-sized facial pustules[e2] and abnormal liver function tests.
+	(9, 33)	phenytoin	tibial and facial oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5998	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, [s2]tibial and facial oedema[e2]  pinhead-sized facial pustules and abnormal liver function tests.
+	(8, 19)	phenytoin hypersensitivity syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5999	Systemic corticosteroids in the [s1]phenytoin hypersensitivity syndrome[e1]  [s2]phenytoin[e2] hypersensitivity syndrome.
+	(9, 15)	sarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6000	A patient is described who developed a poorly differentiated [s1]sarcoma[e1] after [s2]cyclophosphamide[e2] was used to treat his rheumatoid arthritis.
+	(0, 11)	Sarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6001	 [s1]Sarcoma[e1] complicating therapy with [s2]cyclophosphamide[e2] 
+	(10, 27)	nitrofurantoin	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6002	A chronic reaction associated with long-term treatment with [s1]nitrofurantoin[e1] has also been reported and causes irreversible [s2]pulmonary fibrosis[e2] 
+	(0, 6)	Acute pulmonary reactions	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6003	 [s1]Acute pulmonary reactions[e1] to [s2]nitrofurantoin[e2] are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.
+	(4, 26)	nitrofurantoin	pulmonary dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6004	Acute pulmonary reactions to [s1]nitrofurantoin[e1] are an uncommon side effect of therapy and can cause minor or life-threatening [s2]pulmonary dysfunction[e2] 
+	(3, 9)	pulmonary side effects	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6005	Despite the known [s1]pulmonary side effects[e1] of [s2]nitrofurantoin[e2]  there is no report of this toxicity occurring in pregnant patients.
+	(0, 8)	Nitrofurantoin	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6006	 [s1]Nitrofurantoin[e1] induced [s2]pulmonary toxicity[e2] during pregnancy: a report of a case and review of the literature.
+	(5, 24)	respiratory failure	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6007	We present a case of [s1]respiratory failure[e1] occurring in a woman at 16 weeks' gestation who was being treated with [s2]nitrofurantoin[e2] for a urinary tract infection.
+	(5, 23)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6008	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and [s2]agranulocytosis[e2]  cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 77)	dapsone	an infectious mononucleosis-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6009	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, [s2]an infectious mononucleosis-like syndrome[e2]  and minor neurological and gastrointestinal complaints.
+	(5, 44)	dapsone	cholestatic jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6010	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, [s2]cholestatic jaundice[e2]  nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 29)	dapsone	cutaneous eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6011	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, [s2]cutaneous eruptions[e2]  peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 18)	dapsone	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6012	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of [s2]leukopenia[e2] and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 88)	dapsone	minor neurological and gastrointestinal complaints	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6013	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and [s2]minor neurological and gastrointestinal complaints[e2] 
+	(5, 52)	dapsone	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6014	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, [s2]nephrotic syndrome[e2]  renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 33)	dapsone	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6015	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, [s2]peripheral neuropathy[e2]  psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 38)	dapsone	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6016	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, [s2]psychosis[e2]  toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 58)	dapsone	renal papillary necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6017	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, [s2]renal papillary necrosis[e2]  severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 65)	dapsone	severe hypoalbuminemia without proteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6018	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, [s2]severe hypoalbuminemia without proteinuria[e2]  an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(5, 41)	dapsone	toxic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6019	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, [s2]toxic hepatitis[e2]  cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
+	(0, 15)	Methemoglobinemia	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6020	 [s1]Methemoglobinemia[e1] is another common finding among patients receiving [s2]dapsone[e2] therapy, but rarely does it result in prominent symptoms other than transient pallor.
+	(0, 13)	Acetazolamide	osteomalacia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6021	 [s1]Acetazolamide[e1] accelerated anticonvulsant [s2]osteomalacia[e2] 
+	(0, 13)	Acetazolamide	osteomalacia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6022	 [s1]Acetazolamide[e1] may have accelerated the development of [s2]osteomalacia[e2] by several mechanisms, including increased renal calcium excretion.
+	(0, 40)	Severe osteomalacia	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6023	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and [s2]acetazolamide[e2] 
+	(0, 33)	Severe osteomalacia	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6024	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, [s2]phenobarbital[e2]  and acetazolamide.
+	(0, 28)	Severe osteomalacia	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6025	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of [s2]phenytoin[e2]  phenobarbital, and acetazolamide.
+	(2, 23)	encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6026	The delayed [s1]encephalopathy[e1] developed 9 and 22 months respectively after the first dose of intrathecal [s2]methotrexate[e2] 
+	(38, 64)	hydrocephalus	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6027	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and [s1]hydrocephalus[e1] related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
+	(38, 64)	hydrocephalus	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6028	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and [s1]hydrocephalus[e1] related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
+	(30, 64)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6029	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed [s1]leukoencephalopathy[e1] and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
+	(30, 64)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6030	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed [s1]leukoencephalopathy[e1] and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
+	(7, 14)	loperamide poisoning	loperamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6031	A retrospective study was conducted of 40 [s1]loperamide poisoning[e1]  [s2]loperamide[e2] poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires.
+	(0, 10)	Loperamide poisoning	Loperamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6032	 [s1]Loperamide poisoning[e1] in the dog [s2]Loperamide[e2] poisoning in the dog.
+	(12, 24)	Creutzfeldt-Jakob like syndrome	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6033	a 67-year-old man with bipolar disorder developed a [s1]Creutzfeldt-Jakob like syndrome[e1] during [s2]lithium carbonate[e2] treatment.
+	(0, 4)	Lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6034	 [s1]Lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] 
+	(0, 12)	Lithium	Creutzfeldt-Jakob disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6035	 [s1]Lithium[e1] neurotoxicity should be considered in [s2]Creutzfeldt-Jakob disease[e2] differential diagnosis, serial electroencephalograms being the most valuable.
+	(0, 33)	Lithium neurotoxicity	Lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6036	 [s1]Lithium neurotoxicity[e1] should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable [s2]Lithium[e2] neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.
+	(3, 7)	lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6037	"Several cases of [s1]lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] have been reported to date; all of them were elderly patients and a half had ""therapeutic"" lithium serum levels."
+	(3, 7)	lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6038	"Several cases of [s1]lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] have been reported to date; all of them were elderly patients and a half had ""therapeutic"" lithium serum levels."
+	(18, 22)	magnesium	protracted neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6039	A noninvasive method in the differential diagnosis of vecuronium-induced and [s1]magnesium[e1] induced [s2]protracted neuromuscular block[e2] in a severely preeclamptic patient.
+	(11, 22)	vecuronium	protracted neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6040	A noninvasive method in the differential diagnosis of [s1]vecuronium[e1] induced and magnesium-induced [s2]protracted neuromuscular block[e2] in a severely preeclamptic patient.
+	(3, 20)	neuromuscular blockade	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6041	The occurrence of [s1]neuromuscular blockade[e1] and the resulting potentiation of muscle relaxants during [s2]magnesium sulfate[e2] (MgSO4) administration is well known.
+	(3, 22)	neuromuscular blockade	MgSO4	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6042	The occurrence of [s1]neuromuscular blockade[e1] and the resulting potentiation of muscle relaxants during magnesium sulfate  [s2]MgSO4[e2]  administration is well known.
+	(11, 20)	potentiation of muscle relaxants	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6043	The occurrence of neuromuscular blockade and the resulting [s1]potentiation of muscle relaxants[e1] during [s2]magnesium sulfate[e2] (MgSO4) administration is well known.
+	(11, 22)	potentiation of muscle relaxants	MgSO4	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6044	The occurrence of neuromuscular blockade and the resulting [s1]potentiation of muscle relaxants[e1] during magnesium sulfate  [s2]MgSO4[e2]  administration is well known.
+	(13, 17)	magnesium	neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6045	We also describe a new, noninvasive method to assess [s1]magnesium[e1] induced [s2]neuromuscular block[e2] when curariform muscle relaxant was given simultaneously.
+	(0, 13)	Hepatobiliary disorders	terbinafine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6046	 [s1]Hepatobiliary disorders[e1] associated with orally administered [s2]terbinafine[e2] have rarely been reported.
+	(0, 6)	Terbinafine	cholestatic liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6047	 [s1]Terbinafine[e1] induced [s2]cholestatic liver disease[e2] 
+	(6, 12)	terbinafine	cholestatic liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6048	We describe a case of prolonged [s1]terbinafine[e1] induced [s2]cholestatic liver disease[e2] 
+	(19, 29)	metabolic acidosis	cetrimide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6049	A patient with a large hydatid cyst of the left lobe of the liver developed [s1]metabolic acidosis[e1] following rather liberal use of [s2]cetrimide[e2] chlorhexidine solution as a scolicidal agent.
+	(19, 32)	metabolic acidosis	chlorhexidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6050	A patient with a large hydatid cyst of the left lobe of the liver developed [s1]metabolic acidosis[e1] following rather liberal use of cetrimide [s2]chlorhexidine[e2] solution as a scolicidal agent.
+	(0, 7)	Metabolic acidosis	cetrimide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6051	 [s1]Metabolic acidosis[e1] induced by [s2]cetrimide[e2] chlorhexidine solution in hydatid cyst surgery.
+	(0, 10)	Metabolic acidosis	chlorhexidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6052	 [s1]Metabolic acidosis[e1] induced by cetrimide [s2]chlorhexidine[e2] solution in hydatid cyst surgery.
+	(4, 8)	Ecstasy poisoning	Ecstasy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6053	An unusual case of [s1]Ecstasy poisoning[e1]  [s2]Ecstasy[e2] poisoning.
+	(5, 9)	poisoning	3,4-methylenedioxymet-amphetamine Ecstasy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6054	We describe a case of [s1]poisoning[e1] with [s2]3,4-methylenedioxymet-amphetamine Ecstasy[e2] that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.
+	(10, 19)	photosensitivity	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6055	However, dermatologists should be cautious about a [s1]photosensitivity[e1] reaction induced by [s2]mequitazine[e2] or other phenothiazine-derivative drugs.
+	(5, 23)	erythematous macule	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6056	In addition, an immediate [s1]erythematous macule[e1] was observed on the photopatch test site of [s2]mequitazine[e2] directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.
+	(4, 24)	immediate erythema	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6057	In addition, an [s1]immediate erythema[e1] ous macule was observed on the photopatch test site of [s2]mequitazine[e2] directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.
+	(27, 54)	mequitazine	cross-reaction to promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6058	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s2]cross-reaction to promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 54)	mequitazine	cross-reaction to promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6059	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s2]cross-reaction to promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(52, 62)	cross-reaction to promethazine	promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6060	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s1]cross-reaction to promethazine[e1]  [s2]promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 63)	mequitazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6061	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 63)	mequitazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6062	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(56, 62)	promethazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6063	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to [s1]promethazine[e1]  [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 49)	mequitazine	erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6064	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate [s2]erythema[e2] reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 49)	mequitazine	erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6065	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate [s2]erythema[e2] reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(47, 58)	erythema	promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6066	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate [s1]erythema[e1] reaction, cross-reaction to [s2]promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 74)	mequitazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6067	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
+	(27, 74)	mequitazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6068	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
+	(56, 73)	promethazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6069	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to [s1]promethazine[e1]  decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
+	(20, 27)	mequitazine	photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6070	Mequitazine seemed to play a part similar to chlorpromazine, and absence of [s1]mequitazine[e1] induced [s2]photosensitivity[e2] may be due to a relatively low dosage of the drug.
+	(3, 10)	mequitazine	photosensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6071	Two cases of [s1]mequitazine[e1] induced [s2]photosensitivity reactions[e2] 
+	(5, 12)	mequitazine	photosensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6072	We experienced 2 cases of [s1]mequitazine[e1] induced [s2]photosensitivity reaction[e2] in patients who took mequitazine for their dermatologic problems.
+	(5, 12)	mequitazine	photosensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6073	We experienced 2 cases of [s1]mequitazine[e1] induced [s2]photosensitivity reaction[e2] in patients who took mequitazine for their dermatologic problems.
+	(0, 6)	Keratitis	methamphetamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6074	 [s1]Keratitis[e1] in [s2]methamphetamine[e2] abusers.
+	(0, 29)	Methamphetamine	injury to the cornea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6075	 [s1]Methamphetamine[e1] s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for [s2]injury to the cornea[e2] 
+	(10, 57)	keratitis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6076	"Potential causes of methamphetamine-related [s1]keratitis[e1] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as [s2]lidocaine[e2] and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(3, 11)	methamphetamine	keratitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6077	"Potential causes of [s1]methamphetamine[e1] related [s2]keratitis[e2] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(10, 61)	keratitis	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6078	"Potential causes of methamphetamine-related [s1]keratitis[e1] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as lidocaine and [s2]quinine[e2]  (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(43, 57)	toxic effects	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6079	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s1]toxic effects[e1] of diluting or ""cutting"" agents such as [s2]lidocaine[e2] and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(3, 44)	methamphetamine	toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6080	"Potential causes of [s1]methamphetamine[e1] related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s2]toxic effects[e2] of diluting or ""cutting"" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(43, 61)	toxic effects	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6081	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s1]toxic effects[e1] of diluting or ""cutting"" agents such as lidocaine and [s2]quinine[e2]  (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
+	(4, 39)	methamphetamine	keratitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6082	The increasing prevalence of [s1]methamphetamine[e1] abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related [s2]keratitis[e2] 
+	(4, 18)	methamphetamine	ulcers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6083	The increasing prevalence of [s1]methamphetamine[e1] abuse and the severity of the associated [s2]ulcers[e2] should alert ophthalmologists to the problem of methamphetamine-related keratitis.
+	(5, 14)	severe corneal ulceration	methamphetamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6084	We report four cases of [s1]severe corneal ulceration[e1] in [s2]methamphetamine[e2] abusers.
+	(2, 31)	Methotrexate	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6085	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or [s2]cirrhosis[e2] 
+	(7, 29)	MTX	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6086	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce liver damage, which in some psoriatics will lead to fibrosis or [s2]cirrhosis[e2] 
+	(2, 27)	Methotrexate	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6087	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce liver damage, which in some psoriatics will lead to [s2]fibrosis[e2] or cirrhosis.
+	(7, 25)	MTX	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6088	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce liver damage, which in some psoriatics will lead to [s2]fibrosis[e2] or cirrhosis.
+	(2, 15)	Methotrexate	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6089	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce [s2]liver damage[e2]  which in some psoriatics will lead to fibrosis or cirrhosis.
+	(7, 13)	MTX	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6090	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce [s2]liver damage[e2]  which in some psoriatics will lead to fibrosis or cirrhosis.
+	(9, 14)	MTX	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6091	CONCLUSIONS: This study confirmed that in most patients [s1]MTX[e1] induced [s2]liver cirrhosis[e2] is not aggressive.
+	(6, 30)	MTX	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6092	However, continued low-dose [s1]MTX[e1] led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and [s2]death[e2] in 1 of our patients.
+	(6, 27)	MTX	liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6093	However, continued low-dose [s1]MTX[e1] led, in spite of normal liver tests, 8 years after the last biopsy to [s2]liver failure[e2] and death in 1 of our patients.
+	(0, 8)	Methotrexate	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6094	 [s1]Methotrexate[e1] induced [s2]liver cirrhosis[e2] 
+	(9, 15)	MTX	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6095	Studies performed 10 years ago on 25 patients with [s1]MTX[e1] induced liver [s2]cirrhosis[e2] indicated that this type of cirrhosis was not of an aggressive nature.
+	(9, 14)	MTX	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6096	Studies performed 10 years ago on 25 patients with [s1]MTX[e1] induced [s2]liver cirrhosis[e2] indicated that this type of cirrhosis was not of an aggressive nature.
+	(16, 40)	cresol	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6097	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a [s2]high fever[e2] and respiratory and metabolic acidosis and lost consciousness.
+	(8, 41)	insulin	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6098	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a [s2]high fever[e2] and respiratory and metabolic acidosis and lost consciousness.
+	(16, 33)	cresol	increasing myalgia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6099	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of [s2]increasing myalgia[e2]  developed a high fever and respiratory and metabolic acidosis and lost consciousness.
+	(8, 34)	insulin	increasing myalgia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6100	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of [s2]increasing myalgia[e2]  developed a high fever and respiratory and metabolic acidosis and lost consciousness.
+	(16, 49)	cresol	lost consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6101	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and [s2]lost consciousness[e2] 
+	(8, 50)	insulin	lost consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6102	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and [s2]lost consciousness[e2] 
+	(16, 43)	cresol	respiratory and metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6103	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and [s2]respiratory and metabolic acidosis[e2] and lost consciousness.
+	(8, 44)	insulin	respiratory and metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6104	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and [s2]respiratory and metabolic acidosis[e2] and lost consciousness.
+	(11, 20)	cresol	MH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6105	However, other factors or drugs (e.g. [s1]cresol[e1]  are thought to induce [s2]MH[e2] 
+	(6, 17)	MH	cresol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6106	This case supports the assessment that [s1]MH[e1] and diabetes are associated diseases and that [s2]cresol[e2] could possibly trigger MH.
+	(3, 24)	beclomethasone diproprionate	eosinophilic pneumonia reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6107	The use of [s1]beclomethasone diproprionate[e1] inhaler complicated by the development of an [s2]eosinophilic pneumonia reaction[e2] 
+	(0, 16)	Fatal intravascular autoimmune hemolytic anemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6108	 [s1]Fatal intravascular autoimmune hemolytic anemia[e1] after [s2]fludarabine[e2] treatment for chronic lymphocytic leukemia.
+	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6109	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6110	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6111	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6112	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(22, 32)	positivation of the DAT	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6113	Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or [s1]positivation of the DAT[e1] during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(22, 32)	positivation of the DAT	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6114	Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or [s1]positivation of the DAT[e1] during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
+	(4, 14)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6115	The occurrence of severe [s1]AIHA[e1] in CLL patients treated with [s2]fludarabine[e2] has been reported by several authors.
+	(34, 39)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6116	We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia  [s1]AIHA[e1]  after [s2]fludarabine[e2] treatment.
+	(21, 41)	fatal intravascular autoimmune hemolytic anemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6117	We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed [s1]fatal intravascular autoimmune hemolytic anemia[e1] (AIHA) after [s2]fludarabine[e2] treatment.
+	(7, 17)	fludarabine	DAT became positive with anti-IgG and anti-C3d antiglobulins	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6118	When the patient was treated again with [s1]fludarabine[e1] nine months later, the [s2]DAT became positive with anti-IgG and anti-C3d antiglobulins[e2] after the second course of treatment.
+	(13, 42)	tobramycin	tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6119	She had just finished a 3-week course of intravenous [s1]tobramycin[e1] for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of [s2]tetany[e2] 
+	(0, 14)	Tetany	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6120	 [s1]Tetany[e1] in a child with AIDS receiving intravenous [s2]tobramycin[e2] 
+	(6, 12)	renal toxicity	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6121	This pattern is suggestive of [s1]renal toxicity[e1] due to [s2]tobramycin[e2] 
+	(27, 33)	insulin	dedifferentiation of the adipocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6122	CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected [s1]insulin[e1] could explain the [s2]dedifferentiation of the adipocytes[e2] of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.
+	(9, 29)	hyperproduction of TNF-alpha	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6123	CONCLUSIONS: In our reported case, a local [s1]hyperproduction of TNF-alpha[e1] from macrophages that was induced by the injected [s2]insulin[e2] could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.
+	(0, 4)	Insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6124	 [s1]Insulin[e1] induced [s2]lipoatrophy[e2] in type I diabetes.
+	(37, 41)	insulin	lipoatrophies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6125	OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the [s1]insulin[e1] induced [s2]lipoatrophies[e2] of a diabetic patient who presented extensive lesions.
+	(0, 12)	Erosion of psoriatic plaques	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6126	 [s1]Erosion of psoriatic plaques[e1]  an early sign of [s2]methotrexate[e2] toxicity.
+	(11, 19)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6127	Erosion of psoriatic plaques: an early sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity.
+	(0, 11)	Methotrexate	potentially toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6128	 [s1]Methotrexate[e1] is an effective but [s2]potentially toxic[e2] treatment for psoriasis.
+	(13, 27)	methotrexate	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6129	Painful erosion of psoriatic plaques is a less common sign of [s1]methotrexate[e1] toxicity that may precede evidence of [s2]bone marrow suppression[e2] 
+	(13, 21)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6130	Painful erosion of psoriatic plaques is a less common sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity that may precede evidence of bone marrow suppression.
+	(0, 15)	Painful erosion of psoriatic plaques	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6131	 [s1]Painful erosion of psoriatic plaques[e1] is a less common sign of [s2]methotrexate[e2] toxicity that may precede evidence of bone marrow suppression.
+	(20, 28)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6132	We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity and review the literature, emphasizing the risk factors associated with this manifestation.
+	(6, 22)	painful erosions of their psoriasis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6133	We describe two patients in whom [s1]painful erosions of their psoriasis[e1] developed as the presenting sign of [s2]methotrexate[e2] toxicity and review the literature, emphasizing the risk factors associated with this manifestation.
+	(5, 14)	methotrexate	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6134	Well-known signs of [s1]methotrexate[e1] toxicity include [s2]bone marrow suppression[e2] and oral and gastrointestinal ulceration.
+	(5, 13)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6135	Well-known signs of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity include bone marrow suppression and oral and gastrointestinal ulceration.
+	(5, 18)	methotrexate	oral and gastrointestinal ulceration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6136	Well-known signs of [s1]methotrexate[e1] toxicity include bone marrow suppression and [s2]oral and gastrointestinal ulceration[e2] 
+	(3, 15)	cimetidine	decreased oxygen saturation and arterial PO2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6137	After treatment with [s1]cimetidine[e1]  there was a rapid deterioration with [s2]decreased oxygen saturation and arterial PO2[e2] values.
+	(4, 16)	cimetidine	upper gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6138	Caution with use of [s1]cimetidine[e1] in tolazoline induced [s2]upper gastrointestinal bleeding[e2] 
+	(9, 16)	tolazoline	upper gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6139	Caution with use of cimetidine in [s1]tolazoline[e1] induced [s2]upper gastrointestinal bleeding[e2] 
+	(17, 39)	cimetidine	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6140	However, given the clinically significant result to the interaction between tolazoline and [s1]cimetidine[e1] we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
+	(17, 39)	cimetidine	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6141	However, given the clinically significant result to the interaction between tolazoline and [s1]cimetidine[e1] we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
+	(12, 39)	tolazoline	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6142	However, given the clinically significant result to the interaction between [s1]tolazoline[e1] and cimetidine we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
+	(12, 39)	tolazoline	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6143	However, given the clinically significant result to the interaction between [s1]tolazoline[e1] and cimetidine we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
+	(7, 17)	tolazoline	gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6144	Hypoxemia improved during continuous [s1]tolazoline[e1] infusion, but [s2]gastrointestinal bleeding[e2] occurred.
+	(4, 29)	Ambien	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6145	Zolpidem  [s1]Ambien[e1] , a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the [s2]death[e2] of a 39-year-old obese male who was being treated for depression and insomnia.
+	(0, 31)	Zolpidem	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6146	 [s1]Zolpidem[e1] (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the [s2]death[e2] of a 39-year-old obese male who was being treated for depression and insomnia.
+	(11, 15)	death	Ambien	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6147	Zolpidem tissue concentrations in a multiple drug related [s1]death[e1] involving [s2]Ambien[e2] 
+	(0, 13)	Zolpidem	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6148	 [s1]Zolpidem[e1] tissue concentrations in a multiple drug related [s2]death[e2] involving Ambien.
+	(1, 7)	nitrite toxicity	nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6149	Acute [s1]nitrite toxicity[e1]  [s2]nitrite[e2] toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion.
+	(6, 10)	nitrate	methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6150	Infants are particularly susceptible to chronic [s1]nitrate[e1] induced [s2]methemoglobinemia[e2] because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.
+	(1, 8)	esmolol toxicity	esmolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6151	Acute [s1]esmolol toxicity[e1]  [s2]esmolol[e2] toxicity may be self-limiting because of its extremely short half-life.
+	(16, 31)	esmolol hydrochloride	asystole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6152	After induction of general anesthesia and administration of a standard dose of intravenous [s1]esmolol hydrochloride[e1]  her cardiac rhythm progressed to [s2]asystole[e2] 
+	(0, 5)	Cardiac arrest	esmolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6153	 [s1]Cardiac arrest[e1] after [s2]esmolol[e2] administration: a review of acute beta-blocker toxicity.
+	(0, 7)	Atenolol	memory impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6154	 [s1]Atenolol[e1] induced [s2]memory impairment[e2]  a case report.
+	(1, 12)	impaired memory	atenolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6155	His [s1]impaired memory[e1] was found to be due to the [s2]atenolol[e2] he was on and he made a complete recovery on withdrawing the beta-blocker.
+	(17, 23)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6156	A potential role for renal and hepatic impairment in the observed protracted course of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] is suggested.
+	(26, 32)	amiodarone	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6157	Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted [s1]amiodarone[e1] induced [s2]thyroiditis[e2] 
+	(5, 11)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6158	We report a case of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions.
+	(0, 6)	Psychotic disorder	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6159	 [s1]Psychotic disorder[e1] associated with [s2]isoniazid[e2] 
+	(7, 15)	psychotic disorder	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6160	We evaluated a patient who developed a [s1]psychotic disorder[e1] after 4 months of [s2]isoniazid[e2] prophylaxis for a positive tuberculosis tine test.
+	(17, 37)	pulmonary vasoconstriction	protamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6161	A case report is presented concerning the administration of ketanserin in the treatment of [s1]pulmonary vasoconstriction[e1] and right ventricular failure following the infusion of [s2]protamine[e2] in a patient undergoing coronary artery bypass surgery and mitral valve replacement.
+	(25, 37)	right ventricular failure	protamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6162	A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and [s1]right ventricular failure[e1] following the infusion of [s2]protamine[e2] in a patient undergoing coronary artery bypass surgery and mitral valve replacement.
+	(8, 14)	protamine	pulmonary hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6163	Ketanserin in the treatment of [s1]protamine[e1] induced [s2]pulmonary hypertension[e2] 
+	(7, 35)	protamine	bronchoconstriction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6164	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and [s2]bronchoconstriction[e2] 
+	(7, 30)	protamine	pulmonary hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6165	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by systemic hypotension, [s2]pulmonary hypertension[e2]  and bronchoconstriction.
+	(7, 14)	protamine	severe hemodynamic deterioration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6166	The reversal of heparin by [s1]protamine[e1] may cause [s2]severe hemodynamic deterioration[e2]  characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.
+	(7, 23)	protamine	systemic hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6167	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by [s2]systemic hypotension[e2]  pulmonary hypertension, and bronchoconstriction.
+	(16, 28)	methicillin	acute nephritic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6168	A drug addict with staphylococcal endocarditis treated with [s1]methicillin[e1]  who developed massive proteinuria and [s2]acute nephritic syndrome[e2] is described.
+	(16, 24)	methicillin	massive proteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6169	A drug addict with staphylococcal endocarditis treated with [s1]methicillin[e1]  who developed [s2]massive proteinuria[e2] and acute nephritic syndrome is described.
+	(0, 20)	Focal glomerulonephritis	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6170	 [s1]Focal glomerulonephritis[e1] and interstitial nephritis in [s2]methicillin[e2] treated, heroin-related infective endocarditis.
+	(10, 20)	interstitial nephritis	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6171	Focal glomerulonephritis and [s1]interstitial nephritis[e1] in [s2]methicillin[e2] treated, heroin-related infective endocarditis.
+	(11, 17)	rifabutin	uveitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6172	METHODS/RESULTS: This paper presents a new case of [s1]rifabutin[e1]  [s2]uveitis[e2] and a review of the various published reports to date.
+	(11, 18)	uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6173	over the past 3 years there have been several reports of [s1]uveitis[e1] associated with [s2]rifabutin[e2] therapy.
+	(0, 7)	Uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6174	 [s1]Uveitis[e1] associated with [s2]rifabutin[e2] therapy: a clinical alert.
+	(21, 29)	large cerebral infarction	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6175	CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a [s1]large cerebral infarction[e1] during [s2]praziquantel[e2] therapy.
+	(0, 8)	Large cerebral infarction	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6176	 [s1]Large cerebral infarction[e1] during [s2]praziquantel[e2] therapy in neurocysticercosis.
+	(17, 54)	5-FU	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6177	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., [s2]diarrhea[e2]  stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(17, 54)	5-FU	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6178	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., [s2]diarrhea[e2]  stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(17, 63)	5-FU	mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6179	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, [s2]mucositis[e2]  myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(17, 63)	5-FU	mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6180	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, [s2]mucositis[e2]  myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(17, 67)	5-FU	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6181	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, [s2]myelosuppression[e2]  neurotoxicity) to standard doses of 5-FU.
+	(17, 67)	5-FU	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6182	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, [s2]myelosuppression[e2]  neurotoxicity) to standard doses of 5-FU.
+	(17, 74)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6183	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, [s2]neurotoxicity[e2]  to standard doses of 5-FU.
+	(17, 74)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6184	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, [s2]neurotoxicity[e2]  to standard doses of 5-FU.
+	(17, 58)	5-FU	stomatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6185	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, [s2]stomatitis[e2]  mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(17, 58)	5-FU	stomatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6186	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, [s2]stomatitis[e2]  mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
+	(20, 26)	severe adverse reactions	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6187	Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing [s1]severe adverse reactions[e1] to [s2]5-fluorouracil[e2] based chemotherapy.
+	(40, 46)	lethal adverse reactions	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6188	PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially [s1]lethal adverse reactions[e1] following [s2]5-fluorouracil[e2] (5-FU)-based chemotherapy.
+	(40, 53)	lethal adverse reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6189	PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially [s1]lethal adverse reactions[e1] following 5-fluorouracil  [s2]5-FU[e2] -based chemotherapy.
+	(13, 52)	5-FU	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6190	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and [s2]coma[e2] 
+	(13, 52)	5-FU	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6191	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and [s2]coma[e2] 
+	(13, 46)	5-FU	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6192	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as [s2]encephalopathy[e2] and coma.
+	(13, 46)	5-FU	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6193	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as [s2]encephalopathy[e2] and coma.
+	(13, 40)	5-FU	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6194	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced [s2]neurologic symptoms[e2] such as encephalopathy and coma.
+	(13, 40)	5-FU	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6195	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced [s2]neurologic symptoms[e2] such as encephalopathy and coma.
+	(11, 19)	severe acute 5-FU reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6196	The principle treatment for DPD-deficient patients with [s1]severe acute 5-FU reactions[e1]  [s2]5-FU[e2] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.
+	(11, 19)	severe acute 5-FU reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6197	The principle treatment for DPD-deficient patients with [s1]severe acute 5-FU reactions[e1]  [s2]5-FU[e2] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.
+	(24, 35)	5-ASA	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6198	A 49-year-old man with Crohn's disease treated with prednisone and mesalamine  [s1]5-ASA[e1]  developed worsening respiratory distress and [s2]fever[e2] 
+	(21, 37)	mesalamine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6199	A 49-year-old man with Crohn's disease treated with prednisone and [s1]mesalamine[e1] (5-ASA) developed worsening respiratory distress and [s2]fever[e2] 
+	(16, 37)	prednisone	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6200	A 49-year-old man with Crohn's disease treated with [s1]prednisone[e1] and mesalamine (5-ASA) developed worsening respiratory distress and [s2]fever[e2] 
+	(24, 30)	5-ASA	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6201	A 49-year-old man with Crohn's disease treated with prednisone and mesalamine  [s1]5-ASA[e1]  developed [s2]worsening respiratory distress[e2] and fever.
+	(21, 32)	mesalamine	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6202	A 49-year-old man with Crohn's disease treated with prednisone and [s1]mesalamine[e1] (5-ASA) developed [s2]worsening respiratory distress[e2] and fever.
+	(16, 32)	prednisone	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6203	A 49-year-old man with Crohn's disease treated with [s1]prednisone[e1] and mesalamine (5-ASA) developed [s2]worsening respiratory distress[e2] and fever.
+	(0, 6)	Mesalamine	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6204	 [s1]Mesalamine[e1] induced [s2]hypersensitivity pneumonitis[e2] 
+	(0, 7)	Mesalamine	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6205	 [s1]Mesalamine[e1] may cause [s2]hypersensitivity pneumonitis[e2] in patients with Crohn's disease.
+	(14, 29)	prednisolone	mite infestation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6206	Immunosuppression elicited by the extensive administration of [s1]prednisolone[e1] was suspected for the initiation of the generalized [s2]mite infestation[e2] 
+	(2, 10)	Colchicine	adverse effect on wound healing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6207	BACKGROUND: [s1]Colchicine[e1] has a known [s2]adverse effect on wound healing[e2] through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation.
+	(2, 29)	Colchicine	collagenase activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6208	BACKGROUND: [s1]Colchicine[e1] has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through [s2]collagenase activation[e2] 
+	(10, 16)	colchicine	delay corneal wound healing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6209	CONCLUSION: The findings in these two patients suggest that [s1]colchicine[e1] may [s2]delay corneal wound healing[e2] 
+	(0, 12)	Delay of corneal wound healing	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6210	 [s1]Delay of corneal wound healing[e1] in patients treated with [s2]colchicine[e2] 
+	(7, 26)	corneal ulcers refractory to conventional treatment	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6211	The authors report on two patients with [s1]corneal ulcers refractory to conventional treatment[e1] while the patients were undergoing oral [s2]colchicine[e2] therapy.
+	(7, 23)	corneal ulcers refractory to conventional treatment	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6212	The authors suggest that in patients with [s1]corneal ulcers refractory to conventional treatment[e1] who are receiving [s2]colchicine[e2]  cessation of colchicine therapy should be considered.
+	(0, 12)	Fulminant hepatic failure	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6213	 [s1]Fulminant hepatic failure[e1] associated with [s2]bicalutamide[e2] 
+	(13, 34)	minocycline	eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6214	A 17-year-old female patient who had been taking oral [s1]minocycline[e1] (50 mg twice daily) for 3 weeks for acne developed an [s2]eruption[e2] that progressed to an exfoliative dermatitis.
+	(13, 39)	minocycline	exfoliative dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6215	A 17-year-old female patient who had been taking oral [s1]minocycline[e1] (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an [s2]exfoliative dermatitis[e2] 
+	(25, 35)	dermatitis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6216	Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and [s1]dermatitis[e1]  a severe adverse reaction to [s2]minocycline[e2] 
+	(9, 35)	eosinophilia	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6217	Fever, lymphadenopathy, [s1]eosinophilia[e1]  lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
+	(0, 35)	Fever	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6218	 [s1]Fever[e1]  lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
+	(22, 35)	hepatitis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6219	Fever, lymphadenopathy, eosinophilia, lymphocytosis, [s1]hepatitis[e1]  and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
+	(2, 35)	lymphadenopathy	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6220	Fever, [s1]lymphadenopathy[e1]  eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
+	(15, 35)	lymphocytosis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6221	Fever, lymphadenopathy, eosinophilia, [s1]lymphocytosis[e1]  hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
+	(7, 34)	minocycline	lymphocyte over-activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6222	This severe illness was likely caused by [s1]minocycline[e1]  and we speculate that minocycline may have acted as a superantigen, causing [s2]lymphocyte over-activation[e2] and massive cytokine release.
+	(7, 43)	minocycline	massive cytokine release	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6223	This severe illness was likely caused by [s1]minocycline[e1]  and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and [s2]massive cytokine release[e2] 
+	(1, 9)	severe illness	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6224	This [s1]severe illness[e1] was likely caused by [s2]minocycline[e2]  and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.
+	(0, 8)	Delayed hypersensitivity	flurbiprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6225	 [s1]Delayed hypersensitivity[e1] to [s2]flurbiprofen[e2] 
+	(0, 11)	Eye movement disorders	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6226	 [s1]Eye movement disorders[e1] in bone marrow transplant patients on [s2]cyclosporin[e2] and ganciclovir.
+	(0, 17)	Eye movement disorders	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6227	 [s1]Eye movement disorders[e1] in bone marrow transplant patients on cyclosporin and [s2]ganciclovir[e2] 
+	(3, 11)	MRI T2 abnormalities	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6228	One patient had [s1]MRI T2 abnormalities[e1] compatible with [s2]cyclosporin[e2] neurotoxicity.
+	(9, 16)	cyclosporin	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6229	One patient had MRI T2 abnormalities compatible with [s1]cyclosporin[e1]  [s2]neurotoxicity[e2] 
+	(4, 31)	cyclosporin	eye movement abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6230	We postulate that [s1]cyclosporin[e1]  possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with [s2]eye movement abnormality[e2] in occasional patients.
+	(13, 31)	ganciclovir	eye movement abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6231	We postulate that cyclosporin, possibly together with [s1]ganciclovir[e1]  can produce transient brain stem or neuromuscular dysfunction with [s2]eye movement abnormality[e2] in occasional patients.
+	(4, 21)	cyclosporin	transient brain stem or neuromuscular dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6232	We postulate that [s1]cyclosporin[e1]  possibly together with ganciclovir, can produce [s2]transient brain stem or neuromuscular dysfunction[e2] with eye movement abnormality in occasional patients.
+	(13, 21)	ganciclovir	transient brain stem or neuromuscular dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6233	We postulate that cyclosporin, possibly together with [s1]ganciclovir[e1]  can produce [s2]transient brain stem or neuromuscular dysfunction[e2] with eye movement abnormality in occasional patients.
+	(3, 13)	thrombosis	GnRH-a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6234	CONCLUSION: While [s1]thrombosis[e1] has been reported with [s2]GnRH-a[e2] therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size.
+	(4, 31)	tamoxifen	endometrial carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6235	The possible effects of [s1]tamoxifen[e1] upon the uterus are discussed in this article, in view of reports of tamoxifen associated with [s2]endometrial carcinoma[e2] and endometriosis.
+	(4, 39)	tamoxifen	endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6236	The possible effects of [s1]tamoxifen[e1] upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and [s2]endometriosis[e2] 
+	(3, 8)	adverse response	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6237	Case study: [s1]adverse response[e1] to [s2]clonidine[e2] 
+	(3, 8)	adverse experiences	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6238	Four cases of [s1]adverse experiences[e1] with [s2]clonidine[e2] are described.
+	(17, 32)	confusion	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6239	In one instance a systemic hypoglycemic reaction resulting in head trauma and [s1]confusion[e1] ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
+	(14, 32)	head trauma	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6240	In one instance a systemic hypoglycemic reaction resulting in [s1]head trauma[e1] and confusion ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
+	(4, 32)	systemic hypoglycemic reaction	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6241	In one instance a [s1]systemic hypoglycemic reaction[e1] resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
+	(6, 17)	itraconazole	drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6242	Discontinuation of the [s1]itraconazole[e1] caused resolution of the [s2]drug eruption[e2] 
+	(12, 17)	drug eruption	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6243	Primary cutaneous coccidioidomycosis and subsequent [s1]drug eruption[e1] to [s2]itraconazole[e2] in a dog.
+	(0, 17)	Primary cutaneous coccidioidomycosis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6244	 [s1]Primary cutaneous coccidioidomycosis[e1] and subsequent drug eruption to [s2]itraconazole[e2] in a dog.
+	(23, 34)	potentially fatal symptom	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6245	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a [s1]potentially fatal symptom[e1] complex referred to as  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
+	(32, 39)	retinoic acid syndrome	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6246	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as  [s1]retinoic acid syndrome[e1]  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
+	(2, 34)	toxicity	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6247	"Its overall [s1]toxicity[e1] is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
+	(7, 26)	amiodarone	polymorphous ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6248	Eleven days after initiation of therapy with [s1]amiodarone[e1]  the patient experienced syncope and was noted to have recurrent episodes of [s2]polymorphous ventricular tachycardia[e2] 
+	(7, 15)	amiodarone	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6249	Eleven days after initiation of therapy with [s1]amiodarone[e1]  the patient experienced [s2]syncope[e2] and was noted to have recurrent episodes of polymorphous ventricular tachycardia.
+	(0, 18)	Nonsustained polymorphous ventricular tachycardia	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6250	 [s1]Nonsustained polymorphous ventricular tachycardia[e1] during [s2]amiodarone[e2] therapy for atrial fibrillation complicating cardiomyopathy.
+	(2, 12)	proarrhythmic	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6251	The probable [s1]proarrhythmic[e1] action of [s2]amiodarone[e2]  although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.
+	(0, 9)	Acute asthma	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6252	 [s1]Acute asthma[e1] associated with sustained-release [s2]verapamil[e2] 
+	(7, 40)	verapamil	acute asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6253	Although dyspnea associated with [s1]verapamil[e1] administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an [s2]acute asthma[e2] attack following sustained-release verapamil administration.
+	(1, 9)	dyspnea	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6254	Although [s1]dyspnea[e1] associated with [s2]verapamil[e2] administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration.
+	(5, 19)	verapamil	asthma attack	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6255	CONCLUSIONS: Sustained-release [s1]verapamil[e1] is thought to be the cause of the [s2]asthma attack[e2] in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
+	(5, 19)	verapamil	asthma attack	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6256	CONCLUSIONS: Sustained-release [s1]verapamil[e1] is thought to be the cause of the [s2]asthma attack[e2] in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
+	(22, 32)	acute asthma	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6257	OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an [s1]acute asthma[e1] attack after receiving sustained-release [s2]verapamil[e2] 
+	(3, 34)	verapamil	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6258	She continued taking [s1]verapamil[e1] for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her [s2]asthma[e2] symptoms disappeared.
+	(0, 13)	Cephalexin rash	Cephalexin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6259	 [s1]Cephalexin rash[e1] in infectious mononucleosis [s2]Cephalexin[e2] rash in infectious mononucleosis.
+	(1, 7)	ampicillin rash	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6260	The [s1]ampicillin rash[e1]  [s2]ampicillin[e2] rash occurring in cases of infectious mononucleosis is well documented.
+	(13, 23)	cephalexin	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6261	The case of a patient with infectious mononucleosis treated with [s1]cephalexin[e1] who later showed a [s2]rash[e2] is presented and the previous literature is reviewed.
+	(1, 13)	rash	cephalexin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6262	The [s1]rash[e1] seen in this patient, who was treated with [s2]cephalexin[e2]  may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis.
+	(1, 26)	rash	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6263	The [s1]rash[e1] seen in this patient, who was treated with cephalexin, may be similar to the rash seen with [s2]ampicillin[e2] treatment of patients with infectious mononucleosis.
+	(4, 12)	carbamazepine	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6264	A possible case of [s1]carbamazepine[e1] induced [s2]pancreatitis[e2] 
+	(7, 23)	pancreatitis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6265	The authors report a case of acute [s1]pancreatitis[e1] (AP) occurring in a patient under treatment with [s2]carbamazepine[e2] (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.
+	(7, 28)	pancreatitis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6266	The authors report a case of acute [s1]pancreatitis[e1] (AP) occurring in a patient under treatment with carbamazepine  [s2]CBZ[e2]  for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.
+	(8, 45)	CBZ	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6267	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of [s2]acute pancreatitis[e2] 
+	(8, 45)	CBZ	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6268	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of [s2]acute pancreatitis[e2] 
+	(4, 80)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6269	Although risk factors for [s1]MTX[e1] induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX [s2]pneumonitis[e2] 
+	(4, 9)	MTX	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6270	Although risk factors for [s1]MTX[e1] induced [s2]pulmonary toxicity[e2] are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.
+	(0, 8)	Methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6271	 [s1]Methotrexate[e1] induced [s2]pneumonitis[e2] in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.
+	(5, 10)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6272	On the other hand, [s1]MTX[e1] induced [s2]pneumonitis[e2] seems to be very rare in psoriatic arthritis (PsA).
+	(12, 31)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6273	Our review of 194 RA patients and 38 PsA patients receiving [s1]MTX[e1] has identified four RA patients and one PsA patient with MTX-induced [s2]pneumonitis[e2]  giving a prevalence of 2.1% and 0.03%, respectively.
+	(0, 24)	Pneumonitis	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6274	 [s1]Pneumonitis[e1] is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with [s2]MTX[e2] 
+	(65, 70)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6275	The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in [s1]MTX[e1] induced [s2]pneumonitis[e2] 
+	(10, 67)	hepatic angiosarcoma	inorganic arsenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6276	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and [s2]inorganic arsenic[e2]  and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
+	(10, 59)	hepatic angiosarcoma	Thorotrast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6277	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride,  [s2]Thorotrast[e2] , and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
+	(10, 55)	hepatic angiosarcoma	vinyl chloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6278	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes  [s2]vinyl chloride[e2]  'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
+	(8, 15)	ferrous sulfate	reduce the gastrointestinal absorption of orally administered levothyroxine sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6279	Recent studies have shown that under experimental conditions [s1]ferrous sulfate[e1] may [s2]reduce the gastrointestinal absorption of orally administered levothyroxine sodium[e2] in patients with primary hypothyroidism.
+	(6, 15)	hypothyroid	ferrous sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6280	We describe a patient who became [s1]hypothyroid[e1] while taking [s2]ferrous sulfate[e2] 
+	(6, 21)	hepatitis B vaccination	mental nerve neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6281	However, as the use of [s1]hepatitis B vaccination[e1] is growing, adverse side effects, including [s2]mental nerve neuropathy[e2]  should be observed with an increased frequency.
+	(0, 11)	Mental nerve neuropathy	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6282	 [s1]Mental nerve neuropathy[e1] as a result of [s2]hepatitis B vaccination[e2] 
+	(7, 17)	tamoxifen	proliferative lesions of the endometrium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6283	Although its side effects are few, [s1]tamoxifen[e1] increases the incidence of [s2]proliferative lesions of the endometrium[e2]  which theoretically should be preventable with progestational agents.
+	(11, 35)	tamoxifen	intermittent spotting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6284	CASES: Two postmenopausal women treated with [s1]tamoxifen[e1] and progestational agents for breast carcinoma developed uterine enlargement and [s2]intermittent spotting[e2] 
+	(11, 29)	tamoxifen	uterine enlargement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6285	CASES: Two postmenopausal women treated with [s1]tamoxifen[e1] and progestational agents for breast carcinoma developed [s2]uterine enlargement[e2] and intermittent spotting.
+	(12, 30)	carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6286	CONCLUSIONS: The value of multihormonal therapy in breast [s1]carcinoma[e1] is not established, and the addition of progestogens to [s2]tamoxifen[e2] may not reduce of developing endometrial lesions, including carcinoma.
+	(28, 39)	tamoxifen	endometrial lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6287	CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to [s1]tamoxifen[e1] may not reduce of developing [s2]endometrial lesions[e2]  including carcinoma.
+	(0, 16)	Bleomycin	metastatic nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6288	 [s1]Bleomycin[e1] and cyclophosphamide toxicity simulating [s2]metastatic nodules[e2] to the lungs in childhood cancer.
+	(5, 16)	cyclophosphamide	metastatic nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6289	Bleomycin and [s1]cyclophosphamide[e1] toxicity simulating [s2]metastatic nodules[e2] to the lungs in childhood cancer.
+	(12, 24)	fibrotic lesions	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6290	Thoracoscopic biopsy to confirm metastasis revealed instead [s1]fibrotic lesions[e1] apparently attributable to [s2]bleomycin[e2] or cyclophosphamide.
+	(12, 29)	fibrotic lesions	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6291	Thoracoscopic biopsy to confirm metastasis revealed instead [s1]fibrotic lesions[e1] apparently attributable to bleomycin or [s2]cyclophosphamide[e2] 
+	(4, 15)	procainamide hydrochloride	lupus syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6292	An elderly man with [s1]procainamide hydrochloride[e1] induced [s2]lupus syndrome[e2] had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis.
+	(8, 15)	procainamide	lupus syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6293	Circulating anticoagulant in the [s1]procainamide[e1] induced [s2]lupus syndrome[e2] 
+	(3, 19)	hypermagnesemia	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6294	Clinical signs of [s1]hypermagnesemia[e1] are an uncommon complication following oral administration of [s2]magnesium sulfate[e2] 
+	(17, 22)	magnesium toxicosis	magnesium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6295	Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of [s1]magnesium toxicosis[e1]  [s2]magnesium[e2] toxicosis in horses.
+	(0, 8)	Magnesium toxicosis	Magnesium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6296	 [s1]Magnesium toxicosis[e1] in two horses [s2]Magnesium[e2] toxicosis in two horses.
+	(2, 33)	magnesium	magnesium toxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6297	Overdose of [s1]magnesium[e1] sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to [s2]magnesium toxicosis[e2] 
+	(2, 33)	magnesium sulfate	magnesium toxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6298	Overdose of [s1]magnesium sulfate[e1] in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to [s2]magnesium toxicosis[e2] 
+	(17, 25)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6299	CASE SUMMARIES: In each case, the patients were treated over 5 years with [s1]lovastatin[e1] and developed [s2]rhabdomyolysis[e2] that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic.
+	(8, 26)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6300	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between lovastatin and [s2]azithromycin[e2] or clarithromycin should be considered before the concomitant use of these agents.
+	(8, 32)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6301	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between lovastatin and azithromycin or [s2]clarithromycin[e2] should be considered before the concomitant use of these agents.
+	(8, 21)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6302	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between [s2]lovastatin[e2] and azithromycin or clarithromycin should be considered before the concomitant use of these agents.
+	(30, 38)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6303	DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with [s1]rhabdomyolysis[e1]  including [s2]lovastatin[e2]  a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
+	(0, 25)	Erythromycin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6304	 [s1]Erythromycin[e1] is a macrolide antibiotic that may increase the risk of lovastatin-induced [s2]rhabdomyolysis[e2] 
+	(17, 24)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6305	Erythromycin is a macrolide antibiotic that may increase the risk of [s1]lovastatin[e1] induced [s2]rhabdomyolysis[e2] 
+	(6, 23)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6306	Lovastatin-induced [s1]rhabdomyolysis[e1] possibly associated with clarithromycin and [s2]azithromycin[e2] 
+	(6, 16)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6307	Lovastatin-induced [s1]rhabdomyolysis[e1] possibly associated with [s2]clarithromycin[e2] and azithromycin.
+	(0, 7)	Lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6308	 [s1]Lovastatin[e1] induced [s2]rhabdomyolysis[e2] possibly associated with clarithromycin and azithromycin.
+	(7, 43)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6309	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and [s2]azithromycin[e2] 
+	(7, 36)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6310	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics [s2]clarithromycin[e2] and azithromycin.
+	(7, 17)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6311	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking [s2]lovastatin[e2] that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.
+	(18, 27)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6312	To our knowledge, these cases are the first published reports of lovastatin-induced [s1]rhabdomyolysis[e1] associated with [s2]azithromycin[e2] and clarithromycin.
+	(18, 33)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6313	To our knowledge, these cases are the first published reports of lovastatin-induced [s1]rhabdomyolysis[e1] associated with azithromycin and [s2]clarithromycin[e2] 
+	(12, 19)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6314	To our knowledge, these cases are the first published reports of [s1]lovastatin[e1] induced [s2]rhabdomyolysis[e2] associated with azithromycin and clarithromycin.
+	(35, 49)	died	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6315	These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients [s1]died[e1] of PCP occurring during the first month of treatment with [s2]prednisone[e2] 
+	(9, 32)	severe hypertension	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6316	We report the specifics of 12 cases of [s1]severe hypertension[e1] after the intraoperative use of topical phenylephrine, submucosal [s2]epinephrine[e2]  or both.
+	(9, 22)	severe hypertension	phenylephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6317	We report the specifics of 12 cases of [s1]severe hypertension[e1] after the intraoperative use of topical [s2]phenylephrine[e2]  submucosal epinephrine, or both.
+	(0, 7)	Acute leukaemia	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6318	 [s1]Acute leukaemia[e1] during [s2]tamoxifen[e2] therapy.
+	(0, 10)	Tamoxifen	carcinogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6319	 [s1]Tamoxifen[e1] is suggested to be [s2]carcinogenic[e2] both through direct genotoxic and epigenetic mechanisms.
+	(6, 20)	acute myeloid leukaemia	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6320	We report two cases that developed [s1]acute myeloid leukaemia[e1] (AML) during [s2]tamoxifen[e2] therapy for breast cancer.
+	(13, 18)	AML	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6321	We report two cases that developed acute myeloid leukaemia  [s1]AML[e1]  during [s2]tamoxifen[e2] therapy for breast cancer.
+	(0, 21)	Relapse in the external auditory canal of acute promyelocytic leukemia	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6322	 [s1]Relapse in the external auditory canal of acute promyelocytic leukemia[e1] after treatment with [s2]all-trans retinoic acid[e2] 
+	(9, 24)	extramedullary relapse	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6323	This case suggests the importance of careful observation for [s1]extramedullary relapse[e1] in patients who are treated with [s2]ATRA[e2] 
+	(0, 13)	Cutaneous reactions	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6324	 [s1]Cutaneous reactions[e1] to propylthiouracil and [s2]methimazole[e2] occur in 3%-5% of adults.
+	(0, 6)	Cutaneous reactions	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6325	 [s1]Cutaneous reactions[e1] to [s2]propylthiouracil[e2] and methimazole occur in 3%-5% of adults.
+	(0, 22)	Generalized maculopapular and papular purpuric eruptions	thionamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6326	 [s1]Generalized maculopapular and papular purpuric eruptions[e1] are perhaps the most common [s2]thionamide[e2] induced reactions.
+	(0, 9)	Propylthiouracil	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6327	 [s1]Propylthiouracil[e1] induced [s2]cutaneous vasculitis[e2] 
+	(3, 14)	cutaneous vasculitis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6328	The observation of [s1]cutaneous vasculitis[e1] during administration of [s2]propylthiouracil[e2] suggested that clinical awareness of this complication should be of considerable importance.
+	(23, 31)	heat stroke	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6329	A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled [s1]heat stroke[e1] during the administration of [s2]zonisamide[e2] 
+	(2, 20)	zonisamide	neurological symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6330	Children receiving [s1]zonisamide[e1] should be monitored for oligohidrosis and the development of [s2]neurological symptoms[e2] associated with an elevation of body temperature.
+	(2, 12)	zonisamide	oligohidrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6331	Children receiving [s1]zonisamide[e1] should be monitored for [s2]oligohidrosis[e2] and the development of neurological symptoms associated with an elevation of body temperature.
+	(0, 12)	Heat stroke-like episode	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6332	 [s1]Heat stroke-like episode[e1] in a child caused by [s2]zonisamide[e2] 
+	(1, 9)	oligohidrosis	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6333	The [s1]oligohidrosis[e1] caused by [s2]zonisamide[e2] was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.
+	(0, 11)	Acute renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6334	 [s1]Acute renal failure[e1] in a patient receiving treatment with [s2]suramin[e2] 
+	(1, 14)	renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6335	Acute [s1]renal failure[e1] should be recognized as a potential complication of [s2]suramin[e2] treatment.
+	(4, 26)	renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6336	Other potential causes of [s1]renal failure[e1] were not present in our patient and his renal function gradually recovered with the cessation of [s2]suramin[e2] treatment.
+	(11, 22)	nonoliguric renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6337	We describe a patient with metastatic prostate cancer who developed [s1]nonoliguric renal failure[e1] during treatment with [s2]suramin[e2] 
+	(0, 6)	Clozapine	polyserositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6338	 [s1]Clozapine[e1] induced [s2]polyserositis[e2] 
+	(13, 38)	pericardial effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6339	We report the case of a patient who developed polyserositis  [s1]pericardial effusion[e1]  pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(13, 38)	pericardial effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6340	We report the case of a patient who developed polyserositis  [s1]pericardial effusion[e1]  pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(29, 39)	pericarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6341	We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and [s1]pericarditis[e1]  after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(29, 39)	pericarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6342	We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and [s1]pericarditis[e1]  after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(21, 39)	pleural effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6343	We report the case of a patient who developed polyserositis (pericardial effusion, [s1]pleural effusion[e1]  and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(21, 39)	pleural effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6344	We report the case of a patient who developed polyserositis (pericardial effusion, [s1]pleural effusion[e1]  and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(9, 40)	polyserositis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6345	We report the case of a patient who developed [s1]polyserositis[e1] (pericardial effusion, pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(9, 40)	polyserositis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6346	We report the case of a patient who developed [s1]polyserositis[e1] (pericardial effusion, pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
+	(7, 25)	amphotericin B	severe side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6347	When the disease recurred conventional [s1]amphotericin B[e1] was used again, but had to be stopped because of [s2]severe side effects[e2] 
+	(34, 54)	ARA-C	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6348	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced [s2]fever[e2]  infectious complications, gastrointestinal tract symptoms and severe myalgias.
+	(28, 56)	cytosine arabinoside	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6349	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced [s2]fever[e2]  infectious complications, gastrointestinal tract symptoms and severe myalgias.
+	(34, 59)	ARA-C	gastrointestinal tract symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6350	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, infectious complications, [s2]gastrointestinal tract symptoms[e2] and severe myalgias.
+	(28, 61)	cytosine arabinoside	gastrointestinal tract symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6351	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, [s2]gastrointestinal tract symptoms[e2] and severe myalgias.
+	(34, 56)	ARA-C	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6352	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, [s2]infectious complications[e2]  gastrointestinal tract symptoms and severe myalgias.
+	(28, 58)	cytosine arabinoside	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6353	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, [s2]infectious complications[e2]  gastrointestinal tract symptoms and severe myalgias.
+	(34, 66)	ARA-C	severe myalgias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6354	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and [s2]severe myalgias[e2] 
+	(28, 68)	cytosine arabinoside	severe myalgias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6355	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and [s2]severe myalgias[e2] 
+	(12, 18)	rhGH	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6356	CONCLUSION: We believe this to be the first reported case of [s1]rhGH[e1] induced [s2]hypercalcemia[e2] in an HIV-infected patient.
+	(0, 12)	Hypercalcemia	growth hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6357	 [s1]Hypercalcemia[e1] in an AIDS patient treated with [s2]growth hormone[e2] 
+	(1, 14)	hypercalcemia	rhGH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6358	The [s1]hypercalcemia[e1] responded to discontinuation of [s2]rhGH[e2] and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up.
+	(10, 21)	hypercalcemia	rhGH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6359	We report a male patient with advanced AIDS who developed [s1]hypercalcemia[e1] 2 weeks after institution of [s2]rhGH[e2] therapy.
+	(0, 8)	Hypersensitivity reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6360	 [s1]Hypersensitivity reactions[e1] to [s2]cisplatin[e2] following multiple uncomplicated courses: a report on two cases.
+	(13, 71)	cisplatin	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6361	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested [s2]abdominal pain[e2]  general erythema, and fever.
+	(13, 71)	cisplatin	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6362	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested [s2]abdominal pain[e2]  general erythema, and fever.
+	(13, 48)	cisplatin	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6363	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, [s2]dyspnea[e2]  and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 48)	cisplatin	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6364	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, [s2]dyspnea[e2]  and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 80)	cisplatin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6365	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and [s2]fever[e2] 
+	(13, 80)	cisplatin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6366	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and [s2]fever[e2] 
+	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6367	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6368	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6369	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6370	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 21)	cisplatin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6371	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced [s2]hypersensitivity reactions[e2] to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 21)	cisplatin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6372	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced [s2]hypersensitivity reactions[e2] to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 54)	cisplatin	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6373	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and [s2]hypotension[e2]  the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(13, 54)	cisplatin	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6374	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and [s2]hypotension[e2]  the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
+	(15, 21)	cisplatin	renal tubular salt wasting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6375	We report an unusually short lived and asymptomatic episode of severe [s1]cisplatin[e1] induced [s2]renal tubular salt wasting[e2] in a fit 41-year-old patient with malignant teratoma.
+	(4, 22)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6376	Clinicians should include [s1]phenolphthalein[e1] in their list of possible causes of drug-induced [s2]TEN[e2] 
+	(2, 32)	Phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6377	DISCUSSION: [s1]Phenolphthalein[e1] is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause [s2]TEN[e2] 
+	(7, 23)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6378	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced toxic epidermal necrolysis  [s2]TEN[e2]  in a patient maintained on several other medications more commonly known to be associated with TEN.
+	(7, 23)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6379	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced toxic epidermal necrolysis  [s2]TEN[e2]  in a patient maintained on several other medications more commonly known to be associated with TEN.
+	(7, 16)	phenolphthalein	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6380	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced [s2]toxic epidermal necrolysis[e2] (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.
+	(0, 9)	Phenolphthalein	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6381	 [s1]Phenolphthalein[e1] induced [s2]toxic epidermal necrolysis[e2] 
+	(5, 21)	rash	phenolphthalein	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6382	The patient's previous [s1]rash[e1] and the temporal relation of this event and the ingestion of [s2]phenolphthalein[e2]  as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient.
+	(19, 51)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6383	The patient's previous rash and the temporal relation of this event and the ingestion of [s1]phenolphthalein[e1]  as well as the similarity of this case to other reports, point to phenolphthalein as the cause of [s2]TEN[e2] in this patient.
+	(0, 24)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6384	 [s1]Carbamazepine toxicity[e1] induced by clarithromycin coadministration in psychiatric patients [s2]Carbamazepine[e2] toxicity induced by clarithromycin coadministration in psychiatric patients.
+	(0, 10)	Carbamazepine toxicity	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6385	 [s1]Carbamazepine toxicity[e1] induced by [s2]clarithromycin[e2] coadministration in psychiatric patients.
+	(28, 45)	carbamazepine	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6386	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
+	(1, 46)	clarithromycin	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6387	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
+	(1, 46)	clarithromycin	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6388	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
+	(28, 41)	carbamazepine	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6389	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 42)	clarithromycin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6390	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 42)	clarithromycin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6391	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(28, 37)	carbamazepine	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6392	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 38)	clarithromycin	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6393	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 38)	clarithromycin	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6394	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(25, 30)	toxic symptoms	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6395	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe [s1]toxic symptoms[e1] of [s2]carbamazepine[e2]  such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 27)	clarithromycin	toxic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6396	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe [s2]toxic symptoms[e2] of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(1, 27)	clarithromycin	toxic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6397	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe [s2]toxic symptoms[e2] of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
+	(20, 33)	carbamazepine	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6398	The present report suggests that clarithromycin coadministration induces increased plasma [s1]carbamazepine[e1] concentrations, which may result in [s2]carbamazepine toxicity[e2] 
+	(20, 33)	carbamazepine	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6399	The present report suggests that clarithromycin coadministration induces increased plasma [s1]carbamazepine[e1] concentrations, which may result in [s2]carbamazepine toxicity[e2] 
+	(5, 33)	clarithromycin	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6400	The present report suggests that [s1]clarithromycin[e1] coadministration induces increased plasma carbamazepine concentrations, which may result in [s2]carbamazepine toxicity[e2] 
+	(18, 27)	increased plasma carbamazepine	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6401	The present report suggests that clarithromycin coadministration induces [s1]increased plasma carbamazepine[e1]  [s2]carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
+	(18, 27)	increased plasma carbamazepine	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6402	The present report suggests that clarithromycin coadministration induces [s1]increased plasma carbamazepine[e1]  [s2]carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
+	(5, 20)	clarithromycin	increased plasma carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6403	The present report suggests that [s1]clarithromycin[e1] coadministration induces [s2]increased plasma carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
+	(11, 21)	acetazolamide intoxication	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6404	Acute hemorrhagic gastritis associated with [s1]acetazolamide intoxication[e1]  [s2]acetazolamide[e2] intoxication in a patient with chronic renal failure.
+	(0, 13)	Acute hemorrhagic gastritis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6405	 [s1]Acute hemorrhagic gastritis[e1] associated with [s2]acetazolamide[e2] intoxication in a patient with chronic renal failure.
+	(13, 26)	acute hemorrhagic gastritis	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6406	As far as we know, this is the first case report of [s1]acute hemorrhagic gastritis[e1] associated with [s2]AZ[e2] intoxication.
+	(24, 30)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6407	As far as we know, this is the first case report of acute hemorrhagic gastritis associated with [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
+	(6, 12)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6408	She was thus diagnosed as having [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
+	(13, 26)	acute hemorrhagic gastritis	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6409	We experienced a case of chronic renal failure in a patient suffering from [s1]acute hemorrhagic gastritis[e1] associated with [s2]AZ[e2] intoxication.
+	(24, 30)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6410	We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
+	(8, 13)	AZ	destroyed the gastric mucosal barrier	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6411	We thus concluded that an excessive dose of [s1]AZ[e1] had probably [s2]destroyed the gastric mucosal barrier[e2] or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.
+	(8, 41)	AZ	hemorrhagic gastritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6412	We thus concluded that an excessive dose of [s1]AZ[e1] had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of [s2]hemorrhagic gastritis[e2] 
+	(8, 22)	AZ	thrombocytopenia due to bone marrow disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6413	We thus concluded that an excessive dose of [s1]AZ[e1] had probably destroyed the gastric mucosal barrier or [s2]thrombocytopenia due to bone marrow disorder[e2] and thus eventually led to the development of hemorrhagic gastritis.
+	(8, 15)	urinary calculus	magnesium ammonium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6414	In association with this tocolysis, [s1]urinary calculus[e1] of [s2]magnesium ammonium phosphate[e2] occurred at 34 weeks gestation.
+	(0, 10)	Magnesium	urinary calculus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6415	 [s1]Magnesium[e1] tocolysis as the cause of [s2]urinary calculus[e2] during pregnancy.
+	(0, 6)	Danazol	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6416	 [s1]Danazol[e1] induced [s2]thrombocytopenia[e2] 
+	(14, 19)	danazol	gingival bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6417	On the next day, after a total dose of only 600 mg of [s1]danazol[e1]  [s2]gingival bleeding[e2] and purpura occurred.
+	(14, 24)	danazol	purpura	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6418	On the next day, after a total dose of only 600 mg of [s1]danazol[e1]  gingival bleeding and [s2]purpura[e2] occurred.
+	(5, 11)	danazol	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6419	We diagnosed this case as [s1]danazol[e1] induced [s2]thrombocytopenia[e2] 
+	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6420	It occasionally accompanies the [s1]heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis syndrome.
+	(6, 19)	heparin	thrombosis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6421	It occasionally accompanies the [s1]heparin[e1] associated thrombocytopenia and [s2]thrombosis syndrome[e2] 
+	(0, 14)	Skin necrosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6422	 [s1]Skin necrosis[e1] is a rare complication of subcutaneous [s2]heparin[e2] therapy that usually occurs at injection sites.
+	(0, 7)	Skin necrosis	low-molecular weight heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6423	 [s1]Skin necrosis[e1] secondary to [s2]low-molecular weight heparin[e2] in a patient with antiphospholipid antibody syndrome.
+	(15, 22)	skin necrosis	low-molecular weight heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6424	We describe a patient with the antiphospholipid syndrome who had [s1]skin necrosis[e1] develop from [s2]low-molecular weight heparin[e2] therapy at sites distant from injection sites.
+	(2, 8)	reserpine toxicity	reserpine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6425	Finally, [s1]reserpine toxicity[e1]  [s2]reserpine[e2] toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects.
+	(3, 11)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6426	A case of [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] in an ophthalmic solution.
+	(7, 15)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6427	Therefore, we diagnosed her eruption as [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] 
+	(5, 15)	eruption	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6428	Therefore, we diagnosed her [s1]eruption[e1] as contact dermatitis due to [s2]sodium bisulfite[e2] 
+	(5, 13)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6429	We report a case of [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] in Tathion eye drops.
+	(0, 11)	Acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6430	 [s1]Acute pancreatitis[e1] after long-term [s2]5-aminosalicylic acid[e2] therapy.
+	(0, 17)	Acute pancreatitis	mesalamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6431	 [s1]Acute pancreatitis[e1] is a known, although rare, complication of [s2]mesalamine[e2] treatment.
+	(15, 21)	mesalamine	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6432	A rechallenge, performed in both patients, confirmed the diagnosis of [s1]mesalamine[e1] induced [s2]pancreatitis[e2] 
+	(6, 18)	5-aminosalicylic acid	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6433	These case reports provide evidence that [s1]5-aminosalicylic acid[e1] may induce [s2]acute pancreatitis[e2] after long term treatment.
+	(5, 17)	acute pancreatitis	mesalamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6434	We describe two cases of [s1]acute pancreatitis[e1] that occurred after long term [s2]mesalamine[e2] therapy for ulcerative colitis.
+	(12, 37)	acute renal failure	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6435	A 35-year-old nephrotic man developed [s1]acute renal failure[e1] with serum creatinine to 1543 micromol/l after a month of therapy with [s2]enalapril[e2] 
+	(0, 27)	Acute renal failure	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6436	 [s1]Acute renal failure[e1] with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with [s2]enalapril[e2] 
+	(4, 27)	severe tubulointerstitial changes	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6437	Acute renal failure with [s1]severe tubulointerstitial changes[e1] in a patient with minimal change nephrotic syndrome treated with [s2]enalapril[e2] 
+	(1, 8)	ritonavir	maculopapular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6438	Early [s1]ritonavir[e1] induced [s2]maculopapular eruption[e2] 
+	(0, 17)	Ritonavir	adverse cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6439	 [s1]Ritonavir[e1] should be added to the list of drugs that can induce [s2]adverse cutaneous reactions[e2] in HIV patients.
+	(12, 37)	fever	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6440	We report 2 cases of maculopapular eruption and [s1]fever[e1] in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of [s2]ritonavir[e2]  a protease inhibitor.
+	(5, 37)	maculopapular eruption	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6441	We report 2 cases of [s1]maculopapular eruption[e1] and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of [s2]ritonavir[e2]  a protease inhibitor.
+	(0, 8)	Nephropathy	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6442	 [s1]Nephropathy[e1] caused by [s2]methicillin[e2] therapy for staphylococcal septicemia.
+	(6, 13)	methicillin	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6443	Review of the literature relating to [s1]methicillin[e1] induced [s2]nephropathy[e2] suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis.
+	(19, 33)	retroperitoneal fibrosis	methysergide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6444	A 25-year-old woman sought medical attention because of iliocaval manifestations of [s1]retroperitoneal fibrosis[e1] while she was taking [s2]methysergide[e2] 
+	(0, 8)	Methysergide	retroperitoneal fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6445	 [s1]Methysergide[e1] induced [s2]retroperitoneal fibrosis[e2]  successful outcome and two new laboratory features.
+	(0, 8)	Vitiligo	alpha-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6446	 [s1]Vitiligo[e1] associated with [s2]alpha-interferon[e2] in a patient with chronic active hepatitis C.
+	(5, 18)	vitiligo	interferon alpha 2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6447	We report a case of [s1]vitiligo[e1] that occurred during the second month of [s2]interferon alpha 2a[e2] therapy for chronic active hepatitis C.
+	(10, 24)	febrile agranulocytosis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6448	A case is reported of an elderly woman who developed [s1]febrile agranulocytosis[e1] several weeks after commencing [s2]ticlopidine[e2] but who had a favorable outcome after cessation of that drug and treatment with filgastrim.
+	(0, 9)	Agranulocytosis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6449	 [s1]Agranulocytosis[e1] associated with [s2]ticlopidine[e2]  a possible benefit with filgastim.
+	(0, 37)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6450	 [s1]Ticlopidine[e1] is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically [s2]aplastic anemia[e2] 
+	(0, 31)	Ticlopidine	severe bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6451	 [s1]Ticlopidine[e1] is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with [s2]severe bone marrow suppression[e2]  typically aplastic anemia.
+	(9, 16)	ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6452	Hemodialysis was also shown to reverse [s1]ifosfamide[e1] related [s2]neurotoxicity[e2] 
+	(0, 7)	Ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6453	 [s1]Ifosfamide[e1] associated [s2]neurotoxicity[e2] was noted within hours of drug administration and improved rapidly following hemodialysis.
+	(14, 25)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6454	PURPOSE: We evaluated the in vitro hemodialysis ratio and subsequent [s1]toxicity[e1] and pharmacokinetics of [s2]ifosfamide[e2] in an anephric patient with Wilms' tumor.
+	(1, 22)	toxicity	4-hydroxyifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6455	The [s1]toxicity[e1] and plasma concentrations of ifosfamide, chloroacetaldehyde, and [s2]4-hydroxyifosfamide[e2] were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
+	(1, 13)	toxicity	chloroacetaldehyde	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6456	The [s1]toxicity[e1] and plasma concentrations of ifosfamide, [s2]chloroacetaldehyde[e2]  and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
+	(1, 8)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6457	The [s1]toxicity[e1] and plasma concentrations of [s2]ifosfamide[e2]  chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
+	(1, 8)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6458	The [s1]toxicity[e1] and plasma concentrations of [s2]ifosfamide[e2]  chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
+	(0, 19)	Toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6459	 [s1]Toxicity[e1]  pharmacokinetics, and in vitro hemodialysis clearance of [s2]ifosfamide[e2] and metabolites in an anephric pediatric patient with Wilms' tumor.
+	(12, 20)	hepatitis	methyldopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6460	A 55-year-old woman developed symptoms suggestive of [s1]hepatitis[e1] 12 weeks after first receiving [s2]methyldopa[e2] for hypertension.
+	(0, 6)	Methyldopa	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6461	 [s1]Methyldopa[e1] induced [s2]liver injury[e2] 
+	(7, 13)	methyldopa	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6462	Such a rapid and relentless progression of [s1]methyldopa[e1] induced [s2]liver injury[e2] is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.
+	(0, 14)	Acute respiratory depression	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6463	 [s1]Acute respiratory depression[e1] as a complication of nebulised [s2]morphine[e2] 
+	(12, 20)	morphine	bradypneic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6464	Approximately 15 min after the first administration of nebulised [s1]morphine[e1] the patient became markedly [s2]bradypneic[e2] (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.
+	(12, 35)	morphine	hypotensive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6465	Approximately 15 min after the first administration of nebulised [s1]morphine[e1] the patient became markedly bradypneic (respiratory rate: 4-5 bpm), [s2]hypotensive[e2] (BP 70/40 mmHg), and responded only partially to command.
+	(7, 19)	respiratory depression	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6466	PURPOSE: To present a case of [s1]respiratory depression[e1] following the administration of nebulised [s2]morphine[e2] 
+	(0, 16)	Acute dystonia	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6467	 [s1]Acute dystonia[e1] with thalamic and brainstem lesions after initial [s2]penicillamine[e2] treatment in Wilson's disease.
+	(5, 16)	thalamic and brainstem lesions	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6468	Acute dystonia with [s1]thalamic and brainstem lesions[e1] after initial [s2]penicillamine[e2] treatment in Wilson's disease.
+	(4, 28)	acute generalized dystonia	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6469	From these data, [s1]acute generalized dystonia[e1] with brainstem and thalamic lesions may occur in WD patients after an initial [s2]d-penicillamine[e2] therapy.
+	(10, 28)	brainstem and thalamic lesions	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6470	From these data, acute generalized dystonia with [s1]brainstem and thalamic lesions[e1] may occur in WD patients after an initial [s2]d-penicillamine[e2] therapy.
+	(6, 23)	acute generalized dystonia	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6471	We reported 3 patients who developed [s1]acute generalized dystonia[e1] and akinetic rigid syndrome following an initial therapy with [s2]d-penicillamine[e2] 125-500 mg daily.
+	(12, 23)	akinetic rigid syndrome	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6472	We reported 3 patients who developed acute generalized dystonia and [s1]akinetic rigid syndrome[e1] following an initial therapy with [s2]d-penicillamine[e2] 125-500 mg daily.
+	(0, 16)	Ballistic movements	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6473	 [s1]Ballistic movements[e1] due to ischemic infarcts after intravenous [s2]heroin[e2] overdose: report of two cases.
+	(4, 16)	ischemic infarcts	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6474	Ballistic movements due to [s1]ischemic infarcts[e1] after intravenous [s2]heroin[e2] overdose: report of two cases.
+	(3, 14)	bilateral ballism	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6475	Patient 1 presented [s1]bilateral ballism[e1] 1 week after intravenous [s2]heroin[e2] injection.
+	(0, 14)	Stroke	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6476	 [s1]Stroke[e1] is an infrequent but recognized complication of [s2]heroin[e2] addiction.
+	(1, 14)	heroin	ballistic movements	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6477	Two [s1]heroin[e1] addicts, aged 34 and 19 years, developed [s2]ballistic movements[e2] after intravenous heroin overdose.
+	(10, 18)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6478	A MEDLINE search identified all the reported cases of [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] 
+	(0, 11)	Anaphylaxis	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6479	 [s1]Anaphylaxis[e1] to intravenous [s2]cyclosporine[e2] and tolerance to oral cyclosporine: case report and review.
+	(2, 10)	Hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6480	BACKGROUND: [s1]Hypersensitivity reactions[e1] to [s2]cyclosporine[e2] are rare.
+	(2, 18)	Hypersensitivity reactions	Cremophor EL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6481	CONCLUSIONS: [s1]Hypersensitivity reactions[e1] to cyclosporine are due to [s2]Cremophor EL[e2] 
+	(2, 10)	Hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6482	CONCLUSIONS: [s1]Hypersensitivity reactions[e1] to [s2]cyclosporine[e2] are due to Cremophor EL.
+	(3, 14)	hypersensitivity reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6483	Fortunately, a [s1]hypersensitivity reaction[e1] to one formulation of [s2]cyclosporine[e2] does not preclude use of a different formulation.
+	(9, 24)	anaphylactic reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6484	METHODS: We report a patient who had an [s1]anaphylactic reaction[e1] during the intravenous infusion of [s2]cyclosporine[e2] 
+	(8, 16)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6485	OBJECTIVE: To investigate the mechanisms involved in [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] and determine the feasibility of future cyclosporine use.
+	(8, 16)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6486	OBJECTIVE: To investigate the mechanisms involved in [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] and determine the feasibility of future cyclosporine use.
+	(7, 15)	hypersensitivity reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6487	The literature search revealed 22 cases of [s1]hypersensitivity reaction[e1] to [s2]cyclosporine[e2] 
+	(0, 13)	Prothipendylhydrochloride	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6488	 [s1]Prothipendylhydrochloride[e1] induced [s2]priapism[e2]  case report.
+	(9, 24)	priapism	prothipendylhydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6489	We present the first case of a patient with [s1]priapism[e1] after oral intake of the phenothiazine [s2]prothipendylhydrochloride[e2] 
+	(14, 49)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6490	The chemotherapeutics, including vincristine, [s1]actinomycin D[e1]  and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
+	(14, 49)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6491	The chemotherapeutics, including vincristine, [s1]actinomycin D[e1]  and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
+	(21, 50)	epirubicin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6492	The chemotherapeutics, including vincristine, actinomycin D, and [s1]epirubicin[e1] in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
+	(9, 49)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6493	The chemotherapeutics, including [s1]vincristine[e1]  actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
+	(9, 49)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6494	The chemotherapeutics, including [s1]vincristine[e1]  actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
+	(8, 23)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6495	We conclude that vincristine and [s1]actinomycin D[e1] were the cause of this rare from of [s2]hepatotoxicity[e2] and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.
+	(3, 23)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6496	We conclude that [s1]vincristine[e1] and actinomycin D were the cause of this rare from of [s2]hepatotoxicity[e2] and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.
+	(4, 46)	bleomycin	acral necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6497	Because the combination of [s1]bleomycin[e1] and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking [s2]acral necrosis[e2] in patients who develop Raynaud's phenomenon under chemotherapy.
+	(4, 54)	bleomycin	Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6498	Because the combination of [s1]bleomycin[e1] and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop [s2]Raynaud's phenomenon[e2] under chemotherapy.
+	(8, 14)	gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6499	In this report, one patient who developed [s1]gangrene[e1] after [s2]bleomycin[e2] and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
+	(8, 23)	gangrene	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6500	In this report, one patient who developed [s1]gangrene[e1] after bleomycin and vincristine [s2]vinblastine[e2] chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
+	(8, 19)	gangrene	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6501	In this report, one patient who developed [s1]gangrene[e1] after bleomycin and [s2]vincristine[e2] vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
+	(12, 51)	bleomycin	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6502	In this report, one patient who developed gangrene after [s1]bleomycin[e1] and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
+	(21, 50)	vinblastine	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6503	In this report, one patient who developed gangrene after bleomycin and vincristine [s1]vinblastine[e1] chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
+	(17, 50)	vincristine	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6504	In this report, one patient who developed gangrene after bleomycin and [s1]vincristine[e1] vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
+	(3, 16)	thrombocythemia	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6505	Development of essential [s1]thrombocythemia[e1] in a patient treated with [s2]interferon alfa[e2] and pentostatin for hairy cell leukemia.
+	(3, 21)	thrombocythemia	pentostatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6506	Development of essential [s1]thrombocythemia[e1] in a patient treated with interferon alfa and [s2]pentostatin[e2] for hairy cell leukemia.
+	(6, 27)	hematological malignancy	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6507	Second cancers including various types of [s1]hematological malignancy[e1] have been reported in patients with hairy cell leukemia treated with chemotherapy or [s2]interferon alfa[e2] 
+	(0, 27)	Second cancers	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6508	 [s1]Second cancers[e1] including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or [s2]interferon alfa[e2] 
+	(10, 18)	dexamethasone	hypertrophic obstructive cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6509	Effect of beta-blockade on symptomatic [s1]dexamethasone[e1] induced [s2]hypertrophic obstructive cardiomyopathy[e2] in premature infants: three case reports and literature review.
+	(4, 21)	lower average heart rate	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6510	One patient had a [s1]lower average heart rate[e1] and two patients had lower average mean blood pressure values during [s2]propranolol[e2] treatment, none of which was clinically significant.
+	(12, 21)	lower average mean blood pressure	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6511	One patient had a lower average heart rate and two patients had [s1]lower average mean blood pressure[e1] values during [s2]propranolol[e2] treatment, none of which was clinically significant.
+	(38, 50)	left ventricular outflow tract obstruction	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6512	STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and [s1]left ventricular outflow tract obstruction[e1] developed during [s2]dexamethasone[e2] treatment for bronchopulmonary dysplasia.
+	(32, 50)	septal hypertrophy	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6513	STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant [s1]septal hypertrophy[e1] and left ventricular outflow tract obstruction developed during [s2]dexamethasone[e2] treatment for bronchopulmonary dysplasia.
+	(20, 32)	abdominal cramping	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6514	CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and [s1]abdominal cramping[e1] on day 6 of therapy with [s2]clindamycin[e2] vaginal cream for bacterial vaginosis.
+	(15, 32)	multiple watery stools	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6515	CASE SUMMARY: A 25-year-old postpartum white woman developed [s1]multiple watery stools[e1] and abdominal cramping on day 6 of therapy with [s2]clindamycin[e2] vaginal cream for bacterial vaginosis.
+	(0, 18)	Clostridium difficile toxin-induced colitis	clindamycin phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6516	 [s1]Clostridium difficile toxin-induced colitis[e1] after use of [s2]clindamycin phosphate[e2] vaginal cream.
+	(5, 21)	clindamycin	CDIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6517	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of [s2]CDIC[e2] due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
+	(5, 21)	clindamycin phosphate	CDIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6518	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of [s2]CDIC[e2] due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
+	(5, 53)	clindamycin	C. difficile toxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6519	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of [s2]C. difficile toxin[e2] 
+	(5, 53)	clindamycin phosphate	C. difficile toxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6520	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of [s2]C. difficile toxin[e2] 
+	(5, 32)	clindamycin	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6521	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of [s2]diarrhea[e2] and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
+	(5, 32)	clindamycin phosphate	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6522	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of [s2]diarrhea[e2] and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
+	(9, 25)	clindamycin	C. difficile toxin in stool	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6523	DISCUSSION: No published clinical studies in patients receiving [s1]clindamycin[e1] vaginal cream for bacterial vaginosis have documented [s2]C. difficile toxin in stool[e2] samples of patients with diarrhea.
+	(9, 38)	clindamycin	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6524	DISCUSSION: No published clinical studies in patients receiving [s1]clindamycin[e1] vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with [s2]diarrhea[e2] 
+	(7, 31)	toxin-positive Clostridium difficile-induced colitis	clindamycin phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6525	OBJECTIVE: To report a case of [s1]toxin-positive Clostridium difficile-induced colitis[e1] (CDIC) after use of [s2]clindamycin phosphate[e2] vaginal cream.
+	(8, 15)	TEN	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6526	A 54-year-old man developed [s1]TEN[e1] 4 weeks after beginning [s2]lamotrigine[e2] for complex partial seizures related to a glioblastoma multiforme brain tumor.
+	(2, 24)	lamotrigine	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6527	Administration of [s1]lamotrigine[e1]  especially in combination with valproic acid, may lead to the development of [s2]TEN[e2] 
+	(12, 24)	valproic acid	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6528	Administration of lamotrigine, especially in combination with [s1]valproic acid[e1]  may lead to the development of [s2]TEN[e2] 
+	(0, 12)	Fatal toxic epidermal necrolysis	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6529	 [s1]Fatal toxic epidermal necrolysis[e1] related to [s2]lamotrigine[e2] administration.
+	(22, 51)	lamotrigine	accumulation of a toxic intermediate metabolite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6530	It was hypothesized that valproic acid may interfere with glucuronidation of [s1]lamotrigine[e1]  leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in [s2]accumulation of a toxic intermediate metabolite[e2] 
+	(8, 52)	valproic acid	accumulation of a toxic intermediate metabolite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6531	It was hypothesized that [s1]valproic acid[e1] may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in [s2]accumulation of a toxic intermediate metabolite[e2] 
+	(22, 31)	lamotrigine	increased serum lamotrigine levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6532	It was hypothesized that valproic acid may interfere with glucuronidation of [s1]lamotrigine[e1]  leading to [s2]increased serum lamotrigine levels[e2]  or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.
+	(8, 32)	valproic acid	increased serum lamotrigine levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6533	It was hypothesized that [s1]valproic acid[e1] may interfere with glucuronidation of lamotrigine, leading to [s2]increased serum lamotrigine levels[e2]  or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.
+	(10, 16)	SJS	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6534	To date, eight cases of TEN and one of [s1]SJS[e1] related to [s2]lamotrigine[e2] administration have been reported in the literature.
+	(6, 16)	TEN	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6535	To date, eight cases of [s1]TEN[e1] and one of SJS related to [s2]lamotrigine[e2] administration have been reported in the literature.
+	(1, 10)	syndrome of increased affect	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6536	A [s1]syndrome of increased affect[e1] in response to [s2]risperidone[e2] among patients with schizophrenia.
+	(18, 46)	risperidone	depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6537	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and [s2]depression[e2] and periods of crying and insomnia.
+	(18, 42)	risperidone	feelings of agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6538	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including [s2]feelings of agitation[e2] and depression and periods of crying and insomnia.
+	(18, 52)	risperidone	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6539	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and [s2]insomnia[e2] 
+	(18, 36)	risperidone	intolerable affect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6540	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of [s2]intolerable affect[e2]  including feelings of agitation and depression and periods of crying and insomnia.
+	(18, 48)	risperidone	periods of crying	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6541	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and [s2]periods of crying[e2] and insomnia.
+	(4, 11)	risperidone	increase affect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6542	The authors suggest that [s1]risperidone[e1] may [s2]increase affect[e2] in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.
+	(0, 19)	Methanol	bilateral putaminal injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6543	 [s1]Methanol[e1] toxicity can cause severe central nervous system insult in which a characteristic pattern of [s2]bilateral putaminal injury[e2] is noted on brain imaging studies.
+	(0, 30)	Methanol toxicity	Methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6544	 [s1]Methanol toxicity[e1] can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies [s2]Methanol[e2] toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.
+	(0, 8)	Methanol	severe central nervous system insult	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6545	 [s1]Methanol[e1] toxicity can cause [s2]severe central nervous system insult[e2] in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.
+	(7, 15)	methanol intoxication	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6546	Putaminal infarct in [s1]methanol intoxication[e1]  [s2]methanol[e2] intoxication: case report and role of brain imaging studies.
+	(0, 9)	Putaminal infarct	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6547	 [s1]Putaminal infarct[e1] in [s2]methanol[e2] intoxication: case report and role of brain imaging studies.
+	(9, 15)	methanol poisoning	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6548	Theoretical basal ganglia toxicologic mechanisms of [s1]methanol poisoning[e1]  [s2]methanol[e2] poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed.
+	(9, 22)	methanol	bilateral putaminal necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6549	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including [s2]bilateral putaminal necrosis[e2] and cerebral edema with ventricular compression.
+	(9, 29)	methanol	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6550	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and [s2]cerebral edema[e2] with ventricular compression.
+	(9, 17)	methanol	diffuse brain involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6551	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated [s2]diffuse brain involvement[e2]  including bilateral putaminal necrosis and cerebral edema with ventricular compression.
+	(3, 11)	fatal	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6552	We present a [s1]fatal[e1] case of subacute [s2]methanol[e2] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.
+	(9, 15)	methanol toxicity	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6553	We present a fatal case of subacute [s1]methanol toxicity[e1]  [s2]methanol[e2] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.
+	(9, 33)	methanol	ventricular compression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6554	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with [s2]ventricular compression[e2] 
+	(15, 30)	risperidone	dyskinetic movements	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6555	A 28 year old white schizophrenic male has been under [s1]risperidone[e1] monotherapy for about one year when he developed [s2]dyskinetic movements[e2] 
+	(0, 7)	Risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6556	 [s1]Risperidone[e1] induced [s2]tardive dyskinesia[e2] 
+	(7, 14)	risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6557	This report presents a potential case of [s1]risperidone[e1] induced [s2]tardive dyskinesia[e2] 
+	(0, 18)	Increased ocular pressure	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6558	 [s1]Increased ocular pressure[e1] in two patients with narrow angle glaucoma treated with [s2]venlafaxine[e2] 
+	(8, 53)	clinical lupus syndrome	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6559	A 61-year-old man developed [s1]clinical lupus syndrome[e1] with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of [s2]procainamide[e2] therapy.
+	(35, 53)	diffuse proliferative glomerulonephritis	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6560	A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and [s1]diffuse proliferative glomerulonephritis[e1] following 26 months of [s2]procainamide[e2] therapy.
+	(21, 53)	lupus erythematosus	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6561	A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive [s1]lupus erythematosus[e1] (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of [s2]procainamide[e2] therapy.
+	(0, 11)	Glomerulonephritis	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6562	 [s1]Glomerulonephritis[e1] in [s2]procainamide[e2] induced lupus erythematosus: report of a case and review of the literature.
+	(9, 16)	procainamide	lupus erythematosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6563	Glomerulonephritis in [s1]procainamide[e1] induced [s2]lupus erythematosus[e2]  report of a case and review of the literature.
+	(12, 23)	acute blistering eruption	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6564	We report a 76-year-old man who developed an [s1]acute blistering eruption[e1] following high-dose [s2]penicillin[e2] treatment for pneumococcal septicaemia.
+	(4, 11)	suxamethonium	apnoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6565	A case of prolonged [s1]suxamethonium[e1]  [s2]apnoea[e2] successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported.
+	(0, 7)	Suxamethonium	apnoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6566	 [s1]Suxamethonium[e1]  [s2]apnoea[e2] terminated with commercial serumcholinesterase.
+	(0, 6)	Cardiac arrest	sulprostone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6567	 [s1]Cardiac arrest[e1] associated with [s2]sulprostone[e2] use during caesarean section.
+	(8, 23)	sulprostone	cardiac arrest	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6568	We postulate that the bolus of [s1]sulprostone[e1] resulted in possible coronary spasm that resulted in [s2]cardiac arrest[e2] 
+	(8, 16)	sulprostone	coronary spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6569	We postulate that the bolus of [s1]sulprostone[e1] resulted in possible [s2]coronary spasm[e2] that resulted in cardiac arrest.
+	(24, 38)	desmethylsertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6570	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and [s1]desmethylsertraline[e1] blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
+	(36, 48)	doubling of the lamotrigine blood level	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6571	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s1]doubling of the lamotrigine blood level[e1]  [s2]lamotrigine[e2] blood level with symptoms of toxicity.
+	(11, 37)	sertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6572	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
+	(11, 37)	sertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6573	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
+	(24, 49)	desmethylsertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6574	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and [s1]desmethylsertraline[e1] blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
+	(39, 49)	lamotrigine	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6575	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the [s1]lamotrigine[e1] blood level with [s2]symptoms of toxicity[e2] 
+	(11, 48)	sertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6576	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
+	(11, 48)	sertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6577	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
+	(0, 13)	Lamotrigine toxicity	Lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6578	 [s1]Lamotrigine toxicity[e1] secondary to sertraline [s2]Lamotrigine[e2] toxicity secondary to sertraline.
+	(0, 10)	Lamotrigine toxicity	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6579	 [s1]Lamotrigine toxicity[e1] secondary to [s2]sertraline[e2] 
+	(0, 11)	Flutamide	decrease in prostate-specific antigen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6580	 [s1]Flutamide[e1] withdrawal syndrome is characterized by a [s2]decrease in prostate-specific antigen[e2] (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
+	(9, 22)	decrease in prostate-specific antigen	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6581	Flutamide withdrawal syndrome is characterized by a [s1]decrease in prostate-specific antigen[e1] (PSA) after [s2]flutamide[e2] withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
+	(0, 41)	Flutamide withdrawal syndrome	Flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6582	 [s1]Flutamide withdrawal syndrome[e1] is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate [s2]Flutamide[e2] withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
+	(0, 22)	Flutamide withdrawal syndrome	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6583	 [s1]Flutamide withdrawal syndrome[e1] is characterized by a decrease in prostate-specific antigen (PSA) after [s2]flutamide[e2] withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
+	(7, 14)	flutamide withdrawal syndrome	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6584	Prolonged prostate-specific antigen response in [s1]flutamide withdrawal syndrome[e1]  [s2]flutamide[e2] withdrawal syndrome despite disease progression.
+	(0, 9)	Prolonged prostate-specific antigen response	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6585	 [s1]Prolonged prostate-specific antigen response[e1] in [s2]flutamide[e2] withdrawal syndrome despite disease progression.
+	(5, 18)	decoupling of PSA response	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6586	This case illustrates the potential [s1]decoupling of PSA response[e1] from disease status in [s2]flutamide[e2] withdrawal.
+	(13, 27)	PSA continued to decrease	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6587	We describe a patient with androgen-independent prostate cancer in whom [s1]PSA continued to decrease[e1] for a period of 15 months after [s2]flutamide[e2] withdrawal.
+	(0, 9)	Anaphylactic reaction	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6588	 [s1]Anaphylactic reaction[e1] to oral [s2]prednisone[e2]  a case report and review of the literature.
+	(31, 40)	anaphylactic reaction	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6589	We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic [s1]anaphylactic reaction[e1] to oral [s2]prednisone[e2] 
+	(3, 9)	HAL	significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6590	Animals treated with [s1]HAL[e1] showed a highly [s2]significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons[e2] in the substantia nigra, and 20% contraction of the TH stained dendritic arbour.
+	(23, 40)	vomiting	Pancrease MT 16	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6591	METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite [s1]vomiting[e1] within 1 to 1.5 hours after challenges with Viokase and [s2]Pancrease MT 16[e2]  but not with placebo.
+	(23, 36)	vomiting	Viokase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6592	METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite [s1]vomiting[e1] within 1 to 1.5 hours after challenges with [s2]Viokase[e2] and Pancrease MT 16, but not with placebo.
+	(4, 14)	Pancrease MT 16	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6593	She was treated with [s1]Pancrease MT 16[e1]  but had consistent [s2]vomiting[e2] 1 to 2 hours after administration of enzymes.
+	(1, 17)	vomiting	Creon 10	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6594	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, [s2]Creon 10[e2]  Viokase, and Pancrease MT 16.
+	(1, 26)	vomiting	Pancrease MT 16	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6595	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and [s2]Pancrease MT 16[e2] 
+	(1, 21)	vomiting	Viokase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6596	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, [s2]Viokase[e2]  and Pancrease MT 16.
+	(1, 11)	valproate	symptomatic methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6597	Acute [s1]valproate[e1] ingestion induces [s2]symptomatic methemoglobinemia[e2] 
+	(9, 33)	symptomatic methemoglobinemia	Depakote	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6598	We report for the first time the development of [s1]symptomatic methemoglobinemia[e1] after an acute ingestion of divalproex sodium  [s2]Depakote[e2] , resulting in serum concentrations 10 times greater than the therapeutic range.
+	(9, 28)	symptomatic methemoglobinemia	divalproex sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6599	We report for the first time the development of [s1]symptomatic methemoglobinemia[e1] after an acute ingestion of [s2]divalproex sodium[e2] (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range.
+	(3, 30)	mitomycin C	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6600	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by [s2]hemolytic anemia[e2]  thrombocytopenia and progressive renal failure.
+	(7, 28)	MMC	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6601	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by [s2]hemolytic anemia[e2]  thrombocytopenia and progressive renal failure.
+	(3, 18)	mitomycin C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6602	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated [s2]hemolytic uremic syndrome[e2]  which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.
+	(7, 16)	MMC	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6603	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated [s2]hemolytic uremic syndrome[e2]  which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.
+	(3, 43)	mitomycin C	progressive renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6604	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and [s2]progressive renal failure[e2] 
+	(7, 41)	MMC	progressive renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6605	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and [s2]progressive renal failure[e2] 
+	(3, 36)	mitomycin C	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6606	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, [s2]thrombocytopenia[e2] and progressive renal failure.
+	(7, 34)	MMC	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6607	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, [s2]thrombocytopenia[e2] and progressive renal failure.
+	(0, 7)	Mitomycin C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6608	 [s1]Mitomycin C[e1] related [s2]hemolytic uremic syndrome[e2] in cancer patients.
+	(5, 10)	MMC	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6609	We report a case of [s1]MMC[e1] related [s2]hemolytic uremic syndrome[e2]  and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome.
+	(0, 31)	CD4 T-lymphocyte depletion	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6610	 [s1]CD4 T-lymphocyte depletion[e1]  myelosuppression, and subsequent severe infections are the major side effects of [s2]fludarabine phosphate[e2] therapy.
+	(13, 31)	myelosuppression	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6611	CD4 T-lymphocyte depletion, [s1]myelosuppression[e1]  and subsequent severe infections are the major side effects of [s2]fludarabine phosphate[e2] therapy.
+	(22, 32)	severe infections	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6612	CD4 T-lymphocyte depletion, myelosuppression, and subsequent [s1]severe infections[e1] are the major side effects of [s2]fludarabine phosphate[e2] therapy.
+	(0, 15)	Severe respiratory syncytial virus pulmonary infection	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6613	 [s1]Severe respiratory syncytial virus pulmonary infection[e1] in a patient treated with [s2]fludarabine[e2] for chronic lymphocytic leukemia.
+	(14, 45)	respiratory syncytial virus (RSV) infection	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6614	We report here on a heretofore undescribed [s1]respiratory syncytial virus (RSV) infection[e1] in a patient with a long-standing history of refractory CLL that was treated with [s2]fludarabine phosphate[e2] 
+	(0, 11)	Serotonin syndrome	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6615	 [s1]Serotonin syndrome[e1] induced by transitioning from [s2]phenelzine[e2] to venlafaxine: four patient reports.
+	(0, 16)	Serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6616	 [s1]Serotonin syndrome[e1] induced by transitioning from phenelzine to [s2]venlafaxine[e2]  four patient reports.
+	(2, 9)	G-CSF	leucocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6617	Although this [s1]G-CSF[e1] driven [s2]leucocytosis[e2] was alarming it did not appear to have adversely affected the patient's prognosis.
+	(0, 17)	Leukaemoid monocytosis	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6618	 [s1]Leukaemoid monocytosis[e1] in M4 AML following chemotherapy and [s2]G-CSF[e2] 
+	(15, 24)	G-CSF	monocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6619	We describe a patient with M4 AML treated with standard chemotherapy followed by [s1]G-CSF[e1] who developed marked [s2]monocytosis[e2] on day 8 of G-CSF therapy.
+	(15, 24)	G-CSF	monocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6620	We describe a patient with M4 AML treated with standard chemotherapy followed by [s1]G-CSF[e1] who developed marked [s2]monocytosis[e2] on day 8 of G-CSF therapy.
+	(7, 19)	chlorambucil	balanced translocation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6621	Case 2 demonstrated after 40 months on [s1]chlorambucil[e1] the presence of a [s2]balanced translocation[e2]  t (1;5) (p36;q31) in 90% of the cells.
+	(0, 5)	Chromosome abnormalities	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6622	 [s1]Chromosome abnormalities[e1] after [s2]chlorambucil[e2] therapy of polycythaemia vera.
+	(9, 20)	PTU	ANCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6623	Administration of steroid and decreasing the dose of [s1]PTU[e1] produced a good clinical response and the [s2]ANCA[e2] disappeared.
+	(0, 26)	Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6624	 [s1]Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis[e1] associated with [s2]propylthiouracil[e2] therapy.
+	(15, 36)	antineutrophil cytoplasmic antibody	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6625	A teenage girl with crescentic glomerulonephritis had [s1]antineutrophil cytoplasmic antibody[e1] (ANCA) detected after she had received [s2]propylthiouracil[e2] (PTU) for hyperthyroidism without cutaneous vasculitis.
+	(15, 42)	antineutrophil cytoplasmic antibody	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6626	A teenage girl with crescentic glomerulonephritis had [s1]antineutrophil cytoplasmic antibody[e1] (ANCA) detected after she had received propylthiouracil  [s2]PTU[e2]  for hyperthyroidism without cutaneous vasculitis.
+	(4, 30)	ANCA	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6627	It was concluded that [s1]ANCA[e1] is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with [s2]PTU[e2] appeared to induce ANCA.
+	(4, 30)	ANCA	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6628	It was concluded that [s1]ANCA[e1] is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with [s2]PTU[e2] appeared to induce ANCA.
+	(1, 12)	drug interaction	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6629	A [s1]drug interaction[e1] between zafirlukast and [s2]theophylline[e2] 
+	(1, 6)	drug interaction	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6630	A [s1]drug interaction[e1] between [s2]zafirlukast[e2] and theophylline.
+	(9, 31)	theophylline	reaction to the drug became more toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6631	Attempts were made to stop and then restart the [s1]theophylline[e1] therapy at progressively lower doses; however, with each attempt, the patient's [s2]reaction to the drug became more toxic[e2]  with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).
+	(9, 31)	theophylline	reaction to the drug became more toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6632	Attempts were made to stop and then restart the [s1]theophylline[e1] therapy at progressively lower doses; however, with each attempt, the patient's [s2]reaction to the drug became more toxic[e2]  with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).
+	(5, 15)	increase in the theophylline level	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6633	One explanation for the noted [s1]increase in the theophylline level[e1]  [s2]theophylline[e2] level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast.
+	(5, 47)	increase in the theophylline level	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6634	One explanation for the noted [s1]increase in the theophylline level[e1] is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of [s2]zafirlukast[e2] 
+	(4, 44)	theophylline levels had increased to the toxic range	Accolate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6635	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1] (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast  [s2]Accolate[e2]  Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
+	(4, 17)	theophylline levels had increased to the toxic range	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6636	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1]  [s2]theophylline[e2] levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
+	(4, 39)	theophylline levels had increased to the toxic range	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6637	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1] (133.2 micromol/L [24 microg/mL]) shortly after the addition of [s2]zafirlukast[e2] (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
+	(2, 12)	increase in the theophylline level	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6638	The noted [s1]increase in the theophylline level[e1]  [s2]theophylline[e2] level after zafirlukast administration is in contrast to the original reports by the manufacturer.
+	(2, 13)	increase in the theophylline level	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6639	The noted [s1]increase in the theophylline level[e1] after [s2]zafirlukast[e2] administration is in contrast to the original reports by the manufacturer.
+	(14, 27)	drug-drug interaction	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6640	We present the first case (to our knowledge) of a potentially serious [s1]drug-drug interaction[e1] between zafirlukast and [s2]theophylline[e2] 
+	(14, 21)	drug-drug interaction	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6641	We present the first case (to our knowledge) of a potentially serious [s1]drug-drug interaction[e1] between [s2]zafirlukast[e2] and theophylline.
+	(8, 22)	rhabdomyolysis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6642	A 21-year-old patient developed [s1]rhabdomyolysis[e1] during his nineteenth week of treatment with [s2]clozapine[e2] for drug-resistant schizophrenia.
+	(0, 9)	Clozapine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6643	 [s1]Clozapine[e1] is speculated to cause [s2]rhabdomyolysis[e2] in patients with defective calcium-activated K+ channels.
+	(0, 9)	Rhabdomyolysis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6644	 [s1]Rhabdomyolysis[e1] associated with [s2]clozapine[e2] treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.
+	(23, 34)	anticholinergic symptoms	diphenhydramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6645	We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or [s1]anticholinergic symptoms[e1] with the use of [s2]diphenhydramine[e2] 
+	(18, 34)	drug-seeking behavior	diphenhydramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6646	We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited [s1]drug-seeking behavior[e1] or anticholinergic symptoms with the use of [s2]diphenhydramine[e2] 
+	(4, 10)	Pentasa	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6647	Excluding other causes, [s1]Pentasa[e1] associated [s2]pancytopenia[e2] was considered.
+	(6, 23)	diarrhea	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6648	He developed fever, nausea, [s1]diarrhea[e1]  and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
+	(2, 23)	fever	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6649	He developed [s1]fever[e1]  nausea, diarrhea, and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
+	(11, 24)	malaise	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6650	He developed fever, nausea, diarrhea, and [s1]malaise[e1] and stopped taking on the third day after commencing [s2]Pentasa[e2] 
+	(4, 23)	nausea	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6651	He developed fever, [s1]nausea[e1]  diarrhea, and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
+	(0, 8)	Pancytopenia	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6652	 [s1]Pancytopenia[e1] associated with [s2]5-aminosalicylic acid[e2] use in a patient with Crohn's disease.
+	(5, 30)	pancytopenia	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6653	We report a case of [s1]pancytopenia[e1] in a 23-year-old man with Crohn's disease who was treated with [s2]5-aminosalicylic acid[e2] (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.
+	(5, 38)	pancytopenia	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6654	We report a case of [s1]pancytopenia[e1] in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid  [s2]Pentasa[e2]  Nisshin, Tokyo, Japan) 3.0 g/day.
+	(2, 28)	Changes in the plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6655	1. [s1]Changes in the plasma cortisol level[e1] were reported in a male patient with panic disorder during the period of low-dose [s2]alprazolam[e2] treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day).
+	(5, 14)	decreased plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6656	3. Thus, the [s1]decreased plasma cortisol level[e1] during [s2]alprazolam[e2] treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself.
+	(0, 9)	Decreased plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6657	 [s1]Decreased plasma cortisol level[e1] during [s2]alprazolam[e2] treatment of panic disorder: a case report.
+	(8, 21)	cyclosporine	Nocardia Asteroides brain abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6658	We describe a renal transplant recipient maintained on [s1]cyclosporine[e1] and prednisone developing [s2]Nocardia Asteroides brain abscess[e2] 
+	(14, 21)	prednisone	Nocardia Asteroides brain abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6659	We describe a renal transplant recipient maintained on cyclosporine and [s1]prednisone[e1] developing [s2]Nocardia Asteroides brain abscess[e2] 
+	(3, 16)	cisplatin	progressive sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6660	Young children undergoing [s1]cisplatin[e1] chemotherapy are known to be at risk for [s2]progressive sensorineural hearing loss[e2] 
+	(17, 34)	pentazocine	gradual stiffness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6661	A 47 year-old woman who had a 4-year history of intramuscular [s1]pentazocine[e1] injections in the lower extremities, developed [s2]gradual stiffness[e2] and weakness of the lower extremities.
+	(17, 38)	pentazocine	weakness of the lower extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6662	A 47 year-old woman who had a 4-year history of intramuscular [s1]pentazocine[e1] injections in the lower extremities, developed gradual stiffness and [s2]weakness of the lower extremities[e2] 
+	(10, 38)	pentazocine	fibrous myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6663	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced [s2]fibrous myopathy[e2] and localized neuropathy.
+	(10, 19)	pentazocine	neuromuscular complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6664	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a [s2]neuromuscular complication[e2] are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.
+	(10, 46)	pentazocine	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6665	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized [s2]neuropathy[e2] 
+	(10, 17)	pentazocine toxicity	pentazocine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6666	Caution in longterm usage and early recognition of [s1]pentazocine toxicity[e1]  [s2]pentazocine[e2] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.
+	(0, 7)	Pentazocine	fibrous myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6667	 [s1]Pentazocine[e1] induced [s2]fibrous myopathy[e2] and localized neuropathy.
+	(0, 15)	Pentazocine	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6668	 [s1]Pentazocine[e1] induced fibrous myopathy and localized [s2]neuropathy[e2] 
+	(5, 14)	akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6669	In two of these cases [s1]akathisia[e1] resolved after withdrawal of [s2]olanzapine[e2] and substitution by a classical or an atypical neuroleptic agent, respectively.
+	(10, 23)	olanzapine	extrapyramidal side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6670	Like other atypical neuroleptics [s1]olanzapine[e1] is considered to show a reduced prevalence of [s2]extrapyramidal side effects[e2] when compared to classical neuroleptic drugs.
+	(7, 16)	extrapyramidal side effects	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6671	One should therefore be aware of possible [s1]extrapyramidal side effects[e1] with [s2]olanzapine[e2] that are reduced compared to classical neuroleptic drugs but not completely eliminated.
+	(0, 7)	Severe akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6672	 [s1]Severe akathisia[e1] during [s2]olanzapine[e2] treatment of acute schizophrenia.
+	(11, 20)	severe akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6673	We report on three patients with acute schizophrenia, who developed [s1]severe akathisia[e1] during treatment with [s2]olanzapine[e2] (20-25 mg/d).
+	(0, 21)	Seizures	metrifonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6674	 [s1]Seizures[e1] occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with [s2]metrifonate[e2]  an irreversible acetylcholinesterase inhibitor.
+	(5, 19)	vitreous hemorrhage	tPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6675	However, 1 eye had [s1]vitreous hemorrhage[e1] after repeated injections of [s2]tPA[e2] 
+	(6, 18)	tPA	vitreous hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6676	However, repeated intracameral [s1]tPA[e1] injections may cause unwanted complications such as [s2]vitreous hemorrhage[e2] 
+	(1, 29)	praziquantel	inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6677	Although [s1]praziquantel[e1] administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked [s2]inflammation[e2] as a result of treatment.
+	(0, 16)	NMS	Haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6678	 [s1]NMS[e1] is a drug-related response to various medications, such as [s2]Haloperidol[e2]  which the patient was receiving.
+	(0, 7)	Methimazole	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6679	 [s1]Methimazole[e1] induced [s2]aplastic anemia[e2] in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.
+	(19, 27)	AA	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6680	We present a case of a 58-year-old female patient with Graves' disease who developed [s1]AA[e1] in the third exposure to [s2]methimazole[e2] (MMI).
+	(0, 7)	FSGS	Adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6681	 [s1]FSGS[e1] induced by [s2]Adriamycin[e2] (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats.
+	(10, 19)	pranlukast	ATIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6682	The case demonstrates that hypersensitivity reaction to [s1]pranlukast[e1] and resultant [s2]ATIN[e2] is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
+	(10, 19)	pranlukast	ATIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6683	The case demonstrates that hypersensitivity reaction to [s1]pranlukast[e1] and resultant [s2]ATIN[e2] is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
+	(4, 12)	hypersensitivity reaction	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6684	The case demonstrates that [s1]hypersensitivity reaction[e1] to [s2]pranlukast[e2] and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
+	(4, 12)	hypersensitivity reaction	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6685	The case demonstrates that [s1]hypersensitivity reaction[e1] to [s2]pranlukast[e2] and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
+	(0, 22)	Tubulointerstitial nephritis	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6686	 [s1]Tubulointerstitial nephritis[e1] induced by the leukotriene receptor antagonist [s2]pranlukast[e2] 
+	(4, 13)	pranlukast	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6687	Within 6 months of [s1]pranlukast[e1] withdrawal, [s2]anemia[e2] resolved and urinary sediment and renal function normalized.
+	(15, 27)	syncope	isosorbide dinitrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6688	A 65-year-old woman with angina pectoris presented with [s1]syncope[e1] after sublingual ingestion of [s2]isosorbide dinitrate[e2] (5 mg).
+	(4, 17)	nitrate	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6689	Elderly patients for whom [s1]nitrate[e1] has been prescribed should be warned of the occurrence of [s2]hypotension[e2]  leading to unconsciousness.
+	(4, 25)	nitrate	unconsciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6690	Elderly patients for whom [s1]nitrate[e1] has been prescribed should be warned of the occurrence of hypotension, leading to [s2]unconsciousness[e2] 
+	(9, 23)	isosorbide dinitrate	blood pressure decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6691	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), [s2]blood pressure decreased[e2] from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.
+	(9, 43)	isosorbide dinitrate	sudden decrease in pulse rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6692	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a [s2]sudden decrease in pulse rate[e2] from 85 to 60 beats/min.
+	(9, 39)	isosorbide dinitrate	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6693	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by [s2]syncope[e2] with a sudden decrease in pulse rate from 85 to 60 beats/min.
+	(0, 13)	Syncope	nitrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6694	 [s1]Syncope[e1] in a 65-year-old woman after [s2]nitrate[e2] ingestion.
+	(6, 16)	acute dizziness	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6695	Three diabetic cases of [s1]acute dizziness[e1] due to initial administration of [s2]voglibose[e2] 
+	(8, 36)	intolerable dizziness	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6696	We observed 3 diabetic patients with [s1]intolerable dizziness[e1] followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
+	(15, 36)	nausea	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6697	We observed 3 diabetic patients with intolerable dizziness followed by [s1]nausea[e1] and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
+	(17, 36)	vomiting	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6698	We observed 3 diabetic patients with intolerable dizziness followed by nausea and [s1]vomiting[e1] immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
+	(0, 7)	Naproxen	sudden sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6699	 [s1]Naproxen[e1] associated [s2]sudden sensorineural hearing loss[e2] 
+	(0, 26)	Naproxen	tinnitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6700	 [s1]Naproxen[e1] is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include [s2]tinnitus[e2] and transient hearing loss.
+	(0, 30)	Naproxen	transient hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6701	 [s1]Naproxen[e1] is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and [s2]transient hearing loss[e2] 
+	(13, 25)	sensorineural hearing loss	naproxen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6702	This article reports the case of an otherwise healthy patient who experienced permanent [s1]sensorineural hearing loss[e1] after a brief course of [s2]naproxen[e2] and reviews the literature on NSAID-related permanent sensorineural hearing loss.
+	(0, 12)	Dental and gingival pain	niacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6703	 [s1]Dental and gingival pain[e1] as side effects of [s2]niacin[e2] therapy.
+	(12, 38)	niacin	hyperalgesia of sensory nerve receptors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6704	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, [s2]hyperalgesia of sensory nerve receptors[e2]  and potentiation of inflammation in the gingiva with referral of pain to the teeth.
+	(12, 61)	niacin	pain to the teeth	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6705	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of [s2]pain to the teeth[e2] 
+	(12, 48)	niacin	potentiation of inflammation in the gingiva	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6706	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and [s2]potentiation of inflammation in the gingiva[e2] with referral of pain to the teeth.
+	(12, 25)	niacin	prostaglandin-mediated vasodilatation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6707	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to [s2]prostaglandin-mediated vasodilatation[e2]  hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.
+	(15, 32)	niacin	intense dental and gingival pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6708	Two 65-year-old white men with coronary heart disease, given [s1]niacin[e1] therapy for dyslipidemia for 5 months, developed [s2]intense dental and gingival pain[e2] that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.
+	(15, 32)	niacin	intense dental and gingival pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6709	Two 65-year-old white men with coronary heart disease, given [s1]niacin[e1] therapy for dyslipidemia for 5 months, developed [s2]intense dental and gingival pain[e2] that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.
+	(20, 40)	calcitriol	potassium loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6710	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are secondary hyperparathyroidism and vitamin D intoxication, [s2]potassium loss[e2] also should be kept in mind.
+	(8, 38)	phosphate	potassium loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6711	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, [s2]potassium loss[e2] also should be kept in mind.
+	(20, 27)	calcitriol	secondary hyperparathyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6712	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are [s2]secondary hyperparathyroidism[e2] and vitamin D intoxication, potassium loss also should be kept in mind.
+	(8, 25)	phosphate	secondary hyperparathyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6713	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are [s2]secondary hyperparathyroidism[e2] and vitamin D intoxication, potassium loss also should be kept in mind.
+	(20, 34)	calcitriol	vitamin D intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6714	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are secondary hyperparathyroidism and [s2]vitamin D intoxication[e2]  potassium loss also should be kept in mind.
+	(8, 32)	phosphate	vitamin D intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6715	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and [s2]vitamin D intoxication[e2]  potassium loss also should be kept in mind.
+	(3, 9)	phosphate	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6716	High-dose [s1]phosphate[e1] treatment leads to [s2]hypokalemia[e2] in hypophosphatemic osteomalacia.
+	(18, 22)	phosphate	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6717	It was concluded that potassium loss occurred by a non-renal (intestinal) route in [s1]phosphate[e1] induced [s2]hypokalemia[e2] 
+	(4, 20)	potassium loss	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6718	It was concluded that [s1]potassium loss[e1] occurred by a non-renal (intestinal) route in [s2]phosphate[e2] induced hypokalemia.
+	(0, 10)	Progressive hypokalemia	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6719	 [s1]Progressive hypokalemia[e1] developed during [s2]phosphate[e2] treatment.
+	(4, 12)	decrease in plasma potassium	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6720	The mechanism of the [s1]decrease in plasma potassium[e1] induced by [s2]phosphate[e2] treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations.
+	(0, 27)	Transtubular potassium gradient (TTKG) also decreased	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6721	 [s1]Transtubular potassium gradient (TTKG) also decreased[e1] and an inverse correlation was found between TTKG and doses of [s2]phosphate[e2] (r = -0.37; p < 0.02; N = 38).
+	(0, 15)	Alveolar-interstitial pneumopathy	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6722	 [s1]Alveolar-interstitial pneumopathy[e1] after [s2]gold[e2] salts compounds administration, requiring mechanical ventilation.
+	(1, 6)	pulmonary toxicity	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6723	The [s1]pulmonary toxicity[e1] of [s2]gold[e2] salts is an uncommon cause of life-threatening respiratory failure.
+	(4, 16)	gold	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6724	The pulmonary toxicity of [s1]gold[e1] salts is an uncommon cause of life-threatening [s2]respiratory failure[e2] 
+	(6, 12)	respiratory failure	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6725	We report a case of severe [s1]respiratory failure[e1] due to [s2]gold[e2] salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation.
+	(14, 22)	hypersensitivity response	tuberculin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6726	As this relapse coincided with development of a strong delayed-type [s1]hypersensitivity response[e1] to [s2]tuberculin[e2] and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity.
+	(35, 56)	glycosuria	halcinonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6727	A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and [s1]glycosuria[e1] during a period of topical administration of a corticosteroid cream, [s2]halcinonide[e2] cream 0.1%, under occlusion.
+	(26, 56)	postprandial hyperglycemia	halcinonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6728	A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed [s1]postprandial hyperglycemia[e1] and glycosuria during a period of topical administration of a corticosteroid cream, [s2]halcinonide[e2] cream 0.1%, under occlusion.
+	(11, 25)	postprandial hyperglycemia	betamethasone valerate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6729	A second patient with a similar glucose tolerance test result showed [s1]postprandial hyperglycemia[e1] when treated similarly with [s2]betamethasone valerate[e2] cream 0.1%.
+	(4, 17)	nefazodone	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6730	"After 1 week of [s1]nefazodone[e1] therapy the patient experienced headache, [s2]confusion[e2]  and ""gray areas"" in her vision, without abnormal ophthalmologic findings."
+	(4, 20)	nefazodone	gray areas	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6731	After 1 week of [s1]nefazodone[e1] therapy the patient experienced headache, confusion, and  [s2]gray areas[e2]  in her vision, without abnormal ophthalmologic findings.
+	(4, 15)	nefazodone	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6732	"After 1 week of [s1]nefazodone[e1] therapy the patient experienced [s2]headache[e2]  confusion, and ""gray areas"" in her vision, without abnormal ophthalmologic findings."
+	(13, 43)	nefazodone	interfere with tacrolimus metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6733	Coadministration of antidepressant agents such as [s1]nefazodone[e1]  or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to [s2]interfere with tacrolimus metabolism[e2] 
+	(42, 51)	interfere with tacrolimus metabolism	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6734	Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to [s1]interfere with tacrolimus metabolism[e1]  [s2]tacrolimus[e2] metabolism.
+	(0, 9)	Interaction	nefazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6735	 [s1]Interaction[e1] between tacrolimus and [s2]nefazodone[e2] in a stable renal transplant recipient.
+	(0, 4)	Interaction	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6736	 [s1]Interaction[e1] between [s2]tacrolimus[e2] and nefazodone in a stable renal transplant recipient.
+	(3, 10)	nefazodone	inhibits metabolism of tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6737	We suspect that [s1]nefazodone[e1]  [s2]inhibits metabolism of tacrolimus[e2] 
+	(8, 18)	inhibits metabolism of tacrolimus	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6738	We suspect that nefazodone [s1]inhibits metabolism of tacrolimus[e1]  [s2]tacrolimus[e2] 
+	(5, 24)	intoxication	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6739	We report the case of [s1]intoxication[e1] of a 41-year-old female patient suffering from major depression with [s2]mirtazapine[e2] complicated by severe hypothermia.
+	(22, 28)	acute vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6740	CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to [s1]acute vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
+	(16, 25)	hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6741	CONCLUSION: We report a case of the use of pamidronate for significant [s1]hypercalcemia[e1] secondary to acute [s2]vitamin D[e2] poisoning.
+	(17, 23)	acute vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6742	Pamidronate therapy should be considered in patients with hypercalcemia secondary to [s1]acute vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
+	(11, 20)	hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6743	Pamidronate therapy should be considered in patients with [s1]hypercalcemia[e1] secondary to acute [s2]vitamin D[e2] poisoning.
+	(9, 16)	furosemide	congestive heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6744	The patient was initially treated with hydration and [s1]furosemide[e1] but developed [s2]congestive heart failure[e2] 
+	(15, 22)	vitamin D intoxication	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6745	The use of pamidronate for hypercalcemia secondary to acute [s1]vitamin D intoxication[e1]  [s2]vitamin D[e2] intoxication.
+	(12, 24)	severe hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6746	We report the use of pamidronate for acute, [s1]severe hypercalcemia[e1] secondary to iatrogenic [s2]vitamin D[e2] poisoning.
+	(22, 27)	vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6747	We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic [s1]vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
+	(22, 34)	MTX	overwhelming hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6748	A 40-year-old man with a long standing history of rheumatoid arthritis was treated with [s1]MTX[e1] over a 6 month period and developed an [s2]overwhelming hepatic necrosis[e2] 
+	(0, 8)	Methotrexate	hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6749	 [s1]Methotrexate[e1] induced [s2]hepatic necrosis[e2] requiring liver transplantation in a patient with rheumatoid arthritis.
+	(0, 5)	MTX	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6750	 [s1]MTX[e1] induced [s2]hepatic injury[e2] and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.
+	(0, 10)	MTX	liver enzyme elevations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6751	 [s1]MTX[e1] induced hepatic injury and [s2]liver enzyme elevations[e2] have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.
+	(9, 22)	vinorelbine	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6752	Clinicians should be aware of the possibility that [s1]vinorelbine[e1] may cause SIADH and possibly [s2]hypokalemia[e2] 
+	(9, 17)	vinorelbine	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6753	Clinicians should be aware of the possibility that [s1]vinorelbine[e1] may cause [s2]SIADH[e2] and possibly hypokalemia.
+	(16, 28)	vinorelbine	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6754	CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, [s1]vinorelbine[e1] is believed to be responsible for [s2]SIADH[e2] in our patient.
+	(14, 21)	SIADH	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6755	OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone  [s1]SIADH[e1]  associated with [s2]vinorelbine[e2] therapy for advanced breast cancer.
+	(6, 23)	syndrome of inappropriate antidiuretic hormone	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6756	OBJECTIVE: To describe onset of [s1]syndrome of inappropriate antidiuretic hormone[e1] (SIADH) associated with [s2]vinorelbine[e2] therapy for advanced breast cancer.
+	(0, 12)	Syndrome of inappropriate antidiuretic hormone	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6757	 [s1]Syndrome of inappropriate antidiuretic hormone[e1] associated with [s2]vinorelbine[e2] therapy.
+	(0, 11)	Pirmenol hydrochloride	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6758	 [s1]Pirmenol hydrochloride[e1] induced [s2]QT prolongation[e2] and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation.
+	(0, 17)	Pirmenol hydrochloride	T wave inversion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6759	 [s1]Pirmenol hydrochloride[e1] induced QT prolongation and [s2]T wave inversion[e2] on electrocardiogram during treatment for symptomatic atrial fibrillation.
+	(14, 21)	pirmenol	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6760	Thus, an immunological mechanism might be involved in the mechanism of [s1]pirmenol[e1] induced [s2]QT prolongation[e2] and T wave inversion on the electrocardiogram.
+	(14, 27)	pirmenol	T wave inversion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6761	Thus, an immunological mechanism might be involved in the mechanism of [s1]pirmenol[e1] induced QT prolongation and [s2]T wave inversion[e2] on the electrocardiogram.
+	(29, 60)	prolongation of the QT interval	pirmenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6762	We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked [s1]prolongation of the QT interval[e1] and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral [s2]pirmenol[e2] therapy.
+	(38, 60)	T wave inversion	pirmenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6763	We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and [s1]T wave inversion[e1] on electrocardiogram was demonstrated reproducibly shortly after the administration of oral [s2]pirmenol[e2] therapy.
+	(10, 17)	myositis	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6764	Disseminated muscular cysticercosis with [s1]myositis[e1] induced by [s2]praziquantel[e2] therapy.
+	(22, 46)	diffuse myalgia	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6765	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, [s1]diffuse myalgia[e1]  weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
+	(19, 45)	fever	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6766	We describe a case of disseminated muscular cysticercosis followed by myositis  [s1]fever[e1]  diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
+	(34, 46)	inflammatory reaction around dying cysticerci	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6767	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and [s1]inflammatory reaction around dying cysticerci[e1]  induced by [s2]praziquantel[e2] therapy, an event not described previously.
+	(16, 47)	myositis	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6768	We describe a case of disseminated muscular cysticercosis followed by [s1]myositis[e1] (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
+	(27, 46)	weakness of the lower limbs	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6769	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, [s1]weakness of the lower limbs[e1]  and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
+	(0, 11)	Massive subfascial hematoma	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6770	 [s1]Massive subfascial hematoma[e1] after [s2]alteplase[e2] therapy for acute myocardial infarction.
+	(12, 21)	alteplase	subfascial hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6771	Physicians should be aware of the possible association between the use of [s1]alteplase[e1] and the development of [s2]subfascial hemorrhage[e2] 
+	(10, 26)	alteplase	subfascial hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6772	The authors report a case of a patient who received [s1]alteplase[e1] for acute myocardial infarction and developed spontaneous [s2]subfascial hematoma[e2] without any evidence of direct trauma.
+	(3, 25)	cutaneous ecchymosis	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6773	The development of [s1]cutaneous ecchymosis[e1] associated with a sudden fall in hemoglobin after the administration of [s2]alteplase[e2] should strongly suggest the possibility of diffuse subfascial hematoma.
+	(23, 34)	alteplase	diffuse subfascial hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6774	The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of [s1]alteplase[e1] should strongly suggest the possibility of [s2]diffuse subfascial hematoma[e2] 
+	(12, 25)	sudden fall in hemoglobin	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6775	The development of cutaneous ecchymosis associated with a [s1]sudden fall in hemoglobin[e1] after the administration of [s2]alteplase[e2] should strongly suggest the possibility of diffuse subfascial hematoma.
+	(1, 12)	fatal case of pancytopenia	levomepromazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6776	A [s1]fatal case of pancytopenia[e1] due to [s2]levomepromazine[e2] 
+	(1, 39)	fatal pancytopenia	diazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6777	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, [s2]diazepam[e2] and lithium carbonate.
+	(1, 33)	fatal pancytopenia	levomepromazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6778	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with [s2]levomepromazine[e2]  diazepam and lithium carbonate.
+	(1, 43)	fatal pancytopenia	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6779	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and [s2]lithium carbonate[e2] 
+	(0, 6)	Amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6780	 [s1]Amiodarone[e1] induced [s2]thyrotoxicosis[e2] associated with thyrotropin receptor antibody.
+	(0, 13)	Amiodarone	thyrotropin receptor antibody	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6781	 [s1]Amiodarone[e1] induced thyrotoxicosis associated with [s2]thyrotropin receptor antibody[e2] 
+	(29, 39)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6782	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed [s2]thyrotoxicosis[e2] with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).
+	(29, 71)	amiodarone	thyrotropin-binding inhibiting immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6783	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or [s2]thyrotropin-binding inhibiting immunoglobulin[e2] (TBII).
+	(29, 52)	amiodarone	transiently positive thyrotropin (TSH) receptor antibody	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6784	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed thyrotoxicosis with subacute onset, accompanied by [s2]transiently positive thyrotropin (TSH) receptor antibody[e2] (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).
+	(1, 27)	amiodarone	AIT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6785	Since [s1]amiodarone[e1] was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis  [s2]AIT[e2]  has been increasing.
+	(1, 22)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6786	Since [s1]amiodarone[e1] was first marketed in 1992 in Japan, the incidence of amiodarone-induced [s2]thyrotoxicosis[e2] (AIT) has been increasing.
+	(24, 30)	amiodarone	destructive thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6787	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced [s2]destructive thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
+	(24, 30)	amiodarone	destructive thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6788	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced [s2]destructive thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
+	(24, 31)	amiodarone	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6789	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced destructive [s2]thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
+	(9, 26)	TRAb/TBII without thyroid-stimulating activity	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6790	These in vitro findings and clinical course suggest that [s1]TRAb/TBII without thyroid-stimulating activity[e1] may develop in patients with [s2]amiodarone[e2] induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
+	(2, 11)	Lipoid pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6791	CONCLUSION: [s1]Lipoid pneumonia[e1] as a result of [s2]mineral oil[e2] aspiration still occurs in the pediatric population.
+	(11, 23)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6792	In patients with swallowing dysfunction and pneumonia, a history of [s1]mineral oil[e1] use should be obtained and a diagnosis of [s2]ELP[e2] should be considered in the differential diagnoses if mineral oil use has occurred.
+	(11, 23)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6793	In patients with swallowing dysfunction and pneumonia, a history of [s1]mineral oil[e1] use should be obtained and a diagnosis of [s2]ELP[e2] should be considered in the differential diagnoses if mineral oil use has occurred.
+	(6, 12)	pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6794	In patients with swallowing dysfunction and [s1]pneumonia[e1]  a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
+	(6, 12)	pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6795	In patients with swallowing dysfunction and [s1]pneumonia[e1]  a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
+	(3, 13)	swallowing dysfunction	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6796	In patients with [s1]swallowing dysfunction[e1] and pneumonia, a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
+	(3, 13)	swallowing dysfunction	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6797	In patients with [s1]swallowing dysfunction[e1] and pneumonia, a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
+	(0, 10)	Lipoid pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6798	 [s1]Lipoid pneumonia[e1]  a silent complication of [s2]mineral oil[e2] aspiration.
+	(0, 19)	Mineral oil	impair mucociliary transport	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6799	 [s1]Mineral oil[e1]  a hydrocarbon, may not elicit a normal protective cough reflex and may [s2]impair mucociliary transport[e2] 
+	(16, 21)	potential hazards	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6800	Our case points to the need for increased awareness by the general pediatricians of the [s1]potential hazards[e1] of [s2]mineral oil[e2] use for chronic constipation.
+	(2, 29)	ELP	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6801	Treatment of [s1]ELP[e1] in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of [s2]mineral oil[e2] 
+	(14, 29)	roentgenographic abnormalities	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6802	Treatment of ELP in children is generally supportive, with the symptoms and [s1]roentgenographic abnormalities[e1] resolving within months after stopping the use of [s2]mineral oil[e2] 
+	(26, 46)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6803	We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic [s1]mineral oil[e1] ingestion presenting as asymptomatic exogenous lipoid pneumonia  [s2]ELP[e2] .
+	(26, 40)	mineral oil	exogenous lipoid pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6804	We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic [s1]mineral oil[e1] ingestion presenting as asymptomatic [s2]exogenous lipoid pneumonia[e2] (ELP).
+	(4, 18)	burn injury	psoralens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6805	An unusual cause of [s1]burn injury[e1]  unsupervised use of drugs that contain [s2]psoralens[e2] 
+	(1, 16)	psoralens	phototoxic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6806	Because [s1]psoralens[e1] sensitize skin to ultraviolet A light, [s2]phototoxic reactions[e2] are the most frequent adverse effect of this treatment.
+	(23, 32)	intense burn	8-methoxypsoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6807	In this article, we present the case of a vitiligo patient who was admitted to our facility with an [s1]intense burn[e1] after the topical use of [s2]8-methoxypsoralen[e2] solution as a suntanning agent.
+	(9, 27)	psoralen	skin extremely sensitive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6808	Sunburn may sometimes be a major injury in [s1]psoralen[e1] users because high doses or inappropriate use of the drug may render the [s2]skin extremely sensitive[e2] 
+	(0, 11)	Sunburn	psoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6809	 [s1]Sunburn[e1] may sometimes be a major injury in [s2]psoralen[e2] users because high doses or inappropriate use of the drug may render the skin extremely sensitive.
+	(2, 15)	Metoclopramide	nonthrombocytopenic vascular-type palpable purpura	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6810	CONCLUSIONS: [s1]Metoclopramide[e1] may cause reversible [s2]nonthrombocytopenic vascular-type palpable purpura[e2] 
+	(10, 28)	nonthrombocytopenic palpable purpura	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6811	OBJECTIVE: To report a case of reversible [s1]nonthrombocytopenic palpable purpura[e1] associated with [s2]metoclopramide[e2] 
+	(3, 21)	nonthrombocytopenic palpable purpura	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6812	Reversible [s1]nonthrombocytopenic palpable purpura[e1] associated with [s2]metoclopramide[e2] 
+	(0, 16)	Lithium	diabetes insipidus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6813	 [s1]Lithium[e1] treatment was terminated in 1975 because of lithium intoxication with a [s2]diabetes insipidus-like syndrome[e2] 
+	(8, 16)	lithium	diabetes insipidus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6814	Lithium treatment was terminated in 1975 because of [s1]lithium[e1] intoxication with a [s2]diabetes insipidus-like syndrome[e2] 
+	(0, 10)	Lithium	lithium intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6815	 [s1]Lithium[e1] treatment was terminated in 1975 because of [s2]lithium intoxication[e2] with a diabetes insipidus-like syndrome.
+	(8, 14)	lithium intoxication	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6816	Lithium treatment was terminated in 1975 because of [s1]lithium intoxication[e1]  [s2]lithium[e2] intoxication with a diabetes insipidus-like syndrome.
+	(0, 9)	Eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6817	 [s1]Eosinophilia[e1] caused by [s2]clozapine[e2] was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).
+	(0, 20)	Eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6818	 [s1]Eosinophilia[e1] has been encountered from 0.2 to 61.7% in [s2]clozapine[e2] treated patients, mostly with a transient course and spontaneous remission.
+	(3, 12)	clozapine	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6819	Successful challenge with [s1]clozapine[e1] in a history of [s2]eosinophilia[e2] 
+	(20, 27)	methotrexate	1500 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	0	An episode of subacute encephalopathy after the infusion of a moderate dose of [s1]methotrexate[e1]  [s2]1500 mg/m2[e2]  (MTX) is reported in a young adult with metastastic gastric cancer.
+	(5, 8)	insulin	4 times per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	1	She continued to receive regular [s1]insulin[e1]  [s2]4 times per day[e2] over the following 3 years with only occasional hives.
+	(16, 21)	1 drop	brimonidine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	2	A 5-month-old infant became lethargic and poorly responsive after receiving [s1]1 drop[e1] of [s2]brimonidine[e2] in each eye.
+	(6, 10)	200 mg	TCA	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	3	The presented patient was treated with [s1]200 mg[e1]  [s2]TCA[e2] and developed Cushing's syndrome 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).
+	(7, 13)	ibuprofen	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	4	Central nervous system manifestations of an [s1]ibuprofen[e1]  [s2]overdose[e2] reversed by naloxone.
+	(0, 6)	Ibuprofen	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	5	 [s1]Ibuprofen[e1]  [s2]overdose[e2] is usually characterized by GI upset, dizziness, and mild sedation.
+	(20, 24)	low	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	6	In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and [s1]low[e1] dose [s2]methotrexate[e2] therapy might have promoted the development of lung cancer.
+	(14, 18)	high	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	7	A case of normotensive scleroderma renal crisis after [s1]high[e1] dose [s2]methylprednisolone[e2] treatment.
+	(20, 26)	regular	colchicine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	8	A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a [s1]regular[e1] dosage of [s2]colchicine[e2] 
+	(7, 12)	25 UI	Miacalcic	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	9	The intramuscular challenge test with [s1]25 UI[e1] of [s2]Miacalcic[e2] was positive with an immediate anaphylactic reaction.
+	(11, 16)	ARA-C	2 g/m2 intravenously every 12 hours	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	10	On the fifth day after administration of a high dose of [s1]ARA-C[e1]  [s2]2 g/m2 intravenously every 12 hours[e2] , she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.
+	(8, 13)	high	ARA-C	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	11	On the fifth day after administration of a [s1]high[e1] dose of [s2]ARA-C[e2] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.
+	(11, 15)	high	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	12	Toxic epidermal necrolysis after the use of [s1]high[e1] dose [s2]cytosine arabinoside[e2] 
+	(19, 30)	high	ARA-C	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	13	We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a [s1]high[e1] dose of cytosine arabinoside  [s2]ARA-C[e2] .
+	(19, 24)	high	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	14	We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a [s1]high[e1] dose of [s2]cytosine arabinoside[e2] (ARA-C).
+	(14, 20)	clomipramine	150 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	15	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1]  [s2]150 mg/d[e2]  he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.
+	(3, 20)	clozapine	150 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	16	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine [s2]150 mg/d[e2]  he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.
+	(13, 17)	15 mg	meloxicam	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	17	We describe a patient who presented with bloody diarrhoea after [s1]15 mg[e1]  [s2]meloxicam[e2] daily for 10 days for osteoarthritis.
+	(22, 45)	lansoprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	18	Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, [s1]lansoprazole[e1]  or pantoprazole for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
+	(17, 45)	omeprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	19	Pheripheral edema was observed in five female patients after taking proton pump inhibitors [s1]omeprazole[e1]  lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
+	(28, 46)	pantoprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	20	Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or [s1]pantoprazole[e1] for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
+	(29, 34)	12 mg	adenosine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	21	We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given [s1]12 mg[e1] of [s2]adenosine[e2] 
+	(4, 15)	methylprednisolone	40 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	22	After the dose of [s1]methylprednisolone[e1] was reduced from [s2]40 mg[e2] to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.
+	(16, 20)	CBZ	OD	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	23	Continuous EEG monitoring is helpful in managing seizures that occur as a complication of [s1]CBZ[e1]  [s2]OD[e2]  after the course of recovery or worsening, and in providing assistance with prognosis.
+	(1, 5)	CBZ	OD	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	24	Massive [s1]CBZ[e1]  [s2]OD[e2] may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.
+	(39, 43)	taxol	80 mg/m(2)x3	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	25	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly [s1]taxol[e1]  [s2]80 mg/m(2)x3[e2] .
+	(8, 12)	low	IFN-alpha	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	26	Myasthenia gravis during [s1]low[e1] dose [s2]IFN-alpha[e2] therapy for chronic hepatitis C.
+	(21, 26)	100 mg	sodium aurothiomalate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	27	A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after [s1]100 mg[e1] of [s2]sodium aurothiomalate[e2] 
+	(2, 6)	LTG	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	28	CONCLUSIONS: [s1]LTG[e1]  [s2]overdose[e2] may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.
+	(14, 18)	overdose	lamotrigine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	29	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with [s2]lamotrigine[e2] (LTG) and valproic acid (VPA) tablets.
+	(14, 23)	overdose	LTG	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	30	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine  [s2]LTG[e2]  and valproic acid (VPA) tablets.
+	(14, 28)	overdose	valproic acid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	31	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine (LTG) and [s2]valproic acid[e2] (VPA) tablets.
+	(14, 32)	overdose	VPA	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	32	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine (LTG) and valproic acid  [s2]VPA[e2]  tablets.
+	(29, 37)	10 g	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	33	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of [s1]10 g[e1] and 4 g of [s2]carbamazepine[e2] respectively.
+	(32, 37)	4 g	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	34	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and [s1]4 g[e1] of [s2]carbamazepine[e2] respectively.
+	(48, 53)	2 mg	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	35	We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including [s1]2 mg[e1] of [s2]vincristine[e2] 
+	(12, 17)	benztropine	abuse	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	36	A 33-year-old man with a history of recreational [s1]benztropine[e1]  [s2]abuse[e2] presented to the emergency department with confusion, abdominal pain, and distention.
+	(35, 53)	metoclopramide	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	37	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when [s1]metoclopramide[e1] is coadministered even in a single, [s2]conventional[e2] dose.
+	(25, 53)	sertraline	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	38	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving [s1]sertraline[e1] or venlafaxine when metoclopramide is coadministered even in a single, [s2]conventional[e2] dose.
+	(29, 53)	venlafaxine	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	39	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or [s1]venlafaxine[e1] when metoclopramide is coadministered even in a single, [s2]conventional[e2] dose.
+	(5, 11)	lansoprazole	60 mg twice daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	40	He was started on oral [s1]lansoprazole[e1]  [s2]60 mg twice daily[e2] and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).
+	(11, 20)	mitomycin C	144 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	41	We describe a patient who developed HUS after treatment with [s1]mitomycin C[e1] (total dose [s2]144 mg/m2[e2]  due to a carcinoma of the ascending colon.
+	(15, 31)	rosiglitazone	4 mg twice/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	42	A 53-year-old man developed lower leg edema 4 weeks after [s1]rosiglitazone[e1] was increased from 4 mg once/day to [s2]4 mg twice/day[e2] 
+	(21, 26)	lidocaine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	43	We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to [s1]lidocaine[e1]  [s2]overdose[e2] 
+	(5, 9)	low	vasopressin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	44	CONCLUSIONS: Peripheral administration of [s1]low[e1] dose [s2]vasopressin[e2] for septic shock should be discouraged because of the risk of ischemic skin complications.
+	(23, 28)	500 mg	ticlopidine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	45	The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with [s1]500 mg[e1] of [s2]ticlopidine[e2] daily.
+	(5, 30)	gemcitabine	21.9 +/- 10.9	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	46	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of HUS was 7.4 +/- 3.5 months, or [s2]21.9 +/- 10.9[e2] doses of gemcitabine.
+	(5, 30)	gemcitabine	21.9 +/- 10.9	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	47	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of HUS was 7.4 +/- 3.5 months, or [s2]21.9 +/- 10.9[e2] doses of gemcitabine.
+	(7, 14)	amiodarone HCl	200 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	48	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1]  [s2]200 mg/day[e2] , a 76-year-old man came to us with symptoms of visual ""shining,"" glare, color vision anomalies, and gradually decreased vision."
+	(6, 10)	high	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	49	Successful desensitization to [s1]high[e1] dose [s2]methotrexate[e2] after systemic anaphylaxis.
+	(1, 8)	40 mg/day	prednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	50	While [s1]40 mg/day[e1] of [s2]prednisolone[e2] improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.
+	(19, 32)	clonazepam	0.02 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	51	This report describes an individual with mental retardation who experienced behavioral exacerbation associated with [s1]clonazepam[e1] prescribed at 2 mg/day  [s2]0.02 mg/kg/day[e2]  to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method.
+	(9, 20)	high doses	vecuronium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	52	This entity is probably related to a combination of [s1]high doses[e1] of corticosteroids, [s2]vecuronium[e2] administration and metabolic abnormalities associated with respiratory failure.
+	(20, 33)	bleomycin	100 U	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	53	We describe the development of cutaneous scleroderma in 3 patients coincident with the use of [s1]bleomycin[e1] in low cumulative doses of less than [s2]100 U[e2] 
+	(24, 47)	low or moderate dosage	CBZ	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	54	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
+	(24, 39)	low or moderate dosage	clozapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	55	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
+	(24, 37)	low or moderate dosage	lithium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	56	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
+	(31, 38)	400 mg/day	L-dopa	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	57	A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with [s1]400 mg/day[e1] of [s2]L-dopa[e2] 
+	(15, 20)	900 mg	glyburide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	58	We present a case of a 20-year-old woman who ingested [s1]900 mg[e1] of [s2]glyburide[e2] causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide.
+	(17, 24)	dexamethasone	10 mg/m(2)/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	59	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1]  [s2]10 mg/m(2)/day[e2] for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
+	(17, 24)	dexamethasone	10 mg/m(2)/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	60	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1]  [s2]10 mg/m(2)/day[e2] for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
+	(4, 12)	vitamin D3	20 micro g/g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	61	After initiation of topical [s1]vitamin D3[e1] ointment  [s2]20 micro g/g[e2] of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.
+	(21, 29)	ciprofloxacin	250 mg bid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	62	DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with [s1]ciprofloxacin[e1]  [s2]250 mg bid[e2]  treatment.
+	(11, 15)	high	colchicine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	63	However here we reported two patients, presenting with PD during [s1]high[e1] dose [s2]colchicine[e2] treatment for familiar mediterranean fever (FMF).
+	(9, 14)	overdose	pilocarpine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	64	We report a case of unintentional [s1]overdose[e1] of oral [s2]pilocarpine[e2] tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.
+	(37, 41)	BCNU	600 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	65	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose [s1]BCNU[e1]  [s2]600 mg/m2[e2] .
+	(34, 39)	high-dose	BCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	66	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of [s1]high-dose[e1]  [s2]BCNU[e2] (600 mg/m2).
+	(8, 14)	nimodipine	overdosage	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	67	In this paper we report a case of [s1]nimodipine[e1]  [s2]overdosage[e2] resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.
+	(0, 5)	Tiagabine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	68	 [s1]Tiagabine[e1]  [s2]overdose[e2] causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use.
+	(7, 29)	CAP	2000 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	69	Neurologic symptoms resolved after stopping [s1]CAP[e1] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at [s2]2000 mg/m2[e2] 
+	(7, 29)	CAP	2000 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	70	Neurologic symptoms resolved after stopping [s1]CAP[e1] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at [s2]2000 mg/m2[e2] 
+	(14, 20)	CAP-XRT	1600 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	71	Patient A reported right leg weakness (foot drop) during week 4 of [s1]CAP-XRT[e1]  [s2]1600 mg/m2[e2] .
+	(19, 23)	CAP	2500 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	72	Patient B developed perioral and upper extremity paresthesias during the fourth cycle of [s1]CAP[e1] alone  [s2]2500 mg/m2[e2] .
+	(8, 37)	quetiapine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	73	In all cases, drugs in addition to [s1]quetiapine[e1] were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine [s2]overdose[e2] and the other drugs were not considered to be contributory.
+	(18, 25)	overdose	quetiapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	74	We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal [s1]overdose[e1] deaths were associated with [s2]quetiapine[e2] 
+	(11, 17)	flupirtine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	75	Paradoxical cerebral cortical hyperexcitability following [s1]flupirtine[e1]  [s2]overdose[e2] 
+	(21, 28)	400 mg/day	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	76	The patient was found to have no motile sperm with a normal sperm count, while taking a dose of [s1]400 mg/day[e1] of [s2]carbamazepine[e2] 
+	(18, 23)	higher doses	quetiapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	77	A 64-year-old man with schizophrenia developed myoclonic jerks when given [s1]higher doses[e1] of [s2]quetiapine[e2] 
+	(15, 22)	cerivastatin	0.15 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	78	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1]  [s2]0.15 mg/day[e2]  for 22 days complained of general muscle weakness and muscle pain.
+	(0, 12)	Carboplatin	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	79	 [s1]Carboplatin[e1] hypersensitivity induced by [s2]low-dose[e2] paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
+	(10, 19)	low-dose	carboplatin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	80	Carboplatin hypersensitivity induced by [s1]low-dose[e1] paclitaxel [s2]carboplatin[e2] in multiple platinum-treated patients with recurrent ovarian cancer.
+	(10, 15)	low-dose	paclitaxel	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	81	Carboplatin hypersensitivity induced by [s1]low-dose[e1]  [s2]paclitaxel[e2] carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
+	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	82	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
+	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	83	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
+	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	84	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
+	(5, 29)	carboplatin	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	85	We report five cases of [s1]carboplatin[e1] (CBDCA) hypersensitivity after weekly low-dose paclitaxel  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(9, 27)	CBDCA	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	86	We report five cases of carboplatin  [s1]CBDCA[e1]  hypersensitivity after weekly low-dose paclitaxel  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(23, 29)	paclitaxel	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	87	We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose [s1]paclitaxel[e1]  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(5, 22)	carboplatin	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	88	We report five cases of [s1]carboplatin[e1] (CBDCA) hypersensitivity after weekly [s2]low-dose[e2] paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(9, 20)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	89	We report five cases of carboplatin  [s1]CBDCA[e1]  hypersensitivity after weekly [s2]low-dose[e2] paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(20, 25)	low-dose	paclitaxel	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	90	We report five cases of carboplatin (CBDCA) hypersensitivity after weekly [s1]low-dose[e1]  [s2]paclitaxel[e2] (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
+	(6, 9)	massive	fluoxetine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	91	We report an unusual case of [s1]massive[e1]  [s2]fluoxetine[e2] ingestion resulting in neurological and cardiovascular toxicity resulting in death.
+	(16, 22)	iron sucrose	16 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	92	The case reported here is of a child given a large dose of intravenous [s1]iron sucrose[e1]  [s2]16 mg/kg[e2]  over 3 hours, who subsequently developed features of systemic iron toxicity.
+	(6, 11)	high-dose	busulfan	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	93	Fatal radiation myelopathy after [s1]high-dose[e1]  [s2]busulfan[e2] and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
+	(6, 15)	high-dose	melphalan	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	94	Fatal radiation myelopathy after [s1]high-dose[e1] busulfan and [s2]melphalan[e2] chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
+	(6, 12)	epinephrine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	95	Inadvertent and accidental [s1]epinephrine[e1]  [s2]overdose[e2] might result in potentially lethal complications.
+	(6, 14)	high-dose	phenylephrine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	96	Prominent positive U waves appearing with [s1]high-dose[e1] intravenous [s2]phenylephrine[e2] 
+	(24, 31)	venlafaxine	75 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	97	A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with [s1]venlafaxine[e1]  [s2]75 mg/day[e2] 
+	(30, 37)	methotrexate	5 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	98	A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high-dose [s1]methotrexate[e1]  [s2]5 g/m2[e2]  infusion.
+	(27, 32)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	99	A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous [s1]high-dose[e1]  [s2]methotrexate[e2] (5 g/m2) infusion.
+	(0, 5)	High-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	100	 [s1]High-dose[e1]  [s2]methotrexate[e2] associated acute renal failure may be an avoidable complication.
+	(28, 33)	500 mg	cloxacillin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	101	A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting [s1]500 mg[e1] of [s2]cloxacillin[e2] for a skin abscess.
+	(8, 13)	high-dose	carmustine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	102	Myocardial ischemia associated with [s1]high-dose[e1]  [s2]carmustine[e2] infusion.
+	(8, 13)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	103	Acute myocardial infarction during [s1]high-dose[e1]  [s2]methylprednisolone[e2] therapy for Graves' ophthalmopathy.
+	(15, 20)	high-dose	glucocorticoids	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	104	We conclude that myocardial infarction may develop in patients treated with [s1]high-dose[e1]  [s2]glucocorticoids[e2] for Graves' ophthalmopathy, and increased blood pressure may herald this complication.
+	(17, 22)	35 g	caffeine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	105	We present the case of a 58-year-old woman who ingested more than [s1]35 g[e1] of [s2]caffeine[e2] in a suicide attempt.
+	(0, 6)	Flecainide	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	106	 [s1]Flecainide[e1]  [s2]overdose[e2] can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality.
+	(5, 11)	flecainide	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	107	Managing cardiovascular collapse in severe [s1]flecainide[e1]  [s2]overdose[e2] without recourse to extracorporeal therapy.
+	(20, 24)	114 g	metronidazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	108	Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and [s1]114 g[e1]  [s2]metronidazole[e2] respectively.
+	(16, 24)	30.6	metronidazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	109	Two patients are described who developed sensory neuropathy after the ingestion of [s1]30.6[e1] and 114 g [s2]metronidazole[e2] respectively.
+	(19, 26)	methotrexate	15 mg/week	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	110	We report a case of a patient with rheumatoid arthritis treated with low-dose [s1]methotrexate[e1]  [s2]15 mg/week[e2]  who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.
+	(16, 21)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	111	We report a case of a patient with rheumatoid arthritis treated with [s1]low-dose[e1]  [s2]methotrexate[e2] (15 mg/week) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.
+	(18, 23)	low-dose	acetylsalicylic acid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	112	The authors describe pericardial hemorrhage, which is related to the use of [s1]low-dose[e1]  [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
+	(6, 11)	low-dose	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	113	Hyponatraemia during [s1]low-dose[e1]  [s2]carbamazepine[e2] therapy.
+	(30, 38)	muzolimine	240 to 1440 mg per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	114	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic [s1]muzolimine[e1] (range [s2]240 to 1440 mg per day[e2]  fatal neuromyeloencephalopathy.
+	(21, 32)	high dosage	muzolimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	115	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a [s1]high dosage[e1] of the new diuretic [s2]muzolimine[e2] (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.
+	(13, 19)	20-mg daily	olanzapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	116	The fourth patient showed RLS symptoms that were initially caused by a [s1]20-mg daily[e1]  [s2]olanzapine[e2] dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.
+	(4, 9)	Copaxone	20 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	117	She had been on [s1]Copaxone[e1]  [s2]20 mg/day[e2] treatment for 2 years when she first exhibited gastrointestinal symptoms.
+	(3, 9)	bupropion	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	118	Multiple seizures after [s1]bupropion[e1]  [s2]overdose[e2] in a small child.
+	(24, 34)	48 mg/kg	bupropion	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	119	The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050  [s1]48 mg/kg[e1]  of extended-release [s2]bupropion[e2] 
+	(26, 32)	propafenone	900 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	120	CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking [s1]propafenone[e1]  [s2]900 mg/d[e2] for >10 years for paroxysmal atrial fibrillation without adverse effects.
+	(17, 22)	low-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	121	Hemorrhage from a falx meningioma after internal use of [s1]low-dose[e1]  [s2]aspirin[e2] 
+	(33, 38)	low-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	122	We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of [s1]low-dose[e1]  [s2]aspirin[e2] for 16 months.
+	(34, 39)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	123	CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received [s1]high-dose[e1]  [s2]methylprednisolone[e2] in late pregnancy.
+	(0, 5)	High-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	124	 [s1]High-dose[e1]  [s2]methylprednisolone[e2] in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.
+	(61, 72)	methotrexate	12 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	125	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose [s1]methotrexate[e1] (MTX)  [s2]12 g/m2[e2] , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
+	(66, 70)	MTX	12 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	126	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate  [s1]MTX[e1]   [s2]12 g/m2[e2] , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
+	(58, 63)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	127	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of [s1]high-dose[e1]  [s2]methotrexate[e2] (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
+	(58, 68)	high-dose	MTX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	128	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of [s1]high-dose[e1] methotrexate  [s2]MTX[e2]  (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
+	(6, 11)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	129	Early recognition of renal toxicity of [s1]high-dose[e1]  [s2]methotrexate[e2] therapy: a case report.
+	(8, 30)	dexmedetomidine	5.0 microg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	130	We report on three cases wherein treatment of [s1]dexmedetomidine[e1] induced bradycardia with i.v. glycopyrrolate  [s2]5.0 microg/kg[e2]  not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.
+	(23, 31)	glycopyrrolate	5.0 microg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	131	We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. [s1]glycopyrrolate[e1]  [s2]5.0 microg/kg[e2]  not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.
+	(10, 17)	bevacizumab	1.25 mg in 0.1 ml	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	132	Three days after receiving intravitreal injection of [s1]bevacizumab[e1]  [s2]1.25 mg in 0.1 ml[e2] , he developed acute vision loss and change of consciousness.
+	(8, 14)	adalimumab	160 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	133	One week after the initial-dose of [s1]adalimumab[e1]  [s2]160 mg[e2] , which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy.
+	(7, 12)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	134	Hepatotoxicity after [s1]high-dose[e1]  [s2]methylprednisolone[e2] for demyelinating disease.
+	(13, 18)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	135	We observed 2 cases of hepatotoxicity after a [s1]high-dose[e1]  [s2]methylprednisolone[e2] treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence.
+	(21, 26)	imatinib	400 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	136	CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with [s1]imatinib[e1]  [s2]400 mg/d[e2] 
+	(15, 20)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	137	Bulbar and pseudobulbar palsy complicating therapy with [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] in children with leukemia.
+	(9, 17)	lacosamide	600 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	138	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to [s2]600 mg/day[e2] include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).
+	(56, 64)	methotrexate	12 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	139	An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 [s1]methotrexate[e1] and [s2]12 mg[e2] intrathecal methotrexate.
+	(52, 58)	500 mg/m2	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	140	An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of [s1]500 mg/m2[e1]  [s2]methotrexate[e2] and 12 mg intrathecal methotrexate.
+	(8, 14)	glipizide	10 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	141	An 83-year-old man receiving [s1]glipizide[e1]  [s2]10 mg[e2] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.
+	(12, 48)	10 mg	SMX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	142	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP [s2]SMX[e2]  to his regimen.
+	(12, 37)	10 mg	sulfamethoxazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	143	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim [s2]sulfamethoxazole[e2] (TMP/SMX) to his regimen.
+	(12, 45)	10 mg	TMP	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	144	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole  [s2]TMP[e2] SMX) to his regimen.
+	(12, 33)	10 mg	trimethoprim	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	145	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding [s2]trimethoprim[e2] sulfamethoxazole (TMP/SMX) to his regimen.
+	(35, 43)	5 g/m2	ifosfamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	146	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after [s1]5 g/m2[e1] bolus [s2]ifosfamide[e2] 
+	(7, 11)	high dose	ifosfamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	147	Lethal anuria complicating [s1]high dose[e1]  [s2]ifosfamide[e2] chemotherapy in a breast cancer patient with an impaired renal function.
+	(16, 21)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	148	Horner's syndrome and demyelinating peripheral neuropathy caused by [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
+	(10, 15)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	149	Peripheral nerve dysfunction is a potentially serious complication of [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
+	(30, 35)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	150	We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
+	(11, 15)	low dose	cyclophosphamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	151	Life-threatening acute hyponatraemia induced by [s1]low dose[e1]  [s2]cyclophosphamide[e2] and indomethacin.
+	(11, 22)	low dose	indomethacin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	152	Life-threatening acute hyponatraemia induced by [s1]low dose[e1] cyclophosphamide and [s2]indomethacin[e2] 
+	(31, 38)	low dose	cyclophosphamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	153	We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and [s1]low dose[e1] intravenous [s2]cyclophosphamide[e2] 
+	(26, 33)	indomethacin	low dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	154	We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral [s1]indomethacin[e1] and [s2]low dose[e2] intravenous cyclophosphamide.
+	(23, 28)	high doses	clofazimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	155	Two cases of lepromatous leprosy with erythema nodosum leprosum who were on [s1]high doses[e1] of [s2]clofazimine[e2]  showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.
+	(16, 40)	Ara-C	100 mg/m2/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	156	Paraplegia following prophylactic intrathecal cytosine arabinoside  [s1]Ara-C[e1]  is described in a patient with acute myelogenous leukemia in remission who received doses of [s2]100 mg/m2/d[e2] for 5 consecutive days.
+	(10, 42)	cytosine arabinoside	100 mg/m2/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	157	Paraplegia following prophylactic intrathecal [s1]cytosine arabinoside[e1] (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of [s2]100 mg/m2/d[e2] for 5 consecutive days.
+	(6, 12)	isotretinoin	1 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	158	Three of 50 patients treated with [s1]isotretinoin[e1]  [s2]1 mg/kg/day[e2]  for cystic acne complained of poor night vision and/or excessive glare sensitivity.
+	(9, 33)	chloral hydrate	overdosage	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	159	The pharmacology and toxicology of [s1]chloral hydrate[e1] are discussed with particular reference to the cardiac arrhythmias that are seen with [s2]overdosage[e2] 
+	(8, 13)	single dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	160	A case of severe visual loss following a [s1]single dose[e1] of [s2]vincristine[e2] is described.
+	(5, 10)	single dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	161	Severe visual loss after a [s1]single dose[e1] of [s2]vincristine[e2] in a patient with spinal cord astrocytoma.
+	(4, 10)	single small dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	162	Visual loss after a [s1]single small dose[e1] of [s2]vincristine[e2] has never been reported.
+	(19, 23)	1 g	doxycycline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	163	Renal hypophosphatemia in this patient was caused by the erroneous intake of [s1]1 g[e1]  [s2]doxycycline[e2] 
+	(7, 12)	low-dose	cyclosporine A	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	164	After a six-week course of [s1]low-dose[e1]  [s2]cyclosporine A[e2]  she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.
+	(40, 48)	propylthiouracil	100 mg orally, three times a day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	165	A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with [s1]propylthiouracil[e1]  [s2]100 mg orally, three times a day[e2] .
+	(39, 53)	D-penicillamine	1,200 g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	166	A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of [s1]D-penicillamine[e1] therapy and a cumulative dose of [s2]1,200 g[e2] 
+	(17, 22)	amiodarone	1400 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	167	We report a case of torsade de pointes following a single oral dose of [s1]amiodarone[e1]  [s2]1400 mg[e2] or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.
+	(17, 26)	amiodarone	30 mg kg-1	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	168	We report a case of torsade de pointes following a single oral dose of [s1]amiodarone[e1] (1400 mg or [s2]30 mg kg-1[e2]  administered after short intravenous loading for prevention of paroxysmal atrial flutter.
+	(5, 13)	prazosin	0.5 to 1 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	169	A small initial dose of [s1]prazosin[e1] ranging from [s2]0.5 to 1 mg[e2] has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.
+	(5, 13)	prazosin	0.5 to 1 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	170	A small initial dose of [s1]prazosin[e1] ranging from [s2]0.5 to 1 mg[e2] has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.
+	(11, 17)	phenytoin	1 g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	171	Phenytoin was discontinued after admission; however, [s1]phenytoin[e1]  [s2]1 g[e2] i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.
+	(13, 20)	carbamazepine	200 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	172	She was receiving phenytoin sodium 300 mg/day; [s1]carbamazepine[e1]  [s2]200 mg[e2] four times daily had been discontinued four days before admission because of leukopenia.
+	(3, 10)	phenytoin sodium	300 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	173	She was receiving [s1]phenytoin sodium[e1]  [s2]300 mg/day[e2]  carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.
+	(5, 10)	amiodarone	2300 mg in 3 days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	174	After therapy with parenteral [s1]amiodarone[e1]  [s2]2300 mg in 3 days[e2]  and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.
+	(67, 71)	20 mg	methimazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	175	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with [s1]20 mg[e1]  [s2]methimazole[e2] daily.
+	(3, 9)	propranolol	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	176	A case of [s1]propranolol[e1]  [s2]overdose[e2] complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.
+	(8, 14)	propranolol	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	177	Esophageal spasm following [s1]propranolol[e1]  [s2]overdose[e2] relieved by glucagon.
+	(13, 18)	low-dose	heparin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	178	Our findings suggest that hyperkalemia can develop with the use of [s1]low-dose[e1]  [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
+	(13, 18)	low-dose	heparin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	179	Our findings suggest that hyperkalemia can develop with the use of [s1]low-dose[e1]  [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
+	(18, 27)	lithium	high doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	180	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance [s1]lithium[e1] therapy developed a movement disorder following [s2]high doses[e2] of trazodone for treatment of an acute depression.
+	(25, 30)	high doses	trazodone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	181	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following [s1]high doses[e1] of [s2]trazodone[e2] for treatment of an acute depression.
+	(26, 31)	15 g	desferrioxamine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	182	Two other patients who did not receive prochlorperazine, developed retinal problems which later improved, one after only [s1]15 g[e1] of [s2]desferrioxamine[e2] 
+	(20, 25)	Intralipid	20%	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	183	Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat  [s1]Intralipid[e1]  [s2]20%[e2] .
+	(7, 15)	175 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	184	Three patients received respectively 190 mg, [s1]175 mg[e1]  and 196 mg of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
+	(4, 15)	190 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	185	Three patients received respectively [s1]190 mg[e1]  175 mg, and 196 mg of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
+	(11, 16)	196 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	186	Three patients received respectively 190 mg, 175 mg, and [s1]196 mg[e1] of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
+	(15, 20)	high-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	187	Two children with rheumatic fever developed anicteric hepatitis while on [s1]high-dose[e1]  [s2]aspirin[e2] therapy.
+	(30, 35)	300 mg	cytarabine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	188	In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of [s1]300 mg[e1] of [s2]cytarabine[e2] daily for the preceding five days.
+	(3, 8)	high-dose	tamoxifen	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	189	Four patients receiving [s1]high-dose[e1]  [s2]tamoxifen[e2] for greater than 1 year have demonstrated similar retinal changes.
+	(30, 39)	200 mg	lorcainide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	190	In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single [s1]200 mg[e1] intravenous dose of [s2]lorcainide[e2] 
+	(10, 16)	low-dosage	amiodarone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	191	In a 61-year-old man receiving chronic [s1]low-dosage[e1]  [s2]amiodarone[e2] an interstitial pneumopathy was observed.
+	(9, 15)	low-dosage	amiodarone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	192	Interstitial pneumopathy and [s1]low-dosage[e1]  [s2]amiodarone[e2] 
+	(32, 36)	80 mg	propranolol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	193	Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with [s1]80 mg[e1]  [s2]propranolol[e2] daily.
+	(6, 11)	high doses	CCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	194	Pulmonary fibrosis subsequent to [s1]high doses[e1] of [s2]CCNU[e2] for chronic myeloid leukemia.
+	(13, 17)	CCNU	1100 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	195	Two patients treated for chronic myeloid leukemia with high doses of [s1]CCNU[e1]  [s2]1100 mg/m2[e2] and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.
+	(13, 23)	CCNU	1240 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	196	Two patients treated for chronic myeloid leukemia with high doses of [s1]CCNU[e1] (1100 mg/m2 and [s2]1240 mg/m2[e2]  respectively) developed a fatal pulmonary fibrosis.
+	(10, 15)	high doses	CCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	197	Two patients treated for chronic myeloid leukemia with [s1]high doses[e1] of [s2]CCNU[e2] (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.
+	(19, 24)	fluoresone	750 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	198	Gynecomastia developed in two epileptic patients some months after the addition of oral [s1]fluoresone[e1]  [s2]750 mg[e2] daily to the phenobarbital and phenytoin already being administered.
+	(22, 29)	750 mg	phenobarbital	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	199	Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone [s1]750 mg[e1] daily to the [s2]phenobarbital[e2] and phenytoin already being administered.
+	(22, 35)	750 mg	phenytoin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	200	Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone [s1]750 mg[e1] daily to the phenobarbital and [s2]phenytoin[e2] already being administered.
+	(10, 24)	quinacrine hydrochloride	100 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	201	Drug-induced psychosis resulted from the administration of [s1]quinacrine hydrochloride[e1] at a dosage of [s2]100 mg[e2] twice daily for the treatment of discoid lupus.
+	(13, 20)	0.05 mg	ergonovine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	202	In four patients, spasm occurred spontaneous and in one patient after [s1]0.05 mg[e1] of [s2]ergonovine[e2] 
+	(13, 20)	disopyramide	300 to 600 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	203	Two years later, 24 hours following an increase in the dose of [s1]disopyramide[e1] from [s2]300 to 600 mg/day[e2]  AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.
+	(4, 9)	digoxin	0.25 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	204	He was started on [s1]digoxin[e1]  [s2]0.25 mg[e2] daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of ventricular fibrillation 15 days later.
+	(9, 13)	high dose	vinblastine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	205	Inappropriate antidiuretic hormone secretion after [s1]high dose[e1]  [s2]vinblastine[e2] 
+	(35, 40)	high dose	vinblastine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	206	We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a [s1]high dose[e1] of [s2]vinblastine[e2] 
+	(10, 16)	high-dose	chlorambucil	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	207	Fatal interstitial pneumonitis following [s1]high-dose[e1] intermittent [s2]chlorambucil[e2] therapy for chronic lymphocyte leukemia.
+	(44, 50)	procainamide	750 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	208	A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release [s1]procainamide[e1]  [s2]750 mg/day[e2] .
+	(44, 50)	40 mg/m2	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	209	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of [s1]40 mg/m2[e1]  [s2]methotrexate[e2] (MTX).
+	(44, 55)	40 mg/m2	MTX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	210	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of [s1]40 mg/m2[e1] methotrexate  [s2]MTX[e2] .
+	(12, 17)	low dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	211	Bone marrow aplasia and severe skin rash after a single [s1]low dose[e1] of [s2]methotrexate[e2] 
+	(34, 42)	30 mg	ketoralac	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	212	We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving [s1]30 mg[e1] of intravenous [s2]ketoralac[e2] 
+	(15, 22)	acyclovir	30 mg/kg per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	213	A 9-year-old boy developed acute renal failure following intravenous [s1]acyclovir[e1]  [s2]30 mg/kg per day[e2]  administered for 6 days to treat herpetic encephalitis.
+	(12, 20)	mefloquine	1,500 mg over two days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	214	We report a case of hypoglycaemia after [s1]mefloquine[e1] therapy  [s2]1,500 mg over two days[e2]  for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea.
+	(3, 18)	doxorubicin	'low' doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	215	Aggressive management of [s1]doxorubicin[e1] induced cardiomyopathy associated with [s2]'low' doses[e2] of doxorubicin.
+	(3, 18)	doxorubicin	'low' doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	216	Aggressive management of [s1]doxorubicin[e1] induced cardiomyopathy associated with [s2]'low' doses[e2] of doxorubicin.
+	(0, 8)	High-dose	mannitol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	217	 [s1]High-dose[e1] intravenous [s2]mannitol[e2] infusion in various clinical settings may result in acute renal failure (ARF).
+	(14, 19)	high-dose	mannitol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	218	This is a report of a case of anuric ARF after [s1]high-dose[e1]  [s2]mannitol[e2] infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis.
+	(16, 21)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	219	Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with [s1]high-dose[e1]  [s2]methotrexate[e2] (HD-MTX) for osteogenic sarcoma.
+	(26, 32)	HD-MTX	8 gm/m2 by 6 h continuous infusion	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	220	This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of [s1]HD-MTX[e1]  [s2]8 gm/m2 by 6 h continuous infusion[e2]  with leucovorin rescue.
+	(8, 13)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	221	Transient neurological disturbances induced by the chemotherapy of [s1]high-dose[e1]  [s2]methotrexate[e2] for osteogenic sarcoma.
+	(23, 35)	metronidazole	21 g over 14 days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	222	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, [s2]21 g over 14 days[e2]  was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
+	(21, 26)	ibopamine	100 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	223	Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive [s1]ibopamine[e1]  [s2]100 mg[e2] t.i.d. for chronic congestive heart failure.
+	(22, 27)	low-dose	bromocriptine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	224	A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting [s1]low-dose[e1]  [s2]bromocriptine[e2] therapy for a macroprolactinoma.
+	(21, 26)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	225	Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of [s1]low-dose[e1]  [s2]methotrexate[e2] therapy during rheumatoid arthritis.
+	(23, 28)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	226	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of [s1]low-dose[e1]  [s2]methotrexate[e2]  an acute megaloblastic anaemia and a pneumonitis.
+	(13, 27)	high dose	Levemepromazine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	227	An 11-year-old boy who was treated with a relatively [s1]high dose[e1] of methotrimeprazine meleate  [s2]Levemepromazine[e2]  a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.
+	(13, 18)	high dose	methotrimeprazine meleate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	228	An 11-year-old boy who was treated with a relatively [s1]high dose[e1] of [s2]methotrimeprazine meleate[e2] (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.
+	(3, 10)	phenothiazine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	229	The association of [s1]phenothiazine[e1]  [s2]overdose[e2] and respiratory distress syndrome merits consideration.
+	(4, 13)	450-mg	morphine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	230	She received an accidental [s1]450-mg[e1] bolus injection of [s2]morphine[e2] intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.
+	(1, 6)	high	cotrimoxazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	231	A [s1]high[e1] dose of [s2]cotrimoxazole[e2] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
+	(4, 9)	low	clofazimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	232	Severe abdominal pain in [s1]low[e1] dosage [s2]clofazimine[e2] 
+	(0, 7)	Amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	233	 [s1]Amphotericin B[e1]  [s2]overdose[e2] in pediatric patients with associated cardiac arrest.
+	(2, 9)	Amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	234	CONCLUSIONS: [s1]Amphotericin B[e1]  [s2]overdose[e2] can be fatal in children and infants.
+	(21, 28)	amphotericin B	overdoses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	235	Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving [s1]amphotericin B[e1]  [s2]overdoses[e2] 
+	(14, 30)	between 4.6 and 40.8 mg/kg/d	amphotericin B	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	236	INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received [s1]between 4.6 and 40.8 mg/kg/d[e1] of [s2]amphotericin B[e2] 
+	(9, 16)	amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	237	OBJECTIVE: To report the first five cases of [s1]amphotericin B[e1]  [s2]overdose[e2] with secondary cardiac complications in a pediatric population.
+	(12, 19)	acyclovir	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	238	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1]  [s2]overdose[e2] who developed coma and nonoliguric renal failure.
+	(34, 38)	low	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	239	We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking [s1]low[e1] dose [s2]methotrexate[e2] weekly over a 10-month period.
+	(46, 53)	prednisolone	25 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	240	We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy  [s1]prednisolone[e1]  [s2]25 mg/day[e2]  for pericardial effusion.
+	(6, 10)	low	pimozide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	241	Acute dystonic reaction with [s1]low[e1] dose [s2]pimozide[e2] 
+	(28, 49)	pimozide	0.032 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	242	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with [s1]pimozide[e1] administration at the doses of 0.096 mg/kg/day and [s2]0.032 mg/kg/day[e2] and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
+	(28, 39)	pimozide	0.096 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	243	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with [s1]pimozide[e1] administration at the doses of [s2]0.096 mg/kg/day[e2] and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
+	(1, 15)	low	gold	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	244	How [s1]low[e1] can you go? Use of very low dosage of [s2]gold[e2] in patients with mucocutaneous reactions.
+	(30, 39)	0.3 ml	phenol-glycerine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	245	We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of [s1]0.3 ml[e1] of 10% [s2]phenol-glycerine[e2] into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.
+	(1, 10)	azathioprine	1 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	246	The [s1]azathioprine[e1] dose was low  [s2]1 mg/kg[e2]  and pancytopenia occurred after 56 days therapy.
+	(4, 21)	Halfan	higher	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	247	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 cardiac arrests, leading to 6 deaths, when a [s2]higher[e2] dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(19, 38)	higher	mefloquine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	248	The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a [s1]higher[e1] dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
+	(13, 17)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	249	FINDINGS: Six children with growth retardation noted after treatment with [s1]high[e1] dose [s2]fluticasone propionate[e2] were found to have adrenal suppression.
+	(12, 16)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	250	Growth and adrenal suppression in asthmatic children treated with [s1]high[e1] dose [s2]fluticasone propionate[e2] 
+	(3, 8)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	251	INTERPRETATION: When [s1]high[e1] doses of [s2]fluticasone propionate[e2] are used, growth may be retarded and adrenal suppression may occur.
+	(17, 21)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	252	METHODS: Growth retardation was observed in six severely asthmatic children after introduction of [s1]high[e1] dose [s2]fluticasone propionate[e2] treatment (dry powder).
+	(26, 33)	metripranolol	0.6	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	253	Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with [s1]metripranolol[e1]  [s2]0.6[e2]  eye drops.
+	(4, 19)	acyclovir	10 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	254	This case suggests that [s1]acyclovir[e1] when given intravenously in doses of [s2]10 mg/kg[e2] may result in increased serum lithium concentrations.
+	(17, 28)	10 mg/kg	lithium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	255	This case suggests that acyclovir when given intravenously in doses of [s1]10 mg/kg[e1] may result in increased serum [s2]lithium[e2] concentrations.
+	(17, 24)	dapsone	low	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	256	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone[e1] reaction after [s2]low[e2] dose therapy, with a fatal outcome in one.
+	(13, 20)	minocycline	50 mg twice daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	257	A 17-year-old female patient who had been taking oral [s1]minocycline[e1]  [s2]50 mg twice daily[e2]  for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.
+	(8, 29)	CBZ	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	258	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the [s2]overdose[e2] of CBZ could have represented the precipitating of the episode of acute pancreatitis.
+	(8, 29)	CBZ	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	259	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the [s2]overdose[e2] of CBZ could have represented the precipitating of the episode of acute pancreatitis.
+	(0, 4)	Overdose	magnesium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	260	 [s1]Overdose[e1] of [s2]magnesium[e2] sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.
+	(0, 4)	Overdose	magnesium sulfate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	261	 [s1]Overdose[e1] of [s2]magnesium sulfate[e2] in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.
+	(5, 10)	excessive	AZ	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	262	We thus concluded that an [s1]excessive[e1] dose of [s2]AZ[e2] had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.
+	(11, 16)	600 mg	danazol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	263	On the next day, after a total dose of only [s1]600 mg[e1] of [s2]danazol[e2]  gingival bleeding and purpura occurred.
+	(21, 29)	d-penicillamine	125-500 mg daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	264	We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with [s1]d-penicillamine[e1]  [s2]125-500 mg daily[e2] 
+	(14, 17)	heroin	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	265	Ballistic movements due to ischemic infarcts after intravenous [s1]heroin[e1]  [s2]overdose[e2]  report of two cases.
+	(1, 21)	heroin	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	266	Two [s1]heroin[e1] addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin [s2]overdose[e2] 
+	(18, 22)	high	penicillin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	267	We report a 76-year-old man who developed an acute blistering eruption following [s1]high[e1] dose [s2]penicillin[e2] treatment for pneumococcal septicaemia.
+	(9, 26)	25 mg	desmethylsertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	268	In case 1, a total daily dose of [s1]25 mg[e1] sertraline, with nondetectable sertraline and [s2]desmethylsertraline[e2] blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
+	(9, 41)	25 mg	lamotrigine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	269	In case 1, a total daily dose of [s1]25 mg[e1] sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the [s2]lamotrigine[e2] blood level with symptoms of toxicity.
+	(9, 13)	25 mg	sertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	270	In case 1, a total daily dose of [s1]25 mg[e1]  [s2]sertraline[e2]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
+	(9, 13)	25 mg	sertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	271	In case 1, a total daily dose of [s1]25 mg[e1]  [s2]sertraline[e2]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
+	(28, 51)	5-aminosalicylic acid	3.0 g/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	272	We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with [s1]5-aminosalicylic acid[e1] (Pentasa; Nisshin, Tokyo, Japan) [s2]3.0 g/day[e2] 
+	(36, 49)	Pentasa	3.0 g/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	273	We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid  [s1]Pentasa[e1]  Nisshin, Tokyo, Japan) [s2]3.0 g/day[e2] 
+	(23, 27)	low	alprazolam	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	274	1. Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of [s1]low[e1] dose [s2]alprazolam[e2] treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day).
+	(18, 23)	olanzapine	20-25 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	275	We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with [s1]olanzapine[e1]  [s2]20-25 mg/d[e2] .
+	(25, 34)	isosorbide dinitrate	5 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	276	A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of [s1]isosorbide dinitrate[e1]  [s2]5 mg[e2] .
+	(9, 18)	isosorbide dinitrate	5 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	277	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1]  [s2]5 mg[e2] , blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.
+	(0, 4)	High	phosphate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	278	 [s1]High[e1] dose [s2]phosphate[e2] treatment leads to hypokalemia in hypophosphatemic osteomalacia.
diff --git a/requirements-dev.txt b/requirements-dev.txt
index affc21e..308b6e0 100644
--- a/requirements-dev.txt
+++ b/requirements-dev.txt
@@ -1,8 +1,8 @@
-medcat~=1.14.0
+medcat~=1.16.0
 pandas<2.0.0
 seaborn~=0.11.2
 pytest-xdist~=2.5.0
-nbmake<1.4
+nbmake<1.5
 nbconvert<6
 jinja2<=3.0
 matplotlib>=3.4.0,<3.8.0